

EANM'17

WORLD LEADING MEETING



Vienna, Austria

Annual Congress of the
European Association of Nuclear Medicine

October 21 – 25, 2017
Vienna, Austria

www.eanm.org

Final Programme

 Visit us on
[.com/officialEANM](https://www.facebook.com/officialEANM)



VISIT THE
FOCUS
MEETING
BOOTH
OUTSIDE
HALL F2

EANM FOCUS 1

THE INTERNATIONAL
CONFERENCE ON
"MOLECULAR IMAGING
AND THERANOSTICS
IN PROSTATE CANCER"

FEBRUARY 1-3, 2018
VALENCIA, SPAIN

Table of Contents

Welcome Message	6
EANM Committees	8
EANM'17 Reviewers	10
EANM National Societies: Delegates & Deputies	14
UEMS/EBNM Committees	16
UEMS/EBNM National Delegates & Deputies	18
General Information	19
Business Meetings	24
Floorplans – ACV Vienna	28
Public Transportation Map	32

SCIENTIFIC PROGRAMME

PROGRAMME OVERVIEWS

Saturday, October 21, 2017	36
Sunday, October 22, 2017	38
Monday, October 23, 2017	40
Tuesday, October 24, 2017	42
Wednesday, October 25, 2017	44
Invited Speaker Sessions	46
Do.MoRe Track	50
M2M Track	50
EANM Young Daily Forum	51
Pre-Congress Symposia	52


ORAL SESSIONS

Saturday, October 21, 2017	58
Sunday, October 22, 2017	63
Monday, October 23, 2017	84
Tuesday, October 24, 2017	106
Wednesday, October 25, 2017	128

e-POSTERS

e-Poster Walks	138
e-Posters	152
Technologist e-Poster Walks	252

INDUSTRY PROGRAMME

Industry Sponsored Symposia	262
List of Exhibitors	268
Exhibition Halls Floorplans	278
Company Profiles	284
Corporate Members 	360
Imprint	362



WELCOME
TO THE

3

88 Milan

89 Strasbourg

90 Amsterdam

91 Vienna

92 Lisbon

93 Lausanne

94 Düsseldorf

95 Brussels

96 Copenhagen

97 Glasgow

98 Berlin

99 Barcelona

00 Paris

01 Naples

02 Vienna

th



ANNUAL CONGRESS
OF THE **EUROPEAN**
ASSOCIATION OF
NUCLEAR MEDICINE

03 Amsterdam

04 Helsinki

05 Istanbul

06 Athens

07 Copenhagen

08 Munich

09 Barcelona

10 Vienna

11 Birmingham

12 Milan

13 Lyon

14 Gothenburg

15 Hamburg

16 Barcelona

17 Vienna

Dear colleagues, dear friends,



It is with great pleasure that the European Association of Nuclear Medicine welcomes you to its 30th Annual Congress in Vienna, Austria.

Over the 30 years since our first Congress, nuclear medicine has made significant strides. Overall usage of nuclear medicine procedures is expanding rapidly, and this trend is especially evident with respect to new imaging technologies. We can affirm that the revolution of tomographic hybrid imaging within the nuclear medicine landscape is now a matter of fact, spurred by evidence-based medicine. Our discipline's next step is the integration of genome-specific targeted theranostics, utilising in vivo whole-body assessment of tissue morphology, physiology and biochemistry. The ultimate goal is to design personalised, super-selective therapies and to identify more precise means of monitoring response to treatment in routine clinical practice.



The annual EANM Congress has become the world-leading meeting in nuclear medicine. In order to maintain the high level of excellence of our Congress, the 2017 meeting will build on the traditions that are highly appreciated by all attendees, with expansion of the newer features introduced by the former Congress Chair. A specific educational track, implemented in collaboration with the European School of Multimodality Imaging and Therapy, will include up-to-date Teaching Sessions, enriched by Pitfalls & Artefacts and Continuous Medical Education (CME) sessions. In all these “active learning” sessions, attendees will have the possibility to enhance their knowledge of multimodality imaging. With similar pedagogic intent, numerous multidisciplinary joint symposia organised by EANM Committees and our sister societies will offer an integrative approach to various topics relevant to the state of the art in our discipline. On the occasion of its 30th anniversary, our Congress will feature two new events (as well as a very big surprise). First, a panel display of the best regional posters will illustrate its global scope. Second, a specific Presidential Session will be dedicated to the best-ranked papers from the under-30s. Our young colleagues represent the future of our discipline and should begin to shape their knowledge in ways that will contribute to a brighter tomorrow for the whole nuclear medicine community!

All these learning sessions will not impact adversely on the predominant role of the entire Congress, which is to enable the presentation of oral papers and posters about the latest achievements in clinical nuclear medicine, science and technology. On the contrary, the Rapid Fire sessions, for example, will be enriched. The spirit of such sessions is to draw attention to the most highly rated abstracts in specific areas: a panel of top-level presentations is followed

by extensive discussions, providing attendees with an integrated and coherent view on a wide variety of topics. Furthermore, featured oral sessions with one invited speaker in combination with “regular” presentations will broaden the perspectives on all topics. The now well-established tracks M2M – Molecule to Man (basic and translational science) and Do.MoRe (radionuclide therapy and dosimetry) will promote high-quality research through interaction between basic and translational clinical scientists and allow presentation of the latest achievements and developments in the fields of clinical molecular imaging and nuclear medicine therapy. During the plenary lectures, distinguished speakers will address state of the art science together with new developments in clinical and allied sciences, covering a broad range of topics with the goal of promoting the best possible care for our patients. At the end of the meeting, two eminent lecturers, Prof. Stefano Fanti from Bologna, Italy and Prof. Clemens Decristoforo from Innsbruck, Austria will present the traditional Highlights Lecture.

The Congress will take place in Vienna, Austria, where the EANM Executive Office is also based. The city – located in the heart of Europe, on the banks of the river Danube – is world famous for its imperial heritage, its cultural attractions and its culinary highlights. To quote the slogan of the city: *Vienna awaits you!*

For all these reasons, I cordially invite you to the EANM'17 Congress and to actively participate in our 30th anniversary. Meet and interact with friends and colleagues from all over the world, break away from the daily routine and enjoy Vienna's hospitality.

Francesco Giammarile

EANM Congress Chair 2017-2019



EANM Board & Committees

Board

President 2017 – 2018

K. Muylle (Belgium)

President Elect 2017 – 2018

W.J.G. Oyen (United Kingdom)

Committee Coordinator 2017 – 2018

R. Delgado-Bolton (Spain)

Congress Chair 2017 – 2019

F. Giammarile (Austria)

Education Chair 2017 – 2019

J. Pruim (Netherlands)

Secretary/Treasurer 2017 – 2018

J. Kunikowska (Poland)

Advisory Council

The EANM Advisory Council is composed of the members of the Board and of the Committee Chairs:

Bone & Joint Committee

F. Paycha (France)

Cardiovascular Committee

H. Verberne (Netherlands)

Dosimetry Committee

M.W. Konijnenberg (Netherlands)

Drug Development Committee

A. Gee (United Kingdom)

Ethics Committee

W. Knapp (Germany)

Inflammation & Infection Committee

A. Signore (Italy)

Neuroimaging Committee

I. Law (Denmark)

Oncology Committee

S. Fanti (Italy)

Paediatrics Committee

Z. Bar-Sever (Israel)

Physics Committee

C. Hindorf (Sweden)

Radionuclide Therapy Committee

tba

Radiation Protection Committee

M. Lassmann (Germany)

Radiopharmacy Committee

M. Behe (Switzerland)

Technologist Committee

P. Fragoso Costa (Germany)

Thyroid Committee

M. Luster (Germany)

Translational Molecular Imaging & Therapy Committee

M. de Jong (Netherlands)



Scientific Programme Committee

Chair

F. Giammarile (Austria)

Members

- M. de Jong (Netherlands)
- S. Fanti (Italy)
- F. Forrer (Switzerland)
- P. Fragoso Costa (Germany)
- V. Garibotto (Switzerland)
- A. Gee (United Kingdom)
- A. Glaudemans (Netherlands)
- M.W. Konijnenberg (Netherlands)
- T. Kuwert (Germany)
- M. Lassmann (Germany)
- T. Mindt (Switzerland)
- B. Sattler (Germany)
- H.J. Verberne (Netherlands)
- F. Verburg (Germany)
- P. Zucchetta (Italy)

Technologist Committee

Chair

P. Fragoso Costa (Germany)

Members

- M. Attard (Netherlands)
- L. Camoni (Italy)
- N. Gulliver (United Kingdom)
- S. Rac (Croatia)
- S. Rep (Slovenia)
- A. Santos (Portugal)
- C. Terwinghe (Belgium)

Senior Advisor

G. Testanera (Italy)

Congress Strategy Committee

Congress Chair 2017 – 2019

F. Giammarile (Austria)

Committee Coordinator 2017 – 2018

R. Delgado-Bolton (Spain)

Education Chair 2017 – 2019

J. Pruim (Netherlands)

Members

- P. Elsinga (Netherlands)
- F. Hyafil (France)
- A. Lammertsma (Netherlands)
- M. Ljungberg (Sweden)
- T. van den Wyngaert (Belgium)



EANM'17 Reviewers

A

E. Aarntzen (Netherlands)
D. Aarstrand (Norway)
B. Abbott (USA)
R. Abgral (France)
W. Acampa (Italy)
J. Adam (Netherlands)
D. Agostini (France)
N. Aide (France)
R. Aigner (Austria)
I. Ak (Turkey)
C. Aktolun (Turkey)
A. Al-Nahhas (United Kingdom)
L. Aloj (United Kingdom)
C. Altini (Italy)
V. Ambrosini (Italy)
S. Ametamey (Switzerland)
C. Anagnostopoulos (Greece)
L. Antunovic (Italy)
J. Arbizu (Spain)
C. Artigas (Belgium)
V. Artiko (Serbia)
S. Asenbaum-Nan (Austria)
L. Atay Kapucu (Turkey)
M. Attard (Netherlands)

B

K. Bacher (Belgium)
S. Baldari (Italy)
L. Balkay (Hungary)
J. Ballinger (United Kingdom)
I. Balogh (Hungary)
M. Baptista (Portugal)
Z. Bar-Sever (Israel)
J. Barbet (France)
M. Bardiès (France)
S. Barrington (United Kingdom)
P. Bartenstein (Germany)
H. Barthel (Germany)
R. Baum (Germany)
J. Bax (Netherlands)
A. Beer (Germany)
M. Behe (Switzerland)
M. Beheshti (Austria)
N. Belcari (Italy)
O. Belohlavek (Czech Republic)

F. Bengel (Germany)
A. Benitez Segura (Spain)
G. Berding (Germany)
H. Bergmann (Austria)
K. Bergström (Finland)
M. Bernsen (Netherlands)
T. Beyer (Switzerland)
B. Bilgin (Turkey)
I. Binse (Germany)
A. Bischof Delaloye (Switzerland)
G. Bisi (Italy)
K. Blokland (Netherlands)
C. Blümel (Germany)
L. Bodei (USA)
R. Boellaard (Netherlands)
O. Boerman (Netherlands)
W. Bolch (USA)
J. Bomanji (United Kingdom)
J. Booij (Netherlands)
K. Borbely (Hungary)
L. Borgwardt (Denmark)
G. Bormans (Belgium)
M. Botelho (Portugal)
C. Bourdeau (France)
M. Bourguignon (France)
P. Bouziotis (Greece)
M. Bozkurt (Turkey)
W. Brenner (Germany)
M. Brom (Netherlands)
A. Brouwers (Netherlands)
J. Bucerius (Netherlands)
R. Buchert (Germany)
T. Buckle (Netherlands)
Z. Burak (Turkey)
L. Burrioni (Italy)
J. Buscombe (United Kingdom)
I. Buvat (France)

C

E. Caballero-Calabuig (Spain)
W. Cai (USA)
C. Caldarella (Italy)
L. Camoni (Italy)
B. Caner (Turkey)
M. Cantinho-Lopes (Portugal)
F. Caobelli (Germany)

G. Capa Kaya (Turkey)
S. Capitanio (Italy)
C. Caridade (Portugal)
I. Carrio (Spain)
J. Castell Conesa (Spain)
M. Castellani (Italy)
P. Castellucci (Italy)
C. Cawthorne (United Kingdom)
F. Ceci (Italy)
J. Cerci (Brasil)
R. Chakravarty (United Kingdom)
G. Chetelat (France)
M. Chianelli (Italy)
A. Chiaravalloti (Italy)
C. Chiesa (Italy)
M. Chinol (Italy)
A. Chiti (Italy)
N. Chouin (France)
F. Cicone (Italy)
M. Coffey (Ireland)
E. Comans (Netherlands)
G. Cook (United Kingdom)
B. Cornelissen (United Kingdom)
G. Costa (Portugal)
F. Courbon (France)
P. Covens (Belgium)
U. Cremerius (Germany)
F. Crippa (Italy)
C. Crivellaro (Italy)
A. Cuocolo (Italy)

D

G. D'Angelo (Italy)
G. Dabasi (Hungary)
S. Dalm (Netherlands)
D. Daou (France)
M. de Jong (Netherlands)
J. de Klerk (Netherlands)
C. De Labriolle-Vaylet (France)
D. De Palma (Italy)
J. De Sutter (Belgium)
J. de Swart (Netherlands)
E. de Vries (Netherlands)
C. Decristoforo (Austria)
B. Degirmenci Polack (Turkey)
A. Del Guerra (Italy)

S. Del Vecchio (Italy)

R. Delgado-Bolton (Spain)

T. Derlin (Germany)

C. Deroose (Belgium)

W. Deuther-Conrad (Germany)

A. Dias (Denmark)

C. Dolci (Italy)

M. Dottorini (Italy)

A. Drzezga (Germany)

A. Duatti (Italy)

H. Durak (Turkey)

E

U. Eberlein (Germany)

M. Eiber (Germany)

M. Eisenhut (Germany)

O. Ekmekcioglu (Turkey)

P. Elsinga (Netherlands)

L. Emmett (Australia)

P. Erba (Italy)

B. Erbas (Turkey)

M. Erdoğan (Turkey)

T. Eriksen (Norway)

T. Erselcan (Turkey)

T. Ertay (Turkey)

M. Essler (Germany)

M. Estorch (Spain)

E. Etchebehere (Brasil)

L. Evangelista (Italy)

H. Everaert (Belgium)

S. Ezziddin (Germany)

F

S. Fanti (Italy)

M. Farsad (Italy)

M. Federspiel (Denmark)

W. Fendler (USA)

A. Fernández León (Spain)

V. Ferrari (United Kingdom)

A. Ferrer-Antunes (Portugal)

A. Fikre (Czech Republic)

B. Fischer (Denmark)

F. Fiz (Italy)

P. Flamen (Belgium)

A. Flotats Giral (Spain)

G. Flux (United Kingdom)

I. Földes (Hungary)

F. Forrer (Switzerland)

S. Förster (Germany)

P. Fragoso Costa (Germany)

H. François (Belgium)

S. Frangos (Cyprus)

C. Franzius (Germany)

G

M. Gabriel (Austria)

H. Gallowitsch (Austria)

L. Galuska (Hungary)

O. Gämperli (Switzerland)

A. Garcia Vicente (Spain)

J. Gear (United Kingdom)

A. Gee (United Kingdom)

O. Gheysens (Belgium)

F. Giammarile (France)

F. Giesel (Germany)

N. Gillings (Denmark)

A. Gimelli (Italy)

A. Giordano (Italy)

L. Giovannella (Switzerland)

R. Giubbini (Italy)

G. Glatting (Germany)

A. Gludemans (Netherlands)

G. Gnanasegaran (United Kingdom)

G. Goerres-Walendzik (Switzerland)

I. Goethals (Belgium)

J. Gonsalvez Pereira (Portugal)

M. Gotthardt (Netherlands)

S. Graf (Austria)

K. Gratz (Germany)

S. Gratz (Germany)

J. Grimm (USA)

C. Gröttinger (Germany)

F. Grünwald (Germany)

P. Guigui (France)

D. Guilloteau (France)

N. Gulliver (United Kingdom)

B. Gulyas (Sweden)

A. Gungor (Turkey)

H

U. Haberkorn (Germany)

M. Hacker (Austria)

C. Halldin (Sweden)

D. Handkiewicz-Junak (Poland)

F. Hanin (Belgium)

T. Hany (Switzerland)

A. Hendlisch (Belgium)

M. Henneman (Netherlands)

K. Herholz (United Kingdom)

K. Herrmann (Germany)

S. Heskamp (Netherlands)

S. Hesse (Germany)

R. Hicks (Australia)

C. Hindorf (Sweden)

M. Hinterreiter (Austria)

C. Hoefnagel (Netherlands)

M. Hoffman (Australia)

M. Hoffmann (Austria)

S. Holm (Denmark)

R. Howell (USA)

V. Husak (Czech Republic)

R. Hustinx (Belgium)

B. Hutton (United Kingdom)

F. Hyafil (France)

I

A. Iagaru (USA)

I. Iakovou (Greece)

O. Israel (Israel)

K. Ito (Japan)

J

F. Jamar (Belgium)

G. Janoki (Hungary)

M. Janssen (Netherlands)

B. Jarzab (Poland)

W. Jentzen (Germany)

K

L. Kabasakal (Turkey)

W. Kampen (Germany)

N. Karabacak (Turkey)

P. Kaufmann (Switzerland)

S. Kirac (Turkey)

M. Kirienko (Italy)

A. Kjaer (Denmark)

T. Klausen (Denmark)

A. Klisarova (Bulgaria)



R. Kluge (Germany)
W. Knapp (Germany)
P. Knöll (Austria)
G. Knudsen (Denmark)
J. Knuuti (Finland)
C. Kobe (Germany)
P. Kolenc Peitl (Slovenia)
M. Konijnenberg (Netherlands)
J. Környei (Hungary)
I. Kostadinova (Bulgaria)
M. Kostkiewicz (Poland)
J. Kotzerke (Germany)
J. Koziarowski (Sweden)
F. Kraeber-Bodéré (France)
S. Krämer (Switzerland)
G. Kramer-Marek (United Kingdom)
B. Krause (Germany)
A. Krizsan (Hungary)
N. Küçük (Turkey)
J. Kunikowska (Poland)
J. Kurth (Germany)
T. Kuwert (Germany)

L

T. Lahoutte (Belgium)
A. Lammertsma (Netherlands)
W. Langsteger (Austria)
C. Lapa (Germany)
P. Lass (Poland)
M. Lassmann (Germany)
C. Lauri (Italy)
P. Laverman (Netherlands)
I. Law (Denmark)
E. Lazzeri (Italy)
D. Le Guludec (France)
E. Lemos Pereira (Portugal)
V. Lewington (United Kingdom)
O. Lindner (Germany)
B. Lipsky (United Kingdom)
M. Ljungberg (Sweden)
A. Loft Jakobsen (Denmark)
M. Lonsdale (Denmark)
E. Lopci (Italy)
M. Luster (Germany)

M

M. Maccauro (Italy)
G. Madeddu (Italy)
H. Maেকে (Germany)
A. Maes (Belgium)
L. Maffioli (Italy)
T. Maina-Nock (Greece)

A. Maldonado (Spain)
N. Manevska (FYROM Former Yugoslav Republic Of Macedonia)
M. Mann (South Africa)
L. Mansi (Italy)
P. Mapelli (Italy)
F. Marafi (Kuwait)
C. Marcassa (Italy)
M. Marengo (Italy)
G. Mariani (Italy)
J. Martin (United Kingdom)
J. Martin-Comin (Spain)
D. Mateo Navarro (Spain)
J. Mayol (Spain)
H. Medvedec (Croatia)
M. Meignan (France)
C. Menzel (Germany)
G. Meyer (Germany)
P. Meyer (Germany)
J. Mihailovic (Serbia)
R. Mikolajczak (Poland)
T. Mindt (Austria)
H. Minn (Finland)
M. Mitjavila Casanovas (Spain)
E. Mittra (USA)
T. Mognetti (France)
H. Mohan (United Kingdom)
M. Monsieurs (Belgium)
L. Mortelmans (Belgium)
E. Mossa (Italy)
F. Mottaghy (Germany)
L. Mu (Switzerland)
A. Mudun (Turkey)
C. Müller (Switzerland)
A. Muxi Pradas (Spain)
K. Muylle (Belgium)
M. Myslivecek (Czech Republic)

N

J. Nagarajah (Netherlands)
K. Nagren (Denmark)
C. Nanni (Italy)
D. Neglia (Italy)
S. Nekolla (Germany)
F. Nobili (Italy)
B. Nock (Greece)
J. Nonnekens (Netherlands)
E. Noriega (Spain)
P. Notta (Spain)
R. Nunez-Miller (Austria)
P. Nuutila (Finland)
J. Nuyts (Belgium)

O

A. Orlova (Sweden)
M. Orrù (Italy)
W. Oyen (United Kingdom)
Z. Ozcan (Turkey)
O. Ozdogan (Turkey)
P. Ozgen Kiratli (Turkey)
M. Ozguven (Turkey)

P

G. Paganelli (Italy)
M. Pagani (Italy)
A. Palmieri (Italy)
M. Papos (Hungary)
S. Pappata (Italy)
C. Pascali (Italy)
M. Patt (Germany)
F. Paycha (France)
P. Payout (France)
K. Pedersen (Denmark)
I. Peñuelas (Spain)
G. Pepe (Italy)
L. Pereira-Arias Bouda (Netherlands)
C. Pestean (Romania)
Z. Petrovic (Slovenia)
A. Pfestroff (Germany)
T. Pfluger (Germany)
B. Pichler (Germany)
R. Pijpers (Netherlands)
P. Pilkington (Spain)
E. Piperkova (Bulgaria)
C. Pirich (Austria)
A. Plachcinska (Poland)
T. Poeppel (Germany)
V. Prassopoulos (Greece)
E. Prats-Rivera (Spain)
J. Pruim (Netherlands)
A. Pupi (Italy)

R

S. Rac (Croatia)
K. Rahbar (Germany)
M. Rajic (Serbia)
I. Rausch (Austria)
L. Rbah-Vidal (France)
F. Redondo (Chile)
S. Rep (Slovenia)
A. Resende Geão (Portugal)
S. Reske (Germany)
M. Rijpkema (Netherlands)
C. Rischpler (Germany)
M. Rodari (Italy)

M. Rodrigues Radischat (Austria)
A. Rodríguez-Gasén (Spain)
V. Roelants (Belgium)
F. Rogowski (Poland)
A. Roivainen (Finland)
J. Roland (Belgium)
A. Rominger (Germany)
F. Rösch (Germany)
C. Rossetti (Italy)
F. Rouzet (France)
D. Rubello (Italy)
J. Ruhlmann (Germany)
D. Ryder (Ireland)

S

O. Sabri (Germany)
L. Salgado (Portugal)
P. Salvadori (Italy)
M. Salvatore (Italy)
M. Šámal (Czech Republic)
A. Santos (Portugal)
A. Santos (Portugal)
B. Sattler (Germany)
S. Savolainen (Finland)
N. Schäfer (Switzerland)
M. Schäfers (Germany)
C. Scheiber (France)
R. Schibli (Switzerland)
T. Schindler (USA)
O. Schober (Germany)
H. Schöder (USA)
P. Schubiger (Switzerland)
M. Schwaiger (Germany)
S. Schwarz (USA)
S. Schwarzenböck (Germany)
R. Sciagrà (Italy)
J. Sciuk (Germany)
R. Sciuto (Italy)
M. Seppänen (Finland)
T. Sera (Hungary)
E. Seregni (Italy)
A. Serena Puig (Spain)
G. Sgouros (USA)
G. Siclari (Italy)
A. Signore (Italy)
K. Sjögren-Gleisner (Sweden)
A. Skanjeti (Italy)
R. Slart (Netherlands)
G. Smith (United Kingdom)
G. Sobal (Austria)
D. Sobic Saranovic (Serbia)
C. Solbach (Germany)

O. Solin (Finland)
M. Sollini (Italy)
A. Soricelli (Italy)
J. Sowinski (Poland)
K. Spaepen (Belgium)
M. Stabin (USA)
J. Steinbach (Germany)
H. Steinert (Switzerland)
H. Stevens (Netherlands)
M. Stokkel (Netherlands)
S. Strand (Sweden)
K. Strobel (Switzerland)
J. Sunderland (USA)
A. Sundin (Sweden)

T

J. Talbot (France)
K. Tatsch (Germany)
M. Teräs (Finland)
S. Terry (United Kingdom)
C. Terwinghe (Belgium)
G. Testanera (United Kingdom)
K. Thielemans (United Kingdom)
S. Todde (Italy)
V. Tolmachev (Sweden)
G. Tosi (Italy)
R. Trebossen (France)
G. Treglia (Switzerland)
L. Tron (Hungary)
C. Türkmen (Turkey)

U

C. Übleis (Germany)
Ö. Ugur (Turkey)
P. Ünak (Turkey)
M. Unlu (Turkey)

V

I. Vaccaro (Italy)
R. Valdés Olmos (Netherlands)
P. Van Boxem (Belgium)
E. Van de Giessen (Netherlands)
C. Van de Wiele (Belgium)
W. van den Broek (Netherlands)
J. van den Hoff (Germany)
T. Van den Wyngaert (Belgium)
W. Van der Bruggen (Netherlands)
M. van Essen (Sweden)
F. Van Leeuwen (Netherlands)
A. van Waarde (Netherlands)
S. Vandenberghe (Belgium)
J. Varga (Hungary)

N. Varmenot (France)
A. Varrone (Sweden)
P. Veit-Haibach (Canada)
H. Verberne (Netherlands)
A. Verbruggen (Belgium)
F. Verburg (Germany)
J. Vercouillie (France)
A. Versari (Italy)
J. Verzijlbergen (Netherlands)
B. Vidovic (Germany)
I. Virgolini (Austria)
E. Visser (Netherlands)
D. Visvikis (France)
M. Vljakovic (Serbia)
W. Vogel (Netherlands)
D. Vriens (Netherlands)
D. Vugts (Netherlands)

W

W. Waddington (United Kingdom)
W. Wadsak (Austria)
Z. Walker (United Kingdom)
S. Walrand (Belgium)
J. Walz (France)
W. Weber (USA)
A. Welch (United Kingdom)
H. Wester (Germany)
A. Windhorst (Netherlands)

X



















C. Xavier (Belgium)












Z

K. Zambo (Hungary)
L. Zanoni (Italy)
M. Zellweger (Switzerland)
S. Zerdoud (France)
I. Zerizer (United Kingdom)
S. Ziegler (Germany)
L. Zimmer (France)
P. Zucchetta (Italy)



EANM National Societies: Delegates & Deputies

<i>Society</i>	<i>Delegate</i>	<i>Deputy</i>
 Armenian Society of Nuclear Medicine	V. Barsegian	G. Kevorkian
 Austrian Society of Nuclear Medicine	A. Becherer	W. Langsteger
 Azerbaijan Society of Nuclear Medicine	F. Novruzov	A. Aliyev
 Belgian Society of Nuclear Medicine	F. Jamar	P. De Bondt
 Bosnian Society of Nuclear Medicine	Z. Rajkovaca	D. Rozic
 British Nuclear Medicine Society	S. Vinjamuri	R. Graham
 Bulgarian Society of Nuclear Medicine	P. Bochev	V. Hadzhiyska
 Croatian Society of Nuclear Medicine	M. Franceschi	D. Šnajder
 Cyprus Society of Nuclear Medicine	S. Frangos	R.K. Demetriadou
 Czech Society of Nuclear Medicine	O. Lang	M. Kaminek
 Danish Society of Clinical Physiology and Nuclear Medicine	L. Jensen	P.S. Oturai
 Dutch Society of Nuclear Medicine	R. Bennink	C. Ticheler
 Estonian Nuclear Medicine Society	K. Ulst	S. Nazarenko
 Finnish Society of Nuclear Medicine	M.P. Seppänen	H. Mussalo
 FYR of Macedonian Society of Nuclear Medicine	A. Ugrinska	E. Janevik-Ivanovska
 French Society of Nuclear Medicine	O.J. Mundler	J.-P. Vuillez
 German Society of Nuclear Medicine	J. Kotzerke	F. M. Mottaghy
 Greek Society of Nuclear Medicine & Biology	D. Apostolopoulos	V.C. Prassopoulos
 George de Hevesy Hungarian Society of NM	L. Pavics	J. Varga
 Icelandic Society of Nuclear Medicine	E. Bjorgvinsson	J. Gudjonsdottir

<i>Society</i>	<i>Delegate</i>	<i>Deputy</i>
 Irish Nuclear Medicine Association	M. O'Connell	J. Feeney
 Israeli Society of Nuclear Medicine	Z. Bar-Sever	Z. Keidar
 Italian Society of Nuclear Medicine	M. Picchio	E. Milan
 Latvian Society of Nuclear Medicine	D. Berzina	J. Kedrova
 Lithuanian Society of Nuclear Medicine	D. Vajauskas	I. Kulakiene
 Luxembourg Society of Nuclear Medicine	C. Als	C.J. Picard
 Malta	M.A. Aquilina	A. Samuel
 Norwegian Society of Nuclear Medicine	T.C. Adamsen	R. Sundset
 Polish Society of Nuclear Medicine	R. Czepczynski	A. Sowa-Staszczak
 Portuguese Society of Nuclear Medicine	G. Costa	A.P. Moreira
 Romanian Society of Nuclear Medicine	R. Mititelu	V.C. Mazilu
 Russian Society of Nuclear Medicine	P. Rumyantsev	V. Soukhov
 Serbian Nuclear Medicine Society	D. Sobic-Saranovic	J. Mihailovic
 Slovak Society of Nuclear Medicine	P. Povinec	L. Kaliska
 Slovenian Society of Nuclear Medicine	I. Zagar	K. Zaletel
 Spanish Society of Nuclear Medicine	J.C. Alonso Farto	J.A. Vallejo Casas
 Swedish Society of Nuclear Medicine	A. Sundin	A. Larsson Strömvall
 Swiss Society of Nuclear Medicine	T. Krause	M. Wissmeyer
 Turkish Society of Nuclear Medicine	B.H. Erbas	L.Ö. Atay
 Ukrainian Society of Nuclear Medicine	to be announced	to be announced



UEMS/EBNM National Delegates & Deputies


nominated from full UEMS Member Countries

<i>Country</i>	<i>Delegate</i>	<i>Deputy</i>
 AUSTRIA	I. Virgolini	R. Lipp
 BELGIUM	K. Spaepen	G. Moulin-Romsee
 BULGARIA	E. Piperkova	A.D. Tzonevska
 CROATIA	D. Huic	S. Kusacicic Kuna
 CYPRUS	R.K. Demetriadou	
 CZECH REPUBLIC	M. Kaminek	O. Lang
 DENMARK	P.S. Oturai	L. T. Jensen
 ESTONIA	E. Kelk	A. Poksi
 FINLAND	K. Timonen	J. Kemppainen
 FRANCE	E. Gremillet	J.-L. Pelletier
 GERMANY	W. Brenner	M. Gotthardt
 GREECE	I. Iakovou	S. Tsiouris
 HUNGARY	L. Pavics	I. Szilvasi
 IRELAND	S. Skehan	R. McDermott
 ITALY	B. Palumbo	A. Ciarmiello
 LATVIA	I. Vevere	A. Berzina
 LITHUANIA	D. Vajauskas	N. Jurkiene
 LUXEMBOURG	P. Paulus	M. Doat
 MALTA	A. Samuel	M. A. Aquilina
 NETHERLANDS	R. J. Bennink	M. Stokkel




<i>Country</i>	<i>Delegate</i>	<i>Deputy</i>
 NORWAY	R. Midha	M. Revheim
 POLAND	M. Dziuk	B. Birkenfeld
 PORTUGAL	L. Salgado	M. T. Ferreira
 ROMANIA	G. Andries	R. Mititelu
 SLOVAKIA	A. Vondrak	
 SLOVENIA	M. Grmek	D. Hrastnik
 SPAIN	J. C. Alonso Farto	F. Pons
 SWEDEN	E. Trägårdh	P. Grybäck
 SWITZERLAND	A. Boubaker	J. Müller-Brand
 UNITED KINGDOM	S. Dizdarevic	

nominated from UEMS Associate Member Countries



 TURKEY	Y. Yurekli	Z. Ozcan
---	------------	----------

nominated from UEMS Observer Countries



 ISRAEL	A. Steinmetz	M. Quastel
---	--------------	------------

UEMS/EBNM Committees

Executive Committee

President

L. Maffioli (Italy)

Secretary & Treasurer

S. Frangos (Cyprus)

Member

S. Mirzaei (Austria)

CME Accreditation

Chair

T. Varetto (Italy)

Members

E. Lopci (Italy)

A. Haug (Austria)

S. Sillanmäki (Finland)

Fellowship Examination

Chair

A. Boubaker (Suisse)

Members

I. Kulakiene (Lithuania)

Z. Ozcan (Turkey)

J. R. Garcia Garzón (Spain)

S. Frangos (Cyprus)

Accreditation of Nuclear Medicine Departments & Training Centres

Chair

J. Prior (Switzerland)

Members

S. Mirzaei (Austria)

A. García-Burillo (Spain)

N. Mutlukoca (Norway)

P.A.L. Van Boxem (Belgium)

M.L. Hall (United Kingdom)

Corresponding Members

F. Giesel (Germany)

A. Jiménez Heffernan (Spain)

I. Sippo-Tujunen (Finland)

N.G. Hartman (United Kingdom)

S.E. Bouyoucef (Algeria)

A. Ciarmiello (Italy)

Education & Syllabus

Chair

R. Hustinx (Belgium)

Members

F. Brunotte (France)

H. B. Sayman (Turkey)

D. Huic (Croatia)

T.V. Bogsrud (Norway)

Ex officio:

L. Maffioli (Italy)



General Information

Congress Venue

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria
URL: www.acv.at

The ACV is within 2 minutes walking distance from the metro station Kaisermühlen VIC, right behind the Vienna International Center and United Nation's headquarters. The metro U1 (red line) is the only one connecting the city centre with the ACV.

Audio & Video Recordings

Audio and/or video recordings during the congress are strictly prohibited and may not be made without prior written permission of the EANM Executive Office.

Badges

Badges must be worn at all times throughout the entire congress and during social events. Colour codes are as follows:

Purple – Attendees
Blue – Exhibitors
Green – Day Badges
Red – Accompanying Persons

Banks & ATMs

Banks are usually open from 08:00 to 12:30 and 13:30 to 15:00 (weekdays) and 08:00 to 12:30 and 13:30 to 17:30 (Thursday) and are closed during the weekends.

There are ATMs (Automatic Teller Machine) in the ACV and all over the city of Vienna. Currency exchange offices can be found at the airport, at the main train station and along the main streets of Vienna.

Certificate of Attendance

To obtain your certificate of attendance please visit www.eanm.org, log in to the vEANM Area with your personal account information and refer to the section vConfirmation > Congress related. The certificate will be available within 24 hours after you have scanned your congress badge.

Churches, Synagogues, Mosques

Although Vienna (like the rest of Austria) is mostly Catholic, different religions are practiced by many citizens. Catholic and Protestant churches as well as Synagogues and Mosques services are available. Please contact your hotel concierge for current times of services or nearby houses of prayer.

Climate

The daytime temperatures in mid-end October range between 7°-14° Celsius and it may also be rainy and windy during the entire month.

CME Credits & Certificates

To acquire CME credits, attendees are required to scan their congress badge upon first arrival at the congress venue as well as upon entrance into each CME session. For CME sessions, an evaluation form must also be completed for each session attended.

To obtain your CME certificate(s) please visit www.eanm.org, log in to the vEANM Area with your personal account information and refer to the section vConfirmation > Congress related. The certificate(s) will be available within 24 hours after you have scanned your congress badge.

Congress App

Get your smartphone prepared for EANM'17 and download our congress app for iOS or Android devices! The app provides you with the Scientific Programme, General Information and much more.



Congress Language

The congress language is English. No simultaneous translation will be provided.

Congress Office

Saturday, October 21, 2017:	07:30 – 18:00
Sunday, October 22, 2017:	07:30 – 18:00
Monday, October 23, 2017:	07:30 – 18:00
Tuesday, October 24, 2017:	07:30 – 18:00
Wednesday, October 25, 2017:	07:30 – 12:00

Congress Social Programme

All registered delegates and accompanying persons are cordially invited to:

Opening Ceremony & Welcome Reception

Saturday, October 21, 2017, 19:30 – 23:00
Hall A/B/C, ACV – Austria Center Vienna

Closing Ceremony & Farewell Cocktail

Wednesday, October 25, 2017, 13:15 – 14:30
Hall A, ACV – Austria Center Vienna

Please note that only delegates and accompanying persons wearing a valid congress name badge will be granted access.

Currency

The official currency in Austria is Euro (€). You can exchange your currency without any limits for total amount at all banks as well as many exchange offices in Vienna. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency.

Disclaimer

Please note that in the event that the congress is cancelled by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organisers at that time. You may wish to insure yourself directly against such a risk.

EANM Executive Office

Schmalzhofgasse 26
1060 Vienna, Austria
Phone: +43-(0)1-890 44 27
Fax: +43-(0)1-890 44 27-9
Email: office@eanm.org
URL: www.eanm.org

EANM Members Assembly

The Members' Assembly will be held on Saturday, October 21, 2017 from 16:00/17:00 – 18:30 (16:00 first call, 17:00 second call).

Please note: Only members in good standing* of the European Association of Nuclear Medicine are eligible to attend the Members' Assembly.

(*Members in good standing are members who have paid their membership fees for the year 2017)

Electricity

The power supply in Austria is 220/240 V. Most electric outlets adhere to the continental standard (Schuko). Appliances from North America require a transformer and British ones an adaptor for the two-pin sockets which are used in Austria.

Industry Exhibition

Sunday, October 22 – Tuesday, October 24, 2017
09:00 – 17:00 (Level 0 and Level -2)

Insurance & Liability

Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

Interactive Programme Planner

As in previous years, the EANM again offers the Interactive Programme Planner (IPP). The IPP gives you the opportunity to create your personal schedule and to download your individual abstract book. Visit <http://onsite.eanm.org> to create your personalized programme.

International Meetings and Announcement Board

Visit Exhibition Hall X2 to get information on upcoming events in Nuclear Medicine and more.

Internet Corner

Internet access will be provided at stations within the industry exhibition in Hall X2 (SUN-TUE) and in Room 2.17 (Level 2) on WED. Please limit the viewing time to max. 5 minutes per person.

Lost & Found

A lost and found service will be provided in the EANM Congress Office for the duration of the congress.

Medical Facilities

Medical assistance and an ambulance service will be available throughout the congress.

Museums

There are many different museums in Vienna. For prices and opening hours please refer to the hotel reception or any tourist information. Some museums and exhibitions are closed on Mondays.

Public Transportation

Public transportation is by far the easiest way to get around the city. The Vienna buses, trams and subways are quick, cheap and all-around excellent. Friday to Sunday the metro services are 24h. If the weather is good, we recommend to take a bike from the public network.

Please make sure to carry a valid ticket! Conductors do not hesitate to fine anyone €103 without a valid ticket (being a tourist is not a valid excuse).

Ticket machines can be found in each metro station.

For further public transportation information of the city of Vienna, please check: <http://www.wienerlinien.at/>

Public Bicycle Sharing System (CityBike Wien)

The city offers the environment-friendly bike system to both, locals and visitors. Bikes can be hired at over 120 bike stations across Vienna. They can be returned at any empty bikebox at any station. You need a one-time registration (either online or directly at the bike station) and a valid credit card. The first hour is free of charge, the second is for € 1,00 and it progressively increases until € 4,00/hour.

For more information or registration please visit: <https://www.citybikewien.at/en/>

Public Transportation Ticket (PTT)

All congress participants who book a hotel through the online registration page of EANM which is more than a 15-minute walk away from the congress venue will receive a complimentary public transportation ticket.

For an overview of hotels and their respective distance to the congress venue, please refer to the hotel list on the official EANM homepage.

Public Transportation Tickets (PPTs) are available for purchase at the Public Transportation Ticket Desk, which is located next to the Vienna Information Desk at the entrance foyer of the ACV (Austria Center Vienna).

Opening hours:

Saturday, October 21, 2017:	10:00 – 19:00
Sunday, October 22, 2017:	09:00 – 18:00
Monday, October 23, 2017:	09:00 – 18:00
Tuesday, October 24, 2017:	09:00 – 18:00
Wednesday, October 25, 2017:	09:00 – 12:00

Ticket types and prices:

24 hours – 7,60€
48 hours – 13,30€
72 hours – 16,50€
4 days – 18,23€
7 days – 25,20€

Please note that the only accepted payment method onsite for PPTs is in cash.

Tickets do not have to be validated prior the first ride – they are valid per date printed on them.



Restaurants & Nightlife

There is a large choice of restaurants in Vienna, offering various kinds of local or international dishes. Downtown restaurants normally open for lunch from 11:00 to 15:00 and for dinner from 19:30 to 23:00. Cafés and breakfast bars may already open at 08:00, some even earlier. Fast food, kebab, and take-away pizza stalls usually serve food all day long, and some of them stay open until midnight. Bars, night clubs and discotheques usually open from 22:00 to 04:00. Wineries in Grinzing usually open from 16:00 onwards.

Safety Tips / Pick-pockets

In general Vienna is a very safe city. Vienna's reputation reflects the country at large: according to the 2015 Global Peace Index, Austria was ranked the third most peaceful country in the world.

Nevertheless – as in each tourist hotspot – simply carry your wallets in closed/zipped bags and keep an eye on your bag when standing/walking in crowded areas, packed metro stations or buses, etc. The main emergency numbers are: Police: 133, Ambulance: 144. European Emergency call: 112.

Shopping

Vienna is an ideal destination to shop for a wide variety of items catering to everybody's tastes and wishes. Shops and department stores are generally open Monday through Friday 9:00 hours to 18:00 hours, some until 19:00 hours, Saturdays 9:00 hours -17:00 hours. In shopping malls and shopping streets, shops are open on Thursdays until 21:00 hours and on Saturdays until 18:00 hours. Only most souvenir shops are open on Sunday. Flea markets, f.e. Naschmarkt, are open every Saturday morning.

The closest shopping mall towards the congress centre is "Donauzentrum". It is two stops with the metro line U1 away from the congress centre. The station is "Kagran".

Social Media

The EANM is represented on several social media platforms to keep members, fans, followers and subscribers up to date on offers and activities of the EANM!

Follow us on [Facebook](#) and share your experiences by using the Hashtag #EANM ! With the tag #EANMLive you can address questions to the lecturers of CME & Plenary Sessions, which you are attending at that very moment.

With EANM on [Twitter](#) you can be sure never to miss anything and to always be right on time.

Subscribe to [YouTube](#) to become one of over 2.000 viewers and enjoy exclusive interviews, videos about social events, making of, insider-information and much more.

Follow us on [Instagram](#), where the EANM shares photos of the annual congress and further meetings & events with you.

Taxis

Taxis are not the most affordable alternative to the public transportation. A 15 minutes journey will cost about € 15.00 depending on the traffic. It is not recommended to use taxis in the inner city as a lot of the streets are pedestrian areas and the traffic is quite high. The rates will be shown on the meter next to the driver. The minimum rate for a taxi is approx. € 4. Night rides start at € 4.50

Possible taxi numbers are: 0043/1 40100 or 0043/1 31300.



YOUNG DAILY FORUM 2017



SALARY

VACATION
TIME

PROMOTION
PROSPECTS

**DO NOT PICK A JOB WITH
GREAT VACATION TIME.
PICK A CAREER THAT DOES
NOT NEED ESCAPING FROM.**

(UNKNOWN)

WORKSHOP 1:

SUN, OCT. 22, 2017, 13:00-14:30
PRESENTATION SKILLS WORKSHOP

WORKSHOP 2:

MON, OCT. 23, 2017, 13:00-14:30
NETWORKING - HOW TO BUILD
PROFESSIONAL RELATIONSHIPS

WORKSHOP 3:

TUE, OCT. 24, 2017, 13:00-14:30
BE STRONGER - MENTALLY,
EMOTIONALLY, PHYSICALLY &
SPIRITUALLY

Business Meetings during EANM'17

(chronological)

EANM Assemblies

	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
EANM Delegates Assembly	Sat. Oct. 21	13:45-15:45	Hall E1	0
EANM Members Assembly	Sat. Oct. 21	17:00-18:30	Hall E2	0

EANM Committee Meetings

	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
Cardiovascular Committee Meeting	Sat. Oct. 21	09:00-11:00	-2.61-2 (<i>Meeting Room 7</i>)	-2
Oncology Committee Meeting	Sat. Oct. 21	13:00-15:00	-2.32-3 (<i>Meeting Room 5</i>)	-2
Bone & Joint Committee Meeting	Sat. Oct. 21	13:00-15:00	-2.61-2 (<i>Meeting Room 7</i>)	-2
Radiation Protection Committee Meeting	Sat. Oct. 21	15:00-17:00	-2.47-8 (<i>Meeting Room 6</i>)	-2
Inflammation & Infection Committee Meeting	Sat. Oct. 21	16:00-18:00	-2.61-2 (<i>Meeting Room 7</i>)	-2
Drug Development Committee Meeting	Sun. Oct. 22	09:00-11:00	-2.61-2 (<i>Meeting Room 7</i>)	-2
Neuroimaging Committee Meeting	Sun. Oct. 22	11:30-12:30	-2.31 (<i>Meeting Room 4</i>)	-2
Extraordinary Committee Meeting	Sun. Oct. 22	13:15-14:15	0.31-2 (<i>Meeting Room 2</i>)	0
Physics Committee Meeting	Mon. Oct. 23	08:00-10:00	-2.61-2 (<i>Meeting Room 7</i>)	-2
Thyroid Committee Meeting	Mon. Oct. 23	10:00-11:15	-2.47-8 (<i>Meeting Room 6</i>)	-2
Dosimetry Committee Meeting	Mon. Oct. 23	10:00-11:15	-2.61-2 (<i>Meeting Room 7</i>)	-2
Technologist Committee Meeting	Mon. Oct. 23	13:00-14:30	-2.61-2 (<i>Meeting Room 7</i>)	-2
Radiopharmacy Committee Meeting	Mon. Oct. 23	13:00-15:00	-2.32-3 (<i>Meeting Room 5</i>)	-2
Congress Strategy Committee Meeting	Mon. Oct. 23	13:15-13:45	-2.16 (<i>Meeting Room 9</i>)	-2
Paediatric Committee Meeting	Mon. Oct. 23	14:30-16:00	-2.61-2 (<i>Meeting Room 7</i>)	-2
EANM'18 Scientific Programme Committee Meeting	Mon. Oct. 23	16:30-18:00	-2.31 (<i>Meeting Room 4</i>)	-2
Translational Molecular Imaging Committee Meeting	Tue. Oct. 24	14:30-16:00	0.49-50 (<i>Meeting Room 3</i>)	0

EANM Committee Interest Group Meetings	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
Inflammation & Infection Committee Interest Group Meeting	Sun. Oct. 22	14:00-15:00	-2.16 (Meeting Room 9)	-2
EANM Neuroimaging Committee Interest Group Meeting	Mon. Oct. 23	10:00-11:00	-2.31 (Meeting Room 4)	-2
EANM Drug Development Committee Interest Group Meeting	Mon. Oct. 23	10:00-11:30	-2.32-3 (Meeting Room 5)	-2
EANM Dosimetry Committee Interest Group Meeting	Mon. Oct. 23	11:30-13:00	-2.31 (Meeting Room 4)	-2
EANM Oncology Committee Interest Group Meeting	Mon. Oct. 23	13:00-14:00	-2.47-8 (Meeting Room 6)	-2
EANM Physics & Radiation Protection Committee Interest Group Meeting	Mon. Oct. 23	14:30-16:00	-2.31 (Meeting Room 4)	-2
EANM Radiopharmacy Committee Interest Group Meeting	Mon. Oct. 23	15:00-16:00	-2.32-3 (Meeting Room 5)	-2
EANM Thyroid Committee Interest Group Meeting	Tue. Oct. 24	08:30-09:30	-2.31 (Meeting Room 4)	-2
EANM Paediatric Committee Interest Group Meeting	Tue. Oct. 24	11:30-13:00	-2.32-3 (Meeting Room 5)	-2
EANM Technologist Committee Interest Group Meeting	Tue. Oct. 24	13:00-14:30	Hall C	2
EANM Translational Molecular Imaging Committee Interest Group Meeting	Wed. Oct. 25	10:00-11:30	0.49-50 (Meeting Room 3)	0

ESMIT Meetings	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
ESMIT Faculty Training	Fri. Oct. 20	09:00-17:00	-2.91 (ESMIT Meeting Room)	-2
ESMIT Leadership Meeting	Sat. Oct. 21	08:00-10:30	-2.91 (ESMIT Meeting Room)	-2
ESMIT Working Groups Meeting	Sun. Oct. 22	11:00-13:00	-2.91 (ESMIT Meeting Room)	-2
ESMIT General Meeting	Sun. Oct. 22	14:30-16:30	-2.31 (Meeting Room 4)	-2

EANM Exhibitors Meeting	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
EANM Exhibitors Meeting	Mon. Oct. 23	10:00-11:15	Room 0.14 (Meeting Room 1)	0



UEMS/EBNM Meetings

	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
UEMS/EBNM CME Committee Meeting	Sun. Oct. 22	14:00-16:00	Room -2.85-6 (<i>Meeting Room 8</i>)	-2
UEMS/EBNM Executive & Committee Chairs Meeting	Mon. Oct. 23	10:00-14:30	Room -2.85-6 (<i>Meeting Room 8</i>)	-2
UEMS/EBNM Delegates Assembly	Mon. Oct. 23	15:00-17:00	Room 0.14 (<i>Meeting Room 1</i>)	0

FEBNM Exam Dates*

	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
FEBNM Written Examination (MCQ)	Fri. Oct. 20	14:30-17:30	EANM Office*	4
FEBNM Oral Examination	Sat. Oct. 21	07:30-15:00	EANM Office*	4
FEBNM Certificates Handover	Sat. Oct. 21	16:00-17:00	EANM Office*	4

*Attention: exam takes place in the EANM Executive Office, Schmalzhofgasse 26, 1060 Vienna

WFNMB Meetings

	<i>Date</i>	<i>Time</i>	<i>Room</i>	<i>Level</i>
WFNMB Governing Council Meeting	Sun. Oct. 22	14:00-16:00	Room -2.61-2 (<i>Meeting Room 7</i>)	-2
WFNMB Delegates Assembly	Mon. Oct. 23	11:15-13:00	Room 0.31-2 (<i>Meeting Room 2</i>)	0

NuclearMedicine Nuklearmedizin

MOLECULAR IMAGING AND THERAPY



Submit your next paper to Nuklearmedizin
<http://mc.manuscriptcentral.com/nukmed>

- Organ der Deutschen Gesellschaft für Nuklearmedizin (DGN)
- Organ der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN)
- Organ der Schweizerischen Gesellschaft für Nuklearmedizin (SGNM, SSNM)

2018. 57. Jahrgang. 6 Hefte
ISSN 0029-5566
www.nuklearmedizin-online.de
Verfügbar:
Abstracts/Volltext/Online-Archiv

Jährliche Bezugspreise inkl. Online-Zugang*

Standard | Inkl. 9 Jahre Online-Archiv
Institute: € 642,-
Privatpersonen: € 290,-
Studierende: € 114,-
Einzelheft: € 58,-

Premium | Inkl. Online-Archiv ab 1961
Institute: € 705,-
Privatpersonen: € 318,-
Studierende: € 129,-

* inkl. Versandkosten / incl. mailing costs

Als Standes- und Fachorgan von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte **Nuklearmedizin/NuclearMedicine** mit bildgebender Diagnostik, therapeutischen nuklearmedizinischen Verfahren, Radiopharmaka und mit Themen zum Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen des Faches dar.

Berichte aus den Fachgesellschaften und den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.

Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.



www.nuklearmedizin-online.de

 **Schattauer**


Level 0

Austria Center Vienna




Level 2

Austria Center Vienna




Level -2

Austria Center Vienna




Disguising and Revealing


Ultimately it is about the game of transforming art into art



Werner Schuster draws on the possibilities that are open to him technically and thereby makes these his muse. He is the connecting link of this exhibition. Schuster illuminates and exposes. In the "Revealed" project, he emerges not merely as a researcher, but as a creator who, with the help of the technical tools at his disposal, can achieve things that we cannot. Here you can see computed tomography images, either left in the CT cross-section or reconstructed in the desired plane in 2D mode. What is concealed in art can even reveal something new. Rosa Roedelius conceals the sculptural core created by Andreas Buisman, providing it with novel form and meaning. Schuster's X-ray photography brings him inevitably to this point, and leads him to new interpretative possibilities.

Visit the Exhibition near Foyer D.





© Wiener Linien, Juli 2016





SCIENTIFIC
PROGRAMME

30th

ANNUAL SCIENTIFIC MEETING





Programme Overview Saturday, October 21, 2017

	Hall A,B,C	Meeting Room	Hall E1	Hall E2
08:00 - 08:30				
08:30 - 09:00				
09:00 - 09:30				
09:30 - 10:00				
10:00 - 10:30				
10:30 - 11:00				
11:00 - 11:30		EANM Advisory Council Meeting		
11:30 - 12:00				
12:00 - 12:30				
12:30 - 13:00				
13:00 - 13:30				
13:30 - 14:00			EANM Delegates Assembly	
14:00 - 14:30				
14:30 - 15:00				
15:00 - 15:30				
15:30 - 16:00				
16:00 - 16:30				EANM Members Assembly (first call 16:00)
16:30 - 17:00				
17:00 - 17:30				
17:30 - 18:00				
18:00 - 18:30				
19:30 - 20:30	EANM Opening Ceremony			

Hall F2

Hall K1

Hall K2

Hall G1





Hall G2

<p>Pre-Symposium 1 Physics/Dosimetry Monte Carlo Simulation / Image Reconstruction – Part I</p>	<p>Pre-Symposium 2 Oncology/ Radionuclide Therapy/EWALT Integrated Approach for the Diagnosis and Treatment of Primary Liver Tumors (HCC & CCC)</p>	<p>Pre-Symposium 3 Dosimetry/ Radiation Protection Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities</p>	<p>Pre-Symposium 4 Neuroimaging/ Drug Development/ Radiopharmacy Tau Imaging in Humans</p>	<p>Pre-Symposium 5 Radiopharmacy Validation & Risk Assessment</p>
--	--	--	---	--

<p>Pre-Symposium 6 Physics/Dosimetry Monte Carlo Simulation / Image Reconstruction – Part II</p>	<p>Pre-Symposium 7 Oncology/ Radionuclide Therapy PET Imaging for Response Assessment of Immune Modulation and Therapy</p>	<p>Pre-Symposium 8 Drug Development/ Neuroimaging The Contribution of Imaging in the Exploration of Autism</p>	<p>Pre-Symposium 9 Translational Molecular Imaging & Therapy/ Radiopharmacy/ Drug Development Bioorthogonal and Click Chemistry for Molecular Imaging</p>	<p>Pre-Symposium 10 Cardiovascular/ Inflammation & Infection Role of Nuclear Medicine in the Detection of Infection of Cardiac Prosthesis or Devices</p>
---	---	---	--	---



Programme Overview Sunday, October 22, 2017

	Hall A	Hall B	Hall C	Hall E1	Hall E2
08:00 - 08:30	101 CME 1 Physics	102 Joint Symposium 1 Oncology/ESTRO	Technologists' Opening	104 Do.MoRe	105 M2M
08:30 - 09:00	Challenges and Solutions for MR-Based Attenuation Correction of PET	Molecular PET Imaging in Adaptive Radiotherapy: Focus on Current Trends, Challenges and Solutions	103 CTE 1 Technologists/SNMMI	Radionuclide Therapy - Miscellaneous (RIT & Bone Palliation)	α-Therapy
09:00 - 09:30			Quality Control and Protocol Standardisation - Tech Guide Launch		
09:30 - 10:00					
10:00 - 10:30	201 Plenary 1 incl. Marie Curie Lecture		203 IN HALL A		
10:30 - 11:00	Theranostic Developments for Prostate Cancer		Plenary 1 incl. Marie Curie Lecture		
11:00 - 11:30			Theranostic Developments for Prostate Cancer		
11:30 - 12:00	301 CME 2	302 Joint Symposium 2	303 CTE 2	304 Do.MoRe	305 M2M
12:00 - 12:30	Inflammation & Infection/ESVS	Radionuclide Therapy/ENETS	Interactive Technologists/EARL	Modeling & Radiobiology	Antibodies
12:30 - 13:00	Vascular Graft Infection 	Establishing a Position for PRRT in the Multidisciplinary Treatment of NETs	Technologist Role in Research and EARL Accreditation		
13:00 - 14:30					
14:30 - 15:00	401 CME 3	402 Joint Symposium 3	403a Mini Course 1	404 Do.MoRe	405 M2M
15:00 - 15:30	Cardiovascular	Thyroid/ETA-CRN	Technologists	Radiopeptides for Therapy	New Targets
15:30 - 16:00	How to Perform Myocardial Perfusion Imaging According to EANM Recommendations 	Update Thyroid Cancer Beyond I-131	Cardiology: Pitfalls & Artefacts		
16:00 - 16:30			403b Mini Course 2		
16:30 - 17:00	501 CME 4	502 Joint Symposium 4	Technologists/Inflammation & Infection	504 Do.MoRe	505 M2M - Featured
17:00 - 17:30	Oncology	Dosimetry/Radiation Protection/ICRP/ICRU	Inflammation: Pitfalls & Artefacts	SPECT Quantification	Combination Therapies
17:30 - 18:00	PET in Multiple Myeloma 	Radiological Protection for Patients Receiving Radiopharmaceutical Therapy	403c Mini Course 3		
			Technologists		
			Interactive		
			Bone and Joint: Pitfalls & Artefacts		





Hall F1	Hall F2	Hall K	Hall G1	Hall G2	e-Posters
<p>106 Pitfalls & Artefacts 1 - ICC* Neuroimaging/ Physics/EFOMP Pitfalls and Artefacts in Visual vs. Quantitative Reading</p>		<p>108 Committee Symposium 1 Inflammation & Infection/ Drug Development ⁶⁸Ga-Tracers for Infection Imaging</p>		<p>110 Joint Symposium 16 Neuroimaging/JSNM Educating Referring Physicians and Recognising Their Needs</p>	<p>e-Poster Walks E-PW01, E-PW02, E-PW03</p>

<p>306 Pitfalls & Artefacts 2 - ICC* Cardiovascular Pitfalls and Artefacts with CZT Cameras</p>	<p>307 Clinical Oncology We Want a New Drug</p>		<p>309 Do.MoRe - Featured Photodynamic Therapy & Molecular Imaging – The Perfect Couple?</p>	<p>310 Conventional & Specialised Nuclear Medicine Benign Thyroid & Parathyroid Diseases</p>	
---	---	--	--	--	--

EANM Young Daily Forum	Industry Sponsored Symposium	Industry Sponsored Symposium	Industry Sponsored Symposium		
<p>406 Teaching Session 1 - ICC* Applied Cross Sectional Anatomy and Correlative Imaging – Head and Neck</p>	<p>407 Clinical Oncology Rapid Fire Session Prostate</p>		<p>409 Neurosciences Imaging Amyloid and Amyloidogenesis</p>	<p>410 Conventional & Specialised Nuclear Medicine Pulmonology & Nephrourology</p>	

<p>506 Teaching Session 2 - ICC* Applied Cross Sectional Anatomy and Correlative Imaging – Foot and Ankle</p>	<p>507 Clinical Oncology NET, a Classic!</p>	<p>508 Cardiovascular System Myocardial Function, Metabolism & Perfusion - From Preclinical to Clinical Practice</p>	<p>509 Neurosciences Imaging Neurotransmission Systems in Parkinson</p>	<p>510 Conventional & Specialised Nuclear Medicine Paediatrics</p>	
---	--	--	---	--	--

Programme Overview

Monday, October 23, 2017

	Hall A	Hall B	Hall C	Hall E1	Hall E2
08:00 - 08:30	601 CME 5 Radiopharmacy/ Drug Development/ Radionuclide Therapy/ SNMMI Theranostics and Companion Drugs CME	602 Joint Symposium 5 Cardiovascular/ESMI Imaging Cardiac Remodelling	603 Technologists Oral Presentations 1	604 Do.MoRe PSMA Therapy	605 M2M Optical/ Multimodality Imaging
08:30 - 09:00					
09:00 - 09:30					
09:30 - 10:00					
10:00 - 10:30	701 Plenary 2 Hot Topics in Nuclear Cardiology!		703 IN HALL A Plenary 2 Hot Topics in Nuclear Cardiology!		
10:30 - 11:00					
11:00 - 11:30					
11:30 - 12:00	801 CME 6 - Interactive Bone & Joint Skeletal Scintigraphy Today - Accurate Diagnosis of Bone Disease with Therapeutic Impact CME	802 Joint Symposium 6 Cardiovascular/EACVI Fast-Track Cardiac Imaging: Is There an Ideal One-Stop Shop?	803 Technologists Oral Presentations 2	804 Do.MoRe - Featured Harmonization of Hybrid Molecular Imaging	805 M2M Peptides
12:00 - 12:30					
12:30 - 13:00					
13:00 - 14:30					
14:30 - 15:00	901 CME 7 Radionuclide Therapy/Thyroid Safety Aspects in Radionuclide Therapy CME	902 Symposium 7 Bone & Joint Painful Hip Arthroplasty	903 CTE 3 Technologists Prostate Imaging and Therapy	904 Committee Symposium 4 Do.MoRe Validation of Quantitative Imaging, Dosimetry & Estimates of Uncertainty	905 M2M SPECT/CT & SPECT/MRI
15:00 - 15:30					
15:30 - 16:00					
16:00 - 16:30					
16:30 - 17:00	1001 CME 8 Radionuclide Therapy/ Radiopharmacy/ Dosimetry Clinical Trial Design for Radionuclide Therapy CME	1002 Joint Symposium 8 Neuroimaging/EANO High Grade Glioma	1003 CTE 4 Technologists/ CAMRT Radionuclide Production	1004 Do.MoRe Dosimetry in Thyroid Disease	1005 M2M PET/CT
17:00 - 17:30					
17:30 - 18:00					



Hall F1	Hall F2	Hall K	Hall G1	Hall G2	e-Posters
<p>606 Pitfalls & Artefacts 3 - ICC* Oncology/ Inflammation & Infection/Bone & Joint Pitfalls and Artefacts in Abdomen and Pelvis</p>	<p>607 Clinical Oncology Rapid Fire Session What's New? Texture Analysis and More!</p>		<p>609 Committee Symposium 2 Neuroimaging PET/MR - Making it Clinical</p>	<p>610 Conventional & Specialised Nuclear Medicine Musculoskeletal (Benign)</p>	<p>e-Poster Walks E-PW04, E-PW05, E-PW06, E-PW07, E-PW08</p>

<p>806 Pitfalls & Artefacts 4 - ICC* Paediatrics Pitfalls and Artefacts - FDG-PET Imaging in Children</p>	<p>807 Clinical Oncology Women's Only</p>	<p>808 Committee Symposium 3 Inflammation & Infection/ Neuroimaging Neurological Autoimmune Disorders</p>	<p>809 Tomorrow's Experts Session Best-Ranked Papers from the Under-30s</p>	<p>810 Committee Symposium 6 Thyroid Update on Ablative Therapies in Thyroid Nodules</p>	
--	---	--	---	---	--





EANM Young Daily Forum	Industry Sponsored Symposium	Industry Sponsored Symposium	Industry Sponsored Symposium	Industry Sponsored Symposium	
<p>906 Teaching Session 3 - ICC* Applied Cross Sectional Anatomy and Correlative Imaging – Spine</p>	<p>907 Clinical Oncology It's in the Blood</p>	<p>908 Cardiovascular System Cardiac Sarcoidosis & Amyloidosis</p>	<p>909 Neurosciences Imaging Neurodegeneration in Alzheimer's Disease by TAU and FDG Imaging</p>	<p>910 Conventional & Specialised Nuclear Medicine Infection & Inflammation</p>	

<p>1006 Teaching Session 4 - ICC* Applied Cross Sectional Anatomy and Correlative Imaging – Abdomen & Pelvis</p>	<p>1007 Joint Symposium 18 Oncology/ESMO Treatment Landscape in Metastatic CRPC</p>	<p>1008 Cardiovascular System Cardiac Sympathetic Innervation - 123I-mIBG & Arrhythmias</p>		<p>1010 Committee Symposium 5 Radiation Protection CT-Optimisation of Hybrid Imaging</p>	
--	--	---	--	---	--



Programme Overview

Tuesday, October 24, 2017

	Hall A	Hall B	Hall C	Hall E1	Hall E2
08:00 - 08:30	1101 CME 9 Paediatrics/ Inflammation & Infection	1102 Joint Symposium 9 Physics/EFOMP	1103 Technologists	1104 Do.MoRe	1105 M2M
08:30 - 09:00	FDG PET in Paediatric Infections	New Developments in CT Technology	Technologist e-Poster Sessions 1, 2, 3, 4	Preclinical & Clinical Dosimetry	Automation & Production
09:00 - 09:30					
09:30 - 10:00					
10:00 - 10:30	1201 Plenary 3		1203		
10:30 - 11:00	Radiobiology of Molecular Radiotherapy		IN HALL A Plenary 3		
11:00 - 11:30			Radiobiology of Molecular Radiotherapy		
11:30 - 12:00	1301 CME 10	1302 Joint Symposium 10	1303 Technologists	1304 Do.MoRe	1305 M2M
12:00 - 12:30	Neuroimaging	Thyroid/ESES/IFCC	Oral Presentations 3	Radiation Protection	Prostate Cancer Targeting
12:30 - 13:00	Brain PET and SPECT in Dementia - Beyond Alzheimer's Disease	Diagnosis and Treatment of Hyperthyroidism			
12:30 - 13:00					
13:00 - 14:30					
14:30 - 15:00	1401 CME 11	1402 Joint Symposium 11	1403 CTE 5	1404 Do.MoRe	1405 M2M
15:00 - 15:30	Paediatrics/ Oncology/ SIOPEN	Cardiovascular/EACVI	Technologists	Dosimetry/ Physics/AAPM	Nanoparticles
15:30 - 16:00	SSR Imaging and Therapy in Children	Quantification of Myocardial Blood Flow	Gastrointestinal Imaging	PET Auto- Segmentation: Review and Evaluation Strategies - Insights from AAPM Task Group No. 211	
15:30 - 16:00					
16:00 - 16:30					
16:30 - 17:00	1501 CME 12	1502 Joint Symposium 12	1503 CTE 6	1504 Do.MoRe	1505 Joint
17:00 - 17:30	Translational Molecular Imaging & Therapy/ Oncology/Neuroimaging	Oncology/EORTC	Technologists/ Dosimetry	Rapid Fire Session	Symposium 15
17:30 - 18:00	18F-DOPA and Radiolabelled Choline PET in Recurrent Glioblastoma	PET Criteria for Response Assessment: Quo vadis PERCIST?	Imaging, Reconstruction and ROI Analysis Techniques for Dosimetry	Radionuclide Therapy, Miscellaneous	M2M/ESMI
17:30 - 18:00					Best of European Molecular Imaging Meeting - EMIM 2017







Hall F1	Hall F2	Hall K	Hall G1	Hall G2	e-Posters
<p>1106 Pitfalls & Artefacts 5 - ICC* Oncology Pitfalls and Artefacts of PET in Neuroendocrine Tumours</p>	<p>1107 Clinical Oncology Cured or Not Cured?</p>			<p>1110 Do.MoRe Clinical Dosimetry for 90Y Radioembolization</p>	<p>Technologist e-Poster Sessions (08:00-09:30) E-TPW1, E-TPW2, E-TPW3, E-TPW4</p> <p>e-Poster Walks (08:30-09:30) E-PW09, E-PW10, E-PW11, E-PW12</p>

<p>1306 Pitfalls & Artefacts 6 - ICC* Dosimetry Pitfalls and Artefacts in Pre- and Post-Therapeutic Imaging</p>	<p>1307 Clinical Oncology Bad Brain</p>	<p>1308 Cardiovascular System Myocardial Perfusion PET - 13N-Ammonia and 15O-Water</p>		<p>1310 Do.MoRe Detector Technology</p>	
--	---	--	--	---	--

EANM Young Daily Forum	Industry Sponsored Symposium	Industry Sponsored Symposium	Industry Sponsored Symposium		
<p>1406 Teaching Session 5 - ICC* Applied Cross Sectional Anatomy and Correlative Imaging – Cross Sectional CT and PETCT for the TNM Staging of Lung Cancer</p>	<p>1407 Clinical Oncology Rapid Fire Session Mix it Up, please!</p>		<p>1409 Neurosciences Rapid Fire Session Imaging Brain Physiology in Preclinical & Clinical Models</p>	<p>1410 Do.MoRe Thyroid Cancer - Clinical</p>	

<p>1506 Teaching Session 6 - ICC* Correlative Imaging for Nuclear Medicine Specialists: Interactive Live Radiology and Nuclear Medicine Quiz Using the Experior Medical System</p>	<p>1507 Clinical Oncology In the Air & Beyond</p>	<p>1508 Cardiovascular System Myocardial Perfusion SPECT: Quantification & Artificial Intelligence</p>		<p>1510 Do.MoRe - Featured PET/MRI</p>	
--	---	--	--	--	--

Programme Overview Wednesday, October 25, 2017

	Hall A	Hall B	Hall C	Hall E1	Hall E2
08:00 - 08:30	1601 CME 13 Dosimetry/ Radionuclide Therapy/ Radiation Protection	1602 Joint Symposium 13 Paediatrics/SNMMI		1604 Do.MoRe Image Reconstruction	1605 M2M Radiolabelling Methods
08:30 - 09:00	Treatment Planning for Radionuclide Therapy, How Simple Can it Be?	Standartisation of Diuresis Renography in Children			
09:00 - 09:30					
09:30 - 10:00					
10:00 - 10:30	1701 CME 14 Dosimetry/ Radiation Protection/ Translational Molecular Imaging & Therapy	1702 Joint Symposium 14 Oncology/ESSO	1703 CTE 7 Interactive Technologists/ Paediatrics	1704 Do.MoRe Molecular Imaging Artefacts & Corrections	1705 M2M CNS/ Neurotransmission/ Brain Targets
10:30 - 11:00	Alpha Particle Dosimetry, Does High LET Lead to High RBE?	Head & Neck Cancer	Practical and Technical Aspects of Paediatric Nuclear Medicine		
11:00 - 11:30					
11:30 - 12:00					
12:00 - 12:30	1801 Awards Ceremony (11:45 - 12:15)		1803 IN HALL A		
12:30 - 13:00	Plenary 4 Highlights Lecture (12:15 - 13:15)		Awards Ceremony (11:45 - 12:15)		
13:00 - 13:30	Closing Ceremony (13:15 - 13:20)		Plenary 4 Highlights Lecture (12:15 - 13:15)		
			Closing Ceremony (13:15 - 13:20)		





Hall F1	Hall F2	Hall K	Hall G1	Hall G2	e-Posters
<p>1606 Pitfalls & Artefacts 7 - ICC* Oncology Pitfalls and Artefacts in PSMA PET Reading</p>	<p>1607 Clinical Oncology Anything Goes</p>	<p>1608 Cardiovascular System Myocardial Perfusion PET - 82-Rubidium</p>		<p>1610 Do.MoRe Dosimetry in Diagnostic Nuclear Medicine</p>	
	<p>1707 Clinical Oncology PSMA - Saving Nuclear Medicine</p>	<p>1708 Cardiovascular System Atherosclerotic Plaque Imaging</p>			

Invited Speaker Sessions

Plenary Sessions

Plenary 1: Theranostic Developments for Prostate Cancer (incl. Marie Curie Lecture)

Plenary 2: Hot Topics in Nuclear Cardiology!

Plenary 3: Radiobiology of Molecular Radiotherapy

Plenary 4: Highlights Lecture

Continuing Medical Education (CME) Sessions

CME 1: Physics: Challenges and Solutions for MR-Based Attenuation Correction of PET

CME 2: Inflammation & Infection/ESVS: Vascular Graft Infection

CME 3: Cardiovascular: How to Perform Myocardial Perfusion Imaging According to EANM Recommendations

CME 4: Oncology: PET in Multiple Myeloma

CME 5: Radiopharmacy/Drug Development/Radionuclide Therapy/SNMMI: Theranostics and Companion Drugs

CME 6: **Interactive:** Bone & Joint: Skeletal Scintigraphy Today - Accurate Diagnosis of Bone Disease with Therapeutic Impact

CME 7: Radionuclide Therapy/Thyroid: Safety Aspects in Radionuclide Therapy

CME 8: Radionuclide Therapy/Radiopharmacy/Dosimetry: Clinical Trial Design for Radionuclide Therapy

CME 9: Paediatrics/ Inflammation & Infection: FDG PET in Paediatric Infections

CME 10: Neuroimaging: Brain PET and SPECT in Dementia – Beyond Alzheimer's Disease

CME 11: Paediatrics/Oncology/SIOPEN: SSR Imaging and Therapy in Children

CME 12: Translational Molecular Imaging & Therapy/ Oncology/Neuroimaging:
18F-DOPA and Radiolabelled Choline PET in Recurrent Glioblastoma

CME 13: Dosimetry/Radionuclide Therapy/Radiation Protection:
Treatment Planning for Radionuclide Therapy, How Simple Can it Be?

CME 14: Dosimetry/Radiation Protection/Translational Molecular Imaging & Therapy:
Alpha Particle Dosimetry, Does High LET Lead to High RBE?

Continuing Technologist Education (CTE) Sessions

CTE 1:	Joint Session with SNMMI: Quality Control and Protocol Standardisation – Tech Guide Launch
CTE 2:	Interactive: Joint Session with EARL: Interactive EARL for Technologists
CTE 3:	Prostate Imaging and Therapy
CTE 4:	Joint Session with CAMRT: Radionuclide Production
CTE 5:	Gastrointestinal Imaging
CTE 6:	Joint Session with Dosimetry Committee: Imaging, Reconstruction and ROI Analysis Techniques for Dosimetry
CTE 7:	Interactive: Joint Session with Paediatrics Committee: Practical and Technical Aspects of Paediatric Nuclear Medicine
Mini Course 1:	Cardiology: Pitfalls & Artefacts
Mini Course 2:	Joint Session with Inflammation & Infection Committee: Inflammation: Pitfalls & Artefacts
Mini Course 3:	Bone and Joint: Pitfalls & Artefacts

Committee Symposia

Committee Symposium 1:	Inflammation & Infection/Drug Development: ⁶⁸ Ga Tracers for Infection Imaging
Committee Symposium 2:	Neuroimaging/Physics: PET/MR – Making it Clinical
Committee Symposium 3:	Inflammation & Infection/Neuroimaging: Neurological Autoimmune Disorders
Committee Symposium 4:	Dosimetry (Do.MoRe Track): Validation of Quantitative Imaging, Dosimetry & Estimates of Uncertainty
Committee Symposium 5:	Radiation Protection: CT-Optimisation of Hybrid Imaging
Committee Symposium 6:	Thyroid: Update on Ablative Therapies in Thyroid Nodules
Symposium 7:	Bone & Joint: Painful Hip Arthroplasty




Joint Symposia

- Joint Symposium 1: EANM/ESTRO: Molecular PET Imaging in Adaptive Radiotherapy: Focus on Current Trends, Challenges and Solutions
- Joint Symposium 2: EANM/ENETS: Establishing a Position for PRRT in the Multidisciplinary Treatment of NETs
- Joint Symposium 3: EANM/ETA-CRN: Update Thyroid Cancer Beyond I-131
- Joint Symposium 4: EANM/ICRP/ICRU: Radiological Protection for Patients Receiving Radiopharmaceutical Therapy
- Joint Symposium 5: EANM/ESMI: Imaging Cardiac Remodelling
- Joint Symposium 6: EANM/EACVI: Fast-Track Cardiac Imaging: Is There an Ideal One-Stop Shop?
- Joint Symposium 8: EANM/EANO: High Grade Glioma
- Joint Symposium 9: EANM/EFOMP: New Developments in CT Technology
- Joint Symposium 10: EANM/ESES/IFCC: Diagnosis and Treatment of Hyperthyroidism
- Joint Symposium 11: EANM/EACVI: Quantification of Myocardial Blood Flow
- Joint Symposium 12: EANM/EORTC: PET Criteria for Response Assessment: Quo Vadis PERCIST?
- Joint Symposium 13: EANM/SNMMI: Standardisation of Diuresis Renography in Children
- Joint Symposium 14: EANM/ESSO: Head & Neck Cancer
- Joint Symposium 15: EANM/ESMI: Best of European Molecular Imaging Meeting – EMIM 2017
- Joint Symposium 16: EANM/JSNM: Educating Referring Physicians and Recognising Their Needs
- Joint Symposium 18: EANM/ESMO: Treatment Landscape in Metastatic CRPC

Special Session

UEMS/EBNM: Clinical Audit Session



Teaching Sessions

Teaching Session 1:	Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Head and Neck
Teaching Session 2:	Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Foot and Ankle
Teaching Session 3:	Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Spine
Teaching Session 4:	Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Abdomen & Pelvis
Teaching Session 5:	Interactive: Applied Cross Sectional Anatomy and Correlative Imaging – Cross Sectional CT and PETCT for the TNM Staging of Cancer
Teaching Session 6:	Interactive: Correlative Imaging for Nuclear Medicine Specialists: Interactive Live Radiology and Nuclear Medicine Quiz Using the Experior Medical System

Pitfalls & Artefacts Track

Pitfalls & Artefacts 1:	Interactive: Neuroimaging/Physics/EFOMP: Pitfalls and Artefacts in Visual vs. Quantitative Reading
Pitfalls & Artefacts 2:	Interactive: Cardiovascular: Pitfalls and Artefacts with CZT Cameras
Pitfalls & Artefacts 3:	Interactive: Oncology/Inflammation & Infection/Bone & Joint: Pitfalls and Artefacts in Abdomen and Pelvis
Pitfalls & Artefacts 4:	Interactive: Paediatrics: Pitfalls and Artefacts – FDG-PET Imaging in Children
Pitfalls & Artefacts 5:	Interactive: Oncology: Pitfalls and Artefacts of PET in Neuroendocrine Tumours
Pitfalls & Artefacts 6:	Interactive: Dosimetry: Pitfalls and Artefacts in Pre- and Post-Therapeutic Imaging
Pitfalls & Artefacts 7:	Interactive: Oncology: Pitfalls and Artefacts in PSMA PET Reading



Do.MoRe

8th International Symposium on DOsimetry and MOlecular Radiotherapy

The format of the dosimetry and therapy meeting has evolved from a series of interesting and important Radiopharmaceutical and dosimetry symposia held approximately every 5 years since 1970. This series was continued at the EANM congresses 2004 (Helsinki) and at the SNM congress 2009 (Toronto). These symposia were formerly known by ISTAR: "International Symposium on Targeted Radiotherapy and Radiopharmaceutical Dosimetry". From 2015 these symposia are organised annually parallel to the EANM congress and the name has changed to Do.MoRe, emphasizing both the importance of dosimetry and the more regular organisation.

As a separate track within the EANM congress, this symposium will aim to bring together all disciplines concerned with Radiopharmaceutical Dosimetry, Physics, Radiobiology and Molecular Radiotherapy stimulating interdisciplinary scientific discussion.

As a prelude to Do.MoRe, a pre-symposium will be held on Monte Carlo based quantitative imaging reconstruction methods, focusing on PET and SPECT quantification for clinical use in dosimetry and impact of image reconstruction techniques. Another pre-symposium will highlight the added value of dosimetry guided radionuclide therapy, although at present it is seen as a great challenge to perform. Within the Do.MoRe a symposium is organised to outline the currently achievable accuracy in absorbed dose assessments and its reliability for predicting radionuclide therapy outcome.

The EANM Dosimetry, Therapy, Physics and Thyroid Committees will coordinate the scientific programme for the meeting jointly.

M2M

4th Molecule to Man Track on Basic and Translational Research in Molecular Imaging and Therapy

As a separate track within the EANM congress, we bring together all disciplines related to basic and translational research in molecular imaging and therapy, stimulating the interdisciplinary scientific discussion and educating the clinic for future developments in the field.

The format of the track consists of a series of plenary lectures, CME sessions, symposia and scientific sessions with a special focus on Basic and Translational Research.

The EANM Translational Molecular Imaging and Therapy, Drug Development, and Radiopharmacy Committees will coordinate the scientific programme for the meeting jointly.

EANM Young Daily Forum

Sun - Tue, 13:00 – 14:30

The EANM Young Daily Forum is the ideal platform for all young talents attending the EANM congress. It consists of a series of lunch-time sessions open to all participants, focusing particularly on those who are at the beginning of their career.

Each 1.5 hours' time focuses on a different hot topic, moderated in an interactive way by the professional facilitator Roy Sheppard. Participants will not only benefit from Roy's vast experience as moderator and speaker, but will also get to know new people in a relaxed atmosphere.

The first two sessions of the EANM Young Daily Forum, that made the lecture room almost burst last year, are back by popular demand. This year's programme is rounded up by a very special session that will equip participants with tools to handle their daily stress level more easily.

Sunday, October 21, 2017 | 13:00 – 14:30 | Hall F1

Presentation Skills Workshop

The key to successful presentations is more than applying solid research methods, working hard and achieving outstanding results. Preparing the right things will be as important as handling heated discussions after your presentation. Back by popular demand, the Presentation Skills Workshop will give you an insight into the secrets of delivering powerful and effective presentations.

Monday, October 22, 2017 | 13:00 – 14:30 | Hall F1

Networking - How to Build Professional Relationships

In times of global connectivity, the value of your personal network cannot be overrated. You are attending events to meet new people and to expand your professional network, but you still feel uncomfortable talking to strangers and cannot remember people's names? Or do you not consider yourself as talented 'networker' at all? In any case, this workshop will be the right one for you to attend.

Tuesday, October 23, 2017 | 13:00 – 14:30 | Hall F1

Be stronger - Mentally, emotionally, physically & spiritually

Are you constantly pushing yourself harder and harder to 'keep up' with your daily business? Do you regularly feel overwhelmed and stressed? Then you need new strategies, practical ideas and simple-to-adopt techniques which will make you more resilient and help you to cope more effectively with your current levels of stress and workload. Learn how to fully recharge your batteries and develop your personal root-system, that will keep you strong and flexible.



Pre-Congress Symposia

Saturday, October 21, 2017

Pre-Congress Symposium 1 (Physics/Dosimetry)

09:00 – 12:00, Hall F2

Monte Carlo Simulation / Image Reconstruction – Part I

Chairs: D. Visvikis (Brest), M. Ljungberg (Lund)

09:00 – 09:30	SPECT/(CT) Quantitative Reconstruction Techniques R. van Holen (Ghent)
09:30 – 10:00	Motion Detection and Correction in PET/CT and PET/MRI K. Thielemans (London)
10:00 – 10:15	Discussion
10:15 – 10:45	Coffee Break
10:45 – 11:10	Basics and Principles of 4D PET Image Reconstruction A. Reader (London)
11:10 – 11:35	TOF Reconstruction Methods and Benefits for Clinical Imaging J. Karp (Philadelphia)
11:35 – 12:00	A Focus on MLAAPET Reconstruction R. Boellaard (Groningen)

Pre-Congress Symposium 2 (EANM/EWALT)

09:00 – 12:00, Hall K1

Integrated Approach for the Diagnosis and Treatment of Primary Liver Tumours (HCC & CCC)

Chairs: E. Lopci (Milan), I. Zerizer (London)

09:00 - 09:20	Pathological Diagnosis and Molecular Predictors in Primary Liver Tumours L. Rubbia-Brandt (Genève)
09:20 - 09:40	Hepatologist Perspective on Primary Liver Tumours from Diagnosis to Prevention Y. Kallis (London)
09:40 - 10:00	Molecular Imaging with FDG and Non-FDG PET Tracers J.-N. Talbot (Paris)
10:00 - 10:20	Cross Sectional Imaging in HCC and CCC Including Novel MRI Techniques for Early Detection M. Ronot (Paris)
10:20 - 10:40	Coffee Break
10:40 - 11:00	Locoregional Treatment in Primary Liver Tumours L. Solbiati (Milan)
11:00 - 11:20	Innovative Surgical Approaches in HCC and CCC G. Torzilli (EWALT, Milan)
11:20 - 11:40	Update on Oncological Management of Cholangiocarcinoma and HCC Including Novel Agent N. Starling (London)
11:40 - 12:00	Role of Transarterial Radioembolisation in Primary Liver Tumours S. Ezzedin (Homburg)

Pre-Congress Symposium 3 (Dosimetry/Radiation Protection)

09:00 – 12:00, Hall K2

Clinical Introduction of New Radiotherapeutics: Challenges and Opportunities*Chairs: G. Flux (London), M. Konijnenberg (Rotterdam)*

09:00 – 09:15	Introduction G. Flux (London) & Mark Konijnenberg (Rotterdam)
09:15 – 09:30	Phosphorous-32 Microparticles A. Soman (Sydney)
09:30 – 09:45	Holmium-166 Microspheres F. Nijsen (Deventer)
09:45 – 10:00	Y-90 Glass Microspheres T. Mauxion (Nantes)
10:00 – 10:15	Alpha Therapy with Radium-223 and Thorium-227 J. Gay (Berlin)
10:15 – 10:45	Coffee Break
10:45 – 11:00	Treatment of NHL with Lutetium-177 Labelled Anti-CD37 Antibodies J. Dahle (Oslo)
11:00 – 11:15	Lutetium-177 Peptides and Antibodies M. Mariani (Saint-Genis-Pouilly)
11:15 – 11:30	Copper Isotopes for Imaging and Therapy M. Harris (Sydney)
11:30 – 12:00	Panel Discussion: Opportunities for Collaborations

Pre-Congress Symposium 4 (Neuroimaging/Drug Development/Radiopharmacy) 09:00 – 12:00, Hall G1**Tau Imaging in Humans***Chairs: V. Garibotto (Geneva), A. Lammertsma (Amsterdam)*

09:00 – 09:20	Tau Pathology in Tauopathies G. Kovacs (Vienna)
09:20 – 09:40	Preclinical Pharmacokinetic Modelling: A Strategy to Select and Compare Tracers? S. Krämer (Zurich)
09:40 – 10:00	Imaging Tau with 18F-THK5317 A. Nordberg (Stockholm)
10:00 – 10:15	Discussion
10:15 - 10:45	Coffee Break
10:45 - 11:05	Imaging Tau with 18F-T807 B. van Berckel (Amsterdam)
11:05 - 11:25	Imaging Tau with 11C-PBB3 and its 18F Derivatives M. Higuchi (Chiba)
11:25 - 11:45	Tau as a Therapeutic Target C. Wischik (Aberdeen)
11:45 - 12:00	Discussion



Pre-Congress Symposium 5 (Radiopharmacy)**09:00 – 12:00, Hall G2****Validation & Risk Assessment***Chairs: S. Todde (Monza), P. Kolenc Peitl (Ljubljana)*

09:00 - 09:20	Economic Impact of Qualification/Validation from Full GMP Perspective R. Suchi (Braunschweig)
09:20 - 09:40	Validation of Analytical Methods N. Mathew Gillings (Copenhagen)
09:40 - 10:00	Risk Assessment - How Much Validation is Needed? V. Ferrari (Buckinghamshire)
10:00 - 10:15	Discussion
10:15 - 10:45	Coffee Break
10:45 - 11:15	Design, Qualification and Validation of a Cyclotron Facility: It's Fun! – Practical Example L. Perk (Nijmegen)
11:15 - 11:45	Risk Assessment – Practical Example P. Colombo (Monza)
11:45 - 12:00	Discussion

Pre-Congress Symposium 6 (Dosimetry/Physics)**13:00 – 16:00, Hall F2****Monte Carlo Simulation / Image Reconstruction – Part II***Chairs: C. Hindorf (Lund), M. Ljungberg (Lund)*

13:00 – 13:15	Short Introduction to the Principles of Monte Carlo Methods D. Visvikis (Brest)
13:15 – 13:45	Monte Carlo Simulation of PET Systems S. Vandenberghe (Ghent)
13:45 – 14:15	Monte Carlo Simulation of SPECT Systems D. Sarrut (Lyon)
14:15 - 14:45	Coffee Break
14:45 – 15:15	Quality Assurance of Nuclear Medicine Procedures Using Monte Carlo Simulated Images of Virtual Patients M. Ljungberg (Lund)
15:15 – 15:40	Full Monte Carlo Based Image Reconstruction – Are we there? Part 1 H. de Jong (Utrecht)
15:40 – 15:50	Full Monte Carlo Based Image Reconstruction – Are we there? Part 2 M. Ljungberg (Lund)
15:50 – 16:00	Concluding Remarks and Panel Discussion

Pre-Congress Symposium 7 (Oncology/Radionuclide Therapy)

13:00 – 16:00, Hall K1

PET Imaging for Response Assessment of Immune Modulation and Therapy*Chairs: N. Aide (Caen), E. de Vries (Groningen)*

- | | |
|---------------|---|
| 13:00 - 13:20 | Introduction to Immune Modulation Therapy Focusing on PD1- anti PDL1 Checkpoint Inhibitors, CAR T-Cell Therapy and Vaccine Therapy
S. Lheureux (Toronto) |
| 13:20 - 13:40 | Unmet Challenges and Clinical Needs for Assessing Response to Immunotherapy
C. Le Tourneau (Paris) |
| 13:40 - 14:00 | Radiologic (CT) Aspects of Immune-Related Tumour Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Immunotherapy
L. Umutlu (Essen) |
| 14:00 - 14:15 | Discussion |
| 14:15 - 14:45 | Coffee Break |
| 14:45 - 15:05 | FDG PET Imaging for Response to Immune Modulating Therapies
E. Lopci (Milan) |
| 15:05 - 15:25 | Case Series: How to Identify Pseudo Progression and Immune Toxicities on FDG PET
R. Hicks (Melbourne) |
| 15:25 - 15:45 | New Emerging PET Probes for Monitoring Immune Modulation Therapy
E. de Vries (Groningen) |
| 15:45 - 16:00 | Panel Discussion |

Pre-Congress Symposium 8 (Drug Development/Neuroimaging)

13:00 – 16:00, Hall K2

The Contribution of Imaging in the Exploration of Autism*Chairs: L. Zimmer (Lyon), A. Gee (London)*

- | | |
|---------------|---|
| 13:00 - 13:20 | Needs in Biomarkers for Autism Spectrum Disorder
F. Bonnet-Brihault (Tours) |
| 13:20 - 13:40 | Social Brain and Autism
M. Zilbovicius (Paris) |
| 13:40 - 14:00 | What Can Bring MRI to Autism Exploration?
A. Retico (Pisa) |
| 14:00 - 14:15 | Discussion |
| 14:15 - 14:45 | Coffee Break |
| 14:45 - 15:05 | Neurotransmission Imaging in Autism
J. Borg (Stockholm) |
| 15:05 - 15:25 | New Targets and Future PET Radiotracers for Autism
A. Gee (London) |
| 15:25 - 15:45 | Discussion |



Pre-Congress Symposium 9 (Translational Molecular Imaging & Therapy / Radiopharmacy / Drug Development)**13:00 - 16:00, Hall G1****Bioorthogonal and Click Chemistry for Molecular Imaging***Chairs: B. Cornelissen (Oxford), M. Robillard (Nijmegen)*

13:00 - 13:35	The Basics of Click Chemistry V. Bouvet (St John's)
13:35 - 14:05	Click Chemistry for Imaging of Glycoconjugates V. Wittmann (Konstanz)
14:05 - 14:15	Discussion
14:15 - 14:45	Coffee Break
14:45 - 15:15	Imaging and Therapy Agents Using Click Chemistry M. Robillard (Nijmegen)
15:15 - 15:45	Pre-Targeted Imaging Using Click Chemistry J. Knight (Oxford)
15:45 - 16:00	Discussion

Pre-Congress Symposium 10 (Cardiovascular/Inflammation and Infection) 13:00 – 16:00, Hall G2**Role of Nuclear Medicine in the Detection of Infection of Cardiac Prosthesis or Devices***Chairs: O. Gheysens (Leuven), F. Hyafil (Paris)*

13:00 - 13:25	Clinical Challenges in Establishing the Diagnosis Endocarditis J. Ambrosioni (Barcelona)
13:25 - 13:50	Role of Echocardiography in the Diagnosis of Endocarditis R. Dulgheru (Liège)
13:50 - 14:15	Role of White Blood Cell Scintigraphy in the Diagnosis of Endocarditis P. Erba (Pisa)
14:15 - 14:45	Coffee Break
14:45 - 15:10	Role of FDG-PET Imaging in the Diagnosis of Endocarditis F. Rouzet (Paris)
15:10 - 15:35	Role of CTA and MRI in the Diagnosis of Endocarditis G. Feuchtner (Innsbruck)
15:35 - 16:00	Is There an Optimal Imaging Strategy for Patients Suspected for Endocarditis? F. Hyafil (Paris)

ESMIT

European School of Multimodality Imaging and Therapy

ESMIT Schools 2018

Level
2



Winter School

February 23 – 25, 2018
Bergamo/IT

Level
2



Spring School

May 4 – 6, 2018
Ghent/BE

Level
2



Autumn School

September 7 – 9, 2018
Belgrade/RS

The **ESMIT initiative** represents EANM's response to huge changes in the educational needs of the nuclear medicine community and the rising demand for greater multimodality content. The EANM is convinced that the community needs not only to be educated on all modalities that are used in imaging, but also to be well prepared in the therapeutic applications of our discipline.

More information at eanm.org/esmit or contact us at esmit@eanm.org

PS1 Saturday, October 21, 2017, 09:00 - 12:00, Hall F2**Pre-Congress Symposium 1 -
Monte Carlo Simulation /
Image Reconstruction – Part I**

*Chairs: D. Visvikis (Brest, FRANCE)
M. Ljungberg (Lund, SWEDEN)*

**PS01
SPECT/(CT) Quantitative Reconstruction
Techniques**

*R. van Holen; Ghent University, Department of
Electronics and Information Systems, Ghent, BELGIUM*

**PS02
Motion Detection and Correction in PET/CT and
PET/MRI**

*K. Thielemans; University College London, UCL
Hospital, Institute of Nuclear Medicine, London, UNITED
KINGDOM.*

**PS05
Basics and Principles of 4D PET Image
Reconstruction**

*A. Reader; King's College London, Biomedical
Engineering Department, London, UNITED KINGDOM.*

**PS06
TOF Reconstruction Methods and Benefits for
Clinical Imaging**

*J. Karp; University of Pennsylvania school of Arts and
Sciences, Department of Radiology, Philadelphia,
UNITED STATES OF AMERICA.*

**PS07
A Focus on MLAAPET Reconstruction**

*R. Boellaard; University of Groningen, Center for
Medical Imaging, Groningen, NETHERLANDS.*

PS2 Saturday, October 21, 2017, 09:00 - 12:00, Hall K1**Pre-Congress Symposium 2 -
EANM/EWALT: Integrated Approach
for the Diagnosis and Treatment of
Primary Liver Tumours (HCC & CCC)**

*Chairs: E. Lopci (Milan, ITALY)
I. Zerizer (London, UNITED KINGDOM)*

**PS08
Pathological Diagnosis and Molecular Predictors
in Primary Liver Tumours**

*L. Rubbia-Brandt; Hôpitaux Universitaires de Genève,
Service de Pathologie Clinique, Geneva, SWITZERLAND.*

**PS09
Hepatologist Perspective on Primary Liver
Tumours from Diagnosis to Prevention**

*Y. Kallis; Barts and the London School of Medicine and
Dentistry, Queen Mary University London, London,
UNITED KINGDOM..*

**PS10
Cross Sectional Imaging in HCC and CCC Including
Novel MRI Techniques for Early Detection**

*M. Ronot; Department of Radiology, Beaujon Hospital,
AP-HP, Paris, FRANCE*

**PS11
Molecular Imaging with FDG and Non-FDG PET
Tracers**

*J.-N. Talbot; Hospital Tenon, AP-HP & Université P&M
Curie, Paris, FRANCE.*

**PS13
Locoregional Treatment in Primary Liver Tumours**

*L. A. Solbiati; Department of Biomedical Sciences -
Humanitas University, Milan, ITALY.*

**PS14
Innovative Surgical Approaches in HCC and CCC**

*G. Torzilli; Humanitas University, School of Medicine,
Humanitas Research Hospital, IRCCS, Milan, ITALY.*

**PS15
Update on Oncological Management of Cholan-
giocarcinoma and HCC Including Novel Agent**

*N. Starling; The Royal Marsden, London, UNITED
KINGDOM.*

**PS16
Role of Transarterial Radioembolisation in
Primary Liver Tumours**

*S. Ezzedin; Universitätsklinikum des Saarlandes, Klinik
für Nuklearmedizin, Homburg, GERMANY.*



PS3 Saturday, October 21, 2017, 09:00 - 12:00, Hall K2

Pre-Congress Symposium 3 -
Clinical Introduction of New
Radiotherapeutics: Challenges and
Opportunities



Chairs: G. Flux (London, UNITED KINGDOM)
M. Konijnenberg (Rotterdam, NETHERLANDS)

PS17**Introduction**

G. Flux; Royal Marsden NHS Trust & Institute of Cancer
Research, London, UNITED KINGDOM.

PS18**Phosphorous-32 Microparticles**

A. Soman; Oncosil medical Ltd, Sydney, AUSTRALIA.

PS19**Holmium-166 Microspheres**

F. Nijssen; Quirem Medical, Groningen, NETHERLANDS.

PS20**Y-90 Glass Microspheres**

T. Mauxion; BTG, Nantes, FRANCE.

PS21**Alpha Therapy with Radium-223 and
Thorium-227**

J. Gay; Bayer Healthcare, Berlin, GERMANY.

PS23**Treatment of NHL with Lutetium-177 Labelled
Anti-CD37 Antibodies**

J. Dahle; Nordic Nanovector, Oslo, NORWAY.

PS24**Lutetium-177 Peptides and Antibodies**

M. Mariani; Advanced Accelerator Applications, Saint-
Genis-Pouilly, FRANCE.

PS25**Copper Isotopes for Imaging and Therapy**

M. Harris; Clarity Pharmaceuticals, Sydney, AUSTRALIA.

PS4 Saturday, October 21, 2017, 09:00 - 12:00, Hall G1

Pre-Congress Symposium 4 -
Tau Imaging in Humans



Chairs: V. Garibotto (Geneva, SWITZERLAND)
A. Lammertsma (Amsterdam, NETHERLANDS)

PS27**Tau Pathology in Tauopathies**

G. Kovacs; Institute of Neurology, Medical University
Vienna, Vienna, AUSTRIA.

PS28**Preclinical Pharmacokinetic Modelling: A
Strategy to Select and Compare Tracers?**

S. Krämer; ETH Zurich, Institute of Pharmaceutical
Sciences, Zurich, SWITZERLAND.

PS29**Imaging Tau with 18F-THK5317**

A. Nordberg; Center for Alzheimer Research, Karolinska
Institutet, Stockholm, SWEDEN.

PS32**Imaging Tau with 18F-T807**

T. Timmers; VUMC, Amsterdam, NETHERLANDS.

PS33**Imaging Tau with 11C-PBB3 and its 18F
Derivatives**

M. Higuchi; National Institutes for Quantum and
Radiological Science and Technology National Institute
of Radiological Sciences, Chiba, JAPAN.

PS34**Tau as a Therapeutic Target**

C. Wischik; School of Medicine, Medical Sciences and
Nutrition, University of Aberdeen, Aberdeen, UNITED
KINGDOM.



PS5 Saturday, October 21, 2017, 09:00 - 12:00, Hall G2**Pre-Congress Symposium 5 -
Validation & Risk Assessment**

Chairs: S. Todde (Monza, ITALY)
P. Kolenc Peitl (Ljubljana, SLOVENIA)

PS36**Economic Impact of Qualification/Validation
from Full GMP Perspective**

R. Suchi; GE Healthcare Buchler GmbH & Co. KG,
Braunschweig, GERMANY.

PS37**Validation of Analytical Methods**

N. M. Gillings; Copenhagen University Hospital,
Rigshospitalet, PET & Cyclotron Unit, Copenhagen,
DENMARK.

PS38**Risk Assessment - How Much Validation is
Needed?**

V. Ferrari; The Grove Centre, QA department,
Amersham, Buckinghamshire, UNITED KINGDOM.

PS41**Design, Qualification and Validation of a
Cyclotron Facility: It's Fun! – Practical Example**

L. Perk; Radboud University Medical Center, Radboud
Translational Medicine, Nijmegen, NETHERLANDS.

PS42**Risk Assessment – Practical Example**

P. Colombo; IBA Molecular Italy, San Gerardo dei Tintori
Hospital, Monza, ITALY.

PS6 Saturday, October 21, 2017, 13:00 - 16:00, Hall F2**Pre-Congress Symposium 6 -
Monte Carlo Simulation /
Image Reconstruction – Part II**

Chairs: C. Hindorf (Lund, SWEDEN)
M. Ljungberg (Lund, SWEDEN)

PS44**Short Introduction to the Principles of Monte
Carlo Methods**

D. Visvikis; CHU MORVAN, Bat 2 bis, U650 INSERM,
LaTIM - I35, Brest, FRANCE.

PS45**Monte Carlo Simulation of PET Systems**

S. Vandenberghe; Ghent University, Department of
Electronics and information systems, Ghent, BELGIUM.

PS46**Monte Carlo Simulation of SPECT Systems**

D. Sarrut; Léon Bérard cancer center, CREATIS, Lyon,
FRANCE.

PS48**Quality Assurance of Nuclear Medicine
Procedures Using Monte Carlo Simulated
Images of Virtual Patients**

M. Ljungberg; Lund University, Medical Radiation
Physics, Lund, SWEDEN.

PS49**Full Monte Carlo Based Image Reconstruction –
Are we there? Part 1**

H. de Jong; University Medical Center Utrecht, Image
Sciences Institute, Utrecht, NETHERLANDS.

PS50**Full Monte Carlo Based Image Reconstruction –
Are we there? Part 2**

M. Ljungberg; Lund University, Medical Radiation
Physics, Lund, SWEDEN.

PS7 Saturday, October 21, 2017, 13:00 - 16:00, Hall K1**Pre-Congress Symposium 7 -
PET Imaging for Response
Assessment of Immune
Modulation and Therapy**

*Chairs: N. Aide (Caen, FRANCE)
E. de Vries (Groningen, NETHERLANDS)*

PS52**Introduction to Immune Modulation Therapy
Focusing on PD1- anti PDL1 Checkpoint
Inhibitors, CART-Cell Therapy and Vaccine
Therapy**

*S. Lheureux; Princess Margaret Hospital, Toronto,
CANADA.*

PS53**Unmet Challenges and Clinical Needs for
Assessing Response to Immunotherapy**

*C. Le Tourneau; Oncology Department Curie Institute,
Paris, FRANCE.*

PS54**Radiologic (CT) Aspects of Immune-Related
Tumour Response Criteria and Patterns of
Immune-Related Adverse Events in Patients
Undergoing Immunotherapy**

*L. Umutlu; Radiology Department, University Hospital,
Essen, GERMANY.*

PS57**FDG PET Imaging for Response to Immune
Modulating Therapies**

*E. Lopci; Istituto Clinico Humanitas IRCCS, Nuclear
Medicine Department, Milano, ITALY.*

PS58**Case Series: How to Identify Pseudo Progression
and Immune Toxicities on FDG PET**

*R. Hicks; Cancer Imaging, Peter Mac Callum Cancer
Institute, Melbourne, AUSTRALIA.*

PS59**New Emerging PET Probes for Monitoring
Immune Modulation Therapy**

*E. de Vries; University Medical Centre, Medical
Oncology Department, Groningen, NETHERLANDS.*

PS8 Saturday, October 21, 2017, 13:00 - 16:00, Hall K2**Pre-Congress Symposium 8 -
The Contribution of Imaging in
the Exploration of Autism**

*Chairs: L. Zimmer (Lyon, FRANCE)
A. Gee (London, UNITED KINGDOM)*

PS61**Needs in Biomarkers for Autism Spectrum
Disorder**

*F. Bonnet-Brihau; University Hospital of Tours, INSERM,
Department of Child Psychiatry, Tours, FRANCE.*

PS62**Social Brain and Autism**

*M. Zilbovicius; University René Descartes, INSERM,
Hôpital Necker, Department of Pediatric Radiology,
Paris, FRANCE.*

PS63**What Can Bring MRI to Autism Exploration?**

*A. Retico; Istituto Nazionale di Fisica Nucleare,
University of Pisa, Pisa, ITALY.*

PS66**Neurotransmission Imaging in Autism**

*J. Borg; Karolinska Institutet, Centre for Psychiatric
Research, Stockholm, SWEDEN.*

PS67**New Targets and Future PET Radiotracers for
Autism**

*A. Gee; King's College London, Division of Imaging
Sciences, London, UNITED KINGDOM.*



**PS9 Saturday, October 21, 2017, 13:00 - 16:00, Hall G1****Pre-Congress Symposium 9 -
Bioorthogonal and Click Chemistry
for Molecular Imaging**

Chairs: B. Cornelissen (Oxford, UNITED KINGDOM)
M. Robillard (Nijmegen, NETHERLANDS)

PS69**The Basics of Click Chemistry**

V. Bouvet; Memorial University of Newfoundland,
Department of Radiology, St. John's, St. John's,
CANADA.

PS70**Click Chemistry for Imaging of Glycoconjugates**

V. Wittmann; Universitaet Konstanz, Konstanz,
GERMANY.

PS73**Imaging and Therapy Agents Using Click
Chemistry**

M. Robillard; Tagworks Pharmaceuticals, Nijmegen,
NETHERLANDS.

PS74**Pre-Targeted Imaging Using Click Chemistry**

J. Knight; University of Oxford, Department of
Oncology, Oxford, UNITED KINGDOM.

PS10 Saturday, October 21, 2017, 13:00 - 16:00, Hall G2**Pre-Congress Symposium 10 -
Role of Nuclear Medicine in the
Detection of Infection of Cardiac
Prosthesis or Devices**

Chairs: O. Gheysens (Leuven, BELGIUM)
F. Hyafil (Paris, FRANCE)

PS76**Clinical Challenges in Establishing the Diagnosis
Endocarditis**

J. Ambrosioni; Hospital Clinic - IDIBAPS, University of
Barcelona, Barcelona, SPAIN.

PS77**Role of Echocardiography in the Diagnosis of
Endocarditis**

R. Dulgheru; Department of Cardiology, University of
Liège Hospital, GIGA-Cardiovascular Sciences, Liège,
BELGIUM.

PS78**Role of White Blood Cell Scintigraphy in the
Diagnosis of Endocarditis**

P. Erba; Nuclear Medicine, Department of Translational
Research and New Technology in Medicine, University
of Pisa, Pisa, ITALY.

PS80**Role of FDG-PET Imaging in the Diagnosis of
Endocarditis**

F. Rouzet; Nuclear Medicine Department and
Département Hospitalo Universitaire Fibrose
Inflammation et Remodelage en Pathologies
Cardiovasculaires, Bichat Claude Bernard Hospital,
AP-HP, University of Paris VII, Paris, FRANCE.

PS81**Role of CTA and MRI in the Diagnosis of
Endocarditis**

G. Feuchtner; Department of Radiology, Innsbruck
Medical University, Innsbruck, AUSTRIA.

PS82**Is There an Optimal Imaging Strategy for
Patients Suspected for Endocarditis?**

F. Hyafil; CHU Bichat, AP-HP, Nuclear Medicine, PARIS,
FRANCE.

101 Sunday, October 22, 2017, 08:00 - 09:30, Hall A**CME 1 - Physics: Challenges and Solutions for MR-Based Attenuation Correction of PET***Chairs: S. Vandenberghe (Ghent, BELGIUM)
S. Nekolla (Munich, GERMANY)***OP-001****Introduction to MR-Based AC***L. Eikenes; Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, NORWAY.***OP-002****MR Based Attenuation Correction for Brain***N. Burgos; University College London, Translational Imaging Group, London, UNITED KINGDOM.***OP-003****MR Based Attenuation Correction for the Body***G. Schramm; University of Leuven, Nuclear Medicine & Molecular Imaging, Leuven, BELGIUM.***102 Sunday, October 22, 2017, 08:00 - 09:30, Hall B****Joint Symposium 1 - EANM/ESTRO: Molecular PET Imaging in Adaptive Radiotherapy: Focus on Current Trends, Challenges and Solutions***Chairs: A. Loft (Copenhagen, DENMARK)
E. Troost (Dresden, GERMANY)***OP-004****Prostate Cancer: The Radiation Oncologist's Point of View***W. Vogel; The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Departments of Nuclear Medicine and Radiation Oncology, Amsterdam, NETHERLANDS.***OP-005****Prostate Cancer: The Nuclear Medicine Physician's Point of View***M. Picchio; IRCCS San Raffaele Scientific Institute, Nuclear Medicine Department, Milan, ITALY.***OP-006****Cervical Cancer: The Radiation Oncologist's Point of View***E. Troost; Universitätsklinikum Carl Gustav Carus, Department of Radiotherapy and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, GERMANY.***OP-007****Cervical Cancer: The Nuclear Medicine Physician's Point of View***J. A. Adam; Academic Medical Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.***103 Sunday, October 22, 2017, 08:00 - 09:45, Hall C****CTE 1 - Joint Session with SNMMI: Quality Control and Protocol Standardisation - Tech Guide Launch***Chairs: S. Rep (Ljubljana, SLOVENIA)
D. Gilmore (Boston, UNITED STATES OF AMERICA)***OP-008****Welcome and Opening of the Technologist's Track****OP-009****Quality Control for PET Systems***C. Pestean; Dept. of Nuclear Medicine, "Ion Chiricuța" Oncology Institute, Cluj-Napoca, ROMANIA.***OP-010****Optimisation of PET-CT – Acquisition & Reconstruction***D. M. York; Chattanooga State Community College, Chattanooga, UNITED STATES OF AMERICA.***OP-011****Radionuclide Dose Calibrator***A. Socan; Department of Nuclear Medicine; University Medical Center, Ljubljana, SLOVENIA.***104 Sunday, October 22, 2017, 8:00 - 9:30, Hall E1****Do.MoRe: Radionuclide Therapy - Miscellaneous (RIT & Bone Palliation)***Chairs: M. Lassmann (Wurzburg, GERMANY)
F. Kraeber-Bodéré (Nantes, FRANCE)***OP-012****Pre-dosing with Lilotomab Prior to Antibody-Radionuclide Conjugate Therapy with ¹⁷⁷Lu-Lilotomab Satetraxetan Significantly Increases the Ratio of Tumour to Red Marrow Absorbed Dose in non-Hodgkin Lymphoma Patients***J. Blakkisrud¹, A. Løndalen², J. Dahle³, A. C. Martinsen^{4,1}, H. Holte⁵, A. Kolstad⁵, C. Stokke^{1,6}; ¹Department of Diagnostic Physics, Oslo University Hospital, Oslo, NORWAY, ²Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, ³Nordic Nanovector ASA, Oslo, NORWAY, ⁴The Department of Physics, University of Oslo, Oslo, NORWAY, ⁵Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, NORWAY, ⁶Oslo and Akershus University College of Applied Science, Oslo, NORWAY.*

OP-013**Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer - a pilot study**

K. Scheidhauer¹, C. Seidl¹, F. Bruchertseifer², C. Apostolidis², M. Autenrieth¹, F. Kurtz¹, T. Horn¹, M. Schwaiger¹, J. Gschwend¹, C. D'Alessandria¹, C. Pfohl¹, R. Senekowitsch-Schmidtke¹, A. Morgenstern²; ¹Technische Universität München, München, GERMANY, ²EC, JRC, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.

OP-014**Synfrizz : A first in Man study investigating the biodistribution, the safety and optimal recommended dose of a new radiolabeled monoclonal antibody targeting Frizzled homolog 10 (FZD10) in patients with relapsed or refractory non resectable synovial sarcomas**

A. Giraudet¹, P. Cassier¹, G. Garin¹, J. Badel¹, S. Baconnier¹, D. Sarrut², D. Kryza³, C. Iwao-Fukukawa⁴, Y. Nakamura⁵, A. Halty⁶, D. Perol¹, J. Blay¹; ¹Centre Léon Bérard, Lyon, FRANCE, ²Créatis, Lyon, FRANCE, ³UCBL1, Lyon, FRANCE, ⁴OncoTherapy Science, Kawasaki City, JAPAN, ⁵University of Tokyo, Tokyo, JAPAN, ⁶Créatis, Lyon, FRANCE.

OP-015**Radioimmunotherapy with Panitumumab Modified with Metal Chelating Polymers (MCP) Labeled with ¹¹¹In and ¹⁷⁷Lu - A Novel Theranostic for Pancreatic Cancer**

S. Aghevlian¹, D. Hedley², M. Winnik³, R. Reilly^{1,4,5}; ¹Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, CANADA, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA, ³Department of Chemistry, University of Toronto, Toronto, ON, CANADA, ⁴Toronto General Research Institute and Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA, ⁵Department of Medical Imaging, University of Toronto, Toronto, ON, CANADA.

OP-016**Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer: Therapy Assessment with 11C-choline PET/CT and Bone Scan**

P. Ghedini¹, T. Graziani¹, E. Lodi Rizzini¹, G. Lima¹, I. Bossert², F. Ceci¹, G. Montini¹, C. Pettinato³, F. Monari⁴, V. Dionisi⁵, A. Morganti⁴, P. Castellucci¹, S. Fanti¹; ¹Nuclear Medicine S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, ²Nuclear Medicine & Physics Unit, Fondazione Salvatore Maugeri, Pavia, ITALY, ³Fisica Sanitaria - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, ⁴U.O. Radioterapia - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, ⁵U.O. Radioterapia - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, Bologna, ITALY.

OP-017**Quantification of skeletal tumor burden on bone scintigraphy for prediction of overall survival in Radium-223 therapy**

M. Ø. Fosbøl, P. M. Petersen, A. Kjaer, J. Mortensen; Rigshospitalet, Copenhagen, DENMARK.

OP-018**Radium-223 in Combination with Paclitaxel in Cancer Patients with Bone Metastases: Safety Results from an Open-Label, Multicenter Phase 1b Study**

J. S. Lopez¹, R. Perets², S. Danson³, H. Joensuu⁴, A. Peer², S. J. Harris¹, F. Souza⁵, B. Ploeger⁶, K. M. C. Pereira⁷, R. Geva⁸; ¹The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UNITED KINGDOM, ²Rambam Health Care Campus, Haifa, ISRAEL, ³Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, UNITED KINGDOM, ⁴Helsinki University Hospital, Helsinki, FINLAND, ⁵Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA, ⁶Bayer Pharma AG, Berlin, GERMANY, ⁷Bayer Pharma AG, São Paulo, BRAZIL, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAEL.

OP-019**Analysis of Clinical parameters for the outcome prediction of mCRPC patients treated with ²²³Ra-dichloride**

V. Frantellizzi, G. A. Follacchio, S. Sollaku, J. Lazri, A. Farcomeni, M. Pacilio, M. Liberatore, F. Monteleone, G. De Vincentis; Sapienza University of Rome, Rome, ITALY.

105 Sunday, October 22, 2017, 08:00 - 09:30, Hall E2

M2M: α-Therapy

Chairs: V. Cavelliers (Brussels, BELGIUM)
J. Nonnekens (Rotterdam, NETHERLANDS)

OP-020**Preclinical evaluation of astatinated nanobodies for targeted alpha therapy**

Y. D. Dekempeneer^{1,2}, M. D'Huyvetter¹, E. Aneheim³, C. Xavier¹, T. Lahoutte^{1,4}, T. Bäck³, H. Jensen⁵, V. Cavelliers^{1,4}, S. Lindegren³; ¹Vrije Universiteit Brussel, Jette/Brussel, BELGIUM, ²Belgian Nuclear Research Center (SCK-CEN), Mol, BELGIUM, ³Targeted Alpha Therapy group, University of Gothenburg, Gothenburg, SWEDEN, ⁴Nuclear Medicine Department (UZBrussel), Jette/Brussel, BELGIUM, ⁵Cyclotron and PET Unit, Copenhagen, DENMARK.

OP-021**Locoregional alpha-RIT, a novel therapeutic option, against peritoneal metastasis of gastric cancer**

H. K. Li^{1,2,3}, Y. Morokoshi³, S. Hasegawa³; ¹Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, JAPAN, ²Research Fellow of Japan Society for the Promotion of Science, Tokyo, JAPAN, ³National Institute of Radiological Sciences, QST, Japan, Chiba, JAPAN.

OP-022**Re-localization of ²¹²Pb from ²²⁴Ra sources due to thoron (²²⁰Rn) diffusion**

E. Napoli^{1,2,3}, S. Westrøm^{1,2,3}, T. B. Bønsdorff³, Ø. S. Bruland^{1,2,3}, R. H. Larsen⁴; ¹University of Oslo, Oslo, NORWAY, ²The Norwegian Radium Hospital, Oslo, NORWAY, ³Oncoinvent AS, Oslo, NORWAY, ⁴Sciencons AS, Oslo, NORWAY.

OP-024**Novel Intracavitary α -Therapeutic Based on Calcium Carbonate Microparticles As Carriers for ²²⁴Ra: Biodistribution and Toxicity in Mice**

S. Westrøm^{1,2,3}, T. B. Bønsdorff³, M. M. Malenge³, Ø. S. Bruland^{1,2,3}, R. H. Larsen⁴; ¹University of Oslo, Oslo, NORWAY, ²The Norwegian Radium Hospital, Oslo University Hospital, Oslo, NORWAY, ³Oncoinvent AS, Oslo, NORWAY, ⁴Sciencons AS, Oslo, NORWAY.

OP-025**A Novel Multi-Component Reaction for ²¹¹At-Astatination: Providing new Tools for (pre) Targeted Alpha Therapy**

C. Denk¹, E. H. K. Aneheim², S. Lindegren², M. Herth^{3,4}, M. Wilkovitsch¹, H. Mikula¹; ¹Vienna University of Technology, Vienna, AUSTRIA, ²The Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ³Ringhospitalet, Copenhagen, DENMARK, ⁴University of Copenhagen, Copenhagen, DENMARK.

OP-026**Bismuth-213 labeled nanobodies as a new treatment approach in Targeted Alpha Therapy**

Y. Dekempeneer, Jr.^{1,2}, D. Maertens², M. Gysemans², T. Lahoutte^{1,3}, M. D'Huyvetter¹, T. Cardinaels^{2,4}, V. Caveliers^{1,3}; ¹Vrije Universiteit Brussel, Jette/Brussel, BELGIUM, ²Belgian Nuclear Research Center (SCK•CEN), Mol, BELGIUM, ³Department of Nuclear Medicine (UZBrussel), Jette/Brussel, BELGIUM, ⁴Department of Chemistry (KU Leuven), Leuven, BELGIUM.

106 Sunday, October 22, 2017, 08:00 - 09:30, Hall F1**Pitfalls & Artefacts 1 (Interactive) - Neuroimaging/Physics/EFOMP: Pitfalls and Artefacts in Visual vs. Quantitative Reading**

Chairs: S. Pappata (Naples, ITALY)
M. Brambilla (Novara, ITALY)

OP-027**Instrumentation Induced Artefacts in PET and SPECT**

N. Belcari; University of Pisa, Pisa, ITALY

OP-028**Brain FDG PET**

S. D. Morbelli; San Martino Hospital, Genoa, ITALY

OP-029**DAT SPECT**

P. Payoux; Centre Hospitalier Universitaire Purpan, Toulouse, FRANCE

OP-030**Amyloid PET**

J. Arbizu; Clinica Universidad de Navarra, University of Navarra, Pamplona, SPAIN

108 Sunday, October 22, 2017, 08:00 - 09:30, Hall K**Committee Symposium 1 - Inflammation & Infection/Drug Development: ⁶⁸Ga-Tracers for Infection Imaging**

Chairs: G. Bormans (Leuven, BELGIUM)
O. Gheysens (Leuven, BELGIUM)

OP-031**Advantages and Possibilities of ⁶⁸Gallium Tracers**

I. Velikyan; Uppsala University, Dep. of Medicinal Chemistry, Uppsala, SWEDEN.

OP-032**⁶⁸Ga-Ubiquitin**

M. Sathekge; University of Pretoria and Steve Biko Academic Hospital, Dep. of Nuclear Medicine, Pretoria, SOUTH AFRICA.

OP-033**⁶⁸Ga-Biotin**

E. Lazzeri; Regional Center of Nuclear Medicine AOUP, Pisa, ITALY.

OP-034**⁶⁸Ga-Citrate**

C. Nanni; Policlinico S.Orsola-Malpighi, Department of Nuclear Medicine, Bologna, ITALY.



**110 Sunday, October 22, 2017, 08:00 - 09:30, Hall G2****Joint Symposium 16 - EANM/JSNM:
Educating Referring Physicians and
Recognising Their Needs**

Chairs: M. Hosono (Osaka-Sayama, JAPAN)
S. Hesse (Leipzig, GERMANY)

OP-036**Increasing the Reliance of Referring Physicians
on Nuclear Cardiology: A Cardiologist's
Perspective**

*T. Chikamori; Department of Cardiology, Tokyo
Medical University, Tokyo, JAPAN.*

OP-037**The Role of PET for Selecting Surgical
Candidates and Deciding a Mode of Surgery for
Lung Cancer**

*K. Suzuki; Department of General Thoracic Surgery,
Juntendo University School of Medicine, Tokyo, JAPAN.*

OP-038**The Integration of Dementia Molecular Imaging
into Clinical Management**

*V. Garibotto; Geneva University and Geneva University
Hospitals, Geneva, SWITZERLAND.*

201/203 Sunday, October 22, 2017, 10:00 - 11:15, Hall A**Plenary 1: Theranostic Developments for
Prostate Cancer (incl. Marie Curie Lecture)**

Chairs: K. Muylle (Brugge, BELGIUM)
F. Giammarile (Lyon, FRANCE)

OP-040**Clinical Aspects**

*J. Walz; Institute Paoli-Calmettes, Dept. of Urology,
Marseille, FRANCE.*

OP-041**PSMA Imaging – Which Knife is the Sharpest?**

*K. Herrmann; Universitätsklinikum Würzburg, Nuclear
Medicine, Würzburg, GERMANY.*

OP-042**PSMA Labelled with Alfa-Emitters**

*U. Haberkorn; University Hospital Heidelberg,
Department of Nuclear Medicine, Heidelberg,
GERMANY.*

301 Sunday, October 22, 2017, 11:30 - 13:00, Hall A**CME 2 - Inflammation &
Infection/ESVS: Vascular Graft
Infection**

Chairs: A. Signore (Rome, ITALY)
N. Chakfé (Strasbourg, FRANCE)

OP-043**Importance of Imaging Vascular Graft Infections
in Clinical Practice**

*N. Chakfé; University Hospital of Strasbourg,
Department of Vascular Surgery and Kidney
Transplantation, Strasbourg, FRANCE.*

OP-044**Radiological Possibilities in Vascular Graft
Infections**

*L. Marques; Ev.-Luth. Diakonissenanstalt zu Flensburg
In guten Händen, Flensburg, GERMANY.*

OP-045**Nuclear Medicine Possibilities in Vascular Graft
Infections**

*C. Lauri; "Sapienza" University, Osepdale S. Andrea,
Nuclear Medicine Unit, Faculty of Medicine and
Psychology, Dept. of Medical-Surgical Sciences and
Translational Medicine, Rome, ITALY.*

302 Sunday, October 22, 2017, 11:30 - 13:00, Hall B**Joint Symposium 2 - EANM/ENETS:
Establishing a Position for PRRT in the
Multidisciplinary Treatment of NETs**

Chairs: L. Bodei (New York, UNITED STATES OF AMERICA)
D. O'Toole (Dublin, IRELAND)

OP-046**Current Status of PRRT in the Post-NETTER1
Phase**

*L. Bodei; Memorial Sloan Kettering Cancer Center, New
York, UNITED STATES OF AMERICA.*

OP-047**Lessons from the Various Clinical Trials in NETs:
Evidence-Based Results and Post-Hoc Analysis**

*M. Pavel; Campus Virchow-Klinikum Charité, Centrum
13, Berlin, GERMANY.*

OP-048**Where does PRRT fit in?**

*D. O'Toole; Trinity College Dublin, the University of
Dublin, St James's Hospital & National Centre for
Neuroendocrine Tumours | St Vincent's University
Hospital, Dublin, IRELAND.*

303 Sunday, October 22, 2017, 11:30 - 13:00, Hall C**CTE 2 - Joint Session with EARL: Technologist Role in Research and EARL Accreditation***Chairs: R. Boellaard (Groningen, NETHERLANDS)
G. Testanera (London, UNITED KINGDOM)***OP-049****Research Opportunities as a Nuclear Medicine Technologist***K. Pathmaraj; Austin Health Melbourne, Department of Molecular Imaging and Therapy, Melbourne, AUSTRALIA.***OP-050****EARL Accreditation Projects and Possible Evolution***R. Boellaard; University of Groningen, Center for Medical Imaging, Groningen, NETHERLANDS.***OP-051****Technologist Involvement in Accreditation and Future Directions***G. Testanera; Department of Nuclear Medicine, Barts Health NHS Trust, London, UNITED KINGDOM.***304 Sunday, October 22, 2017, 11:30 - 13:00, Hall E1****Do.MoRe: Modeling & Radiobiology***Chairs: M. Bardiès (Toulouse, FRANCE)
U. Eberlein (Würzburg, GERMANY)***OP-053****DNA damage in blood leukocytes after internal in-vitro irradiation of blood with the α -emitter ^{223}Ra** *S. Schumann¹, U. Eberlein¹, R. Muhtadi², M. Lassmann¹, H. Scherthan²; ¹University of Würzburg, Würzburg, GERMANY; ²Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, München, GERMANY.***OP-054****Involvement of cell cycle checkpoints in the therapeutic efficacy of ^{177}Lu -lilotomab in non-Hodgkin B-cell lymphoma***A. Pichard¹, A. Courteau², S. Marcatil², G. Cartron³, I. Isabelle Navarro-Teulon¹, A. Repetto-Llamazares⁴, H. Heyerdahl⁴, M. Bardiès², J. Dahle⁴, J. Pouget¹; ¹IRCM/INSERMU1194, Montpellier, FRANCE; ²Centre de Recherche en Cancérologie de Toulouse, Toulouse, FRANCE; ³Centre Hospitalier Universitaire de Montpellier, Montpellier, FRANCE; ⁴Nordic Nanovector ASA, Oslo, NORWAY.***OP-055****Internal exposure of ^{131}I - potential biomarkers and functional analysis for long-term effects in thyroid***M. Larsson¹, N. Rudqvist¹, J. Spetz¹, B. Langen¹, T. Parris², K. Helou², E. Forssell-Aronsson¹; ¹Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, Gothenburg, SWEDEN; ²Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, Gothenburg, SWEDEN.***OP-056****Contribution of macro and micro-dosimetry in alphatherapy***N. Benabdallah¹, M. Bernardini², D. Franck¹, C. de Labriolle-Vaylet^{3,4}, W. Bolch⁵, A. Desbrée¹; ¹IRSN - Institute for Radiological Protection and Nuclear Safety, Fontenay aux Roses, FRANCE; ²Georges Pompidou European Hospital, Paris, FRANCE; ³UPMC, University of Paris 06 Biophysics, Paris, FRANCE; ⁴Trousseau Hospital, Paris, FRANCE; ⁵Department of Biomedical Engineering, University of Florida, Gainesville, FL, UNITED STATES OF AMERICA.***OP-057****Monte-Carlo modelling of energy deposition within a realistic 3D model of follicular lymphoma***J. Bordes^{1,2}, S. Incerti^{3,4}, C. Rossi^{1,2,5}, J. Bordenave^{1,2}, C. Bezombes^{1,2}, M. Bardiès^{1,2}, M. Bordage^{1,2}; ¹Centre de Recherches en Cancérologie de Toulouse, Toulouse, FRANCE; ²UMR 1037 Inserm/UPS, Toulouse, FRANCE; ³Centre d'Etudes Nucléaires de Bordeaux-Gradignan, Gradignan, FRANCE; ⁴CNRS / IN2P3 / Université de Bordeaux, Gradignan, FRANCE; ⁵Service d'hématologie clinique, CHU le Bocage, Dijon, FRANCE.***OP-058****Voxel-based multi-model fitting method for modelling time activity curves in SPECT images***D. Sarrut, Sr.¹, A. Haly¹, J. Bado², L. Ferrer³, M. Bardiès⁴; ¹CREATIS / CLB, Lyon, FRANCE; ²CLB, Lyon, FRANCE; ³ICO / CRCINA, Nantes, FRANCE; ⁴CRCT, Toulouse, FRANCE.***OP-059****A Monte Carlo method to evaluate confidence intervals of time-integrated activity curve in molecular radiotherapy***B. Cassano¹, A. Napolitano¹, M. Longo¹, E. Genovese¹, S. Donatiello¹, T. Inero¹, E. Richetta², M. Pasquino², M. Stasi², M. Pacilio³, V. Cannatà¹; ¹Medical Physics Unit, Bambino Gesù Children's Hospital, Rome, ITALY; ²Medical Physics Department, AO Ordine Mauriziano di Torino, Turin, ITALY; ³Medical Physics Department, Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, ITALY.*

OP-060**Validation of a voxel-dosimetry and radiobiology tool for patient specific peptide receptor radionuclide therapy**

D. Finocchiaro^{1,2}, *S. Berenato*³, *E. Grassi*¹, *F. Fioroni*¹, *G. Castellani*², *N. Lanconelli*², *A. Versari*⁴, *E. Spezi*³, *M. Iori*¹;
¹Medical Physics Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, ITALY, ²Dept. of Physics, University of Bologna, Bologna, ITALY, ³School of Engineering, Cardiff University, Cardiff, UNITED KINGDOM, ⁴Nuclear Medicine Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, ITALY.

OP-064**SPECT imaging of carbonic anhydrase IX with ¹¹¹In-girentuximab-F(ab')₂ as radiotracer in head and neck xenografts**

F. J. Huizing, *B. A. W. Hoeben*, *S. Heskamp*, *J. Bussink*, *O. C. Boerman*; Radboudumc, Nijmegen, NETHERLANDS.

OP-065**Ab-1881, An Anti-PDL1 Immune Checkpoint Inhibitor Serves as A Theranostic Agent for Cancer Immunotherapy**

M. Xu, *Y. Han*, *Z. Liu*; Peking University, Beijing, CHINA.

OP-066**Monitoring tumor PD-L1 expression with microSPECT/CT during radiotherapy**

S. Heskamp, *J. D. M. Molkenboer-Kueneen*, *G. W. Sandker*, *P. J. Wierstra*, *J. Bussink*, *O. C. Boerman*; Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.

OP-067**PET Imaging of Programmed Cell Death Protein 1 (PD-1) in a Humanized Mouse Model of Lung Cancer**

W. Cai, *D. Jiang*, *C. G. England*, *T. E. Barnhart*; University of Wisconsin-Madison, Madison, WI, UNITED STATES.

OP-068a**Radiocobalt-labeled anti-HER1 affibody molecule DOTA-Z_{EGFR:2377} for imaging of low HER1 expression in prostate cancer pre-clinical model**

*B. Mitran*¹, *J. Garousi*¹, *M. Rosestedt*¹, *E. Lindström*¹, *K. G. Andersson*², *S. Ståhl*², *J. Löfblom*², *V. Tolmachev*¹, *A. Orlova*¹; ¹Uppsala University, Uppsala, SWEDEN, ²KTH-Royal Institute of Technology, Stockholm, SWEDEN.

OP-068b**Preclinical evaluation of a single-chain variable anti TEM-1 fragment labeled with ¹¹¹In and ¹⁵²Tb**

F. Ciccone^{1,2}, *T. Denoël*¹, *D. Viertl*¹, *G. Jakka*³, *M. Irving*³, *S. Dunn*³, *T. Stora*^{2,4}, *N. P. van der Meulen*⁵, *C. Müller*⁵, *C. Vermeulen*⁵, *U. Köster*⁶, *K. Johnston*⁴, *S. Gnesin*¹, *N. Riggli*⁷, *N. Schaefer*¹, *G. Coukos*^{2,3}, *J. O. Prior*^{1,2}; ¹Nuclear Medicine, CHUV, Lausanne, SWITZERLAND, ²Marie Skłodowska-Curie Innovative Training Network MEDICIS-PROMED, CERN, Geneva, SWITZERLAND, ³Ludwig Center for Cancer Research, Lausanne, SWITZERLAND, ⁴ISOLDE/CERN, Geneva, SWITZERLAND, ⁵Paul Scherrer Institut, Villigen-PSI, SWITZERLAND, ⁶Institut Laue-Langevin, Grenoble, FRANCE, ⁷Molecular Pathology, CHUV, Lausanne, SWITZERLAND.

305 Sunday, October 22, 2017, 11:30 - 13:00, Hall E2

M2M: Antibodies

Chairs: S. Heskamp (Nijmegen, NETHERLANDS)
V. Tolmachev (Uppsala, SWEDEN)

OP-061**Immunotargeting of Galectin-3 in thyroid orthotopic tumor models opens new challenges for thyroid cancer imaging and biological characterization in vivo**

*C. D'Alessandria*¹, *F. De Rose*¹, *M. T. Kuhlmann*², *M. Braeuer*¹, *S. Reder*¹, *S. Braesh-Andersen*³, *A. Bartolazzi*⁴, *M. Schwaiger*¹; ¹Klinikum rechts der Isar - Technical University of Munich, Munich, GERMANY, ²European Institute for Molecular Imaging (EIMI), University of Münster, Münster, GERMANY, ³Mabtech AB Research Laboratory, Stockholm, SWEDEN, ⁴Pathology Research Laboratory, Sant'Andrea Hospital, University Sapienza, Rome, ITALY.

OP-062**Pretargeted radionuclide therapy of HER2-expressing SKOV-3 human xenografts using an Affibody molecule-based PNA-mediated pretargeting**

*M. Altai*¹, *K. Westerlund*², *M. Konijnenberg*³, *B. Mitran*⁴, *M. Oroujeni*¹, *M. de Jong*³, *A. Eriksson-Karlström*², *A. Orlova*⁴, *V. Tolmachev*¹; ¹Institute of Immunology, Genetics and Pathology, Uppsala, SWEDEN, ²Division of Protein Technology, Royal Institute of Technology, Stockholm, SWEDEN, ³Department of Nuclear Medicine and Radiology, Erasmus MC, Rotterdam, NETHERLANDS, ⁴Division of Molecular Imaging, Uppsala, SWEDEN.

OP-063**Immuno-PET imaging for PD-L1 expression in non-small cell lung cancer xenograft**

D. Li, *S. Cheng*, *S. Zou*, *D. Zhu*, *X. Zhu*; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.



306 Sunday, October 22, 2017, 11:30 - 13:00, Hall F1**Pitfalls & Artefacts 2 (Interactive) - Cardiovascular: Pitfalls and Artefacts with CZT Cameras***Chairs: D. Agostini (Caen, FRANCE)
A. Gimelli (Pisa, ITALY)***OP-069****Acquisition (Detector pbs, Gating, Patient Movement, Quality Control)***O. Lairez; Rangueil University Hospital, Toulouse, FRANCE***OP-070****Image Analysis (Attenuation, Image Quality)***J. van Dijk; Isala Klinieken, afd. Nucleaire Geneeskunde, Enschede, NETHERLANDS.***OP-071****Signal Quantification (LVEF, Bulls Eye, Extent of Myocardial Perfusion Abnormality)***A. Gimelli; Fondazione Toscana Gabriele Monasterio, CNR, Pisa, ITALY***OP-072****Blood Pool Gated Acquisitions / Dual Isotope Acquisitions***A. Manrique; Centre Hospitalier Universitaire de Caen, Caen, France***307 Sunday, October 22, 2017, 11:30 - 12:45, Hall F2****Clinical Oncology: We want a New Drug***Chairs: C. Decristoforo (Innsbruck, AUSTRIA)
M. Picchio (Milan, ITALY)***OP-073****Comparison study between 18F-Choline (FCH) and 68Ga-NODAGA-MJ9 (MJ9, Bombesin) PET-CT in prostate cancer initial staging***L. Haefliger¹, P. Mitsakis¹, T. Zilli², C. Pozzessere¹, J. Delage³, H. Maecke⁴, R. Mansi⁴, R. Miralbell^{2,5}, N. Schaefer¹, J. Prior¹; ¹Department of Nuclear Medicine, Lausanne University Hospital, Lausanne, SWITZERLAND, ²Department of Radiation, Oncology, Geneva University Hospital, Geneva, SWITZERLAND, ³Department of Pharmacy, Lausanne University Hospital, Lausanne, SWITZERLAND, ⁴Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, GERMANY, ⁵Institut Oncològic Teknon, Barcelona, SPAIN.***OP-074****Clinical translation of bombesin antagonist based GRPR targeting PET radiotracer ⁶⁸Ga-NOTA-RM26***J. Zhang^{1,2}, G. Niu², X. Fan³, L. Lang², H. Wu⁴, J. Zang¹, G. Hou¹, F. Li¹, Z. Zhu¹, X. Chen²; ¹Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ²Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA, ³Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ⁴Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.***OP-075****Correlation of Clinical GRP Receptor PET Imaging of Prostate Cancer to Receptor Expression Status***I. L. Bakker¹, G. J. L. H. van Leenders¹, M. Segbers¹, A. C. Fröberg¹, S. U. Dalm¹, J. Veenland¹, M. Konijnenberg¹, M. B. Busstra¹, J. F. Verzijlbergen¹, I. Schoots¹, E. de Blois¹, W. M. van Weerden¹, T. Maina², B. Nock², M. de Jong¹; ¹Erasmus MC, Rotterdam, NETHERLANDS, ²NCSR „Demokritos“, Athens, GREECE.***OP-076****Imaging GRPr expression in metastatic castration resistant prostate cancer with ⁶⁸Ga-RM2 - A head-to-head comparison with ⁶⁸Ga-PSMA-11***V. Kramer^{1,2}, R. Fernandez², J. Ribbeck¹, R. Pruzzo², E. Hernandez-Behm², A. Haeger², B. Morales², H. Lavados², H. Amaral^{1,2}; ¹Positronpharma SA, Santiago de Chile, CHILE, ²Nuclear Medicine & PET/CT Fundación Arturo López Pérez, Santiago de Chile, CHILE.*

OP-077

Imaging tumor biology with ⁸⁹Zr-cetuximab, ¹⁵O-H₂O and ¹⁸F-FDG PET/CT in patients with advanced colorectal cancer treated with cetuximab monotherapy

*E. J. van Helden*¹, *O. S. Hoekstra*², *M. C. Huisman*², *E. Boon*³, *S. C. van Es*⁴, *G. A. M. S. van Dongen*², *D. J. Vugts*², *D. J. de Groot*⁴, *R. Boellaard*^{2,5}, *C. M. L. van Herpen*³, *E. G. E. de Vries*⁴, *H. M. W. Verheul*¹, *C. W. Menke - van der Houven van Oordt*¹; ¹Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ²Department of Radiology and Nuclear Medicine, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ³Department of Medical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS, ⁴Department of Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS, ⁵Department of Radiology and Nuclear Medicine, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-078

A PET imaging study to investigate the biodistribution and clearance of an albumin binding domain antibody (AlbudAb™) in healthy subjects

*K. Thorneloe*¹, *M. Bergstrom*², *L. Galinanes-Garcia*², *P. Galette*¹, *W. Al-Azzam*¹, *V. Vincent*¹, *D. Vugts*³, *G. van Dongen*³, *P. Elsinga*⁴, *J. Wieggers*⁴, *A. Glaudemans*⁴, *J. Renaux*², *M. Cleveland*², *M. Davies*², **S. Zhang**¹; ¹GSK, King of Prussia, PA, UNITED STATES OF AMERICA, ²GSK, Stevenage, UNITED KINGDOM, ³VU University Medical Centre, Amsterdam, NETHERLANDS, ⁴University Medical Center Groningen, Groningen, NETHERLANDS.

OP-079

A proof-of-concept study of ⁶⁸Ga-TATE-RGD PET/CT for dual-target imaging of somatostatin receptor and integrin α_vβ₃ to detect lung cancer and neuroendocrine tumor in a single scan

Y. Zheng^{1,2}, *H. Wang*¹, *X. Cui*¹, *L. Zhang*¹, *H. Tan*², *S. Yao*¹, *Z. Zhu*¹; ¹Peking Union Medical College Hospital, Beijing, CHINA, ²China-Japan Friendship Hospital, Beijing, CHINA.

309 Sunday, October 22, 2017, 11:30 - 12:45, Hall G1

Do.MoRe - Featured: Photodynamic Therapy & Molecular Imaging – The Perfect Couple?

Chairs: M. Gotthardt (Nijmegen, NETHERLANDS)
S. Ezzidin (Homburg, GERMANY)

OP-079a

From Radionuclide Imaging to Photodynamic Therapy – Novel Prospects for Nuclear Medicine

M. Gotthardt; Radboud UMC, Nijmegen, NETHERLANDS.

OP-079b

Core-Satellite Nanomaterials for Multimodal Image-Guided Combination Cancer Therapy

W. Cai, *S. Goel*, *T. E. Barnhart*; University of Wisconsin-Madison, Madison, WI, UNITED STATES.

OP-079c

Targeted Photodynamic Therapy in CEA Expressing Colorectal Tumor Xenografts

F. M. K. Elekonawo, *D. Bos*, *O. C. Boerman*, *A. J. A. Bremers*, *J. H. W. de Wilt*, *M. Rijpkema*; Radboudumc, Nijmegen, NETHERLANDS.

OP-079d

Photodynamic therapy in rheumatoid arthritis; targeting the activated fibroblasts

*D. N. Dorst*¹, *M. Buitinga*¹, *M. Brom*¹, *D. Bos*¹, *A. Freimoser*², *C. Klein*², *B. Walgreen*¹, *M. I. Koenders*¹, *M. Gotthardt*¹; ¹Radboud umc, Nijmegen, NETHERLANDS, ²Roche Pharmaceutical Research and Early Development, Zurich, AUSTRIA.

OP-079e

Photodynamic treatment of rheumatoid arthritis by liposomal targeting of macrophages

*M. Boss*¹, *M. Buitinga*¹, *D. N. Dorst*¹, *B. Walgreen*¹, *L. van Bloois*², *M. Brom*¹, *G. Storm*², *M. I. Koenders*¹, *M. Gotthardt*¹; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Utrecht University, Utrecht, NETHERLANDS.

310 Sunday, October 22, 2017, 11:30 - 13:00, Hall G2

Conventional & Specialised Nuclear Medicine: Benign Thyroid & Parathyroid Diseases

Chairs: L. Giovanella (Bellinzona, SWITZERLAND)
C. Pirich (Salzburg, AUSTRIA)

OP-080

¹⁸F-Choline PET-CT in assessment of primary hyperparathyroidism comparing with ^{99m}Tc-*Se-stamibi* or ^{99m}Tc-Tetrofosmin SPECT-CT: How differentiate parathyroid hyperplasia from adenoma?

*C. Pirich*¹, *L. Hehenwarter*¹, *L. Imamovic*², *G. Rendl*¹, *O. Tsybrovskyy*³, *D. Hackl*⁴, *F. Fitz*², *W. Langsteger*², *M. Beheshti*^{2,1}; ¹Nuclear Medicine & Endocrinology, Medical University of Salzburg, Salzburg, AUSTRIA, ²PET-CT Center Linz, St. Vincent's Hospital, Linz, AUSTRIA, ³Clinical Pathology, St. Vincent's Hospital, Linz, AUSTRIA, ⁴General Surgery, St. Vincent's Hospital, Linz, AUSTRIA.

OP-081**Quantitative Washout Rate of ^{99m}Tc-Sestamibi in Parathyroid and Thyroid Tissues Assessed Using Quantitative SPECT-CT**

J. Gardner, B. Ziebarth, S. Bazarjani, S. Razavi, R. Klein, L. S. Zuckier, **W. Zeng**; *The Ottawa Hospital, Ottawa, ON, CANADA.*

OP-082

A Type of Uptake in Dual-phase ^{99m}Tc-Sestamibi SPECT/CT Parathyroid Scintigraphy & a Level of Parathormone Might Indicate a Histopathology Diagnosis in Patients with Primary Hyperparathyroidism-Experience of One Centre
M. H. Listewnik, H. Piwowarska-Bilska, K. Safranow, M. Ostrowski, J. Iwanowski, M. Chosia, A. Borowiecki, M. Laszczyńska, M. Kurnatowicz, B. Birkenfeld; Pomeranian Medical University in Szczecin, Szczecin, POLAND.

OP-083

Comparison of F-18 Choline PET/CT with Tc-99m MIBI and USG for Detection of Parathyroid Adenomas in Patients with Elevated Parathyroid Hormone Levels: Preliminary Results

L. Uslu-Bešli¹, K. Sönmezoğlu¹, E. Kaymak Akgün¹, S. Teksöz², E. Karayel¹, H. Pehlivanoğlu¹, M. Ocak³, T. Öztürk⁴, S. Sağer¹, L. Kabasakal¹, Y. Bükey²; ¹Istanbul University Cerrahpaşa Medical Faculty Department of Nuclear Medicine, Istanbul, TURKEY, ²Istanbul University Cerrahpaşa Medical Faculty Department of General Surgery, Istanbul, TURKEY, ³Istanbul University Pharmacy Faculty Department of Pharmaceutical Technology, Istanbul, TURKEY, ⁴Istanbul University Cerrahpaşa Medical Faculty Department of Pathology, Istanbul, TURKEY.

OP-084

Impact of F18-Fluorocholine PET/CT in the pre-surgical work up of primary hyperparathyroidism

S. Grimaldi¹, J. Young², P. Kamenicky², D. Hartl¹, M. Terroir¹, S. Leboulleux¹, E. Baudin¹, M. Schlumberger¹, D. Deandreis^{1,3}; ¹Institut Gustave Roussy, Villejuif, FRANCE, ²Hôpital de Bicêtre, Le Kremlin-Bicêtre, FRANCE, ³Università degli Studi, Torino, ITALY.

OP-085

Factors Associated with the Occurrence of Graves' Orbitopathy after Radioiodine Therapy in Patients with Graves' disease

S. Gaberscek^{1,2}, D. Šfiligoj¹, K. Zaletel¹, E. Pirnat¹, P. Jaki Mekjavič^{3,2}; ¹Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, ³University Eye Hospital, University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

OP-086

Factors Associated with the Duration of Graves' Orbitopathy Activity in Patients with Graves' disease

S. Gaberscek^{1,2}, D. Šfiligoj¹, K. Zaletel¹, E. Pirnat¹, P. Jaki Mekjavič^{3,2}; ¹Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, ³University Eye Hospital, University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

YDF1 Sunday, October 22, 2017, 13:00 - 14:30, Hall F1

EANM Young Daily Forum 1: Presentation Skills Workshop

R. Sheppard; Somerset, UNITED KINGDOM.

401 Sunday, October 22, 2017, 14:30 - 16:00, Hall A

CME 3 - Cardiovascular: How to Perform Myocardial Perfusion Imaging According to EANM Recommendations



Chairs: H. Verberne (Amsterdam, NETHERLANDS)
M. Hacker (Vienna, AUSTRIA)

OP-087**Stress Test**

O. Lindner; Institut für Radiologie, Nuklearmedizin und Molekulare Bildgebung, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, GERMANY.

OP-088**Injected Doses and Tracers**

J. Bucerius; Department of Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastrich, NETHERLANDS.

OP-089**Image Analysis**

A. Scholtens; Department of Nuclear Medicine, Meander Medical Center, Amersfoort, NETHERLANDS.

OP-090**Reporting**

E. Trägårdh; Department of Clinical Sciences, Clinical Physiology and Nuclear Medicine Unit, Lund University, Skåne University Hospital, Malmö, SWEDEN.



402 Sunday, October 22, 2017, 14:30 - 16:00, Hall B**Joint Symposium 3 - EANM/ETA-CRN: Update Thyroid Cancer Beyond I-131**

Chairs: F. Verburg (Marburg, GERMANY)
L. Fugazzola (Milan, ITALY)

OP-091**I-131 Refractory Differentiated Thyroid Cancer**

M. Kreissl; Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke Universität, Magdeburg, GERMANY.

OP-092**Medullary Thyroid Cancer**

L. Giovanella; Oncology Institute of Southern Switzerland, Nuclear Medicine and PET Centre, Bellinzona, SWITZERLAND.

OP-093**Anaplastic Thyroid Cancer**

L. Fugazzola; University of Milan, Department of Endocrinology, Milan, ITALY.

403a Sunday, October 22, 2017, 14:30 - 15:30, Hall C**Mini Course 1: Cardiology - Pitfalls & Artefacts**

Chairs: F. Bertagna (Brescia, ITALY)
L. Camoni (Brescia, ITALY)

OP-094**Common Artefacts in Nuclear Cardiology Imaging**

A. Ghilardi; Nuclear Medicine DPT and Medical Physics DPT, ASST Papa Giovanni XXIII, Bergamo, ITALY.

OP-095**Artefacts and Image Interpretation**

A. Flotats; Universitat Autònoma de Barcelona, Consultant, Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

403b Sunday, October 22, 2017, 15:45 - 16:45, Hall C**Mini Course 2: Inflammation and Infection - Pitfalls & Artefacts**

Chairs: A. Glaudemans (Groningen, NETHERLANDS)
C. Terwinghe (Leuven, BELGIUM)

OP-096**Pitfalls and Artefacts in Infection and Inflammation Imaging: Labelled Leukocytes**

E. Lazzeri; Regional Center of Nuclear Medicine AOUP, Pisa, ITALY.

OP-097**Pitfalls in FDG-PET Imaging of Infection and Inflammation**

A. Glaudemans; University of Groningen, Groningen, NETHERLANDS.

403c Sunday, October 22, 2017, 17:00 - 18:00, Hall C**Mini Course 3 (Interactive): Bone and Joint - Pitfalls and Artefacts**

Chairs: M. Attard (Nijmegen, NETHERLANDS)
C. Pestean (Cluj, ROMANIA)

OP-098**Bone and Joint – Pitfalls and Artefacts**

W. Grootjans; Leiden University Medical Centre, Radiology and Nuclear Medicine Department, Leiden, NETHERLANDS.

404 Sunday, October 22, 2017, 14:30 - 16:00, Hall E1**Do.MoRe: Radiopeptides for Therapy**

Chairs: S. Ezzidin (Homburg, GERMANY)
M. Paphiti (Athens, GREECE)

OP-099**177 Lu-Dota-octreotate therapy in advanced Gastrointestinal Neuroendocrine tumors: outcomes after 5 years follow up**

M. Sansovini¹, I. Grassi², S. Severi¹, A. Ianniello¹, S. Nicolini¹, M. Celli¹, E. Amadori³, V. Di Iorio⁴, M. Monti⁵, E. Scarpì⁵, A. Bongiovanni⁶, A. Lambertini⁷, C. Grana⁸, G. Paganelli¹;
¹Nuclear Medicine and Radiometabolic Unit, IRST-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ²Nuclear Medicine Unit, Faenza Hospital, Romagna Local Health Service, Faenza (RA), ITALY, ³Radiology Unit, IRST-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ⁴Oncology Pharmacy, IRST-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ⁵Unit of Biostatistics and Clinical Trials, IRST-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ⁶Osteoncology and Rare Tumors Center, IRST-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ⁷Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna (Bo), ITALY, ⁸Division of Nuclear Medicine, European Institute of Oncology Milan (IEO), Milan (MI), ITALY.



OP-100**Update: Edmonton Lu-177 Protocol (Induction and Maintenance Regimen) Improves Progression Free Survival (PFS) in Patients with Advanced Neuroendocrine Tumours (NETs)**

A. J. B. McEwan¹, M. Wieler¹, D. Murray¹, M. B. Sawyer¹, D. Morrish¹, B. A. Schaite², L. D. Schrader², T. McMullen¹; ¹University of Alberta, Edmonton, AB, CANADA, ²Cross Cancer Institute, Alberta Health Services, Edmonton, AB, CANADA.

OP-101**Improvement of PFS and OS after salvage therapy with 177-Lu[Dota⁰,Tyr³]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumours - the Rotterdam cohort**

W. A. van der Zwan¹, T. Brabander¹, B. L. K. Kam¹, J. J. M. Teunissen¹, E. P. Krenning², D. J. K. Kwekkeboom¹, W. W. de Herder¹; ¹Erasmus MC, Rotterdam, NETHERLANDS, ²Cyclotron BV, Rotterdam, NETHERLANDS.

OP-102**Investigation of Receptor Radionuclide Therapy with 177Lu dotatate in GEP-NEN patients with High Grade Ki67**

S. Nicolini¹, S. Severi¹, M. Sansovini¹, A. Ianniello¹, P. Caroli¹, A. Bongiovanni², A. Rossi³, F. Di Mauro⁴, E. Mezzenga⁵, E. Scarpi⁶, G. Paganelli¹; ¹Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ²Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ³Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ⁴Nuclear Medicine Unit, University of Messina, Messina, Italy, Messina, ITALY, ⁵Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY, ⁶Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), ITALY.

OP-103**177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors**

U. M. M. Jahn¹, E. Ilan¹, M. Sandström¹, M. Bamerny², U. Garske-Roman³, M. Lubberink², A. Sundin¹; ¹Radiology, Uppsala, SWEDEN, ²Nuclear Medicine, Uppsala, SWEDEN, ³Nuclear Medicine, Gothenburg, SWEDEN.

OP-104**Gender-related differences in absorbed dose to risk organs in patients receiving ¹⁷⁷Lu-Octreotate therapy**

M. Sandstrom, Sr.^{1,2}, E. Ilan^{1,2}, K. Fröss-Baron¹, U. Garske-Roman¹, D. Granberg³, B. Eriksson³, A. Sundin¹, M. Lubberink^{1,2}; ¹Nuclear medicine and PET, Uppsala University, Uppsala, SWEDEN, ²Medical physics, Uppsala University Hospital, Uppsala, SWEDEN, ³Endocrine Oncology, Uppsala University, Uppsala, SWEDEN.

OP-105**¹⁷⁷Lu-DOTATATE therapy in radio iodine refractory differentiated thyroid cancer: a single center experience**

W. Roll, B. Riemann, M. Schäfers, L. Stegger, A. Vrachimis; University Hospital Münster, Münster, GERMANY.

OP-106**Best Therapy Response vs Variability of Tumor Size, Absorbed Dose And Ki-67 Index After n.c.a. Lu-177 Dotatate Intra-arterial Infusions**

M. Paphiti¹, I. Karfis¹, E. Z. Dimitriadis², S. Chondroyannis³, G. Nikou¹, V. Michalaki¹, G. Fragulidis⁴, D. Voros⁴, V. R. McCready⁵, D. Rubello³, G. S. Limouris¹; ¹Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, ²Institute Claudus Regaud, University of Paul Sabatier, Toulouse, FRANCE, ³Nuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, ITALY, ⁴II Surgical Dept, of Aretaieion Hospital, Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, ⁵Institute Cancer Research, Sutton Surrey & Royal Sussex County Hospital, Brighton, UNITED KINGDOM.

405 Sunday, October 22, 2017, 14:30 - 16:00, Hall E2

M2M: New Targets

Chairs: M. Gotthardt (Nijmegen, NETHERLANDS)
J. Notni (Garching, GERMANY)

OP-107**Radiochemistry and Preclinical Evaluation of Two Novel Peptide Analogues Targeting Glucagon Receptor for Anti-Diabetic Drug Development**

I. Velikyan^{1,2}, M. Bossart³, T. Haack³, I. Laitinen³, P. Larsen³, O. Plettenburg⁴, L. Johansson⁵, S. Pierrou⁵, M. Wagner³, O. Eriksson^{5,6}; ¹PET Centre, Centre for Medical Imaging, Uppsala University Hospital, Uppsala, SWEDEN, ²Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, ³Sanofi-Aventis, Frankfurt, GERMANY, ⁴Helmholtz Zentrum, München, GERMANY, ⁵Antaros Medical AB, Molndal, SWEDEN, ⁶Uppsala University, Uppsala, SWEDEN.



OP-108**Development of a new 68Ga radiolabelled PET imaging agent to evaluate in vivo expression of angiotensin in malignant brain tumors**

A. Moyon^{1,2,3}, P. Garrigue^{1,2,3}, P. Brige², M. Nollet¹, L. Balasse², S. Fernandez², M. Blot-Chabaud¹, F. Dignat-George^{1,3}, B. Guillet^{1,2,3}; ¹UMR_S1076 VRCM, Marseille, FRANCE, ²CERIMED, Marseille, FRANCE, ³APHM, Marseille, FRANCE.

OP-109**[¹¹C]Erlotinib as a PET radiotracer to measure OATP2B1 transport activity in the human liver**

M. Bauer¹, A. Matsuda¹, B. Wulkersdorfer¹, C. Philippe¹, A. Traxl², C. Özvegy-Laczka³, J. Stanek^{1,2}, L. Nics¹, S. Poschner⁴, W. Jäger⁴, G. Szakács^{1,3}, W. Wadsak^{1,5}, M. Hacker¹, M. Zeitlinger¹, O. Langer^{1,2}; ¹Medical University of Vienna, Vienna, AUSTRIA, ²AIT, Seibersdorf, AUSTRIA, ³Hungarian Academy of Sciences, Budapest, HUNGARY, ⁴University of Vienna, Vienna, AUSTRIA, ⁵CBMed, Graz, AUSTRIA.

OP-110**First in vivo imaging and in vitro studies of ¹⁸F-DABTA in rat model with E46K alpha synuclein mutation**

B. Hooshyar Yousefi¹, K. Shi¹, S. Reder¹, S. Reder¹, M. Herz¹, M. Braeuer¹, H. Wester², I. Yakushev¹, T. Arzberger³, M. Schwaiger¹; ¹Klinikum rechts der Isar, Technical university Munich, Munich, GERMANY, ²LS Pharm. Radiochem., Technical university Munich, Munich, GERMANY, ³Ludwig Maximilians Universität München, Munich, GERMANY.

OP-111**Targeting $\alpha v\beta 6$ -integrin with radiometallated peptides for therapy of pancreatic carcinoma**

S. Färber¹, K. Steiger², F. Reichart¹, M. Schwaiger², H. Kessler¹, H. Wester¹, J. Notni¹; ¹Technische Universität München, Garching, GERMANY, ²Technische Universität München, München, GERMANY.

OP-112**Imaging beta cells in patients after Roux-en-Y gastric bypass (RYGB) surgery by ⁶⁸Ga-NODAGA-exendin-4 PET/CT**

M. Boss, Sr.¹, L. N. Deden², E. O. Aarts³, H. de Boer³, I. M. C. Janssen³, M. Brom¹, F. J. Berends³, M. Gotthardt¹; ¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Rijnstate hospital, Arnhem, NETHERLANDS, ³Rijnstate Hospital, Arnhem, NETHERLANDS.

OP-113**68Ga-Pentixafor PET/CT Imaging Targeting CXCR4 chemokine receptors : The First Clinical Experience in Lung carcinoma subtypes**

A. Watts¹, B. Singh¹, S. Chutani¹, N. Dhanota¹, H. Singh¹, R. Basher¹, A. Bal¹, R. Kapoor¹, S. K. Arora¹, H. J. Wester², B. R. Mittal¹, D. Behera¹; ¹PGIMER, Chandigarh, INDIA, ²Technical University of Munich, Munich, GERMANY.

OP-114**Evaluation of Lu-177 Labelled 6A10 Fab as Carbonic Anhydrase 12 Targeting Agent**

L. Fiedler¹, M. Kellner², A. Gosewisch¹, G. Böning¹, S. Lindner¹, P. Bartenstein¹, R. Zeidler^{2,3}, F. Gildehaus¹; ¹Department of Nuclear Medicine, LMU, Munich, GERMANY, ²Research Group Prevention and Immunomodulation; Helmholtz-Zentrum, Munich, GERMANY, ³Department of Otorhinolaryngology, LMU, Munich, GERMANY.

406 Sunday, October 22, 2017, 14:30 - 16:00, Hall F1**Teaching Session 1 (Interactive): Applied Cross Sectional Anatomy and Correlative Imaging - Head and Neck**

Chair: V. Lewington (London, UNITED KINGDOM)

OP-115**Applied Cross Sectional Anatomy and Correlative Imaging – Head and Neck**

C. Fowler; Brighton and Sussex University Hospital, Brighton, UNITED KINGDOM.

407 Sunday, October 22, 2017, 14:30 - 16:00, Hall F2**Clinical Oncology - Rapid Fire Session: Prostate**

Chairs: S. Fanti (Bologna, ITALY)

S. Schwarzenböck (Rostock, GERMANY)

OP-116**PSMA-targeting alpha-Radiation therapy with ²²⁵Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control**

C. Kratochwil¹, F. Bruchertseifer², F. L. Giesel¹, C. Apostolidis², U. Haberkorn¹, A. Morgenstern²; ¹University Hospital Heidelberg, Heidelberg, GERMANY, ²EC-JRC, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.

OP-117**68Ga-PSMA PET/CT to restage prostate cancer after radical therapy. Results of a prospective single-center trial**

F. Ceci¹, P. Castellucci², T. Graziani², A. Farolfi², R. Renzi², R. Schiavina³, M. Borghesi³, F. Lodi², S. Boschi², S. Fanti²; ¹Department of Surgical Sciences, University of Bologna, Bologna, ITALY, ²Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, ³Department of Urology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

OP-118**Integrated ⁶⁸Ga-PSMA-11 PET/MRI enhances discriminatory power of multi-parametric prostate MRI**

M. Al-Bayati¹, J. Grueneisen¹, S. Lütje¹, L. Sawicki², S. Suntharalingam¹, S. Tschirdewahn¹, M. Forsting¹, K. Herrmann¹, L. Umutlu¹, A. Wetter¹; ¹University Hospital Essen, Essen, GERMANY, ²University Hospital Duesseldorf, Duesseldorf, GERMANY.

OP-119**Tc-99m-MIP-1404 Imaging for the Detection of PSMA-Positive Lesions. A Pilot Study in 380 Patients with Histologically Confirmed Prostate Cancer**

C. Schmidkonz, P. Ritt, C. Hollweg, M. Beck, T. I. Goetz, J. Sanders, J. Reinfelder, D. Schmidt, T. Kuwert; Universitätsklinikum Erlangen, Erlangen, GERMANY.

OP-120**Correlation Between Uptake of ¹⁸F-1-amino-3-fluorocyclobutane-1-carboxylic acid (¹⁸F-fluciclovine) and Expression of Amino Acid Transporters ASCT2 and LAT1 in prostate cancer**

M. Kim^{1,2,3}, I. Saarinen⁴, A. Kuisma⁵, I. Jambor^{6,7}, J. Kemppainen⁸, E. Kähkönen⁹, A. Koskeniemi¹⁰, P. Taimen⁴, H. Minn⁵; ¹Gunma University, Maebashi, JAPAN, ²Turku PET Centre, University of Turku, Turku, FINLAND, ³Japan Society the promotion of science, Tokyo, JAPAN, ⁴Department of Pathology, University of Turku and Turku University Hospital, Turku, FINLAND, ⁵Turku University Hospital, Turku, FINLAND, ⁶Turku University Hospital, Departments of Oncology and Radiotherapy, Turku, FINLAND, ⁷Department of Radiology, Baystate Medical Center, University of Massachusetts, Springfield, MA, UNITED STATES OF AMERICA, ⁸Turku University Hospital, Departments of Nuclear Medicine, Turku, FINLAND, ⁹Turku University Hospital, Departments of Urology, Turku, FINLAND, ¹⁰Turku University Hospital, Departments of Pathology, Turku, FINLAND.

OP-121**Impact of Ga-68 PSMA PET/CT on radiation treatment planning of prostate cancer**

S. M. Schwarzenboeck¹, L. Schubert¹, H. Rennau², J. Kurth¹, B. J. Krause¹, G. Hildebrandt²; ¹Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, GERMANY, ²Department of Radiotherapy, Rostock University Medical Centre, Rostock, GERMANY.

OP-122**[⁶⁸Ga]Ga-PSMA-PET/CT imaging of localized prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost**

L. Thomas¹, S. Kantz², A. Hung³, D. Monaco³, F. C. Gaertner⁴, H. Strunk⁵, M. Essler⁴, C. R. Thomas³, W. Laub³, R. A. Bundschuh⁴; ¹Department of Nuclear Medicine, Universitaetsklinikum Bonn; Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, UNITED STATES OF AMERICA, ²LMU Munich, Department of Radiation Oncology, Munich, GERMANY, ³Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, UNITED STATES OF AMERICA, ⁴Department of Nuclear Medicine, Universitaetsklinikum Bonn, Bonn, GERMANY, ⁵Department of Radiology, Universitaetsklinikum Bonn, Bonn, GERMANY.

OP-123**Intra-individual comparison of ¹⁸F-labelled PSMA-1007-PET/CT, mpMRI and radical prostatectomy specimen in patients with primary prostate cancer**

F. Giesel², C. Kesch¹, M. Vinsensia², J. P. Radtke^{1,3}, H. P. Schlemmer³, M. Heller⁴, E. Ellert⁵, T. Holland-Letz⁶, S. Duensing^{4,1}, N. Grabe^{7,8}, A. Afshar-Oromieh², K. Wieczorek⁵, M. Schäfer⁹, O. C. Neels⁹, J. Cardinale⁹, B. A. Hadaschik¹⁰, M. Hohenfellner¹, K. Kopka⁹, U. Haberkorn², C. Kratochwil²; ¹Department of Urology, University Hospital Heidelberg, Heidelberg, GERMANY, ²Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, ³Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ⁴Section of Molecular Urooncology, Department of Urology, University of Heidelberg, Heidelberg, GERMANY, ⁵Institute of Pathology, University Hospital Heidelberg, Heidelberg, GERMANY, ⁶Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ⁷Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, GERMANY, ⁸Hamamatsu Tissue Imaging and Analysis Center, University of Heidelberg, Heidelberg, GERMANY, ⁹Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ¹⁰Department of Urology, University Hospital Essen, Essen, GERMANY.



OP-124**⁶⁸Ga-PSMA PET/CT for restaging prostate cancer patients with early biochemical recurrence and PSA values lower than 0,5 ng/mL**

A. Farolfi¹, F. Ceci¹, T. Graziani¹, P. Castellucci¹, L. Esposito¹, A. Lambertini¹, E. Lodi Rizzini¹, R. Schiavina², F. Lodi¹, S. Fanti¹; ¹Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, ²Department of Urology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

OP-125**Oligometastatic Prostate Cancer radiotherapy treatment based on ⁶⁸Ga-PSMA PET/CT: preliminary results**

C. Artigas¹, C. Florian¹, D. Van Gestel¹, D. Van Gestel², P. Flamen¹, F. Otte¹; ¹Jules Bordet Institut, Brussels, BELGIUM, ²Jules Bordet Institut Brussels, Brussels, BELGIUM.

OP-126**Impact of ⁶⁸Ga-PSMA-11 PET/CT on salvage radiotherapy planning in post-prostatectomy patients with early biochemical recurrence**

J. Calais¹, J. Czernin¹, W. P. Fendler^{1,2}, K. Herrmann^{1,3}, I. Rauscher⁴, N. Hegemann², T. Poeppel³, M. Cao¹, M. Eiber^{1,4}, N. Nickols¹; ¹UCLA, LOS ANGELES, CA, UNITED STATES OF AMERICA, ²Ludwig-Maximilians-University, Munich, GERMANY, ³Universitätsklinikum Essen, Essen, GERMANY, ⁴Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY.

OP-127**First Clinical Experience with Ultra-High Resolution Multi-Focal Collimators for Tc-99m-PSMA Imaging**

C. Schmidkonz¹, C. Hollweg¹, J. Sanders¹, M. Beck¹, D. Schmidt¹, H. Vija², T. Kuwert¹, P. Ritt¹; ¹Universitätsklinikum Erlangen, Erlangen, GERMANY, ²Siemens Medical Solutions, Hoffman Estates, IL, UNITED STATES OF AMERICA.

409 Sunday, October 22, 2017, 14:30 - 16:00, Hall G1**Neurosciences: Imaging Amyloid and Amyloidogenesis**

Chairs: P. Payoux (Toulouse, FRANCE)

V. Garibotto (Geneva, SWITZERLAND)

OP-128**Incremental value of 18F-florbetaben amyloid PET in the diagnostic work-up of most complex patients with dementia in France: a naturalistic study**

E. Guedj¹, T. Jonveaux², A. Verger³, P. Krolak-Salmon⁴, C. Houzard⁵, O. Godefroy⁶, T. Shields⁷, A. Perrotin⁸, R. Gismond⁹, S. Bullich⁹, A. Jovalekic⁹, N. Raffa¹⁰, F. Pasquier¹¹, F. Semah¹², S. Epelbaum¹³, M. O. Habert¹⁴, D. Wallon¹⁵, M. Chastan¹⁶, P. Payoux¹⁷, NEUUS in AD study group, A. Stephens⁹, M. Ceccaldi¹⁸; ¹AP-HM - Hôpital de la Timone, Nuclear Medicine Department, and Aix-Marseille University, CERIMED, CNRS, INT, Institut de Neurosciences de la Timone, Marseille, FRANCE, ²CHRU de Nancy - Hôpital Brabois, Geriatric Department, Vandoeuvre-les-Nancy, FRANCE, ³INSERM U947, IADI,, Nancy, FRANCE, ⁴Clinical and Research Memory Center of Lyon, Hospices civils de Lyon, UCBL1, Inserm 1028, Lyon, FRANCE, ⁵CHU Lyon, Nuclear Medicine Department, Lyon, FRANCE, ⁶CHU Amiens Picardie - Hôpital Sud, Neurology Department, Amiens, FRANCE, ⁷CHU Amiens Picardie - Hôpital Sud, Nuclear Medicine Department, Amiens, FRANCE, ⁸Piramal Imaging, Medical Affairs, Berlin, GERMANY, ⁹Piramal Imaging, Clinical Research and Development, Berlin, GERMANY, ¹⁰Piramal Imaging, Market Access and HEOR, Berlin, GERMANY, ¹¹Inserm 1171, Université de Lille, CHU, DistAlz, Lille, FRANCE, ¹²Univ. Lille, U1171, CHU Lille, Nuclear Medicine Department, Lille, FRANCE, ¹³AP-HP - Hôpital Pitié Salpêtrière, Memory and Alzheimer Disease Institute IM2A, Paris, FRANCE, ¹⁴Laboratoire d'Imagerie Biomédicale, Sorbonne Universités, UPMC Univ Paris 06, Inserm U 1146, CNRS UMR 7371, Paris, FRANCE, ¹⁵CHU de Rouen - Hôpital Charles Nicolle, Neurology Department, Rouen, FRANCE, ¹⁶Centre Henri Becquerel, Nuclear Medicine Department, Rouen, FRANCE, ¹⁷ToNIC, Toulouse Neurolmaging Center, Université de Toulouse, Inserm, UPS, Toulouse, FRANCE, ¹⁸AP-HM - Hôpital de la Timone, Neurology and Neuropsychology Department, and Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes, Marseille, FRANCE.

OP-129**Impact of 18F-Florbetaben PET on Differential Diagnosis of Unclear Clinical Routine Cases**

M. Brendel¹, J. Schnabel¹, S. Schönecker¹, E. Brendel¹, J. Meyer-Wilmes¹, C. Catak¹, O. Pogarell¹, J. Levin¹, A. Schildan², M. Patt², P. Bartenstein¹, O. Sabri², H. Barthele², A. Danek¹, K. Bürger¹, A. Rominger¹; ¹University of Munich, Munich, GERMANY, ²University of Leipzig, Leipzig, GERMANY.



OP-130**Reshaping the amyloid buildup curve in Alzheimer's disease? - Partial volume effect correction of longitudinal amyloid PET data**

M. Rullmann, O. Sabri, H. Barthel; University of Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY.

OP-131**Improved Risk Stratification for Conversion from Mild Cognitive Impairment to Alzheimer's Disease with a multi-analytical Evaluation of [¹⁸F]-AV45 Amyloid PET**

L. Wagner¹, M. Brendel¹, F. Scheiwein¹, A. Delker¹, J. Sauerbeck¹, P. Bartenstein¹, K. Ishii², C. Hosakawa², A. Rominger¹; ¹Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Muenchen, GERMANY, ²Department of Radiology, Kinki University Osaka, Osaka, JAPAN.

OP-132**Higher amyloid deposition in the striatum in familial Alzheimer's disease: a preliminary PET/CT and PET/MRI study**

L. Fu, J. Zhang, B. Xu, J. Tian; Department of Nuclear Medicine, the Chinese PLA General Hospital, Beijing, CHINA.

OP-133**[¹⁸F]Florbetapir PET/CT to assess the cerebral β -amyloid binding in Parkinson's Disease Dementia - does the striatum still a key player?**

M. Gennaro¹, G. Aghakhanyan¹, S. Mazzarri¹, G. Puccini¹, G. Palermo², D. Frosini², G. Manca¹, L. Antonacci¹, S. Muccioli¹, L. Fantechi¹, I. Paglianiti¹, R. Ceravolo², U. Bonuccelli², D. Volterrani¹; ¹Regional Center of Nuclear Medicine, University Hospital of Pisa, Pisa, ITALY, ²Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ITALY.

OP-134**A Pilot Study on Hybrid 18F-Florbetaben PET/MRI in Patients with White Matter Diseases**

M. Rullmann¹, S. Haars², P. Werner¹, R. Schmidt², J. Orthgieß², S. Tiepolt¹, M. Patt¹, D. Lobsien³, K. Hoffmann³, O. Sabri¹, H. Barthel¹, F. Then Bergh²; ¹University of Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY, ²University of Leipzig, Department of Neurology, Leipzig, GERMANY, ³University of Leipzig, Department of Neuroradiology, Leipzig, GERMANY.

OP-135**Human Whole-body Biodistribution and Radiation Dosimetry of [¹⁸F]PF-06684511, a Novel Radioligand for Brain Imaging of Beta-secretase**

A. Varrone¹, R. Arakawa¹, A. Takano¹, S. Nag¹, V. Stepanov¹, P. Stenkrona¹, P. Grybäck², M. Bolin², L. Chen³, L. Zhang³, P. He³, A. Villalobos⁴, T. McCarthy³, C. Halldin¹; ¹Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, ²Karolinska University Hospital, Medical Radiation Physics and Nuclear Medicine, Stockholm, SWEDEN, ³Worldwide Research & Development, Pfizer Inc., Cambridge, MA, UNITED STATES OF AMERICA, ⁴Worldwide Research & Development, Pfizer Inc., Groton, CT, UNITED STATES OF AMERICA.

410 Sunday, October 22, 2017, 14:30 - 16:00, Hall G2**Conventional & Specialised Nuclear Medicine: Pulmonology & Nephrourology**

Chairs: O. Israel (Haifa, ISRAEL)

V. Prassopoulos (Agios Stefanos, Attiki, GREECE)

OP-136**The impact of Lung Perfusion Scintigraphy in the emergency management of patients with suspected Pulmonary Embolism**

C. Ferrari, A. Niccoli Asabella, A. Cimino, G. Bianco, M. Fanelli, E. P. Mossa, A. Di Palo, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, Bari, ITALY.

OP-137**The Prognostic Significance Of Abnormal Lung Perfusion In Patients With Idiopathic Pulmonary Arterial Hypertension**

L. Wang, R. Ma, D. Wu, W. Fang; Chinese Academy of Medical Science & Fu Wai Hospital, Beijing, CHINA.

OP-138**Assessment Of Lung Glucose Uptake In Patients With Systemic Erythematous Pulmonary Arterial Hypertension: A Quantitative FDG PET Imaging Study**

L. Wang¹, Q. Wang², L. Zhao³, X. Zeng², W. Fang¹; ¹Chinese Academy of Medical Science & Fu Wai Hospital, Beijing, CHINA, ²Peking Union Medical College Hospital, Beijing, CHINA, ³Imperial College London, London, UNITED KINGDOM.



OP-139

Comparative analysis of regional lung perfusion measurements using radiolabeled microspheres and PET/CT and fluorescence-labeled microspheres in an experimental, anesthesiological study of acute lung injury in pigs

A. Braune, A. Gueldner, J. Kotzerke, M. Gama de Abreu; University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, GERMANY.

OP-140

A novel, simple equation improving the accuracy of glomerular filtration rate (GFR) measurement from two blood samples

G. Arsos¹, E. Moravidis¹, D. Katsampoukas¹, E. Manou², C. Sachpekidis³; ¹3rd Department of Nuclear Medicine, Medical School, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, GREECE, ²Nephrology Department, Papageorgiou General Hospital, Thessaloniki, GREECE, ³Institute of Nuclear Medicine, Bern University Hospital, Bern, SWITZERLAND.

OP-141

Contribution Of Isotopic Renogram And SPECT-CT In The Diagnosis Of The Complications Of The Renal Transplantation

J. Gómez Hidalgo, A. Cobo Rodríguez, A. Sainz-Esteban, C. Gamazo Laherran, M. Alonso Rodríguez, M. Ruiz Gómez, M. González Selma, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

OP-142

The usefulness of advanced numerical parameters of kidney output in the analysis of Tc-DTPA diuresis renography

S. Beatovic¹, M. Radulovic², M. Jankovic³, D. Sobic Saranovic¹, B. Ajdinovic², V. Artiko¹; ¹University of Belgrade Faculty of Medicine, Center for Nuclear Medicine, Clinical Center of Serbia, Belgrade, SERBIA, ²Institute for Nuclear Medicine Military Medical Academy, Belgrade, SERBIA, ³University of Belgrade Faculty of Electrical Engineering, Belgrade, SERBIA.

OP-143

Background Subtraction in Dynamic Renal Scintigraphy Revisited

M. Samal¹, V. Ptacnik², H. Jiskrova², D. Skibova²; ¹Charles University, First Faculty of Medicine, Prague, CZECH REPUBLIC, ²General University Hospital, Prague, CZECH REPUBLIC.

501 Sunday, October 22, 2017, 16:30 - 18:00, Hall A

CME 4 - Oncology: PET in Multiple Myeloma



*Chairs: M. Meignan (Créteil, FRANCE)
C. Nanni (Bologna, ITALY)*

OP-144

What is Expected from Imaging in Multiple Myeloma (MM)

C. Touzeau; CHU Nantes, Haematology, Nantes, FRANCE.

OP-145

Standard MRI in MM and Perspectives

C. Messiou; The Royal Marsden Hospital, Department of Radiology, London, UNITED KINGDOM.

OP-146

Role of PET for Initial Evaluation and Response Assessment in Multiple Myeloma: Towards New Imaging Criteria

C. Nanni; Policlinico S.Orsola-Malpighi, Department of Nuclear Medicine, Bologna, ITALY.

502 Sunday, October 22, 2017, 16:30 - 18:00, Hall B

Joint Symposium 4 - EANM/ICRP/ICRU: Radiological Protection for Patients Receiving Radiopharmaceutical Therapy Solutions

*Chairs: R. Howell (Newark, UNITED STATES OF AMERICA)
Y. Yonekura (Chiba, JAPAN)
K. Sjögren Gleisner (Lund, SWEDEN)*

OP-147

Tumour Response - What is Needed and What is Possible?

R. Howell; New Jersey Medical School, Division of Radiation Research, Newark, UNITED STATES OF AMERICA.

OP-148

Stochastic Effects in Patients Treated with Radiopharmaceuticals; Estimations, Observations and Possible Ways to Reduce Their Occurrence

S. Mattsson; Lund University, Medical Radiation Physics, Malmö, SWEDEN.

OP-149

Deterministic Tissue Reactions in Radionuclide Therapy, Observations and Ways to Reduce Their Occurrence

M. Konijnenberg; Erasmus MC, Radiology & Nuclear Medicine, Rotterdam, NETHERLANDS.



OP-150**Low-Dose Radiation Effects on Salivary Gland Stem Cells - Mechanisms and Clinical Relevance**

R. Coppes; University Medical Center Groningen, Department of Cell Biology & Radiation Oncology, Groningen, NETHERLANDS.

504 Sunday, October 22, 2017, 16:30 - 18:00, Hall E1

Do.MoRe: SPECT Quantification

Chairs: C. Hindorf (Lund, SWEDEN)
F. van Velden (Leiden, NETHERLANDS)

OP-151**Internal bremsstrahlung: a forgotten but significant effect in ⁹⁰Y SPECT and ⁹⁰Y PET imaging**

S. Walrand¹, M. Hesse², R. Lhomme², J. Francois²;
¹Cliniques Saint-Luc, Brussels, BELGIUM, ²Université Catholique de Louvain, Brussels, BELGIUM.

OP-152**Quantitative SPECT Neuroimaging using a Data Driven Estimation of Attenuation from the Projection Data Alone**

X. Ding, A. Vija; Siemens Medical Solutions USA, Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA.

OP-153**A 3D-Printed 2-Compartment Kidney Phantom for Evaluating the Accuracy of Quantitative SPECT/CT Imaging**

J. Tran-Gia, M. Lassmann; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

OP-154**Quantitative Lu-177 SPECT/CT validation to assist theragnostic procedures**

S. Gnesin¹, T. Lima², J. Malterre³, F. R. Verdun¹, N. Schaefer³, J. O. Prior³; ¹Institute of Radiation Physics, Lausanne university hospital, Lausanne, SWITZERLAND, ²Kantonal hospital Aarau, Aarau, SWITZERLAND, ³Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, SWITZERLAND.

OP-155**Quantitative gamma camera imaging of ²²⁷Th and ²²³Ra with application in ²²⁷Th targeted alpha therapy**

E. Larsson¹, G. Brolin¹, A. Cleton², T. Ohlsson¹, C. Hindorf¹; ¹Radiation Physics, Lund, SWEDEN, ²Bayer AG, Berlin, GERMANY.

OP-156**Comparison of lesion SUVs between ^{99m}Tc-HDP SPECT/CT and ¹⁸F-NaF PET/CT**

S. Arvola¹, I. Jambor², A. Kuisma³, M. Seppänen^{1,4}, T. Noponen¹; ¹Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, FINLAND, ²Department of Diagnostic Radiology, University of Turku, Turku, FINLAND, ³Department of Oncology and Radiotherapy, University of Turku, Turku, FINLAND, ⁴Turku PET Centre, Turku, FINLAND.

OP-157**Noise and Resolution Analysis of the xSPECT Quant Reconstruction Algorithm for ¹⁷⁷Lu**

J. Tran-Gia, M. Lassmann; Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

OP-158**Quantitative SPECT Imaging of Thorium-227: A phantom experiment**

M. Ghaly, Y. Du, G. Sgouros, D. Thorek, E. C. Frey; Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

505 Sunday, October 22, 2017, 16:30 - 18:00, Hall E2

M2M - Featured: Combination Therapies

Chairs: S. Dalm (Rotterdam, NETHERLANDS)
A. Orlova (Uppsala, SWEDEN)

OP-159**Combination Therapy: Reinforcing Current Therapy**

S. U. Dalm; Erasmus MC, Rotterdam, NETHERLANDS.

OP-160**Combination of Proton Irradiation and Targeted Radionuclide Therapy with ¹⁷⁷Lu-PSMA-617 in a Tumor Mouse Model of Prostate Cancer**

C. Mueller, R. Perrin, C. Umbricht, N. van der Meulen, S. Safai, D. Weber, A. Lomax, R. Schibli; Paul Scherrer Institut, Villigen-PSI, SWITZERLAND.

OP-161**In Vivo Assessment of p53 Therapy as a Way of Enhancing Therapeutic Effects of Radiation**

A. C. Mortensen¹, D. Spiegelberg¹, S. Lundsten¹, C. Brown², D. P. Lane^{2,3}, M. Nestor¹; ¹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²p53 Lab, A*STAR, 8A, Biomedical Grove, #06-04/05 Neuro/Immunos, Singapore 138648, Singapore, SINGAPORE, ³Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Stockholm, SWEDEN.



OP-162**Improvement of peptide receptor radionuclide therapy effects via modulation of the DNA damage response**

J. Nonnekens, M. de Jong, D. C. van Gent; Erasmus MC, Rotterdam, NETHERLANDS.

OP-163**In Vitro and In Vivo Growth Inhibitory and Radiosensitizing Effects of the Anti-HSP90 agent Onalespib**

D. Spiegelberg, S. Lundsten, A. C. Mortensen, A. Abramenkova, B. Stenerlöw, M. Nestor; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN.

OP-164**Boramino Acid: A New Theranostic Platform Serves Imaging Guided Boron Neutron Capture Therapy**

J. Li, Y. Han, Z. Liu; Peking University, Beijing, CHINA.

OP-165**Second Generation Trifunctional PSMA Binding Ligands with Application to the Imaging of Prostate Cancer by Positron Emission Tomography and to its Treatment by Targeted Endoradiotherapy**

J. M. Kelly¹, A. Amor-Coarasa¹, S. Ponnala¹, A. Nikolopoulou^{1,2}, C. Williams, Jr¹, D. Kim², J. W. Babich^{1,2,3}; ¹Division of Radiopharmaceutical Sciences and M13, Department of Radiology, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, ²Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, ³Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA.

506 Sunday, October 22, 2017, 16:30 - 18:00, Hall F1**Teaching Session 2 (Interactive): Applied Cross Sectional Anatomy and Correlative Imaging - Foot and Ankle**

Chair: M. Bozkurt (Ankara, TURKEY)

OP-166**Applied Cross Sectional Anatomy and Correlative Imaging – Foot and Ankle**

C. Fowler; Brighton and Sussex University Hospital, Brighton, UNITED KINGDOM.

507 Sunday, October 22, 2017, 16:30 - 18:00, Hall F2**Clinical Oncology: NET, a Classic!**

Chairs: D. Wild (Basel, SWITZERLAND)

R. Werner (Baltimore, UNITED STATES OF AMERICA)

OP-167**Peptide receptor radionuclide therapy in combination with lanreotide Autogel/Depot: a retrospective study in progressive digestive and bronchopulmonary neuroendocrine tumours (PRELUDE)**

V. Prasad¹, R. Srirajaskanthan², C. Toumpanakis³, C. M. Grana⁴, T. Shah⁵, J. Valle⁶, F. Courbon⁷, X. Truong Thanh⁸, A. Houchard⁸, L. Bode⁹; ¹Charité Universitätsmedizin Berlin, Berlin, GERMANY, ²King's College Hospital NHS Foundation Trust, London, UNITED KINGDOM, ³Royal Free Hospital, London, UNITED KINGDOM, ⁴Instituto Europeo di Oncologia, Milan, ITALY, ⁵Queen Elizabeth Hospital, Birmingham, UNITED KINGDOM, ⁶The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, ⁷IUCT Oncopole, Toulouse, FRANCE, ⁸Ipsen, Boulogne-Billancourt, FRANCE, ⁹Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-168**Clinical, tumour, and treatment parameters to predict overall survival after PRRT - a multivariate analysis in 783 patients**

E. A. Aalbersberg¹, D. M. V. Huizing¹, H. R. Kulkarni², I. Walraven³, B. J. de Wit - van der Veen¹, A. Singh², M. P. M. Stokkel¹, R. P. Baum²; ¹Department of Nuclear Medicine, ENETS Center of Excellence, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS, ²THERANOSTICS Center for Molecular Radiotherapy, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, GERMANY, ³Department of Radiation Oncology, ENETS Center of Excellence, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

OP-169**A Prospective study of Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE and Concurrent Capecitabine in Metastatic Paragangliomas**

S. Ballal, M. P. Yadav, D. Yadav, C. Bal; All India Institute of Medical Sciences, New Delhi, INDIA.

OP-170**First-in-human PET/CT Imaging of somatostatin receptor expressing tumors with the novel somatostatin receptor antagonist ⁶⁸Ga-NODAGA-LM3 - a comparison with ⁶⁸Ga-DOTATOC PET/CT**

A. Singh¹, H. R. Kulkarni¹, T. Langbein¹, D. Müller¹, S. Senftleben¹, M. Fani², H. Maecke³, R. P. Baum¹;
¹Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, GERMANY, ²Division of Radiopharmaceutical Chemistry, University Hospital of Basel, Basel, SWITZERLAND, ³Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, GERMANY.

OP-171**Biodistribution and radiation dosimetry of ⁶⁸Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors**

S. Krebs, J. O'Donoghue, D. Reidy, N. Pandit-Taskar, B. Beattie, L. Bodei, W. A. Weber; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-172**First experience using LMI1195 in patients with the suspicion of pheochromocytoma or paraganglioma**

C. Rischpler¹, A. M. Schlitter¹, M. Herz¹, B. Yousefi¹, A. von Werder¹, R. Tauber¹, T. Maurer¹, K. Scheidhauer¹, S. Robinson², C. Orlandi², S. G. Nekolla¹, M. Schwaiger¹;
¹Technical University Munich, Munich, GERMANY, ²Lantheus Medical Imaging, N. Billerica, MA, UNITED STATES OF AMERICA.

OP-173**⁶⁸Ga-NODAGA-exendin-4 PET/CT for the localization of insulinomas: preliminary data from a prospective multicenter imaging study**

M. Boss, Sr.¹, M. Buitinga¹, M. Brom¹, D. Wild², V. Prasad³, P. Nuutila⁴, A. Brouwers⁵, F. Pattou⁶, M. Gotthardt¹;
¹Radboud University Medical Center, Nijmegen, NETHERLANDS, ²University of Basel Hospital, Basel, SWITZERLAND, ³Charite University Hospital of Berlin, Berlin, GERMANY, ⁴University of Turku, Turku PET Centre, Turku, FINLAND, ⁵University Medical Center Groningen, Groningen, NETHERLANDS, ⁶University Hospital, Lille, Lille, FRANCE.

OP-174**AZEDRA® (iobenguane I 131) in Patients with Malignant and/or Recurrent Pheochromocytoma/ Paraganglioma (PPGL): Overall Tumor Response Assessment**

D. A. Pryma¹, B. B. Chin², R. B. Noto³, J. S. Dillon⁴, L. Solnes⁵, J. Jensen⁶, T. White⁶, N. Stambler⁶, S. Apfel⁶, V. Wong⁶, C. Jimenez⁷;
¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ²Duke University, Durham, NC, UNITED STATES OF AMERICA, ³Warren

Alpert Medical School of Brown University, Providence, RI, UNITED STATES OF AMERICA, ⁴University of Iowa Carver College of Medicine, Iowa City, IA, UNITED STATES OF AMERICA, ⁵Johns Hopkins Medicine, Providence, RI, UNITED STATES OF AMERICA, ⁶Progenics Pharmaceuticals, Inc., New York, NY, UNITED STATES OF AMERICA, ⁷University of Texas M. D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

508 Sunday, October 22, 2017, 16:30 - 18:00, Hall K

Cardiovascular System: Myocardial Function, Metabolism & Perfusion - From Preclinical to Clinical Practice

Chairs: M. Hacker (Vienna, AUSTRIA)
A. Gimelli (Pisa, ITALY)

OP-175**The study of ¹⁸F-FDG PET/CT imaging for myocardial "ischemic memory" in different degrees**

Z. Na, X. Meng, Z. Bai, K. Zhang, G. Zhang, X. Wang; The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CHINA.

OP-176**Myocardial FDG imaging of oxidative damage underlying anthracycline cardiotoxicity**

M. Bauckneht¹, F. Pastorino², A. Buschiazzo¹, A. Bellini¹, V. Cossu¹, A. Orengo¹, P. Piccioli¹, G. Caneva¹, L. Pellegrino¹, L. Emionite¹, S. Ravera¹, S. Morbelli¹, A. Rubartelli¹, M. Ponzone², G. Sambucetti¹, C. Marini³;
¹IRCCS AUO San Martino IST, Genova, ITALY, ²G. Gaslini Institute, Genova, ITALY, ³CNR Institute of Bioimages and Molecular Physiology, Milano, ITALY.

OP-177**The added value on clinical impact of SPECT/CT MPI: a one year experience**

M. L. De Rimini¹, G. Borrelli¹, G. Mazzarella¹, A. Russo², M. Bifulco¹, P. Muto¹;
¹Nuclear Medicine Unit; AO Ospedali dei Colli - Monaldi, Naples, ITALY, ²Cardiovascular Unit; Vanvitelli University of Campania, Naples, ITALY.

OP-178**Clinical value of myocardial perfusion imaging in patients with homozygous familial hypercholesterolemia**

J. Jiao, Q. Wang, T. Mou, L. Wang, H. Mi, X. Zhang; Capital Medical University affiliated Beijing Anzhen Hospital, Beijing, CHINA.



OP-179**Segmental comparison of myocardial inflammation, area at risk, edema and irreversible tissue damage after acute myocardial infarction**

C. Rischpler, U. Handwerker, R. Dirschinger, K. Kunze, H. Kossmann, S. van Marwick, T. Ibrahim, K. Laugwitz, M. Schwaiger, S. G. Nekolla; Technical University Munich, Munich, GERMANY.

OP-180**Prediction of Functional Recovery After Primary PCI Estimating Myocardial Salvage in Early Gated SPECT**

R. Scigrà, R. Calabretta, F. Linguanti, F. Tutino, A. Ciaccio; Nuclear Medicine, DECBS, University of Florence, FLORENCE, ITALY.

OP-181**Association of brain and cardiac glucose metabolism in patients with coronary artery disease and prior myocardial infarction**

X. Lu¹, T. Mou¹, Z. Yang¹, H. Mi¹, Q. Wang¹, X. Xie¹, X. Li², M. Hacker², Y. Wei¹, X. Zhang¹; ¹Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, ²Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP-182**Predictive and prognostic value of left ventricular mechanical dyssynchrony assessed by myocardial perfusion SPECT in asymptomatic patients under hemodialysis**

F. Caobelli¹, C. Popescu², R. Laudicella³, A. Comis³, S. A. Pignata³, R. Sara², C. Rossetti⁴; Young AIMN Working Group; ¹University Hospital Basel, Basel, SWITZERLAND, ²Niguarda Hospital, Milan, ITALY, ³University of Messina, Messina, ITALY, ⁴Niguarda Hospital, Milano, ITALY.

509 Sunday, October 22, 2017, 16:30 - 18:00, Hall G1

Neurosciences: Imaging Neurotransmission Systems in Parkinson

Chairs: E. van de Giessen (Amsterdam, NETHERLANDS)
S. Pappata (Naples, ITALY)

OP-183**Comparisons of glucose metabolism and striatal DAT binding in PD patients with different subtypes**

L. Li¹, C. Jiang¹, P. Wu¹, J. Zhao², C. Zuo¹; ¹PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.

OP-184**Role of an artificial neural network classifier, a classification tree (CIT), to diagnose Parkinson's disease in early phase by using 123I-FP-CIT brain SPECT data**

B. Palumbo¹, A. Santonicola¹, S. Cascianelli², S. Nuvoli³, M. L. Fravolini², M. Minestrini¹, M. Scialpi⁴, N. Tambasco⁵, A. Spanu³, G. Madeddu³; ¹Univ. of Perugia-Dept. of Surgical and Biomed. Sciences- Section of Nuclear Medicine, PERUGIA, ITALY, ²Univ. of Perugia-Dept. of Engineering, PERUGIA, ITALY, ³Univ. of Sassari-Dept. of Clinical and Experimental Medicine- Section of Nuclear Medicine, SASSARI, ITALY, ⁴Univ. of Perugia-Dept. of Surgical and Biomed. Sciences- Section of Diagnostic Imaging, PERUGIA, ITALY, ⁵Unit of Neurology- Perugia University Hospital, PERUGIA, ITALY.

OP-185**Comparison of machine learning and semi-quantification approaches for DaTSCAN classification**

J. Taylor; Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM.

OP-186**Abnormal striatal DAT distribution and PDRP expression in patients with rapid-eye-movement sleep behavior disorder**

P. Wu¹, C. Jiang¹, L. Li¹, J. Ge¹, H. Yu², J. Wu², C. Zuo¹; ¹PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.

OP-187**Striatal and extra-striatal F-Dopa PET binding potential index related to age, gender, smoker status and Carbidopa premedication**

S. Toch¹, S. Poussier¹, E. Micard¹, P. Marie¹, E. Guedj², A. Verger¹; ¹CHU Nancy, Nancy, FRANCE, ²Assistance Publique des Hôpitaux de Marseille, Marseille, FRANCE.

OP-188**Validation of a reliable and convenient PET protocol for striatal dopaminergic dysfunction imaging using ¹⁸F-LBT-999**

N. Arlicot^{1,2,3}, J. Vercoullie^{1,2,3}, K. Mondon^{1,3}, V. Gissot^{1,2}, S. Maia^{1,3}, L. Barantin^{1,2,3}, Y. Peltier^{2,3}, J. Cottier^{1,2,3}, J. Houeto⁴, J. Deloye⁵, D. Guilloteau^{1,2,3}, M. Ribeiro^{1,2,3}; ¹Centre Hospitalier Universitaire, Tours, FRANCE, ²Université François Rabelais, Tours, FRANCE, ³UMR U930 "Imaging and Brain", Tours, FRANCE, ⁴Centre Hospitalier Universitaire, Poitiers, FRANCE, ⁵Laboratoires Cyclopharma, Clermont-Ferrand, FRANCE.

OP-189**Validation of (S,S)-[¹¹C]-Methylreboxetine Positron Emission Tomography in Parkinson's Disease**

J. Brumberg, J. Tran-Gia, C. Kesenheimer, G. Brandt, C. Lapa, J. Volkmann, A. Buck, S. Samnick, I. U. Isaias; University Hospital Würzburg, Würzburg, GERMANY.

OP-190**PET imaging of mGluR5 with [¹⁸F]FPEB in Parkinson's disease**

Y. Kang¹, B. He¹, A. Verma², C. Henchcliffe¹, P. J. Kothari¹, D. Schlyer¹, K. Schmidt², P. C. Chiao², S. Vallabhajosula¹, P. D. Mozley¹; ¹Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, ²Biogen Idec, Inc., Cambridge, MA, UNITED STATES OF AMERICA.

510 Sunday, October 22, 2017, 16:30 - 18:00, Hall G2

Conventional & Specialised Nuclear Medicine: Paediatrics

Chairs: R. Kluge (Leipzig, GERMANY)

L. Biassoni (London, UNITED KINGDOM)

OP-191**Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology: Gazi University Pediatric PET/MRI Experience**

L. Ö. Atay Kapucu¹, L. Uslu Beşli², Ü. Ö. Akdemir¹, U. Aydos¹, M. Özçelik¹, F. G. Pınarlı³, A. Okur³, N. I. Karabacak¹, C. Karadeniz³; ¹Gazi University Medical Faculty, Department of Nuclear Medicine, Ankara, TURKEY, ²Istanbul University Cerrahpaşa Medical Faculty, Department of Nuclear Medicine, Istanbul, TURKEY, ³Gazi University Medical Faculty, Department of Pediatric Oncology, Ankara, TURKEY.

OP-192**Positive & negative predictive value of FDG PET/CT in pre-therapy assessment of Bone Marrow infiltration in pediatric lymphoma patients**

M. A. Abdelwahab¹, S. A. Badr¹, M. H. Kotb¹, H. Mostafa²; ¹National Cancer Institute, Giza, EGYPT, ²NEMROCK, Cairo University, Giza, EGYPT.

OP-193**Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET**

G. Bottoni¹, D. Tortora², A. Piccardo¹, M. Puntoni³, M. Severino², P. Nozza², S. Mascelli², A. Raso², A. Verrico², M. Garrè², A. Rossi², G. Morana²; ¹E.O. Ospedali Galliera, Genia, ITALY, ²Istituto G. Gaslini, Genova, ITALY, ³E.O. Ospedali Galliera, Genova, ITALY.

OP-194**FDG PET in response evaluation of bulky masses in paediatric Hodgkin Lymphoma patients enrolled in the Italian AIEOP LH2004 trial**

E. Lopci¹, M. Mascarin², A. Piccardo³, C. Elia², L. Guerra⁴, E. Borsatti², A. Sala⁴, A. Todisco⁵, A. Todisco⁵, P. Zucchetta⁵, P. Farruggia⁶, A. Cistaro⁷, S. Buffardi⁸, P. Bertolini⁹, M. Bianchi¹⁰, M. Moleti¹¹, F. Bunkheila¹², P. Indolfi¹³, A. Garaventa¹⁴, R. Burnelli¹⁵; ¹Humanitas Clinical and Research Hospital, Milano, ITALY, ²Centro di Riferimento Oncologico, Aviano, Aviano, Pordenone, ITALY, ³Galliera Hospital, Genova, ITALY, ⁴Hospital San Gerardo, Monza, ITALY, ⁵University Hospital, Padova, Padova, ITALY, ⁶Ospedale dei Bambini, Palermo, Palermo, ITALY, ⁷IRMET, Torino, Torino, ITALY, ⁸Napoli – Pausillipon, Napoli, ITALY, ⁹Azienda Ospedaliera, Parma, ITALY, ¹⁰Regina Margherita, Torino, ITALY, ¹¹Università La Sapienza, Roma, ITALY, ¹²Hospital San Salvatore, Pesaro, ITALY, ¹³Napoli – 2° Università, Napoli, ITALY, ¹⁴Gaslini Hospital, Genova, ITALY, ¹⁵University Hospital S. Anna, Ferra, ITALY.

OP-195**Usefulness Of FDG-PET/CT In Assessing Bone And Bone Marrow Involvement In Pediatric Hodgkin Lymphoma**

P. Guglielmo¹, C. Dolci², A. Sala³, M. Spinelli³, F. Elisei⁴, E. Turolla⁵, C. Crivellaro¹, C. Landoni¹, L. Guerra⁴; ¹University of Milan Bicocca, Milano, ITALY, ²Fondazione Tecnomed, ASST Monza - Ospedale San Gerardo, Milano, ITALY, ³Fondazione MBBM, Monza, ITALY, ⁴ASST - Monza, Ospedale San Gerardo, Monza, ITALY, ⁵Fondazione Tecnomed, ASST Monza - Ospedale San Gerardo, Monza, ITALY.



OP-196**The Role of FDG PET/CT Metabolic Parameters In Predicting Metastatic Disease In Pediatric Osteosarcoma Patients and The Prognostic Importance**

A. K. Fidan, G. Ucmak, I. Kerimel, B. E. Akkas, B. B. Demirel; S.B.U. Ankara Oncology Research and Training Hospital, Nuclear Medicine Department, Ankara, TURKEY.

OP-197**Argentinean experience with the use of PET CT 18F DOPA in patient with suspected congenital hyperinsulinism**

M. J. Bastianello^{1,2}; ¹Instituto Universitario CEMIC, CIUDAD DE BUENOS AIRES, ARGENTINA, ²Universidad Nacional de San Martin, Bs. As., ARGENTINA.

OP-198**Lymphoscintigraphic anomalies in children with Gorham's disease**

M. Pizzoferro, M. F. Villani, A. Jenkner, I. Rana, D. Barbuti, M. C. Garganese; IRCCS Bambino Gesù Paediatric Hospital, Rome, ITALY.

601 Monday, October 23, 2017, 08:00 - 09:30, Hall A**CME 5 - Radiopharmacy/ Drug Development/Radionuclide Therapy/SNMMI: Theranostics and Companion Drugs**

Chairs: C. Cutler (St. Louis, UNITED STATES OF AMERICA)
J. Koziorowski (Linköping, SWEDEN)

OP-199**Theranostic Concepts, Exemplified on PSMA and CXCR4**

H.-J. Wester; Technical University of Munich, Faculty of Chemistry and Faculty of Medicine, Munich, GERMANY.

OP-200**Development of Novel Theranostics**

C. Cutler; Brookhaven National Laboratory, Upton, UNITED STATES OF AMERICA.

OP-201**Pretargeting in the Context of Theranostics and Companion Diagnostics**

J. Barbet; Arronax GIP, Saint-Herblain, FRANCE.

602 Monday, October 23, 2017, 08:00 - 09:30, Hall B**Joint Symposium 5 - EANM/ESMI: Imaging Cardiac Remodelling Solutions**

Chairs: F. Bengel (Hanover, GERMANY)
F. Hyafil (Paris, FRANCE)

OP-202**Imaging Cardiac Metabolism with PET**

A. Saraste; Turku PET Centre, Turku University Hospital and University of Turku, Turku, FINLAND.

OP-203**Imaging Cardiac Metabolism with MRI**

J. Prompers; Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, NETHERLANDS.

OP-204**Imaging Cardiac Remodelling Using PET-MRI**

C. Rischpler; Department of Nuclear Medicine, Technical University Munich, Munich, GERMANY.

OP-205**Imaging Cell Trafficking in the Heart**

J. Thackeray; Department of Nuclear Medicine, Hannover Medical School, Hanover, GERMANY.

603 Monday, October 23, 2017, 08:00 - 09:30, Hall C**Technologist Oral Presentations 1**

Chairs: M. Vartzokas (London, UNITED KINGDOM)
C. Copland (London, UNITED KINGDOM)

OP-206**Using an asymmetric energy window improves image quality in planar bone scans**

J. F. Machado¹, S. K. Doshi¹, R. Smith², M. Evans¹, S. Redman¹, R. N. J. Graham¹, D. Little¹; ¹Royal United Hospitals Bath, Bath, UNITED KINGDOM, ²Auckland District Health Board, Auckland City Hospital, Auckland, NEW ZEALAND.

OP-207**Semi-quantitative analysis in salivary glands scintigraphy: a contribution for technical validation**

J. S. Vale¹, D. Neves^{1,2}, L. Pires³, M. F. João², A. I. Ferrer², L. F. Metello^{1,4}; ¹ESS – IPP, ATC & Curso Med. Nuclear, Rua Dr. Antonio Bernardino de Almeida, 400, 4200 – 072, Porto, Porto, PORTUGAL, ²Diaton S.A. – Unidade de Leiria, Rua de Olhalvas, Pousos, 2400 Leiria, Portugal, Leiria, PORTUGAL, ³Diaton S.A. – Unidade de Coimbra, Urb. Espírito Santo, Lote 2 Calçada do Gato 3000-199 Coimbra, Coimbra, PORTUGAL, ⁴IsoPor-Azores, Dept. de Med. Nuclear e Imagiologia Molecular, Angra do Heroísmo, I. Terceira – Azores, Portugal, Açores, PORTUGAL.

OP-208**Advanced method to reconstruct SPECT image from few number of projection data**Y. Yamaguchi¹, Y. Okura², M. Yamamoto²;¹Hiroshima International University Graduate School, Higashihiroshima-shi, JAPAN, ²Hiroshima International University, Higashihiroshima-shi, JAPAN.**OP-209****Wireless Online Monitoring of Radiation Dose Rate of Radioiodine (I-131) Ablation Patients: Saves Staff's Doses and Resources**

M. C. Lehtinen Gil Compte, P. H. Puhakka, K. Levänen, M. Honkanen, S. Myöhänen, J. Heikkinen; South Savo Social and Health Care Authority, Mikkeli, FINLAND.

OP-210**The EU directive 2010/32, prevention from sharp injuries in the hospital and healthcare sector, in relation to ALARA: To recap or not?**

A. F. Rekveld-van Moerkerken, K. Hart, F. Bomert, H. J. Verberne; Academic Medical Center (AMC), Amsterdam, NETHERLANDS.

OP-211**The effect of PET scan time on the off-line PET image quality in proton therapy**

H. Gunchul, J. Joonyung, P. sejoon, C. eunsun, L. hyuk; Samsung medical center, seoul, KOREA, REPUBLIC OF.

OP-212**MOLY Project: a Mo-99 Production Program at ENEA TRIGA RC-1 Nuclear Research Reactor in Italy**F. Pisacane¹, O. Aronica¹, M. Carta¹, N. Cherubini¹, A. Dodaro^{1,2}, G. Giorgiantoni¹, M. Olivetti¹, E. Santoro¹; ¹ENEA, Rome, ITALY, ²Nucleco S.p.A., Rome, ITALY.**OP-213****F-18-FDG PET-CT Studies Reproducible Quantitative Assessment for Clinical Use**D. B. Faria^{1,2,3}, J. Teixeira^{1,2}, A. Martins^{1,2}, J. Fernandes^{1,2}, J. Pinto^{1,2}, J. Vale^{1,2,3}, J. Patrino^{1,2}, A. Roçado^{1,2}, D. Sousa^{1,2}, J. M. P. Oliveira^{1,2}; ¹HPP - Medicina Molecular SA, Porto, PORTUGAL, ²Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL, ³School Of Health Sciences - University of Aveiro, Aveiro, PORTUGAL.**OP-214****Digital PET/CT in clinical routine: Dose reduction and image quality**

J. Trinckauf, M. Hofbauer, M. Hüllner, I. Burger; University Hospital Zürich, ZÜRICH, SWITZERLAND.

604 Monday, October 23, 2017, 08:00 - 09:30, Hall E1**Do.MoRe: PSMA Therapy**Chairs: F. Giesel (Heidelberg, GERMANY)
I. Zerizer (London, UNITED KINGDOM)**OP-215****Variation in the absorbed radiation dose and PSA response after serial Lu-177 PSMA radioligand therapy**

C. Schuchardt, H. R. Kulkarni, S. Wiessalla, A. Singh, M. Shahinfar, D. Mueller, C. Lehmann, R. P. Baum; Zentralklinik Bad Berka GmbH, Bad Berka, GERMANY.

OP-216**¹⁷⁷Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival**E. Demirci¹, R. Akyel², O. Sahin³, M. Ocak⁴, A. Aygün³, H. Pehlivanoglu³, E. Karayel³, L. Kabasaka³; ¹Department of Nuclear Medicine Sisli Etfal Training and Research Hospital, istanbul, TURKEY, ²Department of Nuclear Medicine Umraniye Training and Research Hospital, istanbul, TURKEY, ³Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, istanbul, TURKEY, ⁴Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, istanbul, TURKEY.**OP-217****Targeted Alpha Therapy of mCRPC: Dosimetry estimate of ²¹³Bismuth-PSMA-617**C. Kratochwil¹, K. Schmidt², F. Bruchertseifer³, A. Afshar-Oromieh¹, A. Morgenstern³, U. Haberkorn¹, F. L. Giesel¹; ¹University Hospital Heidelberg, Heidelberg, GERMANY, ²ABX-CRO, Dresden, GERMANY, ³EC-JRC, Karlsruhe, GERMANY.**OP-218****Overall survival and response pattern of castrated-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using Lu-PSMA-617**

H. Ahmadzadehfar, S. Wegen, A. Yordanova, R. Fimmers, S. Kürpig, E. Eppard, X. Wei, C. Schlenkhoff, S. Hauser, M. Essler; University Hospital Bonn, Bonn, GERMANY.

OP-219**The impact of repeated cycles of Lu-PSMA-617 therapies on renal function in patients with hormone refractory metastatic prostate cancer**

A. Yordanova, A. Becker, E. Eppard, S. Kürpig, C. Fisang, G. Feldmann, M. Essler, H. Ahmadzadehfar; University Hospital Bonn, Bonn, GERMANY.



OP-220**Lu-177 PSMA Radioligand Therapy might Prolong Survival in Metastatic Castration-Resistant Prostate Cancer: Results from a Single Center over 4 Years**

H. R. Kulkarni¹, A. Singh¹, C. Schuchardt¹, T. Langbein¹, K. J. Pienta², R. P. Baum¹; ¹Theranostics Center for Molecular Radiotherapy, Bad Berka, GERMANY, ²The Brady Urological Institute, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

OP-221**Targeted Alpha Radioligand Therapy (TART) using Bismuth-213 PSMA in End-stage Progressive Treatment-refractory PSMA-expressing Metastatic Prostate Cancer: Results of a Pilot Study**

H. R. Kulkarni¹, A. Singh¹, T. Langbein¹, C. Lehmann¹, D. Mueller², S. Marx³, K. J. Pienta⁴, R. P. Baum¹; ¹Theranostics Center for Molecular Radiotherapy, Zentralklinik Bad Berka, Bad Berka, GERMANY, ²Division of Radiopharmacy, Zentralklinik Bad Berka, Bad Berka, GERMANY, ³ITG Isotope Technologies Garching GmbH, Munich, GERMANY, ⁴The Brady Urological Institute, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

OP-222**Initial Theranostics Experience Using ⁶⁸Ga-PSMA-11 PET/CT and ¹⁷⁷Lu-PSMA-617 in a Chilean Oncology Center**

H. Amaral^{1,2}, R. Fernández¹, V. Kramer², H. Lavados¹, E. Hernández¹, B. Morales¹, R. Pruzzo¹, A. Haeger¹, J. Ribbeck², J. Flores¹; ¹FALP / PositronMed, Santiago, CHILE, ²PositronPharma, Santiago, CHILE.

605 Monday, October 23, 2017, 08:00 - 09:30, Hall E2

M2M: Optical/Multimodality Imaging

Chairs: M. Schottelius (Garching, GERMANY)
F. van Leeuwen (Leiden, NETHERLANDS)

OP-223**Diagnostic Tumor Imaging Using Renally Excretable Nanoparticles: Focus on Active and Passive Targeting**

K. Pant¹, K. Zarschler¹, C. Neuber¹, J. Pufe¹, J. Steinbach^{1,2}, R. Haag³, J. Pietzsch^{1,2}, H. Stephan¹; ¹Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY, ²Technische Universität Dresden, Department of Chemistry and Food Chemistry, Dresden, GERMANY, ³Freie Universität Berlin, Department of Chemistry and Biochemistry, Berlin, GERMANY.

OP-224**Multicolor fluorescence click-chemistry as a means to select membrane targets for pre-targeting by function of their internalization**

S. van der Wal, C. M. de Korne, L. G. L. Sand, P. C. W. Hogendoorn, K. Szuhai, F. W. B. van Leeuwen, T. Buckle; LUMC, Leiden, NETHERLANDS.

OP-225**Multicolor fluorescence imaging as a means to reduce the toxicity during nodal dissections in prostate cancer**

P. Meershoek^{1,2}, G. H. KleinJan^{1,2}, M. N. van Oosterom¹, E. M. Wit², N. Grivas², A. Mottrie³, F. W. B. van Leeuwen¹, H. G. van der Poel²; ¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Netherlands Cancer Institute (NKI-AvL), Amsterdam, NETHERLANDS, ³OLV Vattikuti Robotic Surgery Institute, Melle, BELGIUM.

OP-226**Development of a tumor microenvironment(FAP alpha) targeted near infrared dye for fluorescence guided surgery of cancers**

J. Roy^{1,2}, P. S. Low²; ¹National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, ²Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA.

OP-227**SPECT-based navigation of fluorescence cameras during soft-tissue surgery - is it possible to use a single navigation setup for various open and laparoscopic radioguided surgery applications?**

M. N. van Oosterom¹, P. Meershoek¹, G. H. KleinJan¹, K. Hendricksen², N. Navab³, C. J. H. van de Velde¹, H. G. van der Poel², F. W. B. van Leeuwen¹; ¹Leiden University Medical Center, Leiden, NETHERLANDS, ²The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, ³Technical University Munich, Munich, GERMANY.

OP-228**Molecular imaging of malaria through fluorescent labelling of Plasmodium species within the mosquito host**

B. M. F. Winkel, M. N. Oosterom, A. Bunschoten, M. M. Welling, M. C. C. Langenberg, B. Franke-Fayard, C. De Korne, S. C. Chevalley, M. Yazdanbakhsh, F. W. B. van Leeuwen, M. Roestenberg; LUMC, Leiden, NETHERLANDS.

OP-229**[⁶⁸Ga]PSMA-I&F: a first successful step towards PSMA-targeted bimodal probes for radio- and fluorescence guided surgery of prostate cancer**

*M. Schottelius*¹, *A. Wurzer*¹, *K. Wissmiller*¹, *R. Beck*¹, *J. Notni*¹, *M. Koch*², *D. Gorpas*², *V. Ntziachristos*², *M. Schwaiger*³, *T. Buckle*⁴, *F. van Leeuwen*⁴, *H. Wester*¹;
¹Pharmaceutical Radiochemistry, TUM, Garching, GERMANY, ²IBMI, Helmholtz Center Munich, Munich, GERMANY, ³Dept. of Nuclear Medicine, TUM, Munich, GERMANY, ⁴Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.

OP-230**s-Tetrazine: a “clickable” platform for the site-specific dual-labeling of proteins**

*C. Canovas*¹, *M. Moreau*¹, *C. Bernhard*¹, *M. Cordonnier*², *J. Gobbo*³, *A. Oudot*³, *F. Denat*¹, **V. Goncalves**¹;
¹Université de Bourgogne, Dijon, FRANCE, ²INSERM, UMR 866, Laboratoire d'Excellence LipSTIC, Dijon, FRANCE, ³Centre Georges-François Leclerc, Dijon, FRANCE.

606 Monday, October 23, 2017, 08:00 - 09:30, Hall F1**Pitfalls & Artefacts 3 (Interactive) - Oncology/ Inflammation & Infection/Bone & Joint: Pitfalls and Artefacts in Abdomen and Pelvis**

Chairs: L. Mansi (Naples, ITALY)
T. Kuwert (Erlangen, GERMANY)

OP-231**CT in Abdomen and Pelvis**

T. Bäuerle; Institute of Radiology, University Hospital Erlangen, Erlangen, GERMANY

OP-232**Pitfalls in Planar Imaging**

L. Mansi; Università della Campania “Luigi Vanvitelli”, Nuclear Medicine Department, Naples, ITALY.

OP-233**Pitfalls in SPECT/CT**

T. Kuwert; Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GERMANY

OP-234**Pitfalls in PET/CT**

L. Evangelista; Istituto Oncologico Veneto I.R.C.C.S., Padova, ITALY

607 Monday, October 23, 2017, 08:00 - 09:30, Hall F2**Clinical Oncology - Rapid Fire Session: What's New? Texture Analysis and More!**

Chairs: J. Adam (Amsterdam, NETHERLANDS)
P. Pilkington (Madrid, SPAIN)

OP-236**Textural features assessed by dual time point 18 FDG PET/CT in locally advanced breast cancer: Relation with SUV-based variables and tumor biology**

*A. García Vicente*¹, *G. Jimenez Londoño*¹, *D. Molina*², *J. Perez-Beteta*², *M. Amo-Salas*³, *A. Martinez Gonzalez*², *M. Tello Galan*¹, *V. Perez-Garcia*², *A. Soriano Castrejon*¹;
¹General Hospital of Ciudad Real, Ciudad Real, SPAIN, ²IMACI. Universidad de Castilla La Mancha, Ciudad Real, SPAIN, ³Departamento de Matemáticas. Universidad de Castilla La Mancha, Ciudad Real, SPAIN.

OP-237**First Interim Results of the Radium-223 REASSURE Observational Study: Analysis of Patient Characteristics and Safety by Prior Use of Chemotherapy**

*S. Dizdarevic*¹, *P. Meidahl Petersen*², *M. Essler*³, *A. Versari*⁴, *J. Bourre*⁵, *C. La Fougère*⁶, *R. Valdagni*⁷, *G. Paganelli*⁸, *S. Ezziddin*⁹, *J. Kalinovsky*¹⁰, *Y. De Sanctis*¹¹, *Y. Du*¹²;
¹Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM, ²Rigshospitalet, Copenhagen, DENMARK, ³Universitätsklinikum Bonn, Bonn, GERMANY, ⁴Azienda Ospedaliera Arcispedale Santa Maria Nuova – IRCCS, Reggio Emilia, ITALY, ⁵Centre Hospitalier Métropole Savoie, Chambéry, FRANCE, ⁶Universitätsklinikum Tübingen, Tübingen, GERMANY, ⁷Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, ⁸Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, ITALY, ⁹Universitätsklinikum des Saarlandes, Hamburg, GERMANY, ¹⁰Bayer, Bratislava, SLOVAKIA, ¹¹Bayer, Whippany, NJ, UNITED STATES OF AMERICA, ¹²Royal Marsden Hospital, London, UNITED KINGDOM.

OP-238**Repeatability of tumour hypoxia imaging using [¹⁸F]EF5 PET/CT in head and neck cancer**

A. Silvoniemi^{1,2}, *S. Suilamo*^{1,2}, *T. Laitinen*¹, *S. Forsback*¹, *E. Löyttyniemi*³, *V. Saunavaara*^{1,2}, *O. Solin*¹, *T. J. Grönroos*^{1,2}, *H. Minn*^{1,2};
¹Turku PET Centre, University of Turku, Turku, FINLAND, ²Turku University Hospital, Turku, FINLAND, ³University of Turku, Turku, FINLAND.



OP-239**Prostate-Specific Antigen Flare Induced by (223)Ra therapy in Patients with Metastatic Castration-Resistant Prostate Cancer**A. Castello^{1,2}, H. A. Macapinlac², E. B. Santos²;¹Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, Florence, ITALY,²Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.**OP-240****The Role of Texture Features Derived from FDG-PET/CT to Characterize Lung Lesions and Predict Survival in Non-Small Cell Lung Cancer Patients Undergoing Surgery**M. Kirienko¹, M. Sollini¹, L. Cozzi², L. Antunovic², E.Voulaz², G. Veronesi², N. Gennaro¹, R. Muglia¹, O.Santonocito¹, A. Chiti¹; ¹Humanitas University, Milano, ITALY, ²Humanitas Clinical and Research Center, Milano, ITALY.**OP-241****Transitioning New Technology into the Reading Room - A Secondary Reconstruction Approach for Evaluation of Next-generation Digital PET/CT**K. Binzel¹, J. Zhang¹, C. L. Wright¹, P. Maniawski², M.V. Knopp¹; ¹The Ohio State University, Columbus, OH,UNITED STATES OF AMERICA, ²Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.**OP-242****Radiomics analysis predicts N- and M-stage of primary cervical cancer using multiple PET/MR-derived quantitative features**

J. Grueneisen, F. Nensa, K. Herrmann, A. Bariye, M.

Forsting, L. Umutlu; University Hospital Essen, Essen, GERMANY.

OP-243**Simultaneous whole-body ¹⁸F-PSMA-1007-PET/MRI with integrated high-resolution multiparametrical imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer**M. T. Freitag¹, C. Kesch², J. Cardinale¹, P. Flechsig²,R. Floca¹, M. Eiber³, D. Bonekamp¹, J. P. Radtke², C.Kratohvil², K. Kopka¹, H. Schlemmer¹, U. Haberkorn^{2,1},F. L. Giesel^{2,1}; ¹German Cancer Research Center,Heidelberg, GERMANY, ²University Hospital Heidelberg,Heidelberg, GERMANY, ³Technical University Hospital Munich, Munich, GERMANY.**OP-244****Combined use of Ga-68 PSMA-HBED and multiparametric MRI imaging of patients with carcinoma of the prostate in the primary staging setting and in cases of biochemical recurrence after radical prostatectomy**Z. E. Ballok^{1,2}, M. Frydenberg³, K. Marshmann¹, R.O'Sullivan¹, D. Reilly¹; ¹BRI, Richmond, AUSTRALIA,²MMC, Melbourne, AUSTRALIA, ³Australian Urology Association, Malvern, AUSTRALIA.**OP-245****Texture analysis is more predictive than SUV in ¹⁸F-Choline PET of the aggressiveness of prostate cancer**F. Hives^{1,2}, A. Fagart², K. Bouharati-Moussa¹, M. Fares³,L. Drelon⁴, P. Danjou⁵, O. Decavel⁶, B. Makki¹, S. Adib¹;¹Service de médecine nucléaire, centre hospitalierde Béthune, Béthune, FRANCE, ²Service de médecinenucléaire, Université Lille 2, Lille, FRANCE, ³Service de

radiothérapie, Centre Pierre Curie, Béthune, FRANCE,

⁴Service d'urologie, clinique des deux caps, Coquelles,FRANCE, ⁵Service d'urologie, centre hospitalier deLens, Lens, FRANCE, ⁶Service d'urologie, clinique Anne

d'Artois, Béthune, FRANCE.

OP-246**SPECT-CT visualization of sentinel and second echelon lymph nodes for lymph flow guided radiotherapy of tongue cancer**

S. Novikov, P. Krzhivitskiy, Z. Radzhabova, O.

Ponomareva, M. Girshovitch, S. Kanaev; N.N.

Petrov Institute Oncology, St Petersburg, RUSSIAN

FEDERATION.

OP-247**¹⁸F-FDG PET/CT radiomics in endometrial cancer**C. Crivellaro^{1,2}, E. De Bernardi¹, D. Vicini¹, F. Elisei², M.Cuzzocrea¹, A. Buda³, E. De Ponti⁴, F. P. Sina³, L. Guerra²,R. Fruscio^{1,3}, C. Landoni^{1,2}; ¹University Milan-Bicocca,Monza, ITALY, ²Nuclear Medicine, ASST-Monza, SanGerardo Hospital, Monza, ITALY, ³Clinic of Obstetrics

and Gynecology, ASST-Monza, San Gerardo Hospital,

Monza, ITALY, ⁴Medical Physics, ASST-Monza, San

Gerardo Hospital, Monza, ITALY.

**609 Monday, October 23, 2017, 08:00 - 09:30, Hall G1****Committee Symposium 2 - Neuroimaging: PET/MR - Making it Clinical**

*Chairs: B. Sattler (Leipzig, GERMANY)
A. Lammertsma (Amsterdam, NETHERLANDS)*

OP-248**Attenuation correction - is it solved?**

C. Ladefoged; Copenhagen University Hospital Rigshospitalet, Nuclear Medicine & PET, Copenhagen, DENMARK.

OP-249**Brain Tumours**

I. Law; Copenhagen University Hospital Rigshospitalet, Nuclear Medicine & PET, Copenhagen, DENMARK.

OP-250**Epilepsy - what does simultaneous PET-MR achieve that PET+MR does not?**

A. Hammers; King's College London, Imaging Sciences and Biomedical Engineering, London, UNITED KINGDOM.

OP-251**Dementia**

A. Drzezga; University of Cologne, Nuclear Medicine, Cologne, GERMANY.

610 Monday, October 23, 2017, 08:00 - 09:30, Hall G2**Conventional & Specialised Nuclear Medicine: Musculoskeletal (Benign)**

*Chairs: F. Paycha (Paris, FRANCE)
S. Gratz (Stuttgart, GERMANY)*

OP-252**Low Dose Radiation 18F-Fluoride PET/CT in the assessment of Unilateral Condylar Hyperplasia of the mandible: preliminary results of a 16 patients single centre experience**

G. M. Lima, S. Diodato, E. Costabile, D. Calabrò, F. Scalorbi, A. Sviridenka, G. Cicoria, S. Civollani, C. Pettinato, P. L. Guidalotti, C. Nanni, S. Fanti; S. Orsola-Malpighi University Hospital, Bologna, ITALY.

OP-253**Diagnostic ability of bone scan index for differentiating dental diseases**

S. Watanabe, K. Nakajima, N. Noguchi, S. Kawashiri, A. Mizokami, M. Inokuchi, S. Kinuya; Kanazawa University Hospital, Kanazawa, JAPAN.

OP-254**Influence of 18F-FDG-PET/CT on therapeutic decision-making of patients with spondylodiscitis**

A. Pöhlmann, D. Moskopp, M. Plotkin; Vivantes Klinikum im Friedrichshain, Berlin, GERMANY.

OP-255**SPECT/CT imaging in Bertolotti's Syndrome**

K. Bayardo^{1,2}, V. Depons², J. Vilar^{1,2}, D. Muñoz¹, A. Battezzare², A. Silveira², R. Ferrando^{1,2}; ¹Clinics Hospital, University of the Republic, Montevideo, URUGUAY, ²Ferrari Ferrando Páez Nuclear Medicine Clinic, Montevideo, URUGUAY.

OP-256**Scintigraphy of rhabdomyolysis - cornerstone in patient management?**

D. Jocius¹, D. Vajauskas¹, A. E. Tamosiūnas^{1,2}, A. Skrebunas¹, M. Gutauskas¹; ¹Vilnius University Hospital Santaros Klinikos, Vilnius, LITHUANIA, ²Vilnius University, Vilnius, LITHUANIA.

OP-257**Clinical relevance of 99mTc-HDP SPECT/CT in the diagnosis of spondyloarthropathies**

A. Bakos¹, Z. Besenyi¹, S. Urbán¹, R. Hemelein², L. Kovács², L. Pávics¹; ¹Department of Nuclear Medicine University of Szeged, Szeged, HUNGARY, ²Department of Rheumatology University of Szeged, Szeged, HUNGARY.

OP-258**Increased Uptake in Synchronosis of the Lower Limbs: Added Value of SPECT/CT.**

K. Bayardo^{1,2}, A. Zamora¹, J. Vilar^{1,2}, R. Ferrando^{1,2}; ¹Clinics Hospital, University of the Republic, Montevideo, URUGUAY, ²Consultorio de Medicina Nuclear Ferrari Ferrando Páez, Montevideo, URUGUAY.

OP-259**SPECT/CT is equivalent to diffusion-weighted MRI in characterizing equivocal osseous lesions detected by planar bone scintigraphy**

M. Khalil¹, Y. G. Abdelhafez¹, H. Atta¹, A. A. Kandeel²; ¹South Egypt Cancer Institute, Assiut University, Assiut, EGYPT, ²Faculty of Medicine, Cairo University, Cairo, EGYPT.

SPS Monday, October 23, 2017, 08:00 - 09:30, Room 0.31-2

UEMS/EBNM: Clinical Audit Session

*Chairs: J. Prior (Lausanne, SWITZERLAND)
S. Mirzaei (Vienna, AUSTRIA)***Welcome and Introduction***J. Prior, Lausanne, SWITZERLAND***NM Resources Manual- Guide for decision makers***D. Paez, IAEA***Clinical Audit in Algeria***S. Bouyoucef, ALGERIA***Clinical Audit in Spain***A. García-Burillo, Barcelona, Spain***Clinical Audit in Switzerland***S. Gnesin, Lausanne, SWITZERLAND***UEMS/EBNM Accreditation from non-ISO-9001 certification***S. Mirzaei, Vienna, AUSTRIA***Presentation of accredited centers and training program since EANM 2016**

701/703 Monday, October 23, 2017, 10:00 - 11:15, Hall A

Plenary 2: Hot Topics in Nuclear Cardiology!

*Chairs: W. Oyen (Sutton, UNITED KINGDOM)
R. Delgado-Bolton (Logroño - La Rioja, SPAIN)***OP-260****Systemic Inflammatory Response Post Myocardial Ischemia: Moving Towards Clinical Application?***E. Stroes; Department of Vascular Medicine, Academic Medical Center, Amsterdam, NETHERLANDS.***OP-261****The Role of Nuclear Medicine in Endocarditis***F. Bengel; Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hanover, GERMANY.***OP-262****Quantification of Myocardial Blood Flow with PET***J. Knuuti; Turku University Hospital, Turku PET Centre, Turku, FINLAND.*

801 Monday, October 23, 2017, 11:30 - 13:00, Hall A

CME 6 (Interactive) - Bone & Joint: Skeletal Scintigraphy Today - Accurate Diagnosis of Bone Disease with Therapeutic Impact*Chairs: F. Paycha (Paris, FRANCE)
T. van den Wyngaert (Antwerp, BELGIUM)***OP-263****High Resolution SPECT/CT and Beyond***P. Ritt; University Hospital Erlangen, Clinic of Nuclear Medicine, Erlangen, GERMANY.***OP-264****SPECT/CT Quantification***T. Kuwert; Friedrich-Alexander-University Erlangen-Nürnberg, Clinic of Nuclear Medicine, Erlangen, GERMANY.***OP-265****The End of Planar: Whole-Body SPECT as New Paradigm***Z. Keidar; Rambam Health Care Campus, Department of Nuclear Medicine, Haifa, ISRAEL.***OP-266****Top Ten Diagnoses Made Possible by SPECT/CT***G. Gnanasegaran; Royal Free London NHS Foundation Trust, Department of Nuclear Medicine, London, UNITED KINGDOM.*

802 Monday, October 23, 2017, 11:30 - 13:00, Hall B

Joint Symposium 6 - EANM/EACVI: Fast-Track Cardiac Imaging: Is There an Ideal One-Stop Shop?*Chairs: O. Gämperli (Zurich, SWITZERLAND)
R. Slart (Groningen, NETHERLANDS)***OP-267****Healthcare Economic Perspectives on One-Stop Shop Cardiac Imaging***L. Hakkaart-van Roijen; Institute of Health Policy & Management (iBMG), Institute for Medical Technology Assessment (iMTA), Rotterdam, NETHERLANDS..***OP-268****Nuclear Medicine Physicians' Perspective on One-Stop Shop Cardiac Imaging***M. Mouden; Isala Hospital, Department of Cardiology, Zwolle, NETHERLANDS.*

OP-269**Radiologists' Perspective on One-Stop Shop Cardiac Imaging**

T. Leiner; Department of Radiology and Nuclear Medicine, Utrecht University Medical Center, Utrecht, NETHERLANDS.

OP-270**Cardiologists' Perspective on One-Stop Shop Cardiac Imaging**

D. Neglia; Fondazione G. Monasterio CNR-Regione Toscana and CNR Institute of Clinical Physiology, Pisa, ITALY.

803 Monday, October 23, 2017, 11:30 - 13:00, Hall C

Technologist Oral Presentations 2

*Chairs: S. Rep (Ljubljana, SLOVENIA)
W. Kemps (Brussels, BELGIUM)*

OP-271**Ultra-low Dose CT for Attenuation Correction of 82Rb Cardiac PET**

M. B. Sørensen, K. Bouchelouche, L. P. Tolbod; Dept. Nuclear Med. & PET-Centre, Aarhus University Hospital, Aarhus, DENMARK.

OP-272**Pediatric Anesthesia on Daily PET/CT workflow: Impact Quantification Based on Three Indicators**

C. Barbosa¹, S. Mendes¹, I. Ferreira¹, P. Gil¹, P. Ribeiro¹, G. Costa^{1,2}, J. Pedrosa de Lima^{1,2,3}; ¹Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, PORTUGAL, ²Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, ³Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL.

OP-273**18F-FDG PET/CT in pediatric lymphoma patients: the role of technologist**

M. Ciaccio¹, C. Nava², D. Bonacina¹, M. Maurizio¹, A. Perri¹, A. Renaioli¹, S. Morzenti³, L. Guerra¹, C. Crivellaro^{1,2}; ¹ASST-Monza, San Gerardo Hospital, Nuclear Medicine, Monza, ITALY, ²University Milan-Bicocca, Nuclear Medicine, Monza, ITALY, ³ASST-Monza, San Gerardo Hospital, Medical Physics, Monza, ITALY.

OP-274**Practical Guide for ¹⁸F-Choline PET Imaging in hyperparathyroidism**

M. Hofbauer, J. Trinckauf, M. Hüllner; UniversitätsSpital, Zurich, SWITZERLAND.

OP-275**⁶⁸Ga-PSMA PET/CT Protocol Review**

E. Poel; Academic Medical Center, Amsterdam, NETHERLANDS.

OP-276**Reducing artefacts in PSMA PET/MR due to hip prosthesis with MAVRIC SL**

T. Oblasser, M. Hofbauer, J. Trinckauf, T. Berthold, K. Friedrich, I. Burger; Department of Nuclear Medicine, PET/CT - MR Zentrum für Klinische Forschung, UniversitätsSpital Zür, Zurich, SWITZERLAND.

OP-277**Improving alignment between 18F-FDG PET and CT scans by controlling breathing movements during the CT-scan.**

T. K. Lehnskov¹, C. P. Jønsson², L. B. Katz², D. A. Riisberg²; ¹Bispebjerg/Frederiksberg Hospital, København NV, DENMARK, ²Metropolitan University College, København N, DENMARK.

OP-278**Myocardium metabolic suppression protocol for 18F-FDG PET Sarcoid Scan**

E. M. Bagi, A. Garcia-Campos, K. Wechalekar; Royal Brompton & Harefield NHS Foundation Trust, 77 Wimpole Street, London, W1G 9RU, London, UNITED KINGDOM.

OP-279**PET imaging with ⁴⁵Ti and the technical challenges involved**

P. Costa¹, N. Arantes²; ¹Nuclear Medicine Department, ESS|P, Porto, Porto, PORTUGAL, ²Independent Nuclear Medicine Technologist, Braga, PORTUGAL.

804 Monday, October 23, 2017, 11:30 - 13:00, Hall E1

Do.MoRe - Featured: Harmonization of Hybrid Molecular Imaging

*Chairs: I. Rausch (Vienna, AUSTRIA)
M. Lubberink (Uppsala, SWEDEN)*

OP-280**Molecular Imaging Systems in Harmony – Necessity and Feasibility**

I. Rausch; Medical University of Vienna, Vienna, AUSTRIA.



OP-281**Feasibility of state-of-the-art PET/CT system performance harmonisation**

A. Kaalep¹, T. Sera^{2,3}, S. Rijnsdorp⁴, M. Yaqub⁵, A. Talsma⁶, M. A. Lodge⁷, R. Boellaard^{8,5,3}; ¹North Estonia Medical Centre, Tallinn, ESTONIA, ²University of Szeged, Szeged, HUNGARY, ³EANM Research Limited, Vienna, AUSTRIA, ⁴Catharina Hospital, Eindhoven, NETHERLANDS, ⁵VU University Medical Center, Amsterdam, NETHERLANDS, ⁶Martini Hospital, Groningen, NETHERLANDS, ⁷Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ⁸University Medical Center Groningen, Groningen, NETHERLANDS.

OP-282**Feasibility of a brain PET harmonization program for state of the art PET/CT systems**

R. Boellaard¹, S. Golla², A. Kaleep³, M. Yaqub², T. Sera⁴, S. Rijnsdorp⁵, R. Kogan¹, N. Leenders¹, A. Lammertsma²; ¹University Medical Center Groningen, GRONINGEN, NETHERLANDS, ²VU University Medical Center, Amsterdam, NETHERLANDS, ³North Estonia Medical Centre Foundation, Tallinn, ESTONIA, ⁴University of Szeged, Szeged, HUNGARY, ⁵Catharina Hospital, Eindhoven, NETHERLANDS.

OP-283**EANM/EARL FDG-PET/CT accreditation - summary results from the first 150 accredited imaging sites**

A. Kaalep¹, T. Sera^{2,3}, W. Oyen⁴, B. J. Krause⁵, A. Chiti^{6,7}, Y. Liu⁸, R. Boellaard^{9,10,3}; ¹North Estonia Medical Centre, Tallinn, ESTONIA, ²University of Szeged, Szeged, HUNGARY, ³EANM Research Limited, Vienna, AUSTRIA, ⁴The Royal Marsden Hospital, London, UNITED KINGDOM, ⁵Rostock University Medical Center, Rostock, GERMANY, ⁶Humanitas University, Rozzano, ITALY, ⁷Humanitas Research Hospital, Rozzano, ITALY, ⁸The European Organisation for Research and Treatment of Cancer, Brussels, BELGIUM, ⁹University Medical Center Groningen, Groningen, NETHERLANDS, ¹⁰VU University Medical Center, Amsterdam, NETHERLANDS.

OP-284**Development of the IAEA-NMQC toolkit for automated analysis of quality control tests on SPECT systems**

G. L. Poli¹, A. Vergara Gil², L. Torres Aroche², E. De Ponti³, A. Kesner⁴; ¹International Atomic Energy Agency, Vienna, AUSTRIA, ²Division of Clinical Research, Centre of Isotopes, Havana, CUBA, ³Department of Medical Physics, ASST Monza, Monza, ITALY, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-285**Implications of a FDG-PET EARL Protocol for Ga-68 PET Imaging**

D. Koopman^{1,2}, W. A. Noortman^{1,2}, P. L. Jager¹, C. H. Slump², J. A. van Dalen³; ¹Isala, Department of Nuclear Medicine, Zwolle, NETHERLANDS, ²MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, ³Isala, Department of Medical Physics, Zwolle, NETHERLANDS.

OP-286**Robustness of EQ•PET SUV harmonization to tumor-to-background variations**

B. S. Spottiswoode¹, M. V. Mattoli², M. Milite³, M. L. Calcagni², A. Giordano², L. Indovina⁴; ¹Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, ²Università Cattolica del Sacro Cuore, Rome, ITALY, ³Siemens Healthcare Srl, Milan, ITALY, ⁴Fondazione Policlinico Universitario A. Gemelli, Rome, ITALY.

805 Monday, October 23, 2017, 11:30 - 13:00, Hall E2**M2M: Peptides**

Chairs: T. Mindt (Vienna, AUSTRIA)

T. Maina-Nock (Athens, GREECE)

OP-287**A New ⁶⁴Cu-Labeled, Metabolic-Resistant Peptide with Nanomolar Affinity for NPY-Y1R for Breast Cancer Targeting**

M. Paquette, V. Dumulon-Perreault, S. Ait-Mohand, B. Guérin; Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-288**New Radiolabeled Exendin Analogue Shows Increased Renal Clearance**

L. Joosten, C. Frielink, M. Gotthardt, M. Brom; Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-289**Metabolic fate of [¹¹¹In]Sarabesin 3 in mice: Identifying radiometabolites in peripheral blood as well as neutral endopeptidase as the key degrading protease**

B. A. Nock¹, E. Lymperis¹, W. Sallegger², A. Kaloudi¹, E. P. Krenning³, M. de Jong⁴, T. Maina⁵; ¹Molecular Radiopharmacy, INRASTES, NCSR, Athens, GREECE, ²PiChem, Graz, AUSTRIA, ³Department of Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, ⁴Department of Radiology, Erasmus MC, Rotterdam, NETHERLANDS, ⁵Molecular Radiopharmacy, INRASTES, NCSR "Demokritos", Athens, GREECE.

OP-290**New radiolabelled minigastrin analogues with improved CCK2R targeting for diagnostic and therapeutic use**

M. Klingler¹, C. Rangger¹, D. Summer¹, J. Foster², J. K. Sosabowski², E. von Guggenberg¹; ¹Medical University of Innsbruck, Innsbruck, AUSTRIA, ²Barts and the London School of Medicine, London, UNITED KINGDOM.

OP-291**Application of SSTR radioligands in Breast Cancer**

S. U. Dalm, G. N. Doeswijk, J. C. Haeck, A. M. Sieuwerts, J. W. M. Martens, C. H. M. van Deurzen, M. de Jong; Erasmus MC, Rotterdam, NETHERLANDS.

OP-292**Radionuclide tumor targeting using ADAPT scaffold proteins: aspects of label positioning and residualizing properties of the label**

J. Garousi¹, S. Lindbo², B. Mitran³, M. Altai¹, J. Buijs⁴, A. Orlova³, S. Hober², V. Tolmachev¹; ¹Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²School of Biotechnology, Division of Protein Technology, KTH Royal Institute of Technology, Stockholm, SWEDEN, ³Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ⁴Uppsala University, Uppsala, SWEDEN.

OP-293**Effectivity of a combined treatment with the m-TOR inhibitor RAD001 and Peptide Receptor Radionuclide therapy with Lu-177 DOTA TATE evaluated with Ga-68 DOTA TATE PET in a tumor model of the mouse**

J. Zellmer¹, L. Vomacka¹, G. Böning¹, F. J. Gildehaus¹, J. Carlsen¹, E. Mille¹, M. Hacker², P. Bartenstein¹, A. R. Haug², H. Ilhan¹; ¹Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP-294**The Receptor UT of Urotensin-II is a New Target for Imaging Solid Tumor with Radiolabeled DOTA-Peptide Ligands**

B. Poret^{1,2}, L. Desrue², N. Perzo², P. M. Coly², J. E. Joubert², M. A. Bonin³, R. Leduc³, R. Modzelewski¹, F. Morin², H. Castel², P. Vera¹, P. Bohn¹, P. Gandolfo²; ¹EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team "QuantIF", Centre Henri Becquerel, Rouen, FRANCE, ²Normandie Univ, UNIROUEN, INSERM 1239, DC2N, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, FRANCE, ³Department of Physiology & Pharmacology, Institute of Sherbrooke, Faculty of Medicine and Health Sciences, Sherbrooke University – Health Campus, Sherbrooke, QC, CANADA.

806 Monday, October 23, 2017, 11:30 - 13:00, Hall F1**Pitfalls & Artefacts 4 (Interactive) - Paediatrics: Pitfalls and Artefacts - FDG-PET Imaging in Children**

*Chairs: L. Kurch (Leipzig, GERMANY)
L. Borgwardt (Copenhagen, DENMARK)*

OP-295**Patient Preparation and Technical Artefacts**

C. Franzius; MR-, Nuklearmedizin und PET/CT-Zentrum Bremen Mitte, Bremen, GERMANY

OP-296**Clinical Pitfalls**

R. Kluge; Universität Leipzig, Leipzig, GERMANY

OP-297**Pitfalls in PET/MR Imaging**

P. Zucchetta; Department of Nuclear Medicine, University of Padova, Padova, ITALY.

807 Monday, October 23, 2017, 11:30 - 13:00, Hall F2**Clinical Oncology: Women's Only**

*Chairs: L. Zanoni (Bologna, ITALY)
R. Hustinx (Liège, BELGIUM)*

OP-298**Combined imaging in cervical cancer with hybrid FDG-PET/MRI for primary staging followed by Tc-99m-SPECT/CT for pre-surgical sentinel lymph node mapping**

S. Sahbai¹, F. Fiz¹, F. Taran², S. Brucker², D. Wallwiener², A. Staebler³, H. Dittmann¹, C. la Fougère¹; ¹Nuclear Medicine, Tübingen, GERMANY, ²Gynecology and Obstetrics, Tübingen, GERMANY, ³Pathology, Tübingen, GERMANY.



OP-299**Utility of multiparametric PET/MRI for response assessment of radiochemotherapy or neoadjuvant chemotherapy in cervical cancer patients**

T. Sarabhai, Y. Erfanian, M. Forsting, K. Herrmann, L. Umutlu, J. Grueneisen; University Hospital Essen, Essen, GERMANY.

OP-300**Preoperative staging of endometrial cancer: prognostic role of PET-derived parameters**

P. Mapelli¹, E. Incerti¹, A. Bergamini², F. Fallanca¹, P. M. V. Rancoita³, R. Cioffi², M. Petrone², E. Rabaiotti², G. Mangili², L. Gianolli¹, M. Picchio¹; ¹Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milano, ITALY; ²Obstetrics and Gynecology, IRCCS San Raffaele Scientific Institute, Milano, ITALY; ³University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milano, ITALY.

OP-301**Prognostic value of 18F-FDG PET/CT in restaging of locally advanced cervical cancer after concomitant chemo-radiation therapy**

G. M. Lima, A. Matti, E. De Crescenzo, G. Polverari, A. M. Perrone, P. De Iaco, C. Nanni, S. Fanti; S.Orsola-Malpighi University Hospital, Bologna, ITALY.

OP-302**Combined FDG and 4FMFES PET Imaging in ER+ Breast Cancer Patients for Improved Diagnostic and Prognostic Value**

M. Paquette, É. Lavallée, S. Phoenix, H. Senta, B. Guérin, J. E. van Lier, R. Lecomte, É. E. Turcotte; Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-303**Qualitative and quantitative analyses of ¹⁸F-FES and ¹⁸F-FDHT uptake in patients with metastatic breast cancer: an interobserver variability study**

L. H. Mammatas¹, C. M. Venema², C. P. Schröder², M. van Kruchten², G. Apollonio², A. W. J. M. Glaudemans³, A. H. H. Bongaerts³, O. S. Hoekstra⁴, H. M. W. Verheul¹, E. Boven¹, B. van der Vegt⁵, E. F. J. de Vries³, E. G. E. de Vries², R. Boellaard^{3,4}, G. A. P. Hospers², C. W. Menke-van der Houven van Oordt¹; ¹Department of Medical Oncology, VUmc Cancer Center Amsterdam, VU University Medical Center, Amsterdam, NETHERLANDS; ²Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS; ³Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS; ⁴Department of Radiology and Nuclear Medicine VU University Medical Center, Amsterdam, NETHERLANDS; ⁵Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-304**⁶⁸Ga-NOTA-BBN-RGD PET/CT for GRPR and Integrin $\alpha\beta 3$ Imaging in Patients with Breast Cancer**

J. Zhang^{1,2}, F. Mao³, G. Niu², L. Peng³, L. Lang², F. Li¹, H. Ying⁴, H. Wu⁵, B. Pan⁵, Z. Zhu¹, X. Chen²; ¹Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA; ²Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA; ³Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA; ⁴Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA; ⁵Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

OP-305**PET Imaging of Chemokine Receptor CXCR4 in Patients with Primary and Recurrent Breast Cancer**

T. Vag¹, A. Rossmann¹, S. Metz¹, H. Wester², M. Schwaiger¹; ¹Klinikum Rechts der Isar, Munich, GERMANY; ²Institute of Pharmaceutical Radiochemistry, Technical University Munich, Munich/Garching, GERMANY.

808 Monday, October 23, 2017, 11:30 - 12:45, Hall K

Committee Symposium 3 - Inflammation & Infection/Neuroimaging: Neurological Autoimmune Disorders

*Chairs: I. Law (Copenhagen, DENMARK)
A. Signore (Rome, ITALY)*

OP-306**Classification and Clinical Approach to Neurological Autoimmune Disorders**

G. Gobbi; Institute of Neurological Sciences of Bologna, Child Neurology Unit, Bologna, ITALY.

OP-307**Role of Brain 18F-FDG-PET in the Syndrome-Based Diagnostic Approach to Autoimmune Encephalitis**

S. Morbelli; IRCCS San Martino - IST, Department of Nuclear Medicine, Genoa, ITALY.

OP-308**PET Imaging of Brain Involvement in Systemic Autoimmune Disorders**

R. Dierckx; University Medical Center Groningen, Medical Imaging Center, Dep. of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

809 Monday, October 23, 2017, 11:30 - 12:45, Hall G1

Tomorrow's Experts Session - Best-Ranked Papers from the Under-30s

Chairs: F. Giammarile (Lyon, FRANCE)
V. Garibotto (Geneva, SWITZERLAND)

OP-309**Quantitative characterization of xSPECT algorithm: influence of reconstruction parameters (number of iterations and subsets) on image quality**

L. Lorenzon¹, A. Fracchetti¹, M. Bonelli¹, M. Tredici², V. Zilioli², M. Farsad², M. Haller¹; ¹Department of Medical Physics, Hospital of Bolzano, Bolzano, ITALY, ²Department of Nuclear Medicine, Hospital of Bolzano, Bolzano, ITALY.

OP-310**Dual-labeled PSMA-11 for PET/CT imaging and precise fluorescence guided intraoperative identification of prostate cancer**

A. Baranski¹, M. Schäfer¹, U. Bauder-Wüst¹, M. Roscher¹, J. Schmidt¹, E. Stenau¹, T. Simpfendorfer², L. Maier-Hein¹, B. Hadaschik³, U. Haberkorn², K. Kopka¹, M. Eder^{4,1,5}; ¹German Cancer Research Center, Heidelberg, GERMANY, ²University Hospital, Heidelberg, GERMANY, ³University Hospital, Essen, GERMANY, ⁴University Hospital, Freiburg, GERMANY, ⁵German Cancer Consortium, Heidelberg, GERMANY.

OP-311**SVM based detection of a disease specific metabolic brain pattern in a rat model for Parkinson's disease using longitudinal 18F-FDG PET imaging**

M. Devrome¹, M. Crabbé², V. Baekelandt³, K. Van Laere¹, C. Casteels², M. Koole¹; ¹Division of Nuclear Medicine, KU Leuven, Leuven, BELGIUM, ²Molecular Small Animal Imaging Centre, KU Leuven, Leuven, BELGIUM, ³Division of Neurobiology and Gene therapy, KU Leuven, Leuven, BELGIUM.

OP-312**Quantitative myocardial stress perfusion in patients with chest pain and normal coronary arteries to assess subsequent improvement of symptoms with transcutaneous electrical nerve stimulation**

A. G. Monroy-Gonzalez¹, M. J. L. De Jongste¹, E. Alexanderson-Rosas², R. A. Tio¹, R. H. J. A. Slart¹; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Department of Physiology, National Autonomous University of Mexico, MEXICO.

OP-313**TSPO-PET for high-grade glioma imaging using the novel ligand [¹⁸F]GE-180 - first in human results in the course of radiotherapy**

M. Unterrainer¹, D. Fleischmann¹, S. Lindner¹, A. Brunegrafl¹, F. Vettermann¹, L. Vomacka¹, M. Brendel¹, R. Rupprecht², C. Belka¹, P. Bartenstein¹, M. Niyazi¹, N. Albert¹; ¹Ludwig-Maximilian-University Munich, München, GERMANY, ²University of Regensburg, München, GERMANY.

OP-314**Relationship between Intraprostatic Hybrid Tracer Deposition and Lymphatic Drainage Pattern in Prostate Cancer Patients**

C. M. de Korne¹, T. Buckle¹, N. S. van den Berg¹, J. de Jong², R. A. Valdés Olmos¹, F. W. B. van Leeuwen¹, H. G. van der Poel²; ¹LUMC, Leiden, NETHERLANDS, ²NKI-AVL, Amsterdam, NETHERLANDS.

OP-315**Efficacy and Safety of 177Lu-PSMA-617 Treatment in Castration Resistant Prostate Cancer with Organ Metastasis**

O. E. Sahin¹, E. Akgün¹, E. Demirci², M. Ocak³, A. Akgün¹, B. Akovali¹, E. Karayel¹, H. Pehlivanoglu¹, L. Kabasakal¹; ¹Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, ²Department of Nuclear Medicine Sisli Etfal Training and Research Hospital, Istanbul, TURKEY, ³Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, TURKEY.



**810 Monday, October 23, 2017, 11:30 - 13:00, Hall G2****Committee Symposium 6 - Thyroid: Update on Ablative Therapies in Thyroid Nodules**

*Chairs: M. Kreissl (Magdeburg, GERMANY)
M. Luster (Marburg, GERMANY)*

OP-316**Ablative Therapies in Thyroid Nodules - The Endocrinologist's Perspective**

L. Hegedüs, University of Odense, Department of Endocrinology and Metabolism, Odense, DENMARK.

OP-317**Ablative Therapies in Thyroid Nodules - The Surgeon's Perspective**

C. Vorländer, Bürgerhospital Frankfurt, Department of Endocrine Surgery, Frankfurt, GERMANY.

OP-318**Ablative Therapies in Thyroid Nodules - The Nucmed Perspective**

M. Kreissl, Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke Universität, Magdeburg, GERMANY.

YDF2 Monday, October 23, 2017, 13:00 - 14:30, Hall F1**EANM Young Daily Forum 2: Networking - How to Build Professional Relationships**

R. Sheppard; Somerset, UNITED KINGDOM.

901 Monday, October 23, 2017, 14:30 - 16:00, Hall A**CME 7 - Radionuclide Therapy/ Thyroid: Safety Aspects in Radionuclide Therapy**

*Chairs: I. Zerizer (London, UNITED KINGDOM)
M. Hoffmann (Vienna, AUSTRIA)*

OP-321**Radiobiological Aspects in Radionuclide Therapy**

J.-P. Pouget; IRCM/INSERMU896, Montpellier, FRANCE.

OP-322**Early and Late Side Effects of Radionuclide Therapy**

L. Bodei; Memorial Sloan Kettering Cancer Center, New York, UNITED STATES OF AMERICA.

OP-323**Prevention of Side Effects in Radionuclide Therapy**

S. Vinjamuri; Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM.

902 Monday, October 23, 2017, 14:30 - 16:00, Hall B**Symposium 7 - Bone & Joint: Painful Hip Arthroplasty**

*Chairs: F. Paycha (Paris, FRANCE)
U. Kampen (Hanburg, GERMANY)*

OP-324**Biomechanics of Normal Hip and Hip Arthroplasty**

D. Pioletti; Ecole Polytechnique Fédérale de Lausanne (EPFL), Lab. of Biomechanical Orthopedics, Lausanne, SWITZERLAND.

OP-325**What the Surgeon Wants to Know From Imaging**

R. Nizard; Hospital Lariboisière - Assistance Publique - Hôpitaux de Paris, Service de Chirurgie Orthopédique et Traumatologique, Paris, FRANCE.

OP-326**Radiologic Imaging**

A. Feydy; Hospital Cochin - Assistance Publique - Hôpitaux de Paris, Service de Radiologie, Paris, FRANCE.

OP-327**Hybrid Imaging: Role and Limits**

F. Paycha; Hospital Lariboisière - Assistance Publique - Hôpitaux de Paris, Nuclear Medicine Department, Paris, FRANCE.

903 Monday, October 23, 2017, 14:30 - 16:00, Hall C**CTE 3: Prostate Imaging and Therapy**

*Chairs: A. Santos (Lisbon, PORTUGAL)
G. Testanera (London, UNITED KINGDOM)*

OP-328**PET-CT Imaging in Prostate Cancer**

P. Castellucci; S. Orsola-Malpighi, Nuclear Medicine, Bologna, ITALY.

OP-329**Radionuclide Therapy in Prostate Cancer**

T. D. Poeppel; University Hospital Essen, Essen, GERMANY.

OP-330**Radiation Therapy and PET-CT Aided Radiotherapy Planning in Prostate Cancer**

A. Skanjeti; Nuclear Medicine Department, Hospices Civils de Lyon, Lyon, FRANCE.


904 Monday, October 23, 2017, 14:30 - 16:00, Hall E1
**Do.MoRe - Committee Symposium 4
- Dosimetry: Validation of Quantitative
Imaging, Dosimetry & Estimates of
Uncertainty**

*Chairs: J. Gear (London, UNITED KINGDOM)
F. Verburg (Marburg, GERMANY)*

OP-331
**The Need for Dosimetry Validation - A Clinician's
View Point**

*F. A. Verburg; Philipps-University of Marburg, Marburg,
GERMANY.*

OP-332
**The Use of Monte Carlo for Validation and
Uncertainty Analysis**

*J. R. Gustafsson; Department of Medical Radiation
Physics, Lund University, Lund, SWEDEN.*

OP-333
**Propagation of Uncertainty Analysis for
Absorbed Dose Calculations**

*J. Gear; Royal Marsden NHSFT & Institute of Cancer
Research, London, UNITED KINGDOM.*

OP-334
**Validation of Calibration Protocols and the
MRT Dosimetry Project**

*A. Robinson; National Physical Laboratory, Teddington,
UNITED KINGDOM.*

905 Monday, October 23, 2017, 14:30 - 16:00, Hall E2
M2M: SPECT/CT & SPECT/MRI

*Chairs: F. Beekman (Delft, NETHERLANDS)
M. Bernsen (Rotterdam, NETHERLANDS)*

OP-336
**Characterization of ¹¹¹In-labeled site-specifically
conjugated anti-PSMA antibody-drug
conjugates for treatment of PSMA-expressing
tumors**

*S. Lütje^{1,2}, D. Gerrits¹, J. D. Molkenboer-Kuenen¹,
K. Herrmann², G. Fracasso³, M. Colombatti³, O.
C. Boerman¹, S. Heskamp¹; ¹Dept. Radiology and
Nuclear Medicine, Radboud university medical center,
Nijmegen, NETHERLANDS, ²Clinic for Nuclear Medicine,
University Hospital Essen, Essen, GERMANY, ³Dept. of
Medicine, University of Verona, Verona, ITALY.*

OP-337
**Novel high affinity affibody for radionuclide
imaging of VEGFR2 in glioma vasculature: proof-
of-principle in murine model**

*B. Mitran¹, R. Güler², F. P. Roche¹, E. Lindström¹, R.
Selvaraju¹, F. Fleetwood², S. S. Rinne¹, L. Claesson-
Welsh¹, V. Tolmachev¹, S. Ståhl², A. Orlova¹, J. Löfblom²;
¹Uppsala University, Uppsala, SWEDEN, ²KTH-Royal
Institute of Technology, Stockholm, SWEDEN.*

OP-338
**Development and evaluation of gonadotropin
releasing hormone SPECT radioligands**

*R. Fjellakse^{1,2,3}, J. Hansen³, A. Oteiza^{1,4}, M. Martin-
Armas^{1,4}, A. Moldes-Anaya^{5,6}, P. Riss^{7,8,9}, R. Sundset^{1,5};
¹Medical Imaging Group, Department of Clinical
Medicine, UiT The Arctic University of Norway,
TROMSØ, NORWAY, ²Drug Transport and Delivery
Group, Department of Pharmacy, UiT The Arctic
University of Norway, Tromsø, NORWAY, ³Organic
Chemistry Group, Department of Chemistry, UiT
The Arctic University of Norway, Tromsø, NORWAY,
⁴Preclinical PET/SPECT/CT, Department of Clinical
Medicine, UiT The Arctic University of Norway,
Tromsø, NORWAY, ⁵PET imaging center, division of
diagnostics, UNN – University Hospital of North-
Norway, Tromsø, NORWAY, ⁶Neurobiology Research
Group, Department of Clinical Medicine, UiT The
Arctic University of Norway, Tromsø, NORWAY,
⁷Department of neuropsychiatry and psychosomatic
medicine, Oslo University Hospital, Oslo, NORWAY,
⁸Realomics SFI, Department of Chemistry,
University of Oslo, Oslo, NORWAY, ⁹Norsk Medisinsk
Syklotronsenter AS, Oslo, NORWAY.*

OP-339
**Somatostatin receptor type 2 as a marker for
pro-inflammatory macrophages**

*S. T. van Tiel, L. Utomo, E. J. Meester, J. de Swart,
N. Kops, R. H. de Blois, M. de Jong, Y. Bastiaansen-
Jenniskens, M. Bernsen; ErasmusMC, Rotterdam,
NETHERLANDS.*

OP-340
**Quantitative Analysis of ^{99m}Tc-DMSA Renal
Scintigraphy of Animal AKI Models; Comparison
with Histopathological and Biochemical Assays**

*K. Tanha¹, H. Fatemikia², M. Seyedabadi¹, K. Tanha³,
Z. Karimi⁴, M. Assadi¹; ¹The Persian Gulf Nuclear
Medicine Research Center, Bushehr University of
Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF,
²Department of Physiology, Medical School, Bushehr
University of Medical Sciences, Bushehr, IRAN, ISLAMIC
REPUBLIC OF, ³Department of Biostatistics, School
of Public Health, Iran University of Medical Sciences,
Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Shiraz Nephron
Urology Research Center, Shiraz University of Medical
Sciences, Shiraz, IRAN, ISLAMIC REPUBLIC OF.*

OP-341**PET/CT And SPECT/CT Based Identification of Novel Rodent BAT and Beige Depots-An Image Guided Exploration Of Human-like Thermogenic Tissues in Mice**

O. K. Oz¹, F. Zhang¹, G. Hao¹, G. Hassan¹, M. Shao¹, Y. An¹, Q. Wang¹, C. Kusminski¹, K. Nham¹, Q. Zhai², P. Scherer¹; ¹UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA, ²Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, CHINA.

OP-342**SPECT-MRI and histological analysis to map PRRT radiobiology for a better understanding of local treatment effects**

J. Nonnekens, G. N. Doeswijk, J. C. Haeck, M. W. Konijnenberg, D. C. van Gent, M. de Jong; Erasmus MC, Rotterdam, NETHERLANDS.

OP-343**Comparison study of TCO-functionalized vector systems for *in vivo* click chemistry using [¹¹¹In] In-DOTA-Tetrazine**

P. E. Edem^{1,2}, J. T. Jørgensen^{1,2}, K. Nørregaard^{1,2}, E. J. L. Stéen², R. Rossin³, A. Birke⁴, C. Denk⁵, A. Yazdani⁶, J. F. Valliant⁶, H. Mikula⁵, M. Barz⁷, M. Robillard³, M. M. Herth^{1,2}, A. Kjær^{1,2}; ¹Rigshospitalet, Copenhagen, DENMARK, ²University of Copenhagen, Copenhagen, DENMARK, ³Tagworks Pharmaceuticals, Eindhoven, NETHERLANDS, ⁴Johannes Gutenberg-University Mainz, Mainz, GERMANY, ⁵TUWien, Vienna, AUSTRIA, ⁶McMaster University, Hamilton, ON, CANADA, ⁷Johannes Gutenberg-University Mainz, Mainz, GERMANY.

906 Monday, October 23, 2017, 14:30 - 16:00, Hall F1**Teaching Session 3 (Interactive): Applied Cross Sectional Anatomy and Correlative Imaging - Spine**

Chair: J. Pruijm (Groningen, NETHERLANDS)

OP-344**Applied Cross Sectional Anatomy and Correlative Imaging – Spine**

A. van der Vliet; University Medical Centre, Groningen, NETHERLANDS.

907 Monday, October 23, 2017, 14:30 - 16:00, Hall F2**Clinical Oncology: It's in the Blood**

Chairs: A. Buck (Wurzburg, GERMANY)

L. Zanoni (Bologna, ITALY)

OP-345**Functional Carbon11-Methionine and Fluorine18-Fluorodeoxyglucose PET/CT parameters in patients with multiple myeloma in a first disease staging setting: could they reflect the underlying pathophysiology?**

C. Caldarella¹, D. Ripani², D. Pizzuto², T. Za³, V. De Stefano³, A. Giordano²; ¹Nuclear Medicine Unit and PET-CT Center, Policlinico "A. Gemelli", Rome, ITALY, ²Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore "A. Gemelli", Rome, ITALY, ³Hematology Service, Università Cattolica del Sacro Cuore "A. Gemelli", Rome, ITALY.

OP-346**Diagnostic performances of normalized FDG-PET parameters in predicting treatment response < progression-free survival after bone marrow transplantation in patients with multiple myeloma**

D. Ripani¹, C. Caldarella², T. Za³, D. Pizzuto¹, E. Rossi³, V. De Stefano³, A. Giordano¹; ¹Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore "A. Gemelli", Rome, ITALY, ²Nuclear Medicine Unit and PET-CT Center, Policlinico "A. Gemelli", Rome, ITALY, ³Hematology Service, Università Cattolica del Sacro Cuore "A. Gemelli", Rome, ITALY.

OP-347**Diagnostic Value of ¹⁸F-FDG PET/CT in Chronic Graft Versus Host Disease (cGVHD)**

C. Lasnon^{1,2}, N. Aide^{3,4}, J. Parienti⁵, S. Chantepie⁶; ¹Nuclear Medicine Department, François Baclesse Centre, CAEN, FRANCE, ²INSERM U1086, Caen, FRANCE, ³Nuclear Medicine Department, University Hospital, CAEN, FRANCE, ⁴INSERM U1086 "ANTICIPE", Caen, FRANCE, ⁵Biostatistical Department, University Hospital, CAEN, FRANCE, ⁶Hematology Institute, University Hospital, CAEN, FRANCE.

OP-348**Ultrafast 8-min scan PET/MR protocol for diagnosis and follow-up of Lymphomas. Preliminary results**

C. Albertti, G. Peña, E. A. Marino, P. Jaime; FUESMEN, Mendoza, ARGENTINA.

OP-349**Staging Patients with Hodgkin Lymphoma - Is Bone Marrow Biopsy Still Necessary in the Era of ¹⁸F-FDG PET?**

C. Voltin¹, S. Stockter¹, C. Baues², M. Fuchs³, M. Dietlein¹, J. Mettler¹, A. Engert^{3,4}, P. Borchmann^{3,4}, A. Drzezga¹, C. Kobe¹; ¹Department of Nuclear Medicine, University Hospital of Cologne, Cologne, GERMANY, ²Department of Radiation Oncology, University Hospital of Cologne, Cologne, GERMANY, ³German Hodgkin Study Group (GHS), University Hospital of Cologne, Cologne, GERMANY, ⁴Department of Internal Medicine I, University Hospital of Cologne, Cologne, GERMANY.

OP-350**FDG-PET/CT at the end of immuno-chemotherapy in Follicular Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)**

S. Annunziata¹, A. Cuccaro², M. C. Tisi², S. Hohaus², A. Giordano¹, V. Rufini¹; ¹Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY, ²Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY.

OP-351**Interim treatment response assessment in paediatric Hodgkin's lymphoma by using Deauville and delta SUVmax in FDG PET CT**

K. Shaha, S. Shah, N. Purandare, A. Agrawal, A. Puranik, V. Rangarajan; TATA Memorial Hospital, Mumbai, INDIA.

OP-352**B-cell lymphoma radioimmunotherapy: effect of co-infusion of cold and radiolabelled antibody on absorbed dose to healthy tissues and tumours, a preclinical study in dogs**

F. Morio^{1,2}, C. Ibsch^{1,2}, F. Nguyen^{1,3}, M. Berthaud², J. Abadie^{1,3}, A. Vidal⁴, M. Bourgeois^{4,2,5}, K. Bernardeau⁶, S. Becavin¹, M. Roussel¹, L. Ferrer^{2,7}, C. Bodet-Milin^{2,5}, N. Chouin^{1,2}, F. Davodeau²; ¹AMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), NANTES, FRANCE, ²Team 13 "Nuclear oncology research", CRCINA, INSERM UMR1232, Université d'Angers, Université de Nantes, Nantes, FRANCE, ³Team 8 "Stress Adaptation and Tumor Escape", CRCINA, INSERM UMR 1232, Université d'Angers, Université de Nantes, Nantes, FRANCE, ⁴Radiopharmacy Department, ARRONAX Cyclotron, Saint-Herblain, FRANCE, ⁵Departement of Nuclear Medicine, University Hospital, Nantes, FRANCE, ⁶Recombinant Protein Core Facility of The University of Nantes, NANTES, FRANCE, ⁷Institut de Cancérologie de l'Ouest, Medical Physics Department, Saint-Herblain, FRANCE.

908 Monday, October 23, 2017, 14:30 - 16:00, Hall K**Cardiovascular System: Cardiac Sarcoidosis & Amyloidosis**

Chairs: A. Flotats (Barcelona, SPAIN)
W. Acampa (Naples, ITALY)

OP-353**Prevalence of myocardial uptake in bone scan in the elderly population**

L. Mohamed Salem, Sr., R. Reyes Marles, M. Godoy Bravo, J. Sánchez Serna, M. Castellon Sanchez, F. Nicolas Ruiz, L. Frutos Esteban, J. Navarro Ferenandez, I. Sime Loayza, M. Perez Martinez, D. Pascual Figal, M. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

OP-354**Prognostic impact of cardiac FDG-PET/CT using quantitative analysis in patients with cardiac sarcoidosis**

T. Ando, Y. Fukushima, S. Kumita, H. Hashimoto, Y. Sugihara; Nippon Medical School, Tokyo, JAPAN.

OP-355**Novel approach for myocardial sarcoidosis diagnosis using Ga-68-DOTATATE PET/CT: Reference values in a normal population**

M. Jreige, M. Nicod Lalonde, A. van der Gucht, N. Schaefer, J. O. Prior; Centre Hospitalier Universitaire Vaudois (CHUV), LAUSANNE, SWITZERLAND.

OP-356**[¹⁸F]-Florbetaben-PET/CT for Imaging of cardiac amyloidosis**

M. Kircher, J. Brumberg, T. Reiter, S. Ihne, S. Knop, K. Kortüm, G. Ertl, A. Buck, W. Bauer, C. Lapa; Uniklinikum Würzburg, Würzburg, GERMANY.

OP-357**[¹⁸F]-Florbetaben PET/CT in cardiac amyloidosis: results from the FLORAMICAR study**

D. Genovesi, G. Vergaro, A. Giorgetti, M. Emdin, E. Volpi, S. Alduini, A. Kusch, B. Favilli, S. Fucci, P. Marzullo; Fondazione CNR-Regione Toscana "Gabriele Monasterio", Pisa, ITALY.

OP-358**Imaging amyloidosis patients with ¹⁸F Florbetapir PET - incidence and significance of non-cardiac soft tissue uptake**

J. Page^{1,2}, T. Wagner², M. Burniston², J. Ross^{1,2}, A. Skillen², D. McCool², T. Lane¹, R. Manwani¹, P. Hawkins¹, A. Wechalekar¹; ¹National Amyloidosis Centre, London, UNITED KINGDOM, ²Royal Free London NHS Foundation Trust, London, UNITED KINGDOM.



OP-359**Cardiac amyloid imaging with ¹⁸F Florbetapir PET - initial results from a UK study**

J. Page^{1,2}, *T. Wagner*², *M. Burniston*², *J. Ross*¹, *A. Skillen*², *D. McCool*², *T. Lane*¹, *R. Manwani*¹, *M. Fontanna*¹, *P. Hawkins*¹, *A. Wechalekar*¹; ¹National Amyloidosis Centre, London, UNITED KINGDOM, ²Royal Free London NHS Foundation Trust, London, UNITED KINGDOM.

OP-360**Cardiac FDG-PET/CT in systemic sclerosis**

*Z. Besenyi*¹, *G. Ágoston*², *R. Hemelein*³, *A. Bakos*¹, *L. Kovács*³, *A. Varga*², *L. Pávics*¹; ¹Department of Nuclear Medicine University of Szeged, Szeged, HUNGARY, ²Department of Family Medicine University of Szeged, Szeged, HUNGARY, ³Department of Rheumatology University of Szeged, Szeged, HUNGARY.

909 Monday, October 23, 2017, 14:30 - 16:00, Hall G1**Neurosciences: Imaging Neurodegeneration in Alzheimer's Disease by TAU and FDG Imaging**

Chairs: *G. Chételat* (Caen, FRANCE)
A. Drzezga (Cologne, GERMANY)

OP-361**Flortaucipir perfusion PET is a suitable replacement for FDG PET in patients with neurodegenerative diseases**

*J. Hammes*¹, *I. Leuwer*¹, *G. N. Bischoff*^{1,2}, *A. Drzezga*¹, *T. van Eimeren*^{1,2,3}; ¹Clinic of Nuclear Medicine, University Hospital Cologne, Cologne, GERMANY, ²INM-3, Research Center Jülich, Jülich, GERMANY, ³Clinic of Neurology, University Hospital Cologne, Cologne, GERMANY.

OP-362**The impact of education on the association between tau deposits and cognition in Mild Cognitive Impairment**

*S. Trombella*¹, *G. B. Frisoni*², *V. G. Garibotto*²; ¹Geneva University, Geneva, SWITZERLAND, ²Geneva University and Geneva University Hospital, Geneva, SWITZERLAND.

OP-363**Parametric imaging of tau load in Alzheimer's patients and controls using Flortaucipir**

*S. S. V. Golla*¹, *E. Wolters*^{1,2}, *T. Timmers*^{1,2}, *R. Ossenkoppele*^{1,2}, *C. Groot*¹, *S. Verfaillie*², *P. Scheltens*², *W. M. van der Flier*^{2,3}, *L. Schwarte*⁴, *M. A. Mintun*⁵, *M. Devous*⁵, *R. C. Schuit*¹, *A. D. Windhorst*¹, *A. A. Lammertsma*¹, *R. Boellaard*^{1,6}, *B. N. M. van Berckel*¹, *M. Yaqub*¹; ¹Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, NETHERLANDS, ²Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, NETHERLANDS, ³Department of Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, NETHERLANDS, ⁴Department of Anaesthesiology, VU University Medical Center, Amsterdam, NETHERLANDS, ⁵Avid Radiopharmaceuticals, Inc., Philadelphia, PA, UNITED STATES OF AMERICA, ⁶Department of Nuclear Medicine & Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-364**Association between tau deposition, amyloid- β , age and memory performance in cognitively normal subjects: influence of partial volume correction**

*I. Sonni*¹, *A. Maaß*², *S. N. Lockhart*², *S. M. Landau*², *S. L. Baker*¹, *W. J. Jagust*^{1,2}; ¹Lawrence Berkeley National Laboratory, Berkeley, CA, UNITED STATES OF AMERICA, ²Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, UNITED STATES OF AMERICA.

OP-365**On- and Off-target binding of [18F]AV-1451 in Substantia Nigra post-mortem tissues of Alzheimer's Disease (AD) patients and Normal Control (NC) subjects**

L. Gomez, *Y. Lin*, *Q. Liang*, *M. Mintun*, *G. Attardo*; Avid R.P., Philadelphia, PA, UNITED STATES OF AMERICA.

OP-366**Clinical evaluation of ¹⁸F-PI-2620, a next generation tau PET agent in subjects with Alzheimer's disease, progressive supranuclear palsy, and non-demented controls**

*J. Seibyl*¹, *O. Barret*¹, *A. Stephens*², *J. Madonia*¹, *D. Alagille*¹, *A. Mueller*², *H. Schieferstein*², *M. Berndt*², *H. Kroth*³, *S. Bullich*², *C. Papin*¹, *V. Carroll*¹, *C. Sandiego*¹, *A. Pfeifer*³, *A. Muhs*³, *L. Dinkelborg*², *G. Tamagnan*¹, *K. Marek*¹; ¹Molecular Neuroimaging, New Haven, CT, UNITED STATES OF AMERICA, ²Piramal Imaging, Berlin, GERMANY, ³AC Immune SA, Lausanne, SWITZERLAND.

OP-367**Metabolic patterns underlying disease heterogeneity and severity in patients with dementia with Lewy Body: a project of the European Consortium for Dementia with Lewy Body (E-DLB)**

S. Morbelli^{1,2}, M. Brendel³, A. Rominger³, V. Garibotto⁴, N. Nicastro⁵, A. Pilotto^{6,7}, A. Padovani⁶, B. Paghera^{8,2}, S. Garcia-Ptacek⁹, I. Savitcheva¹⁰, M. G. Kramberger¹¹, M. Trost¹¹, A. W. Lemstra¹², J. J. van der Zande¹², S. Pappatà^{13,2}, M. Calcagni^{14,2}, A. Cistaro^{15,2}, V. Berti^{16,2}, D. Volterrani^{17,2}, S. Sestini^{18,2}, M. Bauckneht^{1,2}, F. Sensi¹⁹, A. Chincarini¹⁹, D. Aarsland^{20,21}, F. Nobili^{22,2}; ¹IRCCS San Martino - IST, Genoa, ITALY, ²Neurology Study Group of the Italian Association of Nuclear Medicine, (aimn), ITALY, ³Department of Nuclear Medicine, University of Munich, Munich, GERMANY, ⁴Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND, ⁵Division of Neurorehabilitation, Department of Clinical Neurosciences Geneva, Geneva University Hospitals, Geneva, SWITZERLAND, ⁶Neurology Unit, University of Brescia, Brescia, ITALY, ⁷Parkinson's disease rehabilitation Centre, FERB ONLUS S. Isidoro Hospital, Trescore Balneario, (BG), ITALY, ⁸Nuclear Medicine, Spedali Civili Brescia, University of Brescia, Brescia, ITALY, ⁹Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, SWEDEN, ¹⁰Department of Radiology, Karolinska Institutet, Stockholm, SWEDEN, ¹¹Department of Neurology, University Medical Centre, Ljubljana, SLOVENIA, ¹²Alzheimer Center & Department of Neurology, VU University Medical Center and Neuroscience Campus, Amsterdam, NETHERLANDS, ¹³Institute of Biostructure and Bioimaging, CNR, Naples, ITALY, ¹⁴Institute of Nuclear Medicine, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, ITALY, ¹⁵Positron Emission Tomography Centre IRMET S.p.A., Turin, ITALY, ¹⁶Nuclear Medicine Unit, University of Florence, Florence, ITALY, ¹⁷Nuclear Medicine Unit, University Hospital of Pisa, Pisa, ITALY, ¹⁸Nuclear Medicine Unit, U.S.L. Toscana Centro, Prato, ITALY, ¹⁹Istituto Nazionale di Fisica Nucleare, Sezione di Genova, Genoa, ITALY, ²⁰Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, NORWAY, ²¹Wolfson Centre for Age-Related Diseases, King's College London, London, UNITED KINGDOM, ²²Clinical Neurology, Department of Neuroscience (DINOGLI), University of Genoa, Genoa, ITALY.

OP-368**Diagnosis of Alzheimer's Disease Through Identification of Abnormality Patterns in Molecular Brain Imaging**

N. Burgos^{1,2}, J. Samper-González^{1,2}, A. Bertrand^{1,2,3}, M. Habert⁴, S. Ourselin^{5,6}, S. Durrleman^{1,2}, M. Cardoso^{5,6}, O. Colliot^{1,2,3}; ¹Inria, Aramis project-team, Paris, FRANCE, ²Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, ICM, Paris, FRANCE, ³Pitié-Salpêtrière Hospital, Neuroradiology, Paris, FRANCE, ⁴Pitié-Salpêtrière Hospital, Nuclear Medicine, Paris, FRANCE, ⁵University College London, Translational Imaging Group, London, UNITED KINGDOM, ⁶University College London, Dementia Research Centre, London, UNITED KINGDOM.

910 Monday, October 23, 2017, 14:30 - 16:00, Hall G2

Conventional & Specialised Nuclear Medicine: Infection & Inflammation

Chairs: G. Treglia (Bellinzona, SWITZERLAND)
C. Lauri (Rome, ITALY)

OP-369**Role of 18Fluorine-Fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of endocarditis: a bicentre study on 84 patients**

P. Ferro¹, D. Albano², C. Popescu³, M. Bertoli⁴, I. Cersosimo⁵, F. Bertagna⁴, R. Sara³, G. Giubbini⁴, C. Rossetti³; ¹Università Milano-Bicocca, Ospedale Niguarda Ca' Granda, Milano, ITALY, ²Università Milano-Bicocca, Spedali Civili, Brescia, ITALY, ³Ospedale Niguarda Ca' Granda, Milano, ITALY, ⁴Spedali Civili, Brescia, ITALY, ⁵Demographics Pro, Beijing, CHINA.

OP-370**Digestive incidentalomas in FDG-PET/CT images of patients with infectious endocarditis: relationship with the involved microorganisms**

J. J. Ardila, A. Rotger, L. Reguera, M. L. Lozano, J. Ardila, J. Orcajo, C. Duran, A. Mari, R. Pascual, J. C. Alonso; Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

OP-371**Role of 18FDG PET/MR in the diagnosis and follow-up of retroperitoneal fibrosis**

P. Zucchetta, F. Crimi¹, C. Lacognata, R. Marcolongo, D. Cecchin, V. Bodanza, J. Doraku, D. Miotto, F. Bui; University Hospital - Padova, Padova, ITALY.



OP-372**Comparison of F18 FDG and Ga68 citrate PET/CT in the evaluation of patient with tuberculosis**

A. O. Ankrach^{1,2}, I. O. Lawal¹, T. M. G. Boshomane¹, M. Vorster¹, H. C. Klein², A. W. M. J. Glaudemans², M. M. Sathekge¹; ¹University of Pretoria, Pretoria, SOUTH AFRICA, ²University Medical Center Groningen, Groningen, NETHERLANDS.

OP-373**The diagnostic value of ¹⁸F-FDG-PET /CT, MRI and ¹⁸F-FDG-PET/MRI in suspected vertebral osteomyelitis - a prospective study**

I. Kouijzer^{1,2}, H. Scheper³, J. de Rooy¹, J. Bloem³, M. Janssen¹, L. van den Hoven², A. Hosman¹, L. Visser³, W. Oyen^{1,4}, C. Bleeker-Rovers¹, L. de Geus-Oei^{3,2}; ¹Radboudumc, Nijmegen, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³LUMC, Leiden, NETHERLANDS, ⁴The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM.

OP-374**¹⁸F-FDG PET/CT as a diagnostic tool for infection assessment in post-traumatic non-unions**

L. Antunovic, N. Trenti, L. Di Mento, E. Malagoli, G. Cusato, L. Balzarini, A. Kirienko, A. Chiti, M. Berlusconi; Humanitas Clinical and Research Hospital, Rozzano, ITALY.

OP-375**Relationship between WBC scintigraphy with Tc99m HMPAO-labeled leucocytes and clinical outcome in patients with suspected prosthetic joint infections**

T. Pellegrino¹, M. Petretta², V. Cantoni³, V. Piscopo³, G. De Matteis³, S. Pellegrino³, A. Cuocolo³; ¹Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ²Department of Translational Medical Sciences, University Federico II, Naples, ITALY, ³Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY.

OP-376**Typical uptake distribution patterns that help the diagnosis of polymyalgia rheumatica on FDG-PET/CT**

K. Nakatani, S. Yuge, K. Yoshino, T. Koyama; Kurashiki Central Hospital, Kurashiki, JAPAN.

1001 Monday, October 23, 2017, 16:30 - 18:00, Hall A**CME 8 - Radionuclide Therapy/ Radiopharmacy/Dosimetry: Clinical Trial Design for Radionuclide Therapy**

Chairs: J. Gear (London, UNITED KINGDOM)
C. Decristoforo (Innsbruck, AUSTRIA)

OP-377**General Aspects of Clinical Trial Design**

A. Kluge; ABX - CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H., Dresden, GERMANY.

OP-378**Regulatory Affairs in Radiopharmacy**

C. Decristoforo; Universitätskliniken - Landeskrankenhaus Innsbruck, Medizinische Universität Innsbruck, Universitätsklinik für Nuklearmedizin, Innsbruck, AUSTRIA.

OP-379**Dosimetry for Clinical Trials**

R. Gregory; The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UNITED KINGDOM.

1002 Monday, October 23, 2017, 16:30 - 18:00, Hall B**Joint Symposium 8 - EANM/EANO: High Grade Glioma**

Chairs: I. Law (Copenhagen, DENMARK)
J. Tonn (Munich, GERMANY)

OP-380**Tumour Initiation, Progression and Metabolism**

R. Bjerkvig; University of Bergen, KG-Jebsen Brain Tumour Research Centre, Department of Biomedicine, Bergen, NORWAY.

OP-381**Clinical Features and Use of Amino-Acid PET**

I. Law; Rigshospitalet, Dept of Clinical Physiology, Nuclear Medicine and PET, Copenhagen, DENMARK.

OP-382**State of the Art Neurosurgical Treatment**

J. C. Tonn; Ludwig-Maximilians-Universität, Dept. Neurosurgery, Munich, GERMANY.

1003 Monday, October 23, 2017, 16:30 - 18:00, Hall C

**CTE 4 - Joint Session with CAMRT:
Radionuclide Production***Chairs: P. Fragoso Costa (Oldenburg, GERMANY)
F. Couillard (Ottawa, CANADA)***OP-383****Reactor Produced Radioisotopes Used in
Nuclear Medicine***F. Rösch; Johannes Gutenberg-University Mainz,
Institute of Nuclear Chemistry, Mainz, GERMANY.***OP-384****Cyclotron Produced Radioisotopes Used in Nuclear
Medicine***F. Alves; Coimbra University, Institute of Nuclear
Sciences Applied to Health, Coimbra, SPAIN.***OP-385****Molybdenum-99 World Supply***F. Couillard; CAMRT, Ottawa, CANADA.*

1004 Monday, October 23, 2017, 16:30 - 18:00, Hall E1

Do.MoRe: Dosimetry in Thyroid Disease*Chairs: M. Luster (Marburg, GERMANY)
M. Hoffmann (Vienna, AUSTRIA)***OP-386****First biosafety, biodistribution and dosimetry
study of the gastrin analogue ¹¹¹In-CP04 in
medullary thyroid cancer. Phase I clinical trial,
GRANT-T-MTC***M. Konijnenberg¹, P. A. Erba², R. Mikolajczak³, C.
Decristoforo⁴, H. Maecke⁵, T. Maina-Nock⁶, K. Zaletel⁷,
P. Kolenc-Peitl⁷, I. Virgolini⁴, E. Przybylik-Mazurek⁸, C.
Rangger⁴, M. Trofimiuk-Muldner⁸, K. Skorkiewicz⁸, L.
Ležaić⁷, L. Scarpa⁴, G. Di Santo⁴, A. Sowa-Staszczak⁸,
M. de Jong¹, L. Froberg¹, P. Garnuszek³, D. Pawlak³,
G. Göbel⁴, B. Nock⁶, D. Bergant⁹, A. Hubalewska-
Dydejczyk⁸; ¹Erasmus MC, Rotterdam, NETHERLANDS,
²Nuclear Medicine, Azienda Ospedaliera Universitaria
Pisana, Pisa, ITALY, ³Radioisotope Center POLATOM,
NCBJ, Otwock-Świerk, POLAND, ⁴Nuclear Medicine,
Innsbruck Medical University, Innsbruck, AUSTRIA,
⁵Nuclear Medicine, University Hospital Freiburg,
Freiburg, GERMANY, ⁶Molecular Radiopharmacy,
INRASTES, NCSR Demokritos, Athens, GREECE, ⁷Nuclear
Medicine, University Medical Centre Ljubljana,
Ljubljana, SLOVENIA, ⁸Chair and Department of
Endocrinology, Jagiellonian University, Medical College,
Kraków, POLAND, ⁹Institute of Oncology, Ljubljana,
SLOVENIA.***OP-387****Lesion dosimetry in metastatic thyroid cancer
treated with ¹³¹I: method and preliminary
results***E. Richetta, C. Cutaia, M. Pasquino, L. Sacco, A.
Codegone, R. Pellerito, M. Stasi; AO Ordine Mauriziano
di Torino, Turin, ITALY.***OP-388****Analysis deviation of the absorbed dose of
thyroid for Graves' disease with hyperthyroidism
treated by iodine-131 with simplified Quimby-
Marinelli-Hine formula method***Y. Chen; Quanzhou 1st Hospital, Quanzhou, CHINA.***OP-389****Micro-scale Modeling for the Salivary Gland:
Insights into Toxicity from ¹³¹I Therapy for
Thyroid Cancer***R. F. Hobbs¹, A. McGuffey¹, W. Jentzen², D. Plyku¹, A.
Bockisch², G. Sgouros¹; ¹Johns Hopkins University,
Baltimore, MD, UNITED STATES OF AMERICA,
²Universitaet Duisburg-Essen, Essen, GERMANY.***OP-390****Dose-response correlation in radioiodine
therapy of hyperthyroidism from nodular
thyroid disease***M. Pacilio¹, G. Ventroni², V. Frantellizzi³, B. Cassano⁴, E.
Verdolino⁴, T. Montesano³, G. De Vincentis³, L. Mango²;
¹Department of Medical Physics, Azienda Ospedaliera
Universitaria Policlinico Umberto I, Rome, ITALY,
²Department of Nuclear Medicine, Azienda Ospedaliera
San Camillo Forlanini, Rome, ITALY, ³Department of
Radiological, Oncological and Anatomopathological
Sciences, "Sapienza" University of Rome, Rome, ITALY,
⁴Postgraduate School of Medical Physics, "Sapienza"
University of Rome, Rome, ITALY.***OP-391****First-in-human administration of the CCK-2
receptor agonist ¹⁷⁷Lu-PP-F11N in patients with
metastasized medullary thyroid carcinoma -
preliminary results of the "Lumed" trial***C. Rottenburger¹, G. Nicolas¹, L. McDougall¹, F. Kaul¹,
E. Christ¹, R. Schibli², S. Geistlich², M. Béhé², D. Wild¹;
¹University of Basel Hospital, Basel, SWITZERLAND, ²Paul
Scherrer Institut, Villigen, SWITZERLAND.***OP-392****Red marrow dosimetry in metastatic thyroid
cancer treated with ¹³¹I: a simplified method***E. Richetta, G. Lo Moro, C. Cutaia, M. Pasquino, L.
Sacco, G. Brusasco, R. Pellerito, M. Stasi; AO Ordine
Mauriziano di Torino, Turin, ITALY.*

OP-393

Differences in radioiodine biokinetics between papillary thyroid carcinoma low-risk patients treated with 1.11 GBq of ¹³¹I-Nal and high-risk patients treated with 3.7 GBq of ¹³¹I-Nal

P. Mínguez Gabiña¹, M. Domínguez Ayala², A. Expósito Rodríguez², J. Genollá Subirats¹, E. Rodeño Ortiz de Zarate¹; ¹Gurutzeta/Cruces University Hospital, Barakaldo, SPAIN, ²Basurto University Hospital, Barakaldo, SPAIN.

1005 Monday, October 23, 2017, 16:30 - 18:00, Hall E2

M2M: PET/CT

*Chairs: P. Laverman (Nijmegen, NETHERLANDS)
B. Cornelissen (Oxford, UNITED KINGDOM)*

OP-394

Radiolabelling with carbon-11 of sulfasalazine for PET imaging of cystine transporter X_c⁻ involved in the radioresistance of glioblastoma

M. Morloz, M. Ibazizene, C. Perrio, L. Barre, F. Gourand; Cyceron, UNICAEN, CEA, CNRS, ISTCT/LDM-TEP group, Caen, FRANCE.

OP-395

A Successful Triple PET Tracer Approach to Characterize ER and HER2 Status In Vivo in a Breast Cancer Mouse Xenograft Model

M. Paquette, S. Beaudoin, S. Phoenix, L. Fafard-Couture, É. E. Turcotte, B. Guérin, R. Lecomte, J. V. Leyton; Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-396

In vivo tracking of T cells by [18F]BF4 PET/CT in a mouse model of human breast cancer

E. Kurtys¹, L. Lim¹, F. Man¹, A. Volpe¹, J. Maher², G. O. Fruhwirth^{1,3}; ¹Department of Imaging Chemistry and Biology, Division of Imaging Sciences and Biomedical Engineering, St. Thomas' Hospital Campus, King's College London, London, UNITED KINGDOM, ²Division of Cancer Studies, King's College London, SE1 9RT, UK, London, UNITED KINGDOM, ³Comprehensive Cancer Imaging Centre King's College London & UCL, London, UNITED KINGDOM.

OP-397

Differentiation of CNS lymphoma and glioblastoma with [¹⁸F]fludarabine-PET: comparison with [¹⁸F]FDG in human xenograft models

N. Hovhannisyán¹, S. Guillouet¹, M. Dhilly¹, M. Ibazizene¹, F. Fillesoye¹, S. Valable², B. Plancoulaine³, L. Barré¹; ¹Normandie Univ, UNICAEN, CEA, CNRS, CHU Caen, ISTCT/LDM-TEP group, Caen, FRANCE, ²Normandie Univ, UNICAEN, CEA, CNRS, CHU Caen, ISTCT/CERVOxy group, Caen, FRANCE, ³Normandie Univ, UNICAEN, INSERM, ANTICIPE, Caen, FRANCE.

OP-398

Convenient synthesis and biological evaluation of ¹⁸F-labeled MIBG analog with an improved detectability

A. Yamaguchi, H. Hanaoka, T. Higuchi, Y. Tsushima; Gunma University Graduate School of Medicine, Maebashi, JAPAN.

OP-399

Targeting glucose metabolism and EGFR signaling in oncogene-driven non-small cell lung cancer

V. De Rosa¹, F. Iommelli¹, M. Monti², C. Terlizzi², S. Del Vecchio^{2,1}; ¹Institute of Biostructures and Bioimaging, National Research Council, Naples, ITALY, ²Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY.

OP-400

A direct comparison of four different ⁶⁸Ga-labeled RGD peptides for PET/CT imaging of angiogenesis

D. Lobeek¹, S. Y. A. Terry², G. M. Franssen¹, M. T. Ma³, H. Wester⁴, C. Decristoforo⁵, W. J. G. Oyen^{1,6}, O. C. Boerman¹, M. Rijpkema¹; ¹Radboud University Medical Center Nijmegen, Nijmegen, NETHERLANDS, ²King's College London, London, UNITED KINGDOM, ³King's College London, London, UNITED KINGDOM, ⁴Technische Universität München, Garching, GERMANY, ⁵Medical University Innsbruck, Innsbruck, GERMANY, ⁶Institute of Cancer Research, Royal Marsden NHS Trust, London, UNITED KINGDOM.

OP-401

Synthesis and biological evaluation of novel five F-18 labelled radioligands for detection of MAO-B activity

S. Nag¹, A. Jackson², A. Takano¹, K. Jia¹, R. Arakawa¹, M. Jahan¹, R. Ahmad², S. Luthra², R. Maior¹, C. Halldin¹; ¹Karolinska Institutet, Stockholm, SWEDEN, ²GE Healthcare, London, UNITED KINGDOM.

1006 Monday, October 23, 2017, 16:30 - 18:00, Hall F1

Teaching Session 4 (Interactive): Applied Cross Sectional Anatomy and Correlative Imaging - Abdomen & Pelvis

Chair: J. Pruim (Groningen, NETHERLANDS)

OP-402

Applied Cross Sectional Anatomy and Correlative Imaging – Abdomen & Pelvis

D. Yakar; University Medical Centre, Groningen, NETHERLANDS.

1007 Monday, October 23, 2017, 16:30 - 18:00, Hall F2**Joint Symposium 18 - EANM/ESMO:
Treatment Landscape in Metastatic CRPC**

*Chairs: C. Kratochwil (Heidelberg, GERMANY)
W. Gerritsen (Nijmegen, NETHERLANDS)*

OP-403**Current Treatment Algorithm of Metastatic CRPC**

*W. Gerritsen; Radboud University Medical Centre
Nijmegen, Nijmegen, NETHERLANDS.*

OP-404**Imaging of Metastatic CRPC in the PSMA Era**

*P. Castellucci; S. Orsola-Malpighi, Nuclear Medicine,
Bologna, ITALY.*

OP-405**SMA Targeted Radioligand Therapy – What Do
We Know So Far?**

*C. Kratochwil; University Hospital Heidelberg,
Department of Nuclear Medicine, Heidelberg,
GERMANY.*

OP-406**New Treatment Strategies and Options for
Metastatic CRPC – Is There Space for PSMA RLT?**

*R. Tauber; Klinik und Poliklinik für Urologie, Klinikum
rechts der Isar, Technische Universität München,
Munich, GERMANY.*

1008 Monday, October 23, 2017, 16:30 - 18:00, Hall K**Cardiovascular System: Cardiac Sympathetic
Innervation - 123I-mIBG & Arrhythmias**

*Chairs: D. Agostini (Caen, FRANCE)
A. Flotats (Barcelona, SPAIN)*

OP-407**Standardization of MIBG Heart-to-Mediastinum
Ratio Using a Phantom-based Calibration
Method**

*K. Nakajima¹, K. Okuda², K. Yokoyama³, T. Yoneyama³,
S. Tsuji³, S. Tsuji³, H. Oda³, M. Yoshita⁴, K. Kubota²;
¹Kanazawa University Hospital, Kanazawa, JAPAN,
²Kanazawa Medical University, Uchinada, JAPAN,
³Public Central Hospital of Matto Ishikawa, Hakusan,
JAPAN, ⁴Hokuriku National Hospital, Nanto, JAPAN.*

OP-408**Inter-study reproducibility of SPECT ¹²³I-mIBG
left atrial innervation imaging for the
identification of left atrial ganglionated plexi in
patients with paroxysmal atrial fibrillation**

*J. Stirrup¹, U. Voss², S. Gregg², R. Baavour³, N. Roth³,
C. Breault³, S. Ernst², S. Underwood²; ¹Royal Berkshire
NHS Foundation Trust, Reading, UNITED KINGDOM,
²Royal Brompton and Harefield NHS Foundation Trust,
London, UNITED KINGDOM, ³Spectrum Dynamics
Medical Ltd, Caesarea, ISRAEL.*

OP-409**Evaluation of the effectiveness of
radiofrequency ablation of atrial fibrillation: a
123-Iodine-MIBG myocardial scintigraphy study**

*Y. Saushkina, V. Saushkin, K. Zavadovskiy, I. Kisteneva,
I. Kostina, Z. Vesnina, Y. Lishmanov, S. Popov, R. Karpov;
Cardiology Research Institute, Tomsk NRM, Tomsk,
RUSSIAN FEDERATION.*

OP-410**Value of Gated-perfusion SPECT, synchrony and
123-MIBG scintigraphy in predicting cardiac
resynchronization therapy response**

*A. García-Burillo, P. Hinojosa, S. Aguadé, J. Pérez-
Rodón, M. N. Pizzi, G. Cases, M. Andrés, N. Rivas, A.
Moya; Hospital General Universitari Vall d'Hebron,
Barcelona, SPAIN.*

OP-411**Effect of resynchronization therapy on
endothelial dysfunction and functional
parameters in patients with chronic heart failure
and left bundle branch block**

*T. Massardo¹, J. Pereira², C. G. Sáez², I. Aramburu¹, R.
Morris¹, S. Brugère¹, A. Pino¹, E. Swett¹, E. Hiplan¹, R.
Aguayo³, R. Aguayo³, G. Paillahueque¹, L. Alarcón¹,
J. Torres³, J. Spuler¹, R. Fernández¹, E. Sanhueza¹, M.
Palominos², N. Olivares², G. Valenzuela², R. Asenjo¹;
¹Hospital Clínico Universidad de Chile, Santiago, CHILE,
²Pontificia Universidad Católica de Chile, Santiago,
CHILE, ³Hospital San Juan de Dios, Santiago, CHILE.*

OP-412**MIBG scintigraphy to better identify patients
who benefit from AICD in primary prevention**

*G. Bertuccio, G. Scrima; Ospedale S. Croce - ASLTO5,
Moncalieri, ITALY.*



OP-413

The potential role of myocardial viability assessment using 18F-FDG PET-CT in patients with non-ischemic cardiomyopathy eligible for catheter radiofrequency ablation of ventricular tachycardias: preliminary considerations

S. Capitano¹, R. Sara², C. Popescu², G. Colombo², S. Pedretti², P. Ferro², M. Milella², C. Rossetti²; ¹ASUITS Hospital, Trieste, ITALY, ²Niguarda Hospital, Milano, ITALY.

1010 Monday, October 23, 2017, 16:30 - 18:00, Hall G2

Committee Symposium 5 - Radiation Protection: CT-Optimisation of Hybrid Imaging

*Chairs: M. Lassmann (Wurzburg, GERMANY)
K. Muylle (Brugge, BELGIUM)*

OP-414**Technical Optimisation**

K. Bacher; Ghent University, Department of Medical Physics, Ghent, BELGIUM.

OP-415**Optimisation in Oncology**

P. Veit-Haibach; University of Toronto, Joint Department of Medical Imaging, Toronto, CANADA.

OP-416**Optimisation in Paediatric Nuclear Medicine**

P. Dinis de Almeida; Institute of Biophysics and Biomedical Engineering, Faculty of Sciences, University of Lisbon, Lisbon, PORTUGAL.

OP-417**The View of HERCA on Optimisation**

S. Ebdon-Jackson; CRCE, Public Health England, Oxfordshire, UNITED KINGDOM.

1101 Tuesday, October 24, 2017, 08:00 - 09:30, Hall A

CME 9 - (Paediatrics/
Inflammation & Infection:
FDG PET in Paediatric infections



*Chairs: A. Piccardo (Genova, ITALY)
A. Signore (Rome, ITALY)*

OP-419**FDG PET in the Evaluation of Lymphadenopathy in Children**

L. Borgwardt; Clinic for Clinical Physiology, Nuclear Medicine & PET, 4011, Diagnostic Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK.

OP-420**FDG PET in the Evaluation of the Immunocompromised Child with Fever**

I. Kouijzer; Department of Internal Medicine and Infectious Diseases, Radboudumc, Nijmegen, NETHERLANDS.

OP-421**The Clinical Approach to the Immunocompromised Child with Fever**

F. Karup Pedersen; Paediatric and Adolescence Clinic, Juliane Marie Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK.

1102 Tuesday, October 24, 2017, 08:00 - 09:30, Hall B

Joint Symposium 9 - EANM/EFOMP:
New Developments in CT Technology

*Chairs: M. Brambilla (Novara, ITALY)
B. Sattler (Leipzig, GERMANY)*

OP-422**Dual Energy CT**

M. Kachelriess; University of Heidelberg, German Cancer Research Center, Medical Physics Radiology / X-Ray Imaging and CT, Heidelberg, GERMANY.

OP-423**CT Dose Optimisation Techniques**

M. Kortensniemi; University of Helsinki, HUS Medical Imaging Center, Meilahti Hospital, Helsinki, FINLAND.

OP-424**CT in Hybrid Imaging Systems**

M. Brambilla; Az. Ospedaliero Universitaria Maggiore della Carità, SC di Fisica Sanitaria, Novara, ITALY.

OP-425**Motion Compensation in CT**

M. Kachelriess; University of Heidelberg, German Cancer Research Center, Medical Physics Radiology / X-Ray Imaging and CT, Heidelberg, GERMANY.

1104 Tuesday, October 24, 2017, 08:00 - 09:30, Hall E1

Do.MoRe: Preclinical & Clinical Dosimetry

Chairs: K. Sjögren Gleisner (Lund, SWEDEN)
G. Glattig (Ulm, GERMANY)

OP-427

In-vivo biokinetics of ¹⁷⁷Lu-OPS201 in mice and pigs as a model for predicting human dosimetry

S. Beykan¹, M. Fani², G. Nicolas², D. Wild², R. Bejot³, J. Kaufmann³, H. Bouterfa³, S. Jensen⁴, M. Lassmann¹;

¹Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, ²Division of Nuclear Medicine, University Hospital of Basel, Basel, SWITZERLAND, ³Octreopharm Science GmbH, Ipsen Group, Berlin, GERMANY, ⁴Department of Chemistry and Biosciences, Aalborg University, Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK.

OP-428

A comparison of 2D and 3D kidney absorbed dose measures in patients receiving Lutate therapy

K. Willowson¹, H. Ru¹, A. Singh², P. Jackson³, E. Eslick², D. Bailey²; ¹University of Sydney, Sydney, AUSTRALIA, ²Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, AUSTRALIA, ³Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP-429

Patient-specific pharmacokinetics and dosimetry over multiple therapy cycles during ¹⁷⁷Lu-based radionuclide therapy: a study for ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-PSMA

A. Gosewisch, L. Ermoschkin, H. Ilhan, A. Todica, L. Vomacka, P. Bartenstein, G. Böning; University Hospital Munich, Munich, GERMANY.

OP-430

The effect of the total tumour volume on the kidneys, salivary glands and tumour BEDs for ¹⁷⁷Lu-labelled PSMA ligands

N. J. Begum¹, A. Thieme², J. Allmann², M. Eiber², A. J. Beer³, G. Glattig¹, P. Kletting¹; ¹Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ²Department of Nuclear Medicine, Klinikum Rechts der Isar der Technischen Universität München, Munich, GERMANY, ³Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

OP-431

Concurrent use of ⁹⁰Y, ¹⁷⁷Lu and ²²⁵Ac-labelled PSMA-binding radiopharmaceuticals can lead to improved treatment efficacy

A. M. Denis-Bacelar, A. J. Fenwick, K. M. Ferreira, J. L. Wevrett, A. P. Robinson; National Physical Laboratory, Teddington, UNITED KINGDOM.

OP-432

Assessing the impact of registration methods on absorbed dose calculation in Peptide Receptor Radionuclide Therapy

S. Berenato¹, E. Grassi², F. Fioroni², D. Finocchiaro^{2,3}, M. Iori², E. Spezi¹; ¹School of Engineering, Cardiff University, Cardiff, UNITED KINGDOM, ²Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY, ³Department of Physics, University of Bologna, Bologna, ITALY.

OP-433

Evaluation of the Correlations Between the Absorbed Bone Marrow Dose and Bone Marrow Response During the First Cycle of ¹⁷⁷Lu-DOTATATE Treatment

L. Hagmarker¹, J. Svensson², T. Rydén¹, B. Wängberg³, A. Sundlöf⁴, K. Sjögren Gleisner⁵, P. Bernhardt¹; ¹institution of clinical sciences, Göteborg, SWEDEN, ²Department of Oncology, Göteborg, SWEDEN, ³Department of Surgery, Göteborg, SWEDEN, ⁴Department of Oncology, Skåne University Hospital, Lund, SWEDEN, ⁵Department of Radiation Physics, University of Lund, Lund, SWEDEN.

OP-434

Prospective Dosimetry and Optimization of RPT-XRT Combination Therapies

R. F. Hobbs, A. Josefsson, E. C. Frey, S. A. Terezakis, C. Meyer, D. M. Loeb, G. Sgouros; Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

1105 Tuesday, October 24, 2017, 08:00 - 09:30, Hall E2

M2M: Automation & Production

Chairs: W. Wadsak (Vienna, AUSTRIA)

B. Windhorst (Amsterdam, NETHERLANDS)

OP-435

A 3D-Printed Automated Dual Reactor Synthesizer for Challenging Multi-Step ¹⁸F-Fluorinations: Testing and Validation

A. Amor-Coarasa, J. M. Kelly, D. Kim, W. Qu, P. Kothari, J. W. Babich; Weill Cornell Medical College, New York City, NY, UNITED STATES OF AMERICA.

OP-436

Optimization of a Novel Automated Loop Method for Production and Development of Analytical Methods for ¹¹C-Nicotine Injectable

K. Kumar, A. Ghosh, K. Woolum, M. V. Knopp; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.



**OP-437****Synthesis Of ⁶⁴Cu Radiopharmaceuticals For Cell Radiolabelling Using Anion Exchange Column And Labelling Of WBCs**

A. Socan¹, P. Kolenc Peitl¹, M. Kroselj¹, M. Petrik², C. Decristoforo³; ¹Nuclear Medicine Department, University Medical Centre, Ljubljana, SLOVENIA, ²Institute of Molecular and Translational Medicine, Olomouc, CZECH REPUBLIC, ³University Clinic for Nuclear Medicine, University for Medicine, Innsbruck, AUSTRIA.

OP-438**Production and Purification of ^{99m}Tc Pertechnetate from ¹⁰⁰Mo Targets Irradiated in a Nirta Solid Target Station on an IBA Cyclone® 18 Cyclotron**

K. Buckley¹, P. Martini^{2,1}, M. Dodd¹, S. McDiarmid¹, V. Hanemaayer¹, B. Hook¹, J. Kumlin¹, S. Zeisler¹, P. Schaffer¹, C. Marshall³, A. Dabkowski³, M. Talboys³, S. Wiltshire³, F. Devillet⁴, D. Blampain⁴, B. Nactergal⁴; ¹TRIUMF, Vancouver, BC, CANADA, ²University of Ferrara, Ferrara, ITALY, ³Wales Research and Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM, ⁴IBA RadioPharma Solutions, Louvain-la-Neuve, BELGIUM.

OP-439**Cyclotron production and automated new 2-column processing of [⁶⁸Ga]GaCl₃**

M. Nair¹, S. Hoppel², T. Eriksson¹, M. K. Pandey³, T. R. DeGrado³, K. Gagnon¹; ¹General Electric, Uppsala, SWEDEN, ²Triskem, Bruz, FRANCE, ³Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.

OP-440**Fully automated GMP-compliant single-step synthesis of ¹⁸F-PSMA-1007 using SPE-cartridge purification**

O. C. Neels¹, R. Martin², J. Cardinale¹, R. Smits², M. Schäfer¹, A. Hoepfing², M. Müller², K. Kopka¹; ¹German Cancer Research Center, Heidelberg, GERMANY, ²ABX advanced biochemical compounds, Radeberg, GERMANY.

OP-441**Automated Synthesis of Pt-195m Cisplatin for GMP Production**

K. Codee-van der Schilden¹, O. Zwaagstra¹, D. van der Born²; ¹NRG, Petten, NETHERLANDS, ²FutureChemistry Holding BV, Nijmegen, NETHERLANDS.

OP-442**Automatic synthesis of a PSMA ligand with Al¹⁸F**

J. Giglio, M. Zeni, E. Savio, H. Engler; CUDIM, Montevideo, URUGUAY.

1106 Tuesday, October 24, 2017, 08:00 - 09:30, Hall F1**Pitfalls & Artefacts 5 (Interactive) - Oncology: Pitfalls and Artefacts of PET in Neuroendocrine Tumours**

Chairs: J. Talbot (Paris, FRANCE)
M. Bozkurt (Ankara, TURKEY)

OP-443**¹⁸F-fluorodopa**

S. Balogova; Comenius University, Faculty of Medicine & St. Elisabeth Cancer Institute, Nuclear Medicine, Bratislava, SLOVAKIA.

OP-444**Somatostatin Receptor PET/CT in Gastro-Enteropancreatic (GEP) NEN**

V. Ambrosini; University of Bologna and S.Orsola-Malpighi Hospital, Nuclear Medicine, Bologna, ITALY.

OP-445**Somatostatin Receptor PET in Other NET**

J.-N. Talbot; Hospital Tenon, AP-HP & Université P&M Curie, Paris, FRANCE.

1107 Tuesday, October 24, 2017, 08:00 - 09:30, Hall F2**Clinical Oncology: Cured or Not Cured?**

Chairs: N. Aide (Caen, FRANCE)
R. Nuñez Miller (Vienna, AUSTRIA)

OP-446**Accuracy of F-18-FDG-PET/CT in monitoring tumour response after neoadjuvant chemoradiotherapy (nCRT) in patients with locoregional oesophageal cancer**

M. J. Valkema¹, B. J. Noordman¹, B. P. L. Wijnhoven¹, V. M. C. W. Spaander¹, J. P. Ruurda², G. A. P. Nieuwenhuijzen³, M. I. Van Berge Henegouwen⁴, M. N. Sosef⁵, J. J. B. Van Lanschot¹, R. Valkema¹; ¹Erasmus MC University Medical Centre, Rotterdam, NETHERLANDS, ²University Medical Centre, Utrecht, NETHERLANDS, ³Catharina Hospital, Eindhoven, NETHERLANDS, ⁴Academic Medical Centre, Amsterdam, NETHERLANDS, ⁵Atrium Medical Centre, Heerlen, NETHERLANDS.

OP-447**¹⁸F-FDG-PET/CT For Evaluating Bevacizumab-Based Chemotherapy Combined With Regional Deep Capacitive Hyperthermia In Metastatic Cancer Patients**

C. Ferrari¹, G. Ranieri², A. Niccoli Asabella¹, A. Di Palo¹, I. Marech³, M. Porcelli³, M. Fanelli¹, G. Rubini¹, C. Gadaleta³; ¹Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, Bari, ITALY, ²Interventional Radiology Unit with Integrated section of Medical Oncology, National Cancer Research Centre IRCCS "Giovanni Paolo II", Bari, ITALY, ³Interventional Radiology Unit with Integrated Section of Medical Oncology, National Cancer Research Centre, IRCCS "Giovanni Paolo II", Bari, ITALY.

OP-448**SUVmax from ¹⁸F-FDG PET/CT may outperform volumetric biomarkers in assessment of primary tumor response to neoadjuvant chemoradiotherapy in patients with esophageal cancer**

E. R. Hassan¹, Y. G. Abdelhazef¹, M. A. Abougabal², C. Yeh³, Y. Chao⁴, C. Tseng⁵, Y. Chang⁶; ¹South Egypt Cancer Institute, Assiut University, Assiut, EGYPT, ²Faculty of Medicine, Cairo University, Cairo, EGYPT, ³Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Department of Pathology, Taoyuan, TAIWAN, ⁴Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Division of Thoracic Surgery, Taoyuan, TAIWAN, ⁵Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Department of Radiation Oncology, Taoyuan, TAIWAN, ⁶Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Chang Gung Memorial Hospital, Nuclear Medicine Department, Taoyuan, TAIWAN.

OP-449**¹⁸F-FDG PET-CT versus MRI-based External Beam Radiotherapy Volumes in Inoperable Uterine Cervical Cancer**

J. A. Adam¹, H. Arkies², K. Hinnen¹, L. Stalpers¹, J. H. van Waesberghe³, J. Stoker¹, B. L. F. van Eck-Smit¹; ¹Academic Medical Center Amsterdam, Amsterdam, NETHERLANDS, ²Isala Hospital, Zwolle, NETHERLANDS, ³VU University Medical Center Amsterdam, Amsterdam, NETHERLANDS.

OP-450**Low tracer availability of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE in blood for patients with high SSTR density leads to non-linear correlation between SUV and K_i**

E. Ilan^{1,2}, A. Sundin^{1,3}, I. Velikyan^{1,3}, M. Sandström^{1,2}, M. Lubberink^{1,2}; ¹Department of Surgical Science, Uppsala University, SWEDEN, ²Medical Physics, Uppsala University Hospital, SWEDEN, ³Medical Imaging Centre, Uppsala University Hospital, SWEDEN.

OP-451**Evaluation of Surgically Excised Non-functioning Pancreatic Endocrine Tumors Followed Radiopeptide Treatment; To Optimize PRRT, Aiming to a Longer Term Survival**

G. S. Limouris¹, G. Fragulidis², M. Paphiti¹, D. Voros², V. R. McCready³; ¹Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, ²II Surgical Dept of 'Aretaieion' Hospital, Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, ³Institute Cancer Research, Sutton Surrey & Royal Sussex County Hospital, Brighton, UNITED KINGDOM.

OP-452**¹⁷⁷Lu-PSMA Therapy Response Prediction in Metastatic Prostate Cancer Patients by Textural Heterogeneity Parameters in Baseline ⁶⁸Ga-PSMA PET Scans**

Z. Khurshid¹, H. Ahmadzadehfar¹, F. C. Gaertner¹, L. Papp², N. Zsóter³, H. Strunk¹, M. Essler¹, R. A. Bundschuh¹; ¹Universitätsklinikum Bonn, Bonn, GERMANY, ²Universitätsklinikum Wien, Wien, AUSTRIA, ³Mediso Medical Imaging Systems, Budapest, HUNGARY.

OP-453**Dose Escalation Experience with ¹⁷⁷Lu-PSMA-617**

H. Rathke¹, F. L. Giesel¹, P. Flechsig¹, K. Kopka², W. Mier¹, M. Hohenfellner³, U. Haberkorn⁴, C. Kratochwill¹; ¹University Hospital Heidelberg, Heidelberg, GERMANY, ²Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, GERMANY, ³University Hospital Heidelberg, Department of Urology, Heidelberg, GERMANY, ⁴University Hospital Heidelberg; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (dkfz), Heidelberg, GERMANY.

1110 Tuesday, October 24, 2017, 08:00 - 09:30, Hall G2

Do.MoRe: Clinical Dosimetry for ⁹⁰Y Radioembolization

Chairs: S. Walrand (Brussels, BELGIUM)
C. Chiesa (Milan, ITALY)

OP-454**The impact of the hemoglobin level in liver radioembolization is confirmed by TOF-PET/CT based dose-response in hepatocellular carcinoma**

M. Hesse, P. D'Abadie, S. Walrand, F. Jamar, R. Lhommel; Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.



OP-455**Effect of differences in CT- and SPECT-based tumor delineation on tumor dose and dose response following 90Y Selective Internal Radiation Therapy (SIRT)**

A. Balagopal, A. Mahvash, S. C. Kappadath; UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-456**Absorbed dose correlates with metabolic response to radioembolization of liver metastases with resin 90Y-microspheres**

M. Cremonesi, M. E. Ferrari, F. Botta, F. Guerriero, C. Garibaldi, C. De Cicco, M. Colandrea, C. M. Grana, G. Varano, G. Bonomo, D. Paolo, F. Orsi, R. Orecchia; Istituto Europeo di Oncologia, Milano, ITALY.

OP-457**Is there any relationship between 90Y-PET absorbed doses and damage to the target non tumoral liver (TNTL) after SIRT?**

L. Sancho Rodriguez¹, M. Rodríguez-Fraile¹, J. Bilbao¹, M. Iñarrairaegui¹, C. Beorlegui Arteta², A. Benito¹, V. Moran¹, J. Martí-Climent¹, E. Guillen¹, B. Sangro¹; ¹Clinica Universidad de Navarra, Pamplona, SPAIN, ²Universidad de Navarra, Pamplona, SPAIN.

OP-458**Evaluation of 99TcMAA SPECT and 90Y PET similarity metrics on clinical cases with reference values from multiple realizations of phantom scans**

J. Mikell, B. Majdalany, R. Srinivasa, K. Younge, Y. Dewaraja; University of Michigan Hospital and Health Systems, Ann Arbor, MI, UNITED STATES OF AMERICA.

OP-459**Retrospective Dosimetry for Hepatocellular Carcinoma Radioembolization with Yttrium-90 Resin Microspheres Planned using Body Surface Area Method**

M. Kafrouni^{1,2}, M. Fourcade¹, S. Vauclin², A. Ilonca¹, D. Mariano-Goulart¹; ¹Montpellier University Hospital - Department of Nuclear Medicine, Montpellier, FRANCE, ²Dosisoft SA, Cachan, FRANCE.

OP-460**Assessment of dose-response correlation of selective internal radiation therapy (SIRT) for liver metastases from colorectal cancer (mCRC)**

H. Levillain¹, G. Marin¹, T. Guiot¹, Z. Wimana¹, M. Vouche², P. Delatte², E. Woff¹, A. Hendlitz³, B. Vanderlinden¹, P. Flamen¹; ¹Nuclear Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ²Radiology Department, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ³Digestive Oncology Department, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

OP-461**On the origin of spurious extrahepatic activities observed in 90Y nonTOF-PET imaging post radioembolization**

S. Walrand, M. Hesse, F. Jamar, R. Lhommel; Université Catholique de Louvain, Brussels, BELGIUM.

1201/1203 Tuesday, October 24, 2017, 10:00 - 11:15, Hall A

Plenary 3: Radiobiology of Molecular Radiotherapy

Chairs: J. Pruim (Groningen, NETHERLANDS)
J. Kunikowska (Warsaw, POLAND)

OP-462**DNA Damage and Repair Processes at High and Low Dose Rates**

D. van Gent; Erasmus MC, Department of Molecular Genetics, Rotterdam, NETHERLANDS.

OP-463**Feasibility of Non-DNA Targeted Radionuclide Therapy: Contribution of Bystander Effects**

J.-P. Pouget; IRCM/INSERMU896, Montpellier, FRANCE.

OP-464**Selective Targeting of the Cell Membrane; Attacking the Tumour House of Cards**

B. Bednarz; University of Wisconsin-Madison, Department of Medical Physics at Wisconsin Institutes for Medical Research, Madison, UNITED STATES OF AMERICA.

1301 Tuesday, October 24, 2017, 11:30 - 13:00, Hall A

**CME 10 - Neuroimaging:
Brain PET and SPECT in Dementia -
Beyond Alzheimer's Disease***Chairs: S. Morbelli (Genova, ITALY)
J. Arbizu (Pamplona, SPAIN)***OP-465****Brain PET and SPECT in Patients with
FrontoTemporal Dementia***K. Herholz; Wolfson Molecular Imaging Centre,
University of Manchester, Manchester, UNITED
KINGDOM.***OP-466****Brain PET and SPECT Imaging in Lewy Body
Diseases***N. Pavese; Imperial College London, London, UNITED
KINGDOM.***OP-467****Brain SPECT and PET in Tau-Related
Parkinsonism***J. Arbizu; Department of Nuclear Medicine, University
of Navarra, Pamplona, SPAIN.*

1302 Tuesday, October 24, 2017, 11:30 - 13:00, Hall B

**Joint Symposium 10 - EANM/ESES/IFCC:
Diagnosis and Treatment of Hyperthyroidism***Chairs: F. Verburg (Marburg, GERMANY)
L. Giovannella (Bellinzona, SWITZERLAND)***OP-468****Laboratory Testing in the Diagnosis of
Hyperthyroidism***L. C. Giovannella; Oncology Institute of Southern
Switzerland, Bellinzona, SWITZERLAND***OP-469****Nuclear Diagnostics and Therapy of
Hyperthyroidism***F. A. Verburg; Philipps-University of Marburg, Marburg,
GERMANY***OP-470****Surgical Treatment of Hyperthyroidism***M. Barczynski; Jagiellonian University Medical College,
Department of Endocrine Surgery, Third Chair of
General Surgery, JUMC, Krakow, POLAND.*

1303 Tuesday, October 24, 2017, 11:30 - 13:00, Hall C

Technologist Oral Presentations 3*Chairs: N. Gulliver (London, UNITED KINGDOM)
M. Attard (Nijmegen, NETHERLANDS)***OP-471****Feasibility of an Iodine-123 FP-CIT striatal
quantitative measurement method with a partial
volume effect correction***T. Kanenawa¹, S. Ota¹, A. Takaki², S. Ito³; ¹Graduate
School of Health Sciences, Kumamoto University,
Kumamoto, JAPAN, ²Teikyo University, Omuta, JAPAN,
³Faculty of Life Sciences, Kumamoto University,
Kumamoto, JAPAN.***OP-472****Image classification of synaptic dopamine
transporters ¹²³I-Ioflupane by machine learning
techniques***J. Camacho-Cañamón¹, M. Guiote Moreno², A. Santos
Bueno², E. Rodríguez Cáceres², E. Carmona Asenjo²,
J. Vallejo Casas², P. A. Gutiérrez¹, C. Hervás-Martínez¹;
¹University of Córdoba, CORDOBA, SPAIN, ²H.U. Reina
Sofía. UGC Medicina Nuclear Cordoba, CORDOBA,
SPAIN.***OP-473****Optimization Of Acquisition Time For ¹⁸F-
FLUTEMETAMOL PET/CT In Patients With Early-
Onset Dementia***M. Isolani, A. Pieri, G. Serreli, C. Ghetti, M. Scarlattei, C.
Lazzara, L. Ruffini; Azienda Ospedaliera- Universitaria
Ospedale Maggiori di Parma, Parma, ITALY.***OP-474****Clinical, long term efficacy of PRRT in NEN
patients with advanced, nonresectable,
progressive hindgut and cancer of unknown
primary (CUP)***A. D. Kolasinska-Cwikla¹, A. Lewczuk², L. Bodej³, M.
Kidd⁴, J. R. Buscombe⁵, I. M. Modlin⁶, J. B. Ćwikła⁷;
¹MSC Memorial Cancer Centre and Institute Maria
Skłodowska-Curie, Warszawa, POLAND, ²Medical
University of Gdansk, Gdansk, POLAND, ³Memorial
Sloan Kettering Cancer Center, New York, NY, UNITED
STATES OF AMERICA, ⁴Wren Laboratories, Branford, CT,
UNITED STATES OF AMERICA, ⁵Addenbrooke's Hospital,
Cambridge, UNITED KINGDOM, ⁶Yale, New Haven,
CT, UNITED STATES OF AMERICA, ⁷Faculty of Medical
Sciences, University of Warmia and Mazury, Olsztyn,
POLAND.*

**OP-475****A review of thyroid blockade strategies used in paediatric I¹²³ MIBG scintigraphy, and an evaluation of their relative effectiveness**

B. Thurlow¹, T. Melhuish², P. Leanne¹, E. Morris¹, S. Johns², M. Guy², S. King³, L. Biassoni¹; ¹Great Ormond Street Hospital for Children NHS Foundation Trust, London, UNITED KINGDOM, ²University Hospitals Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM, ³University of the West of England, Bristol, UNITED KINGDOM.

OP-476**Evaluation of the influence of adipose tissue in attenuation and scattering correction in Myocardial Perfusion SPECT/CT**

B. Guerreiro¹, S. Valente^{2,1}, P. Pereira¹, R. Rosa¹, L. Vieira^{3,4}, E. Sousa³, F. Branco^{2,1}, T. Freixo², P. Almeida^{4,2}, F. D. Jonge², T. C. Ferreira²; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, ²Hospital dos Lusíadas, Departamento de Medicina Nuclear, Lisboa, PORTUGAL, ³GIReS-Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, ⁴Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, PORTUGAL.

OP-477**Planar versus SPECT Acquisition in Pulmonary Embolism: comparison of some European Practices**

T. C. S. Melo¹, D. Vieira¹, A. Nunes², C. Sibley-Allen², D. Dasgupta², H. Ahmed², S. M. Piekut³, S. Mirzaei³, C. Sonneck-Koenne³, W. Zehetner³, J. A. Silva⁴, M. Oliveira⁴, J. Nery⁴, R. Castro⁴, L. F. Metello^{1,5}; ¹ESS-IPP, ATC & Curso Med. Nuclear, Porto, PORTUGAL, ²Department of Nuclear Medicine Guy's and St. Thomas Hospital, London, UNITED KINGDOM, ³Wilhelminenspital, Department of Nuclear Medicine and PET center, Vienna, AUSTRIA, ⁴CHP-Hosp. Sto. António EPE, Dept. de Med. Nuclear, Porto, PORTUGAL, ⁵IsoPor-Azores, Dept. de Med. Nuclear e Imagiologia Molecular, Angra do Heroísmo, I. Terceira-Azores, PORTUGAL.

OP-478**Preliminary results for: Optimised diagnostics of lung embolus with ventilation/perfusion SPECT/CT with use of CPAP prior to lung scintigraphy**

J. P. Paludan, S. R. Andresen, J. Abrahamsen, M. S. Jensen, C. Høyer; Region Hospital Viborg, Viborg, DENMARK.

1304 Tuesday, October 24, 2017, 11:30 - 13:00, Hall E1**Do.MoRe: Radiation Protection**

*Chairs: N. Varmenot (Saint-Herblain, FRANCE)
P. Covens (Brussels, BELGIUM)*

OP-479**Designing a PET uptake room: ALARA does not like all concrete walls**

M. Hesse, S. Walrand, F. Jamar; Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

OP-480**Comparison of the methods for eye lens dose measurement by a Monte Carlo method**

M. Fulop¹, J. Hudzietzová², P. Ragan¹, J. Sabo³, D. Solivajs⁴, P. Vlk⁵; ¹Slovak Medical University, Bratislava, SLOVAKIA, ²Faculty of Biomedical Engineering, CTU Prague, Kladno, CZECH REPUBLIC, ³Faculty of Safety Management of PACR, Prague, CZECH REPUBLIC, ⁴Slovak Legal Metrology, NGO, Bratislava, SLOVAKIA, ⁵BIONT Inc., Bratislava, SLOVAKIA.

OP-481**The Influence of Age and Gender on Bone Marrow Fat-Fraction**

M. Salas-Ramirez¹, J. Tran-Gia¹, A. M. Weng², H. Köstler², M. Lassmann¹; ¹Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, ²Department of Diagnostic and Interventional Radiology, University of Würzburg, Würzburg, GERMANY.

OP-482**Doses in female carer due to a paediatric nuclear medicine patient using ICRP biokinetic data and Monte Carlo simulations**

V. de Sousa¹, G. Cardoso¹, A. I. Santos^{1,2}; ¹Serviço de Medicina Nuclear – Hospital Garcia de Orta, Almada, PORTUGAL, ²Nova Medical School – Universidade Nova de Lisboa, Lisboa, PORTUGAL.

OP-483**Comparison between fetal dose estimates for [¹⁸F]FDG PET imaging in pregnant patient using static and dynamic bladder voiding models**

C. M. Dartora¹, N. G. Cavedini¹, A. M. Marques da Silva^{1,2}; ¹PUCRS, Porto Alegre, BRAZIL, ²Brain Institute, Porto Alegre, BRAZIL.

OP-484**Optimisation of administered activity for ¹⁸F-FDG examination on children**

J. Oddstig¹, A. Stenvall¹, H. Almquist², L. Jönsson¹, B. Olsson², C. Hindorf¹; ¹Department of Radiation Physics, Lund, SWEDEN, ²Department of Clinical Physiology and Nuclear Medicine, Lund, SWEDEN.

OP-485**Validation of Siemens CARE kV for use with PET/CT: dose reduction and PET quantification**

T. Jørgensen¹, M. A. Micheelsen², E. Dupont³, N. A. Bebbington⁴; ¹Department of Clinical Physiology and Nuclear Medicine, Zealand University Hospital, Næstved, DENMARK, ²Department of Clinical Physiology and Nuclear Medicine, Zealand University Hospital, Køge, DENMARK, ³Department of Biomedical Engineering, Zealand University Hospital, Køge, DENMARK, ⁴Siemens Healthineers, Aarhus, DENMARK.

OP-486**Measuring, Monitoring, and Reporting Effective Dose on an Hybrid Equipment: one year results and challenges to integrate with MDCT**

G. Tosi¹, A. Chiti², K. Marzo³, F. Zanca³; ¹Humanitas Research Hospital, ROZZANO, ITALY, ²Humanitas University, ROZZANO, ITALY, ³GE Healthcare, BUC, FRANCE.

1305 Tuesday, October 24, 2017, 11:30 - 13:00, Hall E2

M2M: Prostate Cancer Targeting

Chairs: J. Cardinale (Vienna, AUSTRIA)
K. Rahbar (Muenster, GERMANY)

OP-487**In vitro and in vivo characterization of a [¹⁸F] AIF-labeled PSMA ligand for imaging of PSMA-expressing xenografts**

S. Lütje^{1,2}, G. M. Franssen¹, M. Gotthardt¹, K. Herrmann², O. C. Boerman¹, S. Heskamp¹; ¹Dept. Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, NETHERLANDS, ²Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY.

OP-488**Synthesis and Radiolabelling of a DOTA-Bisphosphonate-Conjugated PSMA Inhibitor**

N. Pfannkuchen¹, F. Rösch¹, R. Bergmann²; ¹Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, GERMANY, ²Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY.

OP-489**Synthesis and evaluation of ¹⁸F-labeled trifluoroborate derivatives of PSMA-617 for imaging prostate cancer with positron emission tomography**

H. Kuo¹, J. Pan¹, H. Merckens¹, J. Lau¹, C. Zhang¹, N. Colpo¹, D. M. Perrin², K. Lin¹, F. Bénard¹; ¹BC Cancer Research Centre, Vancouver, BC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA.

OP-490**First-in-human PET/CT imaging with ¹⁵²Tb-DOTATOC in neuroendocrine neoplasm and of prostate cancer using ¹⁵²Tb-PSMA-617**

A. Singh¹, R. P. Baum¹, D. Müller¹, S. Senftleben¹, M. Benesova^{2,3}, C. Vermeulen², S. Gnesin⁴, U. Köster⁵, K. Johnston⁶, H. R. Kulkarni¹, A. Türler^{7,8}, R. Schibli^{2,3}, J. O. Prior⁴, N. P. van der Meulen^{2,7}, C. Müller^{2,3}; ¹Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Bad Berka, GERMANY, ²Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen-PSI, SWITZERLAND, ³Department of Chemistry and Applied Biosciences, ETH Zurich, SWITZERLAND, ⁴Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital (CHUV), Lausanne, SWITZERLAND, ⁵Institut Laue-Langevin, Grenoble, FRANCE, ⁶ISOLDE/CERN, Meyrin, SWITZERLAND, ⁷Laboratory of Radiochemistry, Paul Scherrer Institut, Villigen-PSI, SWITZERLAND, ⁸Department of Chemistry and Biochemistry, University of Bern, Bern, SWITZERLAND.

OP-491**Low molecular weight target module for PET imaging and UniCAR T cell immunotherapeutic treatment of PSMA expressing tumors**

R. Bergmann¹, A. Feldmann¹, M. Schäfer², C. Liolios³, S. Koristka¹, N. Berndt¹, K. Kuhne^{1,4}, A. Höpping⁵, J. Pietzsch^{6,7}, J. Kotzerke⁸, J. Steinbach¹, K. Kopka^{2,9}, M. Bachmann^{1,10,11}; ¹Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY, ²Deutsches Krebsforschungszentrum, Abteilung Radiopharmazeutische Chemie, Heidelberg, GERMANY, ³Deutsches Krebsforschungszentrum, Heidelberg, GERMANY, ⁴Technische Universität Dresden, Fachrichtung Chemie und Lebensmittelchemie, Dresden, GERMANY, ⁵ABX GmbH, Radeberg, GERMANY, ⁶Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, ⁷Technische Universität Dresden, Fachrichtung Chemie und Lebensmittelchemie, Dresden, GERMANY, ⁸Technische Universität Dresden, Uniklinikum 'Carl Gustav Carus', Klinik und Poliklinik für Nuklearmedizin, Dresden, GERMANY, ⁹National Center for Tumor Diseases, Heidelberg, GERMANY, ¹⁰Technische Universität Dresden, Uniklinikum 'Carl Gustav Carus', UCC, Tumorimmunology, Dresden, GERMANY, ¹¹National Center for Tumor Diseases, 'Carl Gustav Carus' TU Dresden, Dresden, GERMANY.



OP-492**⁸⁹Zr-df-IAB2M for PET/CT imaging of prostate cancer**

J. S. Batra, Y. S. Jhanwar, S. Vallabhajosula, M. J. Niaz, T. Flynn, S. T. Tagawa, N. H. Bander, D. S. Scherr; Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA.

OP-493**Comparative biodistribution of the parental murine monoclonal antibody 5A10 and its humanized version for PSA-targeting in prostate cancer**

T. Tran; Dept of Radiopharmacy, Stockholm, SWEDEN.

OP-494**GRPR-Targeted Radiotherapy: Influence of Chelator on Labeling and Biodistribution of Four ¹⁷⁷Lu-Labeled Analogues of the GRPR-Antagonist PEG2-RM26**

A. Orlova¹, B. Mitran¹, T. Maina², B. A. Nock², S. S. Rinne¹, V. Tolmachev¹, U. Rosenström¹; ¹Uppsala University, UPPSALA, SWEDEN, ²INRASTES NCSR "Demokritos", Athens, GREECE.

1306 Tuesday, October 24, 2017, 11:30 - 13:00, Hall F1**Pitfalls & Artefacts 6 (Interactive) - Dosimetry: Pitfalls and Artefacts in Pre- and Post-Therapeutic Imaging**

*Chairs: F. Forrer (St. Gallen, SWITZERLAND)
M. Konijnenberg (Rotterdam, NETHERLANDS)*

OP-495**An Imaging Based Guide in Individualisation of Neuroendocrine Tumour Therapy**

P. Manoharan; The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM.

OP-496**Post-Therapy Imaging of the Treatment Effects After ¹⁷⁷Lu-DOTA-Octreotate Therapy**

U. Garske-Román; Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP-497**Prospective Dosimetry Based Treatment Planning Based on pre- (^{99m}Tc-SPECT-CT) and post- (⁹⁰Y PET TOF) Radioembolisation Imaging**

C. Chiesa; Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan, ITALY.

1307 Tuesday, October 24, 2017, 11:30 - 12:45, Hall F2**Clinical Oncology: Bad Brain**

*Chairs: N. Albert (Munich, GERMANY)
I. Law (Copenhagen, DENMARK)*

OP-498**¹⁸F-fluciclovine PET/MRI in the evaluation of brain glioma**

A. Karlberg^{1,2}, E. M. Berntsen^{1,2}, H. Johansen¹, M. Myrthue¹, A. J. Skjulsvik^{3,4}, I. Reinertsen^{5,6}, M. Esmæili², H. Y. Dai³, Y. Xiao^{7,8}, H. Rivaz^{7,8}, P. Borghammer⁹, O. Solheim^{5,10,11}, L. Eikenes²; ¹Department of Radiology and Nuclear Medicine, St. Olavs University Hospital, Trondheim, NORWAY, ²Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, NORWAY, ³Department of Pathology and Medical Genetics, St. Olavs University Hospital, Trondheim, NORWAY, ⁴Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, NORWAY, ⁵Norwegian National Advisory Unit for Ultrasound and Image Guided Therapy, St. Olavs University Hospital, Trondheim, NORWAY, ⁶Department of Medical Technology, SINTEF, Trondheim, NORWAY, ⁷PERFORM Centre, Concordia University, Montreal, QC, CANADA, ⁸Department of Electrical and Computer Engineering, Concordia University, Montreal, QC, CANADA, ⁹Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, ¹⁰Department of Neurosurgery, St. Olavs University Hospital, Trondheim, NORWAY, ¹¹Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, NORWAY.

OP-499**Immunohistochemically evaluated PSMA expression in 122 treatment naive glioma patients related to [¹¹C]-methionine PET and survival**

T. Traub-Weidinger, N. Poetsch, T. Bachnik, A. Woehrer, J. Gesperger, W. Wadsak, M. Markus, M. Preusser, M. Hacker, O. Koperek; MEDICAL UNIVERSITY OF VIENNA, Vienna, AUSTRIA.

OP-500**Improved detection of postoperative remaining meningioma tissue with ⁶⁸Ga-DOTATATE PET/CT scans compared to surgeon's estimated Simpson Grade**

F. J. Vettermann¹, M. Ueberschaerr², M. Unterrainer¹, P. Bartenstein¹, J. Tonn², C. Schichor², N. L. Albert¹; ¹Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, GERMANY, ²Department of Neurosurgery, Ludwig-Maximilians-University, Munich, GERMANY.



OP-501**Impact of chemotherapy with Temozolomide on physiological brain 18F-DOPA uptake in patients with glioma**

L. Carideo¹, F. Cicone¹, C. Scaringi², I. Russo², G. Minniti², F. Scopinaro¹; ¹Nuclear Medicine Unit, Sant'Andrea Hospital, Sapienza University of Rome, Italy, Rome, ITALY, ²Radiotherapy Unit, Sant'Andrea Hospital, Sapienza University of Rome, Italy, Rome, ITALY.

OP-502**IDH1-R132H mutation and semiquantitative [¹¹C]-methionine PET: Independent prognostic factors for characterization of newly diagnosed and treatment naive gliomas**

N. Poetsch, A. Woehrer, J. Gesperger, A. R. Haug, D. Wilhelm, G. Karanikas, M. Weber, I. Rausch, M. Mitterhauser, W. Wadsak, M. Hacker, T. Traub-Weidinger; Vienna General Hospital, Vienna, AUSTRIA.

OP-503**Differential Diagnosis of Recurrence and Radiation Necrosis in High Grade Gliomas Using Multiparametric Analysis of Combined Dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI**

D. A. Hiob¹, C. Preibisch², J. Gempt³, J. Schlegel⁴, C. Straube⁵, C. Zimmer², M. Schwaiger¹, T. Pyka¹; ¹Department of Nuclear Medicine, Klinikum rechts der Isar der TU München, Muenchen, GERMANY, ²Department of Neuroradiology, Klinikum rechts der Isar der TU München, Muenchen, GERMANY, ³Department of Neurosurgery, Klinikum rechts der Isar der TU München, Muenchen, GERMANY, ⁴Institute of Pathology and Neuropathology, Klinikum rechts der Isar der TU München, Muenchen, GERMANY, ⁵Department of Radiation Oncology, Klinikum rechts der Isar der TU München, Muenchen, GERMANY.

OP-504**Voxel-based analysis of dynamic ¹⁸F-FET-PET in gliomas : association with IDH1 mutational status and survival.**

P. Blanc-Durand¹, A. Van Der Gucht¹, A. Kourilsky², V. Dunet¹, A. Verger³, K. Langen⁴, M. Jreige¹, M. Nicod-Lalonde¹, N. Schaefer¹, J. Prior¹; ¹CHUV, Lausanne, SWITZERLAND, ²Beaujon, Paris, FRANCE, ³CH, Nancy, FRANCE, ⁴Forshungszentrum, Jülich, GERMANY.

1308 Tuesday, October 24, 2017, 11:30 - 12:45, Hall K**Cardiovascular System: Myocardial Perfusion PET - ¹³N-Ammonia and ¹⁵O-Water**

Chairs: R. Sciagra (Florence, ITALY)
W. Acampa (Naples, ITALY)

OP-505**AMMO-X: A cross-comparison study of ¹³N-ammonia PET MPQ software tools**

S. V. Nesterov^{1,2}, L. E. Juárez-Orozco¹, R. J. Krol³, R. Sciagra⁴, P. Slomka⁵, A. Alessio⁶, F. van der Zant³, C. Han¹, N. Kartiosuo⁷, J. M. Knuuti¹; ¹Turku PET Centre, Turku, FINLAND, ²Institute of Evolutionary Physiology and Biochemistry, RAS, St. Petersburg, RUSSIAN FEDERATION, ³Cardiac Imaging Division Alkmaar, Northwest Clinics, Department of Nuclear Medicine, Alkmaar, NETHERLANDS, ⁴Nuclear Medicine Unit, DECBS, University of Florence, Florence, ITALY, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, ⁶University of Washington, Seattle, WA, UNITED STATES OF AMERICA, ⁷Research Center of Applied and Preventive Cardiovascular Medicine, Turku, FINLAND.

OP-506**Assessment of the functional significance of coronary artery stenoses in patients with CAD using dynamic stress PET / CT with ¹³N-ammonium with the use of absolute values of myocardial blood flow and coronary flow reserve**

I. V. Shurupova, I. P. Aslanidis, M. G. Shavman, E. P. Derevyanko, E. P. Derevyanko, I. V. Ekaeva; Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, RUSSIAN FEDERATION.

OP-507**Prognostic value of quantitative absolute myocardial stress perfusion in patients with chest pain and normal coronary arteries: A Nitrogen-13 Ammonia PET study**

A. G. Monroy-Gonzalez¹, R. A. Tio¹, E. Alexanderson-Rosas², R. H. J. A. Slart¹; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Department of Physiology, National Autonomous University of Mexico, MEXICO.

OP-508**Feasibility of layer myocardial blood flow**

R. Calabretta¹, E. Milan², R. Giubbini³, R. Durmo³, L. Gallo², T. Kubik^{4,5}, R. Sciagra¹; ¹Nuclear Medicine, DECBS, University of Florence, FLORENCE, ITALY, ²Nuclear Medicine, San Giacomo Hospital, ULSS 2, Castelfranco Veneto, ITALY, ³Chair of Nuclear Medicine, University of Brescia, Brescia, ITALY, ⁴Pmod Technologies LLC, Zurich, SWITZERLAND, ⁵Institute of Metrology and Biomedical Engineering, Warsaw University of Technology, Warsaw, POLAND.



**OP-509****Effect of motion-induced PET-CT misalignment on cardiac function and myocardial blood flow measured using dynamic ¹⁵O-water PET**

M. Lubberink¹, M. Ebrahimi¹, H. J. Harms^{2,3,4}, L. Poulsen Tolbod², J. Sörensen^{1,2}; ¹Uppsala University, Uppsala, SWEDEN, ²Århus University, Århus, DENMARK, ³Brigham and Women's Hospital, Boston, MA, UNITED STATES OF AMERICA, ⁴VU University Medical Centre, Amsterdam, NETHERLANDS.

OP-510**Automatic extraction of left ventricular mass and volumes using parametric images from non-ECG-gated ¹⁵O-water PET/CT**

J. Nordström^{1,2}, H. J. Harms³, M. Lubberink^{1,4}, L. Tolbod³, J. van den Berg¹, T. Baron⁵, F. A. Flachskampf⁶, T. Kero^{1,6}, J. Sörensen^{1,6}; ¹Nuclear medicine & PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, ²Centre for Research and Development, Uppsala University / Gävleborg County, Gävle, SWEDEN, ³Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, ⁴Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN, ⁵Cardiology, Department of Medical Sciences, Uppsala University, Uppsala, SWEDEN, ⁶Medical Imaging Centre, Uppsala University Hospital, Uppsala, SWEDEN.

1310 Tuesday, October 24, 2017, 11:30 - 13:00, Hall G2

Do.MoRe: Detector Technology

*Chairs: O. Grosser (Magdeburg, GERMANY)
N. Belcari (Pisa, ITALY)*

OP-511**A Promising PET Detector Design that Achieves 100 ps FWHM Coincidence Time Resolution**

J. W. Cates, C. S. Levin; Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-512**First human images from a next generation SiPM based PET/CT system with improved time and spatial resolution**

M. Casey¹, Z. Burbar¹, H. Rothfuss¹, V. Panin¹, D. Bharkhada¹, W. Howe¹, Y. Bradley²; ¹Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF AMERICA, ²University of Tennessee Graduate School of Medicine, Knoxville, TN, UNITED STATES OF AMERICA.

OP-513**Ultra-high Definition Isotropic 1mm Voxel Reconstruction in Clinical Wholebody PET - Is Digital PET Making It a Reality?**

M. V. Knopp¹, J. Zhang¹, K. Binzel¹, M. I. Knopp¹, R. Moore¹, M. Friel¹, F. Giesel², C. L. Wright¹; ¹The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ²University Hospitals Heidelberg, Heidelberg, GERMANY.

OP-514**Evaluation of Whole-Body and Small FOV CZT Gamma Cameras**

J. W. Hugg, B. W. Harris, H. Tomita; Kromek / eV Products, Saxonburg, PA, UNITED STATES OF AMERICA.

OP-515**First Experience with Fast Imaging Using Discovery MI PET/CT**

I. Sonni, S. Park, L. Baratto, N. Hatami, G. Davidzon, S. Srinivas, S. Gambhir, A. H. Iagaru; Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-516**Phase Ia Trial Comparing Higher Definition Digital Photon Counting PET/CT with Current Photomultiplier PET/CT for Head and Neck Oncology**

C. L. Wright¹, A. D. Bhatt¹, K. Binzel¹, I. R. Washington¹, P. Bhatia¹, P. Subramanian¹, J. Zhang¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ²Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

OP-517**PET 20.0: a cost-efficient, 2mm spatial resolution Total Body PET with point sensitivity up to 22% and adaptive axial FOV of maximum 2.00m**

S. Vandenberghe¹, E. Mikhalyova², B. Brans³, M. Defrise⁴, T. Lahoutte⁴, K. Muylle⁴, R. Van Hoken⁵, D. R. Schaart⁶, J. S. Karp⁷; ¹MEDISIP-Ugent, Gent, BELGIUM, ²Department of Biomedical Engineering, University of California Davis, Davis, CA, UNITED STATES OF AMERICA, ³Department of nuclear medicine UZGent/Ugent, Gent, BELGIUM, ⁴Dept of nuclear medicine, Free University of Brussels, Brussels, BELGIUM, ⁵MEDISIP-Ugent-Molecubes, Gent, BELGIUM, ⁶Radiation Science & Technology, Delft University of Technology, Delft, NETHERLANDS, ⁷PET instrumentation Group, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

OP-518**A New Direction to Explore to Advance Coincidence Time Resolution for Time-of-Flight Positron Emission Tomography**

L. Tao, C. S. Levin; Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

YDF3 Tuesday, October 24, 2017, 13:00 - 14:30, Hall F1

EANM Young Daily Forum 3: Be Stronger - Mentally, Emotionally, Physically & Spiritually

*R. Sheppard; Somerset, UNITED KINGDOM.***1401 Tuesday, October 24, 2017, 14:30 - 16:00, Hall A**

CME 11 - Paediatrics/Oncology/SIOOPEN: SSR Imaging and Therapy in Children

*Chairs: M. Castellani (Milan, ITALY)
L. Borgwardt (Copenhagen, DENMARK)***OP-519****The Importance of miBG in the International Neuroblastoma Community. Perspectives from SIOOPEN Collaborations: Past, Present, Future***R. Ladenstein; St. Anna Kinderkrebsforschung, Vienna, AUSTRIA.***OP-520****Somatostatin Receptor Imaging in Paediatric Tumours***M. F. Bozkurt; Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TURKEY.***OP-521****Theranostic Application of PRRT in Neuroblastoma***G. Kong; Peter MacCallum Cancer Centre, Centre for Molecular Imaging, Melbourne, AUSTRALIA.***1402 Tuesday, October 24, 2017, 14:30 - 16:00, Hall B**

Joint Symposium 11 - EANM/EACVI: Quantification of Myocardial Blood Flow

*Chairs: O. Gämperli (Zurich, SWITZERLAND)
F. Hyafil (Paris, FRANCE)***OP-522****Pathophysiology of Myocardial Blood Flow and Fractional Flow Reserve***J. Piek; AMC Heart Center, Academic Medical Center, University of Amsterdam, Amsterdam, NETHERLANDS.***OP-523****Quantification of Stress Myocardial Blood Flow with PET and SPECT***R. Sciagra; Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, ITALY.***OP-524****Quantification of Myocardial Blood Flow with CTA***G. Pontone; Centro Cardiologico Monzino, IRCCS, Milan, ITALY.***OP-525****Quantification of Myocardial Blood Flow with MRI***S. Nekolla; Clinic of Nuclear Medicine, Technical University, Munich, GERMANY.***1403 Tuesday, October 24, 2017, 14:30 - 16:00, Hall C**

CTE 5: Gastrointestinal Imaging

*Chairs: N. Gulliver (London, UNITED KINGDOM)
I. Larg (Cluj-Napoca, ROMANIA)***OP-526****Pearls & Pitfalls in Gastrointestinal Imaging with Conventional Nuclear Medicine Scintigraphy***G. Vivian; King's College Hospital, London, UNITED KINGDOM.***OP-527****The Clinical Use of PET-CT in Upper Gastrointestinal Oncology***M. Bertoli; University of Brescia, Brescia, ITALY.***OP-528****The Clinical Use of PET-CT in Lower Gastrointestinal Oncology***S. Hess; Odense University Hospital, Odense, DENMARK.***1404 Tuesday, October 24, 2017, 14:30 - 16:00, Hall E1**

Do.MoRe - Dosimetry/Physics/AAPM: PET Auto-Segmentation: Review and Evaluation Strategies - Insights from AAPM Task Group No. 211

*Chairs: A. Kirov (New York, UNITED STATES OF AMERICA)
R. Buchert (Hamburg, GERMANY)***OP-529****Components of a Standard and a Procedure for Evaluation of PET-AS Methods***A. Kirov; Memorial Sloan-Kettering Cancer Center, New York, USA***OP-530****State-of-the-Art of Current PET-AS Algorithms and their Advantages and Limitations for Clinical Application***M. Hatt; Centre Hospitalier Régional Universitaire Morvan INSERM, Brest, FRANCE*

OP-531**Design, Implementation and First Results of the Future Standard for Evaluation of PET-AS Methods**

E. DeBernardi; Università degli Studi di Milano-Bicocca, Milan, ITALY.

1405 Tuesday, October 24, 2017, 14:30 - 16:00, Hall E2

M2M: Nanoparticles

*Chairs: M. Bernsen (Rotterdam, NETHERLANDS)
H. Hong (Ann Arbor, UNITED STATES OF AMERICA)*

OP-532**An intrinsically radioactive metal-organic framework (MOF) nanomaterial for Cerenkov luminescence-triggered cancer phototherapy: focused on deep-tissue tumor**

H. Hong, D. Chen, D. Yang, W. Lu; University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

OP-533**Formulation and in vivo biodistribution of ⁵⁷Co-porphyrin-labelled hydrophobic liquid nanoparticles**

P. Hervella¹, J. Dam², H. Thisgaard², C. Baun², B. B. Olsen², P. Højlund-Carlsen², D. Needham¹; ¹Center for Single Particle Science and Engineering, Odense, DENMARK, ²Odense University Hospital, Odense, DENMARK.

OP-534**Pretargeted tumor imaging with a polymer: Reducing absorbed radiation dose and increasing imaging contrast**

E. J. L. Stéen¹, K. Nørregaard², A. Birke³, P. E. Edem^{2,1}, J. T. Jørgensen², R. Rossin⁴, M. Robillard⁴, A. Kjaer², M. Barz³, M. M. Herth^{1,2}; ¹University of Copenhagen, Copenhagen, DENMARK, ²Rigshospitalet, University Hospital, Copenhagen, DENMARK, ³Johannes-Gutenberg University, Mainz, GERMANY, ⁴Tagworks Pharmaceuticals BV, Eindhoven, NETHERLANDS.

OP-535**Nanoparticle-based radiopharmaceuticals: is there a future to ⁴⁵TiO₂ nanoparticles?**

P. Costa¹, L. F. Metello^{1,2}, F. Alves³, M. D. Naia⁴; ¹Nuclear Medicine Department, ESS|P, Porto, PORTUGAL, ²IsoPor S.A., Porto, PORTUGAL, ³Institute for Nuclear Sciences Applied to Health, University of Coimbra, Coimbra, PORTUGAL, ⁴CEMUC® - Physics Department, ECT-UTAD, Vila Real, PORTUGAL.

OP-536**Radiolabeling and biodistribution studies in a rat model of lipid-based nanosystems designed for the treatment of wounds.**

M. Collantes¹, G. Quincoces², R. Ramos-Membrive², M. Eca^{3,4}, A. Aldave^{3,4}, M. Pastor⁵, G. Gainza⁵, E. Gainza⁵, I. Peñuelas^{1,2,4}; ¹Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, SPAIN, ²Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, ³MicroPET Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, ⁴Center for Applied Medical Research, Pamplona, SPAIN, ⁵Biopraxis Research AIE, Vitoria, SPAIN.

OP-537**Chelator-free Radiolabeling of Iron Oxide Nanoparticles with ⁶⁸Ga For Dual-Modality PET/ MR Imaging**

M. Karageorgou¹, J. Gallo², C. Tsoukalas¹, S. Xanthopoulos¹, M. Paravatou-Petsotas¹, D. Stamopoulos^{3,4}, M. Bañobre-López², P. Bouziotis¹; ¹INRASTES, NCSR 'DEMOKRITOS', Athens, GREECE, ²Advanced (magnetic) Theranostic Nanostructures Lab, INL, Braga, PORTUGAL, ³Department of Solid State Physics, NKUA, Athens, GREECE, ⁴Institute of Nanosciences and Nanotechnology, NCSR "Demokritos", Athens, GREECE.

OP-538**Multifunctional Nanoprobe for Integrated PET / MR Imaging**

S. Roux¹, F. Bouraleh Hoch¹, V. Thakare², C. Bernhard², R. Bazzi¹, A. Oudot³, B. Collin^{2,3}, F. Brunotte³, F. Boschetti⁴, F. Denat²; ¹Université de Bourgogne Franche-Comté, Besançon, FRANCE, ²Université de Bourgogne Franche-Comté, Dijon, FRANCE, ³Centre Georges-François Leclerc, Dijon, FRANCE, ⁴CheMatech S.A.S., Dijon, FRANCE.

OP-539**Biodistribution of ^{99m}Tc-Phytate in a Sterile Inflammation Model in Mice**

D. Priftakis¹, M. Papachristou¹, S. Xanthopoulos², I. Datsiris¹, P. Bouziotis²; ¹Evangelismos Hospital, Athens, GREECE, ²NCSR "Demokritos", Athens, GREECE.



1406 Tuesday, October 24, 2017, 14:30 - 16:00, Hall F1**Teaching Session 5 (Interactive): Applied Cross Sectional Anatomy and Correlative Imaging - Cross Sectional CT and PETCT for the TNM Staging of Lung Cancer***Chair: P. Elsinga (Groningen, NETHERLANDS)***OP-540****Applied Cross Sectional Anatomy and Correlative Imaging – Cross Sectional CT and PETCT for the TNM Staging of Lung Cancer***T. Lynch; Belfast, UNITED KINGDOM.***1407 Tuesday, October 24, 2017, 14:30 - 16:00, Hall F2****Clinical Oncology - Rapid Fire Session: Mix it Up, please!***Chairs: K. Herrmann (Essen, GERMANY)**C. Nanni (Bologna, ITALY)***OP-541****Combination of baseline FDG-PET/CT total metabolic tumor volume and gene expression profil have a robust predictive value in patients with Diffuse Large B-Cell Lymphoma***M. N. Toledano^{1,2}, P. Desbordes², I. Gardin^{1,2}, P. Vera^{1,2}, F. Jardin^{3,4}, P. Ruminy⁴, H. Tilly^{3,4}, S. Becker^{1,2}; ¹Nuclear Medicine Department, Henri Becquerel Centre and Rouen University Hospital, Rouen, FRANCE, ²QuantIF-LITIS (EA 4108-FR CNRS 3638), Faculty of Medicine, University of Rouen, Rouen, FRANCE, ³Hematology department, Henri Becquerel Centre and Rouen University Hospital, Rouen, FRANCE, ⁴INSERM U918, Henri Becquerel Centre, Rouen, FRANCE.***OP-542****Improved Pulmonary Nodule Detection Using a Next Generation ¹⁸F-FDG PET Imaging System***S. Park, L. Baratto, N. Hatami, G. Davidzon, S. Srinivas, V. Nair, A. Iagaru; Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA.***OP-543****Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study Group***C. Kobe¹, H. Goergen², M. Fuchs², H. T. Eich³, C. Baues⁴, V. Diehl⁵, G. Kuhnert¹, A. Drzeczga¹, M. Dietlein¹, A. Engert^{2,5}, P. Borchmann^{2,5}; ¹Department of Nuclear Medicine, University Hospital of Cologne, Cologne, GERMANY, ²German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, GERMANY, ³Department of Radiation Oncology, University Hospital of Muenster, Muenster, GERMANY, ⁴Department of Radiation Oncology, University Hospital of Cologne, Cologne, GERMANY, ⁵Department of Internal Medicine I, University Hospital of Cologne, Cologne, GERMANY.***OP-544****Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer***A. Collarino¹, L. M. Pereira Arias-Bouda^{1,2}, R. A. Valdés Olmos^{1,3,4}, P. van der Tol⁵, P. Dibbets-Schneider¹, L. de Geus-Oei^{1,6,7}, F. H. P. van Velden^{1,5}; ¹Section of Nuclear Medicine, Department of Radiology, Leids Universitair Medisch Centrum, Leiden, NETHERLANDS, ²Department of Nuclear Medicine, Alrijne Ziekenhuis, Leiderdorp, NETHERLANDS, ³Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS, ⁴Department of Nuclear Medicine, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, ⁵Medical Physics, Department of Radiology, Leids Universitair Medisch Centrum, Leiden, NETHERLANDS, ⁶Biomedical Photonic Imaging Group, MIRA Institute, University of Twente, Enschede, NETHERLANDS, ⁷Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, NETHERLANDS.***OP-545****Somatostatin antagonist theranostic pair ⁶⁸Ga-OPS202 and ¹⁷⁷Lu-OPS201 for well-differentiated neuroendocrine tumors (NETs)***D. Reidy, N. Pandit-Taskar, S. Krebs, J. O'Donoghue, N. Raj, E. Cruz, H. Pham, A. Lashley, L. Bodei, W. A. Weber; ; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.***OP-546****Comparison of ¹⁸F-FDG PET/MRI and MRI for primary evaluation and treatment planning of cervical cancer patients***J. Grueneisen¹, T. Sarabhai¹, B. Schaarschmidt², M. Forsting¹, K. Herrmann¹, L. Umutlu¹; ¹University Hospital Essen, Essen, GERMANY, ²University Hospital Düsseldorf, Düsseldorf, GERMANY.***OP-547****[¹²³I/¹³¹I]IMAZA as a new theranostic tool in patients with advanced adrenocortical carcinoma***A. Schirbel¹, C. Blümel¹, B. Heinze², A. Plaß², C. T. Fuß², F. Megerle², T. Deutschbein², M. Fassnacht², M. Kroiss², H. Hänscheid¹, A. K. Buck¹, S. Hahner²; ¹University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg, GERMANY, ²University of Wuerzburg, Department of Medicine I, Division of Endocrinology and Diabetes, Wuerzburg, GERMANY.*

OP-548**ImmunoPET imaging to assess target engagement: Experience from ⁸⁹Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors**

A. Mcgeoch^{1,2}, C. Menke-van der Houven van Oordt³, M. Bergstrom¹, I. McSherry¹, D. Smith⁴, M. Cleveland¹, O. Hoekstra³, D. Vugts³, A. Weber⁵, I. Freedman⁵, M. Huisman³, C. Matheny⁵, G. van Dongen³, S. Zhang⁵; ¹GSK, Stevenage, UNITED KINGDOM, ²University of Cambridge, Cambridge, UNITED KINGDOM, ³VU University Medical Centre, Amsterdam, NETHERLANDS, ⁴PAREXEL International, Durham, NC, UNITED STATES OF AMERICA, ⁵GSK, King of Prussia, PA, UNITED STATES OF AMERICA.

OP-549**FDG-PET/CT in single pulmonary nodule (SPN): a preliminary experience from a multicenter Italian Assessment of Lung Indeterminate Accidental Nodule (ITALIAN) trial**

L. Evangelista¹, M. Spadafora², L. Mansi³, L. Pace⁴, M. Arosio⁵, G. Saladini¹, S. Sanfilippo⁶, M. Salvatore⁷, G. Pepe⁸, G. Cusato⁸, M. Ferdeghini⁹, A. Chiaravalloti¹⁰, M. Giuliano¹¹, M. Farsad¹², S. Pellegrino¹³, S. Del Vecchio¹³, A. Giordano¹⁴, A. Cuocolo¹³; ¹Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, ²Nuclear Medicine Unit, Department of Imaging, S.G. Moscati Hospital, Avellino, ITALY, ³Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale, Second University of Naples, Napoli, ITALY, ⁴Department of Medicine and Surgery, University of Salerno, Baronissi (SA), ITALY, ⁵Nuclear Medicine Unit, San Gerardo Hospital, University of Milano Bicocca, Milano, ITALY, ⁶Service of Nuclear Medicine, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, ITALY, ⁷Nuclear Medicine Unit, Department of Imaging, SDN Foundation, Napoli, ITALY, ⁸Nuclear Medicine Unit, Cancer Center, Humanitas Hospital, Rozzano, Milano, ITALY, ⁹Nuclear Medicine Unit, Department of Imaging, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, ITALY, ¹⁰Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, ITALY, ¹¹Nuclear Medicine Unit, Department of Imaging, Medicina Futura IOS, Acerra, Napoli, ITALY, ¹²Department of Nuclear Medicine, Hospital of Bolzano, Bolzano, ITALY, ¹³Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, ITALY, ¹⁴Institute of Nuclear Medicine, Università Cattolica del S. Cuore, Roma, ITALY.

OP-550**⁶⁸GaNeoBOMB1 in oligometastatic GIST: first results from a Phase-I/IIa study**

L. Gruber¹, C. Uprimny¹, F. Orlandi², H. Margreiter¹, M. F. Mariani², W. Jaschke¹, C. Decristoforo¹, I. Virgolini¹; ¹Medical University Innsbruck, Innsbruck, AUSTRIA, ²Advanced Accelerator Applications S.r.l., Colletterto Giacosa/Ivrea, ITALY.

OP-551**¹⁸F-FDG PET/CT for treatment response assessment in classical Hodgkin Lymphoma (cHL), in the era of innovative immunomodulatory PD-1 blocked (nivolumab) therapy**

I. Sandler¹, A. Broccoli², P. Castellucci¹, C. Nanni¹, C. Pellegrini², F. Quirini², P. Zinzani², S. Fanti¹; ¹Nuclear Medicine Unit, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, ITALY, ²Institute of Hematology and Medical Oncology "L.&A. Seràgnoli", University of Bologna, S.Orsola-Malpighi Hospital, Bologna, ITALY.

1409 Tuesday, October 24, 2017, 14:30 - 16:00, Hall G1**Neurosciences - Rapid Fire Session: Imaging Brain Physiology in Preclinical & Clinical Models**

Chairs: F. Cicone (Rome, ITALY)

S. Hesse (Leipzig, GERMANY)

OP-552**Gender differences in the cerebral uptake of ¹⁸F-FDG**

J. W. A. Sijbesma, A. van Waarde, D. Vázquez García, H. H. Boersma, R. H. J. A. Slart, R. A. J. O. Dierckx, J. Doorduyn; University of Groningen, Groningen, NETHERLANDS.

OP-553**Brain Metabolic Response to Prolonged Starvation: a micro-PET study**

A. Orengo¹, A. Buschiazzo², L. Emiomite³, S. Ravera⁴, V. Cossu¹, S. Bruno⁵, A. Bellini², L. Raffaghello⁶, F. Di Giulio¹, G. Bianchi⁶, S. Morbelli¹, C. Marini^{1,7}, G. Sambucetti^{1,2}; ¹Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Genoa, ITALY, ²Department of Health Sciences, University of Genoa, Genoa, ITALY, ³Animal facility, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁴Department of Pharmacy, Biochemistry Laboratory, University of Genoa, Genoa, ITALY, ⁵Department of Experimental Medicine, University of Genoa, Genoa, ITALY, ⁶Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, ⁷CNR Institute of Biomedicine and Molecular Physiology, Milan, ITALY.

OP-554**Altered Insulin-Dependent Brain Glucose Metabolism During Obesity Depends On Specific Brain Areas**

C. Malbert¹, S. Bahri²; ¹INRA, Saint-Gilles, FRANCE, ²University of Tunis, Tunis, TUNISIA.

OP-555**Brain [11C]PK11195 and [18F]FDG PET imaging in a rat model of postoperative cognitive dysfunction**

E. Kurtys^{1,2}, *I. B. Hovens*², *C. C. Real*³, *P. Kopschina Feltes*⁴, *D. Vázquez García*⁴, *U. L. M. Eisel*², *R. G. Schoemaker*², *J. M. Verkuy*⁵, *L. M. Broersen*⁵, *H. C. Klein*⁴, *R. A. J. O. Dierckx*⁴, *J. Doorduyn*⁴, *E. F. J. de Vries*⁴; ¹King's College London, London, UNITED KINGDOM, ²University of Groningen, Groningen, NETHERLANDS, ³University of São Paulo, São Paulo, BRAZIL, ⁴University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ⁵Nutricia Research, Utrecht, NETHERLANDS.

OP-556**Muscimol Reduces D2 Receptor Binding in the Mesolimbic System of the Rat**

*S. Nikolaus*¹, *H. Wittsack*¹, *M. Beu*¹, *M. A. De Souza Silva*², *C. Antke*¹, *F. Wickrath*¹, *A. Müller-Lutz*¹, *G. Antoch*¹, *J. P. Huston*², *H. Müller*¹, *H. Hautzel*¹; ¹University Hospital Düsseldorf, Düsseldorf, GERMANY, ²Heinrich-Heine University, Düsseldorf, GERMANY.

OP-557**Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using 4FMFES PET Imaging**

M. Paquette, *S. Phoenix*, *J. A. Rousseau*, *O. Sarhini*, *B. Guérin*, *É. E. Turcotte*, *R. Lecomte*; Université de Sherbrooke, Sherbrooke, QC, CANADA.

OP-558**Determining the Effects of Age and Gender on Normal Pediatric Brain Metabolism Using FDG-PET**

*S. Turpin*¹, *P. J. Martineau*², *M. A. Levasseur*³, *R. Lambert*¹; ¹CHU Sainte-Justine, Montreal, QC, CANADA, ²University of Ottawa, Ottawa, ON, CANADA, ³CHU Sherbrooke, Sherbrooke, QC, CANADA.

OP-559**Impact of plasma glucose on the pattern of brain FDG uptake and on its performance for prediction of dementia in mild cognitive impairment**

*I. Apostolova*¹, *C. Lange*², *P. Suppa*³, *S. Klutmann*¹, *L. Spies*³, *M. Grothe*⁴, *R. Buchert*¹; ¹University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, ²University Medicine Charité Berlin, Berlin, GERMANY, ³jung diagnostics GmbH, Hamburg, Hamburg, GERMANY, ⁴German Center for Neurodegenerative Diseases, Rostock, GERMANY.

OP-560**Using EQ-PET to reduce reconstruction-dependent variation in FDG PET brain imaging**

*M. Vanhoute*¹, *R. Lopes*², *G. Petyt*³, *C. Hossein-Foucher*⁴, *A. Aziz*³, *A. Jaillard*⁵, *H. Lahousse*³, *F. Semah*⁴, *R. Fahmi*⁶; ¹Siemens Healthineers / Univ. Lille, Inserm U1171, CHU Lille, F-59000 Lille, France, Lille, FRANCE, ²Univ. Lille, Inserm U1171, CHU Lille / CHU Lille, Department of Neuroradiology, Lille, FRANCE, ³CHU Lille, Department of Nuclear Medicine, Lille, FRANCE, ⁴Univ. Lille, Inserm U1171, CHU Lille / CHU Lille, Department of Nuclear Medicine, Lille, FRANCE, ⁵Univ. Lille, Inserm U1171, CHU Lille, Lille, FRANCE, ⁶Siemens Healthineers, Molecular Imaging, Knoxville, TN, UNITED STATES OF AMERICA.

OP-561**Calculation of image-derived input function for absolute quantification of clinical [18F]FDG PET/MRI studies of the brain**

*I. Shiyam Sundar*¹, *O. Muzik*², *L. Rischka*¹, *A. Hahn*¹, *I. Rausch*¹, *R. Lanzemberger*¹, *M. Hienert*¹, *E. Maria Klebermass*¹, *T. Traub-Weidinger*¹, *T. Beyer*¹; ¹Medical University Vienna, Vienna, AUSTRIA, ²Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA.

1410 Tuesday, October 24, 2017, 14:30 - 16:00, Hall G2

Do.MoRe: Thyroid Cancer - Clinical

Chairs: M. Konijnenberg (Rotterdam, NETHERLANDS)
L. de Geus-Oei (Leiden, NETHERLANDS)

OP-562**18FDopa PET/CT is more sensitive than WB-MRI for the detection of structural disease in medullary thyroid cancer with increased calcitonin.**

M. Terroir, *I. Borget*, *C. Caramella*, *K. El Farsaoui*, *D. Deandrei*, *S. Grimaldi*, *J. Lumbroso*, *A. Berdelou*, *E. Baudin*, *M. Schlumberger*, *S. Leboulloux*; Gustave Roussy, Villejuif, FRANCE.

OP-563**Role of 68Ga-DOTA RGD PET/CT in patients with TENIS (Thyroglobulin elevation with negative Iodine scintigraphy) syndrome and its comparison with 18 F FDG PET/CT**

A. S. Parihar, *R. Basher*, *J. Shukla*, *R. Vatsa*, *A. Sood*, *A. Bhattacharya*, *B. R. Mittal*; Post Graduate Institute of Medical Education & Research, Chandigarh, INDIA.



OP-564**Comparison of F-18 DOPA and Ga-68 DOTA TATE in detection of recurrences or metastasis of medullary thyroid cancer**

S. Asa¹, K. Sönmezoğlu¹, E. Kaymak Akgun¹, S. Razavi Khosroshah¹, S. Toksöz², H. Pehlivanoğlu¹, E. Karayel¹, M. Ocağ³, L. Kabasakal¹, Y. Bükey²; ¹Istanbul University Cerrahpasa Medical Faculty Department of Nuclear Medicine, Istanbul, TURKEY, ²Istanbul University Cerrahpasa Medical Faculty Department of General Surgery, Istanbul, TURKEY, ³Istanbul University Pharmacy Faculty, Istanbul, TURKEY.

OP-565**Characteristics of malignant thyroid lesions on [¹⁸F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT)**

H. Nasr^{1,2}, H. Farghaly^{1,3}, A. Alqarni¹, S. Al-Salem¹; ¹Radiology Departement, Prince Sultan Military Medical City, Riyadh, SAUDI ARABIA, ²Nuclear Medicine Unit, Kasr Al-Aini Cairo University Hospital, Cairo, EGYPT, ³Nuclear Medicine Unit, Assuit University Hospital, Assuit, EGYPT.

OP-566**FDG+/¹⁸F-RAI+ patients with distant metastases from differentiated thyroid cancer can benefit from RAI treatment**

I. Males¹, S. Grimaldi², M. Terroir³, J. Lumbroso¹, D. Deandreis¹, A. Berdelou¹, E. Baudin¹, M. Schlumberger¹, S. Leboulloux¹; ¹Institut Gustave Roussy, Villejuif, FRANCE, ²Serena Grimaldi, villejuif, FRANCE, ³Marie Terroir Cassou de Mouna, Villejuif, FRANCE.

OP-567**Underestimation of the risk of metastatic disease in differentiated thyroid cancer adopting the 2015 ATA guidelines**

D. Albano, M. Gazzilli, M. Bonacina, R. Durmo, E. Cerudelli, M. Panarotto, F. Bertagna, R. Giubbini; Spedali Civili Brescia, Brescia, ITALY.

OP-568**30 mCi Radioiodine Treatment of Thyroid Carcinoma Patients in the post ESTIMABL Era**

D. Rusu¹, V. Fleury¹, C. Palpacuer², M. Le Thiec¹, M. Colombié¹, F. Kraeber-Bodéré^{1,3,4}, C. Rousseau^{1,4}; ¹Nuclear Medicine, ICO Cancer Fighting Center -, SAINT HERBLAIN, FRANCE, ²Statistics Unit, ICO Cancer Fighting Center -, SAINT HERBLAIN, FRANCE, ³Nuclear Medicine, University Hospital, Nantes, FRANCE, ⁴CRCNA, Inserm U892, CNRS UMR 6299, Nantes, FRANCE.

OP-569**Usefulness of I-123-Dx-Whole-Body Scan in planning ¹³¹I-treatment of the differentiated thyroid carcinoma in children and adolescence**

M. F. Villani, A. Grossi, B. Cassano, M. Pizzoferro, G. Ubertini, S. Chiapparelli, M. C. Garganese; Bambino Gesù Children's Hospital, Rome, ITALY.

1501 Tuesday, October 24, 2017, 16:30 - 18:00, Hall A

CME 12 - Translational Molecular Imaging and Therapy/Oncology/ Neuroimaging: ¹⁸F-DOPA and Radiolabelled Choline PET in Recurrent Glioblastoma

Chairs: E. Lopci (Milan, ITALY)
I. Law (Copenhagen, DENMARK)

OP-570**The Need of Oncologists: Can Imaging Satisfy them?**

G. Lombardi; Veneto Institute of Oncology IOV – IRCCS, Oncology 1 Unit, Padova, ITALY.

OP-571**Advanced Imaging with MRI: Impact of DCE/DSC and DWI on the Diagnosis or Relapsed Gliomas**

K. Salzman; University of Utah, Radiology Department, Salt Lake City, UNITED STATES OF AMERICA.

OP-572**Potential Role of F-DOPA and Choline PET in Recurrent Glioblastoma**

J. Darcourt; Centre Antoine Lacassagne, Department of Nuclear Medicine, Nice, FRANCE.

1502 Tuesday, October 24, 2017, 16:30 - 18:00, Hall B

Joint Symposium 12 - EANM/EORTC: PET Criteria for Response Assessment: Quo Vadis PERCIST?

Chairs: N. Aide (Caen, FRANCE)
C. Deroose (Leuven, BELGIUM)

OP-573**PET Response Criteria in Solid Tumours: PERCIST and More**

W. Weber; Memorial Sloan Kettering Cancer Centre, New York, UNITED STATES OF AMERICA.

OP-574**Impact of Harmonization Strategies on EORTC Criteria and PERCIST**

N. Aide; University Hospital, Caen, FRANCE.



OP-575**PET Response Criteria for Patients Undergoing Target Radioligand Therapy**

W. Fendler; Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, UNITED STATES OF AMERICA.

OP-576**Assessing Response to Immunotherapy - Where are we?**

R. Hicks; Cancer Imaging, Peter Mac Callum Cancer Institute, Melbourne, AUSTRALIA.

OP-577**Ongoing EORCT Reflexions on the Use of FDG PET and Other Imaging Biomarkers in Clinical Trials**

C. Deroose; ZU Leuven, Nuclear Medicine Department, Leuven, BELGIUM.

1503 Tuesday, October 24, 2017, 16:30 - 18:00, Hall C**CTE 6 - Joint Session with Dosimetry: Imaging, Reconstruction and ROI Analysis Techniques for Dosimetry**

*Chairs: P. Fragoso Costa (Oldenburg, GERMANY)
C. Chiesa (Milan, ITALY)*

OP-578**Image Reconstruction and Target Delineation on PET/CT for Radiotherapy Treatment Planning**

M. Josipovic; Rigshospitalet, Department of Oncology, section for Radiotherapy, Copenhagen, DENMARK.

OP-579**Technical Challenges in 99mTc-MAA SPECT and 90Y PET Based Radioembolisation Dosimetry**

C. Chiesa; Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan, ITALY.

OP-580**Image Based Radionuclide Dosimetry Techniques**

K. Bacher, Ghent University, Department of Medical Physics, Ghent, BELGIUM;

1504 Tuesday, October 24, 2017, 16:30 - 18:00, Hall E1**Do.MoRe - Rapid Fire Session: Radionuclide Therapy, Miscellaneous**

*Chairs: R. Baum (Bad Berka, GERMANY)
F. Forrer (St. Gallen, SWITZERLAND)*

OP-581**Peptide receptor radionuclide therapy (PRRT) in ENETS Grade 3 (G3) Neuroendocrine Neoplasia (NEN) - a single-institution retrospective analysis**

S. Thang^{1,2}, M. Lung¹, G. Kong¹, M. Hofman¹, J. Callahan¹, M. Michael¹, R. Hicks¹; ¹Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Singapore General Hospital, Singapore, SINGAPORE.

OP-582**The HSP90-inhibitor Onalespib Potentiates ¹⁷⁷Lu-Dotatate Treatment of Neuroendocrine Tumors**

S. Lundsten, A. Mortensen, A. Mäkinen, D. Spiegelberg, B. Stenerlöw, M. Nestor; Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN.

OP-583**Heterogeneity derived by somatostatin receptor PET Predicts Overall Survival in G1/2 Pancreatic NET Patients Envisaged for Endoradiotherapy**

R. A. Werner¹, H. Illhan², M. Mooz¹, S. Lehner², L. Papp³, N. Zsótér⁴, I. Schatka⁵, D. O. Mügge¹, T. Higuchi¹, A. K. Buck¹, P. Bartenstein², F. Bengel⁶, M. Essler⁷, C. Lapa¹, R. A. Bundschuh⁷; ¹Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Munich, GERMANY, ³Department of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ⁴Mediso Medical Imaging Systems Ltd., Budapest, HUNGARY, ⁵Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, GERMANY, ⁶Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, ⁷Department of Nuclear Medicine, University Medical Center Bonn, Bonn, GERMANY.



OP-584**Hyperkalemia in patients treated with radioligand or peptide receptor radionuclide therapy**

C. H. Pfo¹, A. Ott², F. Maurer³, P. Lupp⁴, K. Scheidhauer¹, U. Heemann⁵, M. Schwaiger¹, C. Schmaderer⁵; ¹Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY, ²Biomedical Informatics, Institute of Medical Statistics and Epidemiology, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY, ³Hospital Pharmacy Department, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY, ⁴TU Munich Department of Pathobiochemistry, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY, ⁵Department of Nephrology, Technische Universität München, Klinikum rechts der Isar, Munich, GERMANY.

OP-585**Adjuvant post-operative radiosynovectomy in patients with rare cases of ankle pigmented villonodular synovitis (PVS)**

I. Iakovou¹, J. Kotrotsios¹, K. Badiavas¹, M. Potoupnis², V. Mpalaris¹, G. Arsos¹; ¹Academic Nuclear Medicine dpt, Papageorgiou hsp, THESSALONIKI, GREECE, ²Academic Orthopedic dpt, Papageorgiou hsp, THESSALONIKI, GREECE.

OP-586**Impact of external cooling on PSMA uptake in salivary glands**

L. W. M. van Kalmthout, M. G. E. H. Lam, B. de Keizer, A. J. A. T. Braat; University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-587**Functional imaging of the salivary glands for evaluation of radiation-induced sialadenitis before and after Lu-177 PSMA radioligand therapy**

T. Langbein, H. R. Kulkarni, A. Singh, R. P. Baum; Zentralklinik Bad Berka, Bad Berka, GERMANY.

OP-588**Fluorocholine PET CT parameters predictive for hematological toxicity to 223Radium Therapy**

M. Sinigaglia, L. Vija Racaru, S. Kanoun, S. Zerdoud, M. Bauriaud-Mallet, D. Bastié, L. Dierickx, D. Vallot, O. Caselles, P. Pascal, F. Courbon; Institut Universitaire de Cancérologie-Oncopole, Toulouse, FRANCE.

OP-589**Baseline 18F-Fluoride PET-derived parameters predict modification of toxicity- and response-related blood biomarkers in prostate cancer patients treated with 223Ra-Dichloride: preliminary results**

V. Ceriani¹, G. Fornarini¹, M. Bauckneht¹, S. Morbelli¹, E. Zanardi¹, E. Pomposelli², A. Buschiazio¹, I. Calamia¹, M. Ippoliti¹, F. Fiz³, R. Piva¹, P. Matarci Bettini¹, F. Boccardo¹, G. Sambuceti¹; ¹IRCCS AUO San Martino IST, Genova, ITALY, ²Nuclear Medicine Unit, A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, ITALY, ³Dep. of Nuclear Medicine and Clinical Molecular Imaging University Hospital, Tübingen, GERMANY.

OP-590**Mechanisms of Bone Marrow Failure in Prostate Cancer Patients treated with Radium-223 Therapy**

F. Fiz¹, C. Campi², S. Sahbai¹, J. Schwanck¹, M. Weissinger¹, M. Bauckneht³, R. Piva³, C. Marini⁴, H. Dittman¹, M. Piana³, G. Sambuceti³, C. La Fougère¹; ¹University of Tuebingen, Tuebingen, GERMANY, ²National Council of Research - SPIN, Genoa, ITALY, ³University of Genoa, Genoa, ITALY, ⁴CNR - IBFM, Genoa, ITALY.

OP-591**Prediction of hematological toxicity in Radium-223 therapy in patients with advanced metastatic castration-resistant prostate cancer**

M. Ø. Fosbøl, P. M. Petersen, A. Kjaer, J. Mortensen; Rigshospitalet, Copenhagen, DENMARK.

OP-592**⁹⁰Y PET-CT based method of dose calculation to evaluate the efficacy of internal selective radiotherapy (SIRT)**

E. Kalogianni, N. Heraghty, D. Levart, B. Corcoran, N. Mulholland, M. Vadrucchi, G. Vivian; King's College Hospital, LONDON, UNITED KINGDOM.

OP-593**Correlation of SUVmax values & liver metastasis size/number with survival of colorectal Ca patients undergoing TARE treatment**

B. Sönmezer¹, A. Gülcü², R. Bekiş¹, B. Polack¹; ¹Dokuz Eylül University, Faculty of Medicine, Department of Nuclear Medicine, İzmir, TURKEY, ²Dokuz Eylül University, Faculty of Medicine, Department of Radiology, İzmir, TURKEY.



**1505 Tuesday, October 24, 2017, 16:30 - 18:00, Hall E2**
**Joint Symposium 15 - EANM/ESMI:
Best of European Molecular Imaging
Meeting - EMIM 2017**

Chairs: L. Evangelista (Padova, ITALY)
T. Lahoutte (Brussels, BELGIUM)

OP-594
**Simultaneous Imaging of Tumor Metabolism and
Vascularity During Tumor Growth with a Hybrid
Positron Emission Tomography (PET) / Ultrafast
Sonography (US) System**

A. Garofalakis; Paris-Cardiovascular Research
Center; Paris Descartes University; Georges Pompidou
European Hospital, Paris, FRANCE.

OP-595
**AI18F-Labeling of Heat-Sensitive Biomolecules
for Positron Emission Tomography Imaging**

F. Cleeren; Laboratory for radiopharmacy, University of
Leuven / Department of Pharmacy and Pharmacology,
Leuven, BELGIUM.

OP-596
**Purinergic Receptor P2Y12: A Potential Target
for PET Imaging of Neuroinflammation in
Multiple Sclerosis and EAE**

W. Beaino; VU University Medical Center, Department
of Radiology, Amsterdam, NETHERLANDS.

1506 Tuesday, October 24, 2017, 16:30 - 18:00, Hall F1
**Teaching Session 6 (Interactive): Correlative
Imaging for Nuclear Medicine Specialists:
Interactive Live Radiology and Nuclear
Medicine Quiz Using the Expor Medical
System**

Chair: I. Burger (Zurich, SWITZERLAND)

OP-597
**Correlative Imaging for Nuclear Medicine
Specialists: Interactive Live Radiology and
Nuclear Medicine Quiz Using the Expor
Medical System**

T. Lynch; Belfast, UNITED KINGDOM.

1507 Tuesday, October 24, 2017, 16:30 - 18:00, Hall F2
Clinical Oncology: In the Air & Beyond

Chairs: B. Fischer (Copenhagen, DENMARK)
tba.

OP-598
**Prognostic impact of pre-treatment 18FDG-PET/
CT restaging in patient with HNSCC**

O. Delcroix¹, J. Leclère², P. Robin¹, S. Querellou¹, P.
Le Roux¹, P. Salaun¹, C. Guezennec¹, U. Schick³, G.
Valette², J. Rousset⁴, R. Abgral¹; ¹Department of Nuclear
Medicine, Brest University Hospital, BREST, FRANCE,
²Department of Head and Neck Surgery, University
Hospital of Brest, BREST, FRANCE, ³Department of
Radiotherapy, Brest University Hospital, BREST, FRANCE,
⁴Department of Radiology, Military Hospital of Brest,
BREST, FRANCE.

OP-599
**Inter-observer and inter-contouring method
variability for textural analysis in head and neck
cancer in pre-therapeutic 18-FDG PET/CT**

C. Guezennec, J. Corre, D. Bourhis, P. Robin, O. Delcroix,
Y. Gobel, U. Schick, P. Salaun, R. Abgral; CHRU Morvan,
Brest, FRANCE.

OP-600
**PET/CT imaging of angiogenesis in head and
neck squamous cell carcinoma patients**

D. Lobeek¹, S. Y. A. Terry², M. A. W. Merks¹, R. P. Takes¹,
P. J. Slootweg¹, W. J. G. Oyen^{1,3}, O. C. Boerman¹, M.
Rijkema¹; ¹Radboud University Medical Center
Nijmegen, Nijmegen, NETHERLANDS, ²King's College
London, London, UNITED KINGDOM, ³Institute of
Cancer Research, Royal Marsden NHS Trust, London,
UNITED KINGDOM.

OP-601
**Voxel based comparison and texture analysis of
¹⁸F-FDG and ¹⁸F-FMISO PET of 38 Patients with
head-and-neck cancer**

M. Kroenke^{1,2}, K. Hirata², S. Watanabe², S. Okamoto², K.
Magota², T. Shiga², Y. Kuge³, N. Tamaki²; ¹Department
of Nuclear Medicine, Klinikum rechts der Isar, Technical
University Munich, München, GERMANY, ²Department
of Nuclear Medicine, Graduate School of Medicine of
Hokkaido University, Sapporo, JAPAN, ³Central Institute
of Isotope Science, of Hokkaido University, Sapporo,
JAPAN.

OP-602**Role of FDG-PET in disclosing RECIST-based pseudoprogression in non-small cell lung cancer (NSCLC) patients treated with Nivolumab**

M. Bauckneht, G. Rossi, R. Piva, C. Genova, E. Rijavec, G. Barletta, F. Biello, V. Ceriani, I. Calamia, G. Dal Bello, R. Di Stefano, G. Sambuceti, F. Grossi, S. Morbelli; IRCCS AUO San Martino IST, Genova, ITALY.

OP-603**Heterogeneity in tumours; Validating the use of textural analysis and shape analysis on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. Preliminary analysis**

M. M. K. Krarup¹, L. Nygård¹, I. Vogelius¹, M. M. Siddique², G. Cook³, V. Goh², F. L. Andersen¹, B. M. Fischer¹; ¹University Hospital of Copenhagen, Rigshospitalet, Copenhagen, DENMARK, ²St. thomas' Guy's Hospital/King's College, London, UNITED KINGDOM, ³St. Thomas' Guy's Hospital/King's College, London, UNITED KINGDOM.

OP-604**Segmental FDG-PET/CT In Solitary Pulmonary Nodule: Preliminary Data Of The PET Italian Tailored Assessment of Lung Indeterminate Accidental Nodule (ITALIAN) Trial**

M. Spadafora¹, L. Mansi², A. Cuocolo³, L. Evangelista⁴, V. Rizzo¹, L. Guerra⁵, S. Fantì⁶, E. Nicolai⁷, A. Chiti⁸, M. Zuffante⁹, O. Schillaci¹⁰, G. Peluso¹¹, S. Annunziata¹², A. Fracchetti¹³, D. Ripani¹², C. Gridelli¹⁴, P. Miletto⁷, L. Pace¹⁵; ¹Nuclear Medicine Unit, Department of Imaging, S.G. Moscati Hospital, Avellino, ITALY, ²Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale, Second University of Naples, Napoli, ITALY, ³Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, ITALY, ⁴Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, ⁵Nuclear Medicine Unit, San Gerardo Hospital, University of Milano Bicocca, Monza, ITALY, ⁶Service of Nuclear Medicine, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, ITALY, ⁷Nuclear Medicine Unit, Department of Imaging, SDN Foundation, Napoli, ITALY, ⁸Nuclear Medicine Unit, Cancer Center, Humanitas Hospital, Rozzano, Milano, ITALY, ⁹Nuclear Medicine Unit, Department of Imaging, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, ITALY, ¹⁰Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, ITALY, ¹¹Nuclear Medicine Unit, Department of Imaging, Medicina Futura IOS, Acerra, Napoli, ITALY, ¹²Institute of Nuclear Medicine, Università Cattolica del S. Cuore, Roma, ITALY, ¹³Department of Medical Physics, Hospital of Bolzano, Bolzano, ITALY, ¹⁴Division of Medical Oncology, S. G. Moscati Hospital, Avellino, ITALY, ¹⁵Department of Medicine and Surgery, University of Salerno, Baronissi (SA), ITALY.

OP-605**Quantitative 99mTc-Galacto-RGD2 SPECT/CT to Evaluate Lung Cancer Physiology and Malignancy: A Comparative Multi-center Study with 18F-FDG PET/CT**

T. Wang¹, Y. Liang², G. Zhang¹, M. Li³, W. Fang⁴, H. Dai⁵, B. He⁶, X. Wang¹; ¹The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CHINA, ²Navy General Hospital, Beijing, CHINA, ³First Hospital of Shanxi Medical University, Taiyuan, CHINA, ⁴Fuwai Hospital, Beijing, CHINA, ⁵Dianli Hospital, Beijing, CHINA, ⁶University of Missouri-Columbia, Columbia, MO, UNITED STATES OF AMERICA.

1508 Tuesday, October 24, 2017, 16:30 - 18:00, Hall K

Cardiovascular System: Myocardial Perfusion SPECT: Quantification & Artificial Intelligence

Chairs: R. Slart (Groningen, NETHERLANDS)
H. Gallowitsch (Klagenfurt, AUSTRIA)

OP-606**Evaluating stress and rest absolute quantification of uptake in myocardial perfusion SPECT using GE Q.Metric**

I. Armstrong, N. Fyfe, P. Arumugam; Central Manchester University Hospitals, Manchester, UNITED KINGDOM.

OP-607**Dynamic Single Photon Emission Computer Tomography in assessment of Coronary Flow Reserve in Patients with stable coronary artery diseases**

A. Mochula¹, K. Zavadovsky^{1,2}, S. Andreev¹, Y. Lishmanov^{2,1}; ¹Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

OP-608**One-day protocol for myocardial perfusion stress-testing by combination of Rutland-Patlak analysis of ^{99m}Tc-MIBI uptake and adenosine challenge**

W. Y. Ussov¹, V. M. Gulyaev¹, E. N. Karpov², O. Y. Borodin^{1,2}, E. A. Aleksandrova¹; ¹Institute of Cardiology, Tomsk, RUSSIAN FEDERATION, ²Tomsk Regional Institute of Oncology, Tomsk, RUSSIAN FEDERATION.



OP-609**Modelling Factors Affecting Apparent Transmural Flow Gradient in Ungated Tomographic Myocardial Perfusion Imaging**

A. Bellini¹, C. Marini², F. Ticconi¹, S. D. Morbelli³, M. Bauckneht¹, F. Fiz⁴, I. Calamia¹, A. Nieri¹, S. Maggio³, G. Sambuceti^{1,3}; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, ²CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY, ³IRCCS AOU San Martino-IST, Genoa, ITALY, ⁴Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum Tübingen, Tübingen, GERMANY.

OP-610**Simulation of Patient Motion with Myocardial Perfusion CZT SPECT: Data-Driven Motion Detection and Correction**

D. Daou^{1,2}, R. Sabbah³, Y. Alattar¹, C. Coaguila⁴, H. Boulahdour^{3,5}; ¹Cochin Hospital, APHP, PARIS, FRANCE, ²EA 7334 REMES, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, FRANCE, ³CHU Jean Minjot, Besançon, FRANCE, ⁴Centre Hospitalier de Bigorre, Tarbes, FRANCE, ⁵EA 4662, Université de Franche-Comté, Besançon, FRANCE.

OP-611**Artificial Intelligence for Myocardial Perfusion Imaging Compared with Expert Interpretation**

K. Nakajima¹, K. Kiso², T. Kudo³, Y. Taniguchi⁴, S. Matsuo¹, M. Nakagawa⁵, T. Nakata⁶, S. Hida⁷, H. Tanaka⁸, M. Sarai⁹, K. Yokoyama¹⁰, M. Momose¹¹, K. Okuda¹², L. Edenbrandt¹³; ¹Kanazawa University Hospital, Kanazawa, JAPAN, ²National Cerebral and Cardiovascular Center, Osaka, JAPAN, ³Nagasaki University, Nagasaki, JAPAN, ⁴Hyogo Brain and Heart Center, Himeji, JAPAN, ⁵Akita City Hospital, Akita, JAPAN, ⁶Hakodate Goryokaku Hospital, Hakodate, JAPAN, ⁷Tokyo Medical University Hospital, Tokyo, JAPAN, ⁸Tokyo Medical University Ibaraki Medical Center, Ibaraki, JAPAN, ⁹Fujita Health University Hospital, Toyoake, JAPAN, ¹⁰Public Central Hospital of Matto Ishikawa, Hakusan, JAPAN, ¹¹Tokyo Women's Medical University, Tokyo, JAPAN, ¹²Kanazawa Medical University, Uchinada, JAPAN, ¹³University of Gothenburg, Gothenburg, SWEDEN.

OP-612**Diagnostic Performance of Artificial Neural Network for the localization of coronary artery disease**

H. Shimoyama, S. Nakayama, Y. Kotake, S. Shimamoto, R. Futai; Itami City Hospital, Itami, JAPAN.

1510 Tuesday, October 24, 2017, 16:30 - 18:00, Hall G2**Do.MoRe - Featured: PET/MRI**

Chairs: B. Sattler (Leipzig, GERMANY)
P. Almeida (Lisbon, PORTUGAL)

OP-613**PET/MRI-Technology – State of the Art Systems and Future Perspectives**

S. Nekolla; Clinic of Nuclear Medicine, Technical University, Munich, GERMANY.

OP-614**Methods for reducing 'halo' scatter artefact in Ga-68 PSMA PET/CT and PET/MRI**

T. Sanderson, B. A. Thomas, S. Wan, J. C. Dickson; Institute of Nuclear Medicine, University College London Hospital, London, UNITED KINGDOM.

OP-615**NEMA NU 2-2007 Performance Characteristics of GE Signa Integrated PET/MR: Impact of Using Different PET Isotopes**

P. Caribé^{1,2}, M. Koole³, S. Vandenberghe¹, T. Deller⁴, K. van Laere³; ¹Medical Imaging and Signal Processing – MEDISIP, UZGhent; IMEC, Ghent, BELGIUM, ²National Council for Scientific and Technological Development – CNPq, São Paulo, BRAZIL, ³Division of Nuclear Medicine – UZ/ KU, Leuven, BELGIUM, ⁴General Electric Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.

OP-616**Influence of ignoring bone attenuation in standard PET/MRI of carotid plaques**

I. Rausch¹, J. Cal-Gonzalez¹, D. Beizke¹, A. Haug¹, X. Li¹, M. Fenchel², T. Beyer¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²Siemens Healthcare GmbH, Erlangen, GERMANY.

OP-617**ZTE-based attenuation correction in head and neck PET/MRI**

R. de Laroche^{1,2}, M. Khalife³, D. Bequé⁴, B. Sgard^{1,2}, F. Pérez-García³, M. Soret¹, M. Habert^{1,2}, F. Wiesinger⁴, A. Kas^{1,2}; ¹Groupe Hospitalier Pitié-Salpêtrière, Paris, FRANCE, ²Université Paris 6 UPMC, LIB Inserm U1146, Paris, FRANCE, ³Institut du Cerveau et de la Moelle épinière (ICM), CNRS UMR 7225 - Inserm U1127 - Université Paris 6 UPMC UMR S1127, Paris, FRANCE, ⁴GE Global Research Center, Munich, GERMANY.



OP-618**Joint Hardware and Patient Attenuation Correction for Hybrid PET/MR Imaging**

*T. Heußler¹, Y. Berker^{1,2}, M. T. Freitag¹, M. Kachelrieß¹;
¹German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²RWTH Aachen University, Aachen, GERMANY.*

OP-619**Comparison of quality control between PET/MRI and PET/CT systems using NEMA tests**

M. Abuqbeitah¹, M. Demir¹, N. Yeyin¹, T. Toklu², S. Sezgin³, H. Çetin³, K. Sönmezoğlu⁴; ¹Istanbul university, Istanbul, TURKEY, ²Yeditepe university, Nuclear Medicine Department, Istanbul, TURKEY, ³epsilon laboratory, Istanbul, TURKEY.

1601 Wednesday, October 25, 2017, 08:00 - 09:30, Hall A
CME 13 - Dosimetry/Radionuclide Therapy/Radiation Protection: Treatment Planning for Radionuclide Therapy, How Simple Can it Be?


*Chairs: N. Chouin (Nantes, FRANCE)
 S. Walrand (Brussels, BELGIUM)*

OP-621**Legal Requirements for Nuclear Medicine Therapy Imposed by the BSS as Implemented in the Dutch Law**

L. Keulemans; Dutch Ministry of health, well-being and sports, Medical radiation, The Hague, NETHERLANDS.

OP-622**Radiation Protection and Waste Management in Radionuclide Therapies**

B. Godthelp; Dutch Authority Nuclear Safety and Radiation Protection ANVS, Environmental radiation, The Hague, NETHERLANDS.

OP-623**Are Traditional Fixed Activity Schedules Appropriate for Advancing in Personalised Medicine?**

S. Ezzedin; Universitätsklinikum des Saarlandes, Klinik für Nuklearmedizin, Homburg, GERMANY.

OP-624**Examples of Workflow and Requirements for Patient-Specific Dosimetry-Guided Treatments**

K. Sjögreen-Gleisner; Lund University, Medical radiation Physics, Lund, SWEDEN.

1602 Wednesday, October 25, 2017, 08:00 - 09:30, Hall B**Joint Symposium 13 - EANM/SNMMI: Standardisation of Diuresis Renography in Children**

*Chairs: A. Santos (Lisbon, PORTUGAL)
 Z. Bar-Sever (Petach-Tikva, ISRAEL)*

OP-626**The SNMMI-EANM Joint Guidelines for Diuresis Renogram in Children: The F+0 Protocol**

D. De Palma; Circolo Hospital and Macchi Foudation, Nuclear medicine Unit, Varese, ITALY.

OP-627**The SNMMI-EANM Joint Guidelines for Diuresis Renogram in Children: The F+(20 to 30 minutes) Protocol**

M. Majd; Children's National Med Center, Dept. of Diagnostic Imaging & Radiology, Washington, UNITED STATES OF AMERICA.

OP-628**The Actual Role and Clinical Impact of Diuresis Renogram in Management of Prenatally Diagnosed Hydronephrosis**

A. Springer; EAPU, Medical University of Vienna, Vienna, AUSTRIA.

1604 Wednesday, October 25, 2017, 08:00 - 09:30, Hall E1**Do.MoRe: Image Reconstruction**

*Chairs: B. Sattler (Leipzig, GERMANY)
 I. Armstrong (Manchester, UNITED KINGDOM)*

OP-630**Optimisation of penalized likelihood estimation reconstruction on a digital time-of-flight PET-CT scanner for four different PET tracers**

E. Lindström^{1,2}, A. Sundin^{1,3}, C. Trampa³, L. Lindsjö³, J. Sörensen^{1,3}, M. Lubberink^{1,2}; ¹Department of Surgical Sciences/Nuclear Medicine & PET, Uppsala University, Uppsala, SWEDEN, ²Medical Physics, University Hospital, Uppsala, SWEDEN, ³PET Centre, University Hospital, Uppsala, SWEDEN.

OP-631**Bayesian Penalized Likelihood Image Reconstruction (Q.Clear) in 82Rb Cardiac PET: Impact of Count Statistics**

N. Christensen, L. P. Tolbod; Dept. Nuclear Med. & PET-Centre, Aarhus University Hospital, Aarhus, DENMARK.

OP-632**Determining the Minimum Administered Activity for Tumour FDG PET/CT Imaging that satisfies EARL Specifications, and Investigation of Bayesian Penalised Likelihood Reconstruction**

T. Sanderson, J. Dickson; University College London Hospital, London, UNITED KINGDOM.

OP-633**Investigation into Optimal PET-CT Image Reconstruction for the Detection and Quantification of Inflammation and Infection Associated with Implanted Cardiac Devices**

Y. Bouchareb^{1,2}, J. Thomas², G. Delanerolle¹, H. Jan¹, N. Hartman¹, A. Haroon¹; ¹Barts Health NHS Trust, London, UNITED KINGDOM, ²Queen Marys University, London, UNITED KINGDOM.

OP-634**SMART(SiMulAtion and ReconsTruction) PET: An efficient PET simulation-reconstruction tool**

E. Pfaehler, R. Boellaard, J. De Jong; UMCG Groningen, Groningen, NETHERLANDS.

OP-635**Comparison of a statistical analysis method and a visual assessment of Monte Carlo based SPECT reconstruction concerning liver metastases in ¹¹¹In-octreotide diagnosis**

E. Wikberg¹, M. van Essen², T. Rydén¹, J. Svensson³, P. Gjerdtsson², P. Bernhardt¹; ¹Department of Radiation Physics, Gothenburg, SWEDEN, ²Department of Nuclear Medicine, Gothenburg, SWEDEN, ³Department of Oncology, Gothenburg, SWEDEN.

OP-636**A post-acquisition normalization to co-analyze textural features from multi-center PET images**

F. Orhac¹, S. Boughdad^{1,2}, C. Nioche¹, J. Alberini², M. Soussan^{1,3}, I. Buvat¹; ¹IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris-Saclay, CEA-SHFJ, Orsay, FRANCE, ²Department of Nuclear Medicine, Institut Curie-René Huguenin, Saint-Cloud, FRANCE, ³Department of Nuclear Medicine, Assistance Publique - Hôpitaux de Paris, Avicenne Hospital, Bobigny, FRANCE.

OP-637**Comparison of Tumor Heterogeneity Assessed with Textural Parameters in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT in Patients with Metastatic Prostate Cancer**

L. Schwarte¹, L. Thomas¹, E. Eppard¹, M. Meisenheimer¹, C. Weiss-Wichert², M. Essler¹, R. A. Bundschuh¹; ¹Department of Nuclear Medicine, Universitätsklinikum Bonn, Bonn, Germany, Bonn, GERMANY, ²Mediso GmbH, Münster, GERMANY.

1605 Wednesday, October 25, 2017, 08:00 - 09:30, Hall E2

M2M: Radiolabelling Methods

Chairs: J. Notni (Garching, GERMANY)
P. Laverman (Nijmegen, NETHERLANDS)

OP-638**First radiofluorination of LLP2A and In-vivo PET Imaging of α 4 β 1 integrin-expressing tumors in mice**

D. Perrin¹, A. Roxin¹, C. Zhang², K. Lin², F. Benard²; ¹University of British Columbia, Vancouver, BC, CANADA, ²BC Cancer Research Centre, Vancouver, BC, CANADA.

OP-639**[¹⁸F]fluorination of biorelevant arylboronic acid pinacol ester scaffolds synthesized by convergence techniques**

G. S. Clemente¹, T. Zarganes-Tzitzikas², I. F. Antunes¹, A. Dömling², P. H. Elsinga¹; ¹Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, ²Department of Drug Design, University of Groningen, Groningen, NETHERLANDS.

OP-640**Synthesis and Evaluation of a Novel Tetrakis(3-Hydroxy-4-Pyridinone) Ligand for ⁸⁹Zr-Labeling of Antibodies for ImmunoPET**

C. Buchwalder¹, J. Rousseau², C. Rodríguez-Rodríguez¹, M. G. Jaraquemada-Peláez¹, C. Orvig¹, P. Schaffer^{3,1}, F. Bénard^{1,2}, K. Saatchi¹, U. O. Häfeli¹; ¹University of British Columbia, Vancouver, BC, CANADA, ²BC Cancer Agency, Vancouver, BC, CANADA, ³TRIUMF, Vancouver, BC, CANADA.

OP-641**Piscidin 1: from an antimicrobial peptide to anticancer peptide, a natural chelator for ⁶⁴Cu**

H. Hong, W. Lu, D. Yang, D. Chen; University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

OP-642**Efficient preparation of 2-[¹⁸F] fluorophenylalanine (2-[¹⁸F]FPhe) by Cu-mediated radiofluorination**

D. Modemann¹, B. Zlatopolskiy², J. Ermer¹, B. Neumaier^{1,2}; ¹Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM-5, Jülich, GERMANY, ²Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Köln, GERMANY.



OP-643**Influence of composition of cysteine-containing peptide based chelators on biodistribution of ^{99m}Tc-labelled anti-EGFR affibody molecules**

M. Oroujeni¹, K. G. Andersson², J. Garousi¹, M. Altai¹, A. Vorobyeva¹, X. Steinhardt², B. Mitran¹, S. Ståhl², A. Orlova¹, J. Löfblom², V. Tolmachev¹; ¹Uppsala University, Uppsala, SWEDEN, ²KTH-Royal Institute of Technology, Stockholm, SWEDEN.

OP-644**H4neunpa-trastuzumab: Evaluation of a Novel Bifunctional Chelator for ¹¹¹In Radiopharmaceuticals and Immuno-SPECT Imaging**

S. Spreckelmeyer^{1,2}, C. F. Ramogida³, J. Rousseau⁴, K. Arane¹, I. Bratanovic³, N. Colpo⁴, U. Jermilova³, G. M. Dias⁴, I. Dude⁴, M. Jaraquemada-Pelaez¹, F. Benard⁴, P. Schaffer³, C. Orvig¹; ¹Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver, BC, CANADA, ²Dept. Pharmacokinetics, Toxicology and Targeting, Research Institute of Pharmacy, University of Groningen, Groningen, NETHERLANDS, ³Life Sciences, TRIUMF, Vancouver, BC, CANADA, ⁴BC Cancer Agency, Vancouver, BC, CANADA.

OP-645**2-[¹⁸F]Fluoro-5-iodopyridine ([¹⁸F]FIPy): a novel thiol reactive prosthetic group for the fast site specific labeling at ambient temperature**

A. Omrane^{1,2}, B. Zlatopolskiy^{2,3}, B. Neumaier^{1,2,3}; ¹Forschungszentrum Juelich GmbH: Institute of Neuroscience and Medicine, INM-5, Juelich, GERMANY, ²Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic, Cologne, GERMANY, ³Max Planck Institute for Metabolism Research, Cologne, GERMANY.

1606 Wednesday, October 25, 2017, 08:00 - 09:30, Hall F1**Pitfalls & Artefacts 7 (Interactive) - Oncology: Pitfalls and Artefacts in PSMA PET Reading**

*Chairs: K. Herrmann (Essen, GERMANY)
P. Castellucci (Bologna, ITALY)*

OP-646**Introduction PSMA, EANM Procedure Guideline**

W. Fendler; Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, UNITED STATES OF AMERICA.

OP-647**Staging**

M. Eiber; Technische Universität München, Nuclear Medicine, Munich, GERMANY.

OP-648**Restaging**

P. Castellucci; S. Orsola-Malpighi, Nuclear Medicine, Bologna, ITALY.

OP-649**Response to Therapy**

F. Giesel; Universitätsklinikum Heidelberg, Nuclear Medicine, Heidelberg, GERMANY.

1607 Wednesday, October 25, 2017, 08:00 - 09:30, Hall F2**Clinical Oncology: Anything Goes**

*Chairs: M. Bozkurt (Ankara, TURKEY)
B. Krause (Rostock, GERMANY)*

OP-650**Regional hepatic glucose metabolism correlates with regional distribution of hepatic fat**

A. Dunford¹, G. Keramida², M. Aplin¹, A. M. Peters³; ¹Royal Sussex County Hospital, Brighton, UK, Brighton, UNITED KINGDOM, ²Royal Brompton and Harefield Hospitals NHS, FT, London, UNITED KINGDOM, ³Royal Sussex County Hospital, Brighton, UK & Clinical Imaging Sciences Centre, Brighton Sussex Medical School, Brighton, UK, Brighton, UNITED KINGDOM.

OP-651**Assessment of Effect of Fatty Infiltration on Hepatic FDG Uptake**

F. Özülker¹, T. Özülker²; ¹University of Health Sciences, Okmeydanı Hospital, Department of Nuclear Medicine, Uskumruköy/Sarıyer/İstanbul, TURKEY, ²University of Health Sciences, Okmeydanı Hospital, Department of Nuclear Medicine, Uskumruköy/Sarıyer/İstanbul, TURKEY.

OP-652**The correlation between pathological profile and metabolic parameters of ¹⁸F-FDG PET/CT in patients with gastroesophageal junction cancer**

J. Song; Beijing Cancer Hospital, Beijing, CHINA.

OP-653**Early variation of FDG-PET parameters as predictors of response after treatment in locally advanced pancreatic carcinoma patients**

E. Incerti¹, P. Mapelli¹, E. G. Vanoli¹, M. Maggi², C. Gumina³, N. Slim³, P. Passoni¹, M. Marino², G. M. Cattaneo², L. Gianolli¹, M. Luzzio³, M. Picchio¹; ¹Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ²Unit of Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ³Unit of Radiotherapy, IRCCS San Raffaele Scientific Institute, Milan, ITALY.



OP-654**Robotic arm assisted real time ¹⁸F-FDG PET/CT guided percutaneous metabolic sampling of abdominal lesions- Initial Experience**

R. Kumar, B. R. Mittal, H. Singh, T. K. Jain, A. Sood, A. Bhattacharya; PGIMER, Chandigarh, INDIA.

OP-655**The Role of ¹⁸F-Sodium Fluoride (NaF) PET-CT in the evaluation of metastatic bone disease in morbidly obese patients**

S. Usmani, F. Marafi, A. Esmail, F. al kandari; Kuwait Cancer Control Center, kuwait, KUWAIT.

OP-656**Tc-99m-DPD bone scan quantification: Metastasis of prostate cancer vs. osteoarthritis**

F. Tabotta, M. Jreige, N. Schaefer, J. O. Prior, M. Nicod Lalonde; CHUV, Lausanne, SWITZERLAND.

OP-657**Convolutional neural networks for segmentation of 49 selected bones in CT images show high reproducibility**

M. Sadik¹, R. Kaboteh¹, O. Enqvist², J. Ulén³, E. Trägårdh⁴, M. H. Poulsen⁵, J. A. Simonsen⁶, P. F. Højlund-Carlsen⁶, L. Edenbrandt¹; ¹Department of Clinical Physiology, Göteborg, SWEDEN, ²Department of Signals and Systems, Göteborg, SWEDEN, ³Eigenvision AB, Malmö, SWEDEN, ⁴Department of Translational Medicine, Malmö, SWEDEN, ⁵Department of Urology, Odense, DENMARK, ⁶Department of Nuclear Medicine, Odense, DENMARK.

1608 Wednesday, October 25, 2017, 08:00 - 09:30, Hall K**Cardiovascular System: Myocardial Perfusion PET - 82-Rubidium**

Chairs: R. Sciagra (Florence, ITALY)

R. Slart (Groningen, NETHERLANDS)

OP-658**Prognostic Value of Quantitative Coronary Artery Calcium and Myocardial Blood Flow Assessed by Hybrid Rubidium-82 PET/CT Imaging in Patients With Suspected Coronary Artery Disease**

E. Zampella¹, R. Assante¹, T. Mannarino¹, G. De Simini¹, A. Genova¹, M. Panico², V. Gaudier², C. Nappi¹, C. Mainolfi¹, W. Acampa¹, M. Petretta³, P. Arumugam⁴, A. Cuocolo¹; ¹Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ²Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ³Department of Translational Medical Sciences, University Federico II, Naples, ITALY, ⁴Department of Nuclear Medicine, Central Manchester University Hospitals, Manchester, UNITED KINGDOM.

OP-659**Cardiac ⁸²Rb PET/CT: The added value in diabetic Heart Transplant Patients**

M. L. De Rimini¹, G. Borrelli¹, A. Russo², S. Carrino³, C. Maiello⁴, P. Muto¹; ¹Nuclear Medicine Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, ²Cardiovascular Unit; Vanvitelli University of Campania, Naples, ITALY, ³Pharmacy Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, ⁴Cardiac Transplant Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY.

OP-660**Relationship between microvascular disease assessed using myocardial flow reserve with ⁸²Rubidium positron emission tomography and the severity of diabetic nephropathy**

L. Potier¹, R. Chequer², C. Amouya³, K. Mohammedi⁴, A. Hartemann⁵, M. Marre⁴, R. Roussel⁴, D. Le Guludec², F. Hyafil²; ¹Department of Diabetology, Bichat Hospital, AP-HP, PARIS, FRANCE, ²Department of Nuclear Medicine, Bichat Hospital, APHP, PARIS, FRANCE, ³Department of Diabetology, Pitié-Salpêtrière Hospital, APHP, PARIS, FRANCE, ⁴Department of Diabetology, Bichat Hospital, APHP, PARIS, FRANCE, ⁵Department of Diabetology, Pitié-Salpêtrière Hospital, APHP, PARIS, FRANCE.

OP-661**Low-dose myocardial blood flow imaging using ⁸²Rb-PET (RUBILOW 2.0)**

C. M. Hoff, L. P. Tolbod, H. J. Harms, K. Bouchelouche, J. Frøkiær, J. Sørensen; Aarhus University Hospital, Aarhus, DENMARK.



OP-662**Value of Rubidium-82 Flow Measurements in Patients with CABG**

B. J. H. G. van Gageldonk¹, A. T. L. Fiolet¹, I. E. M. Bank², A. Mosterd¹, H. J. Verberne³, J. M. H. de Klerk¹, A. M. Scholtens¹; ¹Meander Medical Center, Amersfoort, NETHERLANDS, ²University Medical Center, Utrecht, NETHERLANDS, ³Academic Medical Center, Amsterdam, NETHERLANDS.

OP-663**Higher diagnostic performances of 82Rubidium-PET in comparison to SPECT myocardial perfusion scintigraphy for the detection of three-vessel coronary artery disease**

F. Hyafil¹, R. Chequer¹, E. Sorbets², T. Alfaiate³, H. Regaieg¹, F. Rouzet¹, N. Mikail¹, G. Ducrocq⁴, R. Ben Azzouna¹, S. Leygnac¹, M. Milliner¹, C. Estellat³, D. Le Guludec¹; ¹Department of Nuclear Medicine, Bichat Hospital, AP-HP, Paris, FRANCE, ²Department of Cardiology, Avicennes Hospital, AP-HP, Bobigny, FRANCE, ³Unite de Recherche Clinique Paris Nord, Bichat Hospital, AP-HP, Paris, FRANCE, ⁴Department of Cardiology, Bichat Hospital, AP-HP, Paris, FRANCE.

OP-664**Need for Correction of Myocardium Movement during Dynamic Rubidium-82 Stress PET for Accurate Myocardial Blood Flow Quantification**

S. S. Koenders^{1,2}, J. D. van Dijk¹, P. L. Jager¹, C. H. Slump², J. Ottervanger³, J. A. van Dalen⁴; ¹Department of Nuclear Medicine, Isala, Zwolle, NETHERLANDS, ²MIRA: Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, ³Department of Cardiology, Isala, Zwolle, NETHERLANDS, ⁴Department of Medical Physics, Isala, Zwolle, NETHERLANDS.

OP-665**Estimation and reliability of myocardial blood flow after motion correction with dynamic PET using a Bayesian framework**

A. Saillant^{1,2}, K. Saint³, M. Memmott³, I. Armstrong³, V. Shah², S. Zuehlsdorff¹, J. Declerck⁴, M. Jenkinson², M. Chappell²; ¹Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA, ²University of Oxford, Oxford, UNITED KINGDOM, ³Central Manchester University Hospital, Manchester, UNITED KINGDOM, ⁴Siemens Healthineers, Oxford, UNITED KINGDOM.

1610 Wednesday, October 25, 2017, 08:00 - 09:30, Hall G2**Do.MoRe: Dosimetry in Diagnostic Nuclear Medicine**

Chairs: S. Mattsson (Lund, SWEDEN)
M. Ljungberg (Lund, SWEDEN)

OP-666**Voxel based internal dosimetry of radiopharmaceuticals in diagnostic nuclear medicine**

N. Petoussi-Hens¹, J. Ocampo Ramos², M. Zankl¹, W. Li¹, W. Rühm¹; ¹Helmholtz Zentrum München, Neuherberg, GERMANY, ²Universidad Nacional de Colombia, Medellín Branch, COLOMBIA.

OP-667**IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine using the official ICRP specific absorbed fractions for the adult ICRP/ICRU reference computational voxel phantoms**

M. Andersson¹, L. Johansson², K. Eckerman³, S. Mattsson¹; ¹Medical Radiation Physics, Malmö, SWEDEN, ²Department of Radiation Sciences, Umeå, SWEDEN, ³Center for Radiation Protection Knowledge, Oak Ridge National Laboratory, Oak Ridge, TN, UNITED STATES OF AMERICA.

OP-668**Image based preclinical absorbed dose estimation through GATE Monte Carlo simulation using ¹⁸F-FDG PET/CT images of mice**

A. Gupta¹, M. S. Lee¹, J. H. Kim², S. H. Park³, H. S. Park³, S. E. Kim³, D. S. Lee¹, J. S. Lee¹; ¹Seoul National University (SNU), Seoul, KOREA, REPUBLIC OF, ²Korea Research Institute of Standards and Sciences, Daejeon, KOREA, REPUBLIC OF, ³Graduate School of Convergence Science and Technology, Seoul, KOREA, REPUBLIC OF.

OP-669**Radiation dosimetry of the tau PET Tracer ¹⁸F-PI-2620 in humans**

J. Seibyl¹, O. Barret¹, A. Stephens², J. Madonia¹, D. Alagille¹, A. Mueller², H. Schieferstein², M. Berndt², H. Kroth³, S. Bullich², C. Papin¹, V. Carroll¹, C. Sandiego¹, A. Pfeifer³, A. Muhs³, L. Dinkelborg², G. Tamagnan¹, K. Marek¹; ¹Molecular Neuroimaging, New Haven, CT, UNITED STATES OF AMERICA, ²Piramal Imaging, Berlin, GERMANY, ³AC Immune SA, Lausanne, SWITZERLAND.

OP-670**Preliminary Results of Biodistribution and Dosimetric Analysis with [⁶⁸Ga]Ga-DOTA^{ZOL}: A new bone seeking PET radionuclide**

A. Khawar¹, E. Eppard¹, H. Ahmadzadehfar¹, S. Kürpig¹, M. Meisenheimer¹, F. C. Gaertner¹, F. Roesch², M. Essler¹, R. A. Bundschuh¹; ¹Department of nuclear medicine, University Hospital, Bonn, GERMANY, ²Institute for nuclear chemistry, Johannes Gutenberg-University, Mainz, GERMANY.

OP-671**PET-based human dosimetry of ⁶⁸Ga-NODAGA-exendin-4, a tracer for beta cell imaging**

M. Boss, M. Buitinga, T. J. P. Janssen, M. Brom, E. P. Visser, M. Gotthardt; Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-672**PET-based biodistribution and radiation dosimetry of [⁶⁴Cu]copper dichloride, first-in-human healthy volunteer evaluation**

M. A. Avila-Rodriguez¹, C. Rios², J. Carrasco-Hernández¹, J. Manrique-Arias¹, R. Martínez-Hernández², E. Martínez-Rodríguez², F. O. García-Pérez², M. Romero-Piña³, A. Jalilian⁴, A. Díaz-Ruiz²; ¹Universidad Nacional Autónoma de México, CDMX, MEXICO, ²Instituto Nacional de Neurología y Neurocirugía, CDMX, MEXICO, ³Instituto Nacional de Cancerología, CDMX, MEXICO, ⁴International Atomic Energy Agency, Vienna, AUSTRIA.

OP-673**Validation of semi Monte Carlo, voxel-based radionuclide dosimetry software using 3D printed phantom experiments with TLD measurements and patient indium-111 Exendin scans using SPECT/CT**

W. D. Wormgoor¹, A. P. W. Meeuwis², I. Sechopoulos², E. Hippeläinen³, A. Sohlberg⁴, E. P. Visser²; ¹ZGT, Hengelo, NETHERLANDS, ²Radboud University Medical Center, Nijmegen, NETHERLANDS, ³University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND, ⁴Joint Authority for Päijät-Häme Social and Health Care, Lahti, FINLAND.

1701 Wednesday, October 25, 2017, 10:00 - 11:30, Hall A**CME 14 - Dosimetry/Radiation Protection/Translational Molecular Imaging & Therapy: Alpha Particle Dosimetry, Does High LET Lead to High RBE?**

Chairs: M. Hendriks-de Jong (Rotterdam, NETHERLANDS)
U. Eberlein (Wurzburg, GERMANY)

OP-674**Preclinical Experience in Alpha Particle Dosimetry**

S. Palm; University of Gothenburg, Gothenburg, SWEDEN.

OP-675**Small Scale Dosimetry and RBE of Alpha-Particles**

G. Sgouros; Johns Hopkins University, Baltimore, UNITED STATES OF AMERICA.

OP-676**Ra-223: Imaging, Dosimetry and Radiation Protection**

C. Hindorf; Lund university hospital, Medical physics, Lund, SWEDEN.

OP-677**Clinical Experience with ²²⁵Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Prostate Cancer**

C. Kratochwil; University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

1702 Wednesday, October 25, 2017, 10:00 - 11:40, Hall B**Joint Symposium 14 - EANM/ESSO: Head & Neck Cancer**

Chairs: D. Rubello (Rovigo, ITALY)
R. Delgado-Bolton (Logroño - La Rioja, SPAIN)

OP-678**5-year European Survey (SENT Study) on SLNB in H&N Tumours**

G. Tartaglione; Cristo Re Hospital, Department of Nuclear Medicine, Rome, ITALY.

OP-679**Hybrid Gamma- and Fluorescence Imaging in SLN Detection**

R. Valdés Olmos; The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.



OP-680**Additional Non-SLN Metastases in Early Oral Cancer Patients with Positive SLN**

R. de Bree; UMC Utrecht Cancer Center, University Medical Center Utrecht, Department of Head and Neck Surgical Oncology, Utrecht, NETHERLANDS.

OP-681a**The Added Value of PET/MR in H&N Tumours**

M. Hüllner; University Hospital Zurich, Clinic of Nuclear Medicine, Zurich, SWITZERLAND.

OP-681b**Sensitivity of SLNB in H&N Melanoma Patients**

A. J. M. Balm; The Netherlands Cancer Institute, Department of Head and Neck Oncology and Surgery, Amsterdam, NETHERLANDS.

1703 Wednesday, October 25, 2017, 10:00 - 11:30, Hall C**CTE 7 (Interactive) - Joint Session with Paediatrics: Practical and Technical Aspects of Paediatric Nuclear Medicine**

Chairs: S. Rac (Rijeka, CROATIA)
P. Zucchetta (Padova, ITALY)

OP-682**How to Set Up a Paediatric Nuclear Medicine Department**

Z. Bar-Sever; Schneider Children's Medical Center of Israel, Petach-Tikva, ISRAEL.

OP-683**Paediatric Nephrology – What Do We Do With Infants?**

S. Grbac-Ivanković; Clinical hospital centre Rijeka, Department of nuclear medicine, Rijeka, CROATIA.

OP-684**Paediatric Imaging Methods in Oncology - The Key is in Dosimetry, Do We Have a Solution?**

A. Balenović; Dom zdravlja Zagreb-Centar /Health Care Center Zagreb, Zagreb, CROATIA.

1704 Wednesday, October 25, 2017, 10:00 - 11:30, Hall E1**Do.MoRe: Molecular Imaging Artefacts & Corrections**

Chairs: M. Segbers (Rotterdam, NETHERLANDS)
M. Paphiti (Athens, GREECE)

OP-685**Clinical Evaluation of Data-driven Motion Correction for PET Imaging**

*C. F. Uribe*¹, *E. Rousseau*¹, *F. Lacroix-Poisson*¹, *T. Alden*¹, *S. Wollenweber*², *F. Benard*¹; ¹BC Cancer Agency, Vancouver, BC, CANADA, ²GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.

OP-686**ParaPET, A New Statistical Methodology to Derive 3D Maps of FDG-PET Kinetic Parameters**

*E. Colard*¹, *L. Padovani*², *S. Delcourt*³, *S. Thureau*⁴, *B. Farman Ara*³, *P. Gouel*⁵, *I. Gardin*⁶, *P. Vera*⁶, *D. Taïeb*⁷, *D. Barbolosi*⁸, *S. Hapdey*⁶; ¹LITIS QuantIF EA4108, Rouen, FRANCE, ²Department of Radiotherapy, La Timone University Hospital, Marseille, FRANCE, ³Department of Nuclear Medicine, La Timone University Hospital, Marseille, FRANCE, ⁴Department of Radiotherapy, Centre Henri Becquerel and LITIS QuantIF EA4108, Rouen, FRANCE, ⁵Department of Nuclear Medicine, Centre Henri Becquerel, Rouen, FRANCE, ⁶Department of Nuclear Medicine, Centre Henri Becquerel and LITIS QuantIF EA4108, Rouen, FRANCE, ⁷Department of Nuclear Medicine, La Timone University Hospital and European Center for Research in Medical Imaging (CERIMED), Marseille, FRANCE, ⁸SMARTc, INSERM, UMR 911 CR02, Marseille, FRANCE.

OP-687**Assessment of whole-body scatter correction for Ga-68 PSMA PETCT**

*H. Bal*¹, *I. Hong*¹, *F. Buther*², *M. Aykac*¹, *K. Schaefer*², *M. Conti*¹; ¹Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA, ²University of Muenster, Muenster, GERMANY.

OP-688**Impact of motion compensation and partial volume correction on ¹⁸F-NaF PET/CT imaging of coronary plaque**

*J. Cal-Gonzalez*¹, *C. Tsoumpas*², *M. Lassen*¹, *S. Rasu*³, *M. Hacker*³, *K. Schäfers*⁴, *T. Beyer*¹; ¹QIMP group, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, ²Division of Biomedical Imaging, University of Leeds, Worsley Building, LIGHT Labs, LS2 9NL, Leeds, United Kingdom., Leeds, UNITED KINGDOM, ³Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ⁴European Institute for Molecular Imaging, University of Münster, Münster, GERMANY.



OP-689**A phantom evaluation of a commercial algorithm for photopenic artefact reduction in high contrast PET/CT and implications for ¹²⁴I PET/CT**

P. Braad, P. F. Høilund-Carlsen; Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK.

OP-690**Evaluation of respiratory motion correction in PET/CT using a 3D printed phantom**

J. H. Vilsbøll¹, S. W. Hasler¹, L. D. L. Duchstein², J. E. Wilhelm¹, M. N. Lonsdale²; ¹Technical University of Denmark, Copenhagen, DENMARK, ²Bispebjerg and Frederiksberg Hospital, Copenhagen, DENMARK.

OP-691**Evaluation of the Impact of Using TOF Technique on Metal Artifact Reduction in PET/CT Images**

R. Sharifpour^{1,2}, P. Ghafarian^{3,4}, M. R. AY^{1,2}; ¹Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-692**Acquisition optimization for Lutetium-177 SPECT quantification**

D. M. V. Huizing¹, B. J. de Wit - van der Veen¹, E. J. Rijkhorst², M. P. M. Stokkel¹; ¹Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS, ²Department of Medical Physics and Technology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

1705 Wednesday, October 25, 2017, 10:00 - 11:30, Hall E2**M2M: CNS/Neurotransmission/Brain Targets**

Chairs: L. Zimmer (Lyon, FRANCE)

G. Bormans (Leuven, BELGIUM)

OP-693**Injected Mass is a Limiting Factor for Small Animal PET Studies Using High-Affinity Radioligands: Evidence from a Study Using [11C]- and [18F]Fallypride**

M. Toth¹, S. Nag¹, Z. Jia¹, J. Haggkvist¹, J. Mukherjee², A. Varrone¹, C. Halldin¹; ¹Karolinska Institutet, Stockholm, SWEDEN, ²University of California-Irvine, Irvine, CA, UNITED STATES OF AMERICA.

OP-694**Quantitative PET of GABA-A receptor binding in gerbils after intra-peritoneal F-18-Flumazenil injection does not resemble accurate results obtained in rats after intravenous administration**

M. Mamach^{1,2}, M. Kessler^{1,2}, J. P. Bankstahl¹, T. L. Ross¹, F. M. Bengel¹, L. Geworski¹, G. M. Klump^{3,2}, G. Berding^{1,2}; ¹Hannover Medical School, Hannover, GERMANY, ²Cluster of Excellence Hearing4all, Hannover/Oldenburg, GERMANY, ³University of Oldenburg, Oldenburg, GERMANY.

OP-695**In Silico, Design, Synthesis, Pre-clinical studies of [¹¹C]₃-BTZ-MPP: PET neuroimaging agent for 5-HT_{1A/1A}/5-HT_{1A/7} Dimeric Serotonin receptors**

P. Jha^{1,2}, S. Chaturvedi¹, P. P. Hazari¹, S. Pal¹, N. Jain², A. K. Mishra¹; ¹Institute of Nuclear Medicine and Allied Sciences, DRDO, Delhi, INDIA, ²Indian Institute of Technology, Delhi, Delhi, INDIA.

OP-696**Head to head comparison of (R)-[¹¹C]verapamil and [¹⁸F]MC225 in non-human primates; tracers for measuring P-gp function at the blood-brain barrier**

J. Toyohara¹, L. Garcia-Varela², T. Kakiuchi³, O. Hlroyuki³, S. Nishiyama³, T. Tago¹, D. Vallez-Garcia², R. Boellaard², P. H. Elsinga², H. Tsukada³, G. Luurtsema²; ¹Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, ²University of Groningen, Groningen, NETHERLANDS, ³Hamamatsu Photonics, Hamamatsu, JAPAN.



OP-697**Identification and development of a highly specific monoacylglycerol lipase (MAGL) PET tracer ¹¹C-PF-06809247**

C. R. Butler¹, A. Takano², S. Nag², R. Arakawa², K. P. Maresca¹, J. R. Piro¹, T. Samad¹, D. Smith¹, D. Nason¹, S. O'Neil¹, L. McAllister¹, S. Grimwood¹, P. Trapa¹, T. McCarthy¹, A. Villalobos¹, C. Halldin², L. Zhang¹; ¹Pfizer, Inc., Cambridge, MA, UNITED STATES OF AMERICA, ²Karolinska Institutet, Stockholm, SWEDEN.

OP-698**Development of a radiolabeled ligand targeting 5-HT₃ receptors in the brain**

A. Takano¹, V. Stepanov¹, M. Svedberg¹, J. Häggkvist¹, L. Tari¹, M. Tóth¹, R. Krasikova¹, N. Amini¹, C. Sanchez², C. Bundgaard², M. Jessing², B. Bang-Andersen², C. Halldin¹; ¹Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, ²H. Lundbeck A/S, Lundbeck Research, Copenhagen, DENMARK.

OP-699**Radiosynthesis, initial evaluation and whole-body dosimetry of a beta-secretase (BACE) PET radioligand [¹¹C]PF-06684511 in non-human primates**

R. Arakawa¹, L. Chen², A. Takano¹, M. A. Brodney², J. Dutra³, V. Stepanov¹, S. Nag¹, S. Doran³, T. McCarthy², C. Nolan², A. Villalobos³, L. Zhang², C. Halldin¹; ¹Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, ²Worldwide Research & Development, Pfizer Inc., Cambridge, MA, UNITED STATES OF AMERICA, ³Worldwide Research & Development, Pfizer Inc., Groton, CT, UNITED STATES OF AMERICA.

1707 Wednesday, October 25, 2017, 10:00 - 11:30, Hall F2

Clinical Oncology: PSMA - Saving Nuclear Medicine

Chairs: W. Fendler (Los Angeles, UNITED STATES OF AMERICA)
I. Burger (Zurich, SWITZERLAND)

OP-700**Predictor factors of ⁶⁸Ga-PSMA PET/CT positivity in biochemical recurrent Prostate Cancer.**

C. Artigas, R. Diamand, A. Peltier, R. Van Velthoven, F. Otte, S. Sideris, T. Gil, Z. Wimana, P. Flamen; Jules Bordet Institut Brussels, Brussels, BELGIUM.

OP-701**Ga-68 PSMA-11 PET-CT in the Evaluation of Newly Diagnosed Prostate Adenocarcinoma**

N. Ergül, T. F. Çermik; Istanbul Training and Research Hospital, Istanbul, TURKEY.

OP-702**Initial Results with 18F-PSMA-1007 in Prostate Cancer Patients with Biochemical Recurrence**

F. L. Giesel¹, L. Will¹, J. Cardinale², O. C. Neels², J. P. Radtke³, K. Kopka², U. Haberkorn¹, C. Kratochwil¹; ¹Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, ²Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, GERMANY, ³Department of Urology, University Hospital Heidelberg, Heidelberg, GERMANY.

OP-704**The Importance Of Ga-68 PSMA PET CT In Detection Of Recurrence Metastasis Prostate Cancer Without Biochemical Recurrence**

E. Akgun¹, O. E. Sahin¹, E. Demirci², B. Akovali¹, M. Ocak Demirci³, A. Aygün¹, H. Pehlivan¹, E. Karayel¹, A. R. Kural⁴, L. Kabasakal¹; ¹Istanbul University Cerrahpasa Medical Faculty, Istanbul, TURKEY, ²Sisli Etfal Educational Research Hospital, Istanbul, TURKEY, ³Istanbul University Faculty of Pharmacy, Istanbul, TURKEY, ⁴Acibadem University Medical Faculty, Istanbul, TURKEY.

OP-705**Can 68Ga - PSMA PET/CT predict seminal vesicle invasion for patients undergoing radical prostatectomy?**

A. Agrawal, V. Rangarajan, G. Bakshi, G. Prakash, S. Menon, N. Purandare, S. Shah, A. Puranik, N. Sable; TATA Memorial Hospital, Mumbai, INDIA.

OP-706**Dual point 18F-Choline PET/CT in the evaluation of focal hypermetabolic prostate lesions. Acquisition timing protocol**

A. Díaz¹, M. Soler², M. Cozar², G. Reyes², E. Riera², Á. Jaramillo², J. Ferrer-Rebollo², J. R. García²; ¹CHUC (Complejo Hospitalario Universitario de Canarias), La Laguna, SPAIN, ²CETIR-ERESA, Barcelona, SPAIN.

OP-707**Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results**

G. Paganelli¹, E. Mezzenga¹, P. Caroli¹, A. Moretti², R. Galassi², M. Celli¹, L. Fantini¹, V. Di Iorio¹, A. Sarnelli¹, F. Matteucci¹; ¹IRST IRCCS, Meldola, ITALY, ²AUSL Romagna, Forlì, ITALY.

1708 Wednesday, October 25, 2017, 10:00 - 11:30, Hall K

Cardiovascular System: Atherosclerotic Plaque Imaging*Chairs: J. Bucorius (Maastricht, NETHERLANDS)
M. Hacker (Vienna, AUSTRIA)***OP-708****Non-invasive visualization of healing phase 2 after myocardial infarction (MI) using ⁶⁸Ga-NOTA-anti-CD206-Nb: targeting mannose receptor (MR, CD206) on M2 macrophages***Z. Varasteh¹, A. Bartels¹, S. Mohanta², A. Steinsiek³, Y. Li², M. Braeuer¹, N. López Armbruster³, S. Nekolla¹, A. Habenicht², G. Raes⁴, S. Hernot⁴, H. Sager³, M. Schwaiger¹; ¹Klinikum rechts der Isar, München, GERMANY, ²University Hospital of Ludwig-Maximilians-University, München, GERMANY, ³Klinik für Herz und Kreislauferkrankungen, München, GERMANY, ⁴Vrije Universiteit Brussel, Brussels, BELGIUM.***OP-709****Non-invasive visualization of atherosclerotic plaques using ⁶⁸Ga-NOTA-anti-CD206-nanobody: targeting mannose receptor (MR, CD206) on M2 macrophages***Z. Varasteh¹, S. Mohanta², Y. Li², N. López Armbruster³, M. Braeuer¹, S. Nekolla¹, A. Habenicht², H. Sager³, G. Raes⁴, S. Hernot⁴, M. Schwaiger¹; ¹Klinikum rechts der Isar, München, GERMANY, ²University Hospital of Ludwig-Maximilians-University, München, GERMANY, ³Klinik für Herz und Kreislauferkrankungen, München, GERMANY, ⁴Vrije Universiteit Brussel, Brussels, BELGIUM.***OP-710****[⁶⁸Ga]Pentixafor-PET/MRI for atherosclerotic plaque imaging***X. Li¹, D. Heber², X. Lu³, X. Zhang³, M. Mitterhauser⁴, W. Wadsak¹, A. Haug¹, M. Hacker¹; ¹Vienna General Hospital, Medical University of Vienna, Vienna, AUSTRIA, ²Vienna General Hospital, Vienna, AUSTRIA, ³Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, ⁴Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA.***OP-711****Imaging of LFA1 in Atherosclerotic Plaques Using a Novel SPECT Radiotracer***E. J. Meester¹, B. J. Krenning¹, M. R. Bernsen¹, G. Doeswijk¹, E. H. de Blois¹, J. P. Norenberg², M. de Jong¹, K. van der Heiden¹; ¹Erasmus MC, Rotterdam, NETHERLANDS, ²University of New Mexico, Albuquerque, NM, UNITED STATES OF AMERICA.***OP-712****A Bradykinin Derivative Differentiates Vulnerable and Stable Atherosclerosis Plaques in Monkey***Y. Xu¹, Z. Zhang², K. Lin², Z. Liu¹; ¹Peking University, Beijing, CHINA, ²BC Cancer Agency, Vancouver, BC, CANADA.***OP-713****Is FDG-PET/ CT a valuable diagnostic tool for verifying accelerated atherosclerosis secondary to diabetes mellitus in the aortic segments and large arteries?***G. G. Bural¹, D. A. Torigian², M. Housen³, M. K. Sozmen¹, A. Alavi²; ¹Izmir Katip Celebi University, Izmir, TURKEY, ²Hospital of the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ³Liver Institute, Cairo, EGYPT.***OP-714****Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism Using ¹⁸F-GP1 Positron Emission Tomography: An Exploratory Open-label Study***C. Kim¹, J. Lee¹, Y. Han¹, S. Chae¹, S. Oh¹, S. Lee¹, J. Oh¹, I. Oh¹, S. Chun¹, Y. Cho¹, T. Kwon¹, N. Koglin², M. Berndt², A. Stephens², D. Moon¹; ¹Asan Medical Center, Seoul, KOREA, REPUBLIC OF, ²Piramal Imaging, Berlin, GERMANY.*

1801/1803 Wednesday, October 25, 2017, 12:15 - 13:15, Hall A

Plenary 4: Highlights Lecture*Chairs: K. Muylle (Brugge, BELGIUM)
F. Giannarile (Lyon, FRANCE)***OP-715****Highlights Lecture***S. Fanti; University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.***OP-716****Highlights Lecture***C. Decristoforo; Universitätskliniken - Landeskrankenhaus Innsbruck, Medizinische Universität Innsbruck, Universitätsklinik für Nuklearmedizin, Innsbruck, AUSTRIA.*

e-Poster Walks

E-PW01 Sunday, October 22, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer A, Screen 1

Cardiovascular System: Vascular Inflammation

Chairs: W. Acampa (Naples, ITALY)
H. Verberne (Amsterdam, NETHERLANDS)

E-PW001

The FDG-PET metabolic pattern, involving a low baseline-level and a subsequent increase, remains a landmark of less favorable outcome for the abdominal aortic aneurysms treated by endovascular prosthesis

P. Marie¹, D. Plissonnier², S. Bravetti¹, R. Coscas³, M. Rouer², S. Haulon⁴, D. Mandry¹, J. Alsac⁵, S. Malikov¹, N. Settembre¹, Y. Gouëffic⁶, O. Morel⁷, V. Roch¹, E. Micard¹, Z. Lamiral¹, J. Michel⁸, P. Rossignol¹; ¹CHRU-Nancy, Vandoeuvre, FRANCE, ²CHU-Rouen, Rouen, FRANCE, ³Hôpital Ambroise Paré, Paris, FRANCE, ⁴CHRU-Lille, Lille, FRANCE, ⁵Hôpital HEGP, Paris, FRANCE, ⁶CHU-Nantes, Nantes, FRANCE, ⁷CHU-Besançon, Besançon, FRANCE, ⁸INSERM Bichat, UMR 698, Paris, FRANCE.

E-PW002

Prospective study comparing scintigraphy to radiolabeled leukocytes and 18F-FDG PET in patients suspected of vascular prosthesis infection

J. Pinaquy, Sr., M. Puges, X. Berard, J. Ruiz, F. Debordeaux, A. Desclaux, L. Stecken, S. Pereyre, L. Bordenave, C. Cazanave; CHU BORDEAUX, Bordeaux, FRANCE.

E-PW003

Comparison of 3 ¹⁸F-FDG-PET visual interpretation scales for the diagnosis of vascular prosthetic infection

J. Pinaquy, Sr., M. Puges, C. Cazanave, J. Ruiz, F. Debordeaux, A. Desclaux, L. Stecken, S. Pereyre, L. Bordenave, X. Berard; CHU BORDEAUX, Bordeaux, FRANCE.

E-PW004

18-FDG Pet-TC as tool to evaluate the efficacy of tocilizumab as a steroid-sparing agent for the treatment of Giant Cell Arteritis with Large-Vessel Involvement: a real-life single-centre case series

C. Olianti¹, G. Vitiello², C. Orsi Battaglini², N. Orsi Battaglini³, R. Di Dato³, S. Nicolosi⁴, D. Cammelli²; ¹Nuclear Medicine Unit, Hospital-University Careggi, Florence, ITALY, ²Experimental and Clinical Medicine Department, University of Florence, Florence, ITALY, ³Nuclear Medicine Unit, University of Florence, Florence, ITALY, ⁴Nuclear Medicine Unit, Hospital of Palermo, Palermo, ITALY.

E-PW005

Tissue-to-background-ratio in major arterial vessels - comparison of 18F-FDG and 18F-fluoromethylcholine PET-CT

J. Jamsek, M. Grmek, S. Hawlina, L. Lezaic; Klinični center Ljubljana, Ljubljana, SLOVENIA.

E-PW006

Correlation Between Vascular 18F-NaF Avidity and the Presence of Vascular Illness: A PET/CT Study

J. F. Alban¹, P. Lapa^{1,2}, M. Marques¹, A. Albuquerque¹, G. Costa^{1,2}, J. Pedroso de Lima^{1,2,3}; ¹Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, ³Instituto das Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL.

E-PW007

Differences in semiquantitative 18F-FDG PET/CT findings of non-infectious and infectious inflammation

V. Mergen¹, I. Einspieler¹, M. Mustafa¹, H. Wendorff², K. Thürmel³, M. Schwaiger¹; ¹Department of Nuclear Medicine, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY, ²Clinic for Cardiovascular Surgery, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY, ³Department of Nephrology, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY.



E-PW008**18F-FDG PET/CT imaging for detection of aortic wall inflammation in patients with repaired coarctation of aorta**

A. Georgakopoulos¹, N. Pianou¹, E. Oikonomou², A. S. Antonopoulos², I. Koutagiari², P. Kafouris^{3,4}, M. Metaxas¹, D. Tousoulis², S. Bril², C. Anagnostopoulos¹; ¹Center for Experimental Surgery, Clinical and Translational Research, Biomedical Research Foundation, Academy of Athens, Athens, GREECE, ²1st Department of Cardiology, 'Hippokraton' Hospital, University of Athens Medical School, Athens, GREECE, ³Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, GREECE, ⁴Department of Informatics and Telecommunications, University of Athens, Athens, GREECE.

E-PW009**Activity Assessment of Large Vessel Vasculitis with F18-FDG-PET/CT**

N. Schramm¹, J. Ingenhoff², C. Dechant³, F. Proft³, H. Schulze-Koops³, U. Hoffmann², A. Rominger¹, M. Cziha²; ¹Department of Nuclear Medicine, Ludwig-Maximilians University Hospital, Munich, GERMANY, ²Division of Angiology, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, GERMANY, ³Rheumatology Unit, Department of Medicine IV, Ludwig-Maximilians University Hospital, Munich, GERMANY.

E-PW02 Sunday, October 22, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer A, Screen 2

M2M: Small Molecules

Chairs: J. Mihailovic (Sremska Kamenica, SERBIA)
P. Bouziotis (Athens, GREECE)

E-PW010**Clinical translation of the caspase 3/7 specific PET radiotracer [¹⁸F]ICMT-11 for measuring chemotherapy induced apoptosis in breast and lung cancer**

S. Dubash¹, S. Merchant¹, K. Heinzmann¹, F. Mauri², I. Lavdas¹, M. Inglese³, K. Kozlowski¹, N. Rama¹, N. Masrour¹, J. Steel¹, A. Thornton¹, A. K. Lim², C. Lewanski⁴, S. Cleator⁴, R. C. Coombes⁴, L. Kenny⁴, E. Aboagye¹; ¹Department of Surgery and Cancer, Imperial College London, London, UNITED KINGDOM, ²Department of Radiology, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, ³Department of Computer, Control and Management engineering Antonio Ruberti, University of Rome, La Sapienza, ITALY, ⁴Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

E-PW011**¹⁸F-RPS-544: An Imaging Agent Targeting CXCR4. Imaging and Biodistribution**

A. Amor-Coarasa, J. M. Kelly, S. Ponnala, C. Williams, Jr., Y. Vedvyas, D. Kim, J. W. Babich; Weill Cornell Medical College, New York City, NY, UNITED STATES OF AMERICA.

E-PW012**In vitro characterization of [¹⁸F]THK5351 binding to melanin-containing cells**

T. Tago¹, J. Toyohara¹, R. Harada², S. Furumoto², N. Okamura³, Y. Kudo², J. Takahashi-Fujigasaki¹, S. Murayama¹, K. Ishii¹; ¹Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, ²Tohoku University, Sendai, JAPAN, ³Tohoku Medical and Pharmaceutical University, Sendai, JAPAN.

E-PW013**Alcohol-enhanced Cu-mediated radiofluorination**

J. Zischler^{1,2}, N. Kolks², D. Modemann¹, B. D. Zlatopolskiy², B. Neumaier^{1,2}; ¹Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Jülich, GERMANY, ²University Clinic Cologne, Institute of Radiochemistry and Experimental Molecular Imaging, Cologne, GERMANY.

E-PW014**Novel ¹⁸F-labeled triarylphosphonium derivatives for mitochondria imaging**

S. Furumoto¹, T. Tominaga¹, R. Akita¹, A. Kazama¹, Y. Ishikawa¹, R. Iwata¹, K. Ishiwata²; ¹Tohoku University, Sendai, JAPAN, ²Southern TOHOKU Research Institute for Neuroscience, Koriyama, JAPAN.

E-PW015**Synthesis and initial biological evaluation of [¹⁸F]fluorotryptophans ([¹⁸F]FTTrps)**

B. D. Zlatopolskiy^{1,2,3}, J. Zischler^{2,1}, H. Endepols¹, M. Guliyev¹, D. Schäfer², E. A. Urusova^{1,2}, B. Neumaier^{1,2,3}; ¹University Clinic of Cologne, Cologne, GERMANY, ²Forschungszentrum Jülich GmbH, Jülich, GERMANY, ³Max Planck Institute of Metabolism Research, Cologne, GERMANY.

E-PW016**Positron emission tomography imaging of glioblastoma with a monosaccharide-based contrast agent**

H. Hong¹, D. Yang¹, D. Chen¹, W. Lu¹, X. He²; ¹University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, ²Hanjiang University, Wuhan, CHINA.



**E-PW017****The Evolving Role of Succinate in Tumor Metabolism**

P. GARRIGUE¹, A. Bodin-Hugon¹, M. Moyon², L. Balasse¹, S. Fernandez¹, W. Essler¹, M. Dignat-George¹, K. Pacak³, D. Taieb², B. Guillou¹; ¹Marseille Université, Marseille, FRANCE, ²INSERM U1065, Marseille, FRANCE, ³NIH, Bethesda, MD, UNITED STATES OF AMERICA.

E-PW018**The Preparation of Radiolabeled Aromatic Amino Acids via Cu-Mediated Radiofluorination of Ni-Complexes**

A. S. Craig^{1,2}, N. Kolks¹, E. A. Urusova¹, B. D. Zlatopolskiy¹, B. Neumaier¹; ¹Institute for Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Julich, Julich, GERMANY, ²University Clinic of Cologne, Institute for Radiochemistry and Experimental Molecular Imaging, Cologne, GERMANY.

E-PW019**Development of a tumor-associated fetal protein derived peptide as a potential tool for the targeting of estrogen receptor positive breast cancer**

S. M. Okarvi, I. AlJammaz; King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA.

E-PW03

**Sunday, October 22, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer A, Screen 3**

Clinical Oncology: Walk Mixed Tumours

*Chairs: A. Iagaru (Stanford, UNITED STATES OF AMERICA)
M. Mitjavila Casanovas (Madrid, SPAIN)*

E-PW020**Diagnostics of the sentinel lymphatic nodes in laryngeal and laryngopharyngeal cancer**

I. Sinilkina, V.I. Chernov, E.L. Choynozov, S.Yu. Chizhevskaya, A. Medvedeva, R.V. Zelchan, O.D. Bragina, V.S. Skur; Tomsk National Research Medical Center of the Russian Academy of Sciences, tomsk, RUSSIAN FEDERATION.

E-PW021**PET/CT with 18F-FDG and 11C-Methionine for Assessment of Remission Status after Autologous Stem Cell Transplantation in Multiple Myeloma Patients**

O. Mukhortova¹, I. Aslanidis¹, T. Katunina¹, A. Rumjantzev¹, A. Silchenkov¹, M. Solovjev², L. Mendeleeva²; ¹Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, RUSSIAN FEDERATION, ²National Research Center for Hematology, Moscow, RUSSIAN FEDERATION.

E-PW022**Cancer Lesions Detectability Limits in the SPECT Breast Imaging**

E. Stiliaris¹, D. Maintas², D. Zarketan¹; ¹National & Kapodistrian University of Athens, Athens, GREECE, ²Institute of Isotopic Studies, Iatrikon Hospital, Athens, GREECE.

E-PW023**Impact of Postoperative Diagnostic 131I Whole Body Scan with SPECT-CT on Staging, Risk Stratification and Radioiodine Therapy Planning in Low Risk Differentiated Thyroid Cancer**

W. Teeyasoontranon, T. Kaewchur, S. Namwongprom, A. Klaipetch, M. Ekmahachai; Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang mai, THAILAND.

E-PW024**May 18F-Fluorocholine PET/CT Have A Role To Localize Parathyroid Adenoma In Patients With Negative 99mTc-MIBI?**

F. Di Gregorio¹, M. Rensi¹, F. Vescini², D. Capobianco¹, F. Giacomuzzi¹, G. Ferretti¹, M. Povolato¹, O. Geatti¹; ¹Department of Nuclear Medicine University Hospital, Udine, ITALY, ²Department of Endocrinology University Hospital, Udine, ITALY.

E-PW025**Sentinel node biopsy for bladder cancer using ICG-^{99m}Tc-nanocolloid**

P. Meershoek^{1,2}, E. M. Wit², B. W. G. van Rhijn², G. H. KleinJan^{1,2}, E. Vegt², M. L. Donswijk², R. A. Valdés-Olmos¹, H. G. van der Poel², F. W. B. van Leeuwen¹; ¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Netherlands Cancer Institute (NKI-AvL), Amsterdam, NETHERLANDS.

E-PW026**Correlation of hypoxia inducible transcription factor-1 α , glucose transporter-1, carbonic anhydrase IX and FDG uptake in invasive ductal breast cancer**

Y. Jeong, B. Choi, Y. Cho, S. Park, H. Oh, S. Kang; Catholic University of Daegu School of Medicine, Daegu, KOREA, REPUBLIC OF.

E-PW027**Effect of stem cell transplantation on breast cancer-related lymphedema quantified by lymphoscintigraphy**

J. A. Simonsen¹, S. Hvidsten¹, J. A. Sørensen^{1,2}, P. F. Høiland-Carlsen^{1,2}, N. M. Toyserkani^{1,2}; ¹Odense University Hospital, Odense C, DENMARK, ²University of Southern Denmark, Odense C, DENMARK.

E-PW028**Comparison of Magnetic Resonance Imaging (MRI) and 18F-NaF PET/CT for Detection of Spinal Bone Metastases in high-Risk Patients with Breast Carcinoma**

E. Panagiotidis, A. Mistry, A. Farnworth, N. Seshadri, S. Vinjamuri; Royal Liverpool University Hospital, Liverpool, UNITED KINGDOM.

E-PW029**Evaluation of the Total Distribution Volume of 18FBPA in Normal Tissues of Healthy Volunteers by Non-Compartmental Kinetic Modeling**

V. Romanov, K. Isohashi, E. Shimosegawa, T. Watabe, R. Beshr, J. Hatazawa; Osaka University Graduate School of Medicine Department of Nuclear Medicine and Tracer Kinetics, Osaka, JAPAN.

E-PW04 Monday, October 23, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer A, Screen 1

Do.MoRe: SPECT Technology

*Chairs: M. Lonsdale (Copenhagen, DENMARK)
M. Ljungberg (Lund, SWEDEN)*

E-PW030**Uncertainty in activity measurements using radionuclide calibrators due to source geometry effects**

C. Saldarriaga Vargas¹, A. Carbutti², J. Dabin¹, K. Baete³, L. Struelens¹; ¹Belgian Nuclear Research Centre (SCK-CEN), Mol, BELGIUM, ²Politecnico di Torino, Turin, ITALY, ³UZ Gasthuisberg, Leuven, BELGIUM.

E-PW031**Accuracy, Repeatability and Reproducibility of xSPECT Quant Sensitivity Calibrations using a NIST-traceable Point Source**

P. C. Holdgaard¹, H. C. Larsen¹, N. A. Bebbington²; ¹Lillebælt Hospital, Vejle, DENMARK, ²Siemens Healthineers, Aarhus, DENMARK.

E-PW032**Determining the calibration factor of a SPECT/CT camera**

L. Beels¹, F. Lavent¹, I. Decostere², L. Tack², C. Van de Wiele¹, A. Maes¹; ¹AZ Groeninge, Kortrijk, BELGIUM, ²KU Leuven, Leuven, BELGIUM.

E-PW033**Impact of the modelling of charge collection on the simulation of SPECT recordings from semiconductor CZT cameras**

L. Imbert^{1,2,3}, J. Jurczak⁴, G. Karcher^{1,2,5}, P. MARIE^{1,2,5}; ¹CHU Nancy, Vandoeuvre-lès-Nancy, FRANCE, ²Plateforme d'Imagerie Expérimentale Nancyclotep, Nancy, FRANCE, ³IADI, U947, Vandoeuvre-lès-Nancy, FRANCE, ⁴Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, FRANCE, ⁵Université de Lorraine, Faculté de Médecine, Nancy, FRANCE.

E-PW034**Simultaneous High-Sensitivity High-Resolution Molecular SPECT Imaging with Spinning Slit-Hole Collimator: A Monte Carlo Simulation Study**

M. Ay^{1,2}, H. Mahani³, G. Raisali³, A. Kamali-Asl⁴; ¹Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Radiation Medicine Engineering Department, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF.

E-PW035**Accuracy of gamma camera efficiency determination using different experimental configurations**

W. Zhao^{1,2}, P. L. Esquinas^{1,2}, X. Hou², C. F. Uribe³, M. Gonzalez⁴, J. Beauregard^{5,6}, Y. Dewaraja⁷, A. Celler²; ¹Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, ²Medical Imaging Research Group, Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, ³BC Cancer Agency, Vancouver, BC, CANADA, ⁴Vancouver Coastal Health Authority, Vancouver, BC, CANADA, ⁵Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA, ⁶Department of Medical Imaging, CHU de Quebec – Université Laval, Quebec City, QC, CANADA, ⁷Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, UNITED STATES OF AMERICA.

E-PW036**Atlas-based pulmonary lobes segmentation implemented with MIM® for quantitative lung perfusion SPECT/CT analysis**

C. P. L. Fulcheri¹, C. Tranfaglia², V. Reggioli¹, A. Chiappiniello³, R. Tarducci¹, M. E. Dottorini²; ¹Medical Physics Department, Hospital Santa Maria della Misericordia, Perugia, ITALY, ²Nuclear Medicine Department, Hospital Santa Maria della Misericordia, Perugia, ITALY, ³Physics and Geology Department, University of Perugia, Perugia, ITALY.



**E-PW037****Development of a new phantom for DaTSCAN imaging**

J. Taylor¹, R. Holmes², J. Fenner³; ¹Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM, ²University Hospitals Bristol, Bristol, UNITED KINGDOM, ³University of Sheffield, Sheffield, UNITED KINGDOM.

E-PW038**SPECT-CT quantification of 131-Iodine - Reducing uncertainty with PSF modelling based reconstruction**

L. Jenkins^{1,2}, A. Sohlberg^{3,2}; ¹Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM, ²Hermes Medical Solutions, Stockholm, SWEDEN, ³Joint Authority for Päijät-Häme Social and Health Care, Lahti, FINLAND.

E-PW039**Impact of brain ventricle size on semi-quantitative index derived from 123-I-FP-CIT images using a novel 3D-striatum digital brain (3D-SDB)**

H. Onishi¹, A. Furuta¹, K. Nakamoto¹, M. Takayama¹, H. Amijima²; ¹Program in Health and Welfare Sciences, Graduate School of Comprehensive Scientific Research, Prefectural University of Hiroshima, Mihara, Hiroshima, JAPAN, ²Graduate School of Nursing, Hyogo University of Health Sciences, Kobe, Hyogo, JAPAN.

E-PW05

Monday, October 23, 2017, 08:30 - 09:30,

e-Poster Walk Area, Level 2, Foyer A, Screen 2

Do.MoRe: Thyroid Cancer

*Chairs: I. Iakovou (Souroti, GREECE)
L. Giovanella (Bellinzona, SWITZERLAND)*

E-PW040**The role of [18F]FDG PET/CT in monitoring therapy with Lenvatinib in radio-iodine refractory differentiated thyroid cancer patients**

E. Tardelli, G. Puccini, G. Boni, M. Grosso, S. Chiacchio, I. Paglianiti, F. Guidoccio, E. Fiasconaro, S. Bola, S. Muccioli, L. Valerio, C. Giani, L. Pieruzzi, E. Molinaro, R. Elisei, D. Volterrani; University of Pisa, Pisa, ITALY.

E-PW041**Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and ¹³¹I radioiodine diagnostic scan in patients of differentiated thyroid carcinoma with skeletal metastases: evaluation of the role of ¹⁸F-FDG PET/CT in bony metastatic disease from differentiated thyroid cancer**

R. V. Parghane, S. Basu; Radiation Medicine Center (BARC), Mumbai, INDIA.

E-PW042**Incremental value of ultrasonography in incidental focal thyroid uptake at 18F-FDG PET-CT.**

W. Yao; College of Medicine, National Cheng Kung University, TAINAN, TAIWAN.

E-PW043**¹³¹I-SPECT/CT in the diagnosis and characterization of metastatic lesions in patients with differentiated thyroid carcinoma (DTC) in chronic follow-up**

A. Spanu, I. Gelo, L. Mele, B. Piras, S. Nuvoli, G. Madeddu; University of Sassari, SASSARI, ITALY.

E-PW044**Diagnostic Utility of Molecular and Imaging Biomarkers in Cytologically Indeterminate Thyroid Nodules: a Systematic Review and Meta-Analysis**

E. J. de Koster¹, L. F. de Geus-Oei², O. M. Dekkers², I. van Engen-van Grunsven¹, J. F. Hamming², E. P. M. van der Kleij-Corssmit², H. Morreau², A. Schepers², J. W. A. Smit¹, W. J. G. Oyen³, D. Vriens²; ¹Radboud university medical center, Nijmegen, NETHERLANDS, ²Leiden university medical center, Leiden, NETHERLANDS, ³Institute of Cancer Research, London, UNITED KINGDOM.

E-PW045**Thyroid hormone withdrawal versus recombinant human TSH administration in radio-iodine therapy of thyroid cancer: comparison of I-131 effective half-life**

K. Perisinakis, C. Donas, A. Dimitraki, S. Koukouraki; University of Crete, Medical School, Heraklion, GREECE.

E-PW046**Analysis of long-term clinical follow-up outcome, demographic and histopathological risk factors in a large DTC series**

C. Soydal, E. Ozkan, D. Nak, N. O. Kucuk, M. K. Kir; Ankara University Medical Faculty, Nuclear Medicine Department, Ankara, TURKEY.

E-PW047**FDG-PET can predict response to vandetanib treatment in patients suffering from advanced medullary thyroid carcinoma**

R. A. Werner^{1,2}, T. Higuchi^{2,3}, D. O. Mügge², M. S. Javadi¹, B. Märkl⁴, C. Aulmann⁵, A. K. Buck², M. Fassnacht⁶, C. Lapa², M. Kreissl^{7,8}; ¹Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, UNITED STATES OF AMERICA, ²Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, ³National Cardiovascular Center, Osaka, JAPAN, ⁴Institute for Pathology, Hospital Augsburg, Augsburg, GERMANY, ⁵Medical Department II, Hospital Augsburg, Augsburg, GERMANY, ⁶Department of Internal Medicine

I, Division of Endocrinology and Diabetes, Würzburg, GERMANY, ⁷Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Würzburg, GERMANY, ⁸Department of Nuclear Medicine, Hospital Augsburg, Augsburg, GERMANY.

Introduction: The prognosis of medullary thyroid carcinoma (MTC) is poor using common chemotherapeutic approaches. However during the last years encouraging results of recently introduced tyrosine kinase inhibitors (TKI) such as vandetanib have been published. In this study we aimed to correlate the results of 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) imaging with treatment outcome. **Subjects and Methods:** Eighteen patients after thyroidectomy with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline [18F]FDG PET/CT prior to and a follow-up examination 3 months after TKI initiation. During further follow-up, restaging was assessed every 3 months according to RECIST. The predictive ability for progression-free (PFS) and overall survival (OS) was examined by investigating [18F]FDG mean/maximum standardized uptake values (SUVmean/max) of the metabolically most active lesion as well as by analyzing clinical parameters (tumor marker doubling times {calcitonin, carcinoembryonic antigen (CEA)}, prior therapies, RET mutation status, disease type). **Results:** Within a median 3.6 years of follow-up, 9 patients showed disease progression after a median interval of 8.5 months and 8 patients died from their disease (median, 2.9y) after TKI initiation. Pre-therapeutic increased glucose metabolism with an SUVmean >4.0 could predict a significantly shorter PFS (PFS: 2.0y vs. 5.3y; p=0.04). Longer pre-therapeutic CEA doubling times were significantly related to prolonged PFS and OS (r>0.7, p<0.007, respectively). None of the other clinical parameters reached significance in response prediction. **Conclusion:** [18F]FDG PET/CT can serve as a prognostic tool in patients with advanced MTC treated with vandetanib. An elevated glucose consumption assessed by baseline PET was related to shorter PFS; therefore those patients need to be monitored more closely as compared to those with low FDG uptake at baseline. This project has received funding from the European Union's Framework Programme for Research and Innovation Horizon 2020 (2014-2020) under the Marie Skłodowska-Curie Grant Agreement.

E-PW048**Successful redifferentiation of radioiodine refractory BRAF-mutated papillary thyroid cancer using dabrafenib**

M. C. Kreissl^{1,2}, A. Todica³, R. Dorn², A. Pfeiffer², C. Spitzweg³, P. Bartenstein³, P. Bartenstein³; ¹Otto-von-Guericke Universität Magdeburg, Magdeburg, GERMANY, ²Klinikum Augsburg, Augsburg, GERMANY, ³LMU München, München, GERMANY.

E-PW049**Lowest effective ¹³¹I activity for lymph node metastases therapy of differentiated thyroid cancer patients; Dosimetry-based model for estimation**

V. Stebner, J. Phaosrichaen, K. Herrmann, W. Jentzen; Department of Nuclear Medicine, Medical Faculty, University Duisburg-Essen, Essen, GERMANY.

E-PW06

Monday, October 23, 2017, 08:30 - 09:30,

e-Poster Walk Area, Level 2, Foyer A, Screen 3

Do.MoRe: Dosimetry

*Chairs: G. Flux (Sutton Surrey, UNITED KINGDOM)
R. Howell (Newark, UNITED STATES OF AMERICA)*

E-PW050**DNA damage in blood leukocytes after internal irradiation with ⁶⁸Ga - in-vivo and in-vitro studies**

S. Schumann¹, H. Scherthan², C. Lapa¹, C. Bluemel¹, J. Müller², A. K. Buck¹, M. Port², M. Lassmann¹, U. Eberlein¹; ¹University of Würzburg, Würzburg, GERMANY, ²Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

E-PW051**Monte Carlo-Based Bremsstrahlung SPECT Reconstruction for Whole-Liver Dosimetry in Treatments with ⁹⁰Y-Microspheres - Comparison with ⁹⁰Y PET**

J. Gustafsson¹, K. Knešaurek²; ¹Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, SWEDEN, ²Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

E-PW052**Safety, efficacy and outcome of Y-90-resin-microspheres radioembolization in 73 patients with unresectable intrahepatic cholangiocarcinoma: a single center experience**

A. Todica, K. J. Paprottka, F. Schöppe, M. Ingrisch, P. Bartenstein, P. M. Paprottka, H. Ilhan; University of Munich, Munich, GERMANY.



E-PW053**Quantitative Y-90 PET/CT for Dosimetry in Radioembolization**

H. Lim¹, N. Clinthorne¹, M. Conti², J. A. Fessler¹, Y. K. Dewaraja¹; ¹University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, ²Siemens Healthcare Molecular Imaging, Knoxville, TN, UNITED STATES OF AMERICA.

E-PW054**Initial Experiences with Post-Interventional Imaging of Residual Yttrium-90 Activity Within Microsphere Delivery Systems using Next-Generation Digital Photon Counting PET/CT Technology**

C. L. Wright¹, K. Binzel¹, J. Zhang¹, D. Konate¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ²Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

E-PW055**223Ra-Chloride Therapy: The First Multidisciplinary and Multicenter Italian Study**

G. Boni¹, S. Mazzarri¹, C. Cianci², L. Galli¹, A. Farnesi¹, E. Borsatti³, R. Bortulus⁴, L. Fratino⁵, C. Giobbitti⁴, E. Lamaj⁵, P. Ghedini⁶, E. Rodi Rizzini⁶, V. Dionisi⁷, S. Fanti⁶, D. Volterrani¹, F. Monari⁷; ¹Nuclear Medicine Department, pisa, ITALY, ²Medical Oncology Division, pisa, ITALY, ³Nuclear Medicine Unit, aviano, ITALY, ⁴Radiotherapy Unit, aviano, ITALY, ⁵Medical Oncology, aviano, ITALY, ⁶Nuclear Medicine Department, bologna, ITALY, ⁷Radiotherapy Unit, bologna, ITALY.

E-PW056**Age-adjusted risk factors for patients undergoing molecular therapy**

J. Thurston, G. Flinn; ¹Marsden Hospital, London, UNITED KINGDOM

E-PW057**Renal toxicity analysis in a Peptide Receptor Radionuclide Therapy (PRRT) trial with alternated 177Lu and 90Y-DOTATOC**

E. Grassi¹, F. Fioroni¹, M. Cremonesi², D. Finocchiaro^{1,3}, M. Ferrari², F. Botta², G. Castellani³, N. Lanconelli³, A. Filice⁴, A. Versari⁴, M. Iori¹; ¹Medical Physics Unit, Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, ITALY, ²Medical Physics Unit, European Institute of Oncology, Milan, ITALY, ³Dept. of Physics, University of Bologna, Bologna, ITALY, ⁴Nuclear Medicine Unit, Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, ITALY.

E-PW058**3-Dimensional Dose Mapping after PRRT with 177Lu-DOTATATE/-TOC by One-Single Measurement after Four Days**

R. A. Werner^{1,2}, C. Lapa¹, A. K. Buck¹, M. Lassmann¹, H. Hänscheid¹; ¹Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, UNITED STATES OF AMERICA.

E-PW059**Bone metastases affect bone marrow response during 177-Lu-DOTATATE treatments**

J. Svensson¹, L. Hagmarker², T. Rydén², R. Hermann², B. Wängberg³, A. Sundlöf⁴, K. Sjögreen-Gleisner⁵, P. Bernhardt²; ¹Institution of Clinical Sciences, Dep of Oncology, Göteborg, SWEDEN, ²Institution of Clinical Sciences, Dep of Radiation Physics, Göteborg, SWEDEN, ³Institution of Clinical Sciences, Dep of Surgery, Göteborg, SWEDEN, ⁴Clinical Sciences, Dep of Oncology and Pathology, Lund, SWEDEN, ⁵Clinical Sciences, Dep of Radiation Physics, Lund, SWEDEN.

E-PW07

Monday, October 23, 2017, 08:30 - 09:30, e-Poster Walk Area, Level 2, Foyer B, Room 2.44, Screen 4

Clinical Oncology: Walk the Theranostic Way of Life!

Chairs: L. Bodei (New York, UNITED STATES OF AMERICA)
E. Piperkova (Sofia, BULGARIA)

E-PW060**Detecting Prostate Cancer Bone Metastasis With 18F DCFBC (a PSMA Targeted Agent) Compared to 18F Sodium Fluoride**

L. Lindenberg¹, E. Mena Gonzalez¹, I. Turkbey¹, J. Shih¹, E. Bergvall², A. Lindenberg³, W. Dahut¹, M. Pomper⁴, P. Choyke¹; ¹National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, ²Fort Belvoir Community Hospital, Ft Belvoir, VA, UNITED STATES OF AMERICA, ³Fort Belvoir Community Hospital, Fort Belvoir, VA, UNITED STATES OF AMERICA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

E-PW061**177Lu-DOTA-octreotate Therapy of Advanced Pancreatic Neuroendocrine Tumors - a Single Centre Experience**

K. Fröss-Baron¹, U. Garske-Roman^{2,3}, S. Welin¹, D. Granberg¹, B. Eriksson¹, M. Sandström³, A. Sundin³; ¹Department of Medical Sciences, Uppsala University, Uppsala, SWEDEN, ²Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ³Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.



E-PW062**The Value of Somatostatin Receptor Imaging (SRI) in Patients with NENG1/G2 Pancreatic Neuroendocrine Neoplasms (pNENs) Base on Pathological and Clinical Follow-up.**

S. J. Konsek¹, A. Kolasinska-Cwikla², A. Lewczuk³, L. Sawicki², M. Kidd⁴, A. Cichocki², A. Nasierowska-Guttmejer⁵, M. Tenderenda², J. B. Cwikla¹, I. M. Modlin⁶; ¹Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, POLAND, ²MSC Memorial Cancer Centre and Institute Maria Sklodowska-Curie, Warsaw, POLAND, ³Medical University of Gdansk, Gdansk, POLAND, ⁴Wren Laboratories, Branford, CT, UNITED STATES OF AMERICA, ⁵Hospital Ministry of Internal Affairs, Warsaw, POLAND, ⁶Yale University, New Haven, CT, UNITED STATES OF AMERICA.

E-PW063**⁶⁸Ga-PSMA-11 PET/CT in the evaluation of bone metastases in prostate cancer**

C. Sachpekidis¹, P. Bäumer², B. A. Hadaschik³, U. Haberkorn¹, A. Dimitrakopoulou-Strauss¹; ¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), heidelberg, GERMANY, ²Department of Radiology, German Cancer Research Center, DKFZ, heidelberg, GERMANY, ³Department of Urology, University Hospital Heidelberg, heidelberg, GERMANY.

E-PW064**PSMA-PET MRI/TRUS robot-guided targeted prostate biopsy for detection and localisation of Primary prostate cancer**

M. Mix, K. Schaal, M. Krönig, V. Drendel, U. Wetterauer, W. Schultze-Seemann, C. A. Jilg, P. T. Meyer; University of Freiburg, Medical Center, Freiburg, GERMANY.

E-PW065**Usefulness of ¹⁸F-choline PET/CT to evaluate patients eligible for Radium-223 Dichloride Therapy**

E. Biggi¹, C. Fuccio¹, F. Ottavelli¹, F. D'Emidio², L. D'Angelo³, A. Berbellini¹; ¹Nuclear Medicine Unit, Ospedale "C. G. Mazzoni", Ascoli Piceno, ITALY, ²Diagnostic Radiology Unit, Ospedale "C. G. Mazzoni", Ascoli Piceno, ITALY, ³Medical Physics Unit, Ospedale "C. G. Mazzoni", Ascoli Piceno, ITALY.

E-PW066**⁶⁴CuCl₂ PET/CT and Fused-⁶⁴CuCl₂ PET/MRI in prostate cancer relapse. Comparison with ¹⁸F-Choline PET/CT, Fused-¹⁸F-Choline PET/MRI and multiparametric MRI**

G. Ferrarazzo¹, G. Bottoni¹, F. Paparo¹, M. Puntoni¹, L. Bacigalupo¹, S. Zanardi¹, A. DeCensi¹, S. Righi¹, E. Lopci², M. Cabria¹, A. Piccardo¹; ¹E.O. Ospedali Galliera, Genova, ITALY, ²Humanitas Research Hospital, Milano, ITALY.

E-PW067**Additional value of early [⁶⁸Ga-PSMA-11 PET Imaging in the assessment of local recurrence in prostate cancer patients with biochemical recurrence**

C. Uprimny, A. S. Kroiss, J. Fritz, C. Decristoforo, E. vonGuggenberg, B. Nilica, J. Bektic, W. Horninger, I. J. Virgolini; Medical University Innsbruck, Innsbruck, AUSTRIA.

E-PW068**¹⁷⁷Lutetium PSMA radioligand therapy in prostate cancer patients with metastatic castration-resistant prostatic cancer; assessment of response, clinical evaluation, toxicity**

H. R. RATHORE, S. Bhat, P. Aland, C. Kannor, C. Kale, A. Parashar, V. Lele; Jaslok Hospital and Research Center, Mumbai, INDIA.

E-PW069**One-step kit-based radiolabeled ⁶⁸Ga-THP-PSMA for PET imaging of PSMA expression: Biodistribution and first clinical experience**

S. Schmuck; C. Juhl, S. Teichert, A. C. A. Walte, S. Schneefeld, T. L. Ross, F. M. Bengel, T. Derlin; Medizinische Hochschule Hannover, Hannover, GERMANY.

E-PW08

Monday, October 23, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer B, Screen 5

M2M: PET/CT

Chairs: G. Limouris (Athens, GREECE)
J. Mihailovic (Sremska Kamenica, SERBIA)

E-PW070**¹⁸F-Organotrifluoroborate Probes Targeting PSMA for PET Imaging of Prostate Cancer: One-step Radiosynthesis, High Tumor Uptake and High T:NT Ratios**

M. L. Lepage¹, H. Kuo², H. Merckens², N. Colpo², F. Bénard², K. Lin², D. M. Perrin¹; ¹University of British Columbia, Vancouver, BC, CANADA, ²BC Cancer Research Centre, Vancouver, BC, CANADA.



E-PW071**2-deoxy-glucose is a Respiratory Substrate for Endoplasmic Reticulum of Murine Breast Carcinoma Cells: New View on PET-Imaging**

V. Cossu¹, S. Ravera², S. Bruno³, A. Orengo¹, A. Buschiazzo⁴, A. Bellini⁴, F. Grillo⁵, M. Bauckneht⁴, M. Piana⁶, C. Ghersi¹, S. Morbelli¹, C. Marini^{1,7}, G. Sambucetti^{1,4}; ¹Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Genoa, ITALY, ²Pharmacy Department, Biochemistry Laboratory, University of Genoa, Genoa, ITALY, ³Department of Experimental Medicine, University of Genoa, Genoa, ITALY, ⁴Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, ⁵Pathology Unit, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁶Department of Mathematics, University of Genoa, Genoa, ITALY, ⁷CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

E-PW072**Assessment of pharmacokinetic properties of copper-64 and gallium-68 labelled NODAGANOC analogues for neuroendocrine tumours detection.**

M. Asti¹, R. S. B. H. Schreuder², M. Iori¹, P. C. Capponi¹, S. Rubagotti¹, G. Cicoria³, R. Zijlma², G. N. Doeswijk⁴, M. De Jong⁴, P. H. Elsinga², G. Luurtsema²; ¹Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, ITALY, ²University Medical Center Groningen, Groningen, NETHERLANDS, ³S. Orsola-Malpighi University Hospital, Bologna, ITALY, ⁴Erasmus Medical Center, Rotterdam, NETHERLANDS.

E-PW073**¹⁸F-FLT PET/CT imaging and inhibition of multiple signaling pathways downstream EGFR and MET receptors in resistant NSCLC**

F. Iommelli¹, V. De Rosa¹, M. Monti², C. Terlizzi², M. Panico¹, S. Del Vecchio^{2,1}; ¹Institute of Biostructures and Bioimaging, National Research Council, Naples, ITALY, ²Department of Advanced Biomedical Sciences, University "Federico II", Naples, ITALY.

E-PW074**New Sensitive Method For HEPES Quantification in [⁶⁸Ga]-Radiopharmaceuticals**

I. F. Antunes¹, G. M. Franssen², R. Zijlma¹, G. L. K. van der Woude¹, C. B. Yim³, P. Laverman², H. H. Boersma¹, P. H. Elsinga¹; ¹University Medical Center of Groningen, Groningen, NETHERLANDS, ²Radboud University Medical Center, Nijmegen, NETHERLANDS, ³University of Turku, Turku, FINLAND.

E-PW075**Effect of Selective Endothelin B Receptor Agonist IRL-1620 on [¹⁸F]FDG Uptake in a Mouse Model of Breast Cancer**

A. Yatsyna, O. Sarrhini, M. Bentourkia, R. Lecomte, S. V. Selivanova; Sherbrooke Molecular Imaging Centre, CRCHUS, Université de Sherbrooke, Sherbrooke, QC, CANADA.

E-PW076**Prediction of the synergistic efficacy of capecitabine and TAS-102 in mice with colon cancer xenografts using [¹⁸F]fluorothymidine positron emission tomography**

S. Kim¹, J. JUNG¹, H. Lee¹, H. Soh¹, S. Lee², S. Oh², S. Chae², J. Lee³, S. Lee⁴, Y. Hong⁵, T. Kim⁵, D. Moon²; ¹Asan Institute for Life Sciences, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, ³Department of Nuclear Medicine, Dankook University Hospital, Cheonan, KOREA, REPUBLIC OF, ⁴Department of Pharmacology, Chungnam National University College of Pharmacy, Daejeon, KOREA, REPUBLIC OF, ⁵Department of Oncology, Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

E-PW077**[¹⁸F]-5-fluoroaminosuberic acid ([¹⁸F]FASu) superior to [¹⁸F]FDG in small animal PET/CT imaging of human xenografts**

M. Colovic^{1,2}, H. Yang¹, H. Merckens², L. Southcott¹, N. Colpo², J. Rousseau², F. Benard^{2,3}, P. Schaffer^{1,3}; TRIUMF, Vancouver, BC, CANADA, ²British Columbia Cancer Research Centre, Vancouver, BC, CANADA, ³Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

E-PW078**Imaging Cancer Metastases in a Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Rodent Model Using (4S)-4-(3-18F-fluoropropyl)-L-Glutamate (FSPG) by Small-Animal PET/CT: a Preclinical Study**

M. CHENG¹, Y. Huang¹, L. Hsin², C. Shiu³, Y. Chang¹, R. Yen¹, Y. Tien¹; ¹National Taiwan University Hospital, Taipei, TAIWAN, ²School of Pharmacy, Molecular Imaging Center, and Center for Innovative Therapeutics Discovery, National Taiwan University, Taipei, TAIWAN, ³National Taiwan University Hospital and Molecular Imaging Center, Taipei, TAIWAN.



E-PW079**Potential of PET imaging to monitor upregulation of NET-1 transporter**

S. M. Turnock¹, D. R. Turton¹, D. M. Ciobota¹, O. Yogev¹, L. Chesler¹, T. Wilson², V. Gouverneur², G. Smith¹, G. Kramer-Marek¹; ¹The Institute of Cancer Research, Sutton, UNITED KINGDOM, ²University of Oxford, Oxford, UNITED KINGDOM.

E-PW09

Tuesday, October 24, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer A, Screen 1

Clinical Oncology: Walk FDG

Chairs: A. Giraudet (Lyon, FRANCE)
E. Demirci (Istanbul, TURKEY)

E-PW080**Early response evaluation by ¹⁸F-FDG-PET influences management in gastrointestinal stromal tumor patients treated with neo-adjuvant intent**

S. Farag¹, N. Steeghs¹, W. T. van der Graaf^{2,3}, F. van Coevorden¹, D. J. Grunhagen⁴, A. K. L. Reyners⁵, P. A. Boonstra⁵, H. J. Gelderblom⁶, L. de Geus-Oe^{6,7}; ¹Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, ²The Radboud University Medical Center, Nijmegen, NETHERLANDS, ³Institute of Cancer Research, London, UNITED KINGDOM, ⁴Erasmus Medical Center - Cancer Institute, Rotterdam, NETHERLANDS, ⁵University of Groningen, Medical Center Groningen, Groningen, NETHERLANDS, ⁶Leiden University Medical Center, Leiden, NETHERLANDS, ⁷University of Twente, MIRA Institute, Twente, NETHERLANDS.

E-PW081**The prognostic significance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) with F18 FDG PET / CT in non-small cell lung cancer (NSCLC)**

S. Göksel, Y. Yürekli, A. Cengiz; Adnan Menderes University Medical School Department of Nuclear Medicine, Aydın, TURKEY.

E-PW082**Prediction of small early lung adenocarcinoma with aggressive histopathologic subtypes using PET and CT radiomic features**

C. Liu, W. Choi, S. Riyahi, W. Lu, J. Oh, J. Deasy, P. Adusumilli, W. Weber; Memorial Sloan-Kettering Cancer Center, New York City, NY, UNITED STATES OF AMERICA.

E-PW083**Total lesion glycolysis of the primary tumour as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic parameters in oral squamous cell carcinoma**

D. Weidt¹, G. Spanier², T. Reichert², J. Meier², D. Hellwig¹, J. Grosse¹; ¹Department of Nuclear Medicine, University of Regensburg Medical School, 93059 Regensburg, GERMANY, ²Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, 93059 Regensburg, GERMANY.

E-PW084**Adaptive 18F-FDG-PET-guided reirradiation for recurrent and second primary head and neck cancer**

J. Schatteman¹, D. Van Gestel², D. Berwouts¹, W. De Gerssem¹, G. De Kerf³, W. De Neve¹, B. De Ost³, A. Olteanu¹, S. Rottey¹, T. Vercauteren¹, F. Duprez¹, I. Goethals¹; ¹Ghent University Hospital, Ghent, BELGIUM, ²Jules Bordet Institute, Brussels, BELGIUM, ³Antwerp University Hospital, Antwerp, BELGIUM.

E-PW085**Recurrent germinal tumor carcinoma: clinical and prognostic value of FDG-PET/CT**

P. Alongi¹, M. Picchio², F. Caobelli³, M. Spallino⁴, L. Gianolli², M. Midiri¹, L. Evangelista⁵; ¹San Raffaele G. Giglio Institute, Cefalù, ITALY, ²IRCCS San Raffaele Scientific Institute, Milano, ITALY, ³Basel University Hospital, Basel, SWITZERLAND, ⁴University of Milano-Bicocca, Milano, ITALY, ⁵Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY.

E-PW086**Costeffectiveness of second line diagnostic investigation in patients included in DANTE trial**

E. Lopci¹, E. Morengi¹, D. Tanzi¹, S. Cavuto², F. Lutman¹, G. Chiesa³, E. Vanni¹, A. Chiti¹, M. Alloisio¹, M. Infante⁴; ¹Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Milano, ITALY, ²IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, ITALY, ³Humanitas Gavazzeni, Bergamo, ITALY, ⁴AIOU, Verona, ITALY.

E-PW087**User-guided 3D active contour segmentation of complex-shaped tumours: an efficient semi-automatic approach in FDG PET thoracic oncology**

F. L. Besson^{1,2}, T. Henry¹, C. Meyer¹, V. Chevance¹, V. Roblot¹, E. Blanchet³, V. Arnould³, G. Grimon¹, M. Chekroun¹, L. Mabillet⁴, F. Parent¹, A. Seferian¹, S. Bulifon¹, D. Montani¹, M. Humbert¹, P. Chaumet-Riffaud¹, V. Lebon³, E. Durand^{1,2}; ¹AP-HP Université Paris Sud, Le Kremlin bicetre, FRANCE, ²IR4M-UMR 8081 Université Paris-Sud Université Paris-Saclay CNRS, Orsay, FRANCE, ³CEA SHEJ, Orsay, FRANCE, ⁴CCML, Clamart, FRANCE.



E-PW088**In-vivo tumour characterization of breast cancer using [¹⁸F]FDG-PET/CT and supervised machine-learning**

L. Papp, T. Nakuz, H. Magometschnigg, M. Grahovac, T. Helbich, G. Karanikas, A. Haug, K. Pinker, T. Beyer, M. Hacker; Medical University of Vienna, Vienna, AUSTRIA.

E-PW089**Evaluation of diagnostic accuracy and impact of FDG PET/CT in pre-operative management of early breast cancers**

P. Chandra, S. Nath, S. Kumar; MIOT international hospital, Chennai, INDIA.

E-PW10

Tuesday, October 24, 2017, 08:30 - 09:30,

e-Poster Walk Area, Level 2, Foyer A, Screen 2

Cardiovascular System: Cardiac Amyloidosis & Endocarditis

Chairs: R. Sciagra (Florence, ITALY)

J. Bucerius (Maastricht, NETHERLANDS)

E-PW090**Myocardial Technetium-99M Methylene Diphosphate Uptake And Left Ventricular Motion In Transthyretin Related Cardiac Amyloidosis**

F. Ticconi¹, A. Nieri¹, I. Calamia¹, V. Ceriani¹, F. Fiz², M. Canepa³, M. Pennone⁴, M. Sicignano⁴, G. Villa⁴, S. Morbelli⁴, P. Gancitano⁴, G. Sambuceti^{1,4}, C. Marini⁵; ¹Department of Health Sciences, University of Genoa, Genoa, ITALY, ²Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum, Tübingen, GERMANY, ³Cardiovascular Unit, Department of Internal Medicine, University of Genoa, Genoa, ITALY, ⁴Nuclear Medicine Unit, IRCCS San Martino-IST, Genoa, ITALY, ⁵CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

E-PW091**Prevalence of heart failure in elderly patients with myocardial uptake on bone scan**

L. Mohamed Salem, Sr., J. Sánchez Serna, J. Santos Mateo, M. Perez Martinez, R. Reyes Marles, M. Godoy Bravo, I. Sime Loayza, M. Castellon Sanchez, F. Nicolas Ruiz, L. Frutos Esteban, J. Navarro Ferenandez, M. Tomas Redondo, D. Pascual Figal, M. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

E-PW092**Bone^{99m}Tc-DPD Scintigraphy: More Data To Confirm Its Utility For The Diagnosis Of TTR Heart Amyloidosis In Patients With Restrictive Hypertrophic Myocardopathy**

A. Marí Hualde, E. Ardila Manjarres, R. Pérez Pascual, J. Orcajo Rincón, A. Rotger Regí, L. Reguera Berenguer, J. Alonso Farto; Gregorio Marañón Hospital, Madrid, SPAIN.

E-PW093**Tc99m-DPD scan in the diagnosis of Cardiac Transthyretin Amyloidosis**

L. Mohamed Salem, Sr., J. Sánchez Serna, V. Cabanas Perianes, R. Reyes Marles, M. Godoy Bravo, M. Castellon Sanchez, F. Nicolas Ruiz, L. Frutos Esteban, J. Navarro Ferenandez, I. Sime Loayza, M. Tomas Redondo, M. Perez Martinez, J. Santos Mateo, D. Pascual Figal, M. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

E-PW094**A comparison between Tc99m-DPD and Tc99m-HDP myocardial uptake in the diagnosis of cardiac amyloidosis**

L. Mohamed Salem, Sr., R. Reyes Marles, M. Godoy Bravo, I. Sime Loayza, M. Tomas Redondo, M. Castellon Sanchez, L. Frutos Esteban, J. Navarro Ferenandez, F. Nicolas Ruiz, M. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

E-PW095**Myocardial uptake of bone scintigraphic agents associated with cardiac amyloidosis in daily practice**

S. Fukuzawa, S. Okino, T. Uchiyama, N. Kuroiwa, Y. Iwata, M. Inagaki; Funabashi Municipal Medical Center, Chiba, JAPAN.

E-PW096**Is there a relationship between clinical parameters and cardiac uptake in 99mTc-DPD scintigraphy in patients with cardiac amyloidosis?**

E. Abou Jokh Casas, V. Pubul Núñez, M. Garrido Pumar, B. Sopeña, A. Varela Roman, M. Pombo Pasin, J. Cortéz, S. Argibay, Á. Ruibal; Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, SPAIN.

E-PW097**Clinical Utility of ^{99m}Tc-PYP and ²⁰¹Tl-CI SPECT Imaging in Patients with Suspected Cardiac Amyloidosis**

S. Ito, N. Kodani, K. Tanabe; Shimane University, Izumo, Shimane, JAPAN.



E-PW098**Florbetaben Whole-Body PET/MRI for Evaluation of Systemic Amyloid Deposition**

S. Park, L. Baratto, P. Gulaka, R. Herfkens, R. Witteles, A. Iagaru; Stanford University School of Medicine, Stanford, CA, UNITED STATES OF AMERICA.

E-PW099**¹⁸F-FDG-PET/CT as a diagnostic tool in native valve endocarditis**

I. Kouijzer^{1,2}, M. Berrevoets¹, E. Aarntzen¹, M. Janssen¹, J. de Vries¹, A. van Dijk¹, W. Oyen^{1,3}, L. de Geus-Oei^{4,2}, C. Bleeker-Rovers¹; ¹Radboudumc, Nijmegen, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM, ⁴LUMC, Leiden, NETHERLANDS.

E-PW11 Tuesday, October 24, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer A, Screen 3

Neurosciences: Molecular Neuroimaging

Chairs: S. Golla (Amsterdam, NETHERLANDS)
O. Ekmekcioglu (Istanbul, TURKEY)

E-PW100**Effect of blood flow on ¹⁸F-Florbetaben PET quantitation: a simulation study**

S. Bullich¹, N. Koglin¹, G. Becker², S. De Santi³, A. Jovalekic¹, H. Barthele³, O. Sabri³; ¹Piramal Imaging GmbH, Berlin, GERMANY, ²Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Leipzig, GERMANY, ³Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY.

E-PW101**Can relative flow derived from dynamic ¹¹C-PIB scans replace FDG scans in Alzheimer disease PET studies?**

T. van der Goot, F. E. Reesink, D. E. Peretti, D. Váñez García, A. T. M. Willemsen, P. P. De Deyn, R. Boellaard; UMCG, Groningen, NETHERLANDS.

E-PW102**Different Patterns of Dopamine and Serotonin Dysfunction in Manic, Depressive and Euthymic Phases of Bipolar Disorder**

S. Nikolaus, H. Müller, H. Hautzel; University Hospital Düsseldorf, Düsseldorf, GERMANY.

E-PW103**First quantification results for the new TSP0 radioligand [¹⁸F]GE-180 in patients with multiple sclerosis**

L. Vomacka¹, N. L. Albert¹, S. Lindner¹, M. Unterrainer¹, C. Mahler², M. Brendel¹, L. Ermoschkin¹, A. Gosewisch¹, A. Brunegräf¹, C. Buckley³, W. Trigg³, T. Kämpfe², R. Rupprecht⁴, M. Kerschensteiner^{2,5}, P. Bartenstein^{1,5}, G. Böning¹; ¹Department of Nuclear Medicine, LMU Munich, Munich, GERMANY, ²Institute of Clinical Neuroimmunology, LMU Munich, Munich, GERMANY, ³GE Healthcare, Grove Centre, Amersham, UNITED KINGDOM, ⁴Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, GERMANY, ⁵Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.

E-PW104**PET-Analysis: a user-friendly toolbox for epileptic seizure onset zone localization. Evaluation of the performance using simulated data**

A. Niñerola-Baizán^{1,2}, B. Marti-Fuster^{1,2}, A. Martín-Pero², R. Tudela¹, M. Mayoral³, X. Setoain^{3,1}, D. Ros^{2,1}, J. Pavía^{3,1}; ¹Grupo de Imagen Biomédica, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, SPAIN, ²Unitat de Biofísica i Bioenginyeria, Facultat de Medicina, Universitat de Barcelona, Barcelona, SPAIN, ³Servicio de Medicina Nuclear, Hospital Clínic, Barcelona, SPAIN.

E-PW105**¹²³I-Ioflupane scintigraphy in asymptomatic LRRK2-G2019S mutation carriers**

I. Martínez-Rodríguez¹, M. Jiménez-Alonso¹, J. López-Defilló¹, J. Infante², M. Sierra², J. Jiménez-Bonilla¹, N. Martínez-Amador¹, M. De Arcocha-Torres¹, F. Gómez-de la Fuente¹, D. Meza-Escobar¹, I. Banzo¹; ¹Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, ²Neurology Service. Marqués de Valdecilla University Hospital. IDIVAL. Centro de Investigación Biomédica en Red de Enfermedades Degenerativas (CIBERNED). University of Cantabria, Santander, SPAIN.

E-PW106**Impact of Resolution Recovery Reconstruction on Quantitative Analysis of PETCT beta-Amyloid Plaque Brain Imaging**

R. T. Meades¹, L. M. Perry¹, K. S. Nijran¹, Z. Win²; ¹Radiological Sciences Unit, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, ²Nuclear Medicine Department, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.



E-PW107**Asymmetric Parkinson's disease and effects of unilateral subthalamic nucleus deep brain stimulation on neural networks: a pilot PET study**

P. David¹, X. Palard-Novello², S. Drapier³, M. Verin³, F. Le Jeune¹; ¹Hôpital Européen Georges Pompidou, Paris, FRANCE, ²Centre Eugene Marquis, Rennes, FRANCE, ³Centre Hospitalier Universitaire, Rennes, FRANCE.

E-PW108**Cortical metabolic patterns related to CSF total tau, A β 42 and phosphorylated tau protein in Alzheimer disease**

A. Chiaravallotti^{1,2}, M. Ricci³, A. Martorana⁴, F. Calabria⁵, P. Sannino², O. Schillaci^{1,2}; ¹Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, ²IRCCS Neuromed, Pozzilli, ITALY, ³Nuclear Medicine Unit, University La Sapienza, Rome, ITALY, ⁴Department of Neosciences, University Tor Vergata, Rome, ITALY, ⁵Neuroimaging PET/MRI Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, ITALY.

E-PW109**¹⁸F-FDG PET brain in presurgical management of patients with periventricular nodular heterotopias related epilepsy: diagnostic features and long term outcome**

C. E. Popescu¹, C. Rossetti¹, R. Mai¹, R. Sara¹, M. Milella¹, D. Redaelli¹, A. Liuni¹, F. Caobelli²; ¹Niguarda Hospital, Milan, ITALY, ²University Hospital Basel, Basel, SWITZERLAND.

E-PW12 Tuesday, October 24, 2017, 08:30 - 09:30,
e-Poster Walk Area, Level 2, Foyer B, Room 2.44, Screen 4

Do.MoRe: PET & PET/CT Data Analysis & Management

*Chairs: S. Holm (Copenhagen, DENMARK)
T. Beyer (Vienna, AUSTRIA)*

E-PW110**Ultra-fast or Ultra-low Count Density Wholebody PET Imaging - Pushing the Envelope with Next-generation Digital PET**

M. I. Knopp, J. Zhang, K. Binzel, R. Moore, M. Friel, C. L. Wright, M. V. Knopp; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.

E-PW111**A Noise Smoothing Origin Ensemble Algorithm Based on Regional Filtering**

K. Chuang¹, C. Chiang¹, H. Lin², Y. Ni³; ¹National Tsing-Hua University, Hsin-Chu, TAIWAN, ²Chang Gung University/Chang Gung Memorial Hospital, Taoyuan, TAIWAN, ³Institute of Nuclear Energy Research, Long-Tan, TAIWAN.

E-PW112**A Simultaneous Method for MRI-based Partial Volume Correction and Image Registration in Brain PET**

M. Ibaraki, K. Matsubara, T. Kinoshita; Akita Research Institute of Brain and Blood Vessels, Akita, JAPAN.

E-PW113**A lesion detection study to evaluate a weight-based dose protocol combined with Pixon Planar Processing for wholebody bone scans**

N. Gunson¹, V. Militano², N. Ali², A. Spencer², M. J. Memmott², K. J. Saint², J. D. Thompson³, I. S. Armstrong²; ¹Christie Hospital, Manchester, UNITED KINGDOM, ²Central Manchester University Hospitals, Manchester, UNITED KINGDOM, ³University of Salford, Manchester, UNITED KINGDOM.

E-PW114**Image Quantitation for LEHR-collimated Tc-99m-TRODAT-1 SPECT: An Experimental Study with Striatum Phantom**

M. Wu¹, K. Lin¹, B. Hsu²; ¹Dept of Nuclear Medicine, MacKay Memorial Hospital, Taipei, TAIWAN, ²Nuclear Science and Engineering Institute, University of Missouri-Columbia, Columbia, MO, UNITED STATES OF AMERICA.

E-PW115**Initial Experience with a New PET/CT System Using SiPM Detectors**

S. Park, L. Baratto, N. Hatami, G. Davidzon, S. Srinivas, S. Gambhir, A. Igaru; Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA.

E-PW116**Improvements of game-theoretical image segmentation algorithm using PVE correction for nuclear medicine imaging**

D. Borys¹, K. Szczucka-Borys², I. Gorczewska³, A. d'Amico³; ¹Institute of Automatic Control, Silesian University of Technology, Gliwice, POLAND, ²Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, POLAND, ³Department of PET Diagnostics, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, POLAND.

E-PW117**Large bed overlap and short acquisition time or vice versa?**

T. Andersen, P. Braad, P. Hoiland-Carlsen; Odense University Hospital, Odense, DENMARK.

**E-PW118****Optimal quantitative SUV metrics over wide range of lesion sizes in advanced image reconstruction (TOF and PSF) for PET**

I. Shiri¹, P. Ghafarian^{2,3}, S. Ashrafinia⁴, A. Bitarafan-Rajabi^{1,5}, M. AY^{6,7}, A. Rahmim^{8,4}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ⁵Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁶Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁷Department of Medical Physics, School of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁸Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

E-PW119**A demonstration of the concept of numerical twins in esophageal cancer patients**

F. Orlhac¹, C. Nioche¹, S. Boughdad^{1,2}, M. Soussan^{1,3}, I. Buvat¹; ¹IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris-Saclay, CEA-SHFJ, Orsay, FRANCE, ²Department of Nuclear Medicine, Institut Curie – René Huguenin, Saint-Cloud, FRANCE, ³Department of Nuclear Medicine, Assistance Publique - Hôpitaux de Paris, Avicenne Hospital, Bobigny, FRANCE.

e-Posters

EP-01 during congress opening hours, e-Poster Area

Physics & Instrumentation & Data Analysis:
Instrumentation

EP-0001

Conventional and microfluidic PET tracer synthesis on a novel synthesizer platform

C. Rensch¹, C. Frank¹, R. Salvamoser¹, G. Winter¹, S. Lindner², P. Bartenstein², F. Rense³, A. Hienzsch⁴, R. Hesse⁴, H. Lankau⁴, M. Müller⁴, A. Hoepfing⁴, V. Samper¹; ¹GE Global Research, Garching near Munich, GERMANY, ²Department of Nuclear Medicine, University Hospital Munich LMU, Munich, GERMANY, ³GE Healthcare, Uppsala, SWEDEN, ⁴ABX advanced biochemical compounds GmbH, Radeberg, GERMANY.

EP-0002

The Influence of Crystal Material and Size on the Sensitivity of Recently Developed SiPM Based Animal PET Scanner: a Monte Carlo Study

P. Ghahramani^{1,2}, N. Zeraatkar², N. Vosoughi¹, M. R. Ay^{2,3}; ¹Radiation Medicine Engineering Department, Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0003

Monte Carlo Based Performance estimation of breast PET scanners due to reduction of the ring diameter

A. Emami^{1,2,3}, H. Ghadiri^{1,2}, P. Ghafarian^{4,5}, M. Ay^{1,2}; ¹Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³International Campus, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0004

Measurement of 225 ps CRT on 20 mm thick monolithic LYSO and CeBr3 crystals using Temporal imaging

C. Tata Zafarifety¹, A. Ittis¹, G. Zeufack Tadonkeng¹, L. Rodrigues¹, H. Snoussi²; ¹Damavan imaging, TROYES, FRANCE, ²Université de Technologie de Troyes, TROYES, FRANCE.

EP-0005

Design and Development of a Small-Animal PET Scanner Based on Pixelated Crystals and Silicon Photomultipliers

M. Ay^{1,2}, N. Zeraatkar¹, S. Sajedi¹, M. Taheri¹, S. Kaviani¹, S. Sarkar^{1,2}; ¹Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0006

SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions

L. Baratto¹, S. Park¹, N. Hatami¹, G. Davidzon², S. Srinivas¹, S. S. Gambhir³, A. Igaru¹; ¹Stanford University, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford, CA, UNITED STATES OF AMERICA, ²Stanford University, Radiological Sciences Laboratory, Stanford, CA, UNITED STATES OF AMERICA, ³Stanford University School of Medicine, Departments of Radiology, Bioengineering, Materials Science and Engineering, Stanford, CA, UNITED STATES OF AMERICA.

EP-0007

Optimization of the crystal thickness for a monolithic LYSO animal PET detector with anger and CSE positioning method using Monte Carlo simulation

A. Sanaat^{1,2}, M. Shamsaie¹, B. Teymorian¹, R. Hashemi^{2,3}, M. Ay^{3,2}; ¹Department of Energy and Physics, AmirKabir University of Technology (Tehran Polytechnic), Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.



EP-0008**Performance Evaluation of a New High Resolution Non-human Primate (NHP) PET/CT System (LFER 150 PET/CT)**

Z. Sarnyai¹, K. Nagy², G. Patay², M. Molnár², G. Rosenqvist¹, M. Tóth¹, A. Takano¹, B. Gulyás¹, C. Halldin¹, P. Major², A. Varrone¹; ¹Karolinska Institutet, Stockholm, SWEDEN, ²Mediso Ltd, Budapest, HUNGARY.

EP-0009**Design optimization of partial cylindrical PET scanner based on trapezoid-shaped block detector and monolithic crystals using Monte Carlo simulation**

P. Sheikhzadeh^{1,2}, H. Ghadiri^{1,2}, P. Geramifar³, P. Ghaffarian^{4,5}, M. Ay^{1,2}; ¹Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0010**Feasibility of Whole Body Dynamic Acquisitions using Digital PET/CT - A Preclinical Phase I Study**

K. Binzel¹, J. Zhang¹, M. I. Menendez¹, M. Friel¹, M. I. Knopp¹, R. Moore¹, C. L. Wright¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ²Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-02 during congress opening hours, e-Poster Area**Physics & Instrumentation & Data Analysis: Image Reconstruction****EP-0011****Accuracy and precision of activity concentration measurements for GE Q.Metrix absolute SPECT quantification**

I. Armstrong; Central Manchester University Hospitals, Manchester, UNITED KINGDOM.

EP-0012**Impact of Point-Spread Function on the Image Quality in Small-Voxel Reconstructions of ¹⁸F-FDG-PET Images**

N. Assink^{1,2}, J. A. van Dalen³, D. Koopman^{1,2}, H. Stevens¹, C. H. Slump², P. L. Jager¹; ¹Department of Nuclear Medicine, Isala, Zwolle, NETHERLANDS, ²MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, ³Department of Medical Physics, Isala, Zwolle, NETHERLANDS.

EP-0013**A Comparison Study on Two Novel Statistical Reconstruction Algorithms Developed for Slit-Hole Collimation Data in Small Animal SPECT Imaging**

H. Mahani^{1,2}, G. Raisali¹, A. Kamali-Asl³, M. Ay^{2,4}; ¹Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Radiation Medicine Engineering Department, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0014**Development of Monte Carlo Simulation Based Quantitative Image Reconstruction for SPECT/CT**

K. Sakaguchi^{1,2,3}, S. Yoshida¹, S. Watanabe^{1,2}, K. Matano¹, M. Okumura¹, M. Hosono^{4,2}, K. Ishii^{4,2}, T. Murakami^{4,2}; ¹Department of Radiology, Kindai University Hospital, Osaka, JAPAN, ²Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Faculty of Medicine, Kindai University, Osaka, JAPAN, ³Laboratory of Radiation Biology, Department of Biological Science, Graduate School of Science, Osaka Prefecture University, Osaka, JAPAN, ⁴Department of Radiology, Faculty of Medicine, Kindai University, Osaka, JAPAN.

EP-0015**Evaluation of optimized iterative reconstruction parameters using channelized Hotelling observer in brain receptor PET imaging**

K. Matsumoto¹, H. Ogawa¹, Y. Matsumoto¹, G. Akamatsu², M. Senda², K. Murase³, K. Endo¹; ¹Kyoto College Of Medical Science, Kyoto, JAPAN, ²Institute of Biomedical Research and Innovation, Kobe, JAPAN, ³Graduate School of Medicine, Osaka University, Osaka, JAPAN.



**EP-0016****The Impact of a Penalized Likelihood Reconstruction Algorithm on the Quantitative Evaluation of Hepatic Metastases Shown on ¹⁸F-FDG-PET/CT Studies - Preliminary Results**

S. Czibor, Z. Varga, A. Fekesházy, L. Jorgov, B. Kári, B. Magyar, J. Török, G. Dabasi, T. Györke; Semmelweis University, Nuclear Medicine Centre, Budapest, HUNGARY.

EP-0017**Evaluation of FDG PET/CT lesion detectability and quantification harmonization**

J. Devriese¹, L. Beels², E. Deboever¹, B. Decru¹, A. Maes², C. Van de Wiele³, H. Pottel¹; ¹KU Leuven campus Kortrijk, Kortrijk, BELGIUM, ²AZ Groeninge, Kortrijk, BELGIUM.

EP-0018**Phantom and Patient Analysis of the Impact Of Q.Clear Regularization in Texture Indices**

G. Reynés-Llompert¹, J. Robles-Barba¹, E. Llinares-Tello¹, P. C. Notta¹, I. Gil-Viciano¹, A. Sabaté-Llobera¹, J. L. Vercher-Conejero¹, N. Calvo¹, C. Gámez-Cenzano¹, J. M. Martí-Climent²; ¹PET Unit, Nuclear Medicine Department. IDI. Hospital Universitari de Bellvitge. IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0019**Improving Quantitative Accuracy with use of High and Ultra-high Definition PET/CT Reconstruction**

K. Binzel¹, J. Zhang¹, R. Moore¹, M. Friel¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ²Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0020**Assessment of different reconstruction parameters for quantification of FDG-PET brain imaging**

T. C. G. Moalosi^{1,2,3}, P. Dupont^{3,4}, A. Ellmann^{1,3}, J. Warwick^{1,3}, A. Doruyter^{1,3}, M. Du Toit^{2,3}, M. Mix^{1,5}; ¹Tygerberg Hospital (Nuclear Medicine), Cape Town, SOUTH AFRICA, ²Tygerberg Hospital (Medical Physics), Cape Town, SOUTH AFRICA, ³Stellenbosch University, Cape Town, SOUTH AFRICA, ⁴KU Leuven, Leuven, BELGIUM, ⁵University of Freiburg, Freiburg, GERMANY.

EP-0021**Accelerated 3D Detector Modelling using a Lookup-table based on GATE Simulations of a single Detector Block**

H. Xu, J. Scheins, M. Lenz, C. Lerche, N. Shah; Forschungszentrum Juelich, Juelich, GERMANY.

EP-0022**Sub-centimeter lesion detectability in Point-spread function (PSF) and Time of flight (TOF) reconstructed PET images**

I. Shiri¹, P. Ghafarian^{2,3}, A. Bitarafan-Rajabi¹, M. AY^{4,5}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, tehran, IRAN, ISLAMIC REPUBLIC OF, ³PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Department of Medical Physics, School of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0023**Impact of matrix size on metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in PSF-based PET image**

I. Shiri¹, A. Rahmim^{2,3}, S. Ashrafinia³, P. Geramifard⁴, A. Bitarafan-Rajabi^{1,5}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ³Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ⁴Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-03 during congress opening hours, e-Poster Area**Physics & Instrumentation & Data Analysis: Data Analysis & Management****EP-0024****Quantification of ¹⁷⁷-Lu and ¹³¹-I: a phantom study**

J. Kupferschlaeger, H. Dittmann, S. Poth, C. la Fougère; University Hospital Tuebingen/ Nuclear medicine, Tuebingen, GERMANY.

EP-0025**The quantitative SPECT/CT scoring of MIBG cardiac scintigraphy to identify patients with Lewy body diseases**

S. Matsuo¹, H. Wakabayashi¹, K. Nakajima¹, K. Okuda², H. Yoneyama¹, S. Kinuya¹; ¹Kanazawa University, Kanazawa, JAPAN, ²Kanazawa Medical University, Kanazawa, JAPAN.

EP-0026**Relationship between image and clinical indices in the differential diagnosis of dementia using ¹⁸F-FDG-PET images and machine learning**

M. Sakata¹, X. Wang^{1,2}, K. Ishii¹, Y. Kimura^{1,3}, K. Wagatsuma¹, K. Ishibashi¹, J. Toyohara¹, N. Yata², Y. Manabe²; ¹Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, ²Chiba University, Chiba, JAPAN, ³Kindai University, Kinokawa, JAPAN.

EP-0027**Noninvasive quantitation of rat cerebral blood flow using ^{99m}Tc-HMPAO without arterial blood sampling**

C. Suzuki, M. Kosugi, Y. Magata; Hamamatsu University School of Medicine, Hamamatsu, JAPAN.

EP-0028**Dosimetric survey on administered activity of ¹¹C-CHOLINE in PET/CT examinations in Sardinia from 2012 to 2016: a retrospective analysis**

A. Loi¹, S. Zucca², M. Carta¹, D. De Vittor¹, G. Melis³, S. Loi²; ¹Alliance Medical, Cagliari, ITALY, ²C. Fisica Sanitaria Azienda Ospedaliera G. Brotzu, Cagliari, ITALY, ³S.C. Medicina nucleare e Centro PET Azienda Ospedaliera G. Brotzu Cagliari, Cagliari, ITALY.

EP-0029**Regional-wide survey on administered activity of ¹⁸F-FDG in PET/CT examinations in Sardinia**

F. Pinna¹, S. Zucca², D. De Vittor³, M. Carta³, S. Loi², G. Melis⁴, M. Giannoni⁴, A. Spanu⁵, P. Marini¹, A. Loi³; ¹S.S.D Fisica Sanitaria Azienda Ospedaliera Universitaria, Sassari, ITALY, ²S.C. Fisica Sanitaria Azienda Ospedaliera G. Brotzu Cagliari, Cagliari, ITALY, ³Alliance Medical, Cagliari, ITALY, ⁴S.C. Medicina nucleare e Centro PET Azienda Ospedaliera G. Brotzu, Cagliari, ITALY, ⁵S.C. Medicina Nucleare e Centro PET Azienda Ospedaliera Universitaria, Sassari, ITALY.

EP-0030**Plasma to blood ratio derived parent fractions for robust plasma input based kinetic analysis of dynamic ¹⁸F-FLT PET studies in NSCLC cancer patients**

A. Avendaño-Estrada^{1,2,3}, G. Kramer², V. Frings², D. Vallez García¹, E. Smit⁴, A. Lammertsma², O. Hoekstra², R. Boellaard^{1,2}, QuicConcept Consortium; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²VU University Medical Center, Amsterdam, NETHERLANDS, ³Universidad Nacional Autónoma de México, Mexico, MEXICO, ⁴The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

EP-0031**Importance of algorithms in SUV calculation. Quantitative comparison of differences in SUV obtained from OSEM and Q.Clear® algorithms. Our experience**

M. Agolti¹, B. Moglia², J. Biurrun Manresa, 3100³, J. Bustos²; ¹Clinica Modelo, Parana, ARGENTINA, ²Fundación Centro de Medicina Nuclear y Molecular Entre Ríos (CEMENER), Oro Verde, ARGENTINA, ³Centro de Investigaciones y Transferencia de Entre Ríos (CITER) CONICET-UNER, Oro Verde, ARGENTINA.

EP-0032**A quantitative functional and structural multiple sclerosis analysis A ^{99m}TcECD brain SPECT study with statistical parametric mapping SPM evaluation and voxel based morphometry VBM analysis of brain MRI using CAT12 toolbox**

N. Chabi¹, R. Nemati², M. Assadi²; ¹Division of Biomedical Engineering (BME), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ²Division of Neuroscience, The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF.

EP-0033**Prediction of chemotherapy response in osteosarcoma using multi-parametric PET/MRI texture feature**

Y. Park, W. Kim, B. Byun, J. Kang, C. Kong, W. Song, I. Lim, Y. Lee, B. Kim, S. Lim, S. Woo; Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.



**EP-0034****An efficient software tool for measuring the total metabolic tumor volume in whole body PET**

C. Nioche¹, A. Cotterau², M. Meignan³, I. Buvat¹; ¹Service Hospitalier Frédéric Joliot, Imiv, Cea, Inserm, Cnrs, Univ. Paris-sud, Université Paris Saclay, CEA-SHFJ, Orsay, Orsay, FRANCE, ²Médecine Nucléaire, Lysa Im, Hôpital Tenon et Hôpitaux Universitaires Henri Mondor, Paris, Paris, FRANCE, ³Lysa Im, Hôpitaux Universitaires Henri Mondor, Créteil, Créteil, FRANCE.

EP-0035**Motion detection for static objects imaged with CZT cardiac camera**

A. Budzynska, M. Dziuk; Military Institute of Medicine, Warsaw, POLAND.

EP-0036**Monte-Carlo simulated amyloid PET for testing the performance of Partial Volume Correction methods**

G. Salvadó^{1,2,3}, A. Niñerola-Baizán^{2,3}, M. Garcia², J. Pavia^{4,3}, D. Ros^{2,3}, F. Lomeña^{4,5}, J. Molinuevo^{1,6}, J. Gispert^{1,3}, R. Sala-Llonch²; ¹Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, SPAIN, ²Department of Biomedicine, University of Barcelona, Barcelona, SPAIN, ³Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, SPAIN, ⁴Servei de Medicina Nuclear, Hospital Clínic, Barcelona, SPAIN, ⁵Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, SPAIN, ⁶Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN.

EP-0037**Group-Sequential Analysis May Allow for Early Trial Termination: Illustration by an Intra-Observer Repeatability Study**

O. Gerke^{1,2}, M. H. Vilstrup¹, U. Halekoh², P. Højlund-Carlsen^{1,2}; ¹Odense University Hospital, Odense, DENMARK, ²University of Southern Denmark, Odense, DENMARK.

EP-0038**A [¹¹C]-(-)-PK11195 PET human brain template for spatial normalization in statistical parametric mapping of neuroinflammation**

P. N. Schuck¹, A. M. Marques da Silva^{1,2}, C. M. Dartora¹, C. S. Matushita², B. Hochhegger^{1,2}, J. Becker^{1,2}; ¹PUCRS, Porto Alegre, BRAZIL, ²Brain Institute, Porto Alegre, BRAZIL.

EP-04 during congress opening hours, e-Poster Area**Physics & Instrumentation & Data Analysis: Radiation Exposure & Protection****EP-0039****Significantly Low Effective Dose from ¹⁸F-FDG PET/CT Scan Using Dose Reducing Strategies: "Lesser is Better"**

M. U. Zaman¹, N. Fatima¹, A. Zaman², M. Sajid³, S. Zaman²; ¹Aga Khan University Hospital, Karachi, PAKISTAN, ²Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, ³Karachi Institute of Radiotherapy And Nuclear Medicine (KIRAN), Karachi, PAKISTAN.

EP-0040**Reducing Radiophobia in Nuclear Medicine Patients**

A. Shabestani Monfared¹, M. Amiri¹, J. Cameron², A. Gholami¹; ¹Babol University of Medical Sciences, Babol, IRAN, ISLAMIC REPUBLIC OF, ²University of Wisconsin, Madison, WI 53706 USA, Madison, WI, UNITED STATES.

EP-0041**Radiation doses result from radioactive iodine therapy versus living quality**

H. M. Yassin, R. M. Abdel-Halim; Cairo Univeristy, Cairo, EGYPT.

EP-0042**Dosimetry and Radiation Risk in Infants after ^{99m}Tc-MAG3 Scans**

J. Soares Machado, J. Tran-Gia, A. K. Buck, M. Lassmann; University of Wuerzburg - Universitaetsklinikum Wuerzburg, Wuerzburg, GERMANY.

EP-0043**Effective dose of for medical workers during Y 90 microspheres radioembolization**

K. Dalianis¹, F. Vlachou², R. Eftymiadou³, T. Pipikos², J. Andreou³, G. Kollias¹, V. Prassopoulos²; ¹Medical Physics Department, Hygeia SA, Marousi, GREECE, ²Nuclear Medicine & PET/CT Department, Hygeia SA, Marousi, GREECE, ³PET/CT Department, Hygeia SA, Marousi, GREECE.

EP-0044**Radiation exposure to Allied Health personnel handling blood specimens from patients receiving radioactive iodine-131 and recombinant human TSH stimulation**

K. Loke; Singapore General Hospital, Singapore, SINGAPORE.

EP-0045**Occupational exposure for eye, thyroid and gonads to medical workers operating in a PET/CT facility**

K. Dalianis¹, F. Vlachou², R. Eftymiadou³, T. Pipikos², J. Andreou³, G. Kollias¹, V. Prassopoulos²; ¹Medical Physics Department, Hygeia SA, Marousi, GREECE, ²Nuclear Medicine & PET/CT Department, Hygeia SA, Marousi, GREECE, ³PET/CT Department, Hygeia SA, Marousi, GREECE.

EP-0046**Automatic CT Dose Collection Software (OpenREM) for CT Dose Audits in PET/CT and SPECT/CT**

T. Sanderson, J. Dickson; University College London Hospital, London, UNITED KINGDOM.

EP-0047**Area Monitoring in Radionuclide Treatment Ward, Surrounding Areas, and Radiation Exposure to Family Caregiver in Paediatric Patient Receiving High Dose¹³¹Iodine-MIBG**

K. Chuamsaamarkkee¹, N. Kumwang², S. Monthonwattana², W. Changmuang¹, K. Thongklam¹, P. Charoenphun¹, A. Kositwattananerak¹, Y. Anongpornjossakul¹, W. Chamroonrat¹, C. Sritara¹; ¹Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND, ²Thailand Institute of Nuclear Technology (Public Organisation), Nakhonnayok, THAILAND.

EP-0048**Efficiency evaluation of Lead Rubber aprons in Nuclear medicine applications: an approach with Monte Carlo method**

F. Di Matteo¹, F. Zagni², S. Vichi¹, G. Cicoria², D. Pancaldi², D. Mostacci¹, M. Marengo²; ¹Montecucolino Nuclear Engineering Laboratory, Department of Industrial Engineering, University of Bologna, Bologna, ITALY, ²Medical Physics Department, University Hospital "S.Orsola – Malpighi", Bologna, ITALY.

EP-0049**Ionising radiation exposure of children during the course of neuroblastoma or other oncological diseases due to diagnostic procedures- a preliminary report**

J. Iwanowski, H. Piwowarska-Bilska, D. Skupiński, J. Peregud-Pogorzelski, A. Walecka, B. Birkenfeld; Pomeranian Medical University in Szczecin, Szczecin, POLAND.

EP-0050**Dose rates from diagnostic nuclear medicine patients**

V. de Sousa¹, G. Cardoso¹, A. I. Santos^{1,2}; ¹Serviço de Medicina Nuclear – Hospital Garcia de Orta, Almada, PORTUGAL, ²Nova Medical School – Universidade Nova de Lisboa, Lisboa, PORTUGAL.

EP-0051**Personnel dose saving in dispensing of beta emitters-labelled radiopharmaceuticals using automatic device**

F. Fioroni¹, E. Grassi¹, M. Asti², C. Benini³, G. Guidi³, A. Versari², M. Iori¹; ¹Medical Physics Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY, ²Nuclear Medicine Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY, ³Comecer SpA, Castel Bolognese (RA), ITALY.

EP-0052**Belgian Diagnostic Reference Levels for Radiopharmaceuticals in Daily Practice**

T. Vanaudenhove¹, M. Vandecapelle¹, F. Jamar², G. Moulin-Romsee³, R. Hustinx⁴, B. Dehaes⁵, K. Bacher⁶, A. Fremout¹; ¹Federal Agency for Nuclear Control, Brussels, BELGIUM, ²Cliniques universitaires Saint-Luc, UCL, Brussels, BELGIUM, ³Sint-Andries ziekenhuis, Tiel, BELGIUM, ⁴Centre Hospitalier Universitaire de Liège, Liège, BELGIUM, ⁵Ziekenhuis Oost-Limburg, Genk, BELGIUM, ⁶Ghent University, Ghent, BELGIUM.

EP-0053**Exposure of eye lens as a possible limiting factor?**

J. Hudzietzova¹, M. Fülöp², J. Sabol³, J. Doležal⁴, P. Povinec⁵, D. Baček⁵, D. Solivajs⁶, Z. Zelenka⁷; ¹Faculty of Biomedical Engineering CTU in Prague, Kladno, CZECH REPUBLIC, ²Slovak Medical University, Bratislava, SLOVAKIA, ³Faculty of Safety Management of PACR, Prague, CZECH REPUBLIC, ⁴Department of Nuclear Medicine, University Hospital, Hradec Králové, CZECH REPUBLIC, ⁵Nuclear Medicine Clinic, BIONT, Bratislava, SLOVAKIA, ⁶Slovak Legal Metrology, Bratislava, SLOVAKIA, ⁷NUVIA Dosimetry, s.r.o., Prague, CZECH REPUBLIC.

EP-0054**Radiation Protection and Dosimetry for worker used 18F-FDG**

H. M. Yassin¹, M. S. El-Nagdy², A. Wabdan²; ¹Cairo University, Cairo, EGYPT, ²Helwan University, Cairo, EGYPT.

EP-0055**Estimation of Organ and Effective Doses for CT Scan During Whole Body PET/CT examination**

L. Chipiga^{1,2}, V. Golikov¹, C. Bernhardsson³; ¹Institute of Radiation Hygiene after Prof. P.V. Ramzaev, St. Petersburg, RUSSIAN FEDERATION, ²Federal Almazov North-West Medical Research Centre, St. Petersburg, RUSSIAN FEDERATION, ³Scane University Hospital, Malmö, SWEDEN.



**EP-0056****Effects of Nanoparticle and Radiation Doses on Red Blood Cells**

J. Lee¹, M. Hur¹, S. Yang¹, K.-H. Yu², J. Park¹; ¹Korea Atomic Energy Research Institute, Jeongseup, KOREA, REPUBLIC OF, ²Department of Chemistry, Dongguk University-Seoul, Seoul, KOREA, REPUBLIC OF.

EP-0057**Patient release after Lu-177 DOTATATE and Lu-177 PSMA 617 therapies**

C. Mair, B. Warwitz, S. Buxbaum, I. J. Virgolini; LKH Universitätsklinik Innsbruck, Univ.-Klinik für Nuklearmedizin, Innsbruck, AUSTRIA.

EP-0058**Radiation dose rates of post Y90 therapy patients - Is it safe to nurse or visit them?**

M. Tong, H. Cheng, J. M. Lara; National University Hospital, Singapore, SINGAPORE.

EP-0059**Justification of New Radiofarmaceuticals and Methods in Nuclear Medicine**

A. Andersen, Sr.; Norwegian Radiation Protection Authority, Østerås, NORWAY.

EP-05 during congress opening hours, e-Poster Area**Physics & Instrumentation & Data Analysis: Quality Control, Performance and Standardisation****EP-0060****Optimizing Administered Ga-68-DOTATOC Activity for PET Imaging**

D. Koopman^{1,2}, W. A. Noortman^{1,2}, P. L. Jager¹, N. Schreuder³, C. H. Slump², J. A. van Dalen⁴; ¹Isala, Department of Nuclear Medicine, Zwolle, NETHERLANDS, ²MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, NETHERLANDS, ³GE Healthcare Radiofarmacy, Zwolle, NETHERLANDS, ⁴Isala, Department of Medical Physics, Zwolle, NETHERLANDS.

EP-0061**Optimisation of Scintigraphic Imaging of the Novel Therapeutic Agent Ra223 in the Treatment of Metastatic Castration Resistant Prostate Cancer**

S. Maguire, P. Gilligan, M. Carson; Mater Private Hospital, Dublin 7, IRELAND.

EP-0062**Pre-Clinical Assessment of the 99mTc-DMSA Renal Scintigraphy Using HiReSPECT; A Small-Animal SPECT System**

K. Tanha, H. Fatemikia, M. Seyedabadi, M. Assadi; The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF.

EP-0063**Matching and Optimisation of CT Protocols Using Automatic Exposure Control in PET/CT**

S. Gould, J. Mackewn, S. Chicklore, G. Cook, L. Pike; King's College London & Guy's and St Thomas' PET Centre, London, UNITED KINGDOM.

EP-0064**Evaluation of Parameters of Radioisotope Studies to Reduce the Radiation Exposure to the Patient in the Diagnosis of Bone Metastases**

I. Tleulessova^{1,2}, A. Saduakassova^{1,2}; ¹Medical Center Hospital of President's Affairs Administration of the Republic of Kazakhstan, Astana, KAZAKHSTAN, ²National Laboratory Astana, Astana, KAZAKHSTAN.

EP-0065**Intensity Quantisation Effects in Texture-based Tumor Heterogeneity in FDG-PET**

A. Forgacs^{1,2}, L. Balkay², I. Garai¹, M. L. Lassen³, T. Beyer³, M. D. DiFranco³; ¹Scanomed Nuclear Medicine Center, Debrecen, HUNGARY, ²Division of Nuclear Medicine, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY, ³Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA.

EP-0066**An Assessment of Quantitative Analysis Software in Nuclear Medicine Gastric Emptying Studies**

S. Maguire¹, P. Gilligan¹, S. Ross², H. McKeown¹; ¹Mater Private Hospital, Dublin 7, IRELAND, ²Dublin Institute of Technology, Dublin 8, IRELAND.

EP-0067**Audit of Radionuclide Injection Administered Activity for VQ imaging with Tc-99m MAA**

L. M. Perry, R. T. Meades, M. Vartzokas, Z. Win, K. S. Nijran; Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EP-0068**Influence of multiple lesions in the detection of Sentinel lymph nodes**

R. Ringler, K. Gmey, K. Schuller, P. Hammer, L. Bluemlein, M. Stich; Technische Hochschule Amberg-Weiden, Weiden, GERMANY.

EP-0069

Investigation of the axial sampling rate of helical mode multi-pinhole SPECT dedicated for human brain imaging with a Multi-Disk phantom

A. Forgacs, Á. Krizsán, I. Garai, S. Szabó; Scanomed Ltd, Debrecen, HUNGARY.

EP-0070

Comparison of estimated and measured pixel variance in Whole Body PET affecting uncertainty

Á. K. Krizsán¹, G. Nagy², M. Székely³, I. Garai¹, M. Dahlbom³, L. Balkay²; ¹Scanomed Nuclear Medicine Centers, Debrecen, HUNGARY, ²Department of Nuclear Medicine, University of Debrecen, Debrecen, HUNGARY, ³Ahmad Z. Elmaghrabi Translational Imaging Division, David Geffen School of Medicine, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0071

Robustness and reproducibility PET image radiomic features: the impact of delineation and segmentation

I. Shiri¹, A. Rahmim^{2,3}, H. Abdollahi¹, P. Geramifar⁴, A. Bitarafan-Rajabi^{1,5}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ³Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ⁴Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-06 during congress opening hours, e-Poster Area

Physics & Instrumentation & Data Analysis: Miscellaneous

EP-0072

Comparison of estimated and measured isotope specific spatially variant point spread functions on the HRRT PET scanner

J. M. Anton Rodriguez¹, G. Krokos¹, M. Asselin¹, F. Kotasidis², P. Julyan³, A. Archer¹, O. Morris¹, J. C. Matthews¹; ¹Wolfson Molecular Imaging Centre-University of Manchester, Manchester, UNITED KINGDOM, ²Geneva University Hospital Faculty of Medicine, Geneva, SWITZERLAND, ³Christie NHS Foundation, Manchester, UNITED KINGDOM.

EP-0073

Computational 3D Preoperative Simulation As Useful Tool For Sentinel Lymph Node Detection In Breast Carcinoma Surgery

M. Matovic¹, D. Nikolic², N. Filipovic², M. Jeremic¹, S. Jankovic³, S. Ninkovic⁴, A. Cvetkovic⁵, M. Vljakovic⁶; ¹Dpt. of Nuclear Medicine Clinical Center Kragujevac, Kragujevac, SERBIA, ²University of Kragujevac Faculty of Engineering, Kragujevac, SERBIA, ³Dpt. of Clinical Pharmacology Clinical Center Kragujevac, Kragujevac, SERBIA, ⁴Dpt. of Surgery Clinical Center Kragujevac, Kragujevac, SERBIA, ⁵Dpt. of surgery Clinical Center Kragujevac, Kragujevac, SERBIA, ⁶Dpt. of Nuclear Medicine Clinical Center Nis, Kragujevac, SERBIA.

EP-0074

Monte Carlo simulation of ⁹⁰Y PET imaging requires the modelling of internal bremsstrahlung and electron energy resolution tail

S. Walrand, M. Baudouin, Université Catholique de Louvain, Brussels, BELGIUM.

EP-0075

Modelization of trues over prompts events ratio to optimize individual posology on a high-sensitive BGO PET/CT system

D. Vallot, M. Bauriaud, S. Brillouet, L. Dierickx, S. Kanoun, S. Zerdoud, F. Courbon, O. Caselles; Institut Universitaire du Cancer de Toulouse, Toulouse, FRANCE.

EP-0076

Comparison of SUVmax obtained by Non-Time of flight PET system with Time of flight PET system: a phantom based study

A. K. Jha, S. Mithun, A. D. Puranik, N. C. Purandare, S. Shah, A. Agrawal, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

EP-0077

Yield estimation for ^{62,63}Zn via proton induced reactions using GEANT4

M. Rostampour¹, M. Aboudzadeh², M. Sadeghi², S. Hamidi¹, S. Hosseini³; ¹Department of Physics, Arak University, Arak, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Payame Noor University, Tehran, IRAN, ISLAMIC REPUBLIC OF.



**EP-0078****Validation of the GAMOS Monte-Carlo Toolkit for Nuclear Medicine Dosimetry**

P. Ritt¹, K. Reuss¹, J. C. Sanders^{1,2}, N. Lanconelli³, M. Pacilio⁴, T. Kuwert¹; ¹University Hospital Erlangen, Erlangen, GERMANY, ²Pattern Recognition Lab, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, GERMANY, ³Department of Physics and Astronomy, Alma Mater Studiorum, University of Bologna, Bologna, ITALY, ⁴Department of Medical Physics, Azienda Ospedaliera S. Camillo Forlanini, Rome, ITALY.

EP-0079**Partial volume correction changes intra-tumoral heterogeneity in 18F-FDG PET**

I. Shiri¹, A. Rahmim^{2,3}, G. Hajianfar⁴, H. Abdollahi¹, P. Geramifar⁴, P. Ghafarian^{5,6}, A. Bitarafan-Rajabi^{1,7}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ³Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ⁴Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁶PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁷Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0080**Relationship between intra-tumoral heterogeneity indices and metabolic parameters in 18F-FDG PET**

I. Shiri¹, H. Abdollahi¹, P. Geramifar², A. Bitarafan-Rajabi^{1,3}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-07 during congress opening hours, e-Poster Area**Molecular & Multimodality Imaging: PET/CT****EP-0081****The role of 18F-FDG PET-CT in patients with fever of unknown origin**

I. Kostadinova¹, A. Demirev¹, M. Baimakova²; ¹Clinic of nuclear medicine, City Clinic Oncology, Sofia, BULGARIA, ²Military Medical Academy, Sofia, BULGARIA.

EP-0082**Thoracic duct lesion: Detection by ¹²⁴I-heptadecanoic acid PET/CT**

H. Petersen, S. Inglev, P. Braad, S. Hvidsten, P. Høilund-Carlson, J. A. Simonsen; Department of Nuclear Medicine, Odense University hospital, Odense, DENMARK.

EP-0083**The value of dual-time FDG PET/CT for differentiating primary lung cancer from inflammatory nodules with an initial standard uptake value greater than 2.5 in a tuberculosis-endemic area, A preliminary retrospective study**

J. wang¹, J. J. wang¹, C. Y. Pu¹, J. G. Yang²; ¹Chinese Armed force police General Hospital, Beijing, CHINA, ²Beijing Friendship Hospital affiliated to Capital Medical University, Beijing, CHINA.

EP-0084**Uptake patterns and peculiarities of metabolic tumor pointers on initial staging FDG PET/CT in patients with untreated primary gastrointestinal extranodal lymphomas**

E. Alagoz¹, K. Okuyucu¹, S. Ince¹, S. Ozaydin², N. Arslan¹; ¹Gülhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey, Ankara, TURKEY, ²Gülhane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey, Ankara, TURKEY.

EP-0085**Correlation of lymph node size with PSMA expression & SUVmax values on Ga-68 PSMA PET/CT imaging**

B. Sönmezer¹, E. Acar¹, E. Erkoynun², G. Çapa Kaya¹; ¹Dokuz Eylül University, Faculty of Medicine, Department of Nuclear Medicine, İzmir, TURKEY, ²Dokuz Eylül University, Faculty of Medicine, Department of Public Health, İzmir, TURKEY.

EP-0086**18FDG PET-CT for Characterization of Adrenal Lesions in Cancer Patients**

A. Tzonevska, M. Garcheva, I. Kostadinova; Acibadem City Clinic, Sofia, BULGARIA.

EP-0087**Ratio of mediastinal lymph node to primary tumor FDG uptake improves prediction of nodal metastases in lung cancer**

F. Al-Lhedan, R. Klein, J. Gardner, L. S. Zuckier, W. Zeng; The Ottawa Hospital, Ottawa, ON, CANADA.

EP-0088**Artifacts and physiologic soft tissue activities on NaF PET/CT bone images**

I. Sarikaya¹, A. Elgazzar¹, M. Alfeeli², A. Sarikaya³; ¹Kuwait University Faculty of Medicine, Kuwait, KUWAIT, ²Mubarak Al Kabeer Hospital, Kuwait, KUWAIT, ³Trakya University Faculty of Medicine, Edirne, TURKEY.

EP-0089**Normal tissue 18-FDG activities are similar after either 60 or 90 minute uptake**

D. W. Ap Emyr¹, P. A. Fielding¹, C. Marshall², N. C. D. Morley²; ¹Cardiff and Vale University Health Board, Cardiff, UNITED KINGDOM, ²Cardiff University, Cardiff, UNITED KINGDOM.

EP-0090**Irisin, an exercise-induced hormone, targets glioblastoma tumor in vivo PET/CT imaging may serve as a novel theranostic agent**

Y. Lin¹, H. Chiu¹, W. Chang¹, Y. Lin¹, Y. Chung¹, T. Yen¹, F. Huang², C. Huang¹; ¹Chang Gung Memorial Hospital, Taoyuan, TAIWAN, ²National Taiwan University, Taipei, TAIWAN.

EP-0091**Somatostatin receptor PET/CT imaging in patients with sarcoidosis - preliminary report**

J. Kunikowska¹, D. Pawlak², L. Królicki¹; ¹Nuclear Medicine Department, Medical University of Warsaw, Warszawa, POLAND, ²National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND.

EP-0092**Liver-spleen axis: hepatic and splenic metabolic activities are linked**

G. Keramida¹, A. Dunford², C. D. Anagnostopoulos³, A. M. Peters⁴; ¹Royal Brompton and Harefield Hospitals, NHS, FT, London, UNITED KINGDOM, ²Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM, ³Biomedical Research Foundation Academy, Athens, GREECE, ⁴Brighton and Sussex University Hospitals NHS Trust, Clinical Imaging Sciences centre, Brighton Sussex medical School, Brighton, UNITED KINGDOM.

EP-0093**Towards Diagnostic Reference Levels in PET-CT in Finland**

J. Liukkonen, S. P. Kajaluoto, P. M. Toroi, R. Bly; STUK - Radiation and Nuclear Safety Authority in Finland, Helsinki, FINLAND.

EP-0094**Motion correction during dynamic FDG-PET/CT studies performed in the staging of breast cancer**

T. Tokes¹, K. Kajáry², M. Dank¹, Z. Lengyel²; ¹Semmelweis University Center of Oncology, Budapest, HUNGARY, ²Pozitron PET/CT Center, Budapest, HUNGARY.

EP-0095**Mismatch Between 68Ga-PSMA-HBED-CC PET/CT And mpMRI In Prostate Cancer Lesion Detection: Relation With Gleason Score, PSA Kinetics And Previous Therapy**

G. Ferreira, I. Lucena Sampaio, L. Sobral Violante, J. Teixeira, H. Duarte; Instituto Português de Oncologia Francisco Gentil, Porto, PORTUGAL.

EP-0096**Measurement of urinary radiation dose of PET patient by using Compton camera**

D. Kano¹, R. Enomoto², S. Hosokawa³, R. Wakamatsu⁴, T. Watanabe⁵, Y. Nakagami¹, M. Yamaguchi¹; ¹National Cancer Center Hospital East, Kashiwa, JAPAN, ²ICRR, University of Tokyo, Kashiwa, JAPAN, ³University of Hirosaki, Hirosaki, JAPAN, ⁴College of Science, Ibaraki University, Ibaraki, JAPAN, ⁵Tokyo Metropolitan University, Tokyo, JAPAN.

EP-0097**Effects of iMAR on CT and PET reconstructions in patients with metal hip implants**

P. Holdgaard¹, L. Grønnemark¹, N. Bebbington²; ¹Sygehus Lillebælt, Vejle, DENMARK, ²Siemens Healthineers, Århus, DENMARK.

EP-0098**[18F] - NaF positron emission tomography assessed microcalcifications in symptomatic and asymptomatic human carotid plaques**

H. Hop¹, S. A. de Boer¹, M. Reijrink¹, D. J. Mulder¹, P. W. Kamphuisen¹, M. H. de Borst¹, R. A. Pol¹, C. J. Zeebregts¹, J. L. Hillebrands¹, J. Doorduyn¹, H. H. Boersma¹, R. H. J. A. Slart^{1,2}; ¹University Medical Center Groningen, Groningen, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS.



EP-0099**FDG-PET/CT for evaluation of inflammation in the lumbar spine following surgery for lumbar disc herniation**

C. C. Støttrup^{1,2}, M. Zadeh³, C. Constantinescu⁴, S. O'Neill¹, M. Ø. Andersen^{1,2}, A. Alavi³, P. Høiland-Carlsen^{4,2}; ¹Lillebaelt Hospital, Middelfart, DENMARK, ²University of Southern Denmark, Odense, DENMARK, ³University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ⁴Odense University Hospital, Odense, DENMARK.

EP-0100**Diagnostic performance of ¹⁸F-FDG PET/CT semiquantitative analysis in the management of sarcoidosis**

C. Altini, A. Niccoli Asabella, C. Ferrari, A. Cimino, C. Magarelli, E. P. Mossa, M. Fanelli, G. Rubini; Nuclear Medicine Unit, DIM, University of Bari "Aldo Moro", Bari, ITALY.

EP-0101**Comparisons of cerebral glucose metabolism and striatal DAT binding in PD patients with and without RBD**

Q. Xu, P. Wu, C. Jiang, H. Yu, J. Wu, C. Zuo; Huashan Hospital of Fudan University, Shanghai, CHINA.

EP-0102**Quantification and Reduction of respiratory induced errors in attenuation correction of PET data using respiration averaged CT: a simulation study**

P. Ghaffarian^{1,2}, F. Fatemi³, P. Geramifar⁴, M. Ay^{3,5}; ¹PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Chronic Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0103**Is the incremental diagnostic value of Mammi PET higher than MRI on detection and characterization of breast lesions with equivocal conventional imaging modalities?**

L. Pan, M. Sun; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0104**The diagnostic performance of a dedicated breast PET (MAMMI) in patients with small and dense breasts in China**

L. Pan, M. Sun; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0105**FDG uptake in a dedicated breast PET (MAMMI): correlation with histopathological prognostic factors**

L. Pan, M. Sun; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0106**Contribution of ¹⁸F-FDG PET/CT to conventional imaging techniques in the suspicion of recurrence in patients with uterine cervical cancer: preliminary results**

P. Garcia - Talavera¹, F. Gómez-Camínero¹, C. A. Achury¹, L. G. Diaz¹, M. J. Doyague², P. Soria³, J. Corredera², B. Pérez¹, P. Tamayo¹; ¹Nuclear Medicine Department. Hospital Universitario de Salamanca, Salamanca, SPAIN, ²Gynecology and Obstetrics Department. Hospital Universitario de Salamanca, Salamanca, SPAIN, ³Radiotherapy Department. Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0107**Combined model-based and patient-specific dosimetry for ¹⁸F-DCFPyL, a PSMA-targeted PET agent**

R. F. Hobbs, D. Plyku, E. Mena, S. P. Rowe, Z. Szabo, S. Y. Cho, M. G. Pomper, G. Sgouros; Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0108**Determinants of C-X-C motif chemokine receptor CXCR4 Expression after myocardial infarction with [68Ga]Pentixafor-PET/CT in correlation with cardiac MRI**

M. Kircher, T. Reiter, A. Schirbel, S. Kropf, R. Werner, G. Ertl, A. Buck, H. Wester, W. Bauer, C. Lapa; Uniklinikum Würzburg, Würzburg, GERMANY.



e-poster not submitted

EP-0109**Development of low dose CT protocols with acceptable CT image quality for CTAC of PET data: Phantom Study**

Z. Mojabi^{1,2}, P. Ghafarian^{3,4}, H. Ghadiri^{1,2}, M. Bakhshayeshkaram^{3,4}, M. Ay^{1,2}; ¹Department of Medical Physics & Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0110**The relationship between Ga-68 PSMA accumulation intensity and Gleason score, PSA levels in primary staging and evaluation of biochemical recurrence of prostate cancer: The preliminary results**

G. Ege Aktas, 22030¹, V. Çaloglu², N. Can³, H. Akdere⁴, F. Ustun¹, G. Durmus Altun¹; ¹Trakya University Medical Faculty Department of Nuclear Medicine, Edirne, TURKEY, ²Trakya University Medical Faculty Department of Radiation Oncology, Edirne, TURKEY, ³Trakya University Medical Faculty Department of Pathology, Edirne, TURKEY, ⁴Trakya University Medical Faculty Department of Urology, Edirne, TURKEY.

EP-0111**Application of F-18-Sodium Fluoride (NaF) dynamic PET-CT (dPET-CT) for defect healing: comparison of biomaterials in an experimental osteoporotic rat model**

C. Cheng¹, V. Alt², L. Pan¹, U. Thormann², R. Schnettler³, A. Dimitrakopoulou-Strauss¹; ¹DKFZ, Heidelberg, GERMANY, ²University Hospital Giessen-Marburg GmbH, Giessen, GERMANY, ³University Hospital Giessen-Marburg GmbH, giessen, GERMANY.

EP-0112**Correlation between FDG uptake in the lung and pulmonary function in sarcoidosis patients treated with infliximab**

M. Schwillens-Dirkx, M. Vredenduin, D. Hartmans, R. Keijsers; Sint Antonius Hospital, Nieuwegein, NETHERLANDS.

EP-0113**The value of SUVmax is related to major chemotherapy-related tumor markers expression and serum tumor markers in gastric adenocarcinoma patients**

X. Duan; the Affiliated Hospital of Xi'an Jiaotong University, CHINA.

EP-0114**Adrenal Glands Uptake Patterns in 18F-Fluoroethylcholine PET/CT**

E. J. Bialek^{1,2}, P. Kwasiborski³, M. Dziuk^{1,2}, A. Mazurek^{1,2}, E. Witkowska-Patena², A. Giżewska^{1,2}, S. Piszczek^{1,2}, S. Osiecki²; ¹Affidea Mazovian PET/CT Centre, Warsaw, POLAND, ²Department of Nuclear Medicine, Military Institute of Medicine, Warsaw, POLAND, ³Angiology and Hemodynamics Laboratory, Regional Specialist Hospital in Miedzylesie, Warsaw, POLAND.

EP-0115**Fluorodeoxyglucose-positron emission tomography disease activity assessment in patients with biopsy-proven giant cell arteritis**

M. Simó¹, I. NAVALES², J. MESTRES¹, F. MARTINEZ¹, R. SOLANS¹, M. SALCEDO¹, M. BARIOS², M. BORONAT², J. CASTELL¹; ¹HOSPITAL UNIVERSITARI VALL DE HEBRON, BARCELONA, SPAIN, ²UNITAT IDI. HOSPITAL UNIVERSITARI VALL DE HEBRON, BARCELONA, SPAIN.

EP-0116**Automated evaluation of normal uptake in different skeletal parts in 18F-sodium fluoride (NaF) PET/CT using a new convolutional neural network method**

S. Lindgren Belal¹, M. Sadik², R. Kaboteh², O. Enqvist³, J. Ulén⁴, H. Kjölhede⁵, O. Bratt⁵, L. Edenbrandt², E. Trägårdh¹; ¹Department of Translational Medicine, Division of Nuclear Medicine, Lund University, Malmö, SWEDEN, ²Department of Clinical Physiology, Sahlgrenska University Hospital, Göteborg, SWEDEN, ³Department of Signals and Systems, Chalmers University of Technology, Göteborg, SWEDEN, ⁴Eigenvision AB, Malmö, SWEDEN, ⁵Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, SWEDEN.

EP-0117**18FDG-PET/CT clinical impact in patients with pure testicular seminoma and residual retroperitoneal mass post-chemotherapy treatment**

M. Arceluz, 1986, C. Gonzalez, S. Traverso, C. Tinetti, A. Osorio, G. Bruno; Fundación Centro Diagnóstico Nuclear, CABA, ARGENTINA.

e-poster not submitted



EP-0118**Clinical implications of FDG PET/CT in left ventricular assist device (LVAD) infection**

J. M. Sohns^{1,2}, H. Kröhn^{1,2}, J. D. Schmitto¹, A. Schöde¹, A. Haverich¹, F. M. Bengel¹; ¹Hanover Medical School, Hanover, GERMANY, ²*abstract contributed equally, Hanover, GERMANY.

EP-0119**Assessment of Effective Dose estimation in hybrid imaging (PET/CT)**

G. Tosi¹, K. Marzo¹, A. Chiti², F. Zanca³; ¹Humanitas Research Hospital, ROZZANO, ITALY, ²Humanitas University, ROZZANO, ITALY, ³GE Healthcare, BUC, FRANCE.

EP-0120**Impact of Specific Activity of ⁶⁸Ga-PSMA-11 on its accumulations in PSMA-expressing Tumors**

A. Ahad, H. Zhang, A. Sadique, S. Larson, N. Pillarsetty, W. Weber; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0122**Usefulness Of PET-CT In Non-Oncology Pathology: A Review Of Cases Of Patients Diagnosed With Erdheim-Chester Disease**

M. Godoy Bravo, R. Reyes Marles, I. Sime Loayza, L. Frutos Esteban, L. Mohamed Salem, J. Navarro Fernandez, M. Castellon Sanchez, F. Nicolas Ruiz, M. Claver Valderas; Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-0123**18 F FDG PETCT uptake patterns in the diagnosis of vascular graft infection**

J. R. Orozco Cortés¹, H. Bowles², J. Ambrosioni², G. Mestres², M. Hernandez-Meneses², M. Almela², J. Llopis², D. Fuster³, A. Moreno², V. Riambau², F. Lomeña², J. Miró²; Hospital Clinic Endocarditis Study Group; ¹Hospital Clinic Valencia, Valencia, SPAIN, ²Hospital Clinic Barcelona, Barcelona, SPAIN.

EP-0124**Polyostotic Fibrous Dysplasia in McCune-Albright Syndrome Resembling Malignant Bone Dissemination: Pitfalls in PET/CT Interpretation**

G. Horvatic Herceg¹, I. Bracic¹, M. Hrabak Paar², R. Petrovic¹; ¹Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, CROATIA, ²Department of Diagnostic and Interventional Radiology, University Hospital Center Zagreb, Zagreb, CROATIA.

EP-0125**Persistent Pneumothoraces Observed Following Percutaneous Transthoracic Needle Biopsy of Lung Nodules Mandates Vigilance when Interpreting PET-CT Images**

L. S. Zuckier, J. Sommerfeldt, T. L. Miao, A. Gupta; The Ottawa Hospital, Ottawa, ON, CANADA.

EP-0126**FDG-PET/CT in multiple myeloma: dual time point imaging results can predict response to treatment in patients receiving high dose chemotherapy**

B. Oestergaard¹, R. Taghvaei², A. L. Nielsen¹, M. Z. Zirakchian², W. Y. Raynor³, S. T. Asmussen¹, P. Holdgaard³, T. Plesner³, N. Abildgaard¹, A. Alavi², P. F. Hoilund-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ³Vejele Hospital, Vejle, DENMARK.

EP-0127**FDG PET/CT in multiple myeloma: changed FDG uptake in the brain of patients receiving high dose chemotherapy**

B. Oestergaard¹, S. P. Shamir², R. Taghvaei², M. Z. Zirakchian², W. Y. Raynor³, A. L. Nielsen¹, P. Holdgaard³, T. Plesner³, N. Abildgaard¹, A. Alavi², P. F. Hoilund-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ³Vejele Hospital, Vejle, DENMARK.

EP-0128**NaF-PET/CT in multiple myeloma: assessing bone remodeling at baseline in newly diagnosed myeloma patients compared to a healthy control group**

B. Oestergaard¹, M. Z. Zirakchian², W. Y. Raynor³, R. Taghvaei², A. L. Nielsen¹, P. Holdgaard³, J. T. Asmussen¹, T. Plesner³, N. Abildgaard¹, A. Alavi², P. F. Hoilund-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, ³Vejele Hospital, Vejle, DENMARK.



EP-0129**Role of F18-FDG-PET/CT in malignant otitis externa. Preliminary study**

L. Rodríguez-Bel¹, E. Llinares-Tello¹, M. Cortés-Romera¹, J. Robles-Barba¹, X. González-Compta², M. Santín-Cerezales³, S. Castañer-Llanes⁴, A. Sabaté-Llobera¹, L. Gràcia-Sánchez¹, C. Majós-Torro⁴, C. Gámez-Cenzano¹; ¹PET Unit. Department of Nuclear Medicine. IDI., L'Hospitalet de Llobregat. Barcelona, SPAIN, ²Department of Otorhinolaryngology. Hospital U. De Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona, SPAIN, ³Department of Infectious disease. Hospital U. de Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona, SPAIN, ⁴Neuroradiology Unit. Department of Radiology. IDI. Hospital U. de Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona, SPAIN.

EP-0130**Role of ¹⁸F-FDG PET/CT in radiotherapy planning for patients with non-small cell lung cancer**

P. Garcia - Talavera¹, Á. Matías-Pérez², C. Cigarra², F. Gómez-Camín¹, L. A. Pérez-Romasanta², M. E. Martín¹, E. Martín¹, B. Pérez¹, P. Tamayo¹; ¹Nuclear Medicine Department. Hospital Universitario de Salamanca, Salamanca, SPAIN, ²Radiotherapy Department. Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0131**TSPO Brain PET using [¹⁸F]FEPPA in a lipopolysaccharide induced animal model**

W. Huang¹, Y. Huang², Y. Kuo³, C. Shiu^{4,5}, H. Yeh⁶; ¹Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, TAIWAN, ²PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN, ³Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, Taipei, TAIWAN, ⁴PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, TAIWAN, ⁵Molecular Imaging Center, National Taiwan University, Taipei, Taiwan, Taipei, Taiwan, TAIWAN, ⁶Brain Research Center, National Yang-Ming University, Taipei, Taiwan, Taipei, TAIWAN.

EP-0132**Semi-quantitative assessment with PETRA soft-platform of 18F-Florbetaben PET in patients with cognitive impairment**

R. Sánchez-Vañó¹, S. Prado-Wohlwend¹, M. Gómez-Río², F. Segovia-Román³, P. Sopena Novales¹, J. M. Górriz-Sáez³, E. Uruburu-García¹, M. Martínez-Lozano⁴; ¹Nuclear Medicine Department Hospital Nisa 9 de Octubre, VALENCIA, SPAIN, ²Nuclear Medicine Department University Hospital Virgen de las Nieves, Granada, SPAIN, ³Dept. Signal Theory, Networking and Communications, UGR, Granada, SPAIN, ⁴Memory and Dementia Unit. Hospital La Magdalena., Castellón, SPAIN.

EP-0133**Tumour Primary and possible Pitfalls in Paediatric PET/CT**

A. A. Nawwar¹, M. Abou Gabal¹, A. Tawakol¹, W. Omar², H. Mostafa¹; ¹Faculty of Medicine, Cairo University, Cairo, EGYPT, ²National Cancer Institute, Cairo University, Cairo, EGYPT.

EP-0134**Radio-metabolomics: association between CT radiomics features and metabolic indices in 18F-FDG PET**

I. Shiri¹, H. Abdollahi¹, P. Geramifar², A. Bitarafan-Rajabi^{1,3}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-08 during congress opening hours, e-Poster Area**Molecular & Multimodality Imaging: SPECT & SPECT/CT****EP-0135****The influence of gene polymorphism, *cetp1a1*, *cetp1405v*, *abca1*, in the influence of myocardium ischemia with spect imaging, in patients with familial hypercholesterolemia**

A. Iakovidou, F^{1,2}, V. Kolovou^{1,2}, A. Theodorakos^{1,2}, D. Degiannis^{1,2}, M. Koutelou^{1,2}, G. Kolovou²; ¹Onassis Cardiosurgery Center, Athens, GREECE, ²Nuclear Medicine Department Cardiology Department, Onassis Cardiac Surgery Center, Athens, GREECE.



**EP-0136****Gastric & Intestinal Scintigraphy in Adhesive Small Bowel Obstruction**

N. Kudryashova, P. Yartsev, A. Lebedev, E. Migunova, O. Sinyakova, I. Selina, E. Trofimova; Sklifosovsky Research Institute for Emergency Medicine, Moscow, RUSSIAN FEDERATION.

EP-0137**Diagnosis of Urinary Leakage with Scintigraphy**

E. Migunova, A. Pinchuk, B. Khubutia, N. Kudryashova, O. Sinyakova; Sklifosovsky Research Institute for Emergency Medicine, Moscow, RUSSIAN FEDERATION.

EP-0138**LM/SL with SPECT/CT in cervical cancer : A Systematic Review of the Literature Data**

T. Z. Belhocine¹, M. Prefontaine²; ¹Biomedical Imaging Research Centre (BIRC), Western University - London, ON, CANADA, ²London Health Sciences Centre (LHSC), Western University - London, ON, CANADA.

EP-0139**Added value of SPECT/CT over planar bone scintigraphy in the diagnosis and management of patients with breast or prostate cancer**

A. Gafita¹, M. Mereuta¹, G. Andries^{1,2}; ¹Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, ROMANIA, ²Department of Nuclear Medicine, County Emergency Clinical Hospital, Cluj-Napoca, ROMANIA.

EP-0140**An incidentally detected breast cancer on ^{99m}Tc-MIBI SPECT/CT parathyroid imaging**

T. Costa, A. Sanches, C. Cruz, A. Pepe, D. Solano; Hospital Português, Salvador-BA, BRAZIL.

EP-0141**Usefulness of SPECT/CT with ^{99m}Tc-Methylene Diphosphonate Bone Scintigraphy in Patients with Chest Wall Pain**

S. Park¹, J. Hwang¹, J. Park², J. Hwang²; ¹Soonchunhyang University Hospital, Seoul, KOREA, REPUBLIC OF, ²Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF.

EP-0142**Optimisation of acquisition duration in extremities SPECT/CT**

A. C. A. Gomes Moura, A. Nunes, A. Eccles, F. Hassan, D. Dasgupta; Guy's and St Thomas NHS Foundation Trust, London, UNITED KINGDOM.

EP-0143**Complex radionuclide evaluation of response to cardiac resynchronization therapy**

V. Saushkin, K. Zavadovsky, I. Kostina, D. Lebedev, S. Popov; Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION.

EP-0144**Rare paraganglioma localizations caught by MRI and CT hybrid 123I-MIBG SPECT imaging.**

M. Pontico, G. Follacchio, V. Frantellizzi, L. Cosma, M. Ricci, M. Liberatore, F. Monteleone, G. DeVincentis; Università di Roma Sapienza, Rome, ITALY.

EP-0145**Saglikler Syndrome in A patient with Secondary Hyperparathyroidism and Chronic Renal Insufficiency: A Case Report**

S. shakeri, S. Zarepour, M. Moghadam, N. Ayati; Mashhad university of medical science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0146**Comparison of reporting outcomes for Simultaneous and Sequential perfusion SPECT in VQ SPECT/CT**

C. Sibley-Allen, H. Ahmed, S. Johnson, D. Dasgupta; Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

EP-0147**Manual fused single photon emission tomography/computed tomography in 123I-MIBG scintigraphy: a 13 years' experience**

M. F. Villani, M. Pizzoferro, A. Castellano, M. Longo, A. Serra, E. Villanucci, M. C. Garganese; Bambino Gesù' Children's Hospital, Rome, ITALY.

EP-0148**The usefulness of SPECT/CT and neck pinhole SPECT (P-SPECT) as complementary tools to planar parathyroid scintigraphy in hyperparathyroidism (HPT)**

A. Spanu, S. Sanna, S. Galassi, M. Stazza, B. Piras, F. Chessa, A. Falchi, S. Nuvoli, G. Madeddu; University of Sassari, SASSARI, ITALY.

EP-0149**Diagnostic Value of Quantitative ^{99m}Tc-DPD-SPECT/CT for the detection of prosthetic loosening in patients with hip- and knee joint replacement**

M. Braun¹, M. Cachovan², G. Pagenstert¹, A. H. Vija², D. Wild¹, M. Kretschmar¹; ¹University Hospital Basel, Basel, SWITZERLAND, ²Siemens Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY.

EP-0150**Value of hybrid imaging in the detection of bone abnormalities in brucellosis**

O. Ben Hamida, F. Hamza, I. Jardak, W. Amouri, M. Maaloul, F. Kallel, S. Charfeddine, K. Chtourou, F. Guermazi; Habib Bourguiba Hospital, Sfax, TUNISIA.

EP-0151**Concordance Among SPECT-CT, Peroperative Gamma probe Sentinel Localisation and Patent Blue Dye Technique for mapping hidden Sentinel nodes in Early Stage Breast Cancer patients**

M. Siddique, A. Hassan, H. Bashir, M. K. Nawaz, A. I. Khan; Shaukat Khanum Memorial Cancer Hospital and Research Centre., Lahore, PAKISTAN.

EP-0152**Challenges of low count in vivo imaging**

S. T. van Tiel, E. J. Meester, J. de Swart, G. N. Doeswijk, L. Utomo, M. de Jong, M. R. Bensen; ErasmusMC, Rotterdam, NETHERLANDS.

EP-0153**Usefulness of examining hepatic functional volumetry with Tc-99m galactosyl serum albumin (GSA) using SPECT/CT in patients with liver disease**

K. Maruyama, K. Utsunomiya, N. Kan, Y. Kono, Y. Ueno, N. Tanigawa; Kansai Medical University, Hirakata, JAPAN.

EP-0154**SPECT/CT mapping of sentinel lymph nodes in patients with breast cancer**

P. Krzhivitsky, S. Kanaev, S. Novikov, P. Krivorotko, N. Popova; Petrov research oncology institute, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0155**Dual tracer SPECT/CT utility in the localization and exclusion of diagnostic lymph nodes spots**

J. L. Pou, Sr., A. Armerigo, R. Balbuena; DIAGNOSTICO MAIPU, Buenos Aires, ARGENTINA.

EP-0156**Interobserver decreased variability in SPECT/CT fusion technique**

J. L. Pou, A. Armerigo, R. Balbuena; DIAGNOSTICO MAIPU, Buenos Aires, ARGENTINA.

EP-0157**No added diagnostic value of contrast-enhanced CT versus low-dose CT in dual phase MIBI parathyroid SPECT/CT**

T. B. Andersen¹, R. Aleksyniene¹, S. K. Boldsen¹, M. Gade², H. C. Bertelsen¹, L. J. Petersen¹; ¹Aalborg University Hospital, Aalborg, DENMARK, ²Aalborg University, Aalborg, DENMARK.

EP-0158**Collagen-based scaffolds and Non-Invasive SPECT/CT Bone Defect Pre-Clinical Imaging**

E. Fragogeorgi, III¹, M. Rouchota², J. Daich³, M. Georgiou², P. Bouziotis¹, G. Loudos^{1,4}; ¹National Center for Scientific Research, Aghia-Paraskevi, GREECE, ²BioEmission Technology Solutions, Athens, GREECE, ³Bioimag Soluciones de Contraste, S.L., Caceres, SPAIN, ⁴Technological Educational Institute of Athens, Department of Biomedical Engineering, Egaleo-Athens, GREECE.

EP-0159**Additional Value of SPECT-CT Versus SPECT in Progressive Necrotizing External Otitis Management**

L. ZAABAR, D. BEN SELLEM, B. LETAEIF, M. BEN SLIMENE; Salah Azaeiz Institute, Ezzahra, TUNISIA.

EP-0160**SPECT CT in patients with non-specific hand and wrist pain**

O. Ben Hamida¹, W. Amouri¹, F. Hamza¹, Y. Hentati², I. Jardak¹, F. Kallel¹, S. Charfeddine¹, Z. Mni², F. Guermazi¹; ¹Habib Bourguiba Hospital, Sfax, TUNISIA, ²Hedi Chaker Hospital, Sfax, TUNISIA.

EP-0161**The Value of Somatostatin Receptor Imaging (SRI) in Patients with Broncho-Pulmonary Carcinoids (BPCs) including Large Cell NEC Base on Pathological and Clinical Follow-up**

S. J. Konsek¹, M. Franecka¹, M. Lowczak¹, A. Kolasinska-Cwikla², A. Lewczuk³, M. Kidd⁴, A. Nasierowska-Guttmejer⁵, M. Tenderenda², J. B. Cwikla¹, I. M. Modlin⁶; ¹Faculty of Medical Sciences, University of Warmia and Mazury, Warszawska 30, Olsztyn, POLAND, ²MSC Memorial Cancer Centre and Institute Maria Skłodowska-Curie, Warsaw, POLAND, ³Medical University of Gdansk, Gdansk, POLAND, ⁴Wren Laboratories, Branford, CT, UNITED STATES OF AMERICA, ⁵Hospital Ministry of Internal Affairs, Warsaw, POLAND, ⁶Yale University, New Haven, CT, UNITED STATES OF AMERICA.



EP-0173**Impact of MR-based attenuation correction on the evaluation of time-activity-curves and time-to-peak analysis in F-18 FET PET/MRI**

I. Rausch¹, A. Ziterl¹, A. Haug¹, R. Aghamohammadi-Sareshgi¹, M. Fenchel², M. E. Mayerhoefer¹, T. Beyer¹, T. Traub-Weidinger¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²Siemens Healthcare GmbH, Erlangen, GERMANY.

EP-0174**Assessing the impact of different attenuation correction methods on clinical image-derived input functions extracted from 18F-FDG PET/MRI brain data**

I. Rausch¹, L. Shiyam Sundar¹, O. Muzik², L. Rischka¹, A. Hahn¹, R. Lanzenberger¹, M. Hienert¹, E. Klebermass¹, M. Fenchel³, T. Traub-Weidinger¹, T. Beyer¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA, ³Siemens Healthcare GmbH, Erlangen, GERMANY.

EP-0175**An in vivo PET study of a rat fluid-percussion-induced traumatic brain injury model with [¹¹C]PBR28 and [¹⁸F]Flumazenil - A preliminary study**

P. Padmanabhan, Z. Wang, C. Yang, K. K. GHOSH, C. Halldin, B. Z. Gulyás; LKC Medicine, NTU, Singapore, SINGAPORE.

EP-0176**Image fusion analysis of ¹⁸F-Choline-PET-CT and MRI in patients with recurrent or persistent hyperparathyroidism (HPTH)**

J. Kronbichler, J. Röper-Kelmayr, J. Pilz, S. Jäger, M. Hatzl, H. Huber, M. Gabriel; Kepler University Hospital, Linz, AUSTRIA.

EP-0177**Image fusion analysis of ⁶⁸Ga-PSMA-PET-CT and MRI for initial evaluation in suspected prostate carcinoma patients**

J. Kronbichler, J. Röper-Kelmayr, J. Pilz, S. Jäger, M. Hatzl, H. Huber, M. Gabriel; Kepler University Hospital, Linz, AUSTRIA.

EP-0178**Monte Carlo Simulation for Scatter Correction in Brain PET/MRI based on GPU Acceleration**

B. Ma^{1,2}, L. Caldeira^{1,3}, L. Tellmann¹, P. Lohmann¹, J. Scheins¹, E. Kops¹, H. Xu¹, C. Lerche¹, N. J. Shah¹, U. Pietrzyk^{1,3}; ¹Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Jülich GmbH, Jülich, GERMANY, ²Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, CHINA, ³School of Mathematics and Natural Sciences, University of Wuppertal, Wuppertal, GERMANY.

EP-0179**Gadobutrol and ¹⁸F-FDG Do Not Interact When Combined in a Single Syringe for Combined Contrast PET/MRI**

B. Wilk^{1,2}, J. Hicks², F. S. Prato^{1,2}, J. D. Thiessen^{1,2}; ¹University of Western Ontario, London, ON, CANADA, ²Lawson Health Research Institute, London, ON, CANADA.

EP-0180**Feasibility of Multi-Week PET Studies with a Single Injection of ⁸⁹Zr-phosphate on a Clinical PET/MRI**

J. D. Thiessen^{1,2}, J. Sykes¹, L. Keenlside¹, H. Biernaski¹, J. Butler¹, N. Cockburn¹, D. E. Goldhawk^{1,2}, R. T. Thompson^{1,2}, F. S. Prato^{1,2}; ¹Lawson Health Research Institute, London, ON, CANADA, ²Western University, London, ON, CANADA.

EP-0181**PET/MRI technique role in Alzheimer disease**

D. Vieira¹, R. Vardasca^{2,3}, J. M. Tavares¹; ¹INEGI, Faculty of Engineering, University of Porto, Porto, PORTUGAL, ²LABIOMEPI, UISP/LAETA-INEGI, Faculty of Engineering, University of Porto, Porto, PORTUGAL, ³Medical Imaging Research Unit, University of South Wales, Pontypridd, UNITED KINGDOM.

EP-0182**Effect of attenuation and its correction in brain PET/MR imaging: a phantom study**

M. Soret¹, J. Maisonobe¹, M. Khalifé², A. Kas¹; ¹HU Pitié Salpêtrière, Paris, FRANCE, ²Institut du Cerveau et de la Moëlle épinière, Paris, FRANCE.

EP-0183**¹¹C-Choline, multiparametric MR and T2 mapping for the study of prostate cancer with simultaneous PET/MRI**

E. A. Marino^{1,2}, G. Peña¹, R. Isoardi¹, V. Rada¹; ¹FUESMEN, Mendoza, ARGENTINA, ²CNEA(Comision Nacional de Energía Atómica), Mendoza, ARGENTINA.

EP-0184**GE Signa Integrated PET/MR: NEMA NU 2-2007 Performance Characteristics for ⁶⁸Ga PET Imaging**

P. Caribé^{1,2}, M. Koole³, S. Vandenberghe¹, T. Deller⁴; ¹Medical Imaging and Signal Processing – MEDISIP, UZ Ghent; IMEC, Ghent, BELGIUM, ²National Council for Scientific and Technological Development – CNPq, São Paulo, BRAZIL, ³Division of Nuclear Medicine – UZ/KU, Leuven, BELGIUM, ⁴General Electric Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.



EP-0185**Assessment of acute response to bone loading in humans with 18F-NaF PET/MRI: a pilot study**

B. Haddock¹, A. P. Fan², C. Suetta¹, F. Kogan², G. E. Gold^{2,3}; ¹Dep. of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Glostrup, DENMARK, ²Department of Radiology, Stanford University, Stanford, CA, UNITED STATES OF AMERICA, ³Department of Bioengineering, Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-0186**18F-FDG PET/MR imaging in optimizing monitoring and management of patients with sarcoidosis**

D. Jurgilewicz^{1,2}, P. Szumowski^{1,3}, M. Mojsak^{1,2}, B. Kubas^{1,2}, B. Kuklinska⁴, M. Hladunski^{1,2}, A. Amelian^{1,2}, J. Mysliwiec^{1,3}, R. Mroz^{1,4}; ¹Medical University of Bialystok, Bialystok, POLAND, ²Laboratory of Molecular Imaging Medical University of Bialystok, Bialystok, POLAND, ³Nuclear Medicine Department Medical University of Bialystok, Bialystok, POLAND, ⁴Pulmonology Clinic University Hospital of Bialystok, Bialystok, POLAND.

EP-10 during congress opening hours, e-Poster Area**Molecular & Multimodality Imaging: Biology (Benign Disease)****EP-0187****Longitudinal PET studies on bone uptake of F-18-fluoride in healthy mice with respect to age, sex and circadian rhythm**

N. Beindorff¹, V. Dorau¹, K. P. Huang², C. Rosner², O. Schulze², M. Lukas², C. Lange², E. J. Koziol¹, B. Gregor-Mamoudou¹, I. G. Steffen², W. Brenner²; ¹BERIC, Charité - Universitaetsmedizin Berlin, Berlin, GERMANY, ²Department of Nuclear Medicine, Charité - Universitaetsmedizin Berlin, Berlin, GERMANY.

EP-11 during congress opening hours, e-Poster Area**Molecular & Multimodality Imaging: Optical Imaging****EP-0188****In Vitro and In Vivo Bioaffinity Determination of FDG-Conjugated Magnetic Nanoparticles**

V. Yasakci, P. Unak, O. Guldu, V. Tekin; Ege University, Izmir, TURKEY.

EP-0189**The influence of structural alterations on asymmetric cyanine 5 dyes on the photophysical properties and protein conjugation characteristics**

S. J. Spa, A. Hensbergen, S. van der Wal, J. Kuil, T. Buckle, F. W. B. van Leeuwen; Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0190**Optimization of cytotoxic T-cell activation by tracking of dendritic cell migration using reporter gene imaging**

H. Lee¹, H. Lee², Y. Jeon², S. Jeong², S. Lee², J. Lee², B. Ahn²; ¹Dongnam institute of radiological & medical sciences (DIRAMS), Busan, KOREA, REPUBLIC OF, ²Kyungpook National University School of Medicine and Hospital, Daegu, KOREA, REPUBLIC OF.

EP-0191**Evaluation of non-peptidic small molecule targeted imaging and therapeutic agents LHRH receptor expressing tumors**

J. Roy^{1,2}, P. S. LOW²; ¹National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, ²Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA.

EP-0192**Lysine as a versatile platform for the design of multimodal (optical/SPECT or PET) imaging probes**

C. Goze¹, C. Bernhard¹, N. Maindron¹, M. Ipuy¹, D. Lhenry¹, M. Moreau¹, V. Thakare¹, A. Dubois¹, F. Boschetti², F. Denat¹; ¹ICMUB, Dijon, FRANCE, ²Chematech, Dijon, FRANCE.

EP-0193**Pretargeted imaging of peritoneal carcinomatosis using bioorthogonal chemistry**

A. Rondon^{1,2}, N. Ty¹, J. Bequignat¹, M. Quintana¹, A. Briat¹, T. Witkowski¹, B. Bouchon¹, C. Boucheix³, E. Miot-Noirault¹, J. Pouget², J. Chezal¹, I. Navarro-Teulon², E. Moreau¹, F. Degoul¹; ¹INSERM U1240, Clermont-Ferrand, FRANCE, ²INSERM U1194 IRCM, Montpellier, FRANCE, ³INSERM U935, Villejuif, FRANCE.

EP-0194**3D tumor margin demarcation combined with sentinel node resection using the hybrid tracer ICG-^{99m}Tc-nanocolloid**

P. Meershoek^{1,2}, N. S. van den Berg¹, G. H. KleinJan^{1,2}, C. A. H. Lange², B. van der Hiel², R. A. Valdés-Olmos¹, W. M. C. Klop², A. J. M. Balm², F. W. B. van Leeuwen¹; ¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Netherlands Cancer Institute (NKI-AvL), Amsterdam, NETHERLANDS.




EP-12 during congress opening hours, e-Poster Area
**Molecular & Multimodality Imaging:
Miscellaneous**
EP-0195
Utility of combined CT coronary angiography and SPECT myocardial perfusion imaging for the detection of functionally relevant coronary stenoses

P. Mohan, A. Vaidya, U. Kaul, H. Mahajan; Mahajan Imaging, NEW DELHI, INDIA.

EP-0197
Engineered DOTA antibody reporter with infinite affinity for in vivo tracking of lymphocytes

S. Krebs¹, A. Ahad¹, H. Zhang¹, M. G. J. van den Broek¹, S. M. Larson¹, S. Gottschalk², P. Adusumilli¹, A. Jonomarev¹, W. A. Weber¹; ¹Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ²Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, UNITED STATES OF AMERICA.

EP-0198
Development of PET in Europe

A. Stevens; Medical Options, London, UNITED KINGDOM.

EP-0199
Tumor alignment in proton therapy using the onboard functional imaging

H. Lin^{1,2}, H. Chang³, T. Chao^{4,1,2}, Y. Ni^{5,6}, C. Shih⁷, K. Chuang⁶; ¹Medical Physics Research Center, Institute for Radiological Research, Chang Gung University/Chang Gung Memorial Hospital, Taoyuan, TAIWAN, ²Department of Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan, TAIWAN, ³Environmental Protection and Chemistry Section, Kuosheng Nuclear Power Station, Taiwan Power Company, New Taipei, TAIWAN, ⁴Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, TAIWAN, ⁵Health Physics Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, TAIWAN, ⁶Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, TAIWAN, ⁷3D Printing Medical Research Center, China Medical University Hospital, China Medical University, Taichung, TAIWAN.

EP-0200
Development Of Multimodal Mannosylated Dextran For Sentinel Lymph Node Imaging With SPECT/ PET And Optical Imaging

A. Shegani¹, A. Papisavva¹, C. Karachaliou¹, L. Palamaris¹, C. Kiritsis¹, A. Kakalas¹, C. Triantis¹, G. Loudos¹, P. Kyriakidis¹, P. Bouziotis¹, M. Pelecanou², M. Papadimitrakou¹, I. Pirmettis¹; ¹INRASTES, NCSR DEMOKRITOS, ATHENS, GREECE, ²IB-A, NCSR DEMOKRITOS, ATHENS, GREECE.

EP-13 during congress opening hours, e-Poster Area
**Radiopharmaceuticals & Radiochemistry:
Radiopharmaceuticals - PET**
EP-0201
A Total Synthesis of High Optically Pure ¹⁸F-FP-(+)-DTBZ and Its Validation as a PET Imaging Agent for VMAT2

P. Zou, C. Liu, X. Li, J. Tang, C. Zhao, Z. Chen; Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0202
[¹⁸F]Fluoride retention and elution in a SAX microcartridge included in a lab-on-chip for radiopharmaceuticals

L. Fernandez-Maza¹, B. Salvador², A. Corral¹, D. Orta-Castello¹, I. Fernandez-Gomez¹, A. Luque², J. Quero-Rebou²; ¹Centro Nacional de Aceleradores. Universidad de Sevilla. CSIC. Junta de Andalucía, Seville, SPAIN, ²Departamento de Ingenieria Electronica. Escuela Tecnica Superior de Ingenieria. Universidad de Sevilla, Seville, SPAIN.

EP-0203
High yield ¹⁸F-FET production on AllinOne (Trasis) at commercial scale

T. Vergote, M. Otabashi, C. Vriamont, C. Desfours, C. Warnier, J. Morelle, G. Philippart; Trasis SA, Ans, BELGIUM.

EP-0204
PET imaging of Pheochromocytoma with a novel ¹⁸F-FAI labeled exendin-4 analog

D. Pan^{1,2}, Y. Xu¹, Y. Wang¹, Y. Yue¹, L. Wang¹, J. Yan¹, X. Wang¹, R. Yang¹, M. Yang¹; ¹Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, ²Jiangnan University, Wuxi, CHINA.

EP-0205
Influence of Enzyme Inhibitors on FSHR PET Imaging

M. Yang^{1,2}, Y. Xu^{1,2}, D. Pan¹, Y. Wang¹, Y. Yue¹, L. Wang¹, J. Yan¹, X. Wang¹, R. Yang¹; ¹Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, ²Nanjing Medical University, Nanjing, CHINA.

EP-0206
Synthesis Of Novel Copper-64 Labeled Rhodamine: A Potential Pet Myocardial Perfusion Imaging Agent

I. AlJammaz, B. Al-Otaibi, S. Al-Yanbawi, F. Al-Rumayan and S. Okarv; kfsHrc, riYadh, SAUDI ARABIA.

e-Poster not submitted

e-Poster not submitted

EP-0207**A Modified Procedure for the Synthesis of a Potential Tau Imaging Agent [¹⁸F]T807 Employing a Neutral Mobile Phase Containing Acetonitrile and a Buffer for Semi-preparative HPLC Purification**

M. CHEUNG, N. NG, K. LIU, C. HO; HONG KONG SANATORIUM & HOSPITAL, HONG KONG, HONG KONG.

EP-0208**A Modified Procedure for the Synthesis of a Potential Tau Imaging Agent [¹¹C]PBB3**

M. CHEUNG, N. NG, K. LIU, C. HO; HONG KONG SANATORIUM & HOSPITAL, HONG KONG, HONG KONG.

EP-0209**Fully automated ¹⁸F-FAZA production on AllInOne (Trasis) at commercial scale**

T. Vergote, M. Otabashi, C. Vriamont, C. Desfours, J. Morelle, G. Philippart; Trasis SA, Ans, BELGIUM.

EP-0210**Synthesis of Two Neurological PET Tracers, ¹⁸F-FEPPA and ¹⁸F-NAV4694 on a FlexLab Synthesizer**

L. Morandau¹, A. Asad¹, J. Ioppolo¹, S. Poniger^{2,3}, A. Wilson⁴, R. Price^{1,5}; ¹Medical Technology and Physics Dpt, Sir Charles Gairdner Hospital, Nedlands, AUSTRALIA, ²iPHASE technologies Pty Ltd, Melbourne, AUSTRALIA, ³The Austin Hospital, Melbourne, AUSTRALIA, ⁴Centre for Addiction and Mental Health, Toronto, ON, CANADA, ⁵School of Physics, University of Western Australia, Nedlands, AUSTRALIA.

EP-0211**Triphenylphosphonium Modified ¹⁸F-Silica Nanoparticles as Tumor Targeting Agent for PET Imaging**

Y. Kim¹, J. Lee², G. Kim^{2,3}, J. Park², H. J. Jo¹, S. Kim¹; ¹Dongguk university, gyeongju, KOREA, REPUBLIC OF, ²Korea Atomic Energy Research Institute, Jeongseup, KOREA, REPUBLIC OF, ³Dongguk University-Gyeongju, Gyeongju, KOREA, REPUBLIC OF.

EP-0212**[⁶⁸Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors**

S. Migliari, A. Sammartano, B. Pellegrino, V. Regina, D. Cavazzini, S. Ottonello, G. Missale, A. Musolino, L. Ruffini; AOU Pr, Parma, ITALY.

EP-0213**Preparation and preclinical evaluation of ⁶⁴Cu-NOTA-anti MUC1 as a radioimmunoconjugate for diagnosis of MUC1 breast cancer by PET**

B. Alirezapour^{1,2}, M. Davarpanah³, J. Mohammadnejad⁴, A. Jalilian¹, S. Rajabifar¹, E. Maadi³, M. Hashemizadeh³, N. Soltani³, F. Bolourinovin¹, P. Ashtari¹, G. Aslani¹; ¹Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Pars Isotope Company, Teharn, IRAN, ISLAMIC REPUBLIC OF, ³Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0214**Combination of [¹⁸F]F ion into Aromatic Ring Using Pinacol Boran Derivative for the Synthesis of LAT 1 tracer [¹⁸F]FBPA**

S. Naka¹, Y. Kanai¹, Y. Ota², Y. Hattori², H. Takenaka², K. Uehara³, T. Sakai⁴, E. Shimosegawa¹, M. Kirihata², J. Hatazawa¹; ¹Osaka University Graduate School of Medicine, Suita, Osaka, JAPAN, ²Osaka Prefecture University, Sakai, Osaka, JAPAN, ³Stella Pharma, Sakai, Osaka, JAPAN, ⁴Hanwa Intelligent Medical Center, Sakai, Osaka, JAPAN.

EP-0215**Feasibility of radioiodine labeled gold nanoparticle using AS1411 DNA aptamer for targeting of nucleolin-expressing glioma**

M. Kim, K. Kim, S. Woo, T. Lee, K. Lee, J. Kang, Y. Lee; Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.

EP-0216**[¹⁸F] FBPA synthesis from pinacol boran precursor and [¹⁸F] fluoride ion with copper reagent**

Y. Kanai¹, Y. Ohta^{2,3}, Y. Hattori², H. Takenaka³, K. Uehara³, S. Naka¹, T. Sakai⁴, E. Shimosegawa¹, M. Kirihata², J. Hatazawa¹; ¹Osaka University Graduate School of Medicine, Suita, JAPAN, ²Research Center of Boron Neutron Capture Therapy, Osaka Prefecture University, Sakai, JAPAN, ³STELLA PHARMA CORPORATION, Sakai, JAPAN, ⁴Hanwa Intelligent Medical Center, Sakai, JAPAN.

EP-0217**Synthesis and *in vitro* evaluation of ⁶⁸Ga-labeled peptides for metalloproteinase (MT1-MMP/ MMP-14) targeting on HT1080 cells**

C. Liolios, U. Bauder-Wüst, M. Schäfer, K. Kopka; Department of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, GERMANY.



EP-0218**Radiosynthesis of 6-^[18F]Fluoro- α -methyl-L-tryptophan - a prospective tracer for in vivo studies of tryptophan metabolism**

A. Vazquez-Romero¹, E. Revunov¹, R. Krasikova^{1,2}, M. M. Moein¹, S. Cervenka¹, S. Erhardt³, C. Halldin¹, M. Schou^{1,4};
¹Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, SWEDEN, ²Institute of Human Brain of the Russian Academy of Science, St. Petersburg, RUSSIAN FEDERATION, ³Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, SWEDEN, ⁴AstraZeneca PET Science Centre, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN.

EP-0219**Radio-synthesis of ^[18F]NKO028 as a L-type amino acid transporter 1 (LAT 1) PET tracer for cancer diagnosis**

S. Naka¹, Y. Kanai¹, T. Watabe¹, S. Nagamori¹, T. Sakai², H. Kato¹, K. Isohashi¹, M. Tatsumi¹, E. Shimosegawa¹, Y. Kanai¹, J. Hatazawa¹;
¹Osaka University Graduate School of Medicine, Suita, Osaka, JAPAN, ²Hanwa Intelligent Medical Center, Sakai, Osaka, JAPAN.

EP-0220**Minimising residual activities in daily 18F-FDG administrations. Preliminary results**

P. Z. Stavrou, D. Priftakis, K. Kouvelis, M. Papachristou, I. E. Datseris; General Hospital of Athens "Evangelismos", Athens, GREECE.

EP-0221**Ga-68 Labeled Neurotensin Peptide for PET Receptor-targeting Imaging and its first human study**

L. Huo¹, G. Hu¹, L. Wang¹, S. Yao¹, Z. Li², Z. Wu², F. Li¹;
¹Peking Union Medical College Hospital, Beijing, CHINA, ²University of North Carolina at Chapel Hill, North Carolina at Chapel Hill, NC, UNITED STATES OF AMERICA.

EP-0222**Four Runs of ^[18F]FDG on a Single Cassette**

C. Warnier, C. Vriamont, T. Vergote, J. Masset, M. Otabashi, C. Desfours, J. Morelle, G. Philippart; Trasis, Ans, BELGIUM.

EP-0223**Development of novel lipophilic ^[18F]thiosemicarbazone gallium fluoride complexes**

D. H. R. Stimson¹, T. K. Venkatachalam¹, G. K. Pierens¹, P. V. Bernhardt², K. Mardon¹, D. C. Reutens¹, R. Bhalla¹;
¹University of Queensland, Centre for Advanced Imaging, St Lucia, QLD, AUSTRALIA, ²University of Queensland, School of Chemistry and Molecular Biosciences, St Lucia, QLD, AUSTRALIA.

EP-0224**Optimization of C-11 labeled methyl iodide production**

E. V. Nemeth¹, D. Szikra¹, I. Józsa¹, V. Forgács¹, P. Mikecz¹, P. Larsen²;
¹University of Debrecen, Faculty of Medicine, Debrecen, HUNGARY, ²Scansys Laboratorieteknik ApS, Copenhagen, DENMARK.

EP-0225**In-vitro and in-vivo evaluation of 2 enantiomers of Nanocyclix(R) EGFR targeted PET radiotracer**

C. BERTHET^{1,2}, O. RAGUIN^{1,2}, C. MOTHES^{3,2}, P. PROVENT^{1,2}, G. SERIN^{1,2}, X. TIZON¹, A. OUDOT^{4,2}, P. WALKER⁵, J. HOFLACK^{1,2}, G. VIOT^{3,2};
¹ONCODESIGN, DIJON CEDEX, FRANCE, ²Pharmimage, Dijon, FRANCE, ³Cyclopharma, SAINT-BEAUZIRE, FRANCE, ⁴Centre Georges François Leclerc, DIJON, FRANCE, ⁵CHU François Mitterrand, DIJON, FRANCE.

EP-0226**Radiosynthesis of 3/5-^[18F]fluoropyridines by TEMPO-mediated radiofluorination of pyridinyl idonium salts**

M. Pauton¹, C. Aubert², G. Bluet², F. Gruss-Leleu², S. Roy², C. Perrio¹;
¹Normandie Univ, UNICAEN, CEA, CNRS, ISTCT-FRE2001, LDM-TEP, Cyceron, CAEN, FRANCE, ²SANOFI R&D, Vitry sur Seine, FRANCE.

EP-0227**Uptake of the MCHR1 PET-tracers ^[18F]FE@SNAP and ^[11C]SNAP-7941 in BAT: an adrenergic beta-3 receptor mediated effect?**

T. Balber^{1,2}, K. Benčurová¹, M. Mitterhauser^{1,3}, W. Wadsak^{1,4}, H. Viernstein², M. Hacker¹, C. Philippe^{1,2};
¹Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Life Sciences, University of Vienna, Vienna, AUSTRIA, ³Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, ⁴CBmed GmbH, Center for Biomarker Research in Medicine, Graz, AUSTRIA.

EP-0228**Alcohol-supported Cu mediated 18F-fluorination of idonium salts under "minimalist" conditions**

V. V. Orlovskaya¹, O. F. Kuznetsova¹, D. Modemann², O. S. Fedorova¹, B. D. Zlatopolskiy^{2,3,4}, E. A. Urusova^{2,3}, B. Neumaier^{2,3,4}, R. N. Krasikova¹;
¹N.P.Bechtereva Institute of the Human Brain RAS, Saint-Petersburg, RUSSIAN FEDERATION, ²Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum, Jülich, GERMANY, ³Institute of Radiochemistry and Experimental Molecular Imaging University Clinic, Cologne, GERMANY, ⁴Max Planck Institute for Metabolism Research, Cologne, GERMANY.



EP-0229**Microdose Study for Amino Acid Imaging Using D-¹⁸F]FMT PET in Human Brains**

K. Lee¹, B. Byun², B. Kim², I. Lim², C. Choi², S. Youn³, C. Rhee³, S. Chu⁴, C. Park⁴, H. Kil⁴, B. Lee⁴, D. Chi^{4,5}, S. Lim²; ¹KIRAMS, Division of RI-Convergence Research, Seoul, KOREA, REPUBLIC OF, ²KIRAMS, Department of Nuclear Medicine, Seoul, KOREA, REPUBLIC OF, ³KIRAMS, Department of Neurosurgery, Seoul, KOREA, REPUBLIC OF, ⁴FutureChem Co. Ltd., Seoul, KOREA, REPUBLIC OF, ⁵Sogang University, Department of Chemistry, Seoul, KOREA, REPUBLIC OF.

EP-0230**Implementing [¹⁸F]FB-IL2 synthesis in GMP**

J. G. Hessels-Scheper, P. Maarsingh, E. L. van der Veen, I. F. Antunes, R. Zijlma, H. H. Boersma, G. Luurtsema, P. H. Elsinga, E. F. J. de Vries; UMC Groningen, Groningen, NETHERLANDS.

EP-0231**Preparation of [¹⁸F]fluoroalkenyliodonium salts and their application for radiolabeling by Sonogashira coupling reactions**

S. Humpert¹, B. Zlatopolskiy^{2,3}, M. Holschbach¹, B. Neumaier^{1,2,3}; ¹Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Jülich, GERMANY, ²Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Köln, GERMANY, ³Max Planck Institute for Metabolism Research, Cologne, Köln, GERMANY.

EP-0232**Highly Improved and GMP compliant synthesis of [¹¹C]UCB-J: in situ generation of boronic acid precursor**

M. Onega¹, H. Chong¹, A. Roble¹, C. Plisson¹, M. Huiban¹, J. Mercier², M. Vandergeten², J. Passchier¹; ¹Imanova Limited, London, UNITED KINGDOM, ²UCB Biopharma, Braine l'Alleud, BELGIUM.

EP-0234**Optimization of a Novel Automated Loop Method for Production and Development of an Analytical HPLC Method for ¹¹C-PK11195**

K. Kumar, A. Ghosh, K. Woolum, M. V. Knopp; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.

EP-0235**O-TRENTOX, a new chelating agent for ⁶⁸Ga radiopharmaceutical**

J. Leenhardt^{1,2}, M. Desruet^{1,2}, L. Djaileb^{3,2}, A. Jullien¹, C. Ghezzi², P. Bedouch¹, A. Du Moulinet D'Hardemare⁴; ¹Radiopharmacy/pharmacy department, Grenoble Alpes University Hospital (CHUGA), Grenoble 38000, FRANCE, ²INSERM Unit U1039, Radiopharmaceutiques Biocliniques, University of Grenoble Alpes- Faculté de Médecine, Grenoble 38000, FRANCE, ³Department of nuclear medicine, Grenoble Alpes University Hospital (CHUGA), Grenoble 38000, FRANCE, ⁴DCM-Department of Molecular Chemistry, UMR5250, University of Grenoble-Alpes, 301 Rue de la Chimie, BP 53 GRENOBLE cedex 9, FRANCE.

EP-0236**Biodistribution And Micro-TEP Imaging Of ⁶⁸GA-NODAGA-RGD, A New Radiotracer For Tumor Angiogenesis: Human Glioblastoma Xenograft Model In Mice**

S. ISAL¹, A. Clément², J. Pierson², C. Collet², N. Veran², S. Frezier², S. Poussier², G. Karcher¹, P. Marie¹, F. Maskali²; ¹Nuclear Medicine and Nancyclotep imaging platform CHRU Nancy, Nancy, FRANCE, ²Nancyclotep imaging platform, CHRU Nancy, Nancy, FRANCE.

EP-0237**Evaluation Of Nucleophilic Synthesis Of [¹⁸F]-FDOPA HPLC Free On Fastlab Platform**

E. Cazzola¹, A. D'Angelo¹, L. Mora², A. Purgato¹, C. Malizia², D. Peruzzi¹, S. Costa², J. Amico¹, F. Lodi², G. Gorgoni¹; ¹Sacro Cuore Hospital, Negrar, ITALY, ²Sant'Orsola Hospital, Bologna, ITALY.

EP-0238**Synthesis and Biological evaluation of ⁶⁸Ga labeled NOTA-Capsaicin for Targeting Colon Cancer CT-26**

G. Kim^{1,2}, S. Kim², M. Hur¹, S. Yang¹, J. Park¹; ¹korea atomic energy research institute, jeongeup, KOREA, REPUBLIC OF, ²Dongguk University, Gyeongju, KOREA, REPUBLIC OF.

EP-0239**One-pot Synthesis of Surface Modified Gallium Incorporated Zeolitic Imidazole Framework (ZIF-8) as a PET probe**

P. Choi^{1,2}, J. Lee¹, G. Kim¹, S. Kim², J. Park¹; ¹Korea Atomic Energy Research Institute, jeongeup, KOREA, REPUBLIC OF, ²Dongguk University Gyeongju, Gyeongju, KOREA, REPUBLIC OF.



EP-0240

Fully automated one step [¹⁸F]-PSMA-1007 production on AllinOne (Trasis)

A. Fasel¹, M. Otabashi²; ¹ABX advanced biochemical compounds, Radeberg, GERMANY, ²Trasis SA, Liege, BELGIUM.

EP-0241

High activity automated production of Lu-177 radiopharmaceuticals using modular Lab-Eazy system

M. J. Latter¹, S. Taniguchi², J. Kemmann²; ¹Royal Brisbane and Women's Hospital, Herston, AUSTRALIA, ²Eckert and Ziegler, GERMANY.

EP-0242

Fully automated production of [¹⁸F]-LBT999, a dopamine transporter (DAT) radiopharmaceutical, for preclinical and clinical PET studies

C. Vala^{1,2}, C. Mothes^{1,3}, P. Magadur², G. Viot^{1,2}, J. Deloye^{1,2}, R. Bidault^{2,4}, G. Chicheri^{2,4}, Y. Peltier^{2,4}, N. Arlicot^{2,4,5}, D. Guilloteau^{2,4,5}, J. Vercoullie^{2,4,5}; ¹Cyclopharma Laboratories, Saint Beuzire, FRANCE, ²CERRP, Tours, FRANCE, ³Pharm'Image, Dijon, FRANCE, ⁴INSERM U930, Tours, FRANCE, ⁵CHRU Bretonneau, Tours, FRANCE.

EP-0243

Improvement of [¹¹C](+)-PHNO synthesis by evaluation of reaction temperatures

S. Pfaff^{1,2}, C. Philippe¹, V. Pichler¹, A. Weidenauer³, M. Willeit³, M. Hacker¹, M. Mitterhauser^{1,4}, W. Wadsak^{1,2,5}, L. Nics^{1,6}; ¹Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Inorganic Chemistry, University of Vienna, Vienna, AUSTRIA, ³Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, AUSTRIA, ⁴Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, ⁵Centre for Biomarker Research in Medicine, CBmed GmbH, Graz, AUSTRIA, ⁶Department of Nutritional Sciences, University of Vienna, Vienna, AUSTRIA.

EP-0244

Evaluation of benzoxazolone based Tc-99m selective PET radiotracer to access microcirculation in ischemic rat brain

N. Kumari^{1,2}, S. BHAGAT³, A. Tiwari¹; ¹INSTITUTE OF NUCLEAR MEDICINE & ALLIED SCIENCES, DRDO, DELHI, INDIA, ²UNIVERSITY, Delhi, INDIA, ³DELHI UNIVERSITY, DELHI, INDIA.

EP-0245

Measurement of the Stability of [¹⁸F]FDOPA with High Activity Concentration

T. Bali, A. Richárd, G. Tihanyi, T. Cserenyák, Z. Áncsán, T. Csipak, B. Bojtor, I. Repa, G. Bajtek, P. Mikecz; University of Kaposvár, Kaposvár, HUNGARY.

EP-0246

[¹¹C]Me@NEBIQUINIDE: A Real Third Generation TSPO PET Tracer?

N. Berroterán-Infante^{1,2}, S. Schmitz³, T. Kalina⁴, H. Spreitzer³, M. Hacker¹, M. Mitterhauser^{1,5}, K. Pallitsch⁴, W. Wadsak^{1,6}; ¹Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ²Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA, ³Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, AUSTRIA, ⁴Institute of Organic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, AUSTRIA, ⁵LBI Applied Diagnostics, Vienna, AUSTRIA, ⁶Center for Biomarker Research, Graz, AUSTRIA.

EP-0247

⁶⁸Ga(III) complex with morin for kidney cancer cells labeling

K. Kilian, A. Sentkowska, & Cheda, K. Pyrżyńska; University of Warsaw, Warszawa, POLAND.

EP-0248

Evaluation of arylpiperazine analogues as PET radioligand for 5HT7

A. K. Tiwari; Institute of Nuclear Medicine & Allied Sciences, Delhi, INDIA.

EP-14 during congress opening hours, e-Poster Area

Radiopharmaceuticals & Radiochemistry: Radiopharmaceuticals - SPECT

EP-0249

Development of [¹²³I] 6-iodo-deoxy glucose ([¹²³I] 6-IDG) with composite polymer precursor for imaging of brain glucose metabolism with SPECT.

Y. Kanai¹, H. Tanaka², A. Nagasaki³, S. Naka¹, T. Sakai⁴, T. Kamiya¹, G. Horitsugi¹, E. Shimosegawa¹, T. Takahashi⁵, J. Hatazawa¹; ¹Osaka University Graduate School of Medicine, Suita, JAPAN, ²Tokyo Institute of Technology, Tokyo, JAPAN, ³Iwaki Seiyaku Co.,Ltd, Tokyo, JAPAN, ⁴Hanwa Intelligent Medical Center, Sakai, JAPAN, ⁵Yokohama University of Pharmacy, Yokohama, JAPAN.



EP-0250**In vitro assessment of the accumulation of highly specific radiochemical compounds based on ^{99m}Tc-labeled recombinant molecules**

O. Bragina^{1,2}, M. Larkina, E. Stasyuk, V. Chernov, R. Zelchan, A. Medvedeva, Sinilkin I., M. Yusubov, V. Skuridin.; ¹Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0251**The First Experience of Using a Radiopharmaceutical Based on Derivative of Glucose Labeled with Technetium-99m in Breast Cancer Imaging**

R. Zelchan^{1,2}, A. Medvedeva, I. Sinilkin, O. Bragina, V. Chernov, E. Stasyuk, A. Rogov, E. Il'ina, V. Skuridin.; ¹Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0252**Preparation of ¹³¹I-iodohexadecanoic acid: a tracer to localize lymphatic leakage lesions**

H. Kvaternik, S. Stanzel, R. M. Aigner; Medical University of Graz, Graz, AUSTRIA.

EP-0253**A new method for the preparation of astatine-211 (²¹¹At) and iodine-123 (¹²³I) labelled amino acid analogues of phenylalanine, ²¹¹At-Phe and ¹²³I-Phe, for radionuclide therapy and SPECT imaging applications**

Y. Shirakami¹, H. Ikeda^{2,3}, J. Hatazawa¹; ¹Osaka University Graduate School of Medicine, Suita, JAPAN, ²Cyclotron and Radioisotope center, Tohoku University, Sendai, JAPAN, ³Research Center for Electron Photon Science, Tohoku University, Sendai, JAPAN.

EP-0254**Current status of stress myocardial perfusion imaging pharmaceuticals and radiation exposure in Japan: Comparison with European nuclear cardiology practice**

R. Otsuka, Y. Miyamoto, T. Kubo, M. Kawahara, J. Iwatake, K. Takahashi, K. Takahashi; Osaka University Graduate School of Medicine, Suita, JAPAN.

EP-0255**Synthesis And Radiolabeling Of Temozolomide Loaded Solid Lipid Nanoparticles**

K. Ari, S. Teksöz, C. Ichedef, E. Uçar, A. Yurt Kılçar, E. & Medine; Ege University, Izmir, TURKEY.

EP-0256**Partition Coefficient, Plasma Protein Binding Percentage and Pharmacokinetic Studies of ^{99m}Tc^m-ZL and ^{99m}Tc^m-ZLM for New Bone-imaging Agents**

H. Wang, P. Zou, M. Xie, Y. Liu, J. Wu, H. Wu; Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA.

EP-0257**Design Of A Radiolabeled Polymeric Drug Carrier System ^{99m}Tc(CO)₃-Oxaliplatin-PEG-PLA**

K. Senocak, S. Teksoz, A. Yurt Kılçar, E. Uçar, B. Aydın; Ege University Institute of Nuclear Sciences, Izmir, TURKEY.

EP-0258**Evaluation of the SPECT Image Using Probe ¹²³I-EISB for SPECT of the Systemic Amyloidosis**

K. Kashiwa¹, K. Fukuda², Y. Ando³, K. Tomiyoshi⁴; ¹Graduate School of Health Science, Department of Radiological Science Kumamoto University, Kumamoto, JAPAN, ²Radiation Oncology, Yokohama City University Hospital, Kanagawa, JAPAN, ³Graduate School of Medical Science, Department of Neurology, Kumamoto University, Kumamoto, JAPAN, ⁴Department of Medical Physics, Faculty of Life Science, Kumamoto University, Kumamoto, JAPAN.

EP-0259**^{99m}Tc-Al₂O₃ - new radiopharmaceutical for sentinel lymph nodes visualization: first experience in oncogynecologic cancer patients**

V. Chernov^{1,2}, R. Zelchan^{1,2}, Lyapunov A., Sinilkin I., Chernyshova A, Ochirov M., Kolomiets L., Medvedeva A.; ¹Tomsk National Research Medical Center of the Russian Academy of Sciences Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0260**Evaluation of the labeling parameters of ^{99m}Tc-Nanocoll-ICG[®] for multimodal imaging of the sentinel lymph node**

J. Dinet¹, P. Bonijol¹, Q. Becheras², C. Faure³, D. Dauger⁴, F. Giammarile⁵, D. Kryza⁵; ¹GCS Lumen, Lyon, FRANCE, ²Université Claude Bernard Lyon 1, Lyon, FRANCE, ³Centre Léon Bérard, Lyon, FRANCE, ⁴Université d'Auvergne, Montluçon, FRANCE, ⁵Hospices Civils de Lyon - Université Claude Bernard Lyon 1, Lyon, FRANCE.

EP-0261**Optimization of affibody molecule for imaging of HER3 expression: negatively charged metal-chelator complex increases imaging contrast**

S. S. Rinne¹, B. Mitran¹, C. Dahlsson Leitao², S. Ståhl², J. Löfblom², V. Tolmachev¹, A. Orlova¹; ¹Uppsala University, Uppsala, SWEDEN, ²KTH Royal Institute of Technology, Stockholm, SWEDEN.



e-poster not submitted

EP-0262**Preparation of ^{99m}Tc-labelled hydroxyapatite nanoparticles and their in vitro/in vivo characterisation**

Z. Novy¹, M. Petrik¹, S. Gurska¹, J. Kozempe², M. Vlk², V. Lobaz³, J. Kucka³, M. Hruby³, J. Drymlova⁴, M. Hajduch¹;
¹Palacky University Olomouc, Olomouc, CZECH REPUBLIC, ²Czech Technical University in Prague, Praha, CZECH REPUBLIC, ³Czech Academy of Science, Praha, CZECH REPUBLIC, ⁴University Hospital Olomouc, Olomouc, CZECH REPUBLIC.

EP-0263**Cytotoxicity, In vitro binding and imaging evaluation of radiolabeled-DOTA-SP90 in 4T1 breast cancer model**

M. Chen, Y. Huang, S. Lee, S. Lo, L. Chen, C. Chang;
Institute of Nuclear Energy Research, Taoyuan City, TAIWAN.

EP-0264**Radiolabeled AMO conjugated nanoparticle for in vivo tumor imaging of cervical cancer**

L. Kang, Y. Huo, C. Zhang, P. Yan; Peking University Hospital, Beijing, CHINA.

EP-0265**Proof of Concept for Nucleolipids as potential SPECT tracer: Synthesis and Evaluation of Uridine derived Nucleolipid as Tumor Imaging Agent**

S. Mishra¹, S. Chaturvedi¹, S. Paul¹, P. Barthélémy², B. Singh¹, S. Mishra¹;
¹Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA, ²IRM U869 and Université de Bordeaux, Bordeaux, F-33076, FRANCE, ³Department of Chemistry, Banaras Hindu University, Varanasi, INDIA.

EP-0266**Exendin-4 labeled with ^{99m}Tc, ¹¹¹In and ⁶⁸Ga - a comparative pharmacokinetics evaluation**

B. Janota, U. Karczmarczyk, E. Laszuk, P. Garnuszek, R. Mikołajczak; National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, POLAND.

EP-0267**Radiolabeling and preclinical assessment of ¹⁸⁸Re-HYNIC-trastuzumab for Radioimmunotherapy**

B. Alirezapour^{1,2}, M. Davoodi¹, S. Rajabifar¹, H. Abbasi², B. Aziz Khatami¹, F. Johari Daha¹, M. Hashemizadeh¹, M. Soltani², H. Masoumi², S. Moradlou¹;
¹Nuclear Science and Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0268**Validation of alternative methods for quality control of [^{99m}Tc-EDDA-HYNIC-D-Phe¹, Tyr³]-Octreotide**

M. A. Hernandez Fructuoso¹, S. Ruiz Llama², B. Santos Montero¹, C. Beltran Gracia², E. miñana Olmo¹, J. Castell Conesa¹;
¹Hospital Universitari Vall d'Hebron - Institut de Diagnòstic per la Imatge, Barcelona, SPAIN, ²Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-15 during congress opening hours, e-Poster Area**Radiopharmaceuticals & Radiochemistry: Radiopharmacy****EP-0269****Theranostic probe Lu-177-DOTA-NIR790 for multimodal diagnosis and therapy of cancer**

C. Peng, Y. Shih, P. Chiang, Y. Kuo, T. Luo; Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-0270**Stability assessment after reconstitution and investigation of the biodistribution in a pre-clinical mouse model of ^{99m}Technetium-Sestamibi (CardiovisTM)**

C. Mak¹, S. A. Barker¹, J. K. Sosabowski², J. M. Foster², N. G. Hartman³;
¹UCL School of Pharmacy, London, UNITED KINGDOM, ²John Vane Science Centre, Queen Mary University, London, UNITED KINGDOM, ³Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0271**Evaluation of the physicochemical properties of ^{99m}Technetium-Exametazime (Medi-ExametazimeTM) and its biodistribution in a pre-clinical mouse model**

W. Ahmed¹, S. A. Barker¹, J. Sosabowski², J. M. Foster², R. Soanes³, N. Hartman³;
¹UCL School of Pharmacy, London, UNITED KINGDOM, ²John Vane Science Centre, Queen Mary University, London, UNITED KINGDOM, ³Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0272**Validation of a Cost Effective Alternative Radiochemical Purity Analysis Method**

F. P. Ekoume^{1,2}, S. M. Rubow², H. H. Boersma³;
¹Yaounde General Hospital, Yaounde, CAMEROON, ²Stellenbosch University, Cape Town, SOUTH AFRICA, ³University Medical Center, Groningen, NETHERLANDS.



EP-0273

Analysis of the new rules of radiopharmaceuticals with drugs in Spain

L. Sanz-Ceballos, Á. P. Navarro, J. García-Redondo, J. M. Llamas-Elvira; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0274

Overview of 2.5 years experience of manual synthesis of in-house ⁶⁸Ga labelled radiopharmaceuticals using non metallic ⁶⁸Ge/⁶⁸Ga column generator: An institutional experience

B. S. Shetye, Sr., P. Monteiro, M. Pathan, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

EP-0275

Computer platform for radiopharmaceuticals prescription

J. García-Redondo, E. Morillo-Martínez, Á. Ramírez-Navarro, J. M. Llamas-Elvira; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0276

Leukocyte scintigraphy : biologic criteria for the decision of realization of the scintigraphy using the benchmark method of in vitro ^{99m}Tc-HMPAO (Ceretek®) granulocytes labeling

K. Casagrande¹, J. Woillard², I. Quelven¹; ¹CHU Dupuytren, Nuclear Medicine Department, Limoges, FRANCE, ²CHU Dupuytren, Pharmacology and Toxicology Department, Limoges, FRANCE.

EP-0277

Optimization of Gallium-68 radiolabelling methods : feedback in Centre Jean Perrin cancer institute

H. Nicolas¹, M. Tempier¹, P. Auzeloux², M. Galmier², S. Tarrit², F. Cachin^{1,2}, R. Chevrier¹, S. Levesque¹; ¹CRLCC Jean Perrin, Clermont ferrand, FRANCE, ²Université Clermont d'Auvergne, INSERM U1240, Imagerie Moléculaire et Stratégies Théranostiques, Clermont ferrand, FRANCE.

EP-0278

Routine GMP production of ⁶⁸Ga-radiopharmaceuticals using two ⁶⁸Ge/⁶⁸Ga generators in sequence

G. M. Franssen¹, M. van Riel¹, D. Gerrits¹, R. Bongaerts¹, C. M. van Rij¹, S. Kropf², H. J. Wester², P. Laverman¹; ¹Radboud university medical center, Nijmegen, NETHERLANDS, ²Scintomics GmbH, Furstenfeldbruck, GERMANY.

EP-0279

Establishment of Glomerular Filtration Rate reference values measured by ⁵¹Cr-EDTA clearance in patients over 75 years

I. Gil-Viciano¹, I. Romero-Zayas¹, P. Saldaña-Gutiérrez², M. Roca-Engronyat¹, E. Pineda-Fernández¹, M. Bueno-Raspall¹, A. Rodríguez-Gasén¹, J. L. Vercher-Conejero¹, L. Gracia-Sánchez¹, J. Rodríguez-Rubio¹, L. Rubio-Alvarez¹, C. Munuera-Sañudo¹, N. Calvo-Malvar¹, C. Gamez-Cenzano¹; ¹Radiopharmacy Unit and Nuclear Medicine-PET Department. IDI. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona. Spain., SPAIN, ²Medical Physics Department. ICO, L'Hospitalet de Llobregat. Barcelona. Spain., SPAIN.

EP-0280

Peptides labelling with ⁶⁴Cu and ⁶⁸Ga on heterogeneous phase using a microfluidic system

D. Seifert, M. Kleinova, A. Cepa, J. Ralis, P. Hanc, O. Lebeda; Nuclear Physics Institute of the CAS, Rez, CZECH REPUBLIC.

EP-16 during congress opening hours, e-Poster Area

Radiopharmaceuticals & Radiochemistry: Radiometals

EP-0281

Holmium-166 Phytate: From Suspension To Microspheres

E. Szemenyei, S. Keresztes, N. Halász, Z. Kiss-Gombos, P. Buszlai, D. Zsolnai, J. Környei; Institute of Isotopes Co. Ltd., Budapest, HUNGARY.

EP-0282

Optimal molecular design of radiocopper-labelled affibody molecules

V. Tolmachev¹, C. Yim², J. Garousi¹, Y. Yue³, S. Grimm³, J. Rajander², A. Perols³, M. Haaparanta-Solin², T. J. Grönroos², O. Solin², A. Orlova¹, C. Anderson⁴, A. Eriksson Karlström³; ¹Uppsala University, Uppsala, SWEDEN, ²Turku PET Centre, Turku, FINLAND, ³KTH Royal Institute of Technology, Stockholm, SWEDEN, ⁴University of Pittsburgh, Pittsburgh, PA, UNITED STATES OF AMERICA.

EP-0283

Radiometals Production by only one Solid Target System

M. Malinconico^{1,2}, J. Asp², C. Lang³, F. Boschi¹, G. Guidi¹, P. Takhar²; ¹COMECER SPA, Castelbolognese, ITALY, ²SAHMRI, Adelaide, AUSTRALIA.



EP-0284**Radiolabeling with ⁶⁸Ga and ⁴⁴Sc in a capillary reactor**

D. Szikra¹, G. Nagy², G. Trencsényi¹, N. Dénes¹, V. Forgács¹, E. Berényi¹, I. Garai²; ¹University of Debrecen, Debrecen, HUNGARY, ²Scanomed Ltd., Debrecen, HUNGARY.

EP-0285**High yield separation of ⁶⁷Cu from irradiated zinc targets**

P. Martini^{1,2}, A. Boschi³, M. Pasquali^{1,2}, G. Cicoria⁴, L. Mou², C. Rossi Alvarez², S. Carturan², S. Canella², J. Esposito², L. Uccelli^{5,3}, A. Duatti⁶, F. Haddad⁷, T. Sounalet⁷, G. Pupillo²; ¹University of Ferrara, Physics Department, Ferrara, ITALY, ²Legnaro National Laboratories, National Institute for Nuclear Physics (LNL-INFN), Legnaro (Pd), ITALY, ³University of Ferrara, Laboratory of Nuclear Medicine, Department of Morphology, Surgery and Experimental Medicine, Ferrara, ITALY, ⁴Department of Nuclear Medicine, St. Orsola Hospital, Bologna, ITALY, ⁵Department of Nuclear Medicine, St. Anna Hospital, Ferrara, ITALY, ⁶University of Ferrara, Department of Chemical and Pharmaceutical Sciences, Ferrara, ITALY, ⁷GIP ARRONAX, Saint-Herblain, FRANCE.

EP-0286**Production of Sc radionuclides by separation of scandium from calcium target using UTEVA resin**

D. Pawlak, W. Wojdowska, J. L. Parus, M. Żółtowska, P. Garnuszek, R. Mikołajczak; National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, POLAND.

EP-0287**Development of solid target and automated synthesis module for the production of scandium-44 and scandium-44 labeled peptides**

I. Hajdu, V. Forgács, A. Fekete, E. Várhalminé Németh, D. Szikra; University of Debrecen, Debrecen, HUNGARY.

EP-0288**Preliminary experimental tests of ⁶⁴Cu production in combination with ¹⁸F**

L. Auditore¹, E. Amato², G. Cicoria³, M. Marengo³, S. Baldari¹; ¹Nuclear Medicine Unit, University Hospital "G. Martino", Messina, ITALY, ²Radiological Sciences Section, BIOMORF Dept., Messina, ITALY, ³Medical Physics Department, University Hospital "S. Orsola-Malpighi", Bologna, ITALY.

EP-17 during congress opening hours, e-Poster Area**Radiopharmaceuticals & Radiochemistry: Radiopharmacokinetics & Drug Development****EP-0289****¹¹C-choline pharmacokinetics in recurrent prostate cancer**

M. Grkovski, K. Gharzeddine, P. Sawan, H. Schöder, W. A. Weber, J. L. Humm; Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0290**Development of ¹⁸F-labeled α -methyl L-phenylalanine for tumor specific imaging**

H. Hanaoka¹, A. Yamaguchi¹, Y. Ohshima², T. Higuchi¹, N. S. Ishioka², Y. Tsushima¹; ¹Gunma University, Maebashi, JAPAN, ²National Institutes for Quantum and Radiological Science and Technology, Takasaki, JAPAN.

EP-0291**Synthesis and evaluation of ¹²⁵I-labeled tetrazine prosthetic group for an efficient bioorthogonal radiolabeling of trans-cyclooctene containing biomolecules**

S. Mushtaq^{1,2}, M. Choi¹, H. Shim¹, S. Yun¹, C. Lee¹, S. Park^{1,2}, D. Choi¹, B. Jang¹, J. Jeon^{1,2}; ¹Korea Atomic Energy Research Institute, Jeongeup, Jeonbuk, KOREA, REPUBLIC OF, ²Korea University of Science and Technology, Daejeon 34113, KOREA, REPUBLIC OF.

EP-0292**Generation and evaluation of single chain fragments for molecular imaging of CD44v6-expressing cancers**

A. Haylock¹, J. Nilvebrant², A. C. Mortensen³, I. Velikyan⁴, R. Falk⁵, M. Nestor³; ¹Department of Surgical Sciences, Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN, ²Division of Protein Technology, School of Biotechnology, Royal Institute of Technology, STOCKHOLM, SWEDEN, ³Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN, ⁴Department of Medicinal Chemistry, Uppsala University, UPPSALA, SWEDEN, ⁵Department of Neuroscience, Karolinska Institutet, STOCKHOLM, SWEDEN.

EP-0294**Does nanocarrier tumour uptake increase with increasing size?**

V. Schmitt, C. Rodriguez-Rodriguez, J. L. Hamilton, R. A. Shenoj, J. N. Kizhakkedathu, K. Saatchi, U. O. Hafeli; University of British Columbia, Vancouver, BC, CANADA.



EP-0295

Radiolabeling and biodistribution study of engineered antibody-like protein with ^{99m}Tc for tumor therapy

D. Lee¹, S. Mushtaq^{1,2}, S. Yoon¹, J. Lee³, J. Kang¹, D. Choi¹, H. Kim³; ¹Korea Energy Research Institute, Jeongseon, REPUBLIC OF KOREA, ²Korea University of Science and Technology, Daejeon 34113, KOREA, REPUBLIC OF, ³Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, KOREA, REPUBLIC OF.

EP-0296

Evaluation of ⁸⁹Zr Complexed with Dicarboxylic Acids for PET-Diagnosis of Inflammatory Processes and Metastatic Skeletal Disorders

A. Larenkov¹, M. Zhukova¹, A. Krasnopyorova¹, B. Barnasyk¹; ¹Moscow, RUSSIAN FEDERATION.

EP-0297

Bioaffinity testing of ⁶⁸Ga/¹⁷⁷Lu-DOTA-Neurotensin and neurotensin fragments as theranostic agent in colon cancer

D. Niculae¹, D. Draganescu^{1,2}, E. A. Min^{1,2}, A. Raicu¹, L. Chilug^{1,3}, G. Manda⁴, R. A. Leonte^{1,3}, I. Manea⁵, M. Costache⁵; ¹Horia Hulubei National Institute for Physics and Nuclear Engineering, Magurele Ilfov, ROMANIA, ²University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA, ³University Politehnica, Bucharest, ROMANIA, ⁴Victor Babes National Institute for Pathology and Biomedical Sciences, Bucharest, ROMANIA, ⁵Colentina Clinic Hospital, Bucharest, ROMANIA.

EP-0298

n.c.a. Lu-177-Dotatate Kinetics Comparison With In-111-DTPA-Oc in Intra-arterially Infused Liver Metastasized GEP-NET Patients; From Bench to Bedside

G. S. Limouris¹, M. Paphiti¹, S. Chondroyiannis², D. Rubello², V. R. McCready³; ¹Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, ²Nuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, ITALY, ³Institute Cancer Research, Sutton Surrey & Royal Sussex County Hospital, Brighton, UNITED KINGDOM.

EP-18 during congress opening hours, e-Poster Area

Radiopharmaceuticals & Radiochemistry: Antibodies & Peptides

EP-0299

New ^{99m}Tc labeled peptide for Folate receptor targeting

N. Rahmanian¹, S. Hosseini², A. Khalaj¹, Z. Noaparast³, S. Abedi⁴; ¹University of Medical Sciences, Tehran, ISLAMIC REPUBLIC OF, ²Mazandaran University of Medical Sciences, Sari, IRAN, ISLAMIC REPUBLIC OF.

EP-0300

Biodistribution study of ¹¹¹In-anti-CDH17 minibody using CDH17-positive gastric cancer xenograft mice

K. Fujiwara^{1,2}, K. Koyama², H. Akiba³, H. Iwanari⁴, T. Higashi¹, K. Tsumoto⁵, T. Hamakubo⁴, T. Momose⁶; ¹Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes of Quantum and Radiological Science and Technology, Chiba, JAPAN, ²Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, JAPAN, ³Laboratory of Pharmacokinetic Optimization, Center for Drug Design Research National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, JAPAN, ⁴Department of Quantitative Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, JAPAN, ⁵Department of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, JAPAN, ⁶Department of Radiology, Faculty of Medicine, International University of Health and Welfare, Chiba, JAPAN.

EP-0301

⁶⁸Ga-labelled Neuropeptide Y short analogue: A potential PET/CT tracer for breast cancer imaging

M. E. Cardoso¹, K. Zirbesegger², E. Savio², H. Engler², M. Terán¹, A. M. Rey¹; ¹Área Radioquímica, Facultad de Química, UdelAR, Montevideo, URUGUAY, ²Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, URUGUAY.

EP-0302

A novel peptide targeting GPC3 for HCC PET/CT imaging

Y. Qin¹, Y. Li², S. Zou¹, D. Zhu¹, H. Wu², L. Zhu³, X. Zhu¹; ¹Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²The First Affiliated Hospital of Xiamen University, Xiamen, CHINA, ³Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA.



EP-0303**99mTc-HYNIC-ramucirumab: in vitro studies on binding to VEGFR2 and internalization in VEGFR2-positive cells**

J. Janousek, Jr., P. Barta, F. Trejtnar; Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, CZECH REPUBLIC.

EP-0304**Development of ⁹⁰Y-DOTA-nimotuzumab: a specific tool for testing a new probe potentially suitable for β^- radio-guided surgery**

T. Scotognella¹, D. Maccora², G. Bancivenga³, N. Misceo³, C. Martelli⁴, V. Marzano⁴, F. Marini⁴, I. Fratoddi⁵, I. Venditti⁵, A. Cartoni⁵, E. Solfaroli-Camillocchi⁶, S. Morganti⁶, C. Mancini-Terraciano⁶, F. Collamati⁶, D. Rotili⁷, M. Chinol⁸, M. Castagnola⁴, R. Faccini⁶, A. Giordano²; ¹Nuclear Medicine Unit, Policlinico "A. Gemelli", Rome, ITALY, ²Institute of Nuclear Medicine, Università Cattolica del S. Cuore "A. Gemelli", Rome, ITALY, ³PET-CT Center, Radiopharmacy Unit, Policlinico "A. Gemelli", Rome, ITALY, ⁴Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del S. Cuore "A. Gemelli", Rome, ITALY, ⁵Department of Chemistry, Sapienza University, Rome, ITALY, ⁶Department of Physics, Sapienza University, Rome, ITALY, ⁷Department of Drug Chemistry and Technologies, Sapienza University, Rome, ITALY, ⁸Division of Nuclear Medicine, European Institute of Oncology, Milan, ITALY.

EP-0305**Site-specific Bimodal Labeling of Proteins on Cysteine Residues with Chlorotetraazines**

C. Canovas¹, M. Moreau¹, C. Bernhard¹, A. Oudot², M. Guillemin², F. Denat¹, V. Goncalves¹; ¹ICMUB, UMR 6302, CNRS, Université de Bourgogne Franche-Comté, Dijon, FRANCE, ²Centre Georges François Leclerc, Dijon, FRANCE.

EP-0306**Feasibility of Z Domain-Mediated Conjugation of PNA to Antibodies for Radionuclide Pretargeting**

A. Vorobyeva¹, M. Altai¹, K. Westerlund², A. Al-Ramadan¹, V. Tolmachev¹, A. Eriksson Karlström²; ¹Uppsala University, Uppsala, SWEDEN, ²KTH Royal Institute of Technology, Stockholm, SWEDEN.

EP-0307**First application of radionuclide labeling and imaging studies to assess the pharmaceutical stability of reconstituted trastuzumab (Herceptin) stored under correct or incorrect conditions**

C. Chan¹, J. Seki², R. Kwong², R. M. Reilly^{1,3}; ¹Departments of Pharmaceutical Sciences and Medical Imaging, University of Toronto, Toronto, ON, CANADA, ²Department of Pharmacy, Princess Margaret Cancer Centre, Toronto, ON, CANADA, ³Toronto General Research Institute, University Health Network, Toronto, ON, CANADA.

EP-0308**Biological evaluation of hybrid peptide radiolabeled with ⁶⁸Ga emitter as melanoma targeting probe**

M. H. AL Qahtani, Y. H. Al-Malki; King Faisal Specialist Hospital & Research Center, Riyadh, SAUDI ARABIA.

EP-0309**Evaluation of Monochloramine as a Novel Reagent for Radiolabeling of Peptides and Proteins**

K. Kumar, K. Woolum; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.

EP-0310**Development of ⁶⁴Cu-labelled Monomeric and Trimeric RGD-recognising Integrin Ligands via 2-Cyanobenzothiazole/1,2-Aminothiol Click Addition**

F. Gao, K. Nguyen, K. Chen, Y. Seimbille; TRIUMF, Vancouver, BC, CANADA.

EP-0311**Development of HER2-targeted Molecular Imaging Probes via a Facile 2-Cyanobenzothiazole (CBT)/1,2-Aminothiol Ligation Approach**

K. Chen, F. Gao, C. Ieritano, Y. Seimbille; TRIUMF, Vancouver, BC, CANADA.



EP-19 during congress opening hours, e-Poster Area

Radiopharmaceuticals & Radiochemistry:
New Targets

EP-0312

The Novel, Stapled HDM2/HDMX-p53 Antagonist PM2 Has Potent Antitumorigenic Activities and Enhances the Effects of External Radiotherapy

A. C. Mortensen¹, D. Spiegelberg¹, C. Brown², D. P. Lane², M. Nestor¹; ¹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ²p53 Lab, A*STAR, 8A, Biomedical Grove, #06-04/05 Neuros/Immunos, Singapore 138648, Singapore, SINGAPORE.

EP-0313

Preliminary Results Of The Production Of Gallium-68 With Cyclotron

G. Cicoria, F. Zagni, S. Vichi, L. Mora, M. Marengo, S. Riga; Policlinico S.Orsola-Malpighi, Bologna, ITALY.

EP-20 during congress opening hours, e-Poster Area

Radiopharmaceuticals & Radiochemistry:
Miscellaneous

EP-0314

Structural Requirement of the 11b-Position Chirality of Tetrabenazine Analogs as VMAT2 Imaging Ligands: Synthesis and in vivo Evaluation

Z. Chen¹, D. Xue^{2,1}, C. Liu¹, X. Li¹, J. Tang¹, L. Cao^{2,1}, Y. Liu²; ¹Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, ²Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, CHINA.

EP-0315

Central Conducting Lymphatic Anomaly in Neonatal Chylothorax Visualized after Oral Administration of [¹³¹I]IHDA

S. Stanzel¹, H. Kvaternik¹, K. Pfurtscheller², R. Ulreich², R. M. Aigner¹; ¹Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, ²Medical University of Graz, University Children's Hospital, Pediatric Intensive Care Unit, Graz, AUSTRIA.

EP-0316

Influence of the use of cryoprotectant on the radiolabelling of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with ^{99m}Tc

R. Iglesias-Jerez¹, M. D. Cayero-Otero², L. Martín-Banderas², I. Borrego-Dorado¹; ¹HU VIRGEN DEL ROCÍO. Avda Manuel Siurot s/n. 41013, Sevilla, SPAIN, ²Dpt. Farmacia y Tecnología Farmacéutica. Facultad de Farmacia. Universidad de Sevilla. c/Prof. Gracia González nº2, 41012., Sevilla, SPAIN.

EP-0317

Gamma Ray Spectroscopy for Determination of Absolute Activities of Cyclotron-Produced Technetium Product Impurities and Waste

L. A. Stothers^{1,2}, X. Hou², M. Vuckovic³, K. Buckley⁴, P. Schaffer⁴, F. Bénard³, T. J. Ruth^{3,4}, A. Celler²; ¹The University of British Columbia, Vancouver, BC, CANADA, ²Medical Imaging Research Group, Vancouver, BC, CANADA, ³BC Cancer Agency, Vancouver, BC, CANADA, ⁴TRIUMF, Vancouver, BC, CANADA.

EP-0318

Radiolabeling optimization of radioaptamers as new heterotrimeric theranostic systems for antimetastatic therapy

R. Ramos-Membrive¹, G. Gan², M. Collantes³, F. Pastor⁴, M. Martínez-Soldevilla⁴, I. de Miguel⁵, M. Villalba⁶, J. Oyarzabal⁵, A. Calvo⁶, I. Peñuelas^{3,1}; ¹Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, ²University College, London, UNITED KINGDOM, ³Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, SPAIN, ⁴Aptamers and Small Molecules Unit, Center for Applied Medical Research (CIMA), Pamplona, SPAIN, ⁵Molecular Therapies, Center for Applied Medical Research (CIMA), Pamplona, SPAIN, ⁶Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, SPAIN.

EP-0319

Forecasting the production of medical radioisotopes at Extreme Light Infrastructure - Nuclear Physics gamma-beam system

D. Niculae¹, F. D. Puicea^{2,3}, S. Ilie^{1,3}, W. Luo⁴, P. V. Cuong^{2,5}, G. Cata Danil³, C. A. Ur², D. Balabanski²; ¹Horia Hulubei National Institute for Physics and Nuclear Engineering, Magurele Ilfov, ROMANIA, ²Extreme Light Infrastructure - Nuclear Physics, "Horia Hulubei" National Institute for Physics and Nuclear Engineering, Magurele Ilfov, ROMANIA, ³Politehnica University, Bucharest, ROMANIA, ⁴School of Nuclear Science and Technology, University of South China, Hengyang, CHINA, ⁵Centre of Nuclear Physics, Institute of Physics, Vietnam Academy of Science and Technology, Hanoi, VIET NAM.

EP-21 during congress opening hours, e-Poster Area

Cardiovascular System: Basic Science

EP-0320

Quantification of Myocardial Perfusion Defect in Rats with Ultra-high Resolution SPECT System using QPS Software: Comparison with High-resolution Autoradiography

H. Wakabayashi¹, J. Taki¹, A. Inaki¹, T. Hiromasa¹, K. Shiba², S. Kinuya¹; ¹Dept. of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, ²Advanced Science Research Center, Kanazawa University, Kanazawa, JAPAN.




EP-22 during congress opening hours, e-Poster Area
Cardiovascular System: Clinical Science: Perfusion, Metabolism and Receptors
EP-0321
Evaluation of diagnostic ability of an artificial neural network for detecting ischemia in myocardial perfusion imaging

T. Yoneyama¹, K. Nakajima², S. Tsuji¹, K. Yokoyama¹, T. Michigishi¹; ¹Public Central Hospital of Mattou Ishikawa, Hakusan, JAPAN, ²Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN.

EP-0322
Lower Annual Cardiac Events in Diabetics with A Normal Exercise GMPI And A Functional Capacity ≥ 7 METS on Treadmill

N. Fatima^{1,2}, M. u. Zaman^{1,2}, D. J. M. baloch³, A. U. Hussaini³, S. Z. Rasheed³; ¹Aga Khan University Hospital, Karachi, PAKISTAN, ²Dept of Nuclear Cardiology, Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN, ³Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN.

EP-0323
The application of ATP stress SPECT cerebral blood flow perfusion imaging in ischemic cerebrovascular disease

R. Wang¹, L. Yin², J. Li², Z. Liu², R. Xu², C. Jin²; ¹Peking University First Hospital, Beijing, CHINA, ²China-Japan Friendship Hospital, Beijing, CHINA.

EP-0324
Investigation of the Impact of Early Imaging on Systolic and Diastolic Dysfunction Parameters on Gated Myocardial Perfusion Scintigraphy

A. O. Karacalioglu, T. Haciosmanoglu, O. Emer, S. Ince, E. Alagoz, K. Okuyucu, N. Arslan; Gulhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, TURKEY.

EP-0325
Measurement of Cardiac Function Before and After TAVI (Transcatheter Aortic Valve Implantation) Using Myocardial Scintigram

K. Yamaguchi; St. Marianna University School of Medicine, Kawasaki, JAPAN.

EP-0326
Myocardial perfusion and neurotropic SPECT features in patients with primary pulmonary hypertension

A. A. Ansheles¹, E. G. Valeeva¹, T. V. Martynyuk¹, R. S. Karpov², V. B. Sergienko¹; ¹Russian Cardiology Research Center, Moscow, RUSSIAN FEDERATION, ²Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION.

EP-0327
Rest/Stress vs. Stress only Myocardial Perfusion Imaging. How many exams could be avoided? Our experience

S. Sollaku, V. Frantellizzi, G. A. Follacchio, J. Lazri, M. Ricci, M. Liberatore, F. Monteleone, G. De Vincentis; Sapienza University of Rome, Rome, ITALY.

EP-0328
The relationship between myocardium sympathetic innervation dysfunction with the occurrence of ventricular tachycardia in patients with coronary artery diseases and implantable cardioverter defibrillator

S. I. Sazonova^{1,2}, T. A. Atabekov¹, R. E. Batalov¹, J. N. Ilushenkova¹, N. V. Varlamova², E. A. Nesterov², A. S. Semenov², S. V. Popov¹, Y. B. Lishmanov¹; ¹Cardiology Research Institute, Tomsk NRCM, Tomsk, RUSSIAN FEDERATION, ²Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0329
Myocardial Glucose Metabolism Evaluated by Fasting 18Fluorodeoxyglucose-Positron Emission Tomography in Pulmonary Hypertension

T. Nakamura, N. Tahara, M. Bekki, Y. Sugiyama, A. Tahara, A. Honda, E. Kumagai, S. Igata, Y. Fukumoto; Department of Internal Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, JAPAN.

EP-0330
Left ventricular diastolic dysfunction in patients with typical angina pectoris and angiographically normal or near normal coronary arteries

E. Khachirova, L. Samoylenko, O. Shevchenko; Moscow, Moscow, RUSSIAN FEDERATION.

EP-0331
Higher event rate in patients with high risk Duke Treadmill Score despite of normal exercise gated MPI

N. Fatima¹, M. U. Zaman¹, A. Zaman², R. Tahseen³, S. Zaman², U. Zaman³; ¹Aga Khan University Hospital, Karachi, PAKISTAN, ²Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN, ³Civil Hospital, Karachi, PAKISTAN.

EP-0332**Arterial Age Estimation in Patients with Suspected Coronary Artery Disease: a Suitable Tool to Predict Myocardial Ischemia**

C. Nappi¹, V. Gaudieri², A. Genova¹, G. De Simini¹, P. Buongiorno¹, V. Cantoni¹, R. Green¹, E. Zampella¹, R. Assante¹, S. Daniele², W. Acampa¹, M. Petretta³, A. Cuocolo¹; ¹Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy, Naples, ITALY, ²Institute of Biostructure and Bioimaging, National Council of Research, Naples, Italy, Naples, ITALY, ³Department of Translational Medical Sciences, University Federico II, Naples, Italy, Naples, ITALY.

EP-0333**Pathological Asynchrony and Progressive Local Reduction of Myocardial Perfusion at the Apex as Important Sign of the Coming Loss of Heart Transplant**

E. N. Ostroumov¹, E. D. Kotina², E. V. Migunova¹, N. E. Kudryashova¹, V. A. Ploskikh², A. V. Babin², S. Y. Shemakin¹, V. V. Golubitsky¹, M. V. Vovchenko¹; ¹N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, RUSSIAN FEDERATION, ²Saint Petersburg State University, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0334**Possibility of software program provided Artificial Neural Network (ANN) analysis supporting interpretation of medical staffs in myocardial perfusion SPECT**

K. Koyama¹, H. Yamada¹, T. Ogura¹, M. Kanou¹, K. Maehara¹, T. Ino¹, H. Hoshizaki¹, S. Oshima¹, T. Toyama²; ¹Gunma Cardiovascular Center, Maebashi, JAPAN, ²Toyama internal medicine and cardiovascular clinic, Maebashi, JAPAN.

EP-0335**Myocardial Perfusion Imaging With CZT SPECT: Impact of Prone Versus Supine Imaging Positions on Cardiac Respiratory-Motion Magnitude**

D. Daou^{1,2}, R. Sabbah³, Y. Alattar¹, C. Coaguila⁴, H. Boulahdour^{3,5}; ¹Cochin Hospital, AHP, PARIS, FRANCE, ²EA 7334 REMES, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, FRANCE, ³CHU Jean Minjoz, Besançon, FRANCE, ⁴Centre Hospitalier de Bigorre, Tarbes, FRANCE, ⁵EA 4662, Université de Franche-Comté, Besançon, FRANCE.

EP-0336**One week extension of a ketogenic diet provides a further decrease in myocardial FDG uptake and a high detectability of myocarditis by FDG PET in rats**

A. Clement¹, S. Poussier¹, H. Boutley¹, J. Pierson¹, M. Lhuillier¹, A. Kolodziej², J. Olivier², G. Karcher^{1,3}, P. Marie^{1,3}, F. Maskali¹; ¹Nancyclotep, Experimental Imaging Platform, Vandoeuvre-Les-Nancy, FRANCE, ²Department of Biochemistry and Molecular Biology, CHRU-Nancy, Nancy, FRANCE, ³Department of Nuclear Medicine, CHRU, Vandoeuvre Les Nancy, FRANCE.

EP-0337**Comparison of the tolerability of Regadenoson and Adenosine in patients undergoing myocardial perfusion scintigraphy**

A. Tsaroucha¹, O. Bourogianni¹, M. Stathaki¹, E. Papadaki¹, M. Alefantinou¹, K. Galanopoulos¹, H. Mavrakis², M. Marketou², S. Koukouraki¹; ¹Department of Nuclear Medicine, University Hospital of Crete, Heraklion, GREECE, ²Department of Cardiology, University Hospital of Crete, Heraklion, GREECE.

EP-0338**SPECT myocardial perfusion assessment in asymptomatic patients with hypercholesterolemia using new quantitative parameters**

A. A. Ansheles, L. A. Martirosyan, I. V. Sergienko, V. B. Sergienko; Russian Cardiology Research Center, Moscow, RUSSIAN FEDERATION.

EP-0339**Cardiac contraction motion compensation in gated Myocardial Perfusion SPECT**

N. Salehi^{1,2}, M. Farahani², E. Fatemzadeh³, S. Farzanefar⁴, M. Ay^{1,2}; ¹Tehran university of medical sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Electrical Engineering Department, Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0340**Prognostic Value of Left Ventricular Shape Index Assessed by Gated SPECT Myocardial Perfusion Imaging**

V. Gaudieri¹, C. Nappi², W. Acampa², E. Zampella², R. Assante², T. Mannarino², A. Genova², S. Daniele¹, G. Melluso², G. De Simini², M. Petretta³, A. Cuocolo²; ¹Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ²Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ³Department of Translational Medical Sciences, University Federico II, Naples, ITALY.

EP-0341**Clinical Value of Late post stress Imaging of Gated SPECT Myocardial Perfusion Scintigraphy after Stress-only injection**

M. Garcheva-Tsacheva, A. Tzonevska, S. Shalamanov, S. Avramova; AcibademCityclinic-Sofia, Sofia, BULGARIA.

EP-0342**Quantitative myocardial-perfusion SPECT. Comparison of three cardiac software programs**

S. Alexiou^{1,2}, P. Georgoulis¹, G. Angelidis¹, V. Valotassiou¹, I. Tsougos³, D. Psimadas¹, D. Tsivaka³, V. Lakiotis², A. Kaspri², D. Alexopoulos⁴, D. Apostolopoulos², P. Vassilakos²; ¹Department of Nuclear Medicine, University Hospital of Larissa, LARISSA, GREECE, ²Department of Nuclear Medicine, University Hospital of Patras, Patras, GREECE, ³Department of Medical Physics, Medical School, University of Thessaly, LARISSA, GREECE, ⁴Department of Cardiology, University Hospital of Patras, Patras, GREECE.

EP-0343**Higher non-fatal cardiac events in diabetics with HBA1C >7.3 and normal stress myocardial perfusion scan**

N. Fatima^{1,2}, M. U. Zaman^{1,2}, D. J. M. Baloch², A. U. Hussaini², S. Z. Rasheed²; ¹Aga Khan University Hospital, Karachi, PAKISTAN, ²Dept of Nuclear Cardiology, Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN.

EP-0344**Hemodynamic and left ventricular mechanical dyssynchrony parameters in patients with ischemic dilated cardiomyopathy: a study with Tc-99m sestamibi stress-rest MPI using adenosine**

G. Kumar, A. Sood, A. Ashwathanarayana, M. Parmar, B. Mittal; Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-0345**Gated Myocardial Perfusion Scintigraphy and Coronary Arteriography Correlation- A Retrospective Evaluation of Our Clinical Experience**

B. T. Okudan¹, Ö. Uçar Elalmış², B. Özyazgan², N. Coşkun¹, P. Arıcan¹; ¹Health Science University Ankara Numune Research and Training Hospital, Nuclear Medicine Clinic, Ankara, TURKEY, ²Health Science University Ankara Numune Research and Training Hospital, Cardiology Clinic, Ankara, TURKEY.

EP-0346**Left Ventricular Dyssynchrony: Influence of Attenuation Correction in Myocardial Perfusion Scintigraphy in an Overweight/Obese Population**

A. Sá Pinto¹, T. Vieira², V. Alves¹, S. Chaves¹, A. Oliveira¹, T. Faria¹, J. Pereira¹; ¹Centro Hospitalar de São João, Porto, PORTUGAL, ²HPP - Medicina Molecular, SA; Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL.

EP-0347**Influence of Stress Test Activity in Left Ventricular Dyssynchrony Evaluation in an Overweight/Obese Population**

A. Sá Pinto¹, T. Vieira², V. Alves¹, S. Chaves¹, A. Oliveira¹, T. Faria¹, J. Pereira¹; ¹Centro Hospitalar de São João, Porto, PORTUGAL, ²HPP - Medicina Molecular, SA; Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL.

EP-0348**Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry Disease**

T. Pellegrino¹, M. Imbriaco², V. Piscopo², M. Petretta³, A. Ponsiglione², C. Nappi², M. Puglia², S. Dell'Aversana², E. Riccio⁴, L. Spinelli², A. Pisanì⁴, A. Cuocolo²; ¹Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ²Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ³Department of Translational Medical Sciences, University Federico II, Naples, ITALY, ⁴Department of Public Health, University Federico II, Naples, ITALY.

EP-0349**Relationship between focal reduction in cardiac I-123 metaiodobenzylguanidine uptake and left ventricular longitudinal function in patients with Anderson-Fabry Disease**

T. Pellegrino¹, L. Spinelli², V. Piscopo², C. Giudice², S. Pellegrino², G. De Matteis², M. Imbriaco², B. Trimarco², A. Cuocolo²; ¹Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY, ²Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY.



EP-0350

A novel clinical risk prediction model for myocardial infarction, coronary revascularization and cardiac death according to clinical, exercise and gated SPECT variables (VHRs)

A. García-Burillo, G. Romero-Farina, S. Aguadé-Bruix, J. Candell-Riera, J. Castell-Conesa, D. García-Dorado; Hospital General Universitari Vall d'Hebron, BARCELONA, SPAIN.

EP-0351

Assessment of normal values of quantitative parameters of tissue muscle perfusion scintigraphy in population without peripheral artery disease - first experience

N. Manevska¹, S. Stojanoski¹, D. Pop Gjorceva¹, L. Todorovska², D. Miladinova¹, V. Majstorov¹; ¹Institute of Pathophysiology and Nuclear medicine, Skopje, MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF, ²Institute of Medical Physiology and Anthropology, Skopje, MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF.

EP-0352

Clinical Follow-Up Post Coronary Artery Bypass Grafting in Patients with Viable Myocardium on 18F-FDG PET

A. S. Kokkadan, M. Shankar, S. H. Venkat Rao, G. K. Chaithanya; Narayanan Hrudayalaya, Bangalore, Karnataka, INDIA.

EP-0353

Evaluation of multipoint pacing-cardiac resynchronization therapy (CRT) by Gated SPECT myocardial perfusion phase analysis and cardiac 123I-MIBG.

I. Casáns-Tormo¹, R. Ruiz-Granel², L. Bondanza-Saavedra², R. Díaz-Expósito¹, V. López-Prior¹; ¹Nuclear Medicine. University Clinic Hospital, Valencia, SPAIN, ²Cardiology. University Clinic Hospital, Valencia, SPAIN.

EP-0354

Hemodynamic Effects of Regadenoson Administration With Respect to MPI Findings: 6 Month Institutional Experience in Greece

J. Koutsikos, G. Angelidis, E. Iliá, M. Vogiatzis, J. Mamarelis, V. Stefanidis, A. Zafirakis, K. Lazaridis, N. Dimakopoulos; Army Share Fund Hospital (417 NIMTS), ATHENS, GREECE.

EP-23 during congress opening hours, e-Poster Area

Cardiovascular System: Clinical Science: Plaque and Vascular Imaging

EP-0355

A novel concept of F-18 NaF PET/CT: Molecular Calcium Scoring measured by F-18 NaF PET/CT in detection and global quantification of cardiovascular molecular calcification

H. Onner, i. Ak Sivriköz, E. Entok; Eskisehir Osmangazi University School of Medicine, Department of Nuclear Medicine, Eskişehir, TURKEY.

EP-0356

Comparison of different semiquantitative approaches for the diagnosis of graft infection after thoracic and abdominal aortic repair using F18-FDG-PET/CT

V. Mergen¹, I. Einspieler¹, M. Mustafa¹, H. Wendorff², K. Thürmel³, M. Schwaiger¹; ¹Department of Nuclear Medicine, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY, ²Clinic for Cardiovascular Surgery, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY, ³Department of Nephrology, Klinikum rechts der Isar TU Muenchen, Munich, GERMANY.

EP-0357

Metabolic Findings Of 18F-FDG PET/CT In Patients With Suspected Inflammatory Vascular Disease

I. Plaza de las Heras, B. Rodriguez Alfonso, R. de Teresa Herrera, C. Field Galán, L. Canales Rodriguez, S. Seijas Marcos, J. Mucientes Rasilla, M. Mitjavila Casanovas; University Hospital Puerta de Hierro, Majadahonda, SPAIN.

EP-0358

Role Of Positron Emission Tomography In The Early Diagnosis Of Infective Endocarditis

E. Abou Jokh Casas, V. Pubul Núñez, M. Garrido Pumar, A. Martínez, M. Pombo Pasin, A. Anxo Martínez, C. Abou Jokh Casas, P. Fierro, I. Dominguez, S. Argibay, Á. Ruibal; Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, SPAIN.

EP-24 during congress opening hours, e-Poster Area

Cardiovascular System: Imaging Systems

EP-0359

Myocardial ischemia in female patients with rheumatoid arthritis

C. Sioka, K. Papadimitropoulos, A. Papadopoulos, J. Al-Boucharali, L. Lakkas, T. Kotrotsios, K. Pappas, A. Fotopoulos; University Hospital of Ioannina, Ioannina, GREECE.



EP-0360**Improving nuclear cardiology efficiency: Novel CZT technology in combination with ^{99m}Tc-tetrofosmin and regadenoson**

S. Kranz, Sr.; Nuklearmedizin Wandsbek Markt, Hamburg, GERMANY.

EP-0361**Advantages of simultaneous dual-isotope SPECT imaging using a cardiac semiconductor camera**

T. Niimi¹, M. Nanasato¹, M. Sugimoto¹, H. Maeda²; ¹Nagoya Daini Red Cross Hospital, Nagoya, JAPAN, ²Nagoya University School of Health Sciences, Nagoya, JAPAN.

EP-0362**Assessment of the impact of small cardiac motions according to motion direction for SPECT images provided by different Anger- and CZT-cameras**

L. Imbert^{1,2,3}, J. Salvadori⁴, Y. Petegnief⁵, S. Rémi⁵, H. Boulahdour⁵, G. Karcher^{1,6,7}, P. Y. Marie^{1,6,7}; ¹CHU Nancy, Vandoeuvre-lès-Nancy, FRANCE, ²Plateforme d'Imagerie Expérimentale Nancyclotep, Vandoeuvre-lès-Nancy, FRANCE, ³IADI, U947, Vandoeuvre-lès-Nancy, FRANCE, ⁴Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, FRANCE, ⁵CHRU de Besançon, Hôpital Jean Minjoz, Besançon, FRANCE, ⁶Plateforme d'Imagerie Expérimentale Nancyclotep, Nancy, FRANCE, ⁷Université de Lorraine, Faculté de Médecine, Nancy, FRANCE.

EP-0363**Radionuclide renoscintigraphy and biochemical markers in the detection of renal dysfunction in patients undergoing myocardial revascularization**

Z. Vesnina, Y. Arsenjeva; Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION.

EP-25 during congress opening hours, e-Poster Area**Cardiovascular System: Miscellaneous****EP-0364****The use of fatty acids labeled with technetium-99m for visualization of the cardiac muscle**

A. Rogov¹, E. Stasyuk¹, N. Varlamova¹, V. Skuridin¹, E. Nesterov¹, S. Sazonova^{2,1}, V. Sadkin¹, E. Ilina¹, V. Chernov^{3,1}, Z. Konstantin^{3,1}; ¹National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ²Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION, ³TOMSK CANCER RESEARCH INSTITUTE, Tomsk, RUSSIAN FEDERATION.

EP-0365**Quantitative evaluation of DNA damage in peripheral blood lymphocyte in patients after cardiac ²⁰¹Tl/¹²³I-BMIPP study**

K. Okuda, N. Watanabe, M. Hashimoto, M. Doai, Y. Kawai, T. Takahashi, T. Arikawa, K. Ooiso, K. Iwabuchi, K. Kajinami, H. Tonami; Kanazawa Medical University, Uchinada, JAPAN.

EP-0366**Cardiac twist quantified by gated myocardial perfusion SPECT: a new insight into nuclear cardiology**

H. Javadi¹, A. Keshavarz², N. Shayestehnia², M. Mansouri², M. Assadi³; ¹Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences (GUOMS), Gorgan, IRAN, ISLAMIC REPUBLIC OF, ²Department of Electrical Engineering, Persian Gulf University, BUSHEHR, IRAN, ISLAMIC REPUBLIC OF, ³The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences (BUMS), BUSHEHR, IRAN, ISLAMIC REPUBLIC OF.

EP-0367**Cardiac SPECT as a predictor of cardiotoxicity in patients with prostate cancer treated with abiraterone acetate after docetaxel therapy**

S. S. Medina-Ornelas, F. O. García-Pérez; Instiuto Nacional de Cancerologia, Mexico City, MEXICO.

EP-0368**Left and Right Ventricular Performance and Cardiovascular Risk in Patients on Maintenance Hemodialysis - an Assessment with Radionuclide Ventriculography at Rest and During Exercise**

N. Topuzović¹, S. Topuzović², I. Mihaljević^{1,2}; ¹Osijek University Hospital, Osijek, CROATIA, ²Faculty of Medicine, University of Osijek, Osijek, CROATIA.

EP-0369**Exercise MPI coupled with impedance cardiography for better cardiac workload assessment - preliminary results**

S. Osiecki, S. Piszczek, E. Witkowska-Patena, M. Dziuk; Military Institute of Medicine, Warszawa, POLAND.



EP-26 during congress opening hours, e-Poster Area

Neurosciences: Basic Science

EP-0370

Amantadine Influences Motor/Exploratory Behavior, but not D2 Receptor Binding in the Rat

S. Nikolaus¹, M. Beu¹, M. A. De Souza Silva², F. Wickrath¹, A. Müller-Lutz¹, C. Antke¹, H. Hautzel¹, J. P. Huston², H. Müller¹, G. Antoch¹, H. Wittsack¹; ¹University Hospital Düsseldorf, Düsseldorf, GERMANY, ²Heinrich-Heine University, Düsseldorf, GERMANY.

EP-0371

Bicuculline Elevates D2 Receptor Binding in the Rat Thalamus

S. Nikolaus¹, H. Wittsack¹, M. Beu¹, M. A. De Souza Silva², C. Antke¹, F. Wickrath¹, A. Müller-Lutz¹, G. Antoch¹, J. P. Huston², H. Müller¹, H. Hautzel¹; ¹University Hospital Düsseldorf, Düsseldorf, GERMANY, ²Heinrich-Heine University, Düsseldorf, GERMANY.

EP-0372

Bilateral stimulation of the abdominal vagus modifies dopamine connectivity in acquired obesity

C. Malbert¹, C. Picq², J. Divoux², C. Henry³; ¹INRA, Saint-Gilles, FRANCE, ²Axonix, Vallorix, FRANCE, ³Livanova, Clamart, FRANCE.

EP-0373

Metformin Effect on Brain Metabolism: the Role of Endoplasmic Reticulum

A. Buschiazzo¹, A. M. Orengo², S. Ravera³, L. Emionite⁴, V. Cossu², A. Bellini¹, S. Morbelli², M. Bauckneht¹, L. Raffaghello⁵, D. Gandolfo², G. Bianchi⁵, S. Bruno⁶, G. Sambuceti^{1,2}, C. Marini^{7,2}; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, ²IRCCS AOU San Martino-IST, Genoa, ITALY, ³Department of Pharmacy, University of Genoa, Genoa, ITALY, ⁴Animal Facility, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁵Laboratory of Oncology, G. Gaslini Institute, Genoa, ITALY, ⁶Department of Experimental Medicine, University of Genoa and IRCCS-AOU San Martino-IST, Genoa, ITALY, ⁷CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

EP-0374

Activations in the gerbil auditory system can be demonstrated in ¹⁸F-FDG PET scans during anesthesia with fentanyl but not if ketamine/xylazine is used

M. Kessler^{1,2}, M. Mamach^{3,2}, R. Beutelmann⁴, J. Bankstahl¹, T. Ross¹, F. Bengel¹, G. Klump^{4,2}, G. Berding^{1,2}; ¹Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, ²Cluster of Excellence Hearing4all, Hannover and Oldenburg, GERMANY, ³Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY, ⁴Animal Physiology and Behaviour Group, Department for Neuroscience, School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, GERMANY.

EP-0375

¹⁸F-FET, ¹⁸F-FCH and ¹⁸F-DOPA uptake on human glioblastoma T98G cells: in vitro study

M. Hodolic¹, M. Persico², L. Lodola³, C. Aprile⁴, R. Nano⁵, F. Pasi⁶; ¹Nuclear Medicine Research Department, Iason, Graz, AUSTRIA, ²Department of Oncohaematology, Nuclear Medicine Unit, Fondazione IRCCS Policlinico San Matteo; Scuola Universitaria Superiore IUSS, Pavia, ITALY, ³Department of Oncohaematology, Nuclear Medicine Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ITALY, ⁴Department of Oncohaematology, Nuclear Medicine Unit, Fondazione IRCCS Policlinico San Matteo; CNAO - National Center of Oncological Hadrontherapy, Pavia, ITALY, ⁵Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, ITALY, ⁶Department of Oncohaematology, Radiotherapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ITALY.

EP-0376

Preclinical evaluation of non-invasive imaging molecules of growth differentiation factor-11 for aging-related diseases' uses

M. C. Weng, M. H. Wang, C. H. Yang, W. M. Li, W. J. Lin; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-0377

Imaging of basal metabolic activity in primary visual cortex in mice. A FDG-microPET study

A. Buschiazzo¹, J. F. Maya-Vetencourt², F. Ticconi¹, L. Emionite³, C. Eleftheriou², C. Marini^{4,5}, S. Icardi⁵, A. Bellini¹, C. Ghersi⁵, A. M. Orengo⁵, F. Benfenati^{2,6}, G. Sambuceti^{1,5}; ¹Department of Health Sciences, University of Genoa, Genoa, ITALY, ²Center for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genoa, ITALY, ³Animal Facility, IRCCS San Martino-IST, Genoa, ITALY, ⁴CNR, Institute of Bioimages and Molecular Physiology, Milan, ITALY, ⁵Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁶Department of Experimental Medicine, University of Genova, Genoa, ITALY.



EP-27 during congress opening hours, e-Poster Area

Neurosciences: Dementia

EP-0378

Brain network alterations in Alzheimer's disease identified by early-phase PIB-PET

L. Fu¹, J. Zhang¹, B. Xu¹, Y. Fan², J. Tian¹; ¹Department of Nuclear Medicine, the Chinese PLA General Hospital, Beijing, CHINA, ²Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, UNITED STATES.

EP-0379

Accuracy of brain FDG PET for detection of Alzheimer's disease in geriatric inpatients with newly manifested cognitive impairment

C. Lange¹, I. Apostolova^{2,3}, A. Mäurer⁴, P. Suppa^{1,5}, H. Amthauer¹, W. Brenner¹, R. Buchert^{1,3}; ¹Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, GERMANY, ²Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, GERMANY, ³Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, ⁴Evangelisches Geriatriezentrum Berlin, Berlin, GERMANY, ⁵jung diagnostics GmbH, Hamburg, GERMANY.

EP-0380

Clinical value of ¹⁸F Florbetaben Amyloid- β PET in a memory clinic.

B. de Kwaasteniet, Jr., D. Raaymakers, senior, J. de Klerk, senior; Meander Medical Center, Amersfoort, NETHERLANDS.

EP-0381

Diagnostic accuracy of FDG-PET/MR for dementia—Estimation of the impact of commercial atlas-based MR attenuation correction

T. Sekine¹, A. Buck², G. Delso³, E. ter Voert², M. W. Huellner², P. Veit-Haibach⁴, G. Warnock²; ¹Nippon Medical School, Tokyo, JAPAN, ²University Hospital Zurich, Zurich, SWITZERLAND, ³GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA, ⁴University of Toronto, Toronto, ON, CANADA.

EP-0382

¹⁸F-FDG PET/CT Usefulness In Primary Progressive Aphasia (PPA) Variants And In Fronto-Temporal Dementia (FTD) Or Alzheimer's Disease (AD) Development

S. Nuvoli¹, M. R. Piras², S. Contu¹, B. L. J. Pung¹, L. Calderoni¹, B. Piras¹, A. Nieddu³, A. Spanu¹, G. Madeddu¹; ¹Unit of Nuclear Medicine, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, ²Unit of Neurology, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, ³Geriatrics DPT, Policlinico Sassarese, Sassari, ITALY.

EP-0383

Midbrain Serotonin transporter (SERT) evaluation by ¹²³I-FP-CIT: a one-year retrospective study

M. Ricci, S. Sollaku, V. Frantellizzi, J. Lazri, F. Monteleone, M. Liberatore, G. De Vincentis; Università di Roma "Sapienza", roma, ITALY.

EP-0384

Topographical overlap of β -amyloid deposition in patients with Alzheimer's disease and mild cognitive impairment - a voxel-wise [¹⁸F] Florbetapir PET/CT study

G. Aghakhanyan¹, M. Gennaro¹, S. Mazzarri¹, A. Vergallo², V. Nicoletti², S. Cintoli², G. Manca¹, L. Garau¹, G. De Laurentis¹, E. Spinelli¹, S. Bola¹, M. Grosso¹, C. Radicchi², G. Tognoni², U. Bonuccelli², D. Volterrani¹; ¹Regional Center of Nuclear Medicine, University Hospital of Pisa, Pisa, ITALY, ²Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ITALY.

EP-0385

The impact of FDG and amyloid PET-CT in a clinical setting consisting of patients with suspected dementia: the Ferrara experience

A. Farolfi^{1,2}, I. Rambaldi², D. Gragnaniello³, P. Milani³, S. Panareo², I. Santi², S. Taralli², M. Bartolomei², V. Tugnoli³, C. Cittanti²; ¹Nuclear Medicine Unit - S. Orsola-Malpighi Hospital - University of Bologna, Bologna, ITALY, ²Nuclear Medicine Unit - Azienda Ospedaliero Universitaria, Ferrara, ITALY, ³Neurology Unit - Azienda Ospedaliero Universitaria, Ferrara, ITALY.

EP-0386

Change of glucose metabolism in white matter of AD patients using F-18 FDG PET

Y. Jeong, H. Yoon, J. Jeong, D. Kang; Dong-A University Hospital, Busan, KOREA, REPUBLIC OF.

EP-0387

How Useful is Amyloid PET in Clinical Diagnosis? A Systematic Review and Meta-analysis

E. R. Fantoni¹, A. Chalkidou^{2,3}, G. Farrar¹, A. Hammers⁴; ¹GE Healthcare, Amersham, UNITED KINGDOM, ²King's College London, St Thomas' Hospital, London, UNITED KINGDOM, ³King's Imaging Technology Evaluation Centre, St Thomas' Hospital, London, UNITED KINGDOM, ⁴King's College London, London, UNITED KINGDOM.



EP-0388

Coupled imaging with 18F FBB and 18F FDG in AD subjects show a selective association between amyloid burden and cortical dysfunction in brain

A. Chiaravalloti^{1,2}, A. Castellano², P. Sannino², M. Zinzi², E. Di Giorgio², F. Scalone¹, R. Giacipoli¹, O. Schillaci^{1,2};
¹Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, ²IRCCS Neuromed, Pozzilli, ITALY.

EP-0389

Evaluation of Magnetic Resonance and PET/CT methods with FDG-18F in the diagnosis of Alzheimer's disease

B. L. Ferrari, G. C. Campos Neto, A. C. Felício, E. Amaro, S. L. Silva, L. F. Gamarra; Hospital Israelita Albert Einstein, São Paulo, BRAZIL.

EP-0390

Semiquantitative analysis of amyloid PET/CT and the performance of its own CT images for ROI's delimitation

F. Segovia Roman¹, N. Testart Dardel^{2,1}, R. Sanchez Vaño^{1,3}, P. Sopena-Navales³, A. Gonzalez-Jimenez², R. Sanchez Sanchez², E. Triviño-Ibañez², J. Ramírez Pérez de Inestrosa¹, M. Gomez-Rio²; ¹Universidad de Granada, Granada, SPAIN, ²Hospital Virgen de las Nieves, IBS, Granada, SPAIN, ³Hospital 9 de octubre, Valencia, SPAIN.

EP-0391

FDG PET as a golden standard in the evaluation of diagnostic significance of metabolic ratios measured with multiple tracers

J. Khomenko, G. Kozlov, A. Gromova, E. Chernysheva, D. Susin, A. Boronina; Bechtereva Institute of the Human Brain, St.Peterburg, RUSSIAN FEDERATION.

EP-0392

Diagnostic implications of total hemispheric glucose metabolism ratio in Mild cognitive impairment and Alzheimer's disease

E. A. Segtnan¹, A. Majd², C. Constantopoulos¹, J. Grupe¹, H. Dali¹, O. Strøm¹, J. Holm¹, M. S. Sørensen¹, A. Alavi³, S. Sadigh-Eteghad³, L. W. Madsen¹, A. Gjedde¹, P. Høilund-Carlsen¹; ¹Odense University Hospital, Odense, DENMARK, ²Neurosciences Research Center (NSRC), Tabriz, IRAN, ³REPUBLIC OF, ³Division of Nuclear Medicine, Department of Radiology, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-0393

Clinical Utility of the Brain SPECT with Ioflupane 123I-FP-Scan in the Imagiological Diagnosis of Possible Dementia with Lewy Bodies

J. F. Alban¹, M. J. Cunha¹, M. Marques¹, A. Albuquerque¹, G. Costa^{1,2}, J. Pedroso de Lima^{1,2,3}; ¹Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, ³Instituto das Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL.

EP-28 during congress opening hours, e-Poster Area

Neurosciences: Psychiatry

EP-0394

The Metabolic Basis of Cognitive Insight in Psychosis: a Positron Emission Tomography Study

G. Marotta, E. Caletti, G. Delvecchio, R. A. Paoli, M. Cigliobianco, C. Prunas, P. Brambilla, C. A. Altamura; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ITALY.

EP-0395

Cerebral metabolism changes and neurocognition in patients with symptoms and related disorders and dissociative disorders: a qualitative study

G. Capriotti¹, M. Capriotti¹, M. Del Casale¹, G. Lauretti¹, L. Carideo¹, P. Carideo¹, D. Prospero², F. Scopinaro¹; ¹Sapienza University, Rome, ITALY, ²Sant'Andrea Hospital, Rome, ITALY.

EP-0396

Protective and restorative effects of the traditional Chinese medicine Jitai tablets against methamphetamine-induced dopaminergic neurotoxicity

S. Xu¹, S. Tu¹, J. Gao¹, J. Liu¹, Z. Guo¹, J. Zhang², X. Liu³, J. Liang⁴, Y. Huang⁵, M. Han¹; ¹Beijing Normal University, Beijing, CHINA, ²Chinese PLA General Hospital, Beijing, CHINA, ³Huashan Hospital, Fudan University, Shanghai, CHINA, ⁴Peking University School of Pharmaceutical Sciences, Beijing, CHINA, ⁵Yale University School of Medicine, New Haven, CT, UNITED STATES OF AMERICA.

EP-0397

Brain hypothyroidism induces the elevation of serotonin 1A receptor bindings in the limbic system

J. Lee¹, Y. Ryu¹, J. Park², K. Lee², K. Kim², J. Cho²; ¹Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, ²Korea Institute of Radiological & Medical Sciences, Seoul, KOREA, REPUBLIC OF.



EP-0398**Striatal Dopaminergic Dysfunction in Patients with Gambling Disorder**

D. Di Giuda¹, F. Cocciolillo², M. Pettorruso³, I. Bruno⁴, V. Valenza¹, G. Camardese³, G. Conte³, L. Janiri³, A. Giordano¹; ¹Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY, ²Nuclear Medicine Unit, Ente Ecclesiastico Ospedale Generale "F. Miulli", Acquaviva delle Fonti, Bari, ITALY, ³Institute of Psychiatry, Università Cattolica del Sacro Cuore, Rome, ITALY, ⁴Nuclear Medicine Unit, Policlinico "A. Gemelli", Rome, ITALY.

EP-0399**Anatomo-Functional Correlations of Personality Traits to Aggression and Aggressive Behavior in Cocaine Addicts**

R. Ferrando, C. Pascovich, M. Langhain, A. Negrin, A. Silveira; Clinics Hospital, University of the Republic, Montevideo, URUGUAY.

EP-29 during congress opening hours, e-Poster Area
Neurosciences: Neurodegeneration

EP-0400**11C-Pittsburgh Compound B PET in Primary Intracerebral Hemorrhage**

R. Yen, H. Tsai, L. Tsai, Y. Chen, J. Jeng; National Taiwan University Hospital, Taipei, TAIWAN.

EP-0401**Divergent Metabolism in Brain and Spinal Cord in Patients with Amyotrophic Lateral Sclerosis: A FDG-PET/CT Study**

A. Buschiazzo¹, C. Marini², M. Piana³, C. Campi³, A. Bellini¹, A. Cistaro⁴, A. Chiò⁵, C. De Vecchi³, I. Calamia¹, A. M. Massone³, F. M. Nobili⁶, C. Caponnetto⁷, S. D. Morbelli⁸, F. Fiz⁹, M. Bauckneht¹, G. Sambuceti^{1,8}; ¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, ²CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY, ³Department of Mathematics, University of Genoa, Genoa, ITALY, ⁴Positron Emission Tomography Centre IRMET S.p.A., Euromedic inc., Turin, ITALY, ⁵Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, ITALY, ⁶Clinical Neurology, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁷Department of Neuroscience, IRCCS AOU San Martino-IST, Genoa, ITALY, ⁸IRCCS AOU San Martino-IST, Genoa, ITALY, ⁹Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum Tübingen, Tübingen, GERMANY.

EP-0402**Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer Disease**

A. Chiaravalloti^{1,2}, C. Liguori³, M. Nuccetelli⁴, F. Izzi³, G. Sancesario⁵, A. Cimini¹, S. Bernardini⁴, O. Schillaci¹, N. Mercuri³, F. Placidi³; ¹Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, ²IRCCS Neuromed, Pozzilli, ITALY, ³Sleep Medicine Centre, Neurophysiopathology Unit, Department of Systems Medicine, University Tor Vergata, Rome, ITALY, ⁴Clinical Biochemistry and Molecular Biology, University Tor Vergata, Rome, ITALY, ⁵Neurology Unit, Department of Systems Medicine, University Tor Vergata, Rome, ITALY.

EP-0403**Cognitive Reserve (CR) interacts with brain metabolism in regions independent of the PD-related network: an ¹⁸F-FDG PET study in Parkinson disease (PD) de novo patients**

H. Efe Türk¹, M. Bauckneht¹, D. Arnaldi², A. Buschiazzo¹, R. Piva¹, F. Ticconi¹, M. Pardini², F. Massa², A. Bugnolo², N. Girtler², J. Accardo², G. Sambuceti¹, F. Nobili², S. Morbelli¹; ¹IRCCS San Martino - IST, University of Genoa, Genoa, ITALY, ²Clinical Neurology, University of Genoa, Genoa, ITALY.

EP-0404**Evaluation of age-related metabolic changes in healthy subjects: an italian brain ¹⁸F-FDG PET study**

V. Berti¹, M. Allocca¹, F. Linguanti¹, M. L. Calcagni², A. Cristaro³, U. P. Guerra⁴, F. Nobili⁵, S. Pappatà⁶, S. Sestini⁷, D. Volterrani⁸, F. Tutino¹, A. Ciaccio¹, R. Sciagrà¹; ¹Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, ITALY, ²Institute of Nuclear Medicine, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, ITALY, ³Positron Emission Tomography Centre IRMET S.p.A., Turin, ITALY, ⁴Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, ITALY, ⁵Clinical Neurology, Department of Neuroscience (DINO GMI), University of Genoa, Genoa, ITALY, ⁶Institute of Biostructure and Bioimaging, CNR, Naples, ITALY, ⁷Nuclear Medicine Unit, U.S.L. Toscana Centro, Prato, ITALY, ⁸Nuclear Medicine Unit, University Hospital of Pisa, Pisa, ITALY.

EP-0405**Voxel and surface-based structural and functional imaging study in patients with idiopathic REM sleep behavior disorder**

X. Han¹, X. Li¹, W. Tang², H. Yu³, P. Wu¹, C. Zuo¹; ¹PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Department of Radiology, Huashan Hospital, Fudan University, Shanghai, CHINA, ³Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.



EP-0406**[¹⁸F]FDG PET imaging study in early phase of unilateral 6-OHDA Parkinson disease rats model submitted to treadmill exercise protocol**

C. C. Real, K. H. Binda, P. C. Garcia, C. G. Carneiro, C. A. Buchpiguel, D. P. Faria, L. R. G. Britto; University of São Paulo, São Paulo, BRAZIL.

EP-0407**Therapeutic effects of dietary intervention on neuroinflammation and brain metabolism in a rat model of photothrombotic stroke**

E. Kurtys^{1,2}, C. Casteels³, C. C. Real⁴, U. L. M. Eisel⁵, J. M. Verkuy⁶, L. M. Broersen⁶, H. C. Klein², R. A. J. O. Dierckx², J. Doorduyn², E. F. J. de Vries²; ¹King's College London, London, UNITED KINGDOM, ²University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ³Catholic University Leuven, Leuven, BELGIUM, ⁴University of São Paulo, São Paulo, BRAZIL, ⁵University of Groningen, Groningen, NETHERLANDS, ⁶Nutricia Research, Utrecht, NETHERLANDS.

EP-0408**Comparison of [¹⁸F]FE-PE2I and [¹⁸F]fluorodopa/PET images in the LPS-induced Parkinsonian rat model**

K. Ma¹, H. Ko¹, S. Weng¹, T. Chou², C. Tsai³, Y. Huang³, R. Yen³, C. Shiu^{2,3}, C. Halldin⁴; ¹Department of Biology and Anatomy, National Defense Medical Center, Taipei, TAIWAN, ²Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, TAIWAN, ³Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN, ⁴Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, Stockholm, SWEDEN.

EP-0409**Evaluating the status of serotonin transporters in the LPS-induced rat model using 4-[¹⁸F]-ADAM/PET**

C. Cheng¹, K. Ma², T. Ho², S. Weng², T. Chou¹, C. Shiu¹; ¹Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, TAIWAN, ²Department of Biology and Anatomy, National Defense Medical Center, Taipei, TAIWAN.

EP-0410**Disease-related Metabolic Brain Patterns Associated with Parkinsonian and Cerebellar Subtypes of Multiple System Atrophy**

P. Wu¹, J. Wang², J. Wu², C. Jiang¹, J. Ge¹, Y. Ma³, Y. Ma³, C. Zuo¹; ¹PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA, ³Center for Neurosciences, Feinstein Institute for Medical Research, Manhasset, NY, UNITED STATES OF AMERICA.

EP-0411**Chronic Exposure to Resveratrol Improves Cerebral Blood Flow and Cognitive Function in Aged Rats**

P. Garrigue, Y. M... L. Seree, M. Alessi, F. Dignat-George, B... Aix-Marseille Université, Marseille, FRANCE.

EP-0412**Effects of Pioglitazone on Amyloidogenesis, Neuroinflammation and Cognition in Transgenic Amyloid Mouse Model**

M. Brendel¹, M. Deussing¹, B... Blume¹, Y. Shi³, G. Kleinberger³, C. Focke... er¹, F. Gildehaus¹, P. Bartenstein¹, K. B... C. Haass³, H. Adelsberger², A. Rominger¹; ¹University of Munich, Munich, GERMANY, ²Techni... University of Munich, Munich, GERMANY, ³DZNE, Munich, GERMANY, ⁴F. Hoffmann-La Roche, Basel, SWITZERLAND.

EP-30 during congress opening hours, e-Poster Area**Neurosciences: Neurotransmission****EP-0413****Dopaminergic, Serotonergic And Glucose Metabolism Disorders At Early Stage Of Disease In Accelerated Mouse Model Of Synucleinopathy**

E. Levigoureux^{1,2}, C. Bouillot³, T. Baron⁴, L. Zimmer^{1,2,3}, S. Lancelot^{1,2}; ¹Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon Neuroscience Research Center, Lyon, France, Lyon, FRANCE, ²Hospices Civils de Lyon, Lyon, FRANCE, ³CERMEP, Imagerie du vivant, Lyon, FRANCE, ⁴ANSES, Lyon, FRANCE.

EP-31 during congress opening hours, e-Poster Area**Neurosciences: Movement Disorders****EP-0414****123I-MIBG Cardiac Scintigraphy And 123I-IOFLUPANE SPECT Combined Use In Uncertain Parkinsonian Syndromes**

S. Nuvoli¹, M. R. Piras², A. Mulas¹, B. L. J. Pung¹, B. Piras¹, A. Santonicola³, B. Palumbo³, A. Spanu¹, G. Madeddu¹; ¹Unit of Nuclear Medicine, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, ²Unit of Neurology, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, ³Section of Nuclear Medicine, Surgical and Biomedical Sciences DPT, University of Perugia, Perugia, ITALY.



EP-0415**Effects of different reconstruction methods on ¹²³I-FP-CIT (DaTSCAN) SPECT quantification**

A. Smith¹, J. Niedbala², Y. Dewaraja², J. C. Dickson¹;
¹University College London Hospital, London, UNITED KINGDOM, ²University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

EP-0416**Right versus left onset Parkinson's disease metabolic patterns: a FDG PET study.**

X. Palard-Novello¹, P. David², J. Houvenaghe³, A. Riou³, G. Robert⁴, S. Drapier³, M. Vérin³, F. Le Jeune¹; ¹Centre Eugène Marquis, Rennes, FRANCE, ²Hôpital Européen Georges Pompidou, Paris, FRANCE, ³CHU Rennes, Rennes, FRANCE, ⁴CH Guillaume Régnier, Rennes, FRANCE.

EP-0417**Evaluation of an automated classification method for DaTscan™ SPECT using a volumetric approach to the Southampton Method**

D. Mirando, A. Kruzer, A. S. Nelson; MIM Software, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0418**Hypometabolism of the putamen and the pallidum in 18F FDG PET is predictive of clinical disability in multiple system atrophy**

F. Hives¹, A. Pavy-Le Traon², J. Dupouy^{3,4}, F. Ory-Magne^{5,6}, C. Brefel-Courbon^{5,6,7}, O. Rascol^{8,9}, A. Hitzel¹, P. Payoux^{10,1}; ¹Department of Nuclear Medicine, University Hospital of Toulouse, Toulouse, FRANCE, ²Institute of Cardiovascular and Metabolic Diseases, National Institute of Health and Medical Research (INSERM), UMR-1048, Toulouse, FRANCE, ³Pharmacoepidemiology Research Unit, INSERM 1027, University of Toulouse, Toulouse, FRANCE, ⁴Academic Department of Family Medicine, Faculty of Medicine Toulouse, University of Toulouse, Toulouse, FRANCE, ⁵INSERM UMR1214, Imagerie cérébrale et handicaps neurologiques, Toulouse, FRANCE, ⁶Department of Neurology, University Hospital of Toulouse, Toulouse, FRANCE, ⁷Department of Clinical Pharmacology, University Hospital of Toulouse, Toulouse, FRANCE, ⁸Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, Toulouse, FRANCE, ⁹INSERM CIC1436 and UMR825, Toulouse, FRANCE, ¹⁰INSERM UMR825, Imagerie cérébrale et handicaps neurologiques, Toulouse, FRANCE.

EP-0419**What is the diagnostic accuracy of FDG-PET in the Atypical Parkinsonian Syndromes**

A. Buschiazzo¹, A. Chincarini², D. Volterrani³, G. Puccini³, B. Paghera⁴, U. P. Guerra⁵, M. Gregianin⁶, V. Fiore⁶, S. Sestini⁷, C. Mazzeo⁷, A. Cistaro⁸, F. Ticconi¹, D. Arnaldi⁹, G. Sambuceti^{1,10}, S. Morbelli¹⁰, F. Nobili⁹; ¹Department of Health Sciences, University of Genoa, Genoa, ITALY, ²National Institute of Nuclear Physics (INFN), Genoa section, Genoa, ITALY, ³Department of Translational Research and Novel Technologies, University of Pisa, Pisa, ITALY, ⁴Nuclear Medicine Spedali Civili and University of Brescia, Brescia, ITALY, ⁵Nuclear Medicine Fondazione Poliambulanza-Istituto ospedaliero, Brescia, ITALY, ⁶Nuclear Medicine Unit, San Giacomo Hospital, Castelfranco Veneto, ITALY, ⁷Department of Diagnostic Imaging, Nuclear Medicine Unit N.O.P.-S. Stefano, U.S.L. Toscana Centro, Prato, ITALY, ⁸Positron Emission Tomography Centre IRMET S.p.A. Euromedic inc., Turin, ITALY, ⁹Clinical Neurology, Department of Neuroscience (DINOGLMI), University of Genoa and IRCCS AOU, San Martino-IST, Genoa, ITALY, ¹⁰Nuclear Medicine Unit, IRCCS AOU San Martino-IST, Genoa, ITALY.

EP-0420**Negative correlation between dopamine transporter activity at caudate nucleus and the symptom duration at FP-CIT PET/CT in Parkinson disease**

J. Park¹, J. Park¹, A. Lee¹, J. Hwang¹, S. Park²;
¹Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF, ²Soonchunhyang University Seoul Hospital, Seoul, KOREA, REPUBLIC OF.

EP-32 during congress opening hours, e-Poster Area**Neurosciences: Data Analysis & Quantification****EP-0421****Cerebral ¹⁸F-FDG PET in macrophagic myofasciitis : an individual SVM based approach for computer aided diagnosis**

P. Blanc-Durand¹, A. van Der Gucht¹, E. Guedj², M. Abulisi¹, M. Sebaiti¹, A. Verger³, L. Lerman¹, F. Authier¹, E. Itti¹; ¹Henri-Mondor, Créteil, FRANCE, ²La Timone, Marseille, FRANCE, ³CH Strasbourg, Strasbourg, FRANCE.

EP-0422**An investigation for intra-observer reproducibility of FP-CIT SPECT in patients with DLB**

A. Okizaki, M. Nakayama, K. Takahashi; Asahikawa Medical University, Asahikawa, JAPAN.



**EP-0423****Impact of Computer Aided Diagnosis (CAD) on DaTSCAN reporting: a pilot study**

J. Taylor¹, M. Kinsella¹, Y. Yong¹, I. Azam¹, R. Balachandar¹, V. Balian¹, M. King¹, C. Lo¹, O. Bandmann², J. Fenner²; ¹Sheffield Teaching Hospitals, Sheffield, UNITED KINGDOM, ²University of Sheffield, Sheffield, UNITED KINGDOM.

EP-0424**Low-dose PET/MRI of patients with non-lesional epilepsy**

J. Cal-Gonzalez¹, G. Schramm², K. Vunckx², I. Rausch¹, L. Shiyam Sundar¹, J. Nuyts², T. Traub-Weidinger³, T. Beyer¹; ¹QIMP group, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, ²KU/UZ Leuven, Department of Imaging and Pathology, Division of Nuclear Medicine, Leuven, BELGIUM, ³Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-0425**The effect of image reconstruction algorithms on topography of characteristic metabolic brain network for Parkinson disease**

L. Jensterle¹, P. Tomše¹, M. Grmek¹, Z. Pirtošek², V. Dhawan³, D. Eidelberg³, Y. Ma³, M. Trošt²; ¹University Medical Centre Ljubljana, Department of Nuclear Medicine, Ljubljana, SLOVENIA, ²University Medical Centre Ljubljana, Neurology Department, Ljubljana, SLOVENIA, ³The Feinstein Institute for Medical Research, Center for Neurosciences, New York, NY, UNITED STATES OF AMERICA.

EP-0426**Application of Attenuation Correction for Quantitative Brain Perfusion SPECT in Patients with Dementia**

A. K. Kondakov¹, D. Y. Mosin², D. S. Kharina², A. V. Grechko³, I. A. Znamenskiy¹; ¹Pirogov RNRMU, Moscow, RUSSIAN FEDERATION, ²Central Clinical Hospital of the RAS, Moscow, RUSSIAN FEDERATION, ³Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, RUSSIAN FEDERATION.

EP-0427**Comparison of an image-based to an atlas-based set of volumes of interest for DaTScan quantification**

R. Fahmi, S. Zuehlsdorff; Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0428**Comparison of tissue time activity curve based image derived input function estimation methods in simulation for non-invasive CBF imaging**

N. Kudomi¹, H. Watabe²; ¹Faculty Of Medicine, Kagawa University, KAGAWA, JAPAN, ²Cyclotron and Radioisotope Center, Tohoku University, Sendai, JAPAN.

EP-0429**Validation of non-invasive tracer kinetic analysis of ¹⁸F-Florbetaben PET using a patient-friendly dual time-window acquisition protocol**

S. Bullich¹, A. Jovalekic¹, N. Koglin¹, G. Becker², S. De Santi³, O. Sabri², H. Barthelemy²; ¹Piramal Imaging GmbH, Berlin, GERMANY, ²Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, GERMANY, ³Piramal Pharma Inc, Boston, MA, UNITED STATES OF AMERICA.

EP-0430**Validation of a dose reduction simulation for neurodegenerative brain indications in ¹⁸F-FDG PET/MR**

M. Soret¹, J. Maisonobe¹, M. Khalife², A. Kas¹; ¹APHP, Hôpital Pitié-Salpêtrière, Paris, FRANCE, ²Institut du Cerveau et de la Moëlle épinière, Paris, FRANCE.

EP-0431**PET Kinetic Modeling with Arterial Sampling of ¹⁸F-Choline Uptake in Patients with a Suspected Initial Diagnosis of High Grade Glioma**

S. Rubí^{1,2}, P. Bibiloni³, M. Galmés⁴, M. Toscano¹, M. Oporto¹, M. Villar¹, M. Ortiz¹, J. Valera¹, G. Matheu¹, J. Molina¹, M. Brell^{1,2}, M. González³, A. Mir³, C. Peña^{1,2}; ¹Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, ²Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, SPAIN, ³Grup Scopia, Universitat de les Illes Balears (UIB), Palma de Mallorca, SPAIN, ⁴Hospital QuirónSalud Palmaplanas, Palma de Mallorca, SPAIN.

EP-0432**Assessment of the Impact of Repeat Scanning on Centiloid Scaling Values using PMOD Image Quantification Software**

M. Battle, C. Buckley; GE Healthcare, Amersham, UNITED KINGDOM.

EP-0433**xSPECT derived absolute SUV: An emerging accurate tool for I-123-ioflupane analysis**

M. Jreige¹, F. Tabotta¹, M. Nicod Lalonde¹, R. Fahmi², N. Schaefer¹, G. Allenbach¹, J. O. Prior¹; ¹Centre Hospitalier Universitaire Vaudois (CHUV), LAUSANNE, SWITZERLAND, ²Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

EP-0434**Decline with Age in Normal Cerebral and Cerebellar Glucose Metabolism in Women and Men Determined by FDG PET/CT**

F. Seifar¹, N. Parnianfar¹, C. Constantinescu², K. Shakouri¹, P. F. Høilund-Carlsen²; ¹Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

EP-0435**Assessment of False-Positive Results in SPM SPECT Group Comparisons**

R. Ferrando, C. Pascovich, S. Parra, M. Langhain; Clinics Hospital, University of the Republic, Montevideo, URUGUAY.

EP-33 during congress opening hours, e-Poster Area**Neurosciences: Miscellaneous****EP-0436****The Effect of Obesity on the Availability of Dopamine and Serotonin Transporter**

K. Pak¹, Y. Lim², S. Kim²; ¹Pusan National University Hospital, Busan, KOREA, REPUBLIC OF, ²Pusan National University Yangsan Hospital, Yangsan, KOREA, REPUBLIC OF.

EP-0437**Interpretation and analysis of PET scans in hypermetabolism in patients with epilepsy**

R. Wang, Z. Tong, X. Cai, X. Liu, J. Zhang; Peking University First Hospital, Beijing, CHINA.

EP-0438**Brain death scintigraphy**

P. Sirucek^{1,2}, D. Novakova¹, M. Havel^{1,2}, O. Kraft^{1,2}; ¹University hospital, Ostrava, CZECH REPUBLIC, ²University of Ostrava, Department of Imaging Methods, Ostrava, CZECH REPUBLIC.

EP-0439**Ictal SPECT injector commercially available: EpiJET**

X. Setoain, F. Campos, J. Pavia, O. Vernet, P. Paredes, M. Mayoral, M. Carreño, F. Lomeña; Hospital Clínic de Barcelona, Barcelona, SPAIN.

EP-0440**Neuromodulatory effects of galvanic white noise vestibular stimulation after bilateral labyrinthectomy in the rat**

M. Lindner¹, E. Eilles¹, L. Günther¹, A. Gosewisch¹, L. Vomacka¹, G. Xiong¹, R. Oos², P. Bartenstein², R. Beck¹, A. Zwergal³; ¹Deutsches Schwindel- und Gleichgewichtszentrum (DSGZ), Klinikum der Universität München, Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY, ²Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY, ³Deutsches Schwindel- und Gleichgewichtszentrum (DSGZ), Klinikum der Universität München, Institut für klinische Neurowissenschaften/Neurologische Klinik, Klinikum der Universität München, München, GERMANY.

EP-0441**Cardiac selectivity of autonomic sympathetic alteration in Parkinson Disease**

A. Nieri¹, R. Piva¹, G. Borgonovo¹, V. Ceriani¹, M. Pennone², G. Siclari², F. Ticconi¹, M. Sicignano², G. Villa², G. Sambuceti^{1,2}, C. Marini³; ¹Nuclear Medicine, Department of Health Sciences, University of Genoa and IRCCS AOU San Martino-IST, Genova, ITALY, ²Nuclear Medicine Unit, IRCCS San Martino-IST, Genova, ITALY, ³CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

EP-0442**Brain ¹⁸F FDG abnormalities in Neurobechet Disease**

A. Chiaravalloti^{1,2}, F. Ursini³, S. D'Angelo⁴, A. Padula⁴, M. Gilio⁴, P. Leccese⁴, P. Sannino², E. Di Giorgio², F. Calabria⁵, O. Schillaci^{1,2}, I. Olivieri⁴; ¹Department of Biomedicine and Prevention, University Tor Vergata, Rome, ITALY, ²IRCCS Neuromed, Pozzilli, ITALY, ³Department of Health Sciences, University Magna Graecia, Catanzaro, ITALY, ⁴Azienda Ospedaliera Regionale San Carlo, Potenza, ITALY, ⁵Neuroimaging PET/MRI Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, ITALY.

EP-0443**Post traumatic olfactory dysfunction assessment by ^{99m}TcHMPAO brain imaging**

I. Konstantinidis¹, I. Iakovou², E. Tsakiropoulou¹, V. Mpalaris², V. Athanasiou², D. Katsampoukas², D. Lo Presti², S. Georga², G. Arsos²; ¹Academic ORL dpt, Papageorgiou hsp., THESSALONIKI, GREECE, ²Academic Nuclear Medicine dpt, Papageorgiou hsp., THESSALONIKI, GREECE.

e-poster not submitted



EP-0444**99mTc HM-PAO Brain Spect Qualitative And Quantitative Analyses (QLA/QNA) In Fibromyalgia Syndrome (FMS) Treated With Hyperbaric Oxygen Therapy (HOT)**

S. Nuvoli¹, A. Bolognini², G. Motroni³, L. Calderoni¹, B. Piras¹, A. Spanu¹, G. Madeddu¹; ¹Unit of Nuclear Medicine, Clinical and Experimental Medicine DPT, University of Sassari, Sassari, ITALY, ²Hyperbaric Center, Sassari, ITALY, ³Unit of Functional Recovery and Rehabilitation AOU Sassari, Sassari, ITALY.

EP-0445**18F-FDG PET/MRI allows improved detection of epileptogenic focus in patients with normal MRI**

C. E. Popescu¹, F. Caobelli², R. Mai¹, R. Sara¹, M. Milella¹, A. Liuni¹, C. Rossetti¹; ¹Niguarda Hospital, Milano, ITALY, ²University Hospital Basel, Basel, SWITZERLAND.

EP-0446**Radionuclide cisternography in the detection of cerebrospinal fluid leakage**

D. Ben Sellem, L. Zaabar, B. Dhaoadi, I. El Bez, B. Letaief, M. F. Ben Slimene; University of Tunis El Manar, Tunis, TUNISIA.

EP-0447**Brain death scintigraphy - a 12 year experience**

A. Fernandes¹, T. Faria¹, A. Oliveira¹, J. Pereira¹, P. Coelho²; ¹Hospital de São João, Porto, PORTUGAL, ²Universidade Fernando Pessoa, Porto, PORTUGAL.

EP-0448**First results of combined brain perfusion SPECT and EEG measurements during speech processing in cochlear-implant users**

M. Kessler^{1,2}, I. Schierholz^{2,3}, M. Mamach^{2,4}, F. Wilke⁴, A. Hahne⁵, L. Geworski⁴, A. Büchner^{3,2}, F. Bengel¹, P. Sandmann⁶, G. Berding^{1,2}; ¹Department of Nuclear Medicine, Hannover Medical School/Hannover Medical School, Hannover, GERMANY, ²Cluster of Excellence Hearing4all, Hannover and Oldenburg, GERMANY, ³Department of Otolaryngology, Hannover Medical School, Hannover, GERMANY, ⁴Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY, ⁵Saxon Cochlear Implant Center, University Hospital, Dresden, GERMANY, ⁶Department of Otorhinolaryngology, University of Cologne, Cologne, GERMANY.

EP-0449**Value of MIBG myocardial scintigraphy in the differential diagnosis of neurodegenerative disorders**

L. Mohamed Salem, Sr., M. Godoy Bravo, R. Reyes Marles, I. Sime Loayza, M. Castellon Sanchez, L. Frutos Esteban, F. Nicolas Ruiz, J. Navarro Ferenandez, J. Marín Muñoz, S. Manzanares Sánchez, F. Noguera Perea, C. Antúñez Almagro, M. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-0450**Advanced FDG PET Imaging of the Orbits using an Ultra-High Definition Digital PET/CT Approach**

C. L. Wright¹, K. Binzel¹, M. Mohamed¹, J. Zhang¹, P. Maniowski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ²Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-0451**Brain SPECT Findings In Patients With Malformations Of The Corpus Callosum: Clues For Neuroimaging Reports**

L. Wichert-Ana^{1,2}, A. C. Trevisan¹, C. E. P. Baltazar¹, L. Alexandre-Santos¹, F. A. Pitella¹, E. N. Itikawa^{1,2}, M. Kato¹, M. V. Simões¹, M. V. Santos¹, H. R. Machado¹, A. C. Sakamoto¹, A. C. Santos¹; ¹Ribeirão Preto Medical School, University of São Paulo - USP, Ribeirão Preto - SP, BRAZIL, ²Bioengineering Interunits Postgraduation Program, São Carlos Engineering School, University of São Paulo - USP, São Carlos - SP, BRAZIL.

EP-0452**Importance Of Using Portable Mini-Gamma Camera In Scintigraphic Brain Death Diagnosis**

M. Godoy Bravo, R. Reyes Marles, A. Abella Tarazona, I. Sime Loayza, M. Castellon Sanchez, L. Mohamed Salem, L. Frutos Esteban, J. Navarro Fernandez, F. Nicolas Ruiz, M. Claver Valderas; Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-0453**Location Of Cerebrospinal Fluid (CSF) Leaks And Treatment With Epidural Blood Patch (EBP) In Spontaneous Intracranial Hypotension Syndrome (SHI) And Assesment Of Neuroimaging, MRI And Radionuclide Cisternography**

P. Plaza¹, N. Mayolas², N. Morollon², E. Rivera², B. Domenech¹, P. Pifarre¹, J. Oglio², A. Banguero², R. Belvis²; ¹Hospital Quironsalud Barcelona, Barcelona, SPAIN, ²Hospital Universitario Dexeus, Barcelona, SPAIN.



EP-0454

Prognostic Contribution Of SISCOM In The Presurgical Evaluation Of Patients With Refractory Epilepsy And Negative 3T MRI

L. Wichert-Ana^{1,2}, E. N. Itikawa^{1,2}, L. Alexandre-Santos¹, F. A. Pitella¹, J. H. Silvah¹, A. C. Trevisan¹, M. Kato¹, V. Alexandre-Junior¹, A. P. Martins¹, F. N. Nakano¹, T. R. Velasco¹, A. P. Martins¹, M. V. Simões¹, A. C. Sakamoto¹, A. C. Santos¹; ¹Ribeirão Preto Medical School, University of São Paulo - USP, Ribeirão Preto - SP, BRAZIL, ²Bioengineering Interunits Postgraduation Program, São Carlos Engineering School, University of São Paulo - USP, São Carlos - SP, BRAZIL.

EP-0455

Contribution of 18F-FDG PET/CT to the clinical diagnosis of Autoimmune Encephalitis: VISUAL vs VOXEL-BASED ANALYSIS

B. Garcia-Garcia, D. Moreno-Ajona, E. Prieto, E. Guillen, A. Minguez, M. Morales, M. Riverol, J. Gallego-Perez Larraya, J. Arbizu; Clinica Universidad de Navarra, Pamplona, SPAIN.

EP-0456

Varying Standards for Brain Death Scintigraphy Across National and Professional Societies

L. S. Zuckier¹, T. L. McFarland²; ¹The Ottawa Hospital, Ottawa, ON, CANADA, ²University of British Columbia, Kelowna, BC, CANADA.

EP-0457

Brain Perfusion Scintigraphy Confirmation Test Of Absent Cerebral Blood Flow

T. Samardzic, R. Petric, M. Golubic, J. Ljevak, V. Stambolija; University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-0458

Betahistine improves vestibular compensation after unilateral labyrinthectomy: a [18F]FDG-μPET study in the rat

M. Lindner¹, E. Eilles¹, L. Günther¹, A. Gosewisch¹, L. Vomacka¹, G. Xiong¹, R. Oos², P. Bartenstein², R. Beck¹, A. Zwergal³; ¹Deutsches Schwindel - und Gleichgewichtszentrum (DSGZ), Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY, ²Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, GERMANY, ³Deutsches Schwindel - und Gleichgewichtszentrum (DSGZ), Neurologische Klinik, Klinikum der Universität München, München, GERMANY.

EP-0459

Role of 18 F FDG PET/CT in determining the disease burden in Parkinson's disease

S. Gambhir; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-0460

Reproducibility Of DAT SPECT Quantification

L. Wichert-Ana^{1,2}, L. W. Alexandre-Santos¹, A. C. Trevisan¹, E. N. Itikawa¹, F. A. Pitella¹, M. Kato¹, M. V. Simões¹, V. Tumas¹; ¹Ribeirão Preto Medical School, University of São Paulo - USP, Ribeirão Preto - SP, BRAZIL, ²Bioengineering Interunits Postgraduation Program, São Carlos Engineering School, University of São Paulo - USP, São Carlos - SP, BRAZIL.

EP-34 during congress opening hours, e-Poster Area

Basic Oncology: Preclinical Imaging

EP-0461

Pilot Study of ⁶⁴Cu(I) for PET Imaging of Melanoma

L. Jiang¹, Z. Cheng²; ¹Zhangjiang Hospital, Shanghai, CHINA, ²Molecular Imaging Program at Stanford, Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-0462

Prognostic value and monitoring after 2-3years of patients subject to a SSNB on melanoma inside our service

F. S. Zelaya Reinquet, Jr., A. Renda Alcalde, M. Castrillon, C. Castillo, B. Nuñez, F. Loira, J. Nogueiras, D. Ruiz, L. Campos; Complejo hospitalario de vigo hospital meioxeiro, vigo, SPAIN.

EP-0463

Preparation of ^{99m}Tc-labeled HER2:V2-Pemetrexed for HER2-Positive lung tumor imaging

X. Zhao, J. Liu, T. Ma, Y. Zhang, F. Jing, T. Yu; The Fourth Hospital of Hebei Medical University, Shijiazhuang, CHINA.

EP-0464

Investigation of MSH receptor expression using ⁶⁸Ga- and ⁴⁴Sc-labeled molecules

G. Nagy¹, A. Kis², N. Dénes², I. Hajdu², I. Kertész², J. Hunyadi², E. Berényi², I. Gara^{2,1}, D. Szikra^{2,1}, G. Trencsényi^{2,1}; ¹Scanomed Ltd., Debrecen, HUNGARY, ²University of Debrecen, Debrecen, HUNGARY.

EP-0465

Positron loss in small objects in preclinical PET

J. de Swart, M. W. Konijnenberg, M. de Jong, M. R. Bernsen, S. F. Petit; Erasmus MC, Rotterdam, NETHERLANDS.



**EP-0466****Molecular imaging of APN/CD13 receptors using 68Ga-labelled NGR peptides**

A. Kis¹, N. Denes¹, J. Peline Szabo¹, T. Nagy^{1,2}, I. Kertesz¹, I. Hajdu¹, G. Mezö³, G. Farkasinszky¹, G. Nagy², I. Gara², E. Berenyi¹, G. Trencsenyi^{1,2}; ¹University of Debrecen, Faculty of Medicine, Division of Nuclear Medicine, Debrecen, HUNGARY, ²Scanomed Ltd., Debrecen, HUNGARY, ³MTA-ELTE, Research Group of Peptide Chemistry, Budapest, HUNGARY.

EP-0467**Application of 68Ga-NODAGA and 68Ga-HBED-CC conjugated procainamide derivatives for preclinical melanoma modeling**

N. Dénes¹, G. Trencsenyi^{1,2}, G. Nagy², A. Kis¹, A. Vida^{3,4}, J. P. Szabó¹, F. Farkas¹, T. Kovács^{3,4}, P. Bay^{3,4,5}, E. Berényi¹, I. Gara², J. Hunyadi⁶, I. Kertész¹; ¹University of Debrecen, Faculty of Medicine, Division of Nuclear Medicine, Debrecen, HUNGARY, ²Scanomed LTD, Debrecen, HUNGARY, ³University of Debrecen, Department of Medical Chemistry, Debrecen, HUNGARY, ⁴MTA-DE Lendület Laboratory of Cellular Metabolism, Debrecen, HUNGARY, ⁵Research Center for Molecular Medicine, Debrecen, HUNGARY, ⁶University of Debrecen, Department of Dermatology, Debrecen, HUNGARY.

EP-0468**In Vivo Imaging Of Ischemia-Reperfusion Using (68)Ga-Labeled Peptides**

G. Farkasinszky¹, N. Denes¹, J. S. Peline¹, T. Nagy¹, G. Trencsenyi^{1,2}, I. Kertesz¹, A. Kis¹, G. Mezö³, J. Hunyadi⁴; ¹Division of Nuclear Medicine, Faculty of Medicine, University of Debrecen, DEBRECEN, HUNGARY, ²Scanomed LTD, Debrecen, HUNGARY, ³Research Group of Peptide Chemistry, MTA-ELTE, BUDAPEST, HUNGARY, ⁴Department of Dermatology, University of Debrecen, DEBRECEN, HUNGARY.

EP-0469**Impact of Hypoxia on the Expression of Amino Acid Transporters and the Uptake of [¹¹C] methionine**

M. Kim^{1,2,3}, T. Ishizu^{1,2,4}, S. Forsback¹, O. Eskola¹, E. Arponen¹, J. Tuomela⁴, H. Minn^{1,5}, T. J. Grönroos^{1,2,6}; ¹Turku PET Centre, University of Turku, Turku, FINLAND, ²MediCity Research Laboratory, University of Turku, Turku, FINLAND, ³Graduate School of Medicine, Gunma University and Japan Society for the promotion of science, Gunma and Tokyo, JAPAN, ⁴Department of Cell Biology and Anatomy, University of Turku, Turku, FINLAND, ⁵Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FINLAND, ⁶Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FINLAND.

EP-0470**Multimodal imaging of tumor invasion by targeting integrin $\alpha_v\beta_3$ in a preclinical model of lung metastasis**

F. Iommelli¹, V. De Rosa¹, M. Monti², C. Terlizzi², M. Gramanzini¹, S. Gargiulo¹, S. Del Vecchio^{2,1}; ¹Institute of Biostructures and Bioimaging, National Research Council, Naples, ITALY, ²Department of Advanced Biomedical Sciences, University "Federico II", Naples, ITALY.

EP-0471**Optimization of High Throughput ¹⁸FDG Murine Imaging Using a Clinical Digital PET/CT System**

K. Briley¹, K. Binzel¹, M. Friel¹, R. Moore¹, J. Ellis¹, J. Zhang¹, P. Maniawski², M. V. Knopp¹; ¹The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ²Philips Healthcare, Cleveland, OH, UNITED STATES OF AMERICA.

EP-35 during congress opening hours, e-Poster Area**Basic Oncology: Metrics & Intervention****EP-0472****Endoscopic non-ablative fractional laser irradiation suppresses early tumor growth in orthotopic colon tumor model**

S. Yoo^{1,2}, G. Oh³, A. Safi², S. Hwang², Y. Seo⁴, K. Lee⁵, H. Song⁶, H. Bom¹, J. Min¹, Y. Kim⁷, E. Chung^{2,3}; ¹Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Jeollanam-do, KOREA, REPUBLIC OF, ²Department of Biomedical Science and Engineering, Institute of Integrated Technology (IIT), Gwangju Institute of Science and Technology (GIST), Gwangju, KOREA, REPUBLIC OF, ³School of Mechanical Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, KOREA, REPUBLIC OF, ⁴R & D center, WONTECH Co., Ltd., Daejeon, KOREA, REPUBLIC OF, ⁵Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, Jeollanam-do, KOREA, REPUBLIC OF, ⁶Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF, ⁷Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA.

EP-36 during congress opening hours, e-Poster Area**Basic Oncology: Tumour Biology****EP-0473****Fluciclovine is a potential imaging biomarker of glutamine utilisation in breast cancer**

E. J. Teoh, E. M. Bridges, M. Morotti, C. E. Zois, S. R. Lord, F. V. Gleeson, A. L. Harris; University of Oxford, Oxford, UNITED KINGDOM.

EP-0474**Diagnostic Importance of 18F-FDG PET/CT Parameters And Total Lesion Glycolysis (TLG) in Differentiating Between Benign And Malignant Adrenal Lesions**

E. Ciftci, B. Turgut, A. Cakmakcilar, S. Erturk; Cumhuriyet University, School of Medicine, Department of Nuclear Medicine, Sivas, TURKEY.

EP-0475**Does F18FDGPET/CT is Able to Differentiate Between Histological Subtypes of Lung Adenocarcinoma (LADC) and Their Mutation Status (ALK, EGFR) - Tertiary Referral Centre Experience**

L. Calovi Motschenbacher, A. Parsai, M. Sheaff, S. Ellis, T. O'Shaughnessy, H. Jan, E. Nowosinska; Barts Health, London, UNITED KINGDOM.

EP-0476**Neutrophil Extracellular Traps as a New Target for Imaging of Integrin-Dependent Dissemination of Cancer Cells**

M. Monti¹, F. Iommelli², V. De Rosa², M. V. Carriero³, G. Di Minno¹, S. Del Vecchio^{2,4}; ¹Department of Clinical Medicine and Surgery, University "Federico II", Naples, ITALY, ²Institute of Biostructures and Bioimages, National Research Council, Naples, ITALY, ³Department of Experimental Oncology, National Cancer Institute, Naples, ITALY, ⁴Department of Advanced Biomedical Sciences, University "Federico II", Naples, ITALY.

EP-0477**Volumetric metabolic parameters on FDG-PET independently predicts PD-L1 expression in patients with non-small cell lung cancer (NSCLC)**

M. Jreige, I. Letovanec, J. O. Prior, N. Schaefer; Centre Hospitalier Universitaire Vaudois (CHUV), LAUSANNE, SWITZERLAND.

EP-37 during congress opening hours, e-Poster Area**Basic Oncology: Animal Models****EP-0478****Brachytherapy of Biodegradable Microspheres for Hepatocellular Carcinoma in Rats by Intra-arterial Chemoembolization**

P. Chiang, C. Peng, Y. Shih, T. Luo; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-0479**18F-FDG-PET imaging of genetically engineered mouse models elucidates oncogenic function of Nlp and FAM135B**

W. Xiao¹, D. Dong¹, J. Li¹, D. Li¹, S. Han², H. Yan², L. Wan³, Q. Xie², Q. Zhan¹; ¹National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CHINA, ²Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, CHINA, ³Wuhan Raydata Technology Co., Ltd, Wuhan, CHINA.

EP-38 during congress opening hours, e-Poster Area**Basic Oncology: Miscellaneous****EP-0480****FDG-PET/CT in the incidental diagnosis of tumour thrombosis**

C. Castillo Berrio, J. M. Nogueiras Alonso, M. A. Castrillon Sanchez, F. Zelaya Reinquet, A. Renda Alcalde, F. Loira Bamio, D. Ruiz Hernandez, L. Campos Villarino, B. Núñez de Oliveira, R. Guitian Iglesias; Hospital do Meixoeiro, Vigo, SPAIN.

EP-0481**Ex-vivo experience with beta- Radiation and Radioguided Surgery Technique in meningioma and neuroendocrine patients**

C. M. Grana¹, R. Faccini², M. Schiariti³, M. Colandrea¹, E. Solfaroli Camillocci², S. L. V. Fracassi¹, L. Gilardi¹, S. M. Baio¹, P. A. Rocca¹, L. L. Travaini¹, S. Papi¹, S. Morganti⁴, M. Cremonesi¹, M. E. Ferrari¹, V. Bocci⁴, C. Mancini Terracciano², A. Russomando⁵, F. Collamati⁶, E. Bertani¹, E. Pisa¹, L. Funicelli¹, N. Fazio¹, L. Bodei⁷, R. Ghisini¹, M. Chinol¹; ¹Istituto Europeo di Oncologia, Milano, ITALY, ²Dipartimento di Fisica, Sapienza Università di Roma; INFN Sezione di Roma, Roma, ITALY, ³Istituto Neurologico Besta, Milano, ITALY, ⁴INFN Sezione di Roma, Roma, ITALY, ⁵Center for Life Nano Science@ Sapienza, Istituto Italiano di Tecnologia, Roma; Centro Científico Tecnológico de Valparaiso-CCTVal, Universidad Técnica Federico Santa María, Chile, Roma, ITALY, ⁶INFN Sezione di Roma; Dip. Scienze di Base e Applicate per l'Ingegneria, Sapienza Univ. di Roma, Roma, ITALY, ⁷Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0482**Influence of androgens (AND) and androgen metabolites on the Expression of the prostate specific Antigen (PSMA) and the cell cycle in In Vitro models of castration resistant prostate carcinoma**

B. Meller, P. Thelen, V. Unterkircher, C. Breunig, C. Sahlmann, C. Bouter, L. Trojan, J. Meller, F. Bremmer; Georg-August-University Göttingen, Göttingen, GERMANY.



EP-0484

Evidence of therapeutic effect of Atorvastatin enhances initial penetration of trastuzumab to solid tumors in a HER2-positive gastric cancer model

J. Kim, Y. Lim, S. Lim; Korea Institute of Radiological & Medical Sciences, Seoul, KOREA, REPUBLIC OF.

EP-0485

Inhibition Of Autophagy During Epithelial To Mesenchymal Transition In Renal Cell Carcinoma Cells: Potential Therapeutic Role With mTOR Inhibitor

S. Bhattacharyya, M. Singla; Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-39 during congress opening hours, e-Poster Area

Clinical Oncology: Brain

EP-0486

Survival prediction of Glioma based on the combined analysis of in-vivo [¹¹C]Methionine -PET, ex-vivo and patient-characteristic features utilizing machine learning approaches

L. Papp, N. Pötsch, M. Grahovac, V. Schmidbauer, M. Mitterhauser, W. Wadsak, T. Beyer, M. Hacker, T. Traub-Weidinger; Medical University of Vienna, Vienna, AUSTRIA.

EP-0487

Diagnostic Value of PET with [¹¹C] Methionine in Recognizing Early Progression of Cerebral Glioma from Pseudoprogression

T. Skvortsova, D. Zakhs, Z. Savintseva, A. Gurchin, S. Medvedev; N. P. Bechtereva Institute of the Human Brain of Russian Academy of Sciences, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0488

¹⁸F-Fluorocholine PET/CT in patients with newly diagnosed glioma: association with tumor biology. Preliminary analysis (FuMeGA study)

G. A. Jimenez Londoño, Sr., F. J. Pena Pardo, A. M. García Vicente, M. Villena Martín, J. González García, M. P. Talavera Rubio, M. J. Tello Galán, Á. M. Soriano Castrejón; Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN.

EP-0489

¹⁸F-FDOPA PET And IDH Mutation As Prognostic Factors Of Velocity Of Diameter Expansion In Newly Diagnosed Diffuse Grade II-III Gliomas

S. Isal¹, G. Gauchotte², F. Rech³, M. Blonski⁴, S. Planel⁵, M. Chawki¹, G. Karcher¹, P. Marie¹, L. Taillandier⁴, A. Verger¹; ¹Nuclear Medecin, CHU Nancy, Nancy, FRANCE, ²Anatomopathology, CHU Nancy, Nancy, FRANCE, ³Neuro-surgery, CHU Nancy, Nancy, FRANCE, ⁴Neuro-oncology, CHU Nancy, Nancy, FRANCE, ⁵Neuro-radiology, CHU Nancy, Nancy, FRANCE.

EP-0490

Relationship between MRI contrast enhancement and ¹⁸F-Fluorocholine PET/CT to improve radiotherapy planning in resected high grade glioma patients

N. Testart Dardel^{1,2,3}, M. Revelles Paniza⁴, E. Triviño Ibañez¹, M. Zurita Herrera⁴, A. Jorques Infante⁴, R. Luque Caro⁴, A. Gonzalez Jimenez¹, M. Gomez-Rio¹, J. Llamas-Elvira¹; ¹Hospital Virgen de las Nieves, IBS, Granada, SPAIN, ²CHU - Lyon, Lyon, FRANCE, ³Universidad de Granada, Granada, SPAIN, ⁴Hospital Virgen de las Nieves, Granada, SPAIN.

EP-0491

FBPA PET/CT of brain tumors after radiotherapy: a differential diagnosis between tumor recurrence and radiation necrosis

R. Beshr, K. Isohashi, T. Watabe, V. Romanov, E. Shimosegawa, J. Hatazawa; Osaka University, Graduate School of Medicine, Yamada Oka 2-2, Suita City, Osaka, JAPAN.

EP-0492

Utility of delayed-phase C-11 methionine PET in the evaluation of focal brain lesions with high methionine uptake: A preliminary study

K. Takanami, Y. Toyama, M. Saito, K. Takase; Tohoku University Hospital, Sendai, JAPAN.

EP-0493

Dynamic ¹⁸F-FET-PET predicts a highly malignant epigenetic signature of IDH wildtype and IDH mutant glioma.

M. Röhrich¹, K. Huang², A. Dimitrakopoulou-Strauss³, A. von Deimling², U. Haberkorn¹; ¹Klinik für Nuklearmedizin, Heidelberg, GERMANY, ²Institut für Neuropathologie, Heidelberg, GERMANY, ³Klinische Kooperationseinheit Nuklearmedizin, Heidelberg, GERMANY.



EP-0494**Value of early and delayed imaging for 18F-FDOPA PET high grade gliomas evaluation**

M. Paquet¹, J. Doyen¹, L. Mondot², E. Saada Bouzid¹, P. Bondiau¹, F. Almairac², D. Fontaine², S. Chanalet², M. Ouvrier¹, C. Zwarthoed¹, A. Schiazza¹, D. Benisvy¹, O. Humbert¹, V. Bourg², J. Darcourt¹; ¹CAL, nice, FRANCE, ²CHU, nice, FRANCE.

EP-0495**FET PET in Brain Tumors: Higher Background Activity under Dexamethasone Therapy and in Female Patients**

C. Stegmayr, G. Stoffels, E. Rota-Kops, C. Filß, L. Phillip, B. Neumaier, K. Langen; Forschungszentrum Juelich, Juelich, GERMANY.

EP-0496**F18-FET tumour to background ratio is a predictor of rate of disease progression in post surgery patients with Glioblastoma**

J. R. Cain^{1,2}, M. Bynevelt², A. Nowak³, N. Loh³, L. Morandeau³, R. Francis³; ¹Lancashire Teaching Hospitals, Preston, UNITED KINGDOM, ²Neurological Intervention & Imaging Service of WA, Perth, AUSTRALIA, ³Sir Charles Gairdner Hospital, Perth, AUSTRALIA.

EP-0497**Stereotactic histologic correlation of dynamic FET-PET/MRI in untreated high-grade glioma patients**

T. Pyka¹, J. Gempt¹, M. Lukas^{1,2}, J. Schlegel¹, F. Ringel^{1,3}, S. Förster^{1,4}, C. Zimmer¹, C. Preibisch¹, M. Schwaiger¹; ¹TU Munich, Munich, GERMANY, ²Charité Universitätsmedizin Berlin, Berlin, GERMANY, ³Universitätsmedizin Mainz, Mainz, GERMANY, ⁴Klinikum Bamberg, Bamberg, GERMANY.

EP-40 during congress opening hours, e-Poster Area**Clinical Oncology: Head & Neck****EP-0498****Prognostic significance of restaging 18F-FDG PET/CT parameters for post-operative relapse and recurrence of head and neck squamous cell carcinoma**

K. Musaieva¹, B. M... Kmetyuk¹, O. Solodianykov... Ukrainian Center of Radiosurgery, Kyiv, UKRAINE, ... National Cancer Institute, Kyiv, UKRAINE.

EP-0499**Predictive value of 11C-Metionine PET/CT (MET-PET) in the restaging of adenoid cystic carcinoma (ACC) of head and neck**

F. Scalorbi¹, E. Lodi Rizzini¹, D. Calabrò¹, G. Lauretti², P. Castellucci¹, F. Dionisi³, A. Tarsitano⁴, S. Battaglia⁴, D. Borsetto⁵, G. M. Lima¹, S. Fanti¹; ¹Department of Nuclear Medicine, S Orsola-Malpighi University Hospital, Bologna, ITALY, ²Department of Nuclear Medicine, S Andrea University Hospital, Rome, ITALY, ³Operative Unit of Protontherapy, S Chiara Hospital, APSSSTN, Trento, ITALY, ⁴Operative Unit of Maxillofacial Surgery, S. Orsola-Malpighi University Hospital, Bologna, ITALY, ⁵Operative Unit of Otolaryngology and Otosurgery, Department of Neuroscience, University Hospital of Padova, Padova, ITALY.

EP-0500**Parotid incidentalomas on positron emission tomography: what is their clinical significance?**

R. Barbara, D. Pawaroo, C. Beadsmoore, N. Hujairi, D. Newman; Norwich Radiology Academy, Norwich, UNITED KINGDOM.

EP-0501**Diagnostic efficacy of FDG-PET/CT in head/neck carcinoma of unknown primary with cervical lymph node metastases**

F. E. Noltenius, A. Pfestroff, D. Librizzi, M. Luster; Philipps-Universität Marburg, Marburg, GERMANY.

EP-0502**^{99m}Tc sestamibi spect in evaluation of neoadjuvant chemotherapy effectiveness in larynx/laryngopharynx cancer patients**

A. Medvedeva^{1,2}, V. Chernov, R. Zelchan, Yu. Belevich, S. Chizhevskaya, E. Choynzonov, I. Sinilkin; ¹Tomsk National Research Medical Center of the Russian Academy of Sciences Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, ²National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0503**Textural and shape features of pretreatment lymph nodes images of FDG PET/CT: correlation to extranodal extension and impacts on survivals of N-positive oral cavity squamous cell carcinoma**

N. Cheng¹, Y. D. Fang², T. Yen³; ¹Chang Gung Memorial Hospital, Keelung, Keelung City, TAIWAN, ²Department of Biomedical Engineering, National Cheng Kung University, Tainan City, TAIWAN, ³Chang Gung Memorial Hospital, Linkou, Taoyuan City, TAIWAN.



EP-0504**Sentinel lymph node in early oral cavity squamous cell carcinoma**

R. C. Capuzzo, E. Rocha, L. F. Bicalho, W. E. Furlan, A. L. Carvalho; Hospital de Câncer de Barretos, Barretos, BRAZIL.

EP-0505**Morphologic and Metabolic differences between HPV-positive and HPV-negative Oropharyngeal cancer patients as detected with FDG F18 PET/CT**

A. M. El-Sabbagh, Z. Asiri, A. Rayan, S. Frye, F. Ahmed, R. Walker, R. Muzaffar, M. M. Osman; Saint Louis University, Saint Louis, MO, UNITED STATES OF AMERICA.

EP-0506**18F-FDG-PET/CT In Locoregional Staging in Oropharynx, Oral Cavity and Lip Tumors and Correlation with Sentinel Lymph Node Biopsy**

F. Gomez-Caminero Lopez, P. Garcia-Talavera San Miguel, B. Perez Lopez, P. Blanco Perez, J. Serradilla Lopez, C. Achury Murcia, L. Diaz Gonzalez, P. Tamayo Alonso; Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EP-0507**Head-and-neck dedicated acquisition after whole-body 18F-FDG PET/CT in head-and-neck tumours: can it provide a real added value?**

M. C. Marzola, S. Chondrogiannis, G. Grassetto, E. Milan, M. L. Manerchia, A. M. Maffione, L. Tamiso, L. Rampin, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

EP-0508**FDG PET/CT And MRI For The Assessment Of Therapeutic Response In Nasopharyngeal Cancer**

F. Aydin, T. Bukulmez, K. Karaali, S. Bozkurt, M. Genc; Akdeniz University Medical School, Antalya, TURKEY.

EP-0509**The impact of PET/CT in therapeutic management of patients with lymph node metastasis and cancer of unknown primary**

P. Nikolova, V. Hadzhiyska, T. Petrov; University Hospital Alexandrovska, Sofia, Bulgaria, Sofia, BULGARIA.

EP-41 during congress opening hours, e-Poster Area**Clinical Oncology: Thyroid****EP-0510****Effect of postoperative thyrotropin suppression on bone mineral density in postmenopausal women with differentiated thyroid carcinoma**

D. Wang, Y. Huo, C. Ma; Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, CHINA.

EP-0511**Stratification of recurrent differentiated thyroid cancer with elevated thyroglobulin and negative I-131 whole body scan by restaging 18F FDG PET/CT**

K. Okuyucu, S. Ince, E. Alagoz, O. Emer, H. San, E. Balkan, A. Ayan, B. Gunalp, A. O. Karacalioglu, N. Arslan; Gulhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, TURKEY.

EP-0512**SPECT/CT somatostatin-receptor scintigraphy in Medullary Thyroid Cancer**

S. Sergieva¹, M. Atanasova², A. Fakirova³, B. Robev⁴, A. Saint-Georges¹; ¹Sofia Cancer Center, Sofia, BULGARIA, ²Central Hospital, Plovdiv, BULGARIA, ³Military Medical Academy, Sofia, BULGARIA, ⁴UH"St.Ivan Rilsky, Sofia, BULGARIA.

EP-0513**Diagnostic Accuracy of [^{99m}Tc]Tc-Sestamibi in the Assessment of Thyroid Nodules**

A. Yordanova¹, S. Mahjoob², P. Lingohr³, A. Türler⁴, H. Palmedo⁵, H. Biersack¹, G. Kristiansen⁶, M. Essler¹, H. Ahmadzadehfar¹; ¹Nuclear Medical Department of the University Hospital of Bonn, Bonn, GERMANY, ²Institute of Radiology and Nuclear Medicine, BG Kliniken Bergmannsheil, Bochum, GERMANY, ³Department of Surgery of University Hospital Bonn, Bonn, GERMANY, ⁴Department of General and Abdominal Surgery, Johanniter-Krankenhaus, Bonn, GERMANY, ⁵Institute of Radiology and Nuclear Medicine and PET-CT Center, Bonn, GERMANY, ⁶Institute of Pathology of University Hospital Bonn, Bonn, GERMANY.

EP-0514**68Ga-DOTA-NOC and 18F-FDG PET/CT for the Diagnosis of Iodine-refractory Differentiated Thyroid Cancer : pilot studies**

S. Li, F. Wang, X. Yao, R. Liu, L. Zhang; Nanjing First Hospital, Nanjing, CHINA.

EP-0515**The role of air pollution in the incidence and mortality of thyroid cancer (TC) in 27 countries of the European Union for the years 1992, 2002,2012**

E. Giannoula¹, I. Katsikavelas², G. Giannoula³, I. Iakovou¹; ¹Academic Nuclear Medicine dpt, Papageorgiou hosp., Thessaloniki, GREECE, ²Aristotle University, Thessaloniki, GREECE, ³Faculty of General Medicine, Comenius University, Bratislava, SLOVAKIA.

EP-0516**Role of radioguided occult lesion localization (ROLL) in the management of cervical recurrences from differentiated thyroid cancer**

V. Garbaccio¹, M. Menga², G. Mensa³, D. Deandrei¹, R. E. Pellerito⁴; ¹Nuclear Medicine AOU S. Giovanni Battista, Città della Salute e della Scienza, Torino, ITALY, ²Nuclear Medicine Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, ITALY, ³General and Oncologic Surgery, Thyroid Unit AO Ordine Mauriziano Umberto I, Torino, ITALY, ⁴Nuclear Medicine AO Ordine Mauriziano Umberto I, Torino, ITALY.

EP-0517**The relevance of the BRAFV600E mutation in the treatment of the Papillary Thyroid Carcinoma**

O. Ajuria, T. Navarro Martinez, B. Lorente Castro, J. Castro Beiras; Hospital Ramon y Cajal, Madrid, SPAIN.

EP-0518**An audit of Differentiated Thyroid Cancer (DTC) patients, post-surgery and Radioiodine therapy in a tertiary care centre and the effect of the ATA 2015 on them in terms of risk stratification and use of RAI**

V. Rangarajan, A. Agrawal, S. Choudhury, G. Pantavaidya, P. Pai, S. Shah, A. D. Puranik, N. Purandare, A. K. D'Cruz; Tata Memorial centre, Mumbai, INDIA.

EP-0519**Serum Calcitonin Increase-guided evaluation of MTC in Patients with Multinodal Goiter and correlation with Tc99m-DMSA (V) scintigraphy**

V. Sukhov¹, P. Kirichenko¹, A. Marin¹, W. Wiedemann², K. Zaplatnikov²; ¹Military Medical Academy, ST. PETERSBURG, RUSSIAN FEDERATION, ²MAZ Nuclear Medicine, Nürnberg, GERMANY.

EP-0520**Correlation between stimulated thyroglobulin levels and positive 18F-FDG PET/CT findings in DTC patients with radioiodine refractory disease**

D. Srbovan, S. Lučić, A. Peter, E. Matovina, V. Cimbajević; Institut of oncology Vojvodina, Sremska Kamenica, SERBIA.

EP-0521**Retropharyngeal lymph nodes metastases in differentiated thyroid carcinoma might be under estimated**

D. Benisvy, I. Birtwisle Peyrottes, J. Santini, C. Zwarthoed, A. Schiazza, O. Humbert, J. Darcourt; Centre Antoine Lacassagne, Nice, FRANCE.

EP-0522**Evaluation of calcium stimulation test for the diagnosis and follow-up of medullary thyroid cancer: comparison with pentagastrin test**

E. Rainer, A. Gessl, M. Krebs, B. Niederle, C. Scheuba, A. Haug, M. Hacker, S. Li; Medical University of Vienna, VIENNA, AUSTRIA.

EP-0523**Usefulness Of SPECT/CT Imaging In Patients With Differentiated Thyroid Carcinoma**

S. Ucak Semirgin¹, T. Basoglu¹, Z. Sahin², M. Sahin¹, O. Yapici¹; ¹Ondokuz Mayıs University Nuclear Medicine Department, Samsun, TURKEY, ²Yıldız Medstar Hospital, Antalya, TURKEY.

EP-42 during congress opening hours, e-Poster Area**Clinical Oncology: Breast****EP-0524****The Role of 18F-FDG PET/CT In the Evaluation of Tumor Marker Increase In Breast Cancer**

I. Goktaş, H. Cayvarli; Ordu State Hospital, Clinic of Nuclear Medicine, Ordu, TURKEY.

EP-0525**Diagnostic accuracy of mammography and scintimammography with 99m Tc-MIBI in detection of early breast cancer**

S. Novikov, S. Kanaev, A. Chernaya, P. Krzhivitskiy, P. Krivorotko, L. Jukova, A. Artemyeva; N.N. Petrov Institute Oncology, St Petersburg, RUSSIAN FEDERATION.

EP-0526**Comparison of the efficiency for Tc-99m Tincolloid and Tc-99m Phytate in sentinel node detection in breast cancer patients**

J. Seok; Chung-Ang University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0527**Comparison of subareolar Injection lymphoscintigraphy with the 1 day and the 2 day protocol for the detection of sentinel lymph nodes in patients with breast cancer**

J. Seok; Chung-Ang University Hospital, Seoul, KOREA, REPUBLIC OF.



EP-0528**Volumetric Retention Indexes by Early Delayed Dual-time-point FDG PET/CT Do Not Correlate with Prognostic Factors in Invasive Breast Cancer**

H. Song; Jeju National University School of Medicine, Jeju-si, KOREA, REPUBLIC OF.

EP-0529**Evaluation of Metabolic Character of Breast Cancer with F-18 FDG PET/CT**

H. Önnér, E. Entok, M. Dinçer, S. M. Erkasap; Eskişehir Osmangazi Üniversitesi, Eskişehir, TURKEY.

EP-0530**CEA, CA15.3 and 18-FDG PET in the follow-up of early breast cancer patients: a prospective, multicentric, randomized trial—KRONOS patient-oriented new surveillance study Italy**

E. Barbieri¹, C. Zamagni¹, M. Gion², L. Mariani³, P. Stieber⁴, D. Rubino¹, R. Wirtz⁵, A. Bernardi¹, N. Cacciari¹, S. Quercia¹, M. Lenzi¹, M. Cubelli¹, C. Pizzirani¹, M. Carapelle¹, M. Pagliaro¹, S. Tomasin¹, S. Toracchio¹, R. Baum⁶, S. Fanti¹; ¹Policlinico S. Orsola - Malpighi, Bologna, ITALY, ²Centro Regionale Indicatori Biochimici di Tumore, Mestre, ITALY, ³Istituto Nazionale Tumori, Milano, ITALY, ⁴Institute of Clinical Chemistry, Munich, GERMANY, ⁵STRATIFYER Molecular Pathology GmbH, Cologne, GERMANY, ⁶Zentralklinik Bad Berka, Bad Berka, GERMANY.

EP-0531**Evaluation of metastatic breast cancer patients on FDG PET scan with PERCIST 1.0: Experience from University Hospital Oman**

A. Jain, A. K. Mittal, S. Raniga, K. Al Baimani, S. Kumar, H. Al Dhuhli; Sultan Qaboos University Hospital, Muscat, OMAN.

EP-0532**Axillary staging for breast cancer during pregnancy. Feasibility and safety of sentinel lymph node biopsy**

S. N. Han¹, F. Amant¹, E. H. Cardonick², S. Loib³, F. A. Peccatori⁴, O. Gheysens¹, C. A. Sangalli³, V. Nekljudova³, K. Dahl Steffensen⁵, M. Mhallem Gzir⁶, C. P. Schröder⁷, C. A. R. Lok⁸, A. Verest¹, A. Smeets¹, G. Pruner⁴, M. Cremonesi⁴, O. Gentilini⁹; ¹University Hospitals Leuven, Leuven, BELGIUM, ²Cooper Medical School at Rowan University, Camden, NJ, UNITED STATES OF AMERICA, ³German Breast Group, Neu-Isenburg, GERMANY, ⁴Istituto Europeo di Oncologia, Milano, ITALY, ⁵Vejle Hospital, Vejle, DENMARK, ⁶University Hospital Gasthuisberg, Leuven, BELGIUM, ⁷Universitair Medisch Centrum Groningen, Groningen, NETHERLANDS, ⁸Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ⁹Ospedale San Raffaele, Milano, ITALY.

EP-0533**68Ga-PSMA PET-CT in the evaluation of Metastatic Breast Cancer**

S. S. Medina Ornelas, F. O. García-Pérez; Instituto Nacional de Cancerología, Mexico City, MEXICO.

EP-0534**Clinical Experience of a dedicated Breast PET and Whole Body PET / CT for Breast imaging with F-18 FDG**

K. Uno¹, H. Sasamori¹, J. Wu¹, M. Irie¹, T. Nakajima¹, Y. Akiba¹, Y. Tsuchiya¹, N. Baba²; ¹gaienhigashi clinic, Tokyo, JAPAN, ²Tokyo kyouzai Hospital, Tokyo, JAPAN.

EP-0535**Clinical value of prone position ¹⁸F-FDG PET/CT and MRI for predicting nipple-areolar complex involvement in breast cancer**

J. Yoo, B. Kim, J. Chung, H. Yoon; Ewha Womans University School of Medicine, Seoul, South Korea, Seoul, KOREA, REPUBLIC OF.

EP-0536**Comparison of 18 F FDG PET CT and tumor marker findings in advanced breast cancer patients with progression**

E. E. Bayar¹, E. Ö. Gür², G. G. Bural¹; ¹Katip Çelebi University Atatürk Training and Research Hospital, Department of Nuclear Medicine, Izmir, TURKEY, ²Katip Çelebi University Atatürk Training and Research Hospital, Department of General Surgery, Izmir, TURKEY.

EP-0537**Prediction of breast tumor response to neoadjuvant chemotherapy through quantitative ^{99m}Tc sestamibi Molecular Breast Imaging (MBI)**

S. C. Kappadath, B. Lopez, B. Adrada, K. Hess, G. Rauch; UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0538**Contribution of Morphologic Assessment of Axillary Lymph Nodes to the Staging of Invasive Lobular Breast Cancer in FDG PET-CT Imaging**

S. Yıldız¹, A. Yıldız², M. Özdoğan³, B. Özcan⁴, A. Özlük⁴, S. Yılmaz⁵; ¹Department of Radiology, SBU Antalya Education and Research Hospital, Antalya, TURKEY, ²Department of Nuclear Medicine, Medstar Hospital, Antalya, TURKEY, ³Department of Medical Oncology, Medstar Hospital, Antalya, TURKEY, ⁴Department of Surgery, Medstar Hospital, Antalya, TURKEY, ⁵Department of Radiology, Medstar Hospital, Antalya, TURKEY.



EP-0539**Value Of 18F-FDG PET/CTIN Locally Advanced Breast Cancer Patiens Treated With Neoadjuvant Chemotherapy**

I. Acevedo Báñez, R. Fernandez Lopez, A. Bonilla Damia, L. Caballero Gullón, F. Frutos Arenas, L. Alfaro Galan, A. Montañó Periañez, B. Vieites Perez-Quintela, I. Borrego Dorado; Hospital Universitario Virgen Del Rocio, Sevilla, SPAIN.

EP-0540**Diagnosing recurrent breast cancer: Accuracy and inter-rater agreement of FDG-PET/CT and bone scintigraphy**

Z. A. Farahani¹, J. Holm¹, C. Baun¹, K. Falch¹, O. Gerke¹, P. Hoiland-Carlsen¹, A. Alavi², M. G. Hildebrandt¹; ¹Odense University Hospital, Odense, DENMARK, ²Department of Radiology, Perelman School of Medicine, Pennsylvania, PA, UNITED STATES OF AMERICA.

EP-0541**Prognostic Value Of Initial 18F-FDG PET/CT IN ER+/HER2- Locally Advanced Breast Cancer Patients**

M. Martinez de Bourio, A. Jiménez-Ballvé, O. Salsidua-Arroyo, A. Serrano-Palacio, M. García García-Esquinas, C. Rodríguez Rey, A. Ortega Candil, J. A. García-Sáenz, M. E. Fuentes Ferrer, J. L. Carreras Delgado; HOSPITAL CLINICO SAN CARLOS, MADRID, SPAIN.

EP-0542**Successful Diagnosis of a CT-Negative, Bone Scintigraphy-Negative and FDG-PET-Negative Metastatic Recurrence Case Using ER-Targeting 4FMFES-PET**

M. Paquette, É. Lavallée, S. Phoenix, H. Senta, J. E. van Lier, R. Lecomte, B. Guérin, É. E. Turcotte; Université de Sherbrooke, Sherbrooke, QC, CANADA.

EP-0543**Contribution Of 18FDG PET-CT For Staging And Prognosis Of Primary Breast Neuroendocrine Carcinoma**

E. Arslan¹, T. Cermik¹, F. Can Trabulus², E. Kelten Talu³; ¹Istanbul Health Science University Education and Research Hospital Clinic of Nuclear Medicine, İstanbul, TURKEY, ²Istanbul Health Science University Education and Research Hospital Clinic of General Surgery, İstanbul, TURKEY, ³Istanbul Health Science University Education and Research Hospital Department of Pathology, İstanbul, TURKEY.

EP-0544**18F FDG PET-CT To Stage And Determine Rarely Seen Apocrine Type And Basal Like-Triple Negative Breast Adenocarcinoma**

E. Arslan¹, T. Cermik², F. Can Trabulus³, E. Kelten Talu⁴; ¹Istanbul Health Science University Education and Research Hospital, İstanbul, TURKEY, ²Istanbul Health Science University Education and Research Hospital Clinic of Nuclear Medicine, İstanbul, TURKEY, ³Istanbul Health Science University Education and Research Hospital Clinic of General Surgery, İstanbul, TURKEY, ⁴Istanbul Health Science University Education and Research Hospital Department of Pathology, İstanbul, TURKEY.

EP-0545**Clinical Significance of Partial-volume Corrected SUVmax of Axillary Lymph Nodes suggesting Intraoperative Examination of Sentinel Lymph Nodes in Early Breast Cancer**

S. Kang^{1,2}, S. Ha^{1,2}, H. An¹, J. Lee¹, G. Cheon^{1,3}, J. Park⁴, W. Han⁴, D. Lee¹, J. Chung¹, K. Kang¹; ¹Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF, ³Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁴Department of Surgery, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0546**Assessment of biological, clinical aggressiveness of invasive ductal breast cancer using baseline fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomography-derived volumetric parameters**

G. Ege Aktas¹, E. Tastekin², A. Sarkaya¹; ¹Trakya University Medical Faculty Department of Nuclear Medicine, Edirne, TURKEY, ²Trakya University Medical Faculty Department of Pathology, Edirne, TURKEY.

EP-0547**^{99m}Tc-Sestamibi Molecular Breast Imaging (MBI) compared with digital mammography plus ultrasound in preoperative cancer detection: preliminary experience**

S. Chiacchio¹, G. Angelini², M. Zotta³, S. Muccioli¹, S. Caputo¹, D. Fontana², G. Gennaro¹, M. Roncella³, C. Marini³, D. Vignati¹; ¹Regional Center of Nuclear Medicine, Ospedale Santa Chiara, Pisa, ITALY, ²Università di Pisa-Ospedale Santa Chiara, Pisa, ITALY, ³Senology Unit-Ospedale Santa Chiara, Pisa, ITALY.

e-poster not submitted



EP-0548**Lymph node staging in primary breast cancer patients: supine FDG PET/CT compared to prone PET/CT, MRI and prone PET fused with MRI**

M. J. Ribelles, M. Rodriguez, A. Fernandez-Montero, L. J. Pina, L. Sancho, E. Prieto, M. Santiesteban, N. Rodriguez-Spiteri, M. A. Idoate, F. Martinez-Regueira, A. Elizalde, M. J. Garcia-Velloso; Clinica Universidad De Navarra, Pamplona, SPAIN.

EP-0549**The Localization of Nonpalpable Suspicious Breast Lesions and Sentinel Lymph Node with Single Injection: Our SNOll Experience**

P. Arican¹, B. T. Okudan¹, G. Dağlar²; ¹Ankara Numune Hospital, Nuclear Medicine Clinic, Ankara, TURKEY, ²Ankara Numune Hospital, General Surgery Clinic, Ankara, TURKEY.

EP-0550**Role of (18)F-3'-deoxy-3'-fluorothymidine (18F-FLT) PET/CT in early prediction of response in patients with breast cancer (BC) treated with neoadjuvant chemotherapy (NCT): preliminary results**

L. Fantini¹, A. Fedeli¹, P. Caroli¹, M. Celli¹, A. Rocca¹, A. Moretti², R. Galassi², M. Dall'Agata¹, P. Serra¹, G. Paganelli¹, F. Matteucci¹; ¹IRST IRCCS, Meldola (FC), ITALY, ²Morgagni-Pierantoni Hospital, Forlì (FC), ITALY.

EP-0551**Myocardial perfusion defects after radiation therapy for left-sided breast cancer: is stress study necessary?**

M. Amoui¹, D. Askari², M. Bakhshandeh², H. R. Mirzaee³, S. Saifollahi⁴, M. Malekzadeh³, E. Pirayesh¹, M. Pishgahi⁵, A. Rakhsha³, S. Azghandi³, P. Hajian³, A. Yousefi Kashi³, M. Hoshiani³, M. Mosavizadeh³; ¹Department of Nuclear Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Radiology Technology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Radiation therapy, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Nuclear Medicine; Arad Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Department of Cardiology; Faculty of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0552**Restaging Infiltrating Lobular Breast Cancer Patients With Nuclear Medicine**

D. Grigolato, F. Pellini, A. Invento, E. Filippi, M. Cucca, L. Locantore, M. Zuffante, G. P. Pollini, M. Ferdeghini; Azienda Ospedaliera Universitaria Integrata, Verona, ITALY.

EP-43 during congress opening hours, e-Poster Area**Clinical Oncology: Lung****EP-0553****Clinical use of F-18 FDG PET/CT in pulmonary pleomorphic carcinoma**

K. Hayasaka, T. Saitoh, H. Inoue, M. Fukasawa, Y. Shiraishi, K. Yoshimori, F. Kikuchi, H. Gotoh; Fukujyuuji Hospital, Anti-tuberculosis Association, Tokyo, JAPAN.

EP-0554**Whole-body bone scintigraphy in comparison with bone metabolism in lung cancer patients**

J. Weissensteiner¹, E. Babusikova²; ¹Hospital Poprad, Poprad, SLOVAKIA, ²Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Medical Biochemistry, Martin, SLOVAKIA.

EP-0555**The utility of dynamic F-18 FDG PET/CT in differentiating histology of primary lung carcinoma**

Y. Otomi¹, T. Shinya², K. Takechi³, M. Yamanaka¹, K. Terazawa¹, M. Kubo¹, N. Uyama¹, H. Otsuka⁴, M. Harada¹; ¹Tokushima University Hospital, Tokushima, JAPAN, ²Okayama University Hospital, Okayama, JAPAN, ³Tokushima Red Cross Hospital, Tokushima, JAPAN, ⁴Tokushima University Graduate School, Tokushima, JAPAN.

EP-0556**Prognostic assessment of 18F-FDG uptake using dual point imaging and partial volume correction in resected non-small cell lung cancer patients**

H. Kaida¹, K. Azuma², A. Kawahara³, S. Takamori⁴, J. Akiba³, K. Fujimoto⁵, R. Axel⁶, K. Ishii⁷, T. Murakami¹, M. Ishibashi⁸; ¹Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, JAPAN, ²Division of Respiriology, Neurology, and Rheumatology, and Department of Internal Medicine, Kurume University School of Medicine, Kurume, JAPAN, ³Department of Diagnostic Pathology, Kurume University Hospital, Kurume, JAPAN, ⁴Department of Surgery, Kurume University School of Medicine, Kurume, JAPAN, ⁵Department of Radiology, Kurume University School of Medicine, Kurume, JAPAN, ⁶Department of Nuclear Medicine, Ludwig Maximilians University Hospital Munich, Munich, GERMANY, ⁷Department of Radiology, Kindai University Faculty of Medicine, Osakasayama City, JAPAN, ⁸Division of Nuclear Medicine, PET Center, and Department of Radiology, Fukuoka Tokushukai Hospital, Kasuga, JAPAN.

EP-0557**PET in radiotherapy planning for lung cancer***O. Solodyannikova; Institute of cancer, Kiev, UKRAINE.***EP-0558****Role of metabolic parameters evaluated from baseline F18-FDG PET/CT as prognostic markers in non-small cell lung cancer (NSCLC) patients undergoing platinum-based chemotherapy***A. Sharma, A. Mohan, A. S. Bhalla, S. Vishnubhatla, M. C. Sharma, C. J. Das, A. K. Pandey, C. D. Patel, C. S. Bal, R. Kumar; All India Institute of Medical Sciences, Delhi, INDIA.***EP-0559****Effect of Respiratory Gating System on PET Image of Lung Cancer: Relationship with Location and Size***T. Kamibayashi, N. Shuke, C. Miyazaki, T. Onishi, S. Aoyagi, K. Saito; Kushiro Kojinkai Memorial Hospital, Kushiro, JAPAN.***EP-0560****Diagnostic abilities of Dynamic and dual-time-point F-18 FDG PET/CT for lymph node metastasis in patients with lung carcinomas***M. Yamanaka¹, T. Shinya², Y. Otomi¹, K. Terazawa¹, K. Takechi³, M. Kubo¹, H. Otsuka⁴, M. Harada¹; ¹Tokushima Univ. Hospital, Tokushima, JAPAN, ²Okayama Univ. Hospital, Okayama, JAPAN, ³Tokushima red cross hospital, Tokushima, JAPAN, ⁴Tokushima Univ. Graduate School, Tokushima, JAPAN.***EP-0561****Quantitative Analysis of Respiratory-Gated PET/CT Images for the Evaluation of Hilar Lymph Nodes in Non-Small Cell Lung Cancer***L. Hehenwarter¹, L. Rettenbacher¹, F. Zehentmayr², C. Pirich¹; ¹Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Salzburg, AUSTRIA, ²Department of Radiotherapy and Radiation-Oncology, University Hospital Salzburg, Salzburg, AUSTRIA.***EP-0562****18F-FAZA PET/CT to assess hypoxia in non-small cell lung cancer: comparison with glucose metabolism and immunohistochemistry***P. Mapelli¹, E. Incerti¹, V. Bettinardi¹, F. Fallanca¹, G. Negri², F. Rossetti², A. Coliva¹, C. Doglioni³, L. Gianolli¹, M. Picchio¹; ¹Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ²Department of Thoracic Surgery, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ³Pathology Unit, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milano, ITALY.***EP-0563****FDG PET-derived parameters as prognostic tool in post-treatment progressive malignant pleural mesothelioma patients***E. Incerti¹, P. Mapelli¹, S. Broggi², A. Fodor³, M. Cuzzocrea⁴, A. M. Samanes Gajate¹, C. Fiorino², I. Dell'Oca³, L. Gianolli¹, N. Di Muzio³, M. Picchio¹; ¹Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ²Unit of Medical Physics, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ³Unit of Radiotherapy, IRCCS San Raffaele Scientific Institute, Milano, ITALY, ⁴University of Milano-Bicocca, Milano, ITALY.***EP-0564****Tumor heterogeneity, hypoxia and immune markers in patients with non-small cell lung cancer candidate to surgery***E. Lopci¹, L. Toschi¹, F. Marchesi¹, D. Rahal¹, G. Castino¹, N. Cortese¹, S. Marchetti¹, G. Finocchiaro¹, S. Rossi¹, P. Allavena², F. Grizzi¹; ¹Humanitas Clinical and Research Hospital, Milano, ITALY, ²Fondazione Humanitas per la Ricerca, Milano, ITALY.***EP-0565****FDG-PET/CT features of cavity-related primary lung cancers***N. Kawano, H. Otsuka, Y. Otomi, M. Otomo; Tokushima University Hospital, Tokushima, JAPAN.***EP-0566****FDG-PET in the assessment of metabolic response in patients with NSCLC treated with nivolumab: Preliminary results***L. Goldfarb, B. Duchemann, A. Chouahnia, G. Pop, L. Gomez, L. Zelek, M. Soussan; Hôpital Avicenne, APHP, Bobigny, FRANCE.***EP-0567****FDG-PET findings provide insights into thyroid-related side-effects in patients with Advanced Non-Small Cell Lung Cancer (NSCLC) treated with the immune checkpoint inhibitor Nivolumab***I. Calamia, M. Albertelli, E. Nazzari, M. Bauckneht, G. Rossi, E. Rijavec, C. Genova, G. Barletta, F. Biello, G. Dal Bello, R. Piva, M. Giusti, G. Sambuceti, M. Bagnasco, D. Ferone, F. Grossi, S. Morbelli; IRCCS AUO San Martino IST, Genova, ITALY.***EP-0568****Comparison between PERCIST and EORTC criteria in the evaluation of response to immune check-point inhibitors in Non-Small Cell Lung Cancer (NSCLC) patients***R. Piva, G. Rossi, M. Bauckneht, C. Genova, V. Ceriani, E. Rijavec, G. Barletta, F. Biello, I. Calamia, G. Dal Bello, R. Di Stefano, G. Sambuceti, F. Grossi, S. Morbelli; IRCCS AUO San Martino IST, Genova, ITALY.*

**EP-0569****Prognostic features in non-small cell lung cancer: difference in metastatic behavior between adenocarcinoma and squamous cell carcinoma**

E. A. Usmanij¹, A. Posthuma¹, N. Hugen¹, R. P. J. van den Ende¹, I. D. Nagtegaal¹, J. Bussink¹, L. F. de Geus-Oei²; ¹Radboudumc, Nijmegen, NETHERLANDS, ²Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0570**Volume-dependent comparative analysis of positron emission tomography and diffusion-weighted magnetic resonance imaging parameters in lung adenocarcinoma tumorous tissue**

S. Lucic¹, I. Djan², M. Bjelan¹, S. Pena-Karan³, A. Peter², N. Andjelic⁴, O. Sveljo⁵, K. Koprivsek¹, D. Kozic¹, M. A. Lucic¹; ¹Oncology Institute of Vojvodina/Medical Faculty University of Novi Sad, Sremska Kamenica/Novi Sad, SERBIA, ²Oncology Institute of Vojvodina, Sremska Kamenica/Novi Sad, SERBIA, ³Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica/Novi Sad, SERBIA, ⁴Medical Faculty University of Novi Sad, Novi Sad, SERBIA, ⁵Oncology Institute of Vojvodina/Faculty of Technical Sciences University of Novi Sad, Sremska Kamenica/Novi Sad, SERBIA.

EP-0571**Diagnostic value of SUVmax cut-off in assessment of lymph node metastases among patients with NSCLC imaged by 18F-FDG PET/CT**

J. Teodorczyk¹, B. Brockhuis¹, G. Romanowicz¹, W. Cytawa¹, I. Wenzel-Duszynska¹, J. Kozłowska-Gładki¹, P. Lass^{1,2}; ¹Medical University of Gdansk, Nuclear Medicine Department, Gdansk, POLAND, ²Division of Molecular Spectroscopy, Institute of Experimental Physics, University of Gdansk, Gdansk, POLAND.

EP-0572**Detection and monitoring of thoracic sarcoidosis using F-18 FLT PET/CT: Comparison with F-18 FDG PET/CT**

Y. Yamamoto, T. Norikane, H. Dobashi, Y. Nishiyama; Kagawa University, Kagawa, JAPAN.

EP-0573**Role Of PET CT In Management Of Resectable Non Small Cell Carcinoma Lung**

P. Gupta, R. Mishra, M. Gupta, P. Choudhury; Rajiv Gandhi Cancer Institute, West DELHI, INDIA.

EP-0574**Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in patients with non-small cell lung cancer ≤ 3 cm in size**

S. Pellegrino¹, R. Fonti², E. Matano³, M. Ottaviano³, V. Damiano³, L. Pace⁴, S. De Placido³, S. Del Vecchio^{1,2}; ¹Department of Advanced Biomedical Sciences, University "Federico II", Naples, ITALY, ²Institute of Biostructures and Bioimages, National Research Council, Naples, ITALY, ³Department of Clinical Medicine and Surgery, University "Federico II", Naples, ITALY, ⁴Department of Medicine and Surgery, University of Salerno, Salerno, ITALY.

EP-0575**Metabolic features measured on 18F-FDG PET and aerogenous spread are prognostic factors for disease-free survival in early stage non-small cell lung cancer patients treated by curative surgical resection without adjuvant therapy**

Y. Kang, Y. Song, W. Lee, S. Kim; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KOREA, REPUBLIC OF.

EP-0576**Association of 18Fluorodeoxyglucose (FDG), complete pathological response and overall survival in patients with Pancoast tumours treated with trimodality therapy**

S. McArthur¹, K. Perera¹, B. Thapa¹, M. Newman¹, T. Fancourt¹, S. Lee¹, S. Berlangieri¹, A. Scott^{1,2}, S. Knight¹, S. Barnett¹; ¹Austin Health, Melbourne, AUSTRALIA, ²Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, AUSTRALIA.

EP-0577**Prognostic value of 18F-FDG PET/CT parameters in patients with operable non-small cell lung cancer: comparison with high-risk clinicopathologic factors**

S. Boo, H. Park, H. Cho; Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

EP-44 during congress opening hours, e-Poster Area**Clinical Oncology: Liver, Upper GI & Pancreatic Cancer****EP-0578****Clinical significance of FDG uptake of bone marrow on PET/CT in patients with gastric cancer**

J. Lee¹, M. Lee², S. Lee³; ¹Catholic Kwandong University College of Medicine, Incheon, KOREA, REPUBLIC OF, ²Soonchunhyang University Hospital, Cheonan, KOREA, REPUBLIC OF, ³Soonchunhyang University Hospital, Cheonan, KOREA, REPUBLIC OF.

EP-0579**Diagnostic value of TOF-¹⁸F-FDG PET/CT in patients with suspected pancreatic cancer**

S. Stanzel¹, F. Quehenberger², B. Pernthaler¹, R. Weinke³, R. M. Aigner¹; ¹Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA, ²Medical University of Graz, Institute for Medical Informatics, Statistics and Documentation, Graz, AUSTRIA, ³University Hospital of Graz, Department of Radiology, Division of General Radiological Diagnostics, Graz, AUSTRIA.

EP-0580**Effectiveness of dual-time-point F-18 FDG PET/CT imaging between fatty liver patients and FDG accumulation in the liver**

M. Nakayama, A. Okizaki, K. Takahashi; Asahikawa Medical University, Asahikawa, Hokkaido, JAPAN.

EP-0581**Significance of ¹¹C-acetate PET/CT in the evaluation of post-treatment recurrence for Gastrointestinal Stromal Tumor**

S. Chen, S. Cheung, K. Cheng, Y. Leung, K. Wong, Y. Wong, C. Ho; Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EP-0582**Incremental role of C11-acetate PET/CT in Hepatocellular carcinoma**

S. Z. Ali^{1,2}, A. Sinha², H. Loi², L. Khor²; ¹Kho Teck Puat Hospital, Singapore, SINGAPORE, ²National University Hospital, Singapore, SINGAPORE.

EP-0583**Prognostic value of F-18 FDG PET/CT in the Pre-transplant Evaluation of Patients with for Hepatocellular Carcinoma Patients without Treatment**

B. Choi, S. Kang; Catholic University of Daegu School of Medicine, Daegu, KOREA, REPUBLIC OF.

EP-0584**Does TLG (total lesion glycolysis) superior value over SUVmax for pancreatic cancer assessment in operable cases and inoperable cases?**

R. Ideguchi¹, A. Myssayev², T. Kudo¹; ¹Department of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, JAPAN, ²Department of Radioisotope Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, JAPAN.

EP-0585**¹⁸F-FMISO PET/CT as a preoperative prognostic factor in patients with pancreas cancer**

T. Yamane¹, M. Aikawa², M. Yasuda³, A. Seto¹, I. Kuji¹; ¹Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, JAPAN, ²Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, JAPAN, ³Department of Diagnostic Pathology, Saitama Medical University International Medical Center, Hidaka, JAPAN.

EP-0586**New exponential functions based on CT density to estimate the percentage of liver that is fat**

G. Keramida¹, A. M. Peters²; ¹Royal Brompton and Harefield Hospitals NHS, FT, London, UNITED KINGDOM, ²Royal Sussex County Hospital & Clinical Imaging Sciences Centre, Brighton, UNITED KINGDOM.

EP-0587**Study on diagnosis of primary liver cancer by PET/CT multimodal imaging**

X. Wu, X. Meng, K. Zhang, X. Bai, X. Wang; The Affiliated Hospital of Inner Mongolia Medical, Hohhot, CHINA.

EP-0588**Improvement Of Survival In Patients With Hepatocellular Carcinoma After 90Y RESIN Microsphere Radioembolization: Our Experience**

F. Di Gregorio¹, M. Rensi¹, A. Vit², G. Ferretti¹, F. Giacomuzzi¹, D. Capobianco¹, M. Povolato¹, L. Peressini³, M. Sponza², F. Bonutti⁴; ¹Department of Nuclear Medicine University Hospital, Udine, ITALY, ²Department of Radiology University Hospital, Udine, ITALY, ³University Hospital, Udine, ITALY, ⁴Department of Medical Physics University Hospital, Udine, ITALY.

EP-0589**Prognostic value of a computer based, machine learning-driven survival model for pancreatic cancer in treatment naive patients**

T. S. Nakuz¹, Y. Bican¹, L. Papp¹, W. Wadsak¹, A. Al-Mukhtar², A. Haug¹, M. Hacker¹, G. Karanikas¹; ¹Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Vienna, AUSTRIA, ²Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Division of Radiology, Vienna, AUSTRIA.

e-Poster not submitted



EP-0590**18F FDG PET CT, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation**

J. Navarro Fernandez, L. Frutos Esteban, M. Laroussi, P. Ramirez Romero, M. Godoy Bravo, R. Reyes Marles, L. Sáenz Mateos, P. Cascales-Campos, E. Llàcer Millán, M. González Sánchez, M. Sánchez Lorenzo, S. Veganzones de Castro, E. Díaz Rubio, P. Parrilla Paricio, M. Claver Valderas; H U Virgen de la Arrixaca, Murcia, SPAIN.

EP-0591**Role of PET-CT with ¹⁸F-FDG in the Detection of Pancreatic Neoplasm Recurrence: Preliminary Study**

A. Sabaté Llobera¹, J. J. Robles Barba¹, P. Notta¹, E. Llinares Tello¹, L. Rodríguez Bel¹, J. Mestres Martí¹, G. Reynes Llompart¹, J. Fabregat Pous², N. Calvo Malvar¹, C. Gámez Cenzano¹; ¹Unitat PET-Servicio de Medicina Nuclear. IDI. Hospital U. de Bellvitge-IDIBELL., L'Hospitalet de Llobregat, SPAIN, ²Servicio de Cirugía General. Hospital U. de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0592**The benefits of 18FDG-PET/CT in the evaluation of pancreatic IPMN**

E. Tabacchi¹, C. Nanni¹, E. Lodi Rizzini¹, P. Ghedini¹, D. Santini², A. De Leo², F. Minni³, N. Pagano⁴, C. Ricci³, L. Calculli⁵, R. Casadei³, S. Fanti¹; ¹Department of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy, Bologna, ITALY, ²Anatomy, Pathological Histology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY, ³General Surgery Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY, ⁴Gastroenterology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY, ⁵Radiology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy, Bologna, ITALY.

EP-0593**Simultaneous FDG-PET/CT and contrast-enhanced CT in cholangiocarcinoma: just pretty images?**

A. Farolfi¹, A. Lambertini¹, L. Zannoni¹, C. Mosconi², S. Brocchi², I. Pettinari², V. Rossetti³, F. Mangiacotti¹, D. Mascherini¹, R. Golfieri², S. Fanti¹, C. Nanni¹; ¹Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY, ²Radiology Unit, Department of Diagnostic and Preventive Medicine, S. Orsola-Malpighi University Hospital, Bologna, ITALY, ³Nuclear Medicine Department, ASUITS, Trieste, ITALY.

EP-0594**The Contribution of Metabolic and Morphological Evaluation in FDG PET/CT in the Staging of Signet Ring Cell Carcinoma of the Stomach**

A. Yıldız¹, B. Özcan², M. Özdoğan³, H. Dikici⁴, C. Ertuğrul⁴, A. Gürkan², Z. Şahin¹; ¹Nuclear Medicine, Medstar Hospital, Antalya, TURKEY, ²General Surgery, Medstar Hospital, Antalya, TURKEY, ³Medical Oncology, Medstar Hospital, Antalya, TURKEY, ⁴Gastroenterology, Medstar Hospital, Antalya, TURKEY.

EP-45 during congress opening hours, e-Poster Area**Clinical Oncology: Neuroendocrine Tumours****EP-0595****The effect of long acting somatostatin analogue administration on ⁶⁸Ga-DOTATATE uptake in primary and metastatic NET lesions**

N. Ayati¹, S. Lee², R. Zakavi¹, K. Pathmaraj³, L. Qatawneh³, A. Poon², A. Scott^{2,4,5}; ¹Mashhad Univesity of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, AUSTRALIA, ³Nuclear Medicine and Cyclotron Unit, King Hussein Medical Center, Jordanian Royal Medical Services, JORDAN, ⁴Olivia Newton-John Cancer Research Institute; and School of Cancer Medicine, La Trobe University, Heidelberg, AUSTRALIA, ⁵Department of Medicine, University of Melbourne, Austin Health, Heidelberg, AUSTRALIA.

EP-0596**⁶⁸Ga-DOTA-TOC PET/CT predicts exact tumor staging in head and neck paragangliomas, compared to ¹⁸F-DOPA PET/CT and ¹²³I-MIBG SPECT/CT**

A. S. Kroiss¹, C. Uprimny¹, L. Gruber¹, B. L. Shulkin², I. J. Virgolini¹; ¹Medical University Innsbruck, Innsbruck, AUSTRIA, ²St Jude Research Hospital, Memphis, TN, UNITED STATES OF AMERICA.

EP-0597**Indication of MDP bone scan after MIBG scintigraphy in patients with neuroblastoma**

K. Chaurasiya, E. Kireeva, I. Krupina, Y. Likar; Dmitry Rogachev National Research and Practical Center of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.



EP-0598**The role of 18F Fluorocholine PET/CT in the imaging of recurrence of parathyroid cancer after surgery**

A. Florczak, I. Gorczywska, A. d'Amico; Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, Gliwice, POLAND.

EP-0599**Orbital Metastasis Detected by Ga-68 Somatostatin Receptor PET/CT in Patients with Neuroendocrine Tumors**

Z. Awang¹, R. Baum²; ¹Ministry of Health Malaysia, Melaka, MALAYSIA, ²Zentralklinik Bad Berka, Zentralklinik, GERMANY.

EP-0600**Performance of somatostatin receptor scintigraphy (SRS) and fluorodeoxyglucose (FDG) PET/CT in initial staging of gastro-entero-pancreatic neuroendocrine tumors (GEP-NET)**

S. P. Dhake, A. Agrawal, M. Ramadwar, N. Purandare, S. Shah, A. Puranik, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

EP-0601**Cell dedifferentiation & somatostatin receptors expression can coexist in neuroendocrine carcinomas?**

V. Ippolito, G. Annunziata, C. Mocerino, D. Scala, F. Scavuzzo, I. Valenti, M. Catalano; aorn cardarelli, Naples, ITALY.

EP-0602**Advanced Digestive Neuroendocrine Neoplasms: prognostic role of 18-F-FDG-PET**

D. Prospero¹, M. Cucinotta¹, M. Rinzivillo¹, F. Panzuto¹, G. Capurso¹, G. Capriotti¹, E. Iannicelli¹, M. Pacilio¹, L. Carideo¹, E. Pillozzi¹, E. Merola¹, O. Schillaci², G. Delle Fave¹, F. Scopinaro¹; ¹Sant'Andrea University Hospital of Rome, Rome, ITALY, ²University of Rome Tor Vergata, Rome, ITALY.

EP-0603**Differences in uptake between ⁶⁸Ga-Dotatate and ⁶⁸Ga-HA-DOTATATE in normal organs and tumour lesions: a retrospective study in 342 patients**

E. A. Aalbersberg, B. J. de Wit - van der Veen, M. M. Geluk - Jonker, L. Bensen, M. P. M. Stokkel; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

EP-0604**Fifty months of somatostatin receptor SPECT/CT with ^{99m}Tc-EDDA Hynic Toc: What have we learned?**

N. Giroto, E. Kukić, M. Maršić, S. Rac, S. Grbac; Clinical Hospital Centre Rijeka, Rijeka, CROATIA.

EP-0605**Biodistribution of [⁶⁸Ga]Ga-DATATOC in comparison with [⁶⁸Ga]Ga-DOTATOC in normal tissues and neuroendocrine tumour lesions**

B. Schmidt-Kreppel¹, T. Plum¹, F. C. Gaertner¹, E. Eppard¹, J. Sinnes², H. Strunk¹, R. A. Bundschuh¹, F. Rösch², M. Essler¹; ¹University Medical Center Bonn, Bonn, GERMANY, ²Johannes Gutenberg-University Mainz, Mainz, GERMANY.

EP-0606**Comparison of ⁶⁸Ga-DATATOC & ⁶⁸Ga-DOTANOC PET/CT Imaging in Patients with Neuroendocrine Tumours**

D. Yadav, M. Tripathi, N. A. Damle, C. Bal; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0607**Association Between Somatostatin Receptor Scintigraphy And Chromogranin Levels In Patients With Neuroendocrine Tumors**

R. H. Reyes Marlés, Sr., M. Castellón Sanchez, F. Nicolas Ruiz, L. Mohamed Salem, J. Navarro, L. Frutos Esteban, M. Godoy Bravo, I. Sime loayza, M. Tomás Redondo, E. Fernandez Muñoz, M. Claver Valderas; Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, SPAIN.

EP-0608**Quality Of Life in Patients with Neuroendocrine Gastroenteropancreatic Tumors Treated with Peptide Receptor Radionuclide Therapy**

A. Georgakopoulos¹, T. Liotsou², S. N. Chatziioannou^{1,2}; ¹Biomedical Research Foundation of the Academy of Athens, Clinical and Translational Research, Nuclear Medicine Division, PET/CT section, Athens, GREECE, ²2nd Radiology Department, "Attikon" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Nuclear Medicine Division, Athens, GREECE.



EP-0609**Quantification of 6-[¹⁸F]fluoro-L-3,4-dihydroxyphenyl alanine Uptake in Neuroendocrine Tumour Lesions: The Effect of Specific Activity**

R. S. B. H. Schreuder¹, A. H. Brouwers¹, P. H. Elsinga¹, R. H. J. A. Slart¹, A. M. E. Walenkamp², A. W. J. M. Glaudemans¹, G. Luurtsema¹; ¹Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, ²Department of Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS.

EP-0610**The role of Ga 68-DOTANOC PET-CT in treatment management of recurrent medullary thyroid cancer**

A. Aliyev¹, A. Aliyeva¹, I. Aliyeva², E. Mehdi³, F. Novruzov³; ¹Azerbaijan National Centre Of Oncology, Department Of Head and Neck Surgery, Baku, AZERBAIJAN, ²Azerbaijan Medical University, Department of Internal Medicine, Baku, AZERBAIJAN, ³Azerbaijan National Centre Of Oncology, Department Of Nuclear Medicine, Baku, AZERBAIJAN.

EP-0611**F-18-DOPA PET/CT in medullary thyroid carcinoma patients**

A. T. Golubić¹, E. Pasini¹, M. Zuvic¹, S. Kusacic Kuna^{1,2}, T. Samardzic¹, M. Despot¹, D. Huic^{1,2}; ¹Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA, ²School of Medicine, University of Zagreb, Zagreb, CROATIA.

EP-0612**Frequency of physiological 111In-DTPA-octreotide SPECT/CT uptake in pancreatic uncinate process: retrospective study on a large 198 patients review and comparison with 68Ga-DOTATOC PET/CT**

P. Schwartz, CHU de Bordeaux, Pessac, FRANCE.

EP-0613**Complementary role of 18F-FDG and 68Ga-DOTATOC PET-TC in patients with cystic pancreatic lesions**

M. Cucca, L. Locantore, M. Frigolito, M. Zuffante, M. Ferdeghini, N. M. ... Medicine Unit, University Hospital of Verona, Verona, ITALY.

EP-0614**Role of ⁶⁸Ga DOTANOC PET/CT in patients of paraganglioma and comparison with ¹³¹I-MIBG SPECT/CT scintigraphy**

S. Arora, M. Tripathi, R. kumar, C. Bal, R. kumar; All India Institute of Medical Sciences, AIIMS, New Delhi, New Delhi, INDIA.

EP-0615**Advantages of Simultaneous PET/MRI in the Evaluation of Neuroendocrine Tumors with Ga-68 DOTATATE**

D. Franceschi, R. Matthews, R. Chimpiri, N. Relan; SUNY at Stony Brook, Stony Brook, NY, UNITED STATES OF AMERICA.

EP-0616**Indium 111 pentetreotide in Neuroendocrine Tumors: SPECT CT is truly needed**

M. L. De Rimini¹, A. Di Sarno², N. De Rosa³, A. Settembre⁴, F. Lassandro⁵, C. Bergaminelli⁶, P. Muto¹; ¹Nuclear Medicine Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, ²Oncology Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, ³Pathology Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, ⁴Surgery Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, ⁵Radiology Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY, ⁶Thoracic Surgery Unit - AO Ospedali dei Colli - Monaldi, Naples, ITALY.

EP-46 during congress opening hours, e-Poster Area**Clinical Oncology: Colorectal Cancer****EP-0617****Preliminary results in the evaluation of PET/CT colonography in preoperative obstructive colorectal cancer diagnosed by incomplete optical colonoscopy**

D. Fuster, M. Pagès, A. Ginés, E. Buxó, D. Momblan, F. Campos, F. Pons, N. Sánchez, A. Tapias, F. Lomeña; Hospital Clinic, BARCELONA, SPAIN.

EP-0618**Clinical role of 18F FDG PET CT in recurrence of colorectal cancer with suspected conventional image findings irrespective of tumor markers**

E. Kaya¹, H. Temiz¹, A. L. Güner¹, ... E. Vardareli¹, M. Emi², A. Karaman³; ¹Acibadem University Medical Faculty, Department of Nuclear Medicine, Istanbul, TURKEY, ²Acibadem Kayseri Hospital, Department of Radiodiagnosis, Kayseri, TURKEY, ³Acibadem University Medical Faculty, Department of Gastroenterology, Istanbul, TURKEY.

EP-0619**Correlation between metabolic tumor volume and prognostic hematological parameters in patients with colorectal cancer**

A. Cengiz, Y. Yürekli; Adnan Menderes University Medical School Department of Nuclear Medicine, Aydın, TURKEY.



EP-0620**Relationship between metabolic parameters and ras mutation status**

*E. Karci¹, C. Soyda², G. Utkan¹, Y. Urun¹, H. Akbulut¹;
¹Ankara University Medical Faculty, Medical Oncology, Ankara, TURKEY, ²Ankara University Medical Faculty, Nuclear Medicine, Ankara, TURKEY.*

EP-0621**The FOXFIRE/SIRFLOX/FOXFIRE-Global randomised studies of first-line selective internal radiation therapy for metastatic colorectal cancer**

*N. K. Sharma¹, P. Gibbs², G. Van Hazel³, V. Heinemann⁴, J. Ricke⁵, M. P. Findlay⁶, V. GebSKI⁷, J. Moschandreass⁸, P. Virdee⁸, P. Dutton⁹, J. Taieb⁹, M. Peeters¹⁰, P. Tait¹¹, P. Boardman¹², V. Lewington¹¹, A. Al-Nahhas¹¹, H. Wasan¹³, R. A. Sharma¹⁴;
¹Penn State Hershey Cancer Institute, Hershey, PA, UNITED STATES OF AMERICA, ²The Royal Melbourne and Western Hospitals, Melbourne, AUSTRALIA, ³University of Western Australia, West Perth, AUSTRALIA, ⁴University of Munich, Munich, GERMANY, ⁵University of Magdeburg, Magdeburg, GERMANY, ⁶University of Auckland, Auckland, NEW ZEALAND, ⁷University of Sydney, Sydney, AUSTRALIA, ⁸University of Oxford, Oxford, UNITED KINGDOM, ⁹Georges Pompidou European Hospital, Paris, FRANCE, ¹⁰Antwerp University Hospital, Antwerp, BELGIUM, ¹¹Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, ¹²Oxford University Hospitals NHS Trust, Oxford, UNITED KINGDOM, ¹³Hammersmith Hospital, London, UNITED KINGDOM, ¹⁴University College London, London, UNITED KINGDOM.*

EP-0622**Diagnostic value of 18F-FDG PET/CT in follow up of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation before surgery**

C. Altini, A. Niccoli Asabella, A. Di Palo, V. Lavelli, A. Cassano, E. P. Mossa, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, Bari, ITALY.

EP-0623**Prognostic value of 18F-FDG PET/CT visual assessment and semiquantitative analysis in locally advanced rectal cancer treated with neoadjuvant chemoradiation**

C. Altini, A. Niccoli Asabella, C. Ferrari, V. Lavelli, S. Sisto, M. Fanelli, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, Bari, ITALY.

EP-0624**18F FDG PET CT vs CT Scan in patients with pulmonary metastases previously operated on for colorectal liver metastases**

J. Navarro Fernandez, L. Frutos Esteban, V. Lopez-Lopez, M. Laroussi, M. Godoy Bravo, R. Reyes Marles, R. Robles Campos, R. Brusadin, A. Lopez Conesa, P. Parrilla Paricio, M. Claver Valderas; H U Virgen de la Arrixaca, Murcia, SPAIN.

EP-0625**Diagnostic value of 18F-FDG-PET/CT in the assessment of colorectal liver metastasis with neoadjuvant therapy pre-metastectomy**

*A. M. Santos Bueno¹, M. V. Guiote Moreno¹, L. M. Mena Bares¹, E. Carmona Asenjo¹, F. R. Maza Muret¹, E. Ortega Moreno¹, E. Rodríguez Cáceres², J. A. Vallejo Casas¹;
¹HU Reina Sofia, Córdoba, SPAIN, ²IMIBIC, Córdoba, SPAIN.*

EP-0626**The Role of 18F-FDG PET/CT in Restaging and Management of Patients with Colorectal Carcinoma**

G. Mateva, I. Kostadinova; Acibadem City Clinic Cancer Center, Sofia, BULGARIA.

EP-47 during congress opening hours, e-Poster Area**Clinical Oncology: Urogenital****EP-0627****Role of 11C-Choline PET/CT in prostate cancer patients with biochemical recurrence after brachytherapy**

J. Garcia, M. Cozar, M. Soler, G. Reyes, A. Diaz, J. Ferrer, E. Riera; CETIR ERESA, Esplugues. Barcelona, SPAIN.

EP-0628**Assessing the value of mediastinal lymph node uptake on ¹⁸F-choline PET/CT scans**

V. Sousa, C. Loewenthal, M. Vieira; Hospital da Luz, Lisbon, PORTUGAL.

EP-0629**F-18 Fluorocholine PET/CT In Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy**

S. K. Vadi, B. Singh, S. K. Singh, A. Watts, R. K. Basher, A. Sood, N. Kakkar, A. Lal; Post graduate institute of medical education and research, Chandigarh, INDIA.



EP-0630**11C-Choline PET/CT in the Diagnostics of Bone Metastases in Prostate Cancer Patients with Biochemical Relapse**

D. M. Pursanova¹, I. P. Aslanidi¹, O. V. Mukhortova¹, T. A. Katunina¹, V. I. Shirokorad², D. A. Roshchin³; ¹A.N.Bakoulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION, ²Moscow City Oncology Hospital N°62, Moscow, RUSSIAN FEDERATION, ³N.Lopatkin Scientific Research Institute of urology and Interventional Radiology - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EP-0632**⁶⁸Ga PSMA PET/CT in prostate cancer - A single centre experience from India**

A. Sasikumar¹, A. Joy¹, M. Pillai¹, R. Nanabala¹, S. Bindu¹, J. Madhavan², B. Thomas², S. S R², R. Thomas²; ¹KIMS-DDNMRC, Trivandrum, INDIA, ²KIMS Hospital, Trivandrum, INDIA.

EP-0633**Therapeutical changes in the management of patients with biochemical relapse of prostate cancer and positive ¹¹C-Choline PET/CT**

F. J. Gómez-de la Fuente, I. Martínez-Rodríguez, R. Quirce, M. De Arcocha-Torres, J. L. López-Defilló, M. Jiménez-Alonso, B. Lucas-Velázquez, D. F. Tovar-Echeverri, G. Molina-Mendoza, I. Banzo; Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

EP-0634**Oligometastatic disease (OMD) in prostate cancer (PCa) detects by 18F-Choline (FCH) PET/CT in patients with PSA levels < 5 ng/mL**

L. Cuppari¹, A. Guttilla², M. Gardi³, A. Agostini³, A. Cervino¹, P. Reccia¹, M. Burei¹, G. Saladini¹, M. Hodolic⁴, L. Evangelista¹; ¹Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, ²Camposampiero Hospital, Camposampiero (PD), ITALY, ³Hospital of Sant'Antonio, Padova, ITALY, ⁴Nuclear Medicine Research Department, Iason, Graz, AUSTRIA.

EP-0635**The effects of 18F-FDG-PET/CT on the management and prognosis of patients with bladder (Bca) and upper urinary tract urothelial carcinoma (UTUC)**

L. Evangelista¹, F. Zattoni², E. Incerti³, V. Lowe⁴, i. Rambaldi⁵, S. Panareo⁶, R. Schiavina⁷, J. R. Karnes⁸, M. Moschini⁹, V. Ficarra², M. Colicchia⁸, S. Fanti¹⁰, A. Briganti¹¹, M. Picchio³; ¹Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, ²Department of Urology, Hospital of Udine, Udine, ITALY, ³Nuclear Medicine Department, IRCCS Ospedale San Raffaele, Milano, ITALY, ⁴Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA, ⁵Nuclear Medicine Unit, Diagnostic Imaging e Laboratory Medicine Department, University Hospital of Ferrara, Ferrara, ITALY, ⁶Nuclear Medicine Unit, Diagnostic Imaging e Laboratory Medicine Department, University Hospital of Ferrara, Padova, ITALY, ⁷Department of Urology, Sant'Orsola-Malpighi Hospital, Bologna, ITALY, ⁸Department of Urology, Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA, ⁹Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milano, ITALY, ¹⁰Service of Nuclear Medicine, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, ITALY, ¹¹Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University, Milano, ITALY.

EP-0637**Predictive value of 11C-Acetate PET/CT in metastatic renal cell carcinoma**

B. Małkowski^{1,2}, V. Pankowski¹, M. Malkowski¹, K. Roszkowski¹; ¹Oncology Centre Bydgoszcz, Bydgoszcz, POLAND, ²Collegium Medicum BydgoszczUMK Torun, Bydgoszcz, POLAND.

EP-0638**Prostate Specific Antigen (PSA) and Gleason Score (GS) as gatekeepers for bone scintigraphy in a resource restricted setting**

K. M. G. Mokoala^{1,2}, M. H. W. Vangu^{1,2}; ¹Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Johannesburg, SOUTH AFRICA, ²University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-0639**Value of ¹⁸F-fluorocholine PET/CT for Targeted Prostate Re-Biopsies in Patients with Rising PSA Levels**

P. Koranda¹, Š. Kudláčková², M. Hodolič¹, A. Fellerová¹, L. Quinn¹, R. Formánek¹, E. Buriánková¹, M. Kamínek¹; ¹Dept. of Nuclear Medicine, Univ. Hospital and Palacký University, OLOMOUC, CZECH REPUBLIC, ²Dept. of Urology, Univ. Hospital and Palacký University, OLOMOUC, CZECH REPUBLIC.



EP-0640**223Radium: analysis of effect of treatment in bone oligo-metastatic CRPC patients**

V. Frantellizzi, G. A. Follacchio, M. Pontico, L. Cosma, A. Farcomeni, F. Monteleone, M. Liberatore, G. De Vincentis; Sapienza University of Rome, Rome, ITALY.

EP-0641**Analytical validation of an automated method for segmentation of the prostate gland in CT images**

E. Polymeri¹, M. Sadik², R. Kaboteh², O. Enqvist³, J. Ulén⁴, E. Trägårdh⁵, M. H. Poulsen⁶, J. A. Simonsen⁷, P. F. Høilund-Carlsen⁷, L. Edenbrandt⁸, Å. Johnsson¹; ¹Department of Radiologi, Göteborg, SWEDEN, ²Department of Clinical Physiology, Göteborg, SWEDEN, ³Department of Signals and Systems, Göteborg, SWEDEN, ⁴Eigenvision AB, Malmö, SWEDEN, ⁵Department of Translational Medicine, Malmö, SWEDEN, ⁶Department of Urology, Odense, DENMARK, ⁷Department of Nuclear Medicine, Odense, DENMARK.

EP-0642**Convolutional neural network based quantification of choline uptake in PET/CT studies is associated with overall survival in patients with prostate cancer**

R. Kaboteh¹, E. Polymeri², M. Sadik¹, O. Enqvist³, J. Ulén⁴, M. Ohlsson⁵, E. Trägårdh⁶, M. H. Poulsen⁷, J. A. Simonsen⁸, P. F. Høilund-Carlsen⁸, Å. Johnsson², L. Edenbrandt¹; ¹Department of Clinical Physiology, Göteborg, SWEDEN, ²Department of Radiologi, Göteborg, SWEDEN, ³Department of Signals and Systems, Göteborg, SWEDEN, ⁴Eigenvision AB, Malmö, SWEDEN, ⁵Department of Theoretical Physics, Lund, SWEDEN, ⁶Department of Translational Medicine, Malmö, SWEDEN, ⁷Department of Urology, Odense, DENMARK, ⁸Department of Nuclear Medicine, Odense, DENMARK.

EP-0643**Correlation between molecular active tumor volume evaluate with 68Ga-PSMA PET-CT and levels of antigen prostatic specific**

F. O. García-Pérez, S. S. Medina-Ornelas, B. L. Abundiz-Lopez, A. Arellano-Zarate; Instituto Nacional De Cancerologia, Mexico City, MEXICO.

EP-0644**18F-choline PET/CT as a prediction diagnostic tool of the disease progression in patients with castration resistant prostate cancer**

M. Grmek, S. Hawlina, L. Lezaic; University medical centre Ljubljana, LJUBLJANA, SLOVENIA.

EP-0645**Bone Scintigraphy Versus PSMA PET-CT in Primary Staging of Prostate Cancer**

P. Kaldeway, H. van Melick, J. Lavalaye; St Antonius Hospital Nieuwegein, Nieuwegein, NETHERLANDS.

EP-0646**Comparison between 18F-Choline (FCH) PET/CT and Conventional Imaging (CI) in Intermediate-high risk prostate cancer (PCa) patients: design and preliminary data of a phase III Italian Multicenter Randomized Trial**

L. Evangelista¹, B. Eugenio², M. Farsad³, G. Trifirò⁴, S. Agostini⁵, E. Bombardieri⁶, T. Baresic², A. Golemi³, E. Brugola⁴, F. Chierichetti⁵, M. Hodolic⁷, G. Saladini¹; ¹Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, ²Department of Nuclear Medicine, Centro Regionale Oncologico (CRO), Aviano (PD), ITALY, ³Department of Nuclear Medicine, Hospital of Bolzano, Bolzano, ITALY, ⁴Department of Nuclear Medicine, Fondazione Salvatore Maugeri IRCCS, Pavia, ITALY, ⁵Department of Nuclear Medicine, Hospital of Trento, Trento, ITALY, ⁶Department of Nuclear Medicine, Istituto Humanitas Gavazzeni IRCCS, Bergamo, ITALY, ⁷Nuclear Medicine Research Department, Iason, Austria Palacky University, Olomouc, CZECH REPUBLIC.

EP-0647**⁶⁸Ga-PSMA PET/CT; current impact on management in prostate cancer**

F. Intema, A. Kooistra, A. P. Lont, L. P. J. Hendriks, J. P. Esser, R. Lange, J. M. H. de Klerk; Meander Medical Center, Amersfoort, NETHERLANDS.

EP-0648**Relationship between metabolic parameters of 18F-FDG PET of prostate cancer bone metastases**

r. g. yang¹, z. j. ren², w. z. huo¹, h. x. wang¹, y. liu¹, q. kong¹; ¹Shandong Cancer Hospital affiliated to Shandong University, Shandong province, CHINA, ²Shandong Jining No.1 People's Hospital, Shandong province, CHINA.

EP-0649**⁶⁸Ga-PSMA-PET/MRI, ¹¹C-acetate-PET/CT and stand-alone multi-parametric MRI with histopathology as reference in intermediate- and high-risk prostate cancer - preliminary data**

S. Strandberg¹, K. Sandgren¹, J. Jonsson¹, J. Axelsson¹, M. Ögren¹, T. Nyholm¹, C. Thellenberg Karlsson¹, L. Blomqvist¹, M. Skorpil¹, K. Riklund¹, B. Friedrich², A. Bergh³, A. Widmark¹; ¹Radiation Sciences, Umea, SWEDEN, ²Surgical and Perioperative Sciences, Umea, SWEDEN, ³Medical Biosciences, Umea, SWEDEN.



EP-0650**Hormonal therapy impact on 18F-Fluorocholine PET-CT detection rates in recurrent prostate cancer**

E. Triviño-Ibáñez, I. Puche-Sanz, A. Rodríguez-Fernández, A. González-Jiménez, E. Moratalla-Aranda, B. El Fahimi, F. Vázquez-Alonso, M. Gómez-Río, J. Llamas-Elvira; Virgen de las Nieves University Hospital, Granada, SPAIN.

EP-0651**Alkaline phosphatase (ALP) is a good predictor of skeletal metastasis in prostate cancer patients**

K. M. G. Mokoala^{1,2}, M. W. H. Vangu^{1,2}; ¹Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Johannesburg, SOUTH AFRICA, ²University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-0652**Dual-phase 18F-FDG PET/CT Combined Diuretic for Restaging of Bladder Cancer**

Q. Zhao, Y. Jia, J. Li, L. He, F. Zhao, X. Zhuang, F. Zhang; General Hospital of Ningxia Medical University, Yinchuan, CHINA.

EP-0653**⁶⁸Ga-PSMA-11 PET/MRI in Primary Intermediate/High-Risk Prostate Cancer**

S. Park, C. Zacharias, C. Harrison, L. Baratto, N. Hatami, A. Igaru; Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA.

EP-0654**⁶⁸Ga-PSMA for radioimaging of prostate cancer: an in-vitro study using LNCaP cells and PC3 cells**

P. Cuber¹, M. Heuschkel¹, J. Rabenstein², A. Hohn¹, W. Rutz¹, O. W. Hackenberg², D. Fischer³, B. J. Krause¹; ¹Department of Nuclear Medicine Rostock, Rostock, GERMANY, ²Department of Urology Rostock, Rostock, GERMANY, ³Department of Paediatrics, Rostock, GERMANY.

EP-0655**Comparison of Ga-68 PSMA-11 PET, Tc-99m DPD bone SPECT and computed tomography for the detection of bone metastases in patients with metastatic prostate cancer**

H. Ilhan¹, S. Reinhardt¹, W. P. Fendler¹, A. Todica¹, F. J. Gildehaus¹, C. Cyran², C. Gratzke³, A. Herlemann³, V. Wenter¹, P. Bartenstein¹, A. Rominger¹; ¹Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY, ²Institute for Clinical Radiology, University Hospital of Munich, Munich, GERMANY, ³Department of Urology, University Hospital of Munich, Munich, GERMANY.

EP-0656**18F-Choline (FCH) PET/CT for initial staging of patients with intermediate and high risk prostate cancer (PCa) in routine use: results and perspective**

C. Rousseau^{1,2}, M. Barbaud¹, L. Ferrer^{3,2}, V. Fleury¹, M. Le Thiec¹, D. Rusu¹, L. Champion^{4,2}, F. Kraeber-Bodéré^{1,2}; ¹ICO Cancer Center, Nuclear Medicine Unit, Saint Herblain, FRANCE, ²CRCINA, Inserm U1232, CNRS UMR 6299, Nantes, FRANCE, ³ICO Cancer Center, Medical Physics Unit, Saint Herblain, FRANCE, ⁴ICO Cancer Center, Biometrics Unit, Saint Herblain, FRANCE.

EP-0657**What factors should be considered before proposing 18-F-Choline (FCH) PET/CT in rising PSA prostate cancer patients who are being considered for targeted therapy ?**

M. Barbaud¹, L. Ferrer^{2,3}, V. Fleury¹, M. Le Thiec¹, D. Rusu¹, T. Rousseau⁴, G. Bochereau⁵, H. Monsaint⁶, F. Kraeber-Bodéré^{1,3}, L. Champion^{7,3}, C. Rousseau^{1,3}; ¹Nuclear Medicine Unit, ICO Cancer Center, Saint Herblain, FRANCE, ²Medical Physics Unit, ICO Cancer Center, Saint Herblain, FRANCE, ³CRCINA, Inserm U1232, CNRS UMR 6299, Nantes, FRANCE, ⁴Urologic Clinic Nantes-Atlantis, Saint Herblain, FRANCE, ⁵Urologic Unit, Saint Augustin Clinic, Nantes, FRANCE, ⁶Urologic Unit, Urologic Medipole Group, Vannes, FRANCE, ⁷Biometrics Unit, ICO Cancer Center, Saint Herblain, FRANCE.

EP-0658**Ga68 PSMA-11 PET/MRI: Influence of Scan Time on Image Quality**

S. Park, L. Baratto, H. Gandhi, P. Gulaka, A. Igaru; Stanford University School of Medicine, STANFORD, CA, UNITED STATES OF AMERICA.

EP-0659**⁶⁸Ga PSMA PETCT improves initial management plan of patients with intermediate and high risk prostate cancer**

A. Al-Ibraheem, A. Alsharif, A. Al-Daghamen, S. Salah, J. Khader, M. Alkhalidi, M. Abu Nasser, J. Khzouz; King Hussein Cancer Center, Amman, JORDAN.

EP-0660**Seminal vesicles infiltration**

L. Holody, M. Tarnawska, M. Obarzanowski, J. Jaskulski, J. Kopczak, M. Kedzierawski; Swietokrzyski Cancer Center, Centrum Onkologii, Kielce, POLAND.

EP-0661**Impact of Whole Body 99m-Tc-HDP SPECT-CT On Treatment Decisions In Patients With High Risk Prostate Cancer**

K. E. Esa Kauppila; Seinäjoki Central Hospital, Seinäjoki, FINLAND.



EP-0662

Correlation of Prostate specific antigen and Gleason score with Standardized uptake values of 68Ga PSMA PET/CT in initial staging of prostate cancer

A. Agrawal, K. Shaha, G. Prakash, G. Bakshi, S. Menon, N. Purandare, S. Shah, A. Puranik, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

EP-0663

Somatostatin receptor expression in neuroendocrine cell carcinoma: a new perspective on an old knowledge

L. Locantore, M. C. ... Angiolato, M. Zuffante, M. Ferdeghini; Nuclear Medicine Unit, University Hospital of Verona, Verona, ITALY.

EP-0664

PSA cutoff for ordering NaF PET/CT bone scan in patients with newly diagnosed prostate cancer

I. Sarikaya¹, A. Elgazzar², A. Baqer³, P. Sharma², M. Alfeeli³; ¹Kuwait University Faculty of Medicine, Kuwait, KUWAIT, ²Kuwait University Faculty of Medicine, Kuwait, KUWAIT, ³Mubarak Al Kabeer Hospital, Kuwait, KUWAIT.

EP-0665

The value of Ga-68 PSMA-11 PET/CT in the primary staging of biopsy proven prostate cancer

H. Ilhan¹, D. Schmidt¹, V. Wenter¹, A. Todica¹, C. Cyran², A. Herlemann³, C. Gratzke³, F. J. Gildehaus¹, P. Bartenstein¹, A. Rominger¹, W. P. Fendler¹; ¹Department of Nuclear Medicine, University Hospital of Munich, Munich, GERMANY, ²Institute for Clinical Radiology, University Hospital of Munich, Munich, GERMANY, ³Department of Urology, University Hospital of Munich, Munich, GERMANY.

EP-0666

Semiquantitative analysis of ¹⁸F-choline uptake in prostate gland of patients with untreated cancer: relationships with Risk Assessment Score and patient's outcome

M. Castellani¹, L. Florimonte¹, M. Vadrucci², V. Longari¹, E. Orunesu¹, R. Benti¹; ¹Department of Nuclear Medicine, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, MILAN, ITALY, ²Department of Nuclear Medicine, King's College Hospital NHS Foundation Trust, London, UNITED KINGDOM.

EP-0667

PSMA Avid Liver Hemangioma

K. Oksuzoglu, T. Ones, H. T. Turoglu, S. Inanir, T. Y. Erdil; Marmara University School of Medicine, Nuclear Medicine Department, Istanbul, TURKEY.

EP-0668

The Value of ⁶⁸Ga-PSMA PET/CT in Biochemical Recurrence of Prostatic Carcinoma (Pca)

E. Abamor¹, T. Çakır¹, A. Çakır², A. Bilici³, S. Güven⁴, T. Atasever¹; ¹Medipol Mega University Hospital, Department of Nuclear Medicine, ISTANBUL, TURKEY, ²Medipol Mega University Hospital, Department of Pathology, ISTANBUL, TURKEY, ³Medipol Mega University Hospital, Department of Oncology, ISTANBUL, TURKEY, ⁴Medipol Mega University Hospital, Department of Urology, ISTANBUL, TURKEY.

EP-0669

Does delayed FDG PET/CT imaging improve diagnostic sensitivity in lymph node staging of muscle invasive bladder cancer?

A. Girard, Jr., S. Tague, S. Birma, D. Vilain, M. Rouanne, C. P. ... Le Stanc, J. Grellier; Hôpital Foch, St Germain, FRANCE.

EP-0670

The influence of postdiuretic late phase imaging in visual and quantitative evaluation of uroepithelial tumors by F-18 FDG PET/CT

Z. Koç, P. Özcan Kara, E. Sezer; Mersin University Hospital, Mersin, TURKEY.

EP-0671

Sarcoid-like reaction in prostate cancer patients assessed by 18-F-choline PET-CT

N. Eftychiou¹, M. Wong¹, J. Hunter², S. Dizdarevic^{1,2}; ¹Brighton and Sussex University Hospitals, Brighton, UNITED KINGDOM, ²Clinical Imaging Science Centre BSMS, Brighton, UNITED KINGDOM.

EP-0672

Early 68Ga-PSMA PET/CT imaging in assessment of prostate cancer and its impact on patient's management comparing to standard protocol

M. Beheshti¹, Z. Paymani^{1,2}, H. Geinitz³, G. Broinger⁴, D. Gehring¹, T. Leopoldseder¹, B. Gruy¹, W. Loidl⁵, W. Langsteger¹; ¹PET-CT Center Linz, St. Vincent's Hospital, Linz, AUSTRIA, ²Research Center for Nuclear Medicine, Shariati Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Radiation Oncology, St. Vincent's Hospital, Linz, AUSTRIA, ⁴Clinical Pathology, St. Vincent's Hospital, Linz, AUSTRIA, ⁵Urology, St. Vincent's Hospital, Linz, AUSTRIA.

EP-0673

¹⁸F-Choline PET/CT & functional parameters in treatment evaluation of patients with castration resistant prostate cancer submitted to Abiraterone: preliminary data

D. Pizzuto¹, S. Annunziata¹, D. Ripani¹, C. Altini¹, C. Caldarella², V. Rufini¹; ¹Institute of Nuclear Medicine, Università Cattolica del S. Cuore "A. Gemelli", Rome, Roma, ITALY, ²PET-CT Center, Policlinico "A. Gemelli", Rome, Roma, ITALY.



EP-0674**Appropriateness of prescription of 18F-Choline PET/CT in 218 patients with prostate cancer**

S. Chondrogiannis, M. C. Marzola, G. Grassetto, G. Borotto, E. Tommasi, L. Tamiso, A. M. Maffione, L. Pavan, L. Rampin, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

EP-0675**⁶⁸Ga-Psma Hbed Pet/Ct in the assessment of biochemical recurrence in radically treated prostate cancer patients**

P. Caroli¹, M. Celli¹, R. Gunelli², V. Lanzetta³, V. Di Iorio³, A. Romeo⁴, L. Fantini¹, M. Pancisi¹, A. Moretti¹, R. Galassi¹, T. Zenico², G. Paganelli¹, F. Matteucci¹; ¹Nuclear Medicine Unit IRCCS IRST, Meldola, ITALY, ²Urology Unit AVR, Forlì, ITALY, ³Radiopharmacy Unit IRCCS IRST, Meldola, ITALY, ⁴Radiotherapy Unit IRCCS IRST, Meldola, ITALY.

EP-0676**The Role of ⁶⁸Ga-PSMA PET/CT in Newly Diagnosed Primary Prostatic Carcinoma (Pca)**

E. Abamor¹, T. Çakır¹, A. Çakır², A. Bilici³, S. Güven⁴, T. Atasever¹; ¹Medipol Mega University Hospital, Department of Nuclear Medicine, ISTANBUL, TURKEY, ²Medipol Mega University Hospital, Department of Pathology, ISTANBUL, TURKEY, ³Medipol Mega University Hospital, Department of Oncology, ISTANBUL, TURKEY, ⁴Medipol Mega University Hospital, Department of Urology, ISTANBUL, TURKEY.

EP-0677**Extracting more information from ⁶⁸Ga-PSMA-11 PET/CT performed for primary staging of prostate cancer**

O. Sahin¹, E. Kaymak Akgun¹, E. Demirci², M. Ocak³, A. Aygün¹, H. Pehlivanoglu¹, E. Karayel¹, A. Kural⁴, L. Kabasakal¹; ¹Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, istanbul, TURKEY, ²Department of Nuclear Medicine Sisli Etfal Training and Research Hospital, Istanbul, istanbul, TURKEY, ³Department of Pharmaceutical Technology, Pharmacy Faculty, Istanbul University, Istanbul, istanbul, TURKEY, ⁴Department of Urology, Acibadem University, istanbul, TURKEY.

EP-0678**Role of [¹⁸F]Choline PET/CT guided stereotactic body radiotherapy in patients with oligometastatic prostate cancer**

R. Boni¹, A. Marciano², R. Zanca², M. Sollini³, E. Notini⁴, D. Baldaccini⁴, F. Matteucci⁴, P. Cocuzza⁴, P. Ferrazza⁴, G. Coraggio⁴, F. Paiar⁴, G. Pasqualetti⁵, L. Galli⁶, L. Mannelli⁷, F. Pasqualetti⁴, P. Erba²; ¹ASST Papa Giovanni XXIII-Nuclear Medicine, Bergamo, ITALY, ²Nuclear Medicine, Department of Translational Research and New Technologies in Medicine, Pisa, ITALY, ³Humanitas University, Milan, ITALY, ⁴Radiation Oncology, AOUP, Pisa, ITALY, ⁵Geriatric Unit, University of Pisa, Pisa, ITALY, ⁶Medical Oncology, AOUP, Pisa, ITALY, ⁷Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0679**Castration-Resistant Prostate Cancer Patterns of Metastasis Evaluated by ⁶⁸Ga-PSMA PET/CT**

M. Silva¹, R. Silva^{1,2}, P. Lapa^{1,3}, G. Costa^{1,3}, J. Pedroso de Lima^{1,2,3}; ¹Centro Hospitalar da Universidade de Coimbra, Coimbra, PORTUGAL, ²Instituto das Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

**EP-48 during congress opening hours, e-Poster Area
Clinical Oncology: Gynaecological****EP-0680****Can We Predict the Sites of the Recurrence of Tuba-Ovarian Cancer by F18-FDG PET/CT Depending on CA-125 Level?**

E. Ciftci¹, B. Turgut¹, S. Erturk¹, Z. Hasbek¹, B. Cetin², H. Aker³; ¹Cumhuriyet University, School Of Medicine, Department Of Nuclear Medicine, Sivas, TURKEY, ²Recep Tayyip Erdogan University, School Of Medicine, Department Of Internal Medicine, Division Of Oncology, Rize, TURKEY, ³cumhuriyet University, School Of Medicine, Department Of Pathology, Sivas, TURKEY.

EP-0681**Differential between ovarian tumor with solid portions and Stage I malignant ovarian cancer by FDG PET/CT**

R. Nakamoto, Y. Nakamoto, T. Ishimori, A. Kido, K. Togashi; Kyoto University Hospital, Kyoto, JAPAN.



EP-0683**Incidence and clinical Significance of Neck Node metastasis in Patients With cervix malignant lesion**

S. Yoon; Women's Cancer Center, Cheil General Hospital, Dankook University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0684**Comparison of Diagnostic Value of PET/CT and Ca-125 Assay in Detection of Residual and Recurrent Tumor in Follow-up Ovarian Cancer**

G. Çekin¹, I. Bezircioğlu², S. Yiğit³; ¹Izmir Katip Çelebi University, Atatürk Training and Research Hospital, Nuclear Medicine Department, Izmir, TURKEY, ²Izmir University of Economics, Medical Faculty, Obstetric and Gynecology Department, Izmir, TURKEY, ³Izmir Katip Çelebi University, Atatürk Training and Research Hospital, Pathology Department, Izmir, TURKEY.

EP-0685**Effect of XbaI G > T Polymorphism of the Glucose Transporter 1 Gene on F 18 FDG Uptake in Gynecological Cancers**

O. Yaylali¹, A. Koseler², D. K. Sakarya³, D. Yuksel¹, T. Sengoz¹, V. Fenkci³; ¹Pamukkale University Dept of Nuclear Medicine, Denizli, TURKEY, ²Pamukkale University Dept of Biophysics, Denizli, TURKEY, ³Pamukkale University Dept of Gynecology, Denizli, TURKEY.

EP-0686**¹⁸F-FDG PET with Low Dose CT versus Contrast Enhanced CT in the Detection of Recurrent or Residual Tumor in Ovarian Cancer**

A. Repetto¹, N. Orta¹, C. Sampo², S. Rub², M. Oporto¹, H. Navalón¹, M. Toscano¹, C. Peña²; ¹Hospital Universitari Son Espases, Palma, SPAIN, ²Hospital Universitari Son Espases/IdISPa, Palma, SPAIN.

EP-0687**The role of PET/CT in the detection of residual/recurrent tumor in patients with ovarian cancer whose Ca-125 value is within normal limits**

G. Cekin¹, I. Bezircioğlu², S. Yiğit³; ¹Izmir Katip Çelebi University, Atatürk Training and Research Hospital, Nuclear Medicine Department, Izmir, TURKEY, ²Izmir University of Economics, Medical Faculty, Obstetric and Gynecology Department, Izmir, TURKEY, ³Izmir Katip Çelebi University, Atatürk Training and Research Hospital, Pathology Department, Izmir, TURKEY.

EP-49 during congress opening hours, e-Poster Area**Clinical Oncology: Lymphoma****EP-0688****Prognostic value of metabolic criteria with ¹⁸F-FDG PET / CT in patients with follicular lymphoma**

M. Cozar Santiago¹, J. Garcia Garzon², M. Soler Peter², C. Iguia Saenz¹, R. Sanz Llorens¹, R. Sanchez Jurado¹, J. Aguilar Barrios¹, V. Faus Rodrigo¹, E. Riera Gil², J. Ferrer Rebolleda¹; ¹ERESA-General University Hospital, Valencia, SPAIN, ²CETIR-PET Unit, Esplugues, SPAIN.

EP-0689**Outcome and survival of patients with primary testicular lymphomas delineated by control or restaging FDG PET/CT**

E. Alagoz, K. Okuyucu, s. ince, N. Arslan; Gülhane Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey, Ankara, TURKEY.

EP-0690**SUVmax of 10 is a Highly Specific and Moderately Sensitive Cutoff Between Aggressive and Indolent Non-Hodgkin Lymphoma: Analysis of 331 Patients with FDG -PET/CT**

G. Alobthani, K. Isoahshi, T. Watabe, K. Matsunaga, H. Kato, M. Tatsumi, E. Shimosegawa, J. Hatazawa; Osaka University, Osaka, JAPAN.

EP-0691**¹⁸F-FDG PET/CT in Primary Extranodal Lymphoma: Evaluation of Treatment Response and Prognosis**

B. Salvatore¹, R. Fonti¹, A. De Renzo², S. Pellegrino², I. L. Ferrara², C. G. Mainolfi², L. Marano², C. Selli², F. Pane², S. Del Vecchio², L. Pace³; ¹IBB-CNR, NAPLES, ITALY, ²University "Federico II", NAPLES, ITALY, ³University of Salerno, Salerno, ITALY.

EP-0692**Diagnostic value of dynamic F-18 FDG PET/CT in patients with malignant lymphoma**

K. Terazawa¹, T. Shinya², Y. Otomi¹, M. Kubo¹, K. Takechi³, H. Otsuka¹, M. Harada¹; ¹Tokushima University Hospital, Tokushima, JAPAN, ²Okayama University Hospital, Okayama, JAPAN, ³Tokushima Red Cross Hospital, Komatsushima, JAPAN.

EP-0693**Limited Benefit of Additional Contrast-Enhanced CT to End-of-Treatment PET/CT Evaluation in Patients with Follicular Lymphoma**

G. Paone, M. Raditchkova-Sarnelli, L. Giovannella, E. Zucca, L. Ceriani; Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND.



EP-0694**Application of Quantitative Indexes on FDG PET to Treatment Response Evaluation of Indolent Lymphoma**

H. Kim, J. Paeng, T. Kim, M. Kim, G. Cheon, D. Lee, J. Chung, K. Kang; Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0695**Does PET reconstruction method affect Deauville scoring in lymphoma patients?**

B. Eniloric¹, C. Nganoa¹, C. Fruchart¹, A. Gac¹, S. Chantepie¹, G. Damaj¹, C. Lasnon^{2,3}, N. Aide^{1,3}; ¹CHU de Caen, Caen, FRANCE, ²Centre François Baclesse, Caen, FRANCE, ³INSERM U1086 "ANTICIPE", Caen, FRANCE.

EP-0696**Do PET textural features have an additional value over visual assessment for the diagnosis of bone involvement on baseline FDG PET scans in diffuse large B cell lymphomas patients?**

N. Aide^{1,2}, M. Talbot³, C. Nganoa¹, C. Fruchart⁴, G. Damaj⁴, C. Lasnon^{5,2}; ¹Nuclear Medicine Department, University Hospital, CAEN, FRANCE, ²INSERM U1086 "ANTICIPE", Caen, FRANCE, ³Normandy University, CAEN, FRANCE, ⁴Hematology Institute, University Hospital, CAEN, FRANCE, ⁵Nuclear Medicine Department, François Baclesse Centre, CAEN, FRANCE.

EP-0697**MTV and TLG of staging PET/CT as predictors of outcome in Hodgkin Lymphoma patients: preliminary results of a single center study**

M. Spallino¹, M. Cuzzocrea¹, C. Spadavecchia^{2,3}, S. Morzenti³, E. De Ponti³, S. Bolis⁴, C. Landoni^{1,5}, L. Guerra⁵; ¹University of Milan-Bicocca, Milan, ITALY, ²Post graduate school of Medical Physics, Milan, ITALY, ³Medical Physics Department, San Gerardo Hospital, Monza, ITALY, ⁴Department of Hematology, San Gerardo Hospital, Monza, ITALY, ⁵Department of Nuclear Medicine, San Gerardo Hospital, Monza, ITALY.

EP-0698**Prognostic role of final FDG-PET in relationship to absolute monocyte count at diagnosis for Diffuse Large B Cell Lymphoma (DLBCL)**

A. Franceschetto¹, R. Marcheselli², R. D'Apollo¹, L. Massi¹, A. Casolo¹, S. Sacchi², N. Prandini¹; ¹Nuclear Medicine, Modena, ITALY, ²Clinical Oncology, Modena, ITALY.

EP-0699**Quantitative and qualitative analyses of metabolic response at end of treatment 18F-FDG PET-CT scan can predict outcome in diffuse large B-cell lymphoma**

L. Baratto¹, F. Wu¹, J. Sabile², T. Liang³, J. Rosemberg³, R. Advani², E. Mittra¹; ¹Stanford University, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford, CA, UNITED STATES OF AMERICA, ²Stanford University, Department of Medicine, Division of Medical Oncology, Stanford, CA, UNITED STATES OF AMERICA, ³Stanford University School of Medicine, Department of Radiology, Stanford, CA, UNITED STATES OF AMERICA.

EP-50 during congress opening hours, e-Poster Area**Clinical Oncology: Leukaemia & Myeloma****EP-0700****Investigation of correlation between PET/CT findings and clinical parameters in patients with multiple myeloma**

R. Wang, L. Di, J. Zhang, G. Zhao, Y. Fan, Z. Fu, X. Zhang, Q. Jiang; Peking University First Hospital, Beijing, CHINA.

EP-0701**Application of F-18-FDG PET/CT in staging and metabolic activity assessment for multiple myeloma**

R. Wang, L. Di, J. Zhang, G. Zhao, Y. Fan, X. Zhang, G. Zhao, Y. Cui, M. Liu, L. Jiang, G. Zhao, Y. Wang; Peking University First Hospital, Beijing, CHINA.

EP-0702**18F-FDG-PET/CT In Solitary Plasmacytoma: Metabolic Behavior And Possible Role In Prediction Of Progression To Multiple Myeloma**

D. Albano, F. Bertagna, M. Bertoli, G. Bosio, M. Bonacina, E. Cerudelli, R. Durmo, M. Gazzilli, R. Giubbini; Spedali Civili Brescia, Brescia, ITALY.

EP-0703**Association between 18F-fluorodeoxyglucose uptake and CD38, CD138 expression in myeloma cells and clinical parameters in patients with multiple myeloma**

A. Cengiz¹, H. Ü. Arda², F. Doger³, I. Yavaşoğlu⁴, Y. Yürekli¹, A. Z. Bolaman⁴; ¹Adnan Menderes University Medical School Department of Nuclear Medicine, Aydın, TURKEY, ²Adnan Menderes University Medical School Department of Internal Medicine, Aydın, TURKEY, ³Adnan Menderes University Medical School Department of Pathology, Aydın, TURKEY, ⁴Adnan Menderes University Medical School Department of Hematology, Aydın, TURKEY.



EP-0704**18F-FDG PET/CT In Premalignant Stages Of Multiple Myeloma: Preliminary Analysis**

F. J. Pena Pardo, G. A. Jiménez Londoño, A. M. García Vicente, A. Palomar Muñoz, N. D. Disotuar Ruiz, Á. Soriano Castrejón; Nuclear Medicine Service. Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN.

EP-0705**¹⁸F-fluorocholine versus ¹⁸F-fluorodeoxyglucose for PET/CT in staging, follow-up or suspected relapse of multiple myeloma**

J. Zhang-Yin¹, O. Benesty¹, A. Cottreau¹, M. Gauthé¹, M. Calzada¹, K. Kerrou¹, J. Ohnona¹, V. Gaura-Schmidt¹, V. Nataf¹, F. Montravers¹, L. Garderet², J. Talbot¹; ¹hôpital Tenon, Paris, FRANCE, ²hôpital Saint-Antoine, Paris, FRANCE.

EP-0706**Monoclonal gammopathy of undetermined significance (MGUS): Computational analysis of PET/CT images**

R. Piva¹, A. Nieri¹, C. Camp², F. Fiz³, A. Bellini¹, M. Bauckneht¹, A. Borra¹, S. Morbelli¹, A. Buschiazzo¹, A. Orenco¹, A. Massone⁴, M. Piana², G. Sambuceti¹, C. Marini⁵; ¹IRCCS AUO San Martino IST, Genova, ITALY, ²Department of Mathematics, University of Genoa, Genova, ITALY, ³Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum, Tübingen, GERMANY, ⁴CNR SPIN (Superconductors, oxides and other innovative materials and devices), Genova, ITALY, ⁵CNR Institute of Bioimages and Molecular Physiology, Milan, ITALY.

EP-0707**¹¹C-Methionine versus ¹⁸F-Fluorodeoxyglucose PET/CT imaging in patients with multiple myeloma and other plasma cell malignancies: initial staging and re-staging**

M. I. Morales-Lozano, B. Garcia-Garcia, S. Villar, E. Guillen, P. Rodriguez Otero, F. Grisanti, L. Sancho, R. Ramos, V. Moran, J. San Miguel, J. Richter, M. J. Garcia-Velloso; Clinica Universidad de Navarra, Pamplona, SPAIN.

EP-0708**Diagnostic Value Of ¹⁸F-FDG PET/CT Imaging In Patients With Multipl Myeloma**

U. Telci, S. Ucak Semirgin, M. Sahin, T. Basoglu; Ondokuz Mayis University Nuclear Medicine Department, Samsun, TURKEY.

EP-51 during congress opening hours, e-Poster Area**Clinical Oncology: Bone****EP-0709****Osteoarthritis of the knee evaluated using images of bone uptake of myocardial perfusion agent**

R. Tanaka, M. Ebine; Chiba Institute of Science, Choshi, JAPAN.

EP-0710**Extraosseous Accumulation of Tc-99m MDP on Bone Scan in a Four-years-old Child With Acute Lymphoblastic Leukemia: Case Report**

F. Banezhad Jannatkhani, N. Ayati; Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF IRAN.

EP-0711**Clinical value of ^{99m}Tc-MIBI scintigraphy for bone lesions with indefinite diagnosis by ^{99m}Tc-MDP bone imaging**

Z. J. Ren¹, r. g. yang², w. z. huo², h. x. wang², y. liu², q. kong²; ¹Shandong Jining No.1 People's Hospital, Shandong province, CHINA, ²Shandong Cancer Hospital affiliated to Shandong University, Shandong province, CHINA.

EP-0712**Interobserver agreement in the evaluation of Sodium Fluoride-PET/CT for the evaluation of bone metastases in prostate cancer**

H. D. Zacho¹, R. F. Fonager¹, J. B. Nielsen¹, C. H. Nielsen², H. W. Hende², L. J. Petersen¹; ¹Dept of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK, ²Dept of Nuclear Medicine, Herlev Hospital, Herlev, DENMARK.

EP-0713**Feasibility Of Nuclear Medicine In Prognosis And Evaluation Of Effectiveness Of Therapy By Bisphosphonates**

V. Sukhov¹, A. Marin¹, P. Kirichenko¹, K. Zaplatnikov²; ¹Military Medical Academy, ST. PETERSBURG, RUSSIAN FEDERATION, ²MAZ Nuclear Medicine, Nuernberg, GERMANY.

EP-0714**When there is no other option: Utility of Bone Scintigraphy in Oncology in a resource constrained environment**

E. N. B. Hammond; Ghana Atomic Energy Commission/ National Centre for Radiotherapy and Nuclear Medicine, Accra, GHANA.

e-Poster not submitted



EP-0715**Comparison of ^{99m}Tc-MDP Bone Scintigraphy and ¹⁸F-FDG PET/CT to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma**

B. Byun, S. Lim, K. Lee, C. Kong, J. Choi; Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF.

EP-0716**The usefulness of maximum standardized uptake value of quantitative bone SPECT/CT**

M. Ishibashi, Y. Tanabe, T. Ogawa; Faculty of Medicine, Tottori University, Yonago, JAPAN.

EP-0717**Tc^{99m} MDP SPECT-CT based modified Mirel's classification - a new approach to evaluate for impending pathologic fractures**

S. Riaz¹, H. Bashir¹, I. K. Niazi², S. Butt³, F. Qamar⁴; ¹Nuclear Medicine department, Shaukat Khanum Memorial Cancer Hospital & Research Centre (SKMCH&RC), Lahore, PAKISTAN, ²Radiology department, SKMCH&RC, Lahore, PAKISTAN, ³Radiation Oncology department, SKMCH&RC, Lahore, PAKISTAN, ⁴Surgical Oncology department, SKMCH&RC, Lahore, PAKISTAN.

EP-0718**Diagnostic impact of quantitative bone SPECT/CT for patients with bone metastasis caused by castration resistant prostate cancer**

Y. Fukushima, S. Kumita, G. Kimura, J. Akatsuka, T. Hamana, Y. Sugihara, T. Ando; Nippon Medical School, TOKYO, JAPAN.

EP-0719**Hybrid bone scintigraphy in gastrointestinal malignancies**

N. Rashid, H. Bashir, S. Riaz, A. Hassan; Nuclear Medicine department, Shaukat Khanum Memorial Cancer Hospital & Research Centre (SKMCH&RC), Lahore, PAKISTAN.

EP-52 during congress opening hours, e-Poster Area**Clinical Oncology: Soft Tissues & Sarcoma****EP-0720****Diagnostic Performance Of F18 FDG PET/CT In Recurrence Evaluation Of Chondrosarcoma -A Tertiary Care Centre Experience**

S. K. Vadi, A. K. R. Gorla, A. Sood, A. Sood, R. K. Basher, N. Kakkar, A. Bhattacharya, B. Singh, B. R. Mittal; Post graduate institute of medical education and research, Chandigarh, INDIA.

EP-0721**The diagnostic ability of dynamic positron emission tomography with F-18 fluorodeoxyglucose and C-11 methionine in patients with musculoskeletal lesions**

T. Shinya¹, Y. Otomi², K. Terazawa², M. Kubo², M. Harada², S. Kanazawa¹; ¹Okayama University Hospital, Okayama-city, JAPAN, ²Tokushima University Hospital, Tokushima-city, JAPAN.

EP-0722**Interval from first symptoms to diagnosis in high-grade primary osteosarcoma and Ewing sarcoma of bone in relation to metabolic activity on FDG-PET/CT**

A. C. M. Luytgaarden¹, E. A. Usmanij¹, L. F. de Geus-Oei², J. J. W. de Rooy¹, U. E. Flucke¹, S. E. J. Kaal¹, V. L. M. N. Soomers¹, C. A. H. P. van Riel¹, H. W. B. Schreuder¹, W. J. G. Oyen³, W. T. A. van der Graaf³; ¹Radboudumc, Nijmegen, NETHERLANDS, ²Leiden University Medical Center, Leiden, NETHERLANDS, ³The Institute of Cancer Research & Royal Marsden Hospital, London, UNITED KINGDOM.

EP-0723**Diagnostic performance of 18F-FDG PET/CT in patients with Kaposi sarcoma: a tertiary retrospective study**

S. Annunziata¹, A. Borghesi¹, Giambenedetto², A. Rizzo¹, M. L. Calcano¹, Giordano¹, V. Rufini¹; ¹Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, ITALY, ²Institute of Infectious Diseases, Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0724**The F-18 FDG PET/CT and CT evaluation of pleural plaques**

Z. Koç, P. Özcan Kara, Y. Balci; Mersin University Hospital, Mersin, TURKEY.

EP-0725**Ga68 DOTATATE PETCT Imaging In Oncogenic Osteomalacia - Experience From A Tertiary Hospital In Southern India**

J. Hephzibah, T. V. Paul, D. Mathew, N. Shanthly, R. Oommen; Christian Medical College, Vellore, VELLORE, INDIA.

e-Poster not submitted



EP-0726**Quantification of tumor blood flow in sarcomas from dynamic ^{99m}Tc-MIBI SPECT : Validation and clinical employment**

W. Y. Ussov¹, V. M. Gulyaev^{1,2}, E. V. Barysheva³, O. Y. Borodin², I. I. Anisenia⁴, Y. I. Tyukalov⁴; ¹Institute of Cardiology, Tomsk, RUSSIAN FEDERATION, ²Tomsk Regional Institute of Oncology, Tomsk, RUSSIAN FEDERATION, ³Clinical and Diagnostic Center, Tomsk, RUSSIAN FEDERATION, ⁴Institute of Oncology, Tomsk, RUSSIAN FEDERATION.

EP-0727**Applying radiomics and machine learning on PET images to predict lung metastases in soft tissue sarcoma patients**

I. Shiri¹, A. Rahmim^{2,3}, H. Abdollahi¹, P. Geramifar⁴, A. Bitarafan-Rajabi^{1,5}; ¹Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Radiology, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ³Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ⁴Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-53 during congress opening hours, e-Poster Area**Clinical Oncology: Melanoma****EP-0728****Voxel-based analysis of I-123 IMP in patients with uveal malignant melanoma: comparison with ROI analysis**

M. Yoshimura¹, T. Aida², D. Hakamata², K. Uchida², K. Suzuki¹, H. Goto¹; ¹Tokyo Medical University, Tokyo, JAPAN, ²Tokyo Medical University Hospital, Tokyo, JAPAN.

EP-0729**Lymphoscintigraphy and sentinel node biopsy optimal visualization in thick and high risk melanoma- five years experience**

A. Koljevic Markovic¹, S. Tasic¹, L. Mijatovic Teodorović^{1,2}, I. Markovic^{1,3}, M. Buta^{1,3}, R. Džodić^{1,3}, M. Janković⁴; ¹National Cancer Research Center Serbia, Belgrade, SERBIA, ²Faculty of Medicine, University of Kragujevac, Kragujevac, SERBIA, ³Faculty of Medicine, University of Belgrade, Belgrade, SERBIA, ⁴School of Engineering, University of Belgrade, Belgrade, SERBIA.

EP-0730**Absolute number of new lesions in ¹⁸F-FDG PET/CT is more predictive of clinical outcome than SUV changes in metastatic melanoma patients receiving ipilimumab**

H. Anwar¹, C. Sachpekidis¹, J. Winkler², A. Kopp-Schneider³, U. Haberkorn⁴, J. Hasse², A. Dimitrakopoulou-Strauss¹; ¹Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY, ²National Center for Tumor Diseases, Heidelberg, GERMANY, ³Department of Biostatistics, German Cancer Research Center, Heidelberg, GERMANY, ⁴Division of Nuclear Medicine, University of Heidelberg, Heidelberg, GERMANY.

EP-0731**FDG-PET/CT in the Evaluation of Non-Melanoma Skin Cancers**

A. Sabaté-Llobera¹, P. C. Notta¹, E. Llinares-Tello¹, J. R. Ferreres², R. Tarragona-Fernández³, T. Soler-Monsó⁴, L. Rodríguez-Bel¹, A. Lucas-Calduch⁵, J. L. Vercher-Conejero¹, M. Cortés-Romera¹, C. Gámez-Cenzano¹;

¹PET Unit, Department of Nuclear Medicine-IDI. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN, ²Department of Dermatology. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN, ³Department of Plastic Surgery. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN, ⁴Department of Pathology. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN, ⁵Department of Radiation Oncology-Institut Català d'Oncologia. Hospital Duran i Reynals-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN.

EP-0732**Is whole body 18F-FDG PET/CT including the extremities routinely warranted in melanoma patients?**

K. Pinker-Domenig^{1,2}, H. Schoeder¹, G. Ulaner¹, T. Saidon¹, K. Juluru¹, S. Huang¹, W. A. Weber¹, C. C. Riedl¹; ¹Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ²Medical University of Vienna, Vienna, AUSTRIA.

EP-0733**Clinical Relevance of Imaging the Lower Limbs When Staging or Restaging Malignant Cutaneous Melanoma Using 18F-FDG PET/CT**

N. Plouznikoff, F. Arsenault; Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, CANADA.



EP-0734**A portable hybrid camera for fused optical and scintigraphic imaging: clinical experience in 90 patients with melanoma**

C. A. Tapias, Sr., N. Sanchez, R. Pigem, R. Rull, p. paredes, p. perla, S. Vidal-Sicart; hospital clinic de Barcelona, barcelona, SPAIN.

EP-0735**18-F-FDG-PET/CT In Head And Neck Mucosal Melanoma**

R. Durmo, F. Bertagna, D. Albano, M. Bertoli, M. Bonacina, M. Gazzilli, E. Cerudelli, R. Giubbini; spedali civili brescia, brescia, ITALY.

EP-0736**Does SPECT/CT Improve Sentinel Node Detection in Melanoma Patients**

K. Nikoletic¹, S. Tonjer¹, S. Hegg¹, M. Møll Dalen¹, E. Spangen Hoset¹, M. Knezevic²; ¹Drammen hospital, Nuclear Medicine Department, Drammen, NORWAY, ²Bærum hospital, Department of Surgery, Bærum, NORWAY.

EP-0737**Comparison of ¹²³I-IMP SPECT, ¹⁸F-FDG PET/CT, and ¹⁸F-FDOPA PET/CT in Detection of Choroidal Malignant Melanoma**

K. Kato¹, T. Odagawa¹, T. Tsutsumi¹, M. Honda¹, K. Kunimoto¹, R. Mukumoto¹, S. Matsuzawa¹, S. Abe², S. Naganawa¹; ¹Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Nagoya University Hospital, Nagoya, JAPAN.

EP-0738**Functional Radiographic Profiling of Immunotherapy Related Toxicities with ¹⁸F-FDG-PET/CT in Patients with Metastasized Malignant Melanoma**

Y. Zhuwu, S. Nekolla, J. Kohlmeyer, A. Krackhardt, M. Schwaiger, M. Mustafa; Klinikum rechts der Isar, Munich, GERMANY.

EP-0739**¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings In Ocular Melanoma**

J. Benouhoud, S. Choukry, Y. Shimi, A. Guensi; CHU Ibn Rochd, Casablanca, MOROCCO.

EP-0740**Necrosis determines FDG-avidity in cerebral metastases of malignant melanoma - correlating ¹⁸F-FDG-uptake with histological parameters**

M. Mustafa, H. Einhellig, M. Boxberg, T. Pyka, J. Kohlmeyer, A. Krackhardt, M. Schwaiger; Klinikum rechts der Isar, Munich, GERMANY.

EP-54 during congress opening hours, e-Poster Area**Clinical Oncology: Paediatric Cancer****EP-0741****Post-therapy outcome in initially positive FDG PET/CT for Bone marrow infiltration in pediatric lymphoma patients**

M. A. Abdelwahab¹, S. A. Badr¹, M. H. Kotb¹, H. Mostafa²; ¹National Cancer Institute, Giza, EGYPT, ²NEMROCK, Cairo University, Giza, EGYPT.

EP-0742**Can FDG PET/CT predict the outcome of pediatric rhabdomyosarcoma?**

E. Elkholy^{1,2}, I. Al-Antabily³, E. ElNadi^{4,5}, S. Ahmed⁶, M. Saad Zahrhlo⁶, H. Hafez⁷, O. Shawky⁷, T. Rifaat⁸, N. El-Kilini⁹, A. Younis¹⁰, G. Taha¹¹, E. Khalid¹²; ¹Nuclear Medicine National cancer Institute (NCI) Egypt, Cairo, EGYPT, ²Children Cancer Hospital Egypt, Cairo, EGYPT, ³Nuclear medicine National cancer Institute (NCI) Egypt, Cairo, EGYPT, ⁴Pediatric Oncology Beniswif Univeristy, Cairo, EGYPT, ⁵CCHE, Cairo, EGYPT, ⁶Radiotherapy CCHE, Cairo, EGYPT, ⁷Pediatric Oncology CCHE, Cairo, EGYPT, ⁸Radiology CCHE, Cairo, EGYPT, ⁹Pathology CCHE, Cairo, EGYPT, ¹⁰Surgery CCHE, Cairo, EGYPT, ¹¹Surgey CCHE, Cairo, EGYPT, ¹²Statistic department CCHE, Cairo, EGYPT.

EP-0743**How can FDG PET CT add benefits in staging pediatric rhabdomyosarcoma?**

E. Elkholy^{1,2}, S. Abd El-Giad¹, H. Fathy¹; ¹Nuclear Medicine National Cancer Institute (NCI) Egypt, Cairo, EGYPT, ²Children Cancer Hospital Egypt, Cairo, EGYPT.

EP-0744**The value of volumetric ¹⁸F-FDG PET parameters in pediatric patients with bone sarcoma**

E. Ozkan, M. Khalizadeh, C. Soydal, N. Tacyildiz, N. O. Kucuk, M. K. Kir; Tip Fakultesi, Ankara, TURKEY.

EP-0745**¹²³I-MIBG scintigraphy and diffusion-weighted whole-body RMI with background body signal suppression (DWIBS) : comparison in HR-Neuroblastoma**

C. Olianti¹, A. Tondo², A. L. Perrone³, C. Favre², C. De Filippi³; ¹Nuclear Medicine Unit, Careggi University-Hospital, Florence, ITALY, ²Oncohematology Unit, Meyer Pediatric University-Hospital, Florence, ITALY, ³Radiology Unit, Meyer Pediatric University-Hospital, Florence, ITALY.



EP-0746**Contribution of FDG PET/CT In Staging and Management of Pediatric Patients with Osteosarcoma**

A. K. Fidan, G. Ucmak, I. Kerimel, B. B. Demirel, B. E. Akkas; S.B.U. Ankara Oncology Research and Training Hospital, Nuclear Medicine Department, Ankara, TURKEY.

EP-0747**Correlation of Tumor Necrosis Ratio and Metabolic Parameters of Initial Staging FDG PET/CT In Pediatric Patients with Osteosarcoma**

G. Ucmak, A. K. Fidan, I. Kerimel, B. E. Akkas, B. B. Demirel; S.B.U. Ankara Oncology Research and Training Hospital, Nuclear Medicine Department, Ankara, TURKEY.

EP-55 during congress opening hours, e-Poster Area**Clinical Oncology: Imaging Guided Surgery (including Sentinel Lymph Node)****EP-0748****Sentinel lymph node biopsy (SLNB) before and after neo-adjuvant chemotherapy (NAC) in locally advanced breast cancer, our results**

J. M. Espejo Niño, A. Esteban Figueruelo, E. Rodeño Ortiz De Zárate, P. Cobos Baena, L. Andres Alvarez; Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-0749**Comparison of the diagnostic value of preoperative sentinel lymph node (SLN) imaging using conventional scintigraphy and SPECT/CT in penile cancer patients with non-palpable inguinal lymph nodes**

U. Lützen, B. Egeler, M. Jüptner, Y. Zhao, M. Marx, C. M. Naumann, K. Jünemann, M. Zuhayra; UKSH, Campus Kiel, Kiel, GERMANY.

EP-0750**Diagnostic Accuracy Of Sentinel Lymph Node Biopsy In Patients With Endometrial Cancer**

S. Sanz-Viedma, T. Gomez, A. Fernandez-Molina, M. De La Torre-Baca, P. Espejo, I. Egea, A. Eslava, J. Jimenez Hoyuela, L. Gonzalez, J. Oliva; University Hospital Virgen de la Victoria, Malaga, SPAIN.

EP-0751**Tc-99m-PSMA-guided intraoperative lymph node localization in recurrent prostate cancer**

M. C. Schmidt¹, D. Pfister², C. Kobe¹, M. Dietlein¹, M. Dietlein¹, A. Heidenreich², A. Drzezga¹; ¹University Hospital of Cologne, Dpt. of Nuclear Medicine, Cologne, GERMANY, ²University Hospital of Cologne, Dpt. of Urology, Cologne, GERMANY.

EP-0752**Wire-guided localization vs ¹²⁵I radioactive seed localization in nonpalpable breast lesions**

R. Sánchez Sánchez, A. González Jimenez, A. Rebollo Aguirre, E. Triviño Ibañez, E. Moratalla Aranda, S. Menjon Beltran, J. Llamas Elvira; Hospital Virgen de las Nieves, Granada, SPAIN.

EP-0753**Time to relapse is associated with altered lymphatic drainage and sentinel node location in recurrent breast cancer**

P. Borrelli¹, S. Teixeira², S. Vidal-Sicart³, M. van Essen¹, H. van Tinteren², R. A. Valdés Olmos^{2,4}; ¹Sahlgrenska University Hospital, Göteborg, SWEDEN, ²Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ³University Hospital Clinic, Barcelona, SPAIN, ⁴Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0754**Sentinel Lymph Node Biopsy in Cutaneous Melanoma: Analysis of 362 Patients from a Single Institution**

L. Jaukovic, M. Radulovic, M. Rajovic, L. Kandolf-Sekulovic; Military Medical Academy, Belgrade, SERBIA.

EP-0755**Incidence and implications of atypical lymphatic drainage in patients with Primary Cutaneous Malignant Melanoma**

M. Oporto¹, C. Sampol^{1,2}, A. Repetto¹, N. Orta¹, H. Navalon¹, S. Rubi^{1,2}, M. Villar¹, C. Peña^{1,2}; ¹hospital Universitari Son Espases, Palma, SPAIN, ²IdISPa, Palma, SPAIN.

EP-0756**Our Experience with ROLL and SNOLL techniques in clinically occult breast carcinoma**

S. M. Nieves Maldonado¹, Z. Bravo Ferrer¹, C. Lancha Hernandez¹, I. Nuñez Cambre¹, J. Rodriguez², J. Corredoira³, A. Rodriguez Pan³; ¹Nuclear Medicine Department. Hospital HM- Modelo de la Coruña, La Coruña, SPAIN, ²Surgery Department. Hospital HM- Modelo de la Coruña, La Coruña, SPAIN, ³Radiology Department. Hospital HM- Modelo de la Coruña, La Coruña, SPAIN.



EP-0757**Prognostic Significance Of The Effect Of Delay Time Between Primary Melanoma Biopsy And Sentinel Lymph Node Biopsy**

M. L. Dominguez¹, J. P. Suarez², P. Fernandez³, J. I. Rayo⁴, O. D. Rodriguez¹, F. M. Gonzalez¹; ¹Nuclear Medicine Department. Central University Hospital of Asturias, Oviedo, SPAIN, ²Nuclear Medicine Department. San Pedro de Alcantara Hospital, Caceres, SPAIN, ³Clinical investigation and trials unit. Virgen del Rocío University Hospital, Sevilla, SPAIN, ⁴Nuclear Medicine Department. University Hospital Infanta Cristina, Badajoz, SPAIN.

EP-0758**Evaluation Of The Influence Of Preoperative Wire-Guided Localization And Radiopharmaceutical Injection With Or Without Radiological Guidance In Global Detection Of Sentinel Lymph Node Biopsy In Patients With Breast Cancer**

V. López-Prior, A. Amr-Rey, R. Díaz-Expósito, Sr., I. Casáns-Tormo, J. Orozco-Cortés, J. Sabater-Sancho; Servicio de Medicina Nuclear. Hospital Clínico Universitario de Valencia, Valencia, SPAIN.

EP-0759**Internal Mammary Lymph Node in Breast Cancer as a Predictive Value in a High Risk Asymptomatic Population**

A. Mestre-Fusco¹, J. Jimeno², M. Suárez-Piñera¹, I. Espallargas¹, M. Vernet³, J. Corominas⁴, S. Vidal-Sicart⁵; ¹Radiology & Nuclear Medicine Department, IMI. Hospital del Mar, PSMar., Barcelona, SPAIN, ²Surgery Department. Hospital del Mar, PSMar., Barcelona, SPAIN, ³Gynecology Department. Hospital del Mar, PSMar., Barcelona, SPAIN, ⁴Pathology Department. Hospital del Mar, PSMar., Barcelona, SPAIN, ⁵Nuclear Medicine Department. Hospital Clínic., Barcelona, SPAIN.

EP-0760**Within-patient comparison of two sentinel lymph node tracers: ^{99m}Tc-Senti-Scint and (ICG-^{99m}Tc-nanocolloid**

P. Meershoek^{1,2}, M. L. Donswijk², G. H. KleinJan^{1,2}, N. S. van den Berg¹, B. van der Hie², R. A. Valdés-Olmos¹, J. A. van der Hage², W. M. C. Klop², F. W. B. van Leeuwen¹; ¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Netherlands Cancer Institute (NKI-AvL), Amsterdam, NETHERLANDS.

EP-0761**Importance of in-transit sentinel node in patients with cutaneous melanoma**

E. Noriega-Álvarez¹, J. Rodríguez-Rubio Corona¹, M. Bajén Lázaro¹, R. Jaller Vanegas¹, A. Benítez Segura¹, J. Marcoval Caus², R. Penin Mosquera³, J. Bermejo Segu⁴, C. Gámez Cenzano¹; ¹Nuclear Medicine-PET Department. IDI. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona, SPAIN, ²Dermatology Department. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona, SPAIN, ³Pathology Department. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona, SPAIN, ⁴Plastic Surgery Department. Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat. Barcelona, SPAIN.

EP-0762**Implementation of sentinel lymph node for cervical and endometrial cancer: early experience**

S. Seijas Marcos, A. Prieto Soriano, J. Cardona Arboniés, I. Plaza de las Heras, R. De Teresa Herrera, L. Canales Rodriguez, A. Sanfeli Delgado, J. Mucientes Rasilla, M. Mitjavila Casanovas; Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain, Madrid, SPAIN.

EP-0763**Comparison between planar and tomographic SPET/CT acquisition on sentinel node identification on patients affected by breast cancer and melanoma**

S. Chondrogiannis, M. C. Marzola, G. Grassetto, A. M. Maffione, A. Zompa, L. Tamiso, E. Milan, A. Bassan, L. Rampin, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

EP-0764**Sentinel Lymph Node Biopsy In Patients With Breast Cancer And Axillary Involvement Treated With Neoadjuvant Chemotherapy**

S. Sanz-Viedma, V. Scholz -Gutierrez, F. Fernandez-Garcia, C. Lacalle, R. Gomez, M. Martinez Del Valle, L. Vicioso, J. Jimenez Hoyuela; Hospital Clinico Virgen de la Victoria, Malaga, SPAIN.



EP-0765**Relationship Between Sentinel Lymph Node Metastasis Size In Cutaneous Melanoma Patients And The Number Of Lymphadenectomies With Presence Of Additional Lymph Nodes Metastasis**

J. Rodriguez-Rubio Corona¹, M. Bajén-Lázaro¹, E. Noriega-Álvarez¹, A. Rodríguez-Gasén¹, J. Suils-Ramón¹, E. Llinares-Tello¹, A. Benítez-Segura¹, J. Mora-Salvadó¹, J. Ferreres-Riera², M. Soler-Monsó³, D. Pérez Sidelnikova⁴, C. Gámez-Cenzano¹;¹Nuclear Medicine-PET Department. IDI. Hospital Universitari de Bellvitge-Idibell, L'Hospitalet de Llobregat (Barcelona), SPAIN, ²Dermatology Department. Hospital Universitari de Bellvitge-Idibell, L'Hospitalet de Llobregat (Barcelona), SPAIN, ³Pathology Department. Hospital Universitari de Bellvitge-Idibell, L'Hospitalet de Llobregat (Barcelona), SPAIN, ⁴Plastic Surgery Department. IDI. Hospital Universitari de Bellvitge-Idibell, L'Hospitalet de Llobregat (Barcelona), SPAIN.

EP-56 during congress opening hours, e-Poster Area**Clinical Oncology: External Beam Radiation Therapy Planning****EP-0766****Gated Reconstruction in 18F-FDG PET/CT Quantitative Imaging: Impact on the Estimation of Tumor Motions in the Lung and Respiration Gated Radiotherapy Treatment with Dynamic Thorax Deformation**

M. Zuffante¹, S. Ghislini¹, F. Sciumè¹, D. Grigolato¹, M. Cucca¹, L. Pizzarello¹, L. Locantore¹, P. Polloniato¹, F. Dusi¹, C. Cavedon¹, M. Ferdeghini¹; AOUI Verona, Verona, ITALY.

EP-0767**Investigation of automatic thresholding on PET images for volume delineation of lung lesions in radiation therapy treatment**

T. Osman¹, B. McBride², T. Hennessy², S. Downes², A. Rosenfeld¹, A. Malaroda¹;¹University of Wollongong, Australia, Wollongong, AUSTRALIA, ²Prince of Wales Hospital, Randwick, AUSTRALIA.

EP-0768**Volume-based assessment of different image reconstruction algorithms and thresholds for FDG-PET/CT based on dose-painting concept**

P. Ghafarian^{1,2}, A. Ketabi^{3,4}, M. A. Mosleh-Shirazi⁵, M. R. Ay^{6,4};¹Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF, ²PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Medical Imaging Research Center, and Physics Unit, Department of Radiotherapy and Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran., Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁶Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0769**The role of 18F-Choline (FCH) PET/CT for the prediction of long-term response to radical radiotherapy (RT) in patients with localized prostate cancer (PCa)**

L. Cuppari¹, M. Sepulcri², M. Fusella³, A. Zorz³, M. Paiusco³, L. Corti², G. Saladini¹, L. Evangelista¹;¹Nuclear Medicine and Molecular Imaging Unit., Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, ²Radiation Oncology Unit., Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY, ³Medical Physics Unit., Veneto Institute of Oncology IOV - IRCCS, Padova, ITALY.

EP-57 during congress opening hours, e-Poster Area**Clinical Oncology: Therapy Response Assessment****EP-0770****Automated quantification of reference levels in liver and mediastinum (blood pool) for the Deauville therapy response classification using FDG-PET/CT in lymphoma patients**

M. Sadik¹, E. Lind², O. Enqvist³, J. Ulén⁴, E. Polymeri⁵, E. Trägårdh⁶, L. Edenbrandt¹;¹Department of Clinical Physiology, Göteborg, SWEDEN, ²Department of Medicine, Göteborg, SWEDEN, ³Department of Signals and Systems, Göteborg, SWEDEN, ⁴Eigenvision AB, Malmö, SWEDEN, ⁵Department of Radiologi, Göteborg, SWEDEN, ⁶Department of Translational Medicine, Malmö, SWEDEN.



EP-0771**Variability in reference levels for Deauville classifications applied to lymphoma patients examined with 18F-FDG-PET/CT**

M. Sadik¹, E. Lind², O. Enqvist³, J. Ulén⁴, E. Polymeri⁵, E. Trägårdh⁶, L. Edenbrandt¹; ¹Department of Clinical Physiology, Göteborg, SWEDEN, ²Department of Medicine, Göteborg, SWEDEN, ³Department of Signals and Systems, Göteborg, SWEDEN, ⁴Eigenvision AB, Malmö, SWEDEN, ⁵Department of Radiologi, Göteborg, SWEDEN, ⁶Department of Translational Medicine, Malmö, SWEDEN.

EP-0772**The value of PET-CT in the evaluation of response to treatment in patients with prostate cancer treated with Radium223**

S. S. Medina Ornelas, F. O. García-Pérez; Instituto Nacional De Cancerologia, Mexico City, MEXICO.

EP-0773**Unicentric experience in the treatment of metastatic castration-resistant prostate cancer with Ra223**

E. Rodeño Ortiz de Zarate, P. Mínguez Gabiña, I. Fernández Tercero, A. Gómez de Iturriaga Plña, R. Larena Ibarguren, A. Urresola Olabarrieta, A. Esteban Figueruelo, J. Espejo Niño, A. Sánchez Salmón; Gurutzeta/Cruces University Hospital, Barakaldo, SPAIN.

EP-0774**Outcomes Of Treatment With Ra223 In Patients With Castration-Resistant Prostate Cancer with symptomatic bone metastases and no known visceral metastatic disease**

R. H. Reyes Marlés, Sr., M. Castellón Sanchez, L. Mohamed Salem, F. Nicolas Ruiz, J. Navarro, L. Frutos Esteban, M. Godoy Bravo, I. Sime loayza, M. Tomás Redondo, E. Fernandez Muñoz, M. Claver Valderas; Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, SPAIN.

EP-0775**Is the averaged SUV from several hottest voxels an alternative to SUV_{peak} for quantification of large heterogeneous or small lesions in oncological PET imaging?**

A. Ketabi^{1,2}, P. Ghafarian³, S. Masjoodi¹, M. A. Mosleh-Shirazi⁴, M. R. Ay^{1,2}; ¹Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Medical Imaging Research Center, and Physics Unit, Department of Radiotherapy and Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, IRAN, ISLAMIC REPUBLIC OF.

EP-58 during congress opening hours, e-Poster Area**Clinical Oncology: Miscellaneous****EP-0776****Back pain in oncology patients does not equal spinal metastases**

L. Louw, M. Vangu; University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-0777**A Systematic Review And Meta-Analysis Of FDG-PET/CT As A Screening Tool For Occult Malignancy In Unprovoked Venous Thromboembolism**

S. Hess^{1,2,3}, E. C. Frary^{1,4}, P. F. Høilund-Carlsen^{1,3}, O. Gerke^{1,5}; ¹Dept. of Nuclear Medicine, Odense University Hospital, Odense, DENMARK, ²Dept. of Radiology and Nuclear Medicine, Hospital Southwest Jutland, Esbjerg, DENMARK, ³Dept. of Clinical Research, Faculty of Health Sciences, University, Odense, DENMARK, ⁴Department of Cardiology, Nephrology, and Endocrinology, Nordsjællands Hospital Hillerød, Hillerød, DENMARK, ⁵Centre of Health Economics Research, University of Southern Denmark, Odense, DENMARK.

EP-0778**Use of ¹⁸F-FDG PET/CT in early diagnosis of primary neoplasm site in patients with neurologic paraneoplastic syndromes**

A. Sowa-Staszczak, M. Opalińska, M. Trófimiuk-Müldner, W. Lenda-Tracz, M. Buziak-Bereza, A. Brzozowska-Czarnek, A. Hubalewska-Dydejczyk; Chair and Department of Endocrinology, Jagiellonian University, Medical College, Kraków, POLAND.



EP-0779**Metabolic characterization of anterior mediastinal mass in adult patients by F-18 FDG PET/CT**

Z. Koç, P. Özcan Kara, E. Ayan; Mersin University Hospital, Mersin, TURKEY.

EP-0780**Clinical Usefulness Of 18F-FDG PET/CT For The Evaluation Of The Atypical Adrenal Tumors**

A. Rubio Rodriguez; Institut Diagnòstic per la Imatge, Girona, SPAIN.

EP-0781**Retrospective Study of Bone Marrow Disease Detection with 18F FDG PET/CT and Correlation with Positive Bone Marrow Biopsies for Haematological Malignancies**

M. Hamidian¹, J. Crook², H. Rizvi², N. Swalding², Y. Bouchareb², S. Hallam², K. Shahabuddin², H. Jan², A. Haroon²; ¹Kowsar Hospital Nuclear Medicine Department, Shiraz, IRAN, ISLAMIC REPUBLIC OF, ²Barts Health NHS Trust, London, UNITED KINGDOM.

EP-0782**Incidental lesions in FDG-PET/CT scans**

G. Sipka¹, Z. Besenyi¹, Z. Lengyel², L. Pavics¹; ¹University of Szeged, Szeged, HUNGARY, ²Pozitron-Diagnosztika Központ, Budapest, HUNGARY.

EP-0783**Synchronic and Metachronic Tumors Detected by PET / CT in the Staging of Primary Tumors**

B. Perez Lopez, F. Gomez-Caminero Lopez, P. Garcia-Talavera San Miguel, C. Achury Murcia, L. Diaz Gonzalez, E. Martin Gomez, E. Martin Gomez, P. Tamayo Alonso; Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EP-0784**Diagnostic Performance of 18F-NaF PET-CT in patients with Osteoporosis: A Meta-analysis**

K. Agrawal, B. M. P. ... India Institute of Medical Sciences, Bhutani, INDIA.

EP-0785**Association Between Gastric FDG Uptake in PET-CT and 14-C UBT Results in Patients Referred for Non-Gastric Cancer PET-CT Studies**

A. Hassanzadeh-Rad, F. Farsiabi, M. Eftekhari, A. Fard-Esfahani, B. Fallahi, A. Emami-Ardekani, D. Beiki; Research Center for Nuclear Medicine, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0786**Clinical Contribution of the Second Primary Cancers Detected by FDG PET/CT**

A. Yildiz¹, M. Özdoğan², S. Yilmaz³, B. Özcan⁴, N. Öz⁵, A. Gürkan⁴, Z. Şahin¹, H. Dikici⁶, A. Kargı²; ¹Nuclear Medicine, Medstar Hospital, Antalya, TURKEY, ²Medical Oncology, Medstar Hospital, Antalya, TURKEY, ³Radiology, Medstar Hospital, Antalya, TURKEY, ⁴General Surgery, Medstar Hospital, Antalya, TURKEY, ⁵Thoracic Surgery, Medstar Hospital, Antalya, TURKEY, ⁶Gastroenterology, Medstar Hospital, Antalya, TURKEY.

EP-59 during congress opening hours, e-Poster Area**Radionuclide Therapy & Dosimetry: Preclinical Studies (Animal & In Vitro)****EP-0787****Neurotensin receptor-1 expression in human prostate cancer and lymph nodes metastases**

C. Morgat^{1,2,3}, V. Molinié⁴, H. de Clermont Gallerande¹, G. Macgrogan^{5,6}, V. Vélasco^{5,6}, G. Robert^{7,8}, B. Malavaud⁹, P. Fernandez^{1,2,3}, E. Hindié^{1,2,3}; ¹Department of Nuclear Medicine, University Hospital of Bordeaux, Bordeaux, FRANCE, ²CNRS, INCIA UMR 5287, Bordeaux, FRANCE, ³University of Bordeaux, INCIA UMR 5287, Bordeaux, FRANCE, ⁴Department of Pathology, University Hospital of Fort de France, Fort de France, MARTINIQUE, ⁵Surgical Pathology unit, Department of BioPathology, Institut Bergonié, Bordeaux, FRANCE, ⁶INSERM, ACTION U1218, Bordeaux, FRANCE, ⁷Department of Urology, University Hospital of Bordeaux, Bordeaux, FRANCE, ⁸Department of Medical Sciences, University of Bordeaux, Bordeaux, FRANCE, ⁹Department of Urology, University Hospital of Toulouse, Toulouse, FRANCE.

EP-0788**Determination of the Rat Kidney Uptake of 99mTc-DMSA Using the Quantitative Radionuclide Imaging and a Computational Method: A Comparison Study**

K. Tanha¹, H. Fatemikia², M. Assadi¹; ¹The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ²Department of Physiology, Medical School, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF.

EP-0789**The difference of tumor accumulation between conventional and site-specific Ga-67 radiolabeled anti-HER2 antibody**

Y. Kono¹, K. Utsunomiya², Y. Ohira³, H. Sato³, N. Kan¹, Y. Matsumoto⁴, Y. Ueno¹, K. Maruyama¹, N. Tanigawa¹; ¹Kansai Medical University, Osaka, JAPAN, ²Kansai Medical University Medical Center, Osaka, JAPAN, ³Perseus Proteomics Inc., Tokyo, JAPAN, ⁴Kansai Medical University, Radioisotope Research Center, Osaka, JAPAN.

e-poster not submitted



EP-0790**Improvement of therapeutic efficacy by combing 90Y-ITGA6B4-mediated radioimmunotherapy (RIT) with dual PI3K and mTOR inhibitor NVP-BE235**

*W. Aung*¹, *A. B. Tsuji*¹, *H. Sudo*¹, *A. Sugyo*¹, *Y. Ukai*², *K. Kouda*², *Y. Kurosawa*³, *T. Furukawa*⁴, *T. Saga*⁵, *T. Higashi*¹;
¹Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, JAPAN, ²Perseus Proteomics Inc., Tokyo, JAPAN, ³Innovation Center for Advanced Medicine, Fujita Health University, Toyoake, JAPAN, ⁴Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ⁵Department of Diagnostic Radiology, Kyoto University Hospital, Kyoto, JAPAN.

EP-0791**Preferential Tumor Accumulation in Mice bearing Human Head and Neck Cancer using Radionuclide-carrying Liposomes aiming for Radiotheranostics**

I. O. Umeda, *S. Hamamichi*, *H. Fujii*; National Cancer Center, Kashiwa, JAPAN.

EP-0792**Combination Therapy of Medullary Thyroid Cancer Using Radiation and Vandetanib**

*V. Sandblom*¹, *J. Spetz*¹, *E. Shubbar*¹, *J. Swanpalmer*², *E. Forssell-Aronsson*¹;
¹Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ²Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EP-0793**Receptor Binding Kinetics of PSMA-Specific Peptides Determined by Surface Plasmon Resonance Measurements**

*G. Winter*¹, *A. Vogt*¹, *G. Glatting*², *P. Kletting*², *A. J. Beer*¹;
¹Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ²Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

EP-0794**Radioiodination Of Small Stapled Peptides For p53 Therapy**

*S. Lundsten*¹, *D. Spiegelberg*¹, *V. Agmo Hernández*², *C. Brown*³, *K. Edwards*², *D. Lane*^{3,4}, *M. Nestor*¹;
¹Department of Immunology, Genetics and Pathology, Uppsala University, UPPSALA, SWEDEN, ²Department of Chemistry - BMC, Uppsala University, UPPSALA, SWEDEN, ³p53Lab, A*STAR, SINGAPORE, SINGAPORE, ⁴Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, SWEDEN.

EP-0795**Radium-223 and metastatic prostate cancer: new insights from cellular studies**

*I. A. Marques*¹, *A. M. Abrantes*^{1,2,3}, *A. R. Neves*¹, *A. S. Pires*^{1,2,3}, *G. Costa*⁴, *F. Caramelo*^{1,5}, *T. Rodrigues*⁶, *P. Matafome*^{6,7}, *E. Tavares-Silva*^{1,8}, *R. Seiça*⁶, *A. Figueiredo*⁸, **M. F. Botelho**^{1,2,3};
¹Biophysics Institute, IBILI-Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ²CIMAGO, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ³CNC.IBILI, University of Coimbra, Coimbra, PORTUGAL, ⁴Department of Nuclear Medicine, CHUC, Coimbra, PORTUGAL, ⁵Laboratory of Biostatistics and Medical Informatics, IBILI-Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ⁶Laboratory of Physiology, IBILI-Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, ⁷Department of Complementary Sciences, Coimbra Health School (ESTeSC), Polytechnic Institute of Coimbra, Coimbra, PORTUGAL, ⁸Department of Urology and Renal Transplantation, CHUC, Coimbra, PORTUGAL.

EP-0796**Cell Survival in Colorectal Cancer under Yttrium-90 and Megavoltage X-ray**

N. Forwood^{1,2}, *Y. Gholami*³, *R. Harvie*⁴, *K. Willowson*³, *R. Bromley*⁵, *V. Howell*⁴, *H. Ryu*⁶, *Z. Kuncic*⁷, *D. L. Bailey*^{1,6};
¹Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, AUSTRALIA, ²Faculty of Health Sciences, Sydney University, Sydney University, AUSTRALIA, ³Institute of Medical Physics, Sydney University, Sydney, AUSTRALIA, ⁴Kolling Institute, St Leonards, AUSTRALIA, ⁵Department of Radiation Oncology, Royal North Shore Hospital, St Leonards, AUSTRALIA, ⁶Faculty of Health Sciences, Sydney University, Sydney, AUSTRALIA, ⁷School of Physics, University of Sydney, Sydney, AUSTRALIA.

EP-0797**Potential use of PRRT with 177Lu-octreotate beyond NETs : preliminary in vitro data in melanoma and multiple myeloma**

W. Delbart, *Z. Wimana*, *M. Verduyssen*, *N. Meuleman*, *G. Ghanem*, *P. Flamen*; Jules Bordet Institute, Brussels, BELGIUM.

EP-0798**Improving Image Quality in Preclinical 18F-FDG TOF PET through Higher Definition Image Reconstruction**

M. I. Menendez, *J. Zhang*, *R. Moore*, *M. Friel*, *K. Binzel*, *M. V. Knopp*; The Ohio State University, Columbus, OH, UNITED STATES OF AMERICA.



EP-0799**Radiotherapeutic Nanoparticles Containing a Ruthenium-Based Radiosensitizer for EGFR-Positive Oesophageal Cancer**

M. R. Gill¹, J. U. Menon¹, R. C. Carlisle¹, J. A. Thomas², P. J. Jarman², K. A. Vallis¹; ¹University of Oxford, Oxford, UNITED KINGDOM, ²University of Sheffield, Sheffield, UNITED KINGDOM.

EP-60 during congress opening hours, e-Poster Area**Radionuclide Therapy & Dosimetry: MIBG & Peptides Therapy****EP-0800****Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30**

M. Marinova, M. Mücke, L. Mahlberg, M. Essler, H. Cuhls, L. Radbruch, R. Conrad, H. Ahmadzadehfar; University Hospital Bonn, Bonn, GERMANY.

EP-0801**I-131-mIBG therapy in high-risk neuroblastoma patients at end of induction chemotherapy**

M. C. Schmidt¹, B. Hero², B. Decarolis², A. Eggert³, F. Berthold², A. Drzezga¹, T. Simon²; ¹University Hospital of Cologne, Dpt. of Nuclear Medicine, Cologne, GERMANY, ²University Hospital of Cologne, Dpt. of Pediatric Hemato-Oncology, Cologne, GERMANY, ³Charité Berlin, Dpt. of Pediatric Hemato-Oncology, Berlin, GERMANY.

EP-0802**Phase 1/2 open-label trial to assess the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours**

G. Nicolas^{1,2}, R. P. Baum³, K. Herrmann^{4,5}, M. Lassmann⁴, R. J. Hicks⁶, A. R. Haug⁷, S. Navalkisoor², H. Oberwittler⁸, T. Wang⁹, D. Wild¹; ¹University of Basel Hospital, Basel, SWITZERLAND, ²Royal Free Hospital, London, UNITED KINGDOM, ³Zentralklinik Bad Berka, Bad Berka, GERMANY, ⁴University Hospital Würzburg, Würzburg, GERMANY, ⁵UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ⁶Peter MacCallum Cancer Centre, East Melbourne, AUSTRALIA, ⁷Medical University of Vienna, Vienna, AUSTRIA, ⁸Ipsen, Les Ulis, FRANCE, ⁹Ipsen, Cambridge, MA, UNITED STATES OF AMERICA.

EP-0803**Association between uptake on ⁶⁸Ga-DOTATOC and ¹⁸F-FDG PET/CT with uptake and mean absorbed dose on ¹⁷⁷Lutetium-SSA gamma imaging during PRRT**

D. M. V. Huizing¹, E. A. Aalbersberg¹, C. Schuchardt², B. J. de Wit - van der Veen¹, I. Walraven³, A. Singh², H. R. Kulkarni², M. P. M. Stokkel¹, R. P. Baum²; ¹Department of Nuclear Medicine, ENETS Center of Excellence, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS, ²THERANOSTICS Center for Molecular Radiotherapy, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, GERMANY, ³Department of Radiation Oncology, ENETS Center of Excellence, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

EP-0804**Quality of Life Improvements in Patients with progressive Midgut Neuroendocrine Tumors: the NETTER-1 Phase III Trial**

J. Strosberg¹, E. Wolin², B. Chasen³, M. Kulke⁴, D. Bushnell⁵, M. Caplin⁶, R. P. Baum⁷, P. Kunz⁸, T. Hobday⁹, A. Hendifar¹⁰, K. Öberg¹¹, M. Lopera Sierra¹², P. Ruszniewski¹³, E. Krenning¹⁴; ¹Moffitt Cancer Center, Tampa, FL, UNITED STATES OF AMERICA, ²Montefiore Einstein Center for Cancer Care, Bronx, NY, UNITED STATES OF AMERICA, ³The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, ⁴Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA, ⁵University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA, ⁶Royal Free Hospital, London, UNITED KINGDOM, ⁷Zentralklinik, Bad Berka, GERMANY, ⁸Stanford University Medical Center, Stanford, CA, UNITED STATES OF AMERICA, ⁹Mayo Clinic College of Medicine, Rochester, MN, UNITED STATES OF AMERICA, ¹⁰Cedars Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, ¹¹University Hospital, Uppsala University, Uppsala, SWEDEN, ¹²Advanced Accelerator Applications, New York, NY, UNITED STATES OF AMERICA, ¹³Hopital Beaujon, Clichy, FRANCE, ¹⁴Erasmus Medical Center, Rotterdam, NETHERLANDS.

EP-0805**Monte Carlo Based SPECT Activity Quantification and Tumor Dosimetry for ¹⁷⁷Lu-DOTATATE Treatments**

I. Marin¹, J. Svensson², T. Rydén¹, E. Wikberg¹, A. Elf³, V. Johansson³, P. Bernhardt¹; ¹Department of Radiation Physics, Gothenburg, SWEDEN, ²Department of Oncology, Gothenburg, SWEDEN, ³Department of Surgery, Gothenburg, SWEDEN.



EP-0806**Haematological toxicity in patients with somatostatin receptor positive tumours showing high bone and bone marrow involvement treated with 177Lu-Dotatate**

M. Cremonesi¹, M. E. Ferrari¹, L. Bode², F. Botta¹, M. Colandrea¹, S. M. Baio¹, P. A. Rocca¹, G. Prisco¹, G. Buonsanti¹, D. Militano¹, C. Garibaldi¹, R. Orecchia¹, C. M. Grana¹; ¹Istituto Europeo di Oncologia, Milano, ITALY, ²Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0807**A long term efficacy of PRRT in patients with advanced, non-resectable paraganglioma/pheochromocytoma tumours, related to SDHx gene mutation**

A. D. Kolańska-Ćwikła¹, M. Pęczkowska², I. Michałowska², A. Lewczuk³, L. Bode⁴, M. Kidd⁵, I. M. Modlin⁶, J. B. Ćwikła⁷; ¹MSC Memorial Cancer Centre and Institute Maria Skłodowska-Curie, Warsaw, POLAND, ²Institute of Cardiology, Warsaw, POLAND, ³Medical University of Gdansk, Gdańsk, POLAND, ⁴Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA, ⁵Wren Laboratories, Branford, CT, UNITED STATES OF AMERICA, ⁶Yale University, New Haven, CT, UNITED STATES OF AMERICA, ⁷Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, POLAND.

EP-0808**Red Bone Marrow Dosimetry and Haematotoxicity in 177Lu-DOTATATE PRRT**

S. Tshori¹, S. Glasberg², D. Luder², Y. Krausz², D. Gross², A. Schwartz², N. Freedman^{2,3}; ¹Kaplan Medical Center, Rehovot, ISRAEL, ²Hadassah Hebrew University Medical Center, Jerusalem, ISRAEL, ³Tel Aviv Sourasky Medical Centre, Tel Aviv, ISRAEL.

EP-0809**Safety, Biodistribution, and Efficacy of ⁶⁷Cu-SARTATE targeted therapy in somatostatin receptor expressing tumours in mice**

E. M. van Dam¹, C. M. Jeffery¹, J. L. Stoner², A. V. Hedt¹, M. J. Harris¹; ¹Clarity Pharmaceuticals, Sydney, AUSTRALIA, ²Idaho State University, Pocatello, ID, UNITED STATES OF AMERICA.

EP-0810**Treatment of 28 Paragangliomas with 177Lu-octreotate based PRRT**

D. Smit Duijzentkunst, T. P. ... , J. Hendriks, A. van Linge, R. Feelders, ... , E. Krenning, D. Kwakkeboom, ... ; Erasmus MC, Rotterdam, NETHERLANDS

EP-0811**Siopen Scoring System to quantifying response to 131I-MIBG metabolic treatment in HR-NB relapse: review of local experience**

C. Olianti¹, P. Saletti², G. Simontacchi³, A. Tondo⁴; ¹Nuclear Medicine Unit - Careggi University Hospital, Florence, ITALY, ²Health Physic Unit, Careggi University Hospital, Florence, ITALY, ³Radiotherapy Unit, Careggi University Hospital, Florence, ITALY, ⁴OncoHematology Unit, Meyer University Hospital, Florence, ITALY.

EP-0812**Outcome of Lutetium DOTANOC therapy in metastatic neuroendocrine tumor: Preliminary experience**

P. K. Pradhan, D. Datta, S. Gambhir, A. Mishra, A. Agarwal; SGPGIMS, Lucknow, INDIA.

EP-61 during congress opening hours, e-Poster Area**Radionuclide Therapy & Dosimetry: Radioimmunotherapy (RIT)****EP-0813****SUVmax predicts survival in patients with diffuse large B-cell lymphoma who received radioimmunotherapy using ¹³¹I-rituximab as consolidation therapy**

J. Choi¹, I. LIM¹, B. Byun¹, B. Kim¹, C. Choi¹, S. LIM¹, D. Shin², H. Kang¹; ¹Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, ²Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0814**FDG uptake at baseline may predict absorbed dose in tumor lesions in indolent Non-Hodgkin lymphoma patients treated With the novel antibody-radionuclide-conjugate 177Lu-lilotomab satetraxetan**

A. Londalen^{1,2}, J. Blakkisrud², J. Dahle³, M. Revheim^{1,4}, H. Holte⁵, A. Kolstad⁵, C. Stokke^{2,6}; ¹Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, ²Department of Diagnostic Physics, Oslo University Hospital, Oslo, NORWAY, ³Nordic Nanovector ASA, Oslo, NORWAY, ⁴Faculty of Medicine, University of Oslo, Oslo, NORWAY, ⁵Department of Oncology, Radiumhospital, Oslo University Hospital, Oslo, NORWAY, ⁶Oslo and Akershus University College of Applied Science, Oslo, NORWAY.



EP-62 during congress opening hours, e-Poster Area

Radionuclide Therapy & Dosimetry: Thyroid

EP-0815**Effect of selenium supplement for protection of salivary glands from I-131 radiation damage in patients with differentiated thyroid cancer**

J. Lee¹, H. Son¹, S. Lee²; ¹Catholic Kwandong University College of Medicine, Incheon, KOREA, REPUBLIC OF, ²Soonchunhyang University Hospital, Cheonan, KOREA, REPUBLIC OF.

EP-0816**Higher Body Weight and Distant Metastasis are Associated with Higher Radiation Exposure to the Household Environment from Patients with Thyroid Cancer after Radioactive Iodine Therapy**

S. Kuo¹, J. Lin², M. Liou², B. Huang¹, K. Chiang¹, R. Cheng¹; ¹Chang Gung Memorial Hospital, Keelung, TAIWAN, ²Chang Gung Memorial Hospital, Taoyuan, TAIWAN.

EP-0817**Abnormal Uptake Of I-131 Iodine On Surgical Clips, A Case Report**

A. Buitrago¹, M. Gallet¹, H. Lasolle¹, C. Bournaud¹, F. Giammarile^{1,2}, E. Levigoureux^{1,2}; ¹Hospices civils de Lyon, Groupement Hospitalier Est, Bron, FRANCE, ²Université Lyon 1 Claude Bernard, Lyon, FRANCE.

EP-0818**Clinical Significance of Iodine-131 ablation therapy post total thyroidectomy in differentiated thyroid cancer**

K. Utsunomiya¹, H. Iwai², K. Suzuki², N. Kan¹, Y. Kono², K. Maruyama², Y. Ueno², N. Tanigawa²; ¹Kansai Medical University Medical Center, Moriguchi, JAPAN, ²Kansai Medical University Hospital, Hirakata, JAPAN.

EP-0819**Acceptable radiation exposure to contacts of patients treated with low dose radioactive iodine (I-131) post family counseling can pave the way for high dose I-131 therapy on outpatient basis**

K. Salman¹, S. Yassin¹, T. Munshy¹, M. Almalki², S. Zatari¹, Z. Khan¹, S. Elmorsy¹, D. Abdelmoety¹, M. Al-Ezzi¹, M. Al-Otaiby¹, H. Fedah¹, M. Alhazmi¹, N. Ali¹; ¹King Abdulla Medical City (KAMC), Makka, SAUDI ARABIA, ²Ministry of health, KSA, Riyad, SAUDI ARABIA.

EP-0820**Thyroid Cancer and Galectin-3**

Z. Hasbek¹, G. DUMAN¹, T. CANDAR², S. A. ERTURK¹, A. CAKMAKÇILAR¹; ¹Cumhuriyet University School of Medicine, SIVAS, TURKEY, ²Ufuk University School of Medicine, ANKARA, TURKEY.

EP-0821**BRAF^{V600E} and ^{99m}Tc-MIBI scintigraphy are useful diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy**

A. Campenni¹, M. Siracusa¹, M. Stipo¹, S. Pignata¹, F. Di Mauro¹, R. Ruggeri², S. Baldari¹; ¹Unit of Nuclear Medicine of Messina, Messina, ITALY, ²Unit of Endocrinology of Messina, Messina, ITALY.

EP-0822**Investigation Of The Effect Of Vitamin C On Oxidative Stress Parameters Due To Radioiodine Treatment In Hyperthyroidism Patients**

S. Ozdemir¹, K. Ukinç², D. Ulker Cakir³, Y. Ziya Tan¹, M. Aşık⁴, F. Celik¹; ¹Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Nuclear Medicine, Canakkale, TURKEY, ²Canakkale Onsekiz Mart University, Faculty Of Medicine, Department of Endocrinology and Metabolic Disease, Canakkale, TURKEY, ³Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Biochemistry, Canakkale, TURKEY, ⁴Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Endocrinology and Metabolic Disease,, Canakkale, TURKEY.

EP-0823**Influence of coexisting Hashimoto thyroiditis on the postoperative residual thyroid tissue ablation success after the first dose of 3.7 GBq of iodine-131 in patients with differentiated thyroid carcinoma**

M. P. Rajic, M. Vljakovic, S. Ilic, M. Stevic, I. Mistic, M. Kojic; University of Niš Medical School, Nis, SERBIA.

EP-0824**Risk factors for predicting osteoporosis in patients who receive tsh-suppressive levothyroxine treatment for differentiated thyroid carcinoma**

C. Soydal¹, E. Ozkan¹, D. Nak¹, A. H. Elhan², N. Kucuk¹, M. K. Kir¹; ¹Ankara University Medical Faculty, Nuclear Medicine, Ankara, TURKEY, ²Ankara University Medical Faculty, Biostatistics, Ankara, TURKEY.

EP-0825**National survey and harmonization of practices of I-131 therapy for thyroid cancer in Finland**

T. E. J. Noponen¹, M. Tenhunen², J. Heikkinen³, V. Tunninen⁴, H. Mäenpää²; ¹Department of Clinical Physiology Nuclear Medicine, Turku University Hospital, Turku, FINLAND, ²Department of Radionuclide Treatments, Cancer Centre, Helsinki University Hospital, Helsinki, FINLAND, ³Department of Medical Physics, Etelä-Savo Hospital District, Mikkeli, FINLAND, ⁴Department of Nuclear Medicine, Satakunta Central Hospital, Pori, FINLAND.



EP-0826**Predictive factors of a disease-free status in post-operative differentiated thyroid cancer patients treated with ¹³¹I**

P. Gouveia, T. Alves, A. Amado, R. Teixeira, R. Brito, R. Castro, I. Amorim, A. Silva, M. Oliveira, A. M. Costa, A. Carvalho, C. Freitas, F. Borges; Centro Hospitalar do Porto, Porto, PORTUGAL.

EP-0827**Radioiodine uptake by thyroglossal duct remnant after radioiodine therapy for differentiated thyroid carcinoma**

M. Jinguji, M. Nakajo, A. Tani, T. Yoshiura; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JAPAN.

EP-0828**Comparison of the Prescribed Dose of Radioiodine Ablation (Low Dose versus High Dose) in patients with Intermediate to High Risk Thyroid Cancer: An Inverse Probability of Treatment Weighting Analysis**

Y. Iizuka, T. Katagiri, K. Ogura, T. Mizowaki; Kyoto University, Kyoto, JAPAN.

EP-0829**False positive thymus uptake on ¹³¹I post therapeutic scan of DTC patients**

I. Iakovou, E. Giannoula, K. Michailo, V. Mpalaris, K. Badiavas, V. Athanasiou, D. Katsampoukas, D. Lo Presti, S. Georga, E. Moralidis, G. Arsos; Nuclear Medicine Academic dpt, Papageorgiou hsp, THESSALONIKI, GREECE.

EP-0830**The long term effect after 10 years of radioiodine therapy in patient with subclinical hyperthyroidism**

S. S. Abdelrazek, P. Szumowski, M. Sykala, A. Polak, J. Mysliwiec; Department of Nuclear Medicine, Medical University of Bialystok, Bialystok, POLAND.

EP-0831**Usefulness of radioiodine therapy in low risk patients with papillary thyroid cancer**

E. Takacsova, M. Bartovic, R. Kralik; St. Elisabeth Cancer Institute, BRATISLAVA, SLOVAKIA.

EP-0832**Radioiodine Treatment of Thyroid Papillary Carcinoma in Patient on Hemodialysis: Treatment Protocol and Dosimetric Results**

J. Bang, H. Lee; Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National Univer, Seongnam, KOREA, REPUBLIC OF.

EP-0833**Comparison Between Preablative Tc-99m Pertechnetate Scintigraphy and Postablative I-131 Whole Body Scan for Evaluation of Remnant Thyroid Tissue in Differentiated Thyroid Cancer**

G. Mutevelizade, Y. Parlak, 45030, E. Sayit, G. Gumuser; Celal Bayar University, Manisa, TURKEY.

EP-0834**The difference of clinical characteristics and outcome according to FDG PET/CT in pulmonary metastases of differentiated thyroid cancer**

S. Wu, H. Wang; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CHINA.

EP-0835**Efficacy And Dosimetry Analysis In Low Risk Thyroid Carcinoma Patients Treated With Low Doses Of ¹³¹I**

M. Guiote Moreno, A. Santos Bueno, L. Mena Bares, F. Maza Muret, E. Carmona Asenjo, M. Albalá González, E. Ortega Moreno, E. Rodríguez Cáceres, J. Vallejo Casas; Hospital Universitario Reina Sofía, IMIBIC, Córdoba, SPAIN.

EP-0836**Is F-18 Fluorodeoxyglucose PET/CT Useful In The Management Of TENIS?**

A. Bhattacharya, D. Singh, A. Jois, A. Sood, B. R. Mittal; Postgraduate Institute of Medical education and Research, Chandigarh, INDIA.

EP-0837**Clinical outcome of radioiodine therapy in Graves' disease related to patient specific thyroid absorbed dose calculations- 3 years of experience in Nuclear Medicine Department of "Theagenio" Anticancer Hospital of Thessaloniki**

M. KOTZASARLIDOU¹, K. GIANOPOULOU², P. EXADAKTILOU¹, V. MAMOUGA¹, T. KALATHAS¹, V. HATZIPAVLIDOU¹; ¹"Theagenio" Anticancer Hospital, Thessaloniki, GREECE, ²Aristotelion University of Thessaloniki, Thessaloniki, GREECE.

EP-0838**Is serum Thyroglobulin level an indication of distant metastasis location?**

F. Norton Brandão, M. Silvestre, M. Rio Carvalho, I. Patrocínio Carvalho, R. Sousa, P. Ratão, T. C. Ferreira, L. Salgado; Instituto Português de Oncologia Lisboa Francisco Gentil E.P.E., Lisboa, PORTUGAL.



EP-0839**Thyroid ablation with 1.1GBq (30mCi) iodine-131 with patients with papillary thyroid carcinoma at intermediate risk for recurrence**

I. El Bez, M. Somai, S. Bennour, I. Slim, M. Ben Slimene; institut Salah Azaiez, Tunis, TUNISIA.

EP-0840**Efficacy of Radiiodine Therapy For Graves' Disease: Standardized Vs Calculated Activity**

I. Slim, N. Sahli, T. Ben Ghachem, I. El Bez, I. Meddeb, K. Limam, A. Mhiri, I. Yeddes, M. F. Ben Slimene; Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA.

EP-0841**The Relationship Between Diagnosis, Perception, Anxiety, Depression And Quality In Thyroid Cancer Patients**

U. Elboga, G. Al... Celen; Gaziantep University, Gaziantep...

EP-0842**Over-time Titers Evolution of Positive Thyroglobulin Antibodies at Radio Iodine Ablation Treatment**

P. Soeiro¹, R. Silva^{1,2}, G. Costa^{1,3}, P. Gil¹, J. Pedroso de Lima^{1,2,3}; ¹Serviço de Medicina Nuclear do Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²Instituto das Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0843**Detecting dedifferentiation in differentiated thyroid carcinoma - our experience**

F. N. Brandão, M. Silvestre, M. Rio Carvalho, I. Patrocínio Carvalho, R. Sousa, P. Ratão, T. C. Ferreira, L. Salgado; Instituto Português de Oncologia Lisboa Francisco Gentil E.P.E., Lisboa, PORTUGAL.

EP-0844**The efficacy of radioiodine therapy in patients with non-toxic multinodular goiter with large cold nodules**

S. S. Abdelrazek, P. Szumowski, A. Polak, M. Mojsak, P. Lisiewicz, A. Konopka, J. Mysliwiec; Department of Nuclear Medicine Medical University of Bialystok, Bialystok, POLAND.

EP-0845**Effect of radioiodine ablation in Graves' ophthalmopathy**

P. K. Pradhan, N. Yadav, A. Arya, S. Yadav, V. Kanojia; SGPGIMS, Lucknow, INDIA.

EP-0846**Low Iodine Diet In Patients With Differentiated Thyroid Cancer**

M. Dobrenic; Clinical Hospital Centre Zagreb, Zagreb, CROATIA.

EP-63 during congress opening hours, e-Poster Area**Radionuclide Therapy & Dosimetry: Bone Metastases - Pain Palliation****EP-0847****Role of tALP and ECOG Performance Status in predicting survival in mCRPC patients receiving 223Ra-dichloride**

G. A. Follacchio¹, V. Frantellizzi¹, S. Sollaku¹, M. S. De Feo¹, F. Monteleone¹, M. Liberatore¹, A. Farcomeni¹, M. Pacilio², G. De Vincentis¹; ¹Sapienza University of Rome, ROME, ITALY, ITALY, ²Policlinico Umberto I, ROME, ITALY, ITALY.

EP-0848**Definition of a Predictive Score to guide therapeutic management in metastatic CRPC patients eligible to 223Ra-dichloride treatment**

G. A. Follacchio¹, V. Frantellizzi¹, M. Pontico¹, M. S. De Feo¹, F. Monteleone¹, M. Liberatore¹, A. Farcomeni¹, M. Pacilio², G. De Vincentis¹; ¹Sapienza University of Rome, Rome, Italy, ITALY, ²Policlinico Umberto I, Rome, Italy, ITALY.

EP-0849**Prediction of the response to the pain palliation radionuclide therapy for metastatic bone pain: the role of 188Re-HEDP SPECT/CT**

C. Liu, Y. Zhang, B. Zhu, Q. Yue; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0850**¹⁸DFG PET is predictive of patient outcome in Xofigo therapy**

A. Tofani¹, R. Pirisino¹, P. Pizzichini¹, F. Scopinaro²; ¹Azienda Ospedaliera Sant'Andrea, Roma, ITALY, ²Sapienza Università di Roma, Roma, ITALY.

e-Poster not submitted



EP-0851**Baseline 18F-FDG PET/CT and bone scintigraphy in the prediction of response and prognosis of patients treated with 223-Ra**

A. García Vicente¹, F. Pena Pardo¹, W. Martinez Bravo¹, M. Amo-Salas², B. Gonzalez Garcia¹, I. Garcia Carbonero³, J. Villa Guzman¹, B. Sanchez Gil⁴, N. Mohedano Mohedano⁵, J. Gomez-Aldaravi Gutierrez⁶, L. Martinez Dhier⁷, A. Soriano Castrejon¹;
¹General Hospital of Ciudad Real, Ciudad Real, SPAIN, ²Universidad de Castilla La Mancha, Ciudad Real, SPAIN, ³Complejo Hospitalario de Toledo, Toledo, SPAIN, ⁴Hospital La Mancha Centro, Alcazar. Ciudad Real, SPAIN, ⁵Hospital General de Guadalajara, Guadalajara, SPAIN, ⁶General Hospital of Albacete, Albacete, SPAIN, ⁷Hospital de las Tres Culturas, Toledo, SPAIN.

EP-0852**The Effects of prior Docetaxel administration on the result of Ra223 therapy**

Z. Képes¹, M. Ilyés², Á. Deák³, A. Vánczku², A. Káplár², O. Sántha⁴, I. Garai²; ¹Department of Medical Imaging, University of Debrecen, Debrecen, HUNGARY, ²ScanoMed Ltd, University of Debrecen, Debrecen, HUNGARY, ³Medical School of University of Debrecen, Debrecen, HUNGARY, ⁴Hospital of the County of Borsod-Abaúj-Zemplén and the Teaching Hospital of the University of Debrecen, Diagnostic and Therapeutic Department of Nuclear Medicine, Miskolc, HUNGARY.

EP-0853**Semiquantitative evaluation of 223Radium-dichloride uptake in bone metastases during radiometabolic therapy in castration-resistant prostate cancer**

A. Cimino, A. Niccoli Asabella, C. Ferrari, V. Lavelli, C. Altini, N. Addante, M. Fanelli, G. Rubini; Nuclear Medicine Unit, AOU Policlinic of Bari, University of Bari, Bari, ITALY.

EP-0854**Description of the first 51 patient treated with Radium 223 dichloride in Argentina**

M. J. Bastianello^{1,2,3}; ¹Instituto Universitario CEMIC, Ciudad de Buenos Aires, ARGENTINA, ²Instituto Alexander Fleming, Ciudad de Buenos Aires, ARGENTINA, ³Clinica Reina Fabiola, Cordoba, ARGENTINA.

EP-0855**Dosimetry of Targeted Ra-223 Treatment for Metastatic Castration-Resistant Prostate Cancer**

S. Matsuo¹, S. Kinuya¹, A. Mizokami¹, K. Nakajima¹, H. Wakabayashi¹, T. Kudo²; ¹Kanazawa University, Kanazawa, JAPAN, ²Nagasaki University, Nagasaki, JAPAN.

EP-0856**Safety, effectiveness and haematological toxicity of ²²³Ra-dichloride: a single Centre experience**

R. Laudicella, F. Minutoli, A. Sindoni, F. E. M. Quattrocchi, L. Sturiale, S. A. Pignata, B. Pagano, S. Baldari; Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and of Morphofunctional Imaging; University of Messina, Messina, ITALY.

EP-0857**Co-existing lymph node and bone metastases may be negative predictive marker of survival in patients with CRPC treated with 223Ra-dichloride**

S. Dizdarevic, M. Jessop, P. Begley, A. Robinson; Brighton and Sussex University Hospitals NHS Trust, Brighton, UNITED KINGDOM.

EP-0858**Experiences with Xofigo (²²³RaCl₂) Therapy**

R. Német¹, Z. Besenyi¹, L. Pávics¹, A. Maráz²; ¹Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY, ²Department of Oncotherapy, University of Szeged, Szeged, HUNGARY.

EP-0859**Samarium-153-EDTMP For Bone Pain Relief in Patients With Metastatic Superscan**

I. Slim, I. El Bez, I. Meddeb, M. Somai, T. Ben Ghachem, A. Mhiri, I. Yeddes, M. F. Ben Slimene; Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA.

EP-0860**Objective response evaluation to therapy with 223Ra-dichloride by absolute quantification of 99mTc-MDP uptake and dose-response relationship evaluation: preliminary results**

C. Tranfaglia¹, C. P. L. Fulcheri², V. Reggioli², R. Tarducci², M. E. Dottorini¹; ¹Nuclear Medicine Department, Hospital Santa Maria della Misericordia, Perugia, ITALY, ²Medical Physics Department, Hospital Santa Maria della Misericordia, Perugia, ITALY.

EP-0861**Optimal selection of patients for Xofigo treatment and case report on our first patient with re-treatment**

R. P. Jóna, S. Czibor, I. Szilvási; Medical Center, Hungarian Defence Forces, Budapest, HUNGARY.



EP-0862**Evolutionary assessment with 18F-Fluoride PET / CT in patients with castration-resistant metastatic prostate cancer treated with Ra-223**

J. S. Blanco Cano, Sr., A. Garcia Burillo, D. Villasboas Rosciolesi, E. Carrillo Villamizar, J. Castell Conesa; Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-64 during congress opening hours, e-Poster Area**Radionuclide Therapy & Dosimetry: Local Radionuclide Treatment****EP-0863****Yttrium-90 resin microspheres radioembolization (SIRT) of primitive and secondary liver tumors : survival and safety study**

V. Frusciante, Sr., G. Castriotta, F. Florio, M. C. D' Arienzo, M. Scarale, A. Ippolito, A. M. Varraso; Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), ITALY.

EP-0864**Clinical Outcome Of "Real Life" HCC Patients Treated With ⁹⁰Y Microspheres Radioembolization: A Single Center Experience**

M. FINESSI, F. CHECCHI, R. PASSERA, M. BELLO, G. BISI, D. DEANDREIS; Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, Torino, ITALY.

EP-0865**Is the Technetium-^{99m} Macroaggregated Albumin Scintigraphy a Certain Surrogate of ⁹⁰Y-loaded Microspheres In the Treatment of Primary and Secondary Liver Cancer?**

R. De Teresa Herrera, I. Plaza De Las Heras, C. Field Galan, S. Seijas Marcos, B. Rodriguez Alfonso, J. Cardona Arbories, S. Mendez Alonso, M. Mitjavila Casanovas; Hospital Universitario Puerta De Hierro, Majadahonda, MA, SPAIN.

EP-0866**Monte Carlo Based Dose Assessment for ⁹⁰Y Radioemboliation, a Comparison Between ^{99m}Tc-MAA SPECT/CT and ⁹⁰Y-TheraSpheres PET/CT**

S. Rijnsdorp¹, A. L. Wolf², D. E. Oprea-Lager³, J. J. J. de Vries³, A. van Lingen³; ¹Catharina Hospital, Eindhoven, NETHERLANDS, ²Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ³VU Medical Center, Amsterdam, NETHERLANDS.

EP-0867**Uncertainties in geometric-mean based lung shunt fraction for ⁹⁰Y radioembolization**

S. C. Kappadath, A. Balagopal, A. Mahvash; UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0868**Hepatic Radioembolization With ⁹⁰Y Glass Microspheres: Our Experience**

M. L. Dominguez¹, C. Vigil¹, J. E. Rodriguez², B. Fernandez¹, A. M. Alvarez¹, N. Martin¹, N. A. Perez¹, C. Salvat¹, F. M. Gonzalez¹; ¹Nuclear Medicine Department, Central University Hospital of Asturias, Oviedo, SPAIN, ²Radiology Department, Central University Hospital of Asturias, Oviedo, SPAIN.

EP-0869**Comparison of Therapy Response Between PERCIST and RECIST Criteria After Yttrium-90 Therapy in HCC Patients**

S. Sager, Sr., E. Akgün, L. Uslu, S. Asa, O. E. Sahin, B. Akozal, F. Gülsen, M. Abuqbeitah, M. Demir, H. B. Sayman, K. Sönmezoglu; Istanbul University, Cerrahpasa Medical School, Istanbul, TURKEY.

EP-0870**Incidence of Kidney Injury Post Y-90 Radioembolization: A Single Centre Experience**

W. Peh, Y. Khor; Singapore General Hospital, Singapore, SINGAPORE.

EP-0871**Autoradiography of a resected hepatocellular carcinoma treated with ⁹⁰Y radioembolization illustrates uptake differences between viable and infarcted areas**

J. Hemmingsson¹, J. Mölne², J. Högberg³, J. Svensson¹, M. Rizell¹, P. Bernhardt¹; ¹Clinical Sciences, Gothenburg, SWEDEN, ²Biomedicine, Gothenburg, SWEDEN, ³Medical Physics, Linköping, SWEDEN.

EP-0872**Multi-modal image analysis for optimized treatment safety and effectiveness of radioembolization of liver tumors**

E. Jafargholi Rangraz, K. Baete, M. Koole, G. Maleux, C. Deroose, J. Nuyts; KU Leuven, Leuven, BELGIUM.



EP-0873**Effectiveness and safety of transarterial Y-90 radioembolization for unresectable intrahepatic cholangiocarcinoma**

G. Boni¹, T. Depalo¹, I. Bargellini², C. Vivaldi³, S. Mazzarri¹, F. Guidoccio¹, E. Bozzi², L. Caponi¹, C. Traino⁴, G. Manca¹, G. Masi³, R. Cioni², D. Volterrani¹; ¹Regional Center of Nuclear Medicine, University Hospital of Pisa, Pisa, ITALY, ²Department of Radiology, Vascular and Interventional Radiology, University Hospital of Pisa, Pisa, ITALY, ³Division of Oncology, Hospital of Pisa, Pisa, ITALY, ⁴Health Physics Unit, Section of Medical Physics, University Hospital of Pisa, Pisa, ITALY.

EP-0874**Radioactive Synoviorthesis on Hemophilic Arthropathy : Tunisian First Cases**

I. Slim¹, I. Meddeb¹, I. El Bez¹, T. Ben Ghachem¹, S. Bennour¹, A. Mhiri¹, W. Saied², I. Yeddes¹, M. F. Ben Slimene¹; ¹Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA, ²Department of orthopaedic surgery, Children hospital of Tunis, Tunis, TUNISIA.

EP-0875**Experience with 223-Radium in the Czech Republic**

A. Chodacki; Masaryk Hospital, Usti n. L., KZ a.s., Usti nad Labem, CZECH REPUBLIC.

EP-0876**Re-188 Patch Radionuclide Therapy for Keloids: A 3 year follow up study**

P. Gupta, K. K. Verma, R. Kumar, P. Kumar, A. Malhotra, G. P. Bandopadhyaya, C. S. Bal; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0877**Radioactive Synoviorthesis In Chronic Sinovitis. Is It A Good Choice? A Review Of Cases**

I. Javato Moreno¹, B. Perez Lopez², M. E. Martin Gomez², P. Garcia-Talavera San Miguel², C. Montilla Morales³, E. Martin Gomez², F. Gomez-Caminero Lopez², C. A. Achury Murcia², M. P. Tamayo Alonso²; ¹University of Salamanca, Salamanca, SPAIN, ²Nuclear Medicine Department. University Hospital of Salamanca, Salamanca, SPAIN, ³Rheumatology Department. University Hospital of Salamanca, Salamanca, SPAIN.

EP-0878**The Relation Between Tumor Metabolic Parameters on F-18 FDG PET/CT, Hepatic Artery Perfusion Scan and Therapy Response in Cholangiocellular Carcinoma Treated with Y-90 Microspheres**

M. Bozkurt, B. Volkan Salanci, U. B. Bozkulut, G. Eldem, M. F. Bozkurt, S. Kilickap, B. Peynircioglu, B. Cil, O. Ugur; Hacettepe University Faculty of Medicine, Ankara, TURKEY.

EP-65 during congress opening hours, e-Poster Area**Radionuclide Therapy & Dosimetry: Data Collection Methods & Pharmacokinetics****EP-0879****Quantification of the Fat Fraction in Bone Marrow using Fat-Water Magnetic Resonance Imaging**

M. Salas-Ramirez¹, J. Tran-Gia¹, C. Kesenheimer¹, A. M. Weng², H. Köstler², M. Lassmann¹; ¹Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY, ²Department of Diagnostic and Interventional Radiology, University of Würzburg, Würzburg, GERMANY.

EP-0880**A method for ¹⁷⁷Lu-PRRT tumour dosimetry based on hybrid planar-SPECT/CT images and semi-automatic segmentation**

D. Roth¹, J. Gustafsson¹, A. Sundlöv^{2,3}, K. Sjögreen-Gleisner¹; ¹Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, SWEDEN, ²Oncology and Pathology, Clinical Sciences Lund, Lund University, Lund, SWEDEN, ³Department of Oncology, Skåne University Hospital, Lund, SWEDEN.

EP-0881**Radiation self-monitoring data of patients receiving ¹⁷⁷Lu-DOTATATE peptide receptor radiotherapy for dosimetry informed radiation protection**

L. Livieratos^{1,2}, T. Brothwood¹, D. Aniceto¹, R. Fernandez¹, C. Sibley-Allen¹, K. Adamson¹, S. Allen¹, V. Lewington^{1,2}; ¹Guy's and St Thomas Hospitals, London, UNITED KINGDOM, ²King's College, London, UNITED KINGDOM.

EP-0882**OpenDose: Generating reference data for Nuclear Medicine dosimetry**

M. CHAUVIN¹, D. BORYS², F. BOTTA³, P. BZOWSKI², M. A. COCA PEREZ⁴, M. CREMONES³, J. DABIN⁵, A. M. DENIS-BACELAR⁶, A. DESBREE⁷, Z. EL BITAR⁸, N. FALZONE⁹, L. FERRER¹⁰, D. FRANCK⁷, N. LANCONELLI¹¹, A. MAIRANI¹², A. MALARODA¹³, K. MATUSIK², E. MCKAY¹⁴, M. PACILIO¹⁵, J. PIETER², J. L. RODRIGUEZ¹⁶, L. STRUELENS⁵, L. A. TORRES AROCHES¹⁷, A. VERGARA GIL¹⁷, J. M. Fernández⁹, B. Lee⁹, A. P. Robinson¹⁸, D. Sarrut¹⁹, M. BARDIES¹; ¹Centre de Recherches en Cancérologie de Toulouse, Toulouse, FRANCE, ²Silesian University of Technology, Gliwice, POLAND, ³Istituto Europeo di Oncologia, Milano, ITALY, ⁴MEDSCAN Nuclear Medicine and PET/CT Centre, Concepción, CHILE, ⁵Belgian Nuclear Research Centre, Mol, BELGIUM, ⁶National Physical Laboratory, Teddington, UNITED KINGDOM, ⁷Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, FRANCE, ⁸Institut Pluridisciplinaire Hubert Curien, Strasbourg, FRANCE, ⁹Oxford Institute for Radiation Oncology, Oxford, UNITED KINGDOM, ¹⁰Institut de Cancérologie de l'Ouest, St Herblain, FRANCE, ¹¹University of Bologna, Bologna, ITALY, ¹²Centro Nazionale di Adroterapia Oncologica, Pavia, ITALY, ¹³University of Wollongong, Wollongong, AUSTRALIA, ¹⁴Saint George Hospital, Sydney, AUSTRALIA, ¹⁵Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, ITALY, ¹⁶Clínica Las Condes, Santiago de Chile, CHILE, ¹⁷Centro de Isótopos (CENTIS), La Habana, CUBA, ¹⁸National Physical Laboratory, Teddington, UNITED KINGDOM, ¹⁹Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé, Lyon, FRANCE.

EP-0883**Compartmental model for ²²³Ra-Dichloride in Patients with metastatic bone disease from castration-resistant prostate cancer**

J. Taprogge¹, I. Murray², G. Flux²; ¹St George's University Hospitals NHS Foundation Trust, London, UNITED KINGDOM, ²Joint Department of Physics, Royal Marsden NHS Hospital, Sutton, UK & the Institute of Cancer Research, London, UNITED KINGDOM.

EP-0884**A method to objectively determine the internalization rate of radiolabelled ligands using mathematical modelling**

A. Vogt¹, G. Winter¹, N. J. Begum², C. Solbach¹, A. J. Beer¹, G. Glatting², P. Kletting²; ¹Department of Nuclear Medicine, Ulm University, Ulm, GERMANY, ²Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY.

EP-0885**A Full Reference Tissue Model with Non-Vanishing Blood Volume Fractions for Kinetic Analysis of Dynamic FDG-PET Data**

M. Scussolini¹, S. Garbarino², G. Sambuceti³, M. Piana¹, A. Buschiazio³, M. Bauckneht³, C. Marini⁴, G. Caviglia¹; ¹Department of Mathematics, University of Genova, Genova, ITALY, ²Centre for Medical Image Computing, Department of Computer Science, University College London, London, UNITED KINGDOM, ³Nuclear Medicine Unit, Department of Health Sciences, University of Genova and IRCCS AOU San Martino-IST, Genova, ITALY, ⁴CNR Institute of Bioimages and Molecular Physiology, Section of Genova, Genova, ITALY.

EP-0886**Investigation of influence of anti-thyroid drug discontinuation time on ¹³¹I biokinetics in patients with benign thyroid disease**

V. Topic Vucenovic¹, K. Vucicevic², Z. Rajkova³, D. Stanimirovic³, G. Vuleta³, D. Jelic⁴, B. Miljkovic²; ¹Department of Pharmacokinetics and Clinical Pharmacy, University of Banja Luka - Faculty of Medicine, Banja Luka, BOSNIA AND HERZEGOVINA, ²Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade - Faculty of Pharmacy, Belgrade, SERBIA, ³Institute of Nuclear Medicine and Thyroid Gland Disease, University Clinical Centre of the Republic of Srpska, Banja Luka, BOSNIA AND HERZEGOVINA, ⁴Department of Physical Chemistry, University of Banja Luka - Faculty of Medicine, Banja Luka, BOSNIA AND HERZEGOVINA.

EP-0887**SPECT/CT calibration using clinical dosimetry workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with ¹⁷⁷Lu-DOTATATE**

E. Mora Ramirez^{1,2,3}, L. Santoro⁴, D. Trauchessec⁴, S. Choua⁴, E. Deshayes^{4,5}, J. Pouget⁵, P. Kotzki^{4,5}, M. Bardies^{1,2}; ¹Centre de Recherche en Cancérologie de Toulouse, France, Toulouse, FRANCE, ²UMR 1037 INSERM/Université Paul Sabatier, Toulouse, FRANCE, ³Universidad de Costa Rica, CICANUM, Escuela de Física, San Pedro, San José, COSTA RICA, ⁴Department of Nuclear Medicine, Institut du Cancer de Montpellier, Montpellier, FRANCE, ⁵INSERM UMR 1194, Montpellier Cancer Research Institute, Montpellier, FRANCE.



EP-0888**Dosimetric estimations using commercial workstations for peptide receptor radionuclide therapy (PRRT) patients treated with ¹⁷⁷Lu-DOTATATE**

E. Mora Ramirez^{1,2,3}, *L. Santoro*⁴, *D. Trauchessec*⁴, *S. Chouaf*⁴, *E. Deshayes*^{4,5}, *J. Pouget*⁵, *P. Kotzki*^{4,5}, *M. Bardies*^{1,2}; ¹Centre de Recherches en Cancérologie de Toulouse, Toulouse, FRANCE, ²UMR 1037 INSERM Université Paul Sabatier, Toulouse, FRANCE, ³Universidad de Costa Rica, CICANUM, Escuela de Física, San Pedro, San José, COSTA RICA, ⁴Department of Nuclear Medicine, Institut du Cancer de Montpellier, Montpellier, FRANCE, ⁵INSERM UMR 1194, Montpellier Cancer Research Institute, Montpellier, FRANCE.

EP-66 during congress opening hours, e-Poster Area**Radionuclide Therapy & Dosimetry: Preclinical and Clinical Dosimetry & Radiobiology****EP-0889****Eye lens dosimetry of workers during medical interventional procedures and surgery**

*G. Bera*¹, *G. Gellie*², *X. Michel*²; ¹Groupe Hospitalier Pitié-Salpêtrière, Paris, FRANCE, ²SPRA HIA PERCY, Clamart, FRANCE.

EP-0890**[⁴⁴Sc] Sc-PSMA-617-an alternative to [⁶⁸Ga]-PSMA-617 for pre therapeutic dosimetry in metastatic castration resistant prostate carcinoma (mCRPC)?**

*A. Khawar*¹, *E. Eppard*¹, *H. Ahmadzadehfar*¹, *S. Kürpig*¹, *M. Meisenheimer*¹, *J. P. Sinnes*², *F. C. Gaertner*¹, *F. Roesch*², *M. Essler*¹, *R. A. Bundschuh*¹; ¹Department of nuclear medicine, University Hospital, Bonn, GERMANY, ²Institute for nuclear chemistry, Johannes Gutenberg-University, Mainz, GERMANY.

EP-0891**Assessment of Statistical Dose Uncertainty Propagation for Lu177 SPECT Imaging with an Automated Internal Dosimetry Research Tool as a result of fast SPECT Acquisition Protocols**

*A. Vija*¹, *M. Cachovan*², *G. Böning*³; ¹Siemens Medical Solutions USA, Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA, ²Siemens Healthcare GmbH, Forchheim, GERMANY, ³Klinikum der Universität München, München, GERMANY.

EP-0892**Identification of mediators in media-transferred radiation-induced bystander effect in breast cancer cells**

K. L. Madsen, *P. F. Høilund-Carlsen*, *B. B. Olsen*; Odense University Hospital, Odense, DENMARK.

EP-0893**The simulation of a 70% decrease in injected dose doesn't affect the measurement of left ventricular ejection fraction with radionuclide equilibrium angiography planed on the highly-sensitive DSPECT CZT-camera**

*H. Tissot*¹, *O. Morel*², *L. Imbert*^{1,3,4}, *V. Roch*^{1,4}, *M. Claudin*¹, *M. Perrin*¹, *A. Verger*^{1,4,5}, *G. Karcher*^{1,4,6}, *P. Marie*^{1,4,6}; ¹CHRU de Nancy, Service de Médecine Nucléaire, Nancy, FRANCE, ²CHRU de Besançon, Hôpital Jean Minjoz, Service de Médecine Nucléaire, Besançon, FRANCE, ³Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, FRANCE, ⁴Plateforme d'imagerie expérimentale Nancyclotep, Nancy, FRANCE, ⁵IADI, U947, Inserm, Nancy, FRANCE, ⁶Université de Lorraine, Faculté de Médecine, Nancy, FRANCE.

EP-0894**Assessment of Dose Uncertainty Propagation using standardized Quantitative Lu177 SPECT Imaging and an Automated Internal Dosimetry Research Tool**

*A. Vija*¹, *M. Cachovan*²; ¹Siemens Medical Solutions USA, Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA, ²Siemens Healthcare GmbH, Forchheim, GERMANY.

EP-0895**Quantification of Gadolinium Nanoparticles Concentration with Preclinical SPECT Scanner**

*O. Kochebina*¹, *A. Halty*¹, *J. Taleb*², *D. Kryza*², *M. Janier*², *C. Mory*¹, *T. Baudier*¹, *D. Bar-Ness*¹, *S. Rit*¹, *D. Sarrut*¹; ¹CREATIS, Lyon, FRANCE, ²LAGEP, Lyon, FRANCE.

EP-0896**Pre-therapy imaging for ⁹⁰Y microsphere treatment demonstrates limited predictability for tumour absorbed dose**

*A. J. Craig*¹, *B. Rojas-Fisher*², *A. M. Denis-Bacelar*³, *I. Murray*¹, *N. Khan*⁴, *A. Maenhout*⁴, *L. Hossen*², *G. Flux*¹; ¹Royal Marsden Hospital NHSFT, Sutton, UNITED KINGDOM, ²Royal Brompton Hospital NHSFT, London, UNITED KINGDOM, ³National Physical Laboratory, London, UNITED KINGDOM, ⁴Chelsea & Westminster Hospital NHSFT, London, UNITED KINGDOM.

EP-0897**Evaluation of dose response after combined bone marrow and lesion based dosimetry**

M. Abuqbeitah, *M. Demir*, *N. Yeyin*, *L. Kabasakal*, *K. Sönmezoğlu*; Istanbul university, istanbul, TURKEY.



EP-0898**Dosimetry study of 99mTc-NTP 15-5 imaging of cartilage in preclinical and clinical trials using the GATE Monte Carlo platform**

G. Fois^{1,2}, C. Valla³, E. Jouberton^{3,4}, P. Auzeloux⁴, N. Sas³, F. Cachin^{3,4}, J. Chezal⁴, E. Miot-Noirault⁴, L. Maigne^{1,2};
¹Clermont Auvergne University, Aubiere, FRANCE,
²UMR6533 CNRS/IN2P3, Clermont-Ferrand, FRANCE,
³CLCC Jean Perrin, Clermont-Ferrand, FRANCE,
⁴UMR1240 INSERM, Clermont-Ferrand, FRANCE.

EP-0899**Relative error in the Survival Fraction and the Biologically Equivalent Dose due to uncertainties on the absorbed dose estimations in Molecular Radiotherapy**

A. Malaroda; University of Wollongong, Wollongong, AUSTRALIA.

EP-0900**Impact of image reconstruction parameters on the dose-volume histogram for PET-based dosimetry for Y-90 radioembolization**

H. Ma¹, X. Hou¹, F. Benard², A. Celler¹; ¹University of British Columbia, Vancouver, BC, CANADA, ²British Columbia Cancer Research Centre, Vancouver, BC, CANADA.

EP-0901**Is there agreement between predicted ^{99m}Tc-MAA-SPECT and post-treatment ⁹⁰Y-PET absorbed doses in SIRT using 3D voxel dosimetry?**

L. Sancho Rodriguez¹, M. Rodríguez-Fraile¹, J. Bilbao¹, M. Iñárraiaegui¹, C. Beorlegui Arteta², A. Benito¹, V. Moran¹, J. Martí-Climent¹, E. Guillen¹, B. Sangro¹;
¹Clinica Universidad de Navarra, Pamplona, SPAIN,
²Universidad de Navarra, Pamplona, SPAIN.

EP-0902**Absorbed kidney doses in patients retreated with Lu-177-octreotate at progression**

V. Reijonen, H. Mäenpää, J. Heikkonen, M. Tenhunen; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FINLAND.

EP-0903**Gelofusine improves the Clinical Feasibility of Insulinoma Treatment using Radiolabeled Exendin**

T. Jansen¹, M. Buitinga¹, I. van der Kroon¹, MW. Woliner-van der Weg¹, M. Boss¹, M. Janssen¹, E. Aarntzen¹, M. Béhé², D. Wild³, M. Brom¹, E. Visser¹, M. Gotthardt¹;
¹Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, NETHERLANDS, ²Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, Villigen, SWITZERLAND, ³Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND.

EP-0904**Influence of Breathing Motion on Kidney Volume Determination for Application in Targeted Radionuclide Therapy**

C. Sebesta¹, J. C. Sanders^{1,2}, C. Schmidkonz¹, M. Beck¹, T. Kuwert¹, P. Ritt¹; ¹University Hospital Erlangen, Erlangen, GERMANY, ²Pattern Recognition Lab, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, GERMANY.

EP-0905**Dose distribution in human kidneys after treatment with ¹⁷⁷Lu-DOTATATE using EUBED**

K. Olde¹, J. Svensson¹, T. Rydén², R. Hermann², E. Forssell-Aronsson², B. Wängberg³, P. Bernhardt²;
¹Department of Oncology, The Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ²Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ³Department of Surgery, The Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EP-0906**Value of personalised radiation absorbed dose calculations for the radioiodine ablation therapy in patients with low-risk well differentiated thyroid cancer**

N. Yeyin¹, N. Alan Selcuk², E. Demirci³, T. Toklu², R. Akyel⁴, O. Sahin¹, A. Boz⁵, F. Yapar⁶, M. Abuqbeith¹, L. Kabasakal¹;
¹Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, TURKEY, ²Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, TURKEY, ³Department of Nuclear Medicine Sisli Etfal Training and Research Hospital, Istanbul, Istanbul, TURKEY, ⁴Department of Nuclear Medicine Umraniye Training and Research Hospital, Istanbul, Istanbul, TURKEY, ⁵Department of Nuclear Medicine, School of Medicine, Akdeniz University, Antalya, TURKEY, ⁶Department of Nuclear Medicine, Cukurova University Faculty of Medicine, Adana, TURKEY.

EP-0907**Prediction vs Prognosis of Ki-67 Index Expression After Combined In-111-DTPA-oc / n.c.a. Lu-177-Dotatate Intra-arterial Infusions, in GEP-NETs Treated Patients**

G. S. Limouris¹, M. Paphiti¹, I. Karfis¹, E. Z. Dimitriadis², S. Chondroyiannis³, V. R. Mccready⁴, D. Rubello³;
¹Medical Faculty, National and Kapodistrian University of Athens, Athens, GREECE, ²Institute Claudus Regaud, University of Paul Sabatier, Toulouse, FRANCE, ³Nuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, ITALY, ⁴Institute Cancer Research, Sutton Surrey & Royal Sussex County Hospital, Brighton, UNITED KINGDOM.





EP-0908

Improved models of hepatic arterial vasculature for improved treatment planning of radioembolization of liver cancer

N. Crookston, E. F. ... Hopkins University, Baltimore, MARYLAND, UNITED STATES OF AMERICA.

e-Poster not submitted

EP-67 during congress opening hours, e-Poster Area

Radionuclide Therapy & Dosimetry: Miscellaneous

EP-0909

Effects of Zinc for Gastrointestinal System as a Radioprotective Agent

A. Akbulut¹, M. Sadic¹, N. Yumusak², F. N. Aydinbelge¹, G. Koca¹, M. Korkmaz¹; ¹Department of Nuclear Medicine, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TURKEY, ²Department of Pathology, Harran University Faculty of Veterinary Medicine, Sanliurfa, Sanliurfa, TURKEY.

EP-0910

Review Of Our Experience In Treatment Of Liver Tumors With Y-90 SIR-Spheres

T. Pipikos¹, M. Glinos², F. Vlachou¹, K. Dalianis³, G. Tsoukalos², M. Vogiatzis¹, E. Tsiakas¹, D. Papoutsani¹, V. Prassopoulos¹; ¹Nuclear Medicine & PET/CT Department, Hygeia SA, Marousi, GREECE, ²Interventional Radiology Department, Hygeia SA, Marousi, GREECE, ³Medical Physics Department, Hygeia SA, Marousi, GREECE.

EP-0911

Uncertainty analysis in the calibration of an emission tomography system for quantitative imaging

M. D'Arienzo¹, M. Cox²; ¹ENEA, National Institute of Ionizing Radiation Metrology, Rome, ITALY, ²NPL, National Physical Laboratories, Teddington, UNITED KINGDOM.

EP-0912

A tool for treatment planning of ⁹⁰Y-microsphere radioembolization

V. Raposo, D. Martínez, N. Gallardo, F. Mañeru, M. Ribelles, F. Caudepón, L. Bragado, N. Fuentemilla, A. Rubio, S. Miquelez, S. Pellejero; Complejo Hospitalario de Navarra, Pamplona, SPAIN.

EP-0913

Dose-rate correlation with tumour volume in NET patients occurring Lu-177 RADIATION therapy

S. Gnesin¹, M. Monteiro², ... J. O. Prior²; ¹Institute of Physics, Lausanne, SWITZERLAND, ²Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, SWITZERLAND.

e-Poster not submitted

EP-68 during congress opening hours, e-Poster Area

Conventional & Specialised Nuclear Medicine: Endocrinology

EP-0914

^{99m}Tc-MIBI Or ¹¹C-Methionine PET/CT In Primary Hyperparathyroidism With Inconclusive Preoperative Work-up?

D. Maccora¹, C. Caldarella², A. Giordano¹, I. Bruno³; ¹Institute of Nuclear Medicine, Università Cattolica del S. Cuore "A. Gemelli", Rome, ITALY, ²PET-CT Center, Policlinico "A. Gemelli", Rome, ITALY, ³Nuclear Medicine Unit, Policlinico "A. Gemelli", Rome, ITALY.

EP-0915

Comparison of ^{99m}Tc-sestaMIBI and ¹⁸F-Fluorocholine PET/CT in localization of hyper-functioning parathyroid glands

I. Bossert¹, S. Chytiris², M. Hodolic^{3,4}, C. Vellani¹, E. Brugola¹, D. D'Ambrosio⁵, G. Mariani⁶, L. Chiovato², G. Trifirò¹; ¹Nuclear Medicine Unit – Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY, ²Endocrinology Unit – Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY, ³Nuclear Medicine Research Department Iason, Graz, AUSTRIA, ⁴University Olomouc, Olomouc, CZECH REPUBLIC, ⁵Medical Physics Unit – Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY, ⁶Regional Center of Nuclear Medicine, University of Pisa, Pisa, ITALY.

EP-0916

F18-choline PET/CT as a second line tracer for parathyroid adenoma detection in primary hyperparathyroidism

E. Quak¹, D. Blanchard¹, B. Houdu², Y. Le Roux², R. Ciappuccini¹, D. De Raucourt¹, J. Grellard¹, Y. Reznik², B. Clarisse¹, N. Aide²; ¹Francois Baclesse Cancer Centre, Caen, FRANCE, ²University Hospital, Caen, FRANCE.

EP-0917

An insulinoma in a critically hypoglycemic newborn identified by F18-FDOPA PET-CT

S. Salamon, H. Kvaternik, C. Gstettner, C. Hosbein, R. M. Aigner; Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA.

EP-0918

Determine the relationship between scintigraphic Sestamibi uptake and biological parameters of parathyroid adenomas in patients underwent surgery at our Center since 2005 to 2015

B. Nuñez, D. Ruiz, A. Renda, F. Zelaya, M. Castrillon, C. Castillo, F. Loira, J. Nogueiras, L. Campos, A. Lopez; Hospital de Meixoeiro, Vigo, SPAIN.

EP-0919**Our experience in the diagnosis of parathyroid adenoma with planar scintigraphy 99mTc-Sestamibi-99mTcO4 during the last 10 years**

B. Nuñez, D. Ruiz, A. Renda, F. Zelaya, M. Castrillon, C. Castillo, F. Loira, J. Nogueiras, L. Campos, A. Lopez; Hospital de Meixoeiro, Vigo, SPAIN.

EP-0920**Serum Osteoprotegerin Levels in Primary Hyperparathyroidism and its Correlation with Hyperparathyroidism Markers: A Randomized Controlled Trial**

B. T. Okudan¹, A. Ç. Karci², M. Kılınçkaya³, N. Coşkun¹, T. Turhan³, D. Berker²; ¹Ankara Numune Hospital Nuclear Medicine Clinic, Ankara, TURKEY, ²Ankara Numune Hospital Endocrinology Clinic, Ankara, TURKEY, ³Ankara Numune Hospital Biochemistry Clinic, Ankara, TURKEY.

EP-0921**SPECT/CT's Superiority over Ultrasonography for Preoperative Localization of Parathyroid Adenomas in Primary Hyperparathyroidism: A Retrospective Clinical Trial**

N. Coşkun, B. T. Okudan; Ankara Numune Hospital, Nuclear Medicine Clinic, Ankara, TURKEY.

EP-0922**Contribution of SPECT/CT Imaging to 131-I NP-59 Planar Images in Patients with Hypersecretory Adrenal Syndromes and Incidentally Discovered Adrenal Masses**

A. Sainz-Esteban, M. Ruiz Gómez, J. Gómez Hidalgo, A. Rodríguez Cobo, M. González Selma, C. Gamazo Laherrán, M. Alonso Rodríguez, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, VALLADOLID, SPAIN.

EP-0923**Comparison of early SPECT/CT and dual-phase planar imaging with early SPECT/CT Tc-99m Sestamibi Parathyroid Scintigraphy. Can we avoid planar imaging?**

J. Gómez Hidalgo, A. Sainz-Esteban, A. Cobo Rodríguez, M. González Selma, M. Ruiz Gómez, C. Gamazo Laherrán, M. Alonso Rodríguez, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, VALLADOLID, SPAIN.

EP-0924**Added Value of SPECT-CT Scintigraphy in The assessment of Patients With Hyperparathyroidism**

I. Slim, I. El Bez, I. Meddeb, T. Ben Ghachem, K. Trabelsi, A. Mhiri, I. Yeddes, M. F. Ben Slimene; Department of Nuclear Medicine, Salah Azaiez Institut, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TUNISIA.

EP-0925**A Type of Uptake in Dual-Phase of ^{99m}Tc Sestamibi SPECT/CT Parathyroid Scintigraphy in Patients with Inadequately Controlled Secondary Hyperparathyroidism in Relation to Histopathology and Parathormone Level-Expierence of One Centre**

M. H. Listewnik, H. Piwowarska-Bilska, K. Safranow, M. Ostrowski, J. Iwanowski, M. Chosia, M. Laszczynska, M. Kurnatowicz, B. Birkenfeld; Pomeranian Medical University in Szczecin, Szczecin, POLAND.

EP-0926**Optimization of ^{99m}Tc-sestamibi/¹²³I subtraction SPECT/CT protocol for parathyroid scintigraphy**

V. Tunninen¹, T. Kauppinen², H. Eskola^{3,4}; ¹Satakunta Central Hospital, PORI, FINLAND, ²Helsinki University Hospital/HUS Medical Imaging Center, Helsinki, FINLAND, ³Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, Tampere, FINLAND, ⁴Department of Radiology, Tampere University Hospital, Tampere, FINLAND.

EP-69 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Thyroid (Benign)****EP-0927****The role of Natural killer T cells in autoimmune thyroid disease during pregnancy and postpartum**

T. Bogović Crncić¹, S. Grbac Ivanković¹, N. Giroto¹, I. Mrakovčić Sutić²; ¹Dept. of Nuclear medicine, Clinical Hospital Centre Rijeka, Rijeka, CROATIA, ²Dept. of physiology and immunology, Medical faculty, University of Rijeka, Rijeka, CROATIA.

EP-0928**Thyroid vascularisation correlates with skin microcirculation in patients with Graves' disease**

K. Zalete¹, N. Bedernjak Bajuk¹, S. Gaberšček^{1,2}, H. Lenasi²; ¹Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-0929**Thyroid disorders in children and teenagers with down syndrom: accidental association or cross linking?**

I. El Bez, M. Somai, D. Ben Sellem, M. Ben Slimene; institut Salah Azaiez, Tunis, TUNISIA.



EP-70 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Pulmonology****EP-0930****The role of SPECT/CT in lymphoscintigraphy for diagnosis of chylothorax**

G. Petracca Ciavarella, Sr., M. Totaro, M. Scarale, F. Dicembrino, V. Frusciante, Sr.; Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG, ITALY).

EP-0931**The Added Value of Low-Dose CT Component of V/Q SPECT/CT: A Meta Analysis**

B. Gunalp, S. Ince, A. Ayan, E. Alagoz, K. Okuyucu; Gulhane Training and Research Center, Ankara, TURKEY.

EP-0932**The role of lung perfusion scintigraphy (LPS) in evaluation of patients suspected for Pulmonary Embolism. Does CTPA have any additional clinical value in cases where LPS findings are discordant with the clinical pretest probability?**

E. Papadaki¹, A. Chatzidakis², I. Mitrouska³, A. Tsaroucha¹, M. Stathaki¹, O. Bourogianni¹, K. Galanopoulos¹, M. Alefantinou¹, G. Notas⁴, K. Perisinakis⁵, S. Koukouraki¹; ¹Department of Nuclear Medicine, University Hospital, Heraklion, Crete, GREECE, ²Department of Radiology, University Hospital of Crete, heraklion, GREECE, ³Department of Thoracic Medicine, University Hospital, Heraklion, Crete, GREECE, ⁴Department of Experimental Endocrinology, University Hospital, Heraklion, Crete, GREECE, ⁵Department of Medical Physics, University Hospital, Heraklion, Crete, GREECE.

EP-0933**Influence of Attenuation Correction on Lung VQ-SPECT/CT 3D Lobar Quantification**

J. Polkey, S. Gregg, E. Reyes, J. Bailey, K. Wechalekar; Royal Brompton Hospital, London, UNITED KINGDOM.

EP-0934**Prognostic impact of deep-inspiratory breath-hold pulmonary perfusion SPECT/CT in patients with pulmonary emphysema**

T. Hamana, Y. Fukushima, S. Kumita, H. Hashimoto, Y. Sugihara; Nippon Medical School Hospital, Bunkyo-ku Tokyo, JAPAN.

EP-0935**Comparison Between Ventilation-Perfusion SPECT/CT And Ventilation-Perfusion Quotient Results**

R. Maleki, T. Ones, K. Oksuzoglu, S. Inanir, H. T. Turoglu, T. Y. Erdil; Marmara University School of Medicine, Nuclear Medicine Department, Istanbul, TURKEY.

EP-0936**Prevalence of Incidental Findings Identified by CTPA in Women of Reproductive Age**

N. Champion, J. Flemming; Memorial University of Newfoundland, St. John's, NL, CANADA.

EP-0937**V/P SPECT to measure lung function deterioration in COPD**

M. Bajc¹, Y. Chen², W. Jun³, J. Xu⁴, C. Wang³, H. Huang², X. He⁵, A. Lindqvist⁶; ¹University Hospital Lund, Lund, SWEDEN, ²Chang zheng Hospital, Shanghai, CHINA, ³Xin qiao Hospital, Chongqing, CHINA, ⁴Hua dong Hospital, Shanghai, CHINA, ⁵Suzhou University Affiliated Tumor Hospital, Suzhou, CHINA, ⁶Helsinki University Hospital, Helsinki, FINLAND.

EP-71 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Gastroenterology****EP-0938****Myotonic Dystrophy With Nonalcoholic Fatty Liver Disease: A Possible Relationship With Intestinal Permeability?**

D. Maccora¹, G. Silvestri², D. Di Giuda¹, D. Ripani¹, S. Rossi², A. Petrucci³, V. Valenza¹; ¹Institute of Nuclear Medicine, Università Cattolica del S. Cuore "A. Gemelli", Rome, ITALY, ²Institute of Neurology, Università Cattolica del S. Cuore "A. Gemelli", Rome, ITALY, ³Neuromuscular and Neurological Rare Diseases Centre - Neurology and Neurophysiology Unit, Ospedale S. Camillo Forlanini, Rome, ITALY.

EP-0939**SPECT Defaecography - a Valuable Tool in Evaluation of Patients with Hirschsprung's Disease**

N. H. Hansen^{1,2}, S. Hvidsten¹, N. Qvist^{1,2}, R. G. Nielsen¹, P. F. Høiland-Carlsen^{1,2}, J. A. Simonsen¹; ¹Odense University Hospital, Odense C, DENMARK, ²University of Southern Denmark, Odense C, DENMARK.

EP-0940**Abdominal retention index of 75sehcata according to response to treatment with resincolestiramine**

P. C. Notta¹, J. Suils ramón¹, L. Rubio-Alvarez¹, A. Rodriguez-Gasén¹, S. Maisterra-Santos², J. Guardiola-Capo², I. Romero-Zayas¹, J. Mora-Salvado¹, P. Saldaña-Gutierrez³, G. Reynès-Llompart³, L. Gràcia-Sanchez¹, J. Mestre-Martí¹, C. Gámez-Cezamo¹; ¹Nuclear Medicine-PET Department. IDI. Hospital Universitari de Bellvitge-IDIBELL. L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Gastroenterology Department. Hospital Universitari de Bellvitge-IDIBELL. L'Hospitalet de Llobregat, Barcelona, SPAIN, ³Medical Physics Department. ICO. L'Hospitalet de Llobregat, Barcelona, SPAIN.



EP-0941**Intra gastric distribution in gastric emptying - Does it help?**

S. Muthu, I. Niematallah, N. Ali, R. Sajjan, M. Prescott; Central Manchester University Hospitals NHS Trust, Manchester, UNITED KINGDOM.

EP-72 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Paediatrics (Benign)****EP-0942****The role of ^{99m}Tc-DMSA scan in the investigative algorithm for children with vesicoureteral reflux - retrospective study**

D. Chroustova¹, J. Langer², I. Urbanova³, J. Trnka⁴, J. Kubinyi¹; ¹Department of Nuclear Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, PRAGUE 2, CZECH REPUBLIC, ²Clinic of Paediatrics and Adolescent Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, PRAGUE 2, CZECH REPUBLIC, ³Department of Paediatrics, University Hospital Bulovka, PRAGUE 9, CZECH REPUBLIC, ⁴Department of Medical Physics, General University Hospital and First Faculty of Medicine, Charles University in Prague, PRAGUE 2, CZECH REPUBLIC.

EP-0943**Lung Perfusion Scintigraphy in Pediatric Age: Quality and Safety in 10-Year Experience regarding Pediatric Nuclear Medicine Practice**

M. Pizzoferro, D. Alabrese, M. F. Villani, E. Villanucci, S. Chiapparelli, M. C. Garganese; IRCCS Bambino Gesù Paediatric Hospital, Rome, ITALY.

EP-0944**The reliability of estimated glomerular filtration rate in South African children**

J. L. Holness¹, A. Brink², M. R. Davids¹, J. M. Warwick¹; ¹Stellenbosch University and Tygerberg Hospital, Cape Town, SOUTH AFRICA, ²University of Cape Town and Red Cross Children's Hospital, Cape Town, SOUTH AFRICA.

EP-0945**Incidental vesicourethral reflux diagnosis on excretory renal nuclear medicine investigations**

D. Ben Sellem, L. Zaabar, I. El Bez, B. Dhaouadi, B. Letaief, M. F. Ben Slimene; University of Tunis El Manar, Tunis, TUNISIA.

EP-0946**Evaluation of the EANM Pediatric Dosage Card Regarding DMSA Scintigraphy**

J. Weng¹, E. Vestergren², E. Wikberg³; ¹Department of Radiation Physics, University of Gothenburg, Gothenburg, SWEDEN, ²Dept of Medical Physics and Biomedicine, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ³Dept Ped Clin Physiol & Ped Nuclear Medicine, The Queen Silvia Children's Hospital, Gothenburg, SWEDEN.

EP-0947**Evaluation of Renal Split Function in Pediatric Patients with ^{99m}-DMSA Scintigraphy, Comparison between Geometric Mean and Voxelbased Analysis on SPECT/IdCT**

M. H. Reichkender, L. Borgwardt; Rigshospitalet Copenhagen University hospital, Copenhagen, DENMARK.

EP-73 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Uro-nephrology****EP-0948****Radio guided surgery of a renal metastasis from differentiated thyroid carcinoma (DTC): a case report**

L. Martino¹, R. Falabella², F. Ponti², A. Fe¹, L. Mussolin¹, A. Vita², G. Vita³, L. Landolfi⁴, M. Veltri⁵; ¹Dept. of Nuclear Medicine A.O.R. San Carlo, Potenza, ITALY, ²Dept. of Urology A.O.R. San Carlo, Potenza, ITALY, ³SIC Dept. of Pathology A.O.R. San Carlo - IRCCS-CROB, Potenza - Rionero in Vulture, ITALY, ⁴Dept. of Internal Medicine University Hospital, Salerno, ITALY, ⁵Dept. of Nuclear Medicine A.O., Cosenza, ITALY.

EP-0949**F+30 versus F-15 Furosemide Tc99m-MAG3 Renogram Drainage Parameters in Hydronephrotic and Normal Pediatric Kidneys**

S. Turpin¹, P. J. Martineau², D. Barriera¹, O. Djahangirian¹, J. Franc-Guimond¹, A. M. Houle¹, R. Lambert¹; ¹CHU Sainte-Justine, Montreal, QC, CANADA, ²The University of Ottawa, Ottawa, ON, CANADA.

EP-0950**Evaluate the effects of age and sex on glomerular filtration rate**

H. M. Yassin¹, M. H. Khedr², M. W. Shafaa², M. Hagar¹; ¹Cairo University, Cairo, EGYPT, ²Helwan University, Cairo, EGYPT.



EP-0951**Impact of furosemide on image quality of Ga-68 PSMA PET-CT in prostate cancer patients**

L. W. M. van Kalmthout, A. J. A. T. Braat, M. G. E. H. Lam, B. de Keizer; University Medical Center Utrecht, Utrecht, NETHERLANDS.

EP-0952**Gravity Assisted Diuresis Renography in patients with Urinary Diversion**

*G. Tartaglione¹, N. Foschi², C. Gandi², P. F. Bassi²;
¹Nuclear Medicine, Cristo Re Hospital, Rome, ITALY,
²Urology, UCSC, Policlinico A. Gemelli, Rome, ITALY.*

EP-0953**Assessment of six different single plasma sample methods measuring glomerular filtration rate in children**

S. Ha, J. Lee; Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0954**Comparison of GFR Estimation by CKD-EPI, C&G, MDRD and GFR Measuring by Tc-99m DTPA**

Z. Hasbek, S. Erturk, E. Ciftci, A. Cakmakcilar, B. Turgut; Cumhuriyet University School of Medicine, Department of Nuclear Medicine, SIVAS, TURKEY.

EP-0956**Testicular Scintigraphy - Our Experience**

A. Sá Pinto, V. M. Alves, A. Oliveira, J. Pereira; Centro Hospitalar de São João, Porto, PORTUGAL.

EP-0957**Our Experience With DMSA In Peadiatrics Patients With Suspected APN**

A. J. Guzmán Cruz, Y. Ramirez Escalante, M. Coronado Poggio, L. García Zoghby, S. Riskallal Monzón., L. Dominguez Gadea; Hospital Universitario La Paz, Madrid, SPAIN.

EP-0958**Relative Renal Efficiency Calculation by Scintigraphy: Tc^{99m} MAG-3 dynamic study Versus Tc^{99m} DMSA static study in Different Renal Diseases**

D. E. Sharaf, H. M. Gad; Urology & Nephrology Center, Mansoura, EGYPT.

EP-0959**Nephrolithiasis:99mTc-DMSA scintigraphy**

D. BEN SELLEM, L. ZAABAR, B. DHAOUADI, I. EL BEZ, B. LETAIEF, M. F. BEN SLIMENE; University of Tunis El Manar, Tunis, TUNISIA.

EP-0960**Is There a Correlation Between MAG3 Tubular Extraction Rate and Estimated Glomerular Filtration Rate in Transplanted Kidney?**

A. Hrelja, S. Grbac-Ivanković, J. Simić, S. Racki, B. Vujčić; Clinical Hospital Rijeka, Rijeka, CROATIA.

EP-0961**Prediction of permanent renal damage using dimercatpo succinic acid renal scintigraphy in children with vesicoureteral reflux and urinary tract infection**

M. Radulovic, L. Jaukovic, M. Sisic, B. Ajdinovic; Military medical academy, Institute of Nuclear medicine, Belgrade, SERBIA.

EP-0962**A new quality control parameter for slope-intercept GFR measurement**

J. L. Holness^{1,2}, J. M. Warwick^{1,2}; ¹Stellenbosch University, Cape Town, SOUTH AFRICA, ²Tygerberg Hospital, Cape Town, SOUTH AFRICA.

EP-0963**Technetium-99m-dimercaptosuccinic acid renal scintigraphy in children with urinary tract infections**

I. El Bez, M. Somai, K. Trabelsi, A. Mhiri, D. Ben Sellem, M. Ben Slimene; institut Salah Azaiez, Tunis, TUNISIA.

EP-0964**Scintigraphic Evaluation of Perconditioning Protection on Renal Ischemia/ Reperfusion Injury in Rats**

Z. Sedaghat¹, H. Fatemikia¹, K. Tanha¹, M. Zahiri¹, B. Seiff², M. Assadi¹; ¹Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ²Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0965**Standardisation of F-15 renography with renal output efficiency**

N. D. Assaf¹, A. A. Nawwar^{1,2}, I. Laurence¹, F. Zananiri¹, M. Darby¹; ¹Southmead Hospital, Bristol, UNITED KINGDOM, ²Clinical Oncology and Nuclear Medicine department, Faculty of Medicine, Cairo University, Cairo, EGYPT.

EP-0966**Activity quantification (E%) in late postmobilization images with mean parenchymal transit time MPTT in dilated and obstructed pelvis when diuretic test is contraindicated**

C. Olianti¹, F. Tutino², A. Ciaccio², M. Allocca³, E. Buti⁴, M. Materassi⁴, M. Antonello⁵, L. Masier⁶; ¹Nuclear Medicine Unit, Careggi University Hospital, Florence, ITALY, ²University of Florence, Florence, ITALY, ³University of Florence, Florence, ITALY, ⁴Nephrology and Dialysis Unit, Meyer Pediatric University Hospital, Florence, ITALY, ⁵Radiodiagnostic Unit, Meyer Pediatric University Hospital, Florence, ITALY, ⁶Pediatric Urology, Meyer Pediatric University Hospital, Florence, ITALY.

EP-0967**Tc99m DTPA renography owes a characteristic pattern in patients with chronic parenchymal renal disease associated with significant renal function impairment**

S. M. W. Yassin¹, K. Salman², A. Bakhsh², H. Abdallah², Z. Khan²; ¹King Abdulla Medical City (KAMC), Jeddah, SAUDI ARABIA, ²King Abdulla Medical City (KAMC), Makkah, SAUDI ARABIA.

EP-0968**Is normalized residual activity a good marker of renal output efficiency in hydronephrosis?**

I. El Bez, M. Somai, K. Trabelsi, A. Mhiri, I. Slim, M. Ben Slimene; institut Salah Azaiez, Tunis, TUNISIA.

EP-0969**Does Anteroposterior Pelvic Diameter Predict of the Need of Diuretic in Cases of 99mTc-MAG3 Stasis after Basal Renogram?**

H. C. Martins¹, G. Costa¹, A. Moreira^{1,2}, R. Silva^{1,2}, J. Pedrosa de Lima^{1,2,3}; ¹Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0970**Value of real-time time-activity curves when evaluating need for diuretic on dynamic renograms**

P. Holdgaard¹, A. Erslev¹, N. Bebbington²; ¹Sygehus Lillebælt, Vejle, DENMARK, ²Siemens Healthineers, Aarhus, DENMARK.

EP-0971**Infected Polycystic Kidney Disease: Role Of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography**

J. Benouhoud, S. CHOUKRY, Y. SHIMI, A. GUENSI; CHU Ibn Rochd, Casablanca, MOROCCO.

EP-74 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Infection & Inflammation****EP-0972****Diagnostic performance of ^{99m}Tc-HMPAO-labeled leucocyte scan for diabetic foot osteomyelitis in relation to foot part involved and imaging technique**

S. Georga¹, C. Manes², T. Didangelos³, G. Arsos¹; ¹3rd Dept of Nuclear Medicine, Aristotle University Medical School, Papageorgiou General Hospital, THESSALONIKI, GREECE, ²Diabetes Center, Papageorgiou General Hospital, THESSALONIKI, GREECE, ³Diabetes Center, 1st Propedeutic Dept. of Internal Medicine, Aristotle University Medical School, 'AHEPA' Hospital, THESSALONIKI, GREECE.

EP-0973**Concordance between MRI and 99mTc-HMPAO WBCs scan in suspect osteomyelitis: results from a single centre experience**

I. Grassi¹, G. Pontone¹, F. Albertini², C. Orzincolo³, E. Del Giudice¹; ¹Nuclear Medicine Unit, Ospedale degli Infermi, Faenza (Ra), ITALY, ²Infectious Diseases Unit, Ospedale degli Infermi, Faenza (Ra), ITALY, ³Radiology Unit, Ospedale degli Infermi, Faenza (Ra), ITALY.

EP-0974**Does Additional Low Dose Heparin Pre-administration Improve Cardiac Glucose Metabolism Suppression in FDG PET/CT?**

N. L. van der Sluis-van der Zee, A.M. van den Berk, A.M Scholtens; Meander Medical Center, Amersfoort, NETHERLANDS.

EP-0975**An enlarged left adrenal gland is an indirect sign of sepsis in patients referred to FDG PET CT for a suspected or proven infectious disease, even in the absence of any evident infectious focus on PET images**

C. Drouet¹, F. Goehringer², C. Besseau², H. Tissot², C. Manca², P. Marie²; ¹CHU de Besançon, Besancon, FRANCE, ²CHU de Nancy, Nancy, FRANCE.

EP-0976**The presence of elevated C-reactive protein (CRP) and fever during ¹⁸F-FDG-PET/CT increases diagnostic yield in patients with fever of unknown origin**

K. Mulders-Manders, I. Kouijzer, M. Janssen, A. Simon, C. Bleeker-Rovers; Radboudumc, Nijmegen, NETHERLANDS.



EP-0977

Usefulness of F-18 FDG PET/CT for Detecting Bone Involvement in Patients with Sarcoidosis

A. Georgakopoulos¹, N. Pianou¹, E. D. Manali², L. Kolilekas³, S. A. Papiris², S. N. Chatziioannou^{4,1};

¹Biomedical Research Foundation of the Academy of Athens, Clinical and Translational Research, Nuclear Medicine Division, PET/CT section, Athens, GREECE, ²2nd Pulmonary Medicine Department, "Attikon" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, GREECE, ³7th Pulmonary Medicine Department and Asthma Center, Sotiria Hospital for Chest Diseases, Athens, GREECE, ⁴2nd Radiology Department, "Attikon" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, GREECE.

EP-0978

Comparative Effectiveness Of 18F-FDG PET-CT And CT Angiography For The Evaluation Of Large-Vessel Vasculitis

M. Moragas, M. Andreu, M. Monteagudo, A. Caresia, J. Martin, A. Rodríguez, C. Diaz, J. Oliva, L. Bernà; Hospital Parc Tauli, Sabadell (Barcelona), SPAIN.

EP-0979

Effectiveness of long-term chronic suppressive antibiotic therapy in chronic joint infection: follow-up by 99mTc-HMPAO-labeled leukocyte scan

M. Ricci, M. Pontico, G. A. Follacchio, M. De feo, F. Monteleone, G. De vincentis, G. Ceccarelli, M. Liberatore; Università di Roma "Sapienza", ROMA, ITALY.

EP-0980

Diagnostic value of Tc99m- Ubiquidine in differentiation between osteomyelitis and bone tumors

K. Aryana^{1,2}, N. Ayati¹, M. Norouzi¹; ¹Mashhad university of medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear medicine research center, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0981

^{99m}Tc-sulesomab and ^{99m}Tc-nanocolloid bone marrow imaging in prosthetic joint infection

P. Gouveia, A. Sousa, R. Sousa, R. Teixeira, R. Brito, I. Amorim, M. Oliveira, A. Silva, R. Castro; Centro Hospitalar do Porto, Porto, PORTUGAL.

EP-0982

Diagnostic Accuracy of ¹⁸F-FDG PET in Evaluating Disease Activity in Patients with Chronic Inflammatory Bowel Disease: a Bivariate Meta-analysis

G. Treglia¹, R. Sadeghi², A. Viccaro¹, B. Muoio³, L. Giovannella¹; ¹Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND, ²Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ³Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona, SWITZERLAND.

EP-0983

Quantitative ¹²³I-SAP scintigraphy in the follow-up of AL Amyloidosis patients

R. W. J. van Rheenen, M. Hazenberg, R. A. J. O. Dierckx, A. W. J. de Boer, J. M. G. Geurts, NETHERLANDS

EP-0984

Valence of F-18-FDG-PET/CT in diagnostics of inflammatory foci

L. Knappe, F. A. Verburg, M. Luster, D. Librizzi; Philipps-Universität Marburg, Marburg, GERMANY.

EP-0986

Multimodal imaging in cardiovascular infections: the case of the infectious complications after Bentall procedure

R. Boni¹, A. Bruno¹, E. Lazzeri², M. Sollini³, R. Zanca², A. Marciano², A. De La Fuente², R. Doria⁴, F. Menichetti⁴, C. Tascini⁴, M. Ferrari⁵, P. Erba²; ¹ASST Papa Giovanni XXIII- Nuclear Medicine, Bergamo, ITALY, ²Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technology in Medicine, University of Pisa, Pisa, ITALY, ³Nuclear Medicine Humanitas University, Rozzano, Milan, ITALY, ⁴Division of Infectious Diseases, University Hospital of Pisa, Pisa, ITALY, ⁵vascular Surgery, University Hospital of Pisa, Pisa, ITALY.

EP-0987

Respective Role of 18F-FDG PET/CT and ^{99m}Tc-HMPAO-WBC SPECT/CT in Patients With Suspected Prosthetic Material-Associated Cardiovascular Infections

K. Šenica¹, D. Šfiligoj Planjšek¹, A. Sočan¹, M. Logar², J. Kšela³, L. Ležaič¹; ¹Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ³Department of Cardiovascular Surgery, University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

e-Poster not submitted



EP-0988**Evaluation of 18-FDG PET/CT in diagnosis of large vessel vasculitis**

A. Bakos¹, Z. Besenyi¹, S. Urbán¹, R. Hemelein², L. Kovács², L. Pávics¹; ¹Department of Nuclear Medicine University of Szeged, Szeged, HUNGARY, ²Department of Rheumatology University of Szeged, Szeged, HUNGARY.

EP-0991**Diagnosing diabetic foot infection: efficiency of radiological methods**

V. Udodov¹, M. Zorkaltsev¹, V. Zavadovskaia¹, M. Zamyshevkaia¹, E. Grigoriev², A. Kurazhov¹; ¹Siberian State Medical University, Tomsk, RUSSIAN FEDERATION, ²Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-0992**Qualitative and semiquantitative [18F]FDG-PET/CT analysis in patients with IE: a strategy to enhance specificity?**

R. Boni¹, A. Bruno¹, E. Lazzeri², M. Sollini³, R. Zanca², A. Marciano², A. De La Fuente², U. Conti⁴, R. Doria⁵, F. Menichetti⁵, A. Cataldi², P. Erba²; ¹ASST Papa Giovanni XXIII-Nuclear Medicine, Bergamo, ITALY, ²Nuclear Medicine, Department of Translational Research and New Technologies in Medicine, Pisa, ITALY, ³Humanitas University, Milan, ITALY, ⁴Cardiology Unit, University Hospital of Pisa, Pisa, ITALY, ⁵Division of Infectious Diseases, University Hospital of Pisa, Pisa, ITALY.

EP-0993**The role of FDG-PET/CT in tuberculosis**

E. Llinares Tello¹, M. Cortés-Romera¹, J. Robles-Barba¹, M. Santin-Cerezales², J. Rodríguez-Rubio¹, A. Sabaté-Llobera¹, J. Vercher-Conejero¹, P. Notta¹, L. Rodríguez-Bel¹, N. Calvo-Malvar¹, C. Gámez-Cenzano¹; ¹PET/CT Unit. Department of Nuclear medicine. IDI. Hospital U. de Bellvitge-IDIBELL, Barcelona, SPAIN, ²Department of Infectology/Internal Medicine. Hospital U. de Bellvitge-IDIBELL. L'Hospitalet de Llobregat (Barcelona). Spain., Barcelona, SPAIN.

EP-75 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Musculoskeletal (Benign)****EP-0994****Evaluation of Kinetic Parameters of Three-phase Bone Scintigraphy of The Hip Joints**

P. Korol^{1,2}, M. Tkachenko², V. Bondar¹; ¹Clinical City Hospital #12, Kiev, UKRAINE, ²A.A. Bohomolets National Medical University, Kiev, UKRAINE.

EP-0995**Heterotopic ossification in Intensive Care Unit patients imaged with bone scan**

C. Sioka, E. Konstanti, K. Papadimitropoulos, A. Papadopoulos, V. Ragos, X. Xourgia, V. Koulouras, A. Fotopoulos; University Hospital of Ioannina, Ioannina, GREECE.

EP-0996**The value of SPECT-CT in the evaluation of pain after total ankle arthroplasty**

J. Mertens¹, T. Lootens², J. Vercruyse³, B. Van Den Bossche¹, F. Temmerman¹, B. Lambert¹; ¹Department of Nuclear Medicine, Maria Middelaes Hospital, Ghent, BELGIUM, ²Department of Orthopaedic Surgery and Traumatology, Maria Middelaes Hospital, Ghent, BELGIUM, ³Department of Radiology, Maria Middelaes Hospital, Ghent, BELGIUM.

EP-0997**Bone SPECT in lumbar facet syndrome. Assessment of a four point scale**

F. Medina-Romero, Sr., A. Diaz-Silván, T. Rodríguez-Méndez, I. Cabrera-Veloz, A. Alonso-De León, M. Gonzalez-Díaz, M. Gómez-R. Bethencourt, M. Gonzalez-Soto, M. Lara-Martinez; Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN.

EP-0998**SPECT/CT Imaging in Fibrous Dysplasia**

D. Muñoz¹, C. Fernández¹, K. Bayardo^{1,2}, A. Zamora¹, M. Musetti¹, M. Ramírez¹, R. Ferrando^{1,2}; ¹Clinics Hospital, University of the Republic, Montevideo, URUGUAY, ²Ferrari Ferrando Páez Nuclear Medicine Clinic, Montevideo, URUGUAY.

EP-0999**Value Of SPECT - CT With HDP 99MTC In The Diagnosis Of Bone Pathology In Feet - Ankles**

C. Mena Melgar, A. Herrero Muñoz, C. Sandoval Moreno, M. Balsa Bretón, M. Garcia Alonso, L. Castillejos Rodriguez, A. Ortega Valle, C. Paniagua Correa, F. Penin Gonzalez; Hospital Universitario Getafe, Getafe, SPAIN.

EP-1000**Paget Disease and Bone Scintigraphy: an 8-Year Single-Center Experience**

S. Diodato, A. Matti, R. Bonfiglioli, L. Zanoni, M. Levorato, S. Fanti; S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.



**EP-1001****The value of 99m Tc bone scintigraphy in detecting a low grade infection of a total hip or knee arthroplasty**

C. Schlenkhoff, Jr.^{1,2}, P. Mantovani¹, T. Randau^{1,3}, F. Gärnter^{1,2}, M. Essler^{1,2}; ¹University Bonn, Bonn, GERMANY, ²Nuclear medicine, University Bonn, GERMANY, ³Orthopaedics and Trauma Surgery, University Bonn, GERMANY.

EP-1002**Assessment of relative uptake of mandibular condyles in a normal population**

A. Fernandes¹, T. Faria¹, P. Coelho², A. Oliveira¹, J. Pereira¹; ¹Hospital de São João, Porto, PORTUGAL, ²Universidade Fernando Pessoa, Porto, PORTUGAL.

EP-1003**Technetium-99m HDP SPECT/CT evaluation of persistent and recurrent pain post lumbar spine fusion**

K. Al Riyami^{1,2}, S. Voo^{3,1}, J. Bomanji¹; ¹UCLH, London, UNITED KINGDOM, ²SQUH, Muscat, OMAN, ³Maastricht University, Maastricht, NETHERLANDS.

EP-1004**Review of bone scan imaging in Bertolotti syndrome**

F. Medina Romero, A. Díaz-Silván, T. Rodríguez-Méndez, I. Cabrera-Veloz, A. Alonso-De León, M. González-Díaz, M. Gómez-R. Bethencourt, M. Gonzalez-Soto, M. Lara-Martinez; Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN.

EP-1005**Predictive value of 18F-NaF PET/CT in the assessment of osteoporosis: comparison with Dual-energy X-ray Absorptiometry (DXA)**

S. Haim¹, R. Zakavi², L. Imamovic¹, M. Beheshti¹, A. Rezaee¹, B. Saboury³, A. Alavi³, W. Langsteger¹, M. Beheshti¹; ¹PET-CT Center Linz, St. Vincent's Hospital, Linz, AUSTRIA, ²Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ³Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.

EP-1006**Scintigraphic Assessment Of Pedicular Screw Loosening In Patients With Spinal Arthrodesis**

J. Sabater-Sancho, A. Amr-Rey, R. Díaz-Expósito, Sr., I. Casáns-Tormo, J. Orozco-Cortés, V. López-Prior; Servicio De Medicina Nuclear. Hospital Clínico Universitario De Valencia, Valencia, SPAIN.

EP-1007**Mandibular Condylar Hyperplasia. Diagnosis And Follow-Up By Bone SPECT And SPECT/CT**

A. Amr-Rey¹, I. Casáns-Tormo¹, M. Puche-Torres², A. Sada-Malumbres², R. Díaz-Expósito¹, J. Sabater-Sancho¹, J. Orozco-Cortés¹, V. López-Prior¹; ¹Nuclear Medicine. University Clinic Hospital, Valencia, SPAIN, ²Maxillofacial Surgery. University Clinic Hospital, Valencia, SPAIN.

EP-76 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Imaging Guided Surgery (Benign)****EP-1008****Value of the pre-iodine ablation thyroglobulin serum levels in predicting remission in differentiated thyroid cancer**

H. Boudriga¹, M. Ben Fredj², M. Ben Rejeb³, A. Ezzine², S. Mensi², M. Guezguez²; ¹Laboratory of medical imaging, LR12ES06 Monastir university, Monastir, TUNISIA, ²University hospital of Sahloul, Nuclear medicine department, Sousse, TUNISIA, ³University hospital of Sahloul, department of prevention and safety of care, Sousse, TUNISIA.

EP-1009**Decrease of the rate of affected margins in non palpable breast lesions with I125 Radioguided Seed Localization technique**

O. Ajuria Illarramendi, M. Rioja Martin, A. Santos Carreño, P. Paredes Rodriguez, A. Puerta Vicente, J. Vilar Tabanera, J. Ocaña Jimenez, J. Castro Beiras; Hospital Ramon y Cajal, madrid, SPAIN.

EP-1010**Radiotracer-guided localization for endoscopic resection of small and subcentimetric parathyroid nodules**

P. K. Rehm, J. Jahjah, L. Flors; University of Virginia Health System, Charlottesville, VA, UNITED STATES OF AMERICA.

EP-1011**Feasibility of portable gamma camera imaging in intraoperative radioguided parathyroid adenoma identification**

Z. Koç, P. Özcan Kara, A. Dağ, M. Berkeşoğlu; Mersin University Hospital, Mersin, TURKEY.

EP-1012**Radioguided surgery for primary hyperparathyroidism by evolved protocol from SPECT and portable gamma camera to SPECT CT and hybrid portable gamma camera**

J. Orozco Cortés, Sr.¹, R. Díaz-Expósito¹, S. Vidal Sicart², N. Sanchez Izquierdo², D. Fuster², N. Cassinello Fernandez¹, O. Vidal², R. Jover¹, F. Lomeña², I. Casans Tormo¹; ¹Hospital Clinic Valencia, Valencia, SPAIN, ²Hospital Clinic Barcelona, Barcelona, SPAIN.

EP-1013**Ultrasmall gold quantum clusters intrinsically labeled with ⁶⁴Cu for in vivo PET/NIRF imaging of lymph nodes**

H. Zhang, J. Yang, A. Ahad, W. Weber, M. Kircher; Memorial Sloan-Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-77 during congress opening hours, e-Poster Area**Conventional & Specialised Nuclear Medicine: Miscellaneous****EP-1014****The Role of SPECT/CT for diagnosis of thoracic splenosis**

M. Totaro, G. Petracca Ciavarella, M. Guerra, M. Scarale, M. Mangiacotti, V. Frusciante, Sr.; Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, ITALY.

EP-1015**The IAEA Quality Management Audit of Nuclear Medicine Facilities: Analysis of Results**

R. Núñez Miller¹, M. Dondi¹, L. Torres², M. Marengo³, T. Masardo⁴, E. Mishani⁵, A. Van Zyl Ellmann⁶, K. Solanki⁷, A. Bishoff-Delaloye⁸, E. Estrada Lobato¹, F. Giammarile¹, D. Paez¹, T. Pascual¹; ¹Division of Human Health - IAEA, Vienna, AUSTRIA, ²Centro de Investigaciones Clinicas, La Habana, CUBA, ³Azienda Ospedaliera S. Orsola-Malpighi, Bologna, ITALY, ⁴Hospital Clinico Universidad de Chile, Santiago, CHILE, ⁵Cyclotron Unit/Nuclear Medicine Department, Hadassah Univeristy Hospital, Jerusalem, ISRAEL, ⁶Tigerberg Hospital, Western Cape, SOUTH AFRICA, ⁷Addenbrooke's Hospital/ Cambridge University Hospitals, Cambridge, UNITED KINGDOM, ⁸CHUV Lausanne, Lausanne, SWITZERLAND.

EP-1016**Kinetic analysis using asialoglycoprotein receptor scintigraphy with Tc-99m GSA dynamic SPECT/CT for assessment of hepatic function**

Y. Fukuda¹, T. Sanomura¹, H. Okuda¹, Y. Yamamoto¹, K. Okano², N. Kudomi¹, Y. Nishiyama¹; ¹Kagawa University, Kita-gun Kagawa, JAPAN, ²Kagawa University Department of Gastrointestinal Surgery, Kita-gun Kagawa, JAPAN.

EP-1017**The Value of Clinical Audit Beyond Measuring Performance: Evidence from the National NHS England PET-CT Clinical Audit Programme**

P. Ross¹, J. Armstrong², S. Albon², W. Wong³; ¹Birkbeck University of London, London, UNITED KINGDOM, ²Alliance Medical Limited, London, UNITED KINGDOM, ³Mount Vernon hospital, Northwood, UNITED KINGDOM.

EP-1018**Optimized Lymphoscintigraphy for Staging of Lymphedema of the Lower Extremities: An Attempt to Clinico-pathologic Staging**

M. A. A. Mostafa; Mohamed Bin Abdelaziz Hospital, Riyadh, SAUDI ARABIA.

EP-1019**Intraperitoneal Scintigraphy in the Diagnosis of Pleural Effusion in Peritoneal Dialysis**

I. Latorre Agraz, B. Cueto Cañadas, D. Balaguer Muñoz, P. Abreu Sánchez, M. D. Reyes Ojeda, T. Mut Dólera, M. C. Plancha Mansanet, E. Caballero Calabuig, M. B. Vizcaíno Castillo; Hospital Dr. Peset, Valencia, SPAIN.

EP-1020**Lymphoscintigraphic findings in patients with lipedema**

P. Olivan-Sasot, C. Ruiz-Llorca, I. Forner-Cordero, J. Muñoz-Langa, A. Yepes-Agudelo, V. Vera-Pinto, L. Agudelo-Cifuentes, B. Martínez-Sanchís, P. Bello-Arques; Hospital Universitario y Politécnico La Fe, Valencia, SPAIN.

EP-1021**Possible substitutes for stable iodine tablet in aim of suppression of radioactive iodine uptake**

T. Hongyo, Sr., M. Namise, Y. Sawai, K. Yanamoto; Osaka University, Suita, JAPAN.

e-Poster not submitted



Technologist e-Poster Walks

E-TPW1 Tuesday, October 24, 2017, 08:00 - 09:30,
e-Poster Walk Area, Level 2,
between Suite B and Suite C, Screen 6

Technologist e-Poster Session 1

Chairs: A. Santos (Lisbon, PORTUGAL)
A. Geão (Lisbon, PORTUGAL)

E-TPW01

Effects of ROI definition and reconstruction method on Standardized Uptake Value

K. Škalič, D. Bogovič, S. Škalič, N. Kusturič, S. Dražumerič; Institut of Oncology, Ljubljana, SLOVENIA.

E-TPW02

The Effects of Different Reconstruction Algorithms on 18F-FDG PET/CT Images

Y. Parlak, D. Goksoy, G. Mutevelizade, G. Gumuser, E. Sayit; Celal Bayar University, Manisa, TURKEY.

E-TPW03

Role of Post reconstruction Gaussian filter in PET scan

S. Tayal, A. Gandhi; Kailash Cancer Hospital & Research Centre, Vadodara, India.

E-TPW04

Discovery IQ 4R- Optimization of parameters of acquisition and reconstruction in clinical 18F-FDG PET-CT studies

H. Paninho¹, D. Faria^{1,2,3}, S. Francesco¹, J. Fernandes^{2,3}, J. Oliveira^{2,3}; ¹ESSUA-Health School of University of Aveiro, Aveiro, PORTUGAL, ²HPP-Medicina Molecular, SA, Porto, PORTUGAL, ³Lenitudes Medical Center & Research, SGPS, SA, Santa Maria da Feira, PORTUGAL.

E-TPW05

Studies on Scattered Radiation out of Field of View and Effect of Scatter Correction in 3D brain PET

M. Honda¹, Y. Sakuragi², S. Abe², N. Fujita², K. Kunimoto¹, T. Odagawa¹, K. Kato¹; ¹Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Department of Radiological Technology, Nagoya University Hospital, Nagoya, Japan, Nagoya, JAPAN.

E-TPW06

The measurement accuracy of analyzing software for PET/CT

S. Matsuzawa¹, S. Abe², Y. Sakuragi², N. Fujita², M. Honda¹, K. Kunimoto¹, R. Mukumoto¹, T. Odagawa¹, K. Kato¹; ¹Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Nagoya University Hospital, Nagoya, JAPAN.

E-TPW07

Influence of Reconstruction Parameters on ¹⁸F-FDG PET Activity Quantification in Small Objects: a Phantom Study

X. Liang¹, S. Han¹, X. Hu¹, P. Xiao¹, Q. Xie¹; ¹Huazhong University of Science and Technology, Wuhan, CHINA, ²Ydata Technology Co., Ltd., Ezhou, CHINA.

E-TPW08

Activity Quantification of ¹⁸F-FDG in the Presence of an Iodinated Contrast Medium

A. Svensson¹, B. Olsson¹, J. Oddstig², C. Hindorf², L. Jönsson^{2,3}; ¹Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, SWEDEN, ²Radiation Physics, Skåne University Hospital, Lund, SWEDEN, ³Department of Medical Radiation Physics, Lund University, Lund, SWEDEN.

E-TPW09

Clinical Trial of PET VCAR and ROVER

N. G. Wolff¹, S. Parameswaran²; ¹Sydvestjysk Sygehus - Department of Radiology and Nuclear Medicine, Esbjerg, DENMARK, ²Odense Universitetshospital - Department of Nuclear Medicine, Odense, DENMARK.

E-TPW10

Studies on the crosstalk rate in simultaneous myocardial imaging with dual radionuclides using cardiac focusing collimator

K. Kunimoto¹, S. Abe², N. Fujita², M. Honda¹, S. Matsuzawa¹, R. Mukumoto¹, T. Odagawa¹, K. Kato¹; ¹Department of Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Department of Radiological Technology, Nagoya University Hospital, Nagoya, JAPAN.



E-TPW11**Nal(Tl) and CZT-camera based detectors: comparison of image parameters**

M. J. F. Sousa¹, D. Vieira¹, C. Alves², L. Santos², L. Olo², P. Oliveira², A. Nunes², F. Godinho^{3,4}, G. Cantinho^{3,4}, L. F. Metello^{1,5}; ¹ESS-IPP, Nuclear Medicine Dept, Porto, PORTUGAL, ²DCC – Dr. Campos Costa, Nuclear Medicine Dept, iCUF Institute, Porto, PORTUGAL, ³Atomical, Nuclear Medicine Dept., Lisbon, PORTUGAL, ⁴Univ. Hosp. of Santa Maria, Nuclear Medicine Dept. – University of Lisbon, Lisbon, PORTUGAL, ⁵IsoPor–Azores, Nuclear Medicine Dept., Angra do Heroísmo, Azores, PORTUGAL.

E-TPW12**Impact of segmentation-based enhancement on conjugated gradient reconstruction system in bone SPECT imaging**

K. Okuda, S. Fujii, S. Sakimoto, T. Ida, S. Moriyama; Tottori University Hospital, Tottori, JAPAN.

E-TPW13**Scintigraphy of the nasal cavity and maxillary sinuses**

M. M. Joergensen; Rigshospitalet, Copenhagen, DENMARK.

E-TPW14**A novel automatic gamma function fitting program of the time activity curve for the input function determination in the ^{99m}Tc-ECD non-invasive quantification method**

Y. Tanaka¹, Y. Uchiyama², A. Takaki³, S. Ito²; ¹Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, ²Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN, ³Teikyo University, Omuta, JAPAN.

E-TPW15**Examination of quantitative bone SPECT images by digital phantom using the anatomical normalization template**

A. Kikuchi¹, G. Okuyama¹, S. Kumazawa¹, M. Kitama¹, K. Miwa², K. Kawakami³; ¹Hokkaido, Sapporo, JAPAN, ²Tochigi, Ootawara, JAPAN, ³Tokyo, Cyuouku, JAPAN.

E-TPW16**An exploitation of the time range for SPECT to calculate the GEP**

Y. Wang, M. Liu; Department of nuclear medicine Fudan University, Shanghai, CHINA.

E-TPW17**Evaluation of SPECT/CT Image Applying to Three-Dimensional Printing Phantom**

J. Lee¹, H. Park²; ¹Songho College, Gangwon-do, KOREA, REPUBLIC OF, ²Shingu College, Seongnam, KOREA, REPUBLIC OF.

E-TPW18**Quality control on DIGIRAD Solid state X-ACT camera: the role of the technologist**

S. Sustar, S. Rep, B. Trebec, B. Simonic, I. Slodnjak, L. Lezaic; Department of Nuclear Medicine, Ljubljana, SLOVENIA.

E-TPW19**SeHCAT measurements of bile acid retention using a collimated gamma camera**

M. Lorentzson, P. Fransson, A. Larsson; Umeå University, Umeå, SWEDEN.

E-TPW20**Comparison of different Attenuation Correction methods in DaTscan examination**

F. H. Gomes¹, M. F. Soares¹, F. Brolund², A. Danielsson³, L. Vieira¹; ¹Lisbon School of Health Technology, Lisbon, PORTUGAL, ²Karolinska Institutet, STOCKHOLM, SWEDEN, ³Karolinska Universitetssjukhuset Solna, STOCKHOLM, SWEDEN.

E-TPW2

**Tuesday, October 24, 2017, 08:00 - 09:30,
e-Poster Walk Area, Level 2, Foyer C, Screen 7**

Technologist e-Poster Session 2

*Chairs: C. Terwinghe (Leuven, BELGIUM)
S. Šuštar (Ljubljana, SLOVENIA)*

E-TPW21**Accuracy of the F-18 Calibration Factor in a Capintec Calibrator**

S. Taştan¹, S. Tanriverdi¹, E. Ozdogan¹, N. O. Kucuk²; ¹eczacibasi Monrol Nuclear Products, Ankara, TURKEY, ²Ankara University, Ankara, TURKEY.

E-TPW22**Resurrection and return to the technological cycle of enriched Molybdenum-98 from liquid waste produced by technetium-99m generators**

A. Rogov, E. Stasyuk, E. Nesterov, E. Ilina, V. Sadkin, L. Larionova; National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

e-Poster not submitted



E-TPW23**Determination of radioquimic purity (RCP) of 99mTc-Tektrotyd with an alternative chromatographic method**

E. López Martínez, J. L. Gómez Perales, E. Ariza Cabrera, F. Martín Estrada; SAS, Algeciras, SPAIN.

E-TPW24**Comparison between two different methods for radionuclide purity determination in the first eluate of a 99mTc/99mTc generator**

A. Bassan, M. C. Marzola, C. Secchiero, A. Patrian, S. Cittadin, T. Tinazzo, A. Ferretti, A. Massaro, S. Chondrogiannis, D. Rubello; Nuclear Medicine - PET/CT centre, Santa Maria della Misericordia Hospital of Rovigo, Rovigo, ITALY.

E-TPW26**Action protocol in breaking the cold chain in cold kits thermolabile**

E. López Martínez, E. Ariza Cabrera, M. Cardoso Rodríguez; SAS, Algeciras, SPAIN.

E-TPW27**Creation of a labeled technetium-99m colloid drug for the detection of guarding lymph nodes**

A. Rogov¹, E. Stasyuk¹, E. Nesterov¹, E. Ilina¹, V. Sadkin¹, L. Larionova¹, V. Chernov^{2,3}; ¹National Research Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ²Tomsk Cancer Research Institute, Tomsk, RUSSIAN FEDERATION, ³National Research Tomsk Polytechnic University, Tomsk, AUSTRIA.

E-TPW28**A method of DOTA-SP90 with ¹¹¹In labeling, has stability and potential for breast cancer imaging**

S. Lee, S. Lo, Y. Huang, M. Chen, M. Li, C. Chang; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

E-TPW29**Dynamic in vivo molecular imaging of ¹⁸F-INER1577 in transgenic mice**

M. Li¹, C. Shiu², C. Feng¹, H. Chang¹; ¹Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan City, TAIWAN, ²PET Center, National Taiwan University Hospital, Taipei, TAIWAN.

E-TPW30**The Effectiveness of Heat-Denatured Red Blood Cell (RBC) SPECT/CT Study for Patient Management When the Pathology is Unclear: A Pictorial Case Series**

M. Carmody, M. A. Vartzokas, S. Yusuf, W. Svensson; Imperial College and Healthcare NHS Trust, London, UNITED KINGDOM.

E-TPW31**Methods of time efficiency improvement following relocation to a new department**

W. Heegaard¹, B. Hoyer Mathiasen², P. Holdgaard¹; ¹Department of Nuclear Medicine, Vejle Hospital, Vejle, DENMARK, ²Department of Procurement & Clinical Engineering, Central Denmark Region, Aarhus, DENMARK.

E-TPW32**Will the new PET radiopharmaceuticals overtake Myocardial Perfusion Imaging in the diagnosis of CAD?**

R. F. S. Moreira, A. I. P. Queiroz, G. Paixao, C. Soares; Queen Elizabeth Hospital Birmingham, UK, Birmingham, UNITED KINGDOM.

E-TPW33**Planning of multi-tracer session for clinical and research activity in a PET center**

M. Scarlattei, Sr., S. Migliari, A. Sammartano, G. Baldari, C. Cidda, G. Serreli, C. Ghetti, O. Ortenzia, L. Ruffini; AOU Pr, Parma, ITALY.

E-TPW34**Impact of different acquisition and reconstruction protocols on image quality in [⁶⁸Ga]PSMA PET/MRI**

S. Milachowski¹, A. Kanzog², F. Büther², T. Allkemper¹, L. Stegger²; ¹Institute of Clinical Radiology, University Hospital Muenster, Muenster, GERMANY, ²Department of Nuclear Medicine, University Hospital Muenster, Muenster, GERMANY.

E-TPW35**Assessment Ga-68 PSMA progress in patient with prostate cancer**

R. R. Farshbaf Aghaenejad; University Tehran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

E-TPW36**Gallium-67 Delayed Imaging in the Evaluation of Sarcoidosis: Is It Really Necessary?**

J. Patrino^{1,2}, D. B. Faria^{1,2,3}, T. S. Vieira^{1,2}, D. Sousa^{1,2}, F. A. Silva^{1,2}, J. M. P. Oliveira^{1,2}; ¹HPP - Medicina Molecular SA, Porto, PORTUGAL, ²Lenitudes Medical Center & Research, Santa Maria da Feira, PORTUGAL, ³School Of Health Sciences - University of Aveiro, Aveiro, PORTUGAL.

**E-TPW37****Copper-64 and its role in Theranostics and Nuclear Medicine**

*M. J. Correia*¹, *P. Costa*¹, *S. Sequeira*², *A. Nunes*³, *L. Olo*³, *C. Alves*³, *L. F. Metello*^{1,4}; ¹Nuclear Medicine Department, ESS-Porto, Porto, PORTUGAL, ²Nuclear Medicine Department, IPOFG, Porto, PORTUGAL, ³Nuclear Medicine Department, DCC – Dr. Campos Costa – iCUF, Matosinhos, Porto, PORTUGAL, ⁴Nuclear Medicine Department, IsoPor – Azores, Angra do Heroísmo, PORTUGAL.

E-TPW38**Optimal collimation for ²²³Ra planar imaging**

*T. Otani*¹, *Y. Kunikane*², *S. Takashi*², *R. Bando*², *A. Fujita*², *M. Amano*², *Y. Fukunaga*¹, *H. Otsuka*¹, *H. Miyoshi*¹; ¹Tokushima University, Tokushima, JAPAN, ²Tokushima University Hospital, Tokushima, JAPAN.

E-TPW39**Radium-223 In The Treatment Of Metastatic Castration- Resistant Prostate Cancer**

*C. Vazzana*¹, *S. Morano*², *A. Di Lascio*³, *C. Grana*⁴, *M. Chinol*⁴; ¹Veneto Oncology Institute - IOV IRCCS, Padova, ITALY, ²Hospital Bianchi Melacrino Morelli, Reggio Calabria, ITALY, ³Hospital A. Cardarelli, Napoli, ITALY, ⁴European Institute of Oncology, Milano, ITALY.

E-TPW40**Half-Time SPECT/CT Acquisition for Targeted Therapy [177Lu--DOTA, Tyr3] Octreotide Imaging**

T. De Sousa, *S. Johnson*, *A. Eccles*, *H. Ahmed*, *V. Lewington*; Guy's and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

E-TPW3 Tuesday, October 24, 2017, 08:00 - 09:30,
e-Poster Walk Area, Level 2, Foyer C,
Room 2.95, Screen 8

Technologist e-Poster Session 3

Chairs: S. Rac (Rijeka, CROATIA)
A. Ghilardi (Bergamo, ITALY)

E-TPW42**Radiation Exposure of Patients During Parathyroid Imaging: Comparison between Dual-Phase 18F-fluorocholine PET/CT, Dual-Phase 99mTc-MIBI SPECT/CT and Planar Subtraction Scintigraphy**

*S. Rep*¹, *M. Mocevar*², *J. Vaupotoc*³, *U. Zdesar*⁴, *K. Zaletel*¹, *L. Lezaic*¹; ¹Department of Nuclear Medicine, Ljubljana, SLOVENIA, ²Oncological Surgery, Oncology Institute, Ljubljana, SLOVENIA, ³Jozef Stefan Institute, Ljubljana, SLOVENIA, ⁴Institute of Occupational Safety, Ljubljana, SLOVENIA.

E-TPW43**The viability of the attenuation CT for calcium scoring**

M. Louwe; Westfriesgasthuis, Hoorn, NETHERLANDS.

E-TPW44**Implication of using cardiac MAR algorithm with regards to the interpretation of infected PM- and ICD wires**

J. Ellingsen, *E. Andersen*, *H. Stokmo*; Oslo University Hospital, Oslo, NORWAY.

E-TPW45**DDS-A, microDDSA and KARI100, what else**

M. Budinsky, *S. Kozakova*; Masaryk Memorial Cancer Institute, Brno, CZECH REPUBLIC.

E-TPW46**Skin Contamination of Nuclear Medicine Staff in NM Departments: preliminary results**

*N. Fernandes*¹, *D. Neves*^{2,1}, *A. Ferrer*², *M. F. Joao*², *A. Araujo*³, *J. Pereira*³, *L. Metello*^{1,4}; ¹ESS – IPP, ATC & Curso Med. Nuclear, Porto, PORTUGAL, ²Diaton S.A. – Leiria, Dept. de Med. Nuclear, Leiria, PORTUGAL, ³Serviço de Med. Nuclear – Hospital de S. Joao, Porto, PORTUGAL, ⁴IsoPor-Azores, Dept. de Med. Nuclear e Imagiologia Molecular, Angra do Heroísmo, I. Terceira – Azores, PORTUGAL.

E-TPW47**Development and Validation of Simple Methods to Reduce Radiation Exposure to Public from FDG PET/CT Patients**

E. Koester, *S. Frye*, *R. Muzaffar*, *M. M. Osman*; Saint Louis University, St. Louis, MO, UNITED STATES OF AMERICA.

E-TPW48**Quantification of technegas continuation**

K. S. Rømer, *N. S. Larsen*, *M. N. Lonsdale*, *L. D. L. Duchstein*; Bispebjerg Hospital, Copenhagen, DENMARK.

E-TPW49**Evaluation of Radiation Exposure to Nurse on Nuclear Medicine examination by Use Radioisotope**

J. Jeong, *C. Lee*, *Y. Seo*, *H. Choi*, *Y. Kim*, *Y. Kim*, *W. Won*; National Cancer Center, Goyang-si, KOREA, REPUBLIC OF.

E-TPW50**Dose Rates from the Patient in Conventional Nuclear Medicine: "To Void or Not to Void", that is the Question!**

A. Cunha¹, D. Neves^{1,2}, R. Oliveira³, A. Nunes⁴, C. Alves⁴, L. Santos⁴, L. F. Metello^{1,5}; ¹ESS – IPP, ATC&CMN, Rua Dr. Antonio Bernardino de Almeida, 400, 4200 – 072, Porto, PORTUGAL, ²DIATON S.A. – Leiria, Dept. de Med. Nuclear, Rua de Olhalvas, Pousos, 2410-197, Leiria, PORTUGAL, ³FEUP – UP, Dept de Estatística, Rua Dr. Roberto Frias, 4200 – 465, Porto, PORTUGAL, ⁴DCC – Dr. Campos Costa, Dept. de Med. Nuclear, Instituto CUF, Rua Fonte das Sete Bicas, 170, 4460 – 188, Matosinhos, PORTUGAL, ⁵IsoPor-Azores, Dept de Med. Nuclear e Imagiologia Molecular, Angra do Heroísmo, I. Terceira, Azores, PORTUGAL.

E-TPW51**Optimization of the exposure to the extremities of the technologists in nuclear medicine based on daily routine workflow**

L. Vojo, K. Zeimpekis; University Hospital Zurich, Zurich, SWITZERLAND.

E-TPW52**The predicting value of ¹⁸F-FDG PET/CT imaging of radioactive iodine treatment efficacy in patients with bone metastasis from differentiated thyroid cancer**

D. Wang, C. Ma; Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, CHINA.

E-TPW53**Use of 4D-PET/CT in the Radiotherapy Treatment Planning of the Retroperitoneal Lesions Near the Diaphragm**

L. Pavanello, F. Sciacca, M. Cuffante, M. Cucca, D. Grigolato, L. J. ... M. Ferdeghini; AOUI Verona, Verona, IT

E-TPW54**Developing an Educational Strategy for Hybrid Imaging Practitioners: A Tailored Approach**

R. Menezes; Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, UNITED KINGDOM.

E-TPW55**In Search of Minimum Time-Interval Between the Two Continuous FDG-PET Scans of The Same Subjects**

S. Han¹, X. Liang¹, X. Hu¹, L. Wan², P. Xiao¹, Q. Xie¹; ¹Huazhong University of Science and Technology, Wuhan, CHINA, ²Raydata Technology Co.,Ltd, Ezhou, CHINA.

E-TPW56**Laser Scanning And Computed Tomography 3D: Application In The Skin Surface Modelling Of PIXI Phantom Head**

E. Sousa¹, L. Vieira¹, D. Costa², D. C. Costa³, R. Parafita³, R. Parafita³, M. A. R. Loja²; ¹Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, ²Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, ³Fundação Champalimaud, Lisboa, PORTUGAL.

E-TPW57**Optimization of parameters for SPECT/CT studies: The impact of acquisition parameters on data quality using quantitative SPECT reconstruction**

B. Mirocha, M. Benke, D. Dokudowicz, A. Sackiewicz, M. Wojewódzka, M. Dedecjus; Maria Skłodowska Curie Memorial Cancer Centre and Institute, Warsaw, POLAND.

E-TPW58**Optimal timing of Furosemide administration for ¹⁸F FDG PET CT Acquisition of pelvic tumors**

G. A. C. van der Ven – van Vroenhoven, E. Leautaud-Diks, I. Verhaak-de Kok, H. J. Pijpers; Instituut Verbeeten, Tilburg, NETHERLANDS.

E-TPW59**FDG PET/CT artifacts - daily practice aspects related to a technologist perspective**

M. I. Larg, C. Pestean, M. Crisan, E. Barbus, D. Piciu; "Ion Chiricuta" Institute of Oncology, Cluj-Napoca, ROMANIA.

E-TPW60**Design and Evaluation of the Reconstruction for a dedicated breast PET/CT**

M. Sun, Y. ZHANG, L. ... an University ShangHai cancer center, CHINA.



E-TPW4 Tuesday, October 24, 2017, 08:00 - 09:30,
e-Poster Walk Area, Level 2,
between Foyer A and Foyer C, Screen 9

Technologist e-Poster Session 4

Chairs: L. Camoni (Brescia, ITALY)
N. Eecloo (Leuven, BELGIUM)

E-TPW61

Residual Activity Correction Successfully Adjusts Myocardial Blood Flow Measurements in Time-efficient ¹³N-ammonia Myocardial Perfusion PET/CT

P. A. Doodeman, S. V. Lazarenko, F. M. van der Zant, M. Wondergem, R. J. J. Knol; Northwest Clinics Alkmaar, Alkmaar, NETHERLANDS.

E-TPW62

Left ventricular volumes and EF measured with ¹³N-ammonia PET/CT varies substantially with the software package used for analysis

V. S. Barten-Bruin^{1,2}, S. V. Lazarenko^{1,2}, L. C. D. Zaat¹, F. M. van der Zant^{1,2}, M. Wondergem^{1,2}, R. J. J. Knol^{1,2}; ¹Department of Nuclear Medicine, Northwest Clinics, Alkmaar, NETHERLANDS, ²Cardiac Imaging Division Alkmaar, Alkmaar, NETHERLANDS.

E-TPW63

Comparison of MPI SPECT/CT scans acquired with LEHR collimator and reduced time IQ-SPECT system

S. Ferreira¹, P. Begley², M. Jessop², A. Aldous³, N. Eftychiou², N. Singh², S. Dizdarevic², E. Sousa¹; ¹Lisbon School of Health Technology, Polytechnic Institute of Lisbon, Lisbon, PORTUGAL, ²Brighton and Sussex University Hospitals, Brighton, UNITED KINGDOM, ³North Cumbria University Hospitals, Cumbria, UNITED KINGDOM.

E-TPW64

Motion reduction activities in patients undergoing myocardial perfusion SPECT with the Discovery NM 530c(D530c)

D. Lee, W. Choi, W. Jung; Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

E-TPW65

The washout rate and the heart to mediastinum ratio of ¹²³I-beta-methyl-iodophenyl pentadecanoic acid can reflect the severity of myocardial damage

T. Iimori¹, H. Miyauchi², K. Sawada¹, T. Umezawa¹, T. Sada¹, Y. Masuda¹, Y. Kuwabara², T. Uno³, Y. Kobayashi²; ¹Department of Radiology, Chiba University Hospital, Chiba, JAPAN, ²Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, JAPAN, ³Department of Diagnostic Radiology and Radiation Oncology, Chiba University Graduate School of Medicine, Chiba, JAPAN.

E-TPW66

A cost effective protocol for increasing patient throughput using a combination of half time imaging with ^{99m}Tc Tetrofosmin and Regadenoson in Stress Myocardial Perfusion Imaging

P. J. Turner, T. Watts, F. Whittingham; The Royal Wolverhampton NHS Trust, Wolverhampton, UNITED KINGDOM.

E-TPW67

Role of F18 Choline PET/CT in Brain Tumors

L. Reiser¹, A. Haroon², Y. Bouchareb², G. Testanara², C. Copland², E. Mckintosh², N. Hartman²; ¹Purdue University College of Pharmacy, West Lafayette, IN, UNITED STATES OF AMERICA, ²Barts Health NHS Trust, St Bartholomew's Hospital, London, UNITED KINGDOM.

E-TPW68

Development of reference values for DaTSCAN semi-quantitative analysis

A. Neves¹, B. Ribeiro¹, M. Correia¹, V. Lameiras¹, E. Pereira^{2,3}, L. Oliveira², E. Carolino⁴, L. Vieira^{5,6}; ¹Nuclear Medicine Degree, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ²NuclearMed, Almada, PORTUGAL, ³Scientific Area of Nuclear Medicine, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ⁴Scientific Area of Mathematics, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ⁵GIReS, Escola Superior de Tecnologia da Saúde de Lisboa/Instituto Politécnico de Lisboa, Lisbon, PORTUGAL, ⁶Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisbon, PORTUGAL.



E-TPW69**Feasibility of an automatic ¹²³I-IMP non-invasive quantitative measurement method for evaluation of regional cerebrovascular reactivity**

T. Tomimatsu¹, D. Koreeda¹, A. Ofuji¹, H. Ohura², A. Takaki³, S. Ito⁴; ¹Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, ²National Organization Saga Hospital, Saga, JAPAN, ³Teikyo University, Ohta, JAPAN, ⁴Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN.

E-TPW70**Fully automatic striatal region of interest setting program using magnetic resonance images for a new 123I-FP-CIT quantification method**

S. Ota¹, Y. Uchiyama², A. Takaki³, S. Ito²; ¹Graduate School of Health Sciences, Kumamoto University, Kumamoto, JAPAN, ²Faculty of Life Sciences, Kumamoto University, Kumamoto, JAPAN, ³Teikyo University, Omuta, JAPAN.

E-TPW71**Clinical Usefulness of [¹⁸F]FC119S PET as an Auxiliary Diagnostic Methods for Dementia**

B. Byun¹, S. Lim¹, K. Lee¹, J. Choi¹, J. Ha¹, S. Park¹, D. Chi²; ¹Korea Institute of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, ²Research Institute of Labeling, Futurechem Co., Ltd, Seoul, KOREA, REPUBLIC OF.

E-TPW72**A Case Study Detailing the Development of a Protocol for the Detection, Diagnosis and Analysis of a Cerebral Spinal Fluid Leak Study**

E. Seal; Queen Elizabeth Hospital Birmingham, Birmingham, UNITED KINGDOM.

E-TPW73**Comparison of Imaging Techniques spect and petct in the pre surgical evaluation of refractory epilepsy**

G. Paixao, A. Queiroz, R. Moreira, C. Soares; Queen Elizabeth Hospital, Birmingham, UNITED KINGDOM.

E-TPW74**Spleen Uptake on Bone Scan after Liver Transplantations**

Y. LIM; Pusan National University Yangsan Hospital, YANG SAN, KOREA, REPUBLIC OF.

E-TPW75**Static Bone Scintigraphy Images of Hands and Feet - How low can we go?**

M. Tayyab, H. Mikkelsen, B. Haddock, U. B. Andersen, C. Suetta, P. Hovind; Rigshospitalet, Glostrup, DENMARK.

E-TPW76**SPECT-MR of Spine for Patients with Back Pain: First UK Experience**

N. Musa, R. Victoria, H. Jan, M. Ahmed, J. Bull, G. Testanara, A. Haroon; Barts Health NHS Trust, St Bartholomew's Hospital, London, UNITED KINGDOM.

E-TPW77**Evaluation of Renal Scarring Using Ultrasound and Renal Scintigraphy**

A. B. Ahmed, IV¹, A. Abdullah²; ¹Ministry of Health, Fujairah, UNITED ARAB EMIRATES, ²Sudan University for science and Technology, Khartoum, SUDAN.

E-TPW78**Interest of the estimation of the GFR with technetium 99m-DTPA in the comparison of the analysis of three methods of creatinine clearance estimation after kidney transplantation**

A. Sellem, K. Limam, W. Elajmi; Military Hospital, Tunis, TUNISIA.

E-TPW79**Interest of 99mTc-DTPA dynamic renal scintigraphy with furosemid test in the exploration of ureteropelvic junction syndrome: Report of 37 cases**

S. Touil^{1,2}, Y. Shimi^{1,2}, A. Koumba^{1,2}, H. Aschawa^{1,2}, A. Guensi^{1,2}; ¹Faculty of medicine and pharmacy of Casablanca, Casablanca, MOROCCO, ²Nuclear medicine service, Ibn Rochd University Hospital, Casablanca, MOROCCO.

E-TPW80**Evaluation of factors that may contribute to the hepatobiliary excretion of ^{99m}Tc-MAG3**

B. Bento, C. Amorim, D. Costa, P. Santos, S. Chin, M. R. Victor, M. Filipe, A. I. Santos; Serviço de Medicina Nuclear - Hospital Garcia de Orta, Almada, PORTUGAL.

E-TPW81**Influence of the geometry and positioning of the regions of interest in the transplanted renogram**

J. F. V. Rodrigues¹, J. Rayo², J. Vicente², E. Carolino³, S. Figueiredo^{4,5}, L. Vieira^{4,5}. ¹Escola Superior de Tecnologia da Saúde de Lisboa, Lisboa, PORTUGAL, ²Department of Nuclear Medicine at the Hospital Santa Cristina, Badajoz, SPAIN, ³Scientific Department of Mathematics, Escola Superior de Tecnologia da Saúde de Lisboa/ Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, ⁴Scientific Department of Nuclear Medicine, Escola Superior de Tecnologia da Saúde de Lisboa/ Instituto Politécnico de Lisboa, Lisboa, PORTUGAL, ⁵GMOSM – Instituto Superior de Engenharia de Lisboa/ Instituto Politécnico de Lisboa, Lisboa, PORTUGAL.

E-TPW82**Tailoring gastric emptying studies to patients needs: a requirement for best practice**

S. Johnson, C. Sibley-Allen, A. Nunes; Guy's and St. Thomas' NHS Foundation Trust, London, UNITED KINGDOM.





INDUSTRY
PROGRAMME

30th

ANNUAL SCIENTIFIC MEETING



Sponsored Symposia

Sunday, October 22, 2017

13:00 – 14:30, Hall F2

Bayer: Four years of radium Ra 223 dichloride on the market: what have we learned?

- 13:00 – 13:20 **Learning from trials and experience in mCRPC**
Joe O'Sullivan (UK)
- 13:20 – 13:30 **Lesson 1: who to treat, when, and why**
Val Lewington (UK)
- 13:30 – 13:40 **All faculty (Chair: Joe O'Sullivan, UK): Panel discussion**
- 13:40 – 13:55 **Lesson 2: 10 key steps to improve your service**
Yong Du (UK)
- 13:55 – 14:05 **Lesson 3: our journey to becoming an expert centre**
Wouter Vogel (The Netherlands)
- 14:05 – 14:15 **All faculty (Chair: Joe O'Sullivan, UK): Panel discussion**

sponsored by:



Sunday, October 22, 2017

13:00 – 14:30, Hall K

Advanced Accelerator Applications: Lutathera® (¹⁷⁷Lu-Dotatate): A New Era of Treatment in GEPNETs

- 13:00 – 13:05 **Welcome**
Prof. Dr. Eric P. Krenning (Erasmus MC, Rotterdam, Netherlands):
- 13:05 – 13:35 **A New Era of Treatment in GEPNETs**
Dr. Christos Toumpanakis (Royal Free and University College London, UK)
- 13:35 – 13:55 **PRRT: Real World Experience**
Dr. Gill Vivian (King's College Hospital, London, UK)
- 13:55 – 14:15 **The Future for PRRT**
Dr. Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, US)
- 14:15 – 14:30 **Questions and Discussion**
Prof. Dr. Eric Krenning

sponsored by:



Sunday, October 22, 2017

13:00 – 14:30, Hall G1

BTG



Monday, October 23, 2017

13:00 – 14:30, Hall F2

GE Healthcare: Clinical Impact of GE Healthcare’s latest innovations

Chairs Prof. Arturo Chiti, Humanitas University, Italy

Managing difficult CAD patients utilising latest technology & techniques

Prof. Richard Underwood, Royal Brompton & Harefield Hospitals, UK

Clinical experience with D670 CZT for bone imaging

Prof. Michael Kreissl, University Hospital Magdeburg, Germany

Improving oncology imaging with digital PET/CT

Dr. Martin Hüllner, University Hospital Zurich, Switzerland

Organizing a productive clinical PET/MR service

Prof. Aurélie Kas, Groupe Hospitalier Pitié-Salpêtrière, France



Monday, October 23, 2017

13:00 – 14:30, Hall K

Siemens: NEW Developments in Molecular Imaging*Join us for lunch as leading experts in molecular imaging share insights into the most recent advances in SPECT/CT including xSPECT Quant¹ and PET/CT focusing on next-generation SiPM-based systems²***Moderator:** Prof. Frank M. Bengel, Medizinische Hochschule, Hannover, Germany**xSPECT Quant: SPECT/CT quantification in clinical practice**

John Prior, Ph.D., M.D. Professor and Head of Nuclear Medicine and Molecular Imaging Lausanne University Hospital (CHUV), Lausanne, Switzerland

Beyond current SiPM-based PET technology: What is achievable?²

Bernard Bendriem, Ph.D., Principal Expert, Research and Development, Siemens Healthineers, Knoxville, Tennessee, USA

Beyond current SiPM-based PET technology: More than a vision, first images.²Carl von Gall, M.D., Product Manager, Siemens Healthineers
Hoffman Estates, Illinois, USAsponsored by:  **SIEMENS**
Healthineers¹ xSPECT Quant is not commercially available in some countries. Due to regulatory reasons, its future availability cannot be guaranteed.² The product mentioned herein is currently under development and does not yet fulfill all the essential requirements according to the European Medical Device Directive (93/42/EEC) and its national implementations. It is not yet commercially available in the European Union and not available for sale in the US or any other country. Future availability cannot be guaranteed

Monday, October 23, 2017

13:00 – 14:30, Hall G1

Sirtex: SIR-Spheres® Y-90 resin microspheres: Establishing the evidence base for SIRT and best practices for everyday use**Chair:** Ken Herrmann, Essen, Germany

- | | |
|---------------|--|
| 13:00 – 13:05 | Welcome and introduction
Ken Herrmann Essen, Germany) |
| 13:05 – 13:25 | Latest evidence on Y-90 resin microspheres in mCRC and HCC
Niklaus Schäfer Lausanne, Switzerland |
| 13:25 – 13:35 | Latest information on Y-90 resin microspheres and Glucose 5%
Philipp Paprottka Munich, Germany |
| 13:35 – 13:50 | Angiographical aspects, interacting with dosimetry calculations for Y90 SIRT
Antonio Martinez de la Cuesta Pamplona, Spain |
| 13:50 – 14:05 | What is new with the European Directive 2013/59/EURATOM and the impact on SIRT dosimetry
Cinzia Pettinato Bologna, Italy |
| 14:05 | Implications of the new data for clinical practice
All |

sponsored by:  **SIRTeX**

Tuesday, October 24, 2017

13:00 – 14:30, Hall F2

Sanofi Genzyme: The Role of Nuclear Medicine in Thyroid Cancer Management

Chair: Prof. Frederik Verburg

- | | |
|---------------|---|
| 13:00 – 13:05 | Welcome and introduction
Prof. Frederik Verburg – Nuclear Medicine department, Marburg University Hospital, Marburg, Hessen, Germany |
| 13:05 – 13:20 | Importance of ablative treatment in Differentiated Thyroid Cancer
Prof. Martha Hoffmann, Radiology Center, Nuclear Medicine and PET/CT, Vienna, Austria |
| 13:20 – 13:35 | How Nuclear Medicine improves Follow-Up in Differentiated Thyroid Cancer
(Note: intermediate and high risk patients and pts with TgAb)
Dr. Alfredo Campenni, AOU Policlinico G. Martin Medicina Nucleare, Messina, Italy |
| 13:35 – 13:50 | Imaging in Diagnosis and Follow-Up of Medullary Thyroid Cancer
Prof. Michael Kreissl, Klinikum Augsburg, Augsburg, Germany |
| 13:50 – 14:00 | Closing remarks
Prof. Frederik Verburg |

sponsored by:  SANOFI GENZYME

Tuesday, October 24, 2017

13:00 – 14:30, Hall K

Blue Earth Diagnostics: Axumin™ (fluciclovine (18F)) - A Newly Approved Imaging Option for Recurrent Prostate Cancer A Scientific Update

- | | |
|---------------|---|
| 13:00 – 13:05 | Welcome and introduction
Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway |
| 13:05 – 13:20 | Clinical Experience of fluciclovine (18F) PET/CT imaging in men with suspected recurrent prostate cancer and PSA values <1ng/mL.
Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway |
| 13:25 – 13:35 | The FALCON Trial - A Phase 3 Study to assess the clinical utility of fluciclovine (18F) PET/CT imaging in patients with prostate cancer with biochemical recurrence.
Dr. Eugene J. Teoh, MRCP, FRCR, Department of Oncology, University of Oxford, UK |
| 13:35 – 13:50 | Practical experience of using fluciclovine (18F) in radiotherapy decisionmaking and field planning: preliminary results from a randomized controlled study
Prof. Ashesh B. Jani, MD, MSEE, Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, US |
| 13:50 – 14:00 | Summary and Closing remarks
Dr. Frode Willoch, MD, PhD, Faculty of Medicine, University of Oslo, Oslo, Norway |

sponsored by:  BLUE EARTH
DIAGNOSTICS



Tuesday, October 24, 2017

13:00 – 14:30, Hall G1

Eli Lilly and Company: Amyloid and Tau imaging in Alzheimer's Disease: What we have learned from the use of PET Neuroimaging in clinical trials

13:00 – 13:05	Welcome and introduction Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)
13:05 – 13:25	Quantitation and its role in Amyvid scan interpretation Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)
13:25 – 13:45	Clinical utility of biomarkers in making a diagnosis of patients with cognitive decline Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)
13:45 – 14:05	The incremental diagnostic value of Amyloid PET in memory clinics Giovanni Frisoni, MD (Geneva, Switzerland)
14:05 – 14:20	Questions and answers All
14:20	Summary & closing remarks Giovanni Frisoni, MD (Geneva, Switzerland)

sponsored by:



A NEW PERSPECTIVE MAKES ALL THE DIFFERENCE

RESEARCH4LIFE
AN EANM INITIATIVE TO FOSTER RESEARCH

List of Exhibitors (A – Z)

<i>Company</i>	<i>Booth No.</i>
ABT Molecular Imaging, Inc.	266
ABX advanced biochemical compounds	420
ABX-CRO advanced pharmaceutical services	264
ACOM SRL	261
Advanced Accelerator Applications (AAA) CM	310
Advanced Cyclotron Systems, Inc	217
AG Medical	216
Agfa HealthCare	425
Ai4R SAS (<i>Isotope4life</i>)	403
AIMN – Italian Association of Nuclear Medicine	370
AIPES – Association of Imaging Producers and Equipment Suppliers	249
Alliance Medical & Life Radiopharma	233/236
ANMI SA (<i>Wallonia Export & Investment Agency</i>)	318
ANZSNM/WFNMB – Australian and New Zealand Society of Nuclear Medicine/ World Federation of Nuclear Medicine and Biology	361
ARCCNM/AOFNMB – Asian Regional Cooperative Council for Nuclear Medicine/ Asia Oceania Federation of Nuclear Medicine and Biology	363
AREVA Med / Macrocylics	234
Arronax / Arronax Plus (<i>Isotope4life</i>)	403
ASNC – American Society of Nuclear Cardiology	367
Atlanpole Biotherapies (<i>Isotope4life</i>)	403
Bayer	245
Berthold Technologies GmbH	205
Best Cyclotron Systems, Inc.	268
Biocompatibles UK Ltd (BTG) CM	417
Biodex Medical Systems, Inc.	204
Biowin (<i>Wallonia Export & Investment Agency</i>)	318
Blue Earth Diagnostics	407
BNMS – British Nuclear Medicine Society	355
Bruker BioSpin CM	309

BV Cyclotron VU (<i>The Pavilion</i>)	238
C.Curie bvba/sprl (<i>The Pavilion</i>)	238
Cambridge Isotope Laboratories, Inc.	251
CANM – Canadian Association of Nuclear Medicine	366
Capintec, Inc.	314
Casram SA	246
CBmed	257
Center of Molecular Research	206
Chelatec (<i>Isotope4life</i>)	403
CHEMATECH	259
Cisbio	260
CMR Naviscan Corporation	218
Comecer Group CM	412
Crystal Photonics GmbH	242
CSNM – Chinese Society of Nuclear Medicine	365
Curium CM	307
Cyclomedica Europe Ltd.	413
Cyclopharma	210
DDD-Diagnostic A/S	311
DGN e.V. – German Society of Nuclear Medicine	353
Diasource SA (<i>Wallonia Export & Investment Agency</i>)	318
diXit s.r.l.	267
DOSIsoft SA	316
EARL – EANM Research Ltd.	351
ec ² Software Solutions	219
Eckert & Ziegler Strahlen- und Medizintechnik AG CM	302
Eczacibasi-Monrol Nuclear Products Co. CM	313
Edizioni Minerva Medica	369
EFRS – European Federation of Radiographer Societies	350
EIBIR – European Institute for Biomedical Imaging Research	362
EITA – European Isotopes Transport Association	368
Elimpex-Medizintechnik GesmbH + Ludlum Measurements Inc.	209
Elysia-raytest	317
Epsilon Elektronik San. ve Tic. A.S. – ERS	312

CM EANM Corporate Member




List of Exhibitors

World Leading Meeting

ESR – European Society of Radiology	204A
Euromedical Instruments (<i>The Pavilion</i>)	238
GAEDE Medizinsysteme GmbH	265
GE Healthcare CM	416
Getinge La Calhène	422
Greek Society of Nuclear Medicine and Biology	352
Hake Medical Technology (Beijing) Co., Ltd.	258
Hermes Medical Solutions CM	301
Hidex Oy	406
HOY Scandinavian ApS	238
Huayi Isotopes Co.	208
IAEA – International Atomic Energy Agency	364
IASON GmbH	253
IBA CM	308
IDB Holland bv	310
Institute of Isotopes Co. Ltd.	305
Inter Medical Medizintechnik GmbH	235
INVIA Medical Imaging Solutions	227
invICRO	207
IQ Medical Services	229
IRE ELiT SA	318
Isotop4Life CM	403
ITD Isotope Technologies Dresden GmbH	239
ITEL Telecomunicazioni	256
ITM Isotopen Technologien München AG	231
JSC Isotope/Rusatom Healthcare CM	415
JSNM – Japanese Society of Nuclear Medicine	358
Keosys (<i>Isotope4life</i>)	403
Kliniken.de – job board	371
KSNM – Korean Society of Nuclear Medicine	203
LabLogic Systems Ltd.	406
Lemer Pax CM	403
Lightpoint Medical Ltd.	228
Lynax s.r.o.	202

EANM Corporate Member **CM**

MAP Medical Technologies Oy	254
MED Nuklear-Medizintechnik Dresden GmbH – a Company of NUVIA (<i>The Pavilion</i>)	238
Medi-Radiopharma Co., Ltd.	319
Mediso CM	304
Medisystem (<i>Isotope4life</i>)	403
MiE medical imaging electronics GmbH	408
MILabs B.V.	226
MIM Software Inc.	237
Mirada Medical	215
MNT Kwint International bv (<i>The Pavilion</i>)	238
MOLECUBES NV	250
MR SOLUTIONS	201
NICESOFT (<i>The Pavilion</i>)	238
Norgine Ltd.	223
NRG CM	306
Nuclear Shields BV	424
Nucleis (<i>Wallonia Export & Investment Agency</i>)	318
NVNG – Dutch Society of Nuclear Medicine	354
OGNMB – Austrian Society of Nuclear Medicine and Molecular Imaging	359
Oncidium Foundation	347
ONCOVISION	421
ORA-NEPTIS – Optimized Radiochemical Applications	211
Osimis SA (<i>Wallonia Export & Investment Agency</i>)	318
PARS ISOTOPE CM	418
PerkinElmer	269
Philips CM	402
PI Medical Diagnostic Equipment B.V. (<i>The Pavilion</i>)	238
PMB-ALCEN	409
PMOD Technologies Ltd.	232
POLATOM, Radioisotope Centre of National Centre for Nuclear Research	410
Progenics Pharmaceuticals, Inc.	411
RAD4MED (<i>Wallonia Export & Investment Agency</i>)	318
rapp-iso GmbH	220
Rotem GmbH	244

CM EANM Corporate Member





ROTOP Pharmaka GmbH	414
RoWe Med AG – Medical 4 Life	214
Sanofi Genzyme	247
Scintomics GmbH	230
Sedecal Molecular Imaging – SMI	241
Seibersdorf Labor GmbH	262
Sichuan Tianle Photonics Co., Ltd.	213
Siemens Healthineers CM	401
Sirtex Medical Europe GmbH	405
SNMI – Society of Nuclear Medicine, India	243
SNMMI – Society of Nuclear Medicine and Molecular Imaging	356
Southern Scientific Ltd.	406
Spectrum Dynamics Medical CM	404
Springer Nature	360
SurgicEye GmbH (<i>The Pavilion</i>)	238
SYNTHRA GmbH	263
Taiyo Nippon Sanso Corporation	255
Tema Sinergie CM	303
TERUMO Europe NV	224
The Pavilion CM	238
THERACLION	423
TRASIS S.A.	419
Triskem International (<i>Isotope4life</i>)	403
TSNM – Turkish Society of Nuclear Medicine	357
UEMS/EBNM – European Union of Medical Specialists/Section and European Board of Nuclear Medicine	348
Uniteko	212
US DOE, Isotopes	240
VANDERWILT techniques b.v. (<i>The Pavilion</i>)	238
Von Gahlen Nederland BV	315
Wallonia Export & Investment Agency	318
WARMTH	349
Wisepress Medical Bookshop	400
WOLFMET (M&I Materials Ltd.) (<i>The Pavilion</i>)	238
Yantai Dongcheng Pharmaceuticals Group Co., Ltd.	248

Exhibitors (sorted by Booth No.)

<i>Company</i>	<i>Booth No.</i>
MR SOLUTIONS	201
Lynax s.r.o.	202
KSNM – Korean Society of Nuclear Medicine	203
Biodex Medical Systems, Inc.	204
ESR – European Society of Radiology	204A
Berthold Technologies GmbH	205
Center of Molecular Research	206
inviCRO	207
Huayi Isotopes Co.	208
Elimpex-Medizintechnik GesmbH + Ludlum Measurements Inc.	209
Cyclopharma	210
ORA-NEPTIS – Optimized Radiochemical Applications	211
Uniteko	212
Sichuan Tianle Photonics Co., Ltd.	213
RoWe Med AG – Medical 4 Life	214
Mirada Medical	215
AG Medical	216
Advanced Cyclotron Systems, Inc	217
CMR Naviscan Corporation	218
ec ² Software Solutions	219
rapp-iso GmbH	220
Norgine Ltd.	223
TERUMO Europe NV	224
MILabs B.V.	226
INVIA Medical Imaging Solutions	227
Lightpoint Medical Ltd.	228
IQ Medical Services	229
Scintomics GmbH	230
ITM Isotopen Technologien München AG	231
PMOD Technologies Ltd.	232

 CM EANM Corporate Member





Alliance Medical & Life Radiopharma	233/236
AREVA Med / Macrocyclics	234
Inter Medical Medizintechnik GmbH	235
MIM Software Inc.	237
BV Cyclotron VU	238
C.Curie bvba/sprl	238
Euromedical Instruments	238
HOY Scandinavian ApS	238
MED Nuklear-Medizintechnik Dresden GmbH – a Company of NUVA	238
MNT Kwint International bv	238
NICESOFT	238
PI Medical Diagnostic Equipment B.V.	238
SurgicEye GmbH	238
The Pavilion CM	238
VANDERWILT techniques b.v.	238
WOLFMET (M&I Materials Ltd.)	238
ITD Isotope Technologies Dresden GmbH	239
US DOE, Isotopes	240
Sedecal Molecular Imaging – SMI	241
Crystal Photonics GmbH	242
SNMI – Society of Nuclear Medicine, India	243
Rotem GmbH	244
Bayer AG	245
Casram SA	246
Sanofi Genzyme	247
Yantai Dongcheng Pharmaceuticals Group Co., Ltd.	248
AIPES – Association of Imaging Producers and Equipment Suppliers	249
MOLECUBES NV	250
Cambridge Isotope Laboratories, Inc.	251
IASON GmbH	253
MAP Medical Technologies Oy	254
Taiyo Nippon Sanso Corporation	255
ITEL Telecomunicazioni	256
CBmed	257

Hake Medical Technology (Beijing) Co., Ltd.	258
CHEMATECH	259
Cisbio	260
ACOM SRL	261
Seibersdorf Labor GmbH	262
SYNTHRA GmbH	263
ABX-CRO advanced pharmaceutical services	264
GAEDE Medizinsysteme GmbH	265
ABT Molecular Imaging, Inc.	266
diXit s.r.l.	267
Best Cyclotron Systems, Inc.	268
PerkinElmer	269
Hermes Medical Solutions CM	301
Eckert & Ziegler Strahlen- und Medizintechnik AG CM	302
Tema Sinergie CM	303
Mediso CM	304
Institute of Isotopes Co. Ltd.	305
NRG CM	306
Curium CM	307
IBA CM	308
Bruker BioSpin CM	309
Advanced Accelerator Applications (AAA) CM	310
IDB Holland bv	310
DDD-Diagnostic A/S	311
Epsilon Elektronik San. ve Tic. A.S. – ERS	312
Eczacibasi-Monrol Nuclear Products Co. CM	313
Capintec, Inc.	314
Von Gahlen Nederland BV	315
DOSIsoft SA	316
Elysia-raytest	317
ANMI SA	318
Biowin	318
Diasource SA	318
Ire Elit SA	318


CM EANM Corporate Member





List of Exhibitors

World Leading Meeting


Nucleis	318
Osimis SA	318
RAD4MED	318
Wallonia Export & Investment Agency	318
Medi-Radiopharma Co., Ltd.	319
Oncidium Foundation	347
UEMS/EBNM – European Union of Medical Specialists/Section and European Board of Nuclear Medicine	348
WARMTH	349
EFRS – European Federation of Radiographer Societies	350
EARL – EANM Research Ltd.	351
Greek Society of Nuclear Medicine and Biology	352
DGN e.V. – German Society of Nuclear Medicine	353
NVNG – Dutch Society of Nuclear Medicine	354
BNMS – British Nuclear Medicine Society	355
SNMMI – Society of Nuclear Medicine and Molecular Imaging	356
TSNM – Turkish Society of Nuclear Medicine	357
JSNM – Japanese Society of Nuclear Medicine	358
OGNMB – Austrian Society of Nuclear Medicine and Molecular Imaging	359
Springer Nature	360
ANZSNM/WFNMB – Australian and New Zealand Society of Nuclear Medicine/ World Federation of Nuclear Medicine and Biology	361
EIBIR – European Institute for Biomedical Imaging Research	362
ARCCNM/AOFNMB – Asian Regional Cooperative Council for Nuclear Medicine/ Asia Oceania Federation of Nuclear Medicine and Biology	363
IAEA – International Atomic Energy Agency	364
CSNM – Chinese Society of Nuclear Medicine	365
CANM – Canadian Association of Nuclear Medicine	366
ASNC – American Society of Nuclear Cardiology	367
EITA – European Isotopes Transport Association	368
Edizioni Minerva Medica	369
AIMN – Italian Association of Nuclear Medicine	370
Kliniken.de – job board	371
Wisepress Medical Bookshop	400
Siemens Healthineers 	401


EANM Corporate Member 

Philips CM	402
Ai4R SAS	403
Arronax / Arronax Plus	403
Atlanpole Biotherapies	403
Chelatec	403
Isotop4Life CM	403
Keosys	403
Lemer Pax CM	403
Medisystem	403
Triskem International	403
Spectrum Dynamics Medical CM	404
Sirtex Medical Europe GmbH	405
Hidex Oy	406
LabLogic Systems Ltd.	406
Southern Scientific Ltd.	406
Blue Earth Diagnostics	407
MiE medical imaging electronics GmbH	408
PMB-ALCEN	409
POLATOM, Radioisotope Centre of National Centre for Nuclear Research	410
Progenics Pharmaceuticals, Inc.	411
Comecer Group CM	412
Cyclomedica Europe Ltd.	413
ROTOP Pharmaka GmbH	414
JSC Isotope/Rusatom Healthcare CM	415
GE Healthcare CM	416
Biocompatibles UK Ltd (BTG) CM	417
PARS ISOTOPE CM	418
TRASIS S.A.	419
ABX advanced biochemical compounds	420
ONCOVISION	421
Getinge La Calhène	422
THERACLION	423
Nuclear Shields BV	424
Agfa HealthCare	425

CM EANM Corporate Member

Exhibition Hall X2







201	MR SOLUTIONS	» HOY Scandinavian ApS	
202	Lynax s.r.o.	» MED Nuklear-Medizintechnik Dresden GmbH – a Company of NUVIA	
203	KSNM – Korean Society of Nuclear Medicine	» MNT Kwint International bv	
204	Biodex Medical Systems, Inc.	» NICESOFT	
204A	ESR – European Society of Radiology	» PI Medical Diagnostic Equipment B.V.	
205	Berthold Technologies GmbH	» SurgicEye GmbH	
206	Center of Molecular Research	» VANDERWILT techniques b.v.	
207	inviCRO	» WOLFMET (M&I Materials Ltd.)	
208	Huayi Isotopes Co.	239	ITD Isotope Technologies Dresden GmbH
209	Elimpex-Medizintechnik GesmbH + Ludlum Measurements, Inc.	240	US DOE, Isotopes
210	Cyclopharma	241	Sedecal Molecular Imaging – SMI
211	ORA-NEPTIS – Optimized Radiochemical Applications	242	Crystal Photonics GmbH
212	Uniteko	243	SNMI - Society of Nuclear Medicine India
213	Sichuan Tianle Photonics Co., Ltd.	244	Rotem GmbH
214	RoWe Med AG – Medical 4 Life	245	Bayer
215	Mirada Medical	243	SNMI – Society of Nuclear Medicine India
216	AG Medical	246	Casram SA
217	Advanced Cyclotron Systems, Inc	247	Sanofi Genzyme
218	CMR Naviscan Corporation	248	Yantai Dongcheng Pharmaceuticals Group Co., Ltd.
219	ec ² Software Solutions	249	AIPES – Association of Imaging Producers and Equipment Suppliers
220	rapp-iso GmbH	250	MOLECUBES NV
223	Norgine Ltd.	251	Cambridge Isotope Laboratories, Inc.
224	TERUMO Europe NV	253	IASON GmbH
226	MILabs B.V.	254	MAP Medical Technologies Oy
227	INVIA Medical Imaging Solutions	255	Taiyo Nippon Sanso Corporation
228	Lightpoint Medical Ltd.	256	ITEL Telecomunicazioni
229	IQ Medical Services	257	CBmed
230	Scintomics GmbH	258	Hake Medical Technology (Beijing) Co., Ltd.
231	ITM Isotopen Technologien München AG	259	CHEMATECH
232	PMOD Technologies Ltd.	260	Cisbio
233/236	Alliance Medical & Life Radiopharma	261	ACOM SRL
234	AREVA Med / Macrocylics	262	Seibersdorf Labor GmbH
235	Inter Medical Medizintechnik GmbH	263	SYNTHRA GmbH
237	MIM Software Inc.	264	ABX-CRO advanced pharmaceutical services
238	The Pavilion CM	265	GAEDE Medizinsysteme GmbH
	» BV Cyclotron VU	266	ABT Molecular Imaging, Inc.
	» C.Curie bvba/sprl	267	diXit s.r.l.
	» Euromedical Instruments	268	Best Cyclotron Systems, Inc.
		269	PerkinElmer



Exhibition Hall X3







301	Hermes Medical Solutions CM	350	EFRS – European Federation of Radiographer Societies
302	Eckert & Ziegler Strahlen- und Medizintechnik AG CM	351	EARL – EANM Research Ltd.
303	Tema Sinergie CM	352	Greek Society of Nuclear Medicine and Biology
304	Mediso CM	353	DGN e.V. – German Society of Nuclear Medicine
305	Institute of Isotopes Co. Ltd.	354	NVNG – Dutch Society of Nuclear Medicine
306	NRG CM	355	BNMS – British Nuclear Medicine Society
307	Curium CM	356	SNMMI – Society of Nuclear Medicine and Molecular Imaging
308	IBA CM	357	TSNM – Turkish Society of Nuclear Medicine
309	Bruker BioSpin CM	358	JSNM – Japanese Society of Nuclear Medicine
310	Advanced Accelerator Applications (AAA) CM	359	OGNMB – Austrian Society of Nuclear Medicine and Molecular Imaging
310	IDB Holland bv	360	Springer Nature
311	DDD-Diagnostic A/S	361	ANZSNM/WFNMB – Australian and New Zealand Society of Nuclear Medicine/World Federation of Nuclear Medicine and Biology
312	Epsilon Elektronik San. ve Tic. A.S. – ERS	362	EIBIR – European Institute for Biomedical Imaging Research
313	Eczacibasi-Monrol Nuclear Products Co. CM	363	ARCCNM/AOFNMB – Asian Regional Cooperative Council for Nuclear Medicine/Asia Oceania Federation of Nuclear Medicine and Biology
314	Capintec, Inc.	364	IAEA – International Atomic Energy Agency
315	Von Gahlen Nederland BV	365	CSNM – Chinese Society of Nuclear Medicine
316	DOSIsoft SA	366	CANM – Canadian Association of Nuclear Medicine
317	Elysia-raytest	367	ASNC – American Society of Nuclear Cardiology
318	Wallonia Export & Investment Agency » ANMI SA » Biowin » Diasource SA » Ire Elit SA » Nucleis » Osimis SA » RAD4MED	368	EITA – European Isotopes Transport Association
319	Medi-Radiopharma Co., Ltd.	369	Edizioni Minerva Medica
347	Oncidium Foundation	370	AIMN – Italian Association of Nuclear Medicine
348	UEMS/EBNM – European Union of Medical Specialists/Section and European Board of Nuclear Medicine	371	Kliniken.de – job board
349	WARMTH		



Exhibition Hall X4





- 400 Wisepress Medical Bookshop
- 401 Siemens Healthineers **CM**
- 402 Philips **CM**
- 403 Isotop4Life **CM**
 - » Ai4R SAS
 - » Arronax / Arronax Plus
 - » Atlanpole Biotherapies
 - » Chelatec
 - » Keosys
 - » Lemer Pax **CM**
 - » Medisystem
 - » Triskem International
- 404 Spectrum Dynamics Medical **CM**
- 405 Sirtex Medical Europe GmbH
- 406 Hidex Oy
- 406 LabLogic Systems Ltd.
- 406 Southern Scientific Ltd.
- 407 Blue Earth Diagnostics
- 408 MiE medical imaging electronics GmbH
- 409 PMB-ALCEN
- 410 POLATOM, Radioisotope Centre of National Centre for Nuclear Research
- 411 Progenics Pharmaceuticals, Inc.
- 412 Comecer Group **CM**
- 413 Cyclomedica Europe Ltd.
- 414 ROTOP Pharmaka GmbH
- 415 JSC Isotope/Rusatom Healthcare **CM**
- 416 GE Healthcare **CM**
- 417 Biocompatibles UK Ltd (BTG) **CM**
- 418 PARS ISOTOPE **CM**
- 419 TRASIS S.A.
- 420 ABX advanced biochemical compounds
- 421 ONCOVISION
- 422 Getinge La Calhène
- 423 THERACLION
- 424 Nuclear Shields BV
- 425 Agfa HealthCare



ABT Molecular Imaging

Booth No. 266

3024 Topside Business Park Drive
37777 Louisville
United States
Phone: +1 865 982 0098
E-Mail: info@abt-mi.com
Web: <http://www.abt-mi.com>

„Simplifying global access to FDG & advanced PET biomarkers“

ABT Molecular Imaging offers the BG-75 “Dose on Demand” Biomarker Generator, providing in-house access to PET biomarkers. The BG-75 System has three principle components that make it unique; a compact accelerator, integrated micro-chemistry, and automated quality control. The system provides simple and efficient single or batch production of F-18 FDG, and other advanced PET radioisotopes. The complete system, including dose synthesis and quality control, can be housed in a 5.6 x 5.6 meter room adjacent to the PET/CT System. The small size and integrated components take the place of a large, conventional systems requiring a 300 square meter facility, with fully equipped hot labs, quality control equipment, and significant staffing for operation. The size and complexity difference provides a much lower barrier to entry to have access to radioisotopes on demand, and enables the expansion of advanced radiochemistry research in clinical and pre-clinical Molecular Imaging. ABT was started in 2006 by Dr. Ron Nutt, and is located in Knoxville, Tennessee. It is very close to where clinical PET was developed over the past 25 years at CTI Molecular Imaging, which Dr. Nutt co-founded.“

ABX advanced biochemical compounds - Biomedizinische Forschungsreagenzien GmbH

Booth No. 420

Heinrich-Glaeser-Str. 10 - 14
1454 Radeberg
Germany
Phone: +49 35 28-40 41 60
Fax: +49-35 28-40 41 65
E-Mail: info@abx.de
Web: <http://www.abx.de/>

ABX is the leading manufacturer of PET precursors and peptides as well as reagent kits and cassettes. We offer:

- FDG reagent kits and cassettes for nearly all FDG modules
- * Mannose Triflate (DMF US and Europe)
- * Cryptand222 (kryptofix)
- F-PSMA-1007 precursor, reagents and cassettes for GE MX, GE FX, ORA Neptis, IBA Synthera and Trasis AIO modules
- nucleophilic and electrophilic F-DOPA precursors as well as reagents and cassettes
- FLT, F-Choline, F-MISO, FET and NAF precursors, reagents and cassettes
- comprehensive range of “scientific” precursors for oncology such as Fluoroestradiol, FAZA... and neurology like Raclopride, Fallypride, PK11195, Flumazenil, beta-CIT, PIB...
- SPECT precursors, e. g. CuMIBI (DMF US and Europe), MIBG, ECD
- PEPTIDES, e. g. PSMA-11, DOTA-TOC, DOTA-TATE and DOTA-NOC for Gallium68 labelling
- novel theranostic PSMA-ligand PSMA-617 for Lutetium-177 labelling
- Gallium-68 reagents kits and cassettes
- Lutetium-177 reagents kits and cassettes
- O-18 WATER
- Performance of stability studies
- Development of radiotracers and labelling as well as purification strategies

We are well experienced in GMP production and also do offer custom synthesis according to Q7 chapter 19 for clinical PET studies (APIs). Our laboratories and clean rooms are GMP certified and meet pharmaceutical standards. We are GMP and ISO13485 certified.



ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H.

Booth No. 264

Blasewitzer Str. 78-80

1307 Dresden

Germany

Phone: +49 351214440

Fax: +49 3512144415

E-Mail: info@abx-cro.comWeb: <http://www.abx-cro.com>

ABX-CRO is a globally operating clinical research organization with a strong focus on pre-clinical and clinical molecular imaging and molecular radiotherapy.

Based on over 15 years' experience in diagnostic and therapeutic oncology, neurology and other disease areas, ABX-CRO provides you with unique opportunities to test your drug candidates in complex pre-clinical disease models, assessed quantitatively using molecular and functional imaging (PET, SPECT, CT, MRI). We translate pre-clinical results into First in Man studies and support you with design and execution of efficient late stage clinical trials, minimizing your costs and time to marketing authorization. ABX-CRO makes translational medicine a visible reality.

ABX-CRO is very proud to present QDOSE, the only comprehensive dosimetry solution, featuring seamless integration of the new ICRP-endorsed IDAC-Dose 2.1 dose calculator enabling anatomically realistic phantom-based dose calculation using the official:

- ICRP Adult Reference Computational Phantoms (ICRP 110)
- ICRP Specific Absorbed Fractions (ICRP 133)

QDOSE is a comprehensive internal dosimetry software suite for both, systemic and selective internal radiation therapy (IRT). QDOSE is platform-independent, clinically validated, and user-friendly. It enables state-of-the-art evaluation of safety and efficacy (e.g. tumour) dosimetry.

Acom

Booth No. 261

LOC. CAVALLINO 39/a-b

62010 MONTECOSARO

Italy

Phone: +39733229739

Fax: +39 733560352

E-Mail: amministrazione@acompet.itWeb: <http://www.acompet.it>

ACOM SrL, established in 1999, is one of the most interesting Company in Europe in Nuclear Medicine. ACOM's aim is to improve the quality of life in oncological, cardiovascular and neurological patients. In 2002 ACOM was officially recognized by the Italian competent Authority for pharmaceutical products (AIFA) as a Pharmaceutical Development Center. In 2007, ACOM was certified by AIFA and in October 2007 by EMEA.

Since its start ACOM has carried out intensive research for developing new radiopharmaceuticals to be used with PET scan devices such as Copper-64 and Iodine-124 produced on a cyclotron using an innovative compact solid target irradiation system (CRIS). In fact, thanks to a long term cooperation with the Washington University of Saint Luis, ACOM has successfully achieved the required know-how to manufacture the copper 64 on industrial scale basis according to GMP standards. Moreover, ACOM is the only existing Company bearing a trade registration which allows the use of Copper 64 in the human body.

The professional skills of the team, the capacity to operate in critical contexts and an innovative approach demonstrated by constant investment in research and development, are just some of the distinctive features developed over more than ten years in business.

For any further information please visit our stand and our WEB page (www.acompet.it) where you can find our news and events continuously updated.



ADVANCED ACCELERATOR APPLICATIONS

Booth No. 310

4 rue de la tour de l ile
1204 Geneva
Switzerland
Phone: +41 225190700
E-Mail: annalisa.zanuso@adacap.com
Web: <http://www.adacap.com/>

Advanced Accelerator Applications (NASDAQ:AAAP) is an innovative radiopharmaceutical company that develops, produces and commercializes innovative diagnostic and therapeutic molecular nuclear medicine products. AAA currently has 21 production and research & development facilities, and over 500 employees in 13 countries.

AAA is an established leader in molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. AAA currently markets 9 radiopharmaceuticals (8 in Europe and 1 in the US) mainly used in clinical oncology, cardiology and neurology.

AAA is also developing a pipeline of theragnostic pairings for oncology indications. The company's theragnostic platform involves radiolabeling a targeting molecule with either Ga 68 for diagnostic use, or Lu 177 for therapy. AAA's first theragnostic pairing addresses neuroendocrine tumors, an orphan indication. The diagnostic drug, marketed as NETSPOT® in the US or SomaKit TOC™ in Europe, is approved for use; while the therapeutic drug, lutetium Lu 177 dotatate (Lutathera®) is under review for registration with the EMA and FDA. Additional pairings target GIST, prostate and breast cancer.

Acquired by AAA in 2016, IDB Holland is a leading manufacturer and worldwide distributor of Lutetium 177 (LuMark® Lu-177 chloride), radiopharmaceuticals and sources for nuclear medicine. IDB supplies customers in over 40 countries in Europe, Africa, Asia, Australia, South America, the United States and Canada.

Advanced Cyclotron Systems Inc (ACSI)

Booth No. 217

#150 - 7280 River Road
V6X 1X5 Richmond, BC
Canada
Phone: +16042761493
E-Mail: info@advancedcyclotron.com
Web: <http://www.advancedcyclotron.com>

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 25 years of experience and more than 50 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production and distribution of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada.

ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market.

The versatility, high beam current and exceptional quality of ACSI cyclotrons are the reasons why many of the world's most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs.

For more information, please visit www.advancedcyclotron.com

AG Medical

Booth No. 216

AGFA HealthCare

Booth No. 425

Septestraat 27

2640 Mortsel

Belgium

Phone: +32 34447527

E-Mail: erik.vanrijn@agfa.com

Web: <http://global.agfahealthcare.com/main/>

As a market leader in the fast-growing sector of enterprise-wide IT, Agfa HealthCare's IT solutions work across departments and disciplines. Integrating medical, nursing, administrative and business information, and streamlining workflows and operations, they allow care providers to increase their efficiency and effectiveness, resulting in improved quality of care, speed and cost-effectiveness.

Imaging systems

Agfa HealthCare's imaging systems are designed to bring vital information to medical professionals, wherever they are, within and beyond the healthcare enterprise. They capture, process and print diagnostic images from multiple sources and across a multitude of image-intensive specialties and departments, including radiology, cardiology, women's care and intensive care units.

Nuclear Medicine

Agfa HealthCare's Integrated Solutions for Nuclear Medicine offer clinicians a unique solution to fully integrate the Nuclear Medicine department's workflow and optimize the inter-departmental communications. Running on one workstation the solution supports the patient's entire exam flow, from arrival at the hospital, to the final distribution of nuclear medicine results, and includes specialized functionality to process, read and report all Nuclear Medicine, SPECT, PET, and multi-modality images.

Ai4R

Booth No. 403

2 Rue Alfred Kastler

CEDEX 3

44307 NANTES

France

Phone: +33 2 51 85 87 42

E-Mail: jerome.donnard@ai4r.comWeb: <http://www.ai4r.com>



AIMN, Italian Association of Nuclear Medicine and Molecular Imaging

Booth No. 370

Via Carlo Farini 81

20159 Milano

Italy

Phone: +39 266802323

E-Mail: segreteria@aimn.it

Web: <https://www.aimn.it/>

AIMN was founded in 1990 unifying two previous Societies, both born in 1956: the Italian Society of Medical Radiology (SIRM), which in 1956 assumed in its acronym a N to become the Italian Society of Medical Radiology and Nuclear Medicine (SIRMN) and the Italian Society of Nuclear Medicine and Biology (SIBMN), founded by leading Internists with a primary interest in Physiology and already working in Nuclear Medicine since late 40's. Pivotal and pioneering events were in 1957 the publication of the first issue of Minerva Nucleare and in 60's the creation of the first Schools of Specialization and of the first autonomous departments of Nuclear Medicine. Actually, AIMN is constituted by almost 800 members, regrouping the large majority of Italian Nuclear Physicians, in strict connection with all the Professionals involved in our field. AIMN is also a founding Member of the Italian Federation of the Medical Radiological Area (FIDESMAR). The scientific quality and the prestige of AIMN may be derived by the leading international role of many associated and by the qualified participation of many Italian members to the most important international scientific events in Nuclear Medicine and Molecular Imaging. Actually the President of AIMN is O. Schillaci, leading an Executive Committee constituted by L. Mansi, vice President, O. Bagni, M. Boero, M. C. Marzola, L. Evangelista and A. Garufo, with A. Cuocolo and T. Varetto as technical members.

AIPES - Association of Imaging Producers and Equipment Suppliers

Booth No. 249

Alliance Medical GmbH

Booth No. 233/236

Westring 168

44579 Castrop-Rauxel

Germany

E-Mail: info@alliancemedical.eu

Web: <http://www.alliancemedical.de>

Alliance Medical and Life Radiopharma provides medical imaging services across Europe in the UK, Germany, Ireland, Italy, the Netherlands, and Spain.

By uniting technical excellence and exceptional service in a business model that delivers outstanding value for money, we have enjoyed consistent growth for more than 25 years. We work collaboratively with clinicians, health care organisations and academic institutions to provide high quality and cost effective imaging for our customers and better services for our patients.

Alliance Medical has a proven track record of service delivery across both the publicly and privately funded healthcare markets in Europe with an emphasis on quality and sustainability.

American Society of Nuclear Cardiology

Booth No. 367

4340 East-West Highway
Suite 1120
20814 Bethesda, Maryland
United States
Phone: +1 301 215 7575
Fax: +1 301-215-7113
E-Mail: info@asnrc.org
Web: <http://www.asnrc.org>

The American Society of Nuclear Cardiology (ASNC) is the recognized world leader in quality, education, advocacy and standards in cardiovascular nuclear imaging, with over 4,000 members worldwide. ASNC is dedicated to continuous quality improvement, education and patient-centered imaging, illustrating the ongoing commitment as a leader in the field of nuclear imaging and improving patient outcomes. ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional education, advocacy and research development. ASNC's members are comprised of cardiologists, radiologists, physicians, scientists, technologists, imaging specialists and other professionals committed to the science and practice of nuclear cardiology. Two upcoming ASNC meetings: ASNC's 23rd Annual Scientific Session will be held in San Francisco, California, September 6-9, 2018 and NC Today will be held in Chicago, Illinois, April 20-22, 2018.

The Society will be celebrating its 25th Anniversary in 2018!

ANMI SA

Booth No. 318

Allée du Six Août 8
4000 Liège Liège
Belgium
Phone: +32 4 366 3099
E-Mail: info@anmi.be
Web: <http://anmi.be>

ANMI SA is a precursor supplier for radiometal labeled radiopharmaceuticals and a global service provider in the nuclear medicine field, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the synthesis of these theranostic radiopharmaceuticals and to ease their daily production in hospitals.

ANMI SA has a strong expertise in peptide synthesis, and modification of peptides or antibodies focused at adding any linker and chelating agent.

The company's expertise is based on a strong market and regulatory knowledge of the nuclear medicine area and can provide premium quality products and services.

ANMI's R&D team is working on several new tracers for different applications such as neuro endocrine tumors or prostate cancer for imaging and therapeutic applications.

ARCCNM/AOFNMB - Asian Regional Cooperative Council for Nuclear Medicine/Asia Oceania Federation of Nuclear Medicine and Biology

Booth No. 363



AREVA Med / Macrocyclics

Booth No. 234

1 Place Jean Millier
92400 Courbevoie
France
Web: <http://www.arevamed.com>

AREVA Med is a biotech company developing innovative therapies in oncology. AREVA Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy. AREVA Med sponsored and completed the 1st phase 1 trial with 212Pb. Today, we are working with our partners and are looking for new partnerships to develop new 212Pb-based targeted therapies to address unmet medical needs. With two world class facilities in France and in the US, we are able to produce and supply 212Pb for preclinical and clinical development needs.

Macrocyclics, global leader in medical chelation chemistry applications acquired by AREVA Med in 2011, is dedicated to leading-edge innovation of new chelating agent platforms critical for the advancement of diagnostic & therapeutic medicine. The company maintains an extensive library of catalog products for basic and applied research clients as well as custom cGMP products to accelerate early stage and advanced clinical development programs. Macrocyclics also offers strategic services including consultation, site-specific bioconjugation, peptide synthesis or proteomic analysis. Macrocyclics has an established reputation for research & development specifically geared toward meeting the emerging needs of the medical community. Macrocyclics platform technologies are adaptable to a broad range of radionuclides such as 64Cu, 68Ga, and 89Zr for PET as well as therapeutic isotopes (177Lu, 166Ho, and 225Ac).

Arronax and ArronaxPlus

Booth No. 403

1 rue Aronnax
BP 10112
44817 SAINT HERBLAIN CEDEX
France
Phone: +33 2 28 21 21 29
E-Mail: arronax@cyclotron-nantes.fr
Web: <http://www.cyclotron-nantes.fr>

Arronax is a cyclotron installed in Nantes/Saint-Herblain in 2009, as a result of a 10-years long scientific partnership between medicine and nuclear physics and is considered as unique by the international scientific community (high energy, high intensity, proton, deuteron, and alpha beams, pulsed alpha beam). Arronax is managed by a public interest group (GIP ARRONAX) whose members are CNRS, Inserm, Nantes University, Institute Mines Telecom, Nantes University Hospital, ICO cancer center, Ministry of Research (MESR) and Pays de la Loire Regional Council. Its mission is to run the high energy (70 MeV), high intensity (750 µA) cyclotron Arronax for research in nuclear medicine and related fields, industrial productions and training.

ArronaxPlus equipment (4 technological and scientific platforms) is driven by GIP Arronax involving five other partners: Subatech, CRCNA, Department of Nuclear Medicine, University Hospital of Nantes and ICO, CEISAM, CEMA-Oniris. It was held in the Equipment Financing Program of Excellence (Equipex) of Investments for the Future. With a budget of € 8 million for the period from 2012 to 2019, ArronaxPlus will make additional investments in existing facilities for the development of multidisciplinary research in nuclear medicine and radiolysis and make Nantes a global hub for R & D and promotion in these areas.

Atlanpole Biotherapies

Booth No. 403



Australian and New Zealand Society of Nuclear Medicine

Booth No. 361

PO Box 6178

Vermont South

Victoria 3133 Melbourne

Australia

Phone: +61 1300 330 402

Fax: +61 3 8677 2970

E-Mail: secretariat@anzsnm.org.auWeb: <https://www.anzsnm.org.au/>

The Australian and New Zealand Society of Nuclear Medicine (ANZSNM.org.au) was founded in 1969 and is the major professional society representing all those practising Nuclear Medicine in Australia and New Zealand. The Society includes physicians, physicists, radiopharmaceutical scientists, technologists, nurses, educators, industry representatives and others interested in the practice of Nuclear Medicine. The Society is distinguished by its inclusion of all different disciplines operating at all levels of office-bearer from President to state branch and Special Interest Group (SIG) membership.

ANZSNM has close ties with other professional groups in Nuclear Medicine including the Australasian Association of Nuclear Medicine Specialists (AANMS), which represents all practising nuclear medicine physicians and nuclear radiologists, and the Australasian College of Physical Scientists & Engineers in Medicine (ACPSEM), which represents medical physicists and radiopharmaceutical scientists. The Society welcomes others such as radiologists, cardiologists and medical and radiation oncologists to participate in the Society and be involved in this expanding area of healthcare.

In 2018 the ANZSNM annual conference will be part of the WFNMB 2018 Congress, to be held at the Melbourne Convention and Exhibition Centre, Victoria, Australia from 20-24 April 2018. More details at wfnmb2018.com.

Bayer AG

Booth No. 245

Müllerstr. 178

13353 Berlin

Germany

Web: <http://www.bayer.com>

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.



Berthold Technologies GmbH & Co. KG

Booth No. 205

Calmbacher Str. 22
75323 Bad Wildbad
Germany
Phone: +49 7081 177-0
Fax: +49 7081 177-100
E-Mail: info@Berthold.com
Web: <https://www.berthold.com/en/rp/home>

BERTHOLD TECHNOLOGIES is located in Bad Wildbad, Germany. Since more than 65 years, we are developing and manufacturing high quality instruments for radiation protection.

Berthold is worldwide established as a premium supplier of radiation protection instrumentation including customised solutions. High reliability and advanced technology are our key features. The portfolio comprises of:

- Radioactive contamination measurement
- Dose and dose rate for Gammas and Neutrons in continuous and pulsed fields
- Low Level counting
- Airborne radioactivity as aerosols, Iodine, noble gas and Tritium

In addition, we provide engineering, installation and commissioning of turnkey solutions in order to meet and exceed the specific requirements of nuclear facilities and PET centres.

We invite you to visit our exhibition booth 205 in Hall X2.

Best Cyclotron Systems

Booth No. 268

413 March Road
K2K 0E4 Kanata
Canada
E-Mail: marketing@theratronics.ca
Web: <http://www.bestcyclotron.com/index.html>

Best Cyclotron Systems manufacture a range of variable energy cyclotrons including 15MeV, 25MeV, 28MeV, 35MeV, and 70MeV. These cost-effective machines are customizable for users based on their needs, and have research, diagnosis, and treatment applications. It is currently the only company in North America that produces these cyclotrons. Included in the package with the cyclotron, we also provide targets, automated radiochemistry, infrastructure, operations and maintenance support. We recently finished installing and testing a collaborative project with the Italian National Laboratory for a 70MeV proton cyclotron.

Biodex Medical Systems, Inc.

Booth No. 204

20 Ramsey Road
11967 Shirley, NY
United States

Phone: +1 631-924-9000

Fax: +1 631-924-9241

E-Mail: info@biodex.com

Web: <http://www.biodex.com/nuclearmedicine>

Biodex Medical Systems, Inc. announces their next generation of Nuclear Medicine products: Atomlab 500 Dose Calibrator, Wipe Test Counter and combination unit, the Atomlab 500 Plus. Now featuring Windows 10 Operating System and Microsoft SQL database in addition to Atomlab software, the all-in-one smart-display takes these quiet, reliable workhorses to the next level.

The Atomlab™ 960 Thyroid Uptake System features unique positioning LED for accurate thyroid centering – a first in Thyroid Uptake System design. A complete, mobile, self-contained Medical Spectrometer System, the Atomlab 960 is an advanced multi-purpose spectrum analysis instrument designed for diverse nuclear medicine applications. The NEW optional DICOM Interface program integrates the Atomlab 960 with your hospital management system, streamlining workflow and improving communication.

Clear-Lead™ Mobile X-Ray Barriers are designed for use around any imaging procedure using ionizing radiation. The unique hour-glass contour of the Clear-Lead™ Personal Mobile Barrier provides “hands-on” patient access while providing radiation protection (0.5 mm LE) where it’s needed. Ideal for CT and PET/CT Suites, Clear-Lead™ Windows are the shatter resistant choice when a large undistorted radiation protection window is necessary.

The Biodex commitment to innovative excellence spans over 60 years. Their customer-driven support is why leading medical facilities around the globe call Biodex first. Visit

Biowin

Booth No. 318

Blue Earth Diagnostics Limited

Booth No. 407

Oxford Science Park
Magdalen Centre
Robert Robinson Avenue
OX4 4GA Oxford
United Kingdom

Phone: +44 (0)1865 784186

E-Mail: contact@blueearthDx.com

Web: <http://www.blueearthdiagnostics.com>

Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The Company's first approved and commercially available product is Axumin™ (fluciclovine F 18), a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. The Company is funded by Syncona Limited, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.



British Nuclear Medicine Society

Booth No. 355

The Sir Colin Campbell Building
Triumph Road
NG7 2TU Nottingham
United Kingdom
Phone: +44 115 7484 504
E-Mail: info@bnms.org.uk
Web: <https://www.bnms.org.uk>

The British Nuclear Medicine Society (BNMS) established in 1966 is the only independent UK forum devoted to all aspects of Nuclear Medicine. The BNMS is concerned with promoting the clinical benefits of nuclear medicine and supporting the clinical practice, education, research and development of nuclear medicine within the UK. Membership is open to those who have a substantial interest and involvement in the provision of nuclear medicine services in the UK and overseas.

The official journal of the Society is Nuclear Medicine Communications.

Officers of the Society: Prof Sobhan Vinjamuri, President, Mrs Jilly Croasdale, Honorary Treasurer, Prof John Buscombe, President-Elect, Dr Richard Graham, Honorary Secretary.

At the BNMS booth, delegates can find:

- Information on BNMS membership - discount to new members signing up at the meeting.
- Information about future meetings in the UK
- BNMS Brochures and Publications
- Answers to any other questions regarding the BNMS

Pass by our stand for a chance to win Free attendance at our Spring Meeting 2018 which will be held at The ICC, Birmingham, UK on 14th – 16th April.

Bruker

Booth No. 309

Rudolf-Plank-Str. 23
76275 Ettlingen
Germany
E-Mail: raphaelle.diss@bruker.com
Web: <http://www.bruker.com>

Offering the largest range of Preclinical Imaging systems, Bruker is committed to supporting the scientific community with high-end instruments dedicated to disease research, translational science and Molecular Imaging. Our non-invasive in-vivo imaging modalities are designed to deliver greater scientific insight based on animal-centric solutions.

Bruker offers advanced preclinical imaging solutions for a broad spectrum of application areas, such as oncology, neurology, cardiology, inflammation, infectious diseases, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Our range of imaging modalities includes PET/SPECT/CT Imaging, MRI imaging, PET/MRI Imaging, and microCT imaging.



BTG

Booth No. 417

Biocompatibles UK Ltd, a BTG International group company

Lakeview, Riverside Way, Watchmoor Park

GU15 3YL Camberley

United Kingdom

Web: <https://www.btgplc.com/>

At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions.

Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers' needs, we're working to meaningfully improve the lives of patients and their healthcare experience.

Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence to help demonstrate the value of our products to doctors, patients, and healthcare systems.

Doing what's right for patients is what gets us to work in the morning. It's part of our DNA. By staying true to this principle and our values, we've earned a strong reputation for the quality of our products and our commitment to innovation.

Whether developed in our own labs or in partnership with clinicians, academics and other companies, we believe passionately that medical innovation has the power to improve human health.

Imagine where we can go.

BV Cyclotron VU

Booth No. 238

De Boelelaan 1081

1081 HV Amsterdam

Netherlands

Phone: +31 20 44 491 23

E-Mail: web@cyclotron.nl

Web: <http://www.cyclotron.nl>

BV Cyclotron VU (BVC) is founded in 1987 and located on the campus of the VU University Amsterdam, The Netherlands. We are a market-leading provider of radiopharmaceuticals and radionuclides used in imaging techniques such as SPECT and PET for medical diagnostics and research. We currently run three modern cyclotrons and several GMP-compliant production units for the production of our radiopharmaceuticals and GMP-grade radionuclides. Driven by our passion to create products that helps to improve patients' lives, our company is strongly committed to R&D. We count on our cooperation partners for the safe and reliable distribution of our products.

Our product portfolio consists of: [18F]-FDG, Zirconium-89 [89Zr], Iodine-124 [124I], other 18F-tracers like Fluoromethylcholine, Florbetaben, and [81Rb/81mKr]-generators.

For more information, please visit www.cyclotron.nl

C.CURIE bvba/sprlBooth No. 238

Jan Dekinderstraat 29/3

1731 Zellik

Belgium

Phone: +32 (0) 2 466 63 42

E-Mail: sales@ccurie.beWeb: <http://www.ccurie.be>

C.CURIE offers now a wide range of products in the nuclear medicine field and is a business partner for introducing new technologies. The new technologies are dosimetry solutions for Lu, Y and others, Cherenkov detection and more important we sell and deliver service for the new CZT technology from Spectrum Dynamics for SPECT/CT gamma cameras.

Cambridge Isotope Laboratories, Inc.Booth No. 251

3 Highwood Drive

1876 Tewksbury

United States

Phone: +1 9787498000

Fax: +1 9787492768

E-Mail: cilsales@isotope.comWeb: <https://isotope.com>

Cambridge Isotope Laboratories, Inc. (CIL) is one of the world's leading suppliers of 18O water and the preferred supplier to premier FDG providers. In response to the increasing needs of the PET community, CIL has undertaken multiple expansions of its 18O separation facility over the past few years. The combined synthetic expertise, cGMP experience and reputation for high-quality cGMP and non-cGMP nuclear medicine compounds and precursors allows CIL and its subsidiary, ABX Advanced Biochemicals, to offer complete PET chemistry solutions for the molecular imaging community. ABX is the leading supplier of PET precursors worldwide and also offers cGMP custom synthesis and development of labeling strategies for new tracers.

Canadian Association of Nuclear Medicine (CANM)Booth No. 366

P.O. Box 4383, Station E

K1S 2L0 Ottawa

Canada

Phone: +1 613-882-5097

E-Mail: canm@canm-acmn.caWeb: <http://www.canm-acmn.ca>

Please stop by the Canadian Association of Nuclear Medicine (CANM) booth (#366) for the latest information about the work of the Association and to learn more about the PANGEA Project and the publication of e-Le Patient.

Come to booth # 366 and register to receive this free e-publication aimed at giving information about nuclear medicine to referring physicians, patients and the general public. Printed copies of this publication will also be available at our booth. Please come and meet dynamic members of our Association! Bienvenue!

Capintec INC

Booth No. 314

7 Vreeland road
7932 Florham Park
United States
Phone: +1 2018259500
Fax: +1 2018251336
E-Mail: getinfo@capintec.com
Web: <http://www.capintec.com>

Capintec is a leading worldwide supplier of energy measurement products and services. Capintec is dedicated to continuous quality improvement that leads to uncompromising quality in the development of the most advanced technology and services in the industry.

For over 50 years, Capintec has been recognized as a world leader in the development, manufacturing and marketing of state-of-the-art radiation measuring and monitoring instrumentation. With thousands of instruments in use world-wide, the company continually provides new and innovative solutions to radiation measuring applications. By offering products with applications in Nuclear Medicine, Nuclear Cardiology, Oncology, Endocrinology, Diagnostic Radiology, and Radiation Therapy, the company continues to grow.

CASRAM SA

Booth No. 246

Via Cantonale 31
6805 Mezzovico
Switzerland
Phone: +41 91 611 21 10
E-Mail: info@casram.com
Web: <http://www.casram.com>

CASRAM is a Swiss producer of sintered Tungsten alloys.

From the powder metallurgy workshop down to the final inspection after machining according to your drawings, CASRAM provides the complete manufacturing process of any kind of radiation shielding devices.

Most common applications are vial containers, syringe shieldings, collimators, MLC's and other various shielding components.

CASRAM is certified by EN 9100, ISO 9001, ISO 14001, OHSAS 18001.



CBmed GmbH - Center for Biomarker Research in Medicine Booth No. 257

Stiftingtalstrasse 5

8010 Graz

Austria

E-Mail: office@cbmed.atWeb: <http://www.cbmed.org>

CBmed, a limited company owned by Austrian (medical) universities and research centers, is a federal funded competence center for excellence that was founded in 2014. CBmed links excellent research infrastructure (e.g. CoreLabs for metabolomics, NGS, proteomics, immunology, MALDI-MS and in-vivo imaging), scientific expertise and medical knowledge with national and international industry partners for systematic medical biomarker research.

CBmed brings together scientific experts with leading pharmaceutical, diagnostic, medical-technology and IT industry partners. In addition, CBmed has a strong network in the area of Biobanking including the largest Biobank in Europe, Biobank Graz, and became the first certified Expert Centre for the European Biobanking Research Initiative, BBMRI-ERIC.

Currently, the 25 running CBmed research projects are identifying new biomarkers, validating potential biomarkers and conducting translational biomarker research for products to be used in clinical practice. CBmed's goal is to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients. Therefore, combining multi-omics technologies with in-vivo molecular imaging is the ultimate aim.

CBmed COMBINES!

Visit our booth to find out more and explore cooperation opportunities!

Center of Molecular Research

Booth No. 206

CHELATEC

Booth No. 403

1 rue Aronnax

44821 SAINT-HERBLAIN

France

Phone: +33 2 51 86 19 59

E-Mail: contact@chelatec.frWeb: <http://www.chelatec.fr>

Chelatec is a private company founded in 2000, providing Research and Development services in Radiolabelling and Preclinical Studies. Areas of expertise include: Radiopharmaceuticals, Customized radiolabeling, Small animal studies, Binding assay, Immunoreactivity...Our three-years perspective: Business Units dedicated to the centralized manufacturing of Radiopharmaceuticals for clinical applications.

CHEMATECH

Booth No. 259

2 rue Pauline Kergomard

Parc Mazen-Sully

21000 Dijon

France

Phone: +33380441900

Fax: 33380441901

E-Mail: info@chematech-mdt.com

Web: <http://www.chematech-mdt.com>

CheMatech is a unique company in Europe specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labelling especillay with ^{67/68}Ga, ¹¹¹In, ^{64/67}Cu. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also realizes custom syntheses of new chelators.

Cisbio

Booth No. 260

Parc Marcel Boiteux

30200 Codolet

France

Phone: +33 466796811

E-Mail: fservert@cisbio.com

Cisbio Bioassays is a privately held life sciences company committed to improving human healthcare. With more than 30 years of experience in vitro diagnostics and drug discovery, we provide creative technological solutions and partnerships to the global scientific community.

With more than 30 years of development in immunoassays (RIA and ELISA) in Oncology and Endocrinology, Cisbio Bioassays is a partner of choice for medical device in ELISA for specialized testing, like Chromogranin A, Hyaluronic Acid, N terminal Procollagen III Peptide and S100A12.

Cisbio Bioassays has facilities in France, the United States, China and Japan, and a network of distributors across the globe.

The Exhibiting COMPANY's main areas of activity are:

- Endocrinology
- Fertility
- Autoimmunity
- Tumors markers



CMR Naviscan Corporation

Booth No. 218

2720 Loker Avenue West Suite O
92010 Carlsbad, CA
United States
Phone: +1 877 260 1360
E-Mail: info@cmr-naviscan.com
Web: <http://www.cmr-naviscan.com>

CMR Naviscan Corporation develops and markets compact, high resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The CMR Naviscan Solo II High Resolution PET scanner is currently installed and available in breast imaging centers throughout the world. Through a unique combination of gentle immobilization, advanced photonics and image processing, the scanner provides tomographic images with a resolution as small as 1.6 mm, with Sensitivity and Specificity greater than 90 % for index lesions. PET-Guided Biopsy Accessory is available with the scanner. CMR Naviscan offers its products and services globally through a team of local representatives.

COMECER GROUP

Booth No. 412

VIA MAESTRI DEL LAVORO 90
48014 CASTELBOLOGNESE
Italy
E-Mail: marketing@comecer.com
Web: <http://www.comecer.com>

Comecer, founded in Castel Bolognese (Italy) in the mid 1970's, is a world leader in protection technologies in the field of nuclear medicine, pharmaceutical isolation technology and nuclear power plant equipment.

Comecer produces shielding systems and equipment for special applications, designed for large industrial groups and research organizations. We work for hospitals, universities and pharmaceutical companies on tailored projects for the production of isolators for the treatment of toxic substances to be kept in safety. For nuclear plant management, we produce equipment for the processing, deactivation and disposal of radioactive substances deriving from nuclear plants.

From 2012 Comecer is became a Part of Comecer Group after the takeover of the companies Veenstra and Vitrae Czech.

At present, the Group employs 280 people and has achieved a turnover of 55 million Euro in 2016.

With two production sites in Castel Bolognese (Italy) and Joure (Holland), locations at Hradec Kralove (Czech Republic), Philadelphia (Usa), Dubai (Uae), Mumbai (India) and Taipei (Taiwan), Comecer markets its products in over 100 countries worldwide through a direct sales network and through partnerships with some of the largest producers of nuclear medicine equipment.

Crystal Photonics GmbH

Booth No. 242

Albert-Einstein-Straße 16

12489 Berlin

Germany

Phone: +49 30 34669300

Fax: +49 30 34669299

E-Mail: info@crystal-photonics.comWeb: <http://www.crystal-photonics.com>

Crystal Photonics is engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and for intraoperative and transcutane sentinel lymph node localization (SLNE) since 20 years. With our probes starts the also new PSMA-technology for Prostate Cancer. We present our very new Hand-Held-Gamma-Camera "CrystalCam" and the surgical Gamma Probe System "Crystal Probe - automatic" with our excellent "Wireless Probe", various cable probes and a set of outstanding Laparoscopic Probes for minimal invasive surgeries (MIC).

A wide range of miniaturized nuclear radiation detectors for synthesis modules and GRP-conform analysis of tracers completed our program. Latest development is the "CrystalAnalyzer" - a coincidence measuring system of positron-emitting tracers for application in the HPLC and small animal investigations, which don't need any shielding. For more information, please visit www.crystal-photonics.com

CSNM - Chinese Society of Nuclear Medicine

Booth No. 365

West China Hospital, Sichuan University**Add: No. 37 Guo Xue Xiang****610041 Chengdu, Sichuan****China**

Chinese Society of Nuclear Medicine (CSNM) is a branch of Chinese Medical Association. In May 1980, the first National Conference of Nuclear Medicine was held in Shijiazhuang, Hebei province, and CSNM was found.

CSNM devotes its great attention to nuclear medicine extend and application in China through academic promotion, professional training, government's adviser, international exchange and related collaboration with other domestic and international associations.

CSNM consists of about 9000 members who come from 31 provinces across China and play very important roles in their local areas from establishing a new unit to developing a novel technology of nuclear medicine. Base on standing committee decisions, suggestions and CSNM's guidelines, all of subcommittees and task groups carry out specialized works and projects dealing with clinical diagnosis, management and basic research for heart, lung, brain, bone, thyroid, kidney, liver, and many other organs and systems. CSNM makes great contributions in many fields to keep up a steady increase of nuclear medicine in China.



Curium

Booth No. 307

20 rue Quentin Bauchard
75008 Paris
France
Phone: +33 1 69 85 70 70
E-Mail: contactus@curiumpharma.com
Web: <http://www.curiumpharma.com>

Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Formed by the merger of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry.

With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine. To learn more, visit curiumpharma.com.

Cyclomedica Europe Ltd.

Booth No. 413

Unit A5 Calmount Business Park, Ballymount
12 Dublin
Ireland
Phone: +32 473 56 05 56
E-Mail: rvanloon@cyclomedica.com
Web: <http://www.cyclopharm.com.au>

Cyclomedica is a radiopharmaceutical company servicing the global medical community. The company's mission is to provide nuclear medicine- and referring physicians with the ability to improve patient care outcomes.

Cyclomedica is well-known for its Technegas Generator. For more than 30 years Technegas is the leading technology for the diagnosis of pulmonary-embolism with a valuable diagnostic contribution to the clinical management of patients suffering from other respiratory diseases like COPD and Asthma.

The Technegas technology produces radioactive labeled carbon nanoparticles, after adding Technetium-99m to a carbon crucible and heating it for a few seconds at around 2.700 °C. In as little as 2 to 3 breaths, a combination of nanoparticles in argon gas is inhaled by the patient via a breathing apparatus, which then allows multiple views and tomography imaging under a SPECT camera to diagnose various types of pulmonary and ventilation disorders.

Recent advances in camera hardware and software technology have created a new landscape for Technegas. The co-registration of SPECT and CT, have now given clinicians the ability to generate a ventilation and perfusion study that is quantifiable to the lobular level. The result is a diagnostic tool that provides quantifiable functional and structural imaging of the lungs.

NEW

During this EANM 2017, Cyclomedica will launch the Radioisotope Concentrator (ULTRALUTE). This device permits high specific activity elution, thereby exten



CYCLOPHARMA

Booth No. 210

3 rue Marie Curie
Biopôle Clermont Limagne
63360 Saint Beauzire
France
Phone: +33 4 73 63 27 00
Fax: +33 4 73 63 27 05
E-Mail: contact@cyclopharma.fr
Web: <http://cyclopharma.fr/fr/>

Created in 2000, Cyclopharma is specialized in the development and the commercialization of molecular imaging solutions resolutely innovation-oriented, capable of characterizing diseases and adapted to patients' specificities.

With more than 100 collaborators and a turnover of 20 millions euros, Cyclopharma is investing intensely in R&D and collaborative development. Thanks to a dense territorial grid, Cyclopharma has been starting its international development since 2015, with the objective of becoming the European leader of personalized medicine.

DDD-Diagnostic A/S

Booth No. 311

Dr. Neergaards Vej 5E
2970 Hørsholm
Denmark
E-Mail: info@ddd-diagnostic.dk
Web: <http://www.ddd-diagnostic.dk>

DDD Diagnostic A/S, based in Denmark, manufactures a range of gamma cameras from organ specific cameras to general purpose cameras. Until 2012, DDD Diagnostic A/S was an OEM manufacturer involved in the design and development of some of the most successful gamma camera systems used in the world. DDD has been in the market since 1987, and presently there are more than 2500 DDD-manufactured gamma cameras installed worldwide.

Today, DDD Diagnostic A/S develops and markets the gamma camera systems described below under its own brand name. DDD cameras are durable and reliable with small footprint and superb image quality.

- QuantumCam, a dual-head general purpose SPECT camera that can be used for routine nuclear medicine procedures and useful in hospitals with limited space
- CorCam, a dedicated cardiac camera with 90-degree fixed detector design that allows performance of prone- and supine cardiac imaging
- Solo, a small Field of View system for planar imaging that can be used for low and high energy isotopes
- Solo Mobile, a mobile small Field of View gamma camera that runs on battery and easily can be moved around the various hospital departments
- NephroCam, a large Field of View, single-detector camera for Radioisotope Renography

DDD-Diagnostic A/S is represented worldwide by independent local companies with exclusive rights for marketing, selling and servicing the products developed and manufactured under DDD Diagnostic's own



DIAsource ImmunoAssays SA

Booth No. 318

rue du Bosquet 2
1348 Louvain-la-neuve
Belgium
Phone: +32 10849911
E-Mail: info@diasource.be
Web: <http://www.diasource-diagnostics.com>

30 years of experience in IVD (kits and instrumentation)

DIAsource ImmunoAssays®, an international diagnostic company based in Belgium, develops, manufactures and markets clinical diagnostic products in the field of endocrinology and infectious diseases.

We are committed to Vitamin D, including IVD and RUO Products. Our panel of assays allows the performant detection and measurement of various forms of Vitamin D metabolites : 25OH Vitamin D, 1,25(OH)₂ Vitamin D.

Constantly looking for new technologies and applications, we put our expertise in the development of new antibodies and assays to measure relevant biomarkers. We are strengthening our position in the diagnostic market by validating our ELISA assays on our open automate. These innovation mark a turning point for our company, and makes of DIAsource, already renowned in the RIA market, a complete diagnostic provider.

We also provide selected instrumentation : we offer Elisa reader, washer and shaker, along with open and closed fully automated Elisa platforms helping our customers to automate their tests.

Present in more than 75 countries through his professional network of 80 distributors, DIAsource ImmunoAssays® also sells directly his own products and products from other selected manufacturers to IVD laboratories in some European countries.

In January of 2016 DIAsource ImmunoAssays® has been acquired by Anteo (www.anteodx.com).

DIXIT s.r.l.

Booth No. 267

Via Giacosa 38
10125 Torino
Italy
Web: <http://www.widen.it>

Dixit, a spin-off of the University of Turin and the Italian National Institute of Nuclear Physics (INFN), is a company specialised in imaging management within clinical trials.

It developed WIDEN (www.widen.it), a Web Service designed to make the management and review of imaging studies in clinical trials simpler, more effective and more reliable. In such a way trials can scale in size and statistical significance can be achieved in a short time.

Dixit works with leading international imaging and oncological societies and cooperative groups that use qualitative and quantitative imaging, especially PET, in their cancer treatment protocols.

Since 2012, WIDEN has been used in more than 20 multi-centre clinical trials, whose coordinating bodies reside in Austria, France, Italy and Switzerland. WIDEN users are located in 25 different countries and more than 200 clinical centres.

WIDEN is also suitable for retrospective imaging-based clinical trials, that could be simply configured and operated. Their data can be easily analysed, so as to quickly evaluate the results and design more ambitious, prospective trials to validate them.

DOSISOFT

Booth No. 316

45-47 Avenue Carnot
94230 CACHAN
France
Phone: +33 141242626
E-Mail: info@dosisoft.com
Web: <http://www.dosisoft.com>

Founded in 2002, DOSIsoft is a leading software editor specialized in RT Planning, Patient QA and Molecular Imaging. Over 160 centers in 18 countries use its comprehensive and innovative vendor-neutral solutions to treat patients suffering from cancer.

PLANET® Onco: solution to help Physicians in the implementation of Oncology techniques like Diagnosis, RT, Chemotherapy, Adaptive therapy with complete structure segmentations: GTV, BTV, CTV, PTV, OAR and quantified therapy monitoring from multimodal imaging (CT, MRI, PET, SPECT).

PLANET® Onco also provides advanced feature extraction and texture analysis for patient therapy response assessment and machine learning / radiomics studies.

PLANET® Dose: complete, versatile and high-performance software for personalized 3D dosimetry applied to Targeted Radionuclide Therapies in particular based on 90-Yttrium microspheres and 177-Lutetium. It provides pre & post-implementation dosimetry, estimation of time-integrated activity and allows comparison possibilities between treatment planning and validation control dose maps. Consolidation of multi-treatment stages is also available.

PLANET® Neuro: solution designed to increase accuracy and confidence in the diagnosis of neurodegenerative diseases especially Alzheimer, dementia with Lewy bodies, Parkinson and Epilepsy. It allows you to create your own database of normality with your SPECT/PET data.

Dutch Society of Nuclear Medicine

Booth No. 354

Emmastraat 2 A
4811 AG Breda
Netherlands
Phone: +31 850200625
E-Mail: info@nvng.nl
Web: <http://www.nvng.nl>

The Dutch Association of Nuclear Medicine (NVNG) was founded in 1968 and has a multidisciplinary character. Its members are predominantly from the disciplines of chemistry, pharmacy, physics, medicine and radiochemistry. The association currently has 420 members.

Aim:

Dutch Association of Nuclear Medicine aims the promotion of nuclear medicine , with particular attention to quality , such as the correct application of radioactive substances in the medical field , as well as scientific research and organizational and social aspects.

In co-operation with Kloosterhof Neer BV the Dutch Association of Nuclear Medicine publish:

- The Procedure Guidelines in Nuclear Medicine

With our first loose leaf edition appearing in 1988, our profession was already aware that the practice of Nuclear Medicine is not an arbitrary matter but that patients deserve that we perform diagnostics and treatment in an unambiguous and accountable manner.

There are three reasons that make this edition a rather special one.

- o Firstly, this is not only a work of revision but also, with many new chapters, of complete renewal.
- o Secondly, this will be the last edition to appear in print. With advancing digitization, revision will be done on a continuous, online and modular basis from now on.
- o Thirdly, owing to surging interest in and from neighbouring nations, this revision has been published in English.



EARL - EANM Research Ltd

Booth No. 351

Schmalzhofgasse 26
1060 Vienna
Austria
Phone: +43 (0)1 890 44 27
Fax: +43 (0)1 890 44 27 9
E-Mail: earl@eanm.org
Web: <http://www.earl.eanm.org>

EARL is a 100% subsidiary of the EANM, founded in 2006 in order to promote research in the field of Nuclear Medicine and Molecular Imaging. Its focus is on enhancing quality of Nuclear Medicine Practice for the benefit of public health. In this regard EARLs main activity is the EARL FDG PET/CT Accreditation for providing a standard of PET/CT Scanner performance to harmonize the acquisition and interpretation of PET/CT Scans, which is essential in multi-centre trials as well as clinical practice.

To learn more about EARL please visit us at the booth!

ec² Software Solutions

Booth No. 219

3035 E. Patrick Lane
Suite 1
89120 Las Vegas
United States
Phone: +1 9738850904
E-Mail: dcarr@ec2software.com
Web: <http://www.ec2software.com>

ec² Software Solutions LLC., the leading software provider to the Molecular Imaging Community, recently acquired Numa LLC., a software company focused on developing and commercializing workflow and compatibility solutions for molecular imaging. Together, ec² and Numa provide innovative management solutions for cyclotrons, radiopharmacies, hot lab operations, image processing, archiving and reporting.

Nuclear Medicine Information System (NMIS) and BioDose:

These programs are used in the largest medical centers and outpatient imaging clinics to manage their Nuclear Medicine, Nuclear Cardiology and PET departments.

BioTrax QMS: This 21CFR Part 11 validated quality management system is used in PET and Pharma manufacturing facilities.

Radiopharmacy Management Information System (RMIS) and BioRx: These programs are used in radiopharmacies worldwide to manage the production and distribution of radioactive isotopes.

NumaStatus: NumaStatus is a web based application that is optimized to accurately and easily report the patient's radiation dose for nuclear medicine and PET procedures in a DICOM format.

NumaLink: NumaLink is a valuable tool for exchanging patient studies between nuclear medicine computer systems or nuclear medicine and PACS.

NumaStore: NumaStore provides a robust, reliable, and user-friendly image





Eckert & Ziegler Radiopharma Segment

Booth No. 302

Robert-Rössle-Straße 10

13125 Berlin

Germany

E-Mail: info.radiopharma@ezag.deWeb: <http://radiopharma.com/>

Eckert & Ziegler Radiopharma is a business division of the Eckert & Ziegler group, with headquarters in Berlin, Germany. We are specialized in the field of nuclear medicine and molecular imaging. Our core competence is the provision of pharmaceutical services as well as versatile, innovative and high-quality technical solutions. Our product portfolio consists of radiochemicals, radiopharmaceuticals (Yttriga and GalliaPharm – the world's first pharmaceutical grade GMP Ge-68/Ga-68 Generator), a wide range of radiosynthesis technology (Modular-Lab), radiochromatography equipment and accessories.

Our expertise in trivalent metals for Theranostics purposes empowers us to support ambitious startups and institutions with knowhow, technical and radiochemical support as well as financial assistance.

Our well established network of production sites produces different radiopharmaceutical products for compound labeling. Furthermore, we offer contract manufacturing of medicinal products or components for clinical trial supply as well as commercial purposes.

Eckert & Ziegler Isotope Products

www.ezag.comisotope@ezag.com

Eckert & Ziegler Isotope Products offers the world's largest range of sealed radiation sources for quality control in nuclear imaging, therapeutic radiology and biomedical applications. Products include Co-57 flood sources, OEM-quality replacement Ge-68 and Gd-153 sources for PET and SPECT applications, a complete range of multi-modal markers and other reference or calibration products necessary for today's nuclear medicine departments.

Eczacibasi Monrol Nuclear Products

Booth No. 313

Barbaros Mh. Sutcu yolu Cad. No:72/A Atasehir

34746 Istanbul

Turkey

Phone: +90 216 544 0 544

Fax: +90 216 472 4148

E-Mail: info@monrol.comWeb: <http://www.monrol.com>

Eczacibasi Monrol Nuclear Products has been leading the development of the Turkish Nuclear Medicine market with the production of high-quality radiopharmaceuticals as a market leader and is the first company carrying out radioisotope R&D activities in Turkey.

Eczacibasi Monrol has 10 world-class production facilities, 6 in Turkey and 4 international (Bulgaria, Poland, Romania, Egypt) employing modern and environment-friendly technologies. The company also has been operating cyclotrons in Kuwait, United Arab Emirates and Ankara. Both local and international facilities are utilized by a range of PET and SPECT products complying fully with all national and international regulations related to its manufacturing and service activities, including current GMP, to ensure that its products are of the highest quality.

Along with its production capabilities Eczacibasi Monrol also offers global brands to Turkish Nuclear Medicine Market via its strong distribution channels. For the international market, Eczacibasi Monrol does not only export over 35 countries but also is the solution partner supplying start-up, operational and hand-over services.

Edizioni Minerva Medica

Booth No. 369

Corso Bramante, 83**10126 Torino****Italy****Web:** <http://www.minervamedica.it>

Edizioni Minerva Medica S.p.A. publishes some forty scientific journals which are indexed by the most important international bibliographic databases. Many of them are the official organs of important Italian and foreign medical societies.

The Minerva Medica catalogue lists over 1,500 scientific titles which target medical students, physicians and nurses and they represent a benchmark in scientific literature for all medical and surgical specialties.

Today the third and fourth generations are perpetuating the tradition of the founder faithful to his belief that it is best if a publisher of medical books and journals always remains in touch with clinical reality.

On these sound foundations, Minerva Medica plans a future packed with new ideas and new projects fully abreast of the times.

EITA

Booth No. 368

Maanstraat 17/19**2800 Mechelen****Belgium****E-Mail:** info@eita.org**Web:** <http://www.eita.org>

EITA is a non-profit association, which was founded in 1998 by European logistics companies, trained, licensed and specialized in handling and transport (by Road, Air and Sea) of radioactive isotopes, which are mainly used for medical purpose and / or research.

The key objectives of EITA:

- To perform all activities related to the handling, packing and transport of radioactive isotopes in full compliance with the highest levels of safety and security taken into account the requests and the demands of the industry including public health care. In order to guarantee this commitment all our members obtained the EITA Quality label.
- To represent our members and the industry at national, international and European meetings aiming for harmonized and clear regulations, taking into account the developments in the industry.
- To provide a forum for our members by means of meetings, symposia, conferences to exchange information and to get updated with the latest changes and developments in the world of radioactive isotopes.
- To increase the awareness of the public in relation to the handling, transport and use of radioactive isotopes.
- To keep permanent contact with the industry and competent authorities to be able to react immediately to any upcoming change in the market as well as to any change in the legal environment.

Contact persons during the conference: Mr. Serge Goossens



Elimpex-Medizintechnik GesmbH

Booth No. 209

Spechtgasse 32

2340 Mödling

Austria

Phone: +43 2236 410450

Fax: +43 2236 410459

E-Mail: info@elimpex.com

Web: <http://www.elimpex.com>

Elimpex-Medizintechnik offers a full range of innovative solutions for Nuclear Medicine, Diagnostic Radiology, Radiation Therapy and Radiation Safety

We offer:

- Software solutions
- Measurement systems for Diagnosis, Radiation Safety, Monitoring
- Hot lab and Iodine therapy equipment

Elysia S.A.

Booth No. 317

Cyclotron, Allée du Six Août 8 (B30)

4000 Liège

Belgium

Phone: +3242427850

E-Mail: info@elysia-raytest.com

Web: <http://www.elysia-raytest.com>

Elysia-raytest is a solution provider for radio-pharmaceutical producers and nuclear medicine departments. We provide radio synthesis units, LIMS solutions, services, chromatography and quality control systems to nuclear medicine departments and to radio-pharmaceutical industries.

We design, manufacture, sell and service instruments used for the measurement of radioactivity and quality control, in close collaboration with radiopharmaceutical providers to develop new products and improve existing solutions.

Our mission is to make the measurement of radioactivity, the peptide labelling and quality control of radiopharmaceuticals easier, faster and safer.

To find out how Elysia can help you, please visit us at booth 317 or check our website.



EPSILON ELEKTRONIK SAN. VE TIC. A.S

Booth No. 312

19 MAYIS MH DR SEVKET BEY SK NO:3/A SISLI
34360 ISTANBUL
Turkey
Phone: +90 212 219 56 57
Fax: +90 212 219 82 22
E-Mail: info@epsilonsources.com
Web: <http://www.epsilonsources.com>

Epsilon Elektronik was established in 1993 to provide sales, marketing, and technical service activities in the healthcare sector. The company has initiated its product research and development activities in 2008 and started to produce high-quality Ge-68 quality assurance sources for PET and PET-CT systems.

In 2013, ERS (Epsilon Radioactive Sources) brand name was established and started to produce nuclear medicine quality assurance sources under this brand name. The company has enriched its product range by adding PET and PET-CT quality assurance sources for other major OEM manufacturers, Co-57 flood sources, dose calibrator reference sources, spot markers, rod sources in 2014 respectively. ERS serves high-quality radioactive source products including PET and PET-CT sources, dose calibrator sources, flood sources, spot markers and rod sources for the nuclear medicine market in Europe, Middle East, South Africa and Far East countries through its specialized distributor network. ERS continues to invest in research and development activities of ERS in order to develop new and customized sources and sustain international growth.

EUROMEDICAL INSTRUMENTS

Booth No. 238

3 rue de l'Arrivée
CIT - BP 241
75749 Paris Cedex 15
France
Phone: +33 (0) 983 62 63 17
Fax: +33 (0) 972 38 81 35
E-Mail: sales@em-instruments.com
Web: <http://www.em-instruments.com>

EUROMEDICAL Instruments sarl is the exclusive worldwide sales and marketing company of the Europrobe, a state-of-the-art surgical gamma probe manufactured by EUROAD SA, Strasbourg, France, one of the main manufacturers in the world for this type of equipment.

EURORAD SA, founded in 1982 (based in France) is a high technology company specialised in R&D, Service and Production of mono and polycrystalline semiconductors for radiation detectors.

The Europrobe has specifically been designed to meet the needs of surgeons and nuclear medicine physicians. It enables to accurately detect areas of increased radionucleotide uptake. Europrobe is unsurpassed in its ability to detect a wide range of isotopes, and is ideal in a wide range of applications including, radioguided surgery, sentinel node detection, direct detection of labeled cells...

With a single Readout Module and a whole range of gamma probe options, Europrobe fulfils all the needs of per-operative and percutaneous detection within 7 major clinical fields: Breast, Gynaecology, Dermatology, Head & Neck, Endocrinology, Urology and Nuclear medicine.

Furthermore, a Fluorescent detection modality was recently added via an add-on module, which in combination to the core gamma detection, enables to reach close to 100% detection of sentinel nodes, and thus fulfils standard of care's dual detection obligation.

Europrobe systems are commercialised in 67 countries worldwide, including the USA, and since



European Federation of Radiographer Societies EFRS

Booth No. 350

Catharijnesingel 73
3511GM Utrecht
Netherlands
Phone: +31 118640703
E-Mail: info@efrs.eu
Web: <http://www.efrs.eu>

The EFRS is a non-profit organisation, set up by professional societies that represent radiographers in the geographic continent Europe.

The role of the EFRS is to represent, promote and develop the profession of radiographers in Europe, within the whole range of medical imaging, nuclear medicine and radiotherapy.

European Institute for Biomedical Imaging Research (EIBIR)

Booth No. 362

Neutorgasse 9
1010 Vienna
Austria
Phone: +43-1-533-4064-13
E-Mail: office@eibir.org
Web: <http://www.eibir.org/>

The European Institute for Biomedical Imaging Research (EIBIR) supports researchers and industry partners in the coordination of biomedical imaging research throughout Europe and beyond. EIBIR offers expert advice, professional project management and coordination, dissemination and exploitation services for dedicated international collaborative research projects and clinical studies. Since its foundation in 2006, EIBIR has helped biomedical imaging researchers gain almost €80 million in funding.

As a non-profit organisation, EIBIR provides its proposal preparation and project management services to researchers on an institutional membership basis. For a moderate annual fee, researchers within an institution can avail of EIBIR's experienced and expert support. EIBIR currently has more than 80 institutional members from 20 countries across Europe.

European Society of Radiology (ESR)

Booth No. 204A

Neutorgasse 9
1010 Vienna
Austria
Phone: +43-1-533-4064
E-Mail: office@myesr.org
Web: <http://www.myesr.org/>



GAEDE Medizinsysteme GmbH

Booth No. 265

Im Moos 6**D-79112 Freiburg****Germany****Phone: +49 (0)7665-93457-0****Fax: +49-(0)7665-93457-20****E-Mail: info@gaede.de****Web: <http://www.gaede.com>**

For more than 25 years GAEDE has been known as the company in Germany that develops, produces and distributes its own nuclear medical systems and software.

The production center is located in Freiburg, in the south west of Germany.

Having regional marketing and service centers as well as distributing companies abroad, GAEDE provides service for many installed systems in Germany, Austria, France and Switzerland as well as in other countries.

With the development of new completely digital detector electronics and a dual detector SPECT system with variable detector positioning the production focus has now shifted to these systems, with interest from customers all over the world.

For certain camera systems of other manufacturers GAEDE offers the refurbishment of detectors and modernization of the nuclear medical processing system.

Range of Products

GKS-2000	Dual Head SPECT Camera	54 cm x 40 cm
GKS-2000	Cardiac Dual Head Cardiac Camera	37 cm x 21.5 cm
GKS-1	Thyroid Camera	18 cm x 18 cm
GKS-1000	SPECT Camera	54 cm x 40 cm
GKS-400	Planar Camera	40 cm x 40 cm
GKS-300	Medium Field Camera	30 cm x 30 cm
GKS-200	Small Field Camera	22 cm x 22 cm

For more details please visit our website : www.gaede.com

GE HEALTHCARE

Booth No. 416

Chalfont St.Giles**HP8 Buckinghamshire****United Kingdom****Web: <http://www.gehealthcare.com>**

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

German Society of Nuclear Medicine (DGN e.V.)

Booth No. 353

Nikolaistraße 29
D-37073 Göttingen
Germany
Phone: +49 551 488 57401
Fax: +49 551 488-5779
E-Mail: office@nuklearmedizin.de
Web: <http://www.nuklearmedizin.de>

The German Society of Nuclear Medicine (DGN e.V.) is a scientific society with headquarter in Göttingen. Its goal is to promote nuclear medicine in basic and applied research in the fields of diagnostics, therapy, and radiation protection. This is done at national and increasingly at international level too. The DGN e.V. has about 1,500 members, including not only specialists in nuclear medicine and physician from other disciplines but also engineers and scientists. Its president is Prof. Dr. Bernd Joachim Krause from the Department of Nuclear Medicine, University Hospital Rostock.

For more information, please visit www.nuklearmedizin.de

Getinge La Calhène

Booth No. 422

1 rue du Comte de Donegal
41100 VENDOME
France
Phone: +33 2 54734747
Fax: +33 254734748
E-Mail: marketing-contact.glc@getinge.com
Web: <http://ic.getinge.com/nuclear/>

Since its founding in the 1960's Getinge La Calhène (part of the Getinge group) has developed innovative solutions complying with safety, security, reliability and performance constraints. The equipment designed, manufactured and serviced by the company contributes to the safe transport of fissile materials / pharmaceutical materials and protection of operators in the nuclear and pharmaceutical industries.

DPTE® patented transfer solutions are installed in hot cells, on isolators and pharmaceutical production lines throughout the world. Our DPTE® equipment ensures secure, ultra-clean transfer of sterile and/or toxic materials, into and out of clean zones. It is the industry standard for transfer of aseptic or toxic products in nuclear and biomedical research institutions and the pharmaceutical industry globally.

Leak-tight bi-directional transfer is assured with our wide range of Beta parts including re-usable containers (PE, stainless steel), tubing and DPTE-BetaBag® in a variety of diameters, volumes and materials to suit a variety of applications.

La Calhène supplies the nuclear industry and nuclear medicine laboratories with a complete range of remote manipulators for all standard and specific applications, from the small capacity MA 30 to the large capacity MT 200 (telescopic type), including the MT 200 TAO computer-assisted remote manipulator with robotic function. Isolators, shielded casks (PADIRAC and AGNES) and glove box equipment complete the company's range.



Hake Medical Technology (Beijing) Co. Ltd.

Booth No. 258

Building 6 No. 9, Tianfu Road
Biomedical Industrial Park
Daxing District
102600 Beijing
China
Web: <http://www.hake.net.cn>

Hake Medical Technology (Beijing) Co., Ltd. is a publicly listed (Stock Code: 837371) professional company in providing one-stop solution for medical radiation. For its innovative products and services, Hake Medical was awarded as National High-tech Enterprise and Zhongguancun High-tech Enterprise, the only company awarded the honor in the industry. Hake Medical focused on providing radiation protection and shielding to nuclear medicine, radiology, radiotherapy and MRI department, as well as detection and monitoring of radiopharmaceuticals.

Hake Medical was founded in 2005, with headquarter in Biomedical Industrial base in Beijing and branch covering main cities of China.

Hellenic Society of Nuclear Medicine and Molecular Imaging (HSNM&MI)

Booth No. 352

Ippokratous 44-46
106 80 Athens
Greece
Phone: +30 210 5238777
Fax: +30 210 5203 710
E-Mail: info@nuclear-medicine.gr
Web: <http://www.nuclear-medicine.gr/>

Hellenic Society of Nuclear Medicine and Molecular Imaging (HSNM&MI) was founded in 1968, as Greek Society of Nuclear Medicine and Biology, by the renowned Honoured Member of the Academy of Athens for Sciences and Philosophy, Professor of Medicine V. Malamos. It is one of the oldest European societies in nuclear medicine and its membership now numbers approximately 400.

Society Mission:

- Expert Consulting for the Greek State that guides and constructs Regulations and Institutions in Nuclear Medicine, like Education, Retraining, Radiation Protection and Dosimetry.
- Actions to ensure the education to Nuclear Doctors, training in the highest possible level and creating the right conditions for continuous education of its members. Simultaneously provide continuous training to trainees and all health professionals working in the field of nuclear medicine.
- Creates committees which are referring and recommending to the Board of Directors issues and solutions affecting the Nuclear Medicine.
- Protecting and establishing the spiritual property of its members.

Nuclear Medicine Departments in Greece:

- 25 departments in the public hospitals and even more departments in private hospitals
- 12 PET-CT cameras (in both public and private practice departments).

International Congresses hosted by HSNM&MI:

- European Nuclear Medicine Congress (Athens, 1970's)
- 19th EANM Congress (Athens, 2006)
- 5th BCNM Congress (Thessaloniki, 2016)
- Candidate for 14th WFNMB (Athens, 2026)



Hermes Medical Solutions AB

Booth No. 301

Skeppsbron 44
111 30 Stockholm
Sweden
Phone: +46 (0) 8 19 03 25
Fax: +46 (0) 8 18 43 54
E-Mail: info@hermesmedical.com
Web: <http://www.hermesmedical.com>

Recognised for over 40 years for Clinical Excellence and Innovation in Molecular Imaging, HERMES Medical Solutions delivers end to end Clinical Workflow for the integration, visualization, processing, reporting and archiving of imaging data from multiple modalities within Molecular Imaging and Radiology. Our solutions enable physicians to provide faster and more accurate diagnosis and more effective treatment of patients, thereby improving patient outcome and increasing efficiency.

HERMES Medical Solutions' leadership within Molecular Imaging has been built upon technological innovation, financial stability and, historical success. We are committed to the continuous development of cutting-edge software solutions for clinical environments, academic institutions and industry partners. HERMES Medical Solutions offers the most comprehensive Enterprise Molecular Imaging solutions available for diagnosis and treatment planning, making Precision Personalised Medicine a reality.

We look forward to welcoming you to booth 301

Hidex Oy

Booth No. 406

Lemminkäisenkatu 62
20520 Turku
Finland
Phone: +358 107435570
E-Mail: marja.lindell@hidex.com
Web: <http://hidex.com/>

Hidex is a high technology company which develops and manufactures high performance analysis equipment for life science research, radiation measurement and nuclear medicine. Our products utilize modern technology and excellent tradition of workmanship. With strong links to the scientific community we continue to innovate and develop to improve scientific research and safety of everyday life.

For Nuclear Medicine applications Hidex offers Oxygen-15 labelled water generator systems. Oxygen-15 water is the gold standard in blood flow studies. Cardiac imaging and PET/MRI applications are convenient, safe and easy with the automated Hidex Radiowater Generator.

During the EANM'17 Hidex is proud to present our Automatic Gamma Counter. The touch screen operated compact and powerful counter is specifically designed for PET and Nuclear medicine applications as well as small animal imaging applications. The system can even be equipped with an on board balance for automatic reporting of activity per mass or volume.



Hoy Scandinavian

Booth No. 238

Jacob Møllersgade 4
9560 Hadsund
Denmark
Phone: +145 702 710 97
E-Mail: info@hoyscandinavian.dk
Web: <http://www.hoyscandinavian.dk>

Our focus is to supply Nuclear, PET and Radiochemistry departments with high quality products and equipment.

The Export marked.

With our own product line "HOY Exclusive", we offer shielding products for radiation protection in general. Our products all have a timeless Scandinavian design and offers ergonomic comfort, and are aligned with European standards.

"HOY Exclusive", are offered worldwide through our highly qualified dealers.

Our Home marked

In Scandinavia, we supply both "HOY Exclusive" and we proudly represent some of the major brands within Nuclear Medicine and Radiochemistry.

We manage the development of customized assignments such as desk, wall, waste covering and customer-made lead glass. Hot cell alteration and moving of radiochemistry departments.

As a part of representing major brands, we also offer routine equipment service.

Our history.

In 1993, the company HOY Scandinavian was founded in Denmark. The company has grown over the years and is today an established expert within its field.

Probably the best shielding in the world.

Contacts: Erik Troue Jensen E*MBA, CEO, Sales and Project Management; Ole Høj, Senior Adviser, Sales and Product Management; Annie Borgersen, Sales assistant

Huayi Isotopes Company

Booth No. 208

4438 Sheppard Ave East, unit 377
M1S 5V9 Toronto
Canada
Phone: +1 6472982102
E-Mail: antony@huayi-isotopes.com
Web: <http://www.hic.cc>

Jiangsu Huayi Technology Co., Ltd. (Huayi Technology), was established in 2001 as a high-tech and innovative enterprise in Jiangsu, China. Huayi Technology is engaged primarily in research, development and production for emerging industries. Our products and services are focused in these categories: Active Pharmaceutical Ingredients (APIs), medical isotopes, reagent kits, sterile vials, radiopharmaceuticals and radioactive tracers. Our API production process follows cGMP standards and is approved by United States Food and Drug Administration (FDA). Our radiopharmaceutical cGMP facility is certified by the Chinese FDA.

Huayi Technology has established a Radioisotope-Labeling Research Center and Molecular Imaging Research Institute equipped with IBA cyclotron, Micro-PET/CT and SPECT/CT, dedicated to the development of new types of tracers as well as the screening and evaluation of new drugs. This facility has significantly shortened the development cycle of new drugs and reduced research and development costs.

We have completed the national 863 Program (or State High-Tech Development Plan), the "Torch Plan" (Torch Program: Promoting Innovation and High-Tech Industrialization), and the provincial Achievement Transformation program. We are recognized by the Chinese Natural Science Foundation and other technology projects.

IASON GmbH

Booth No. 253

Feldkirchner Strasse 4

8054 Graz-Seiersberg

Austria

Phone: +43 316284300

Fax: +43 3162843004

E-Mail: office@iason.eu

Web: <http://www.iason.eu>

IASON is a leading specialist supplier for nuclear medicine application and in the production of PET tracers. By means of constant further development and practice-oriented cooperation with medical institutions, we deliver top quality products and make available our know-how to numerous satisfied customers all over Europe.

The core competencies of IASON include concepts for the distribution of pharmaceuticals with a very short shelf-life and for the increase in efficiency of the process sequences. Furthermore, we implement safety tools in the case of radioactivity and to guarantee modern hygienic standards for the handling of pharmaceuticals. Further areas of competence of IASON include the oncology (early detection and treatment of cancer etc.), the neurology (diagnosis and surgical planning) and the cardiology (detection and treatment of heart diseases). Each area has an investment volume of 4 to 10 billion USD.

In addition, IASON supplies highly sensitive immunoassays to medical institutions, which are used in the diagnosis and treatment of many diseases.

IBA

Booth No. 308

Chemin du cyclotron,3

1348 Louvain-la-Neuve

Belgium

E-Mail: info-cyclo@iba-group.com

Web: <http://www.iba-radiopharmasolutions.com/>

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers.

Our main products:

Cyclone® KIUBE is a fixed-energy cyclotron that accelerates negative ions up to 18 MeV and that host up to two proton sources.

Synthera®+ is a multi-purpose automated synthesizer for the production of 18FDG, other compounds (18FCH, 18FLT, Na18F, 68Ga peptides ...). This smallest available module on the market is designed to accommodate a wide range of radiochemistry processes.

IntegraLab® is a fully integrated solution combining equipment and services for the development of Radiopharmaceutical Production Centers."



IDB HOLLAND BV,
an Advanced Accelerator Applications company

Booth No. 310

Weverstraat 17**5111 PV Baarle-Nassau****Netherlands****Phone: +31 135079558****E-Mail: sales@idb-holland.com****Web: <http://www.idb-holland.com>**

Founded in 1982, IDB Holland is a leading manufacturer and worldwide distributor of Lutetium 177 (LuMark® Lu-177 chloride). IDB Holland also provides radiopharmaceuticals, radioactive sources for PET/SPECT calibrations, and custom made products for Industry, Research Laboratories and Nuclear Medicine Departments. IDB supplies customers in over 40 countries in Europe, Africa, Asia, Australia, South America, the United States and Canada.

IDB was acquired by Advanced Accelerator Applications (NASDAQ:AAAP), an innovative radiopharmaceutical company that develops, produces and commercializes innovative diagnostic and therapeutic molecular nuclear medicine products in 2016. AAA currently has 21 production and research & development facilities, and over 500 employees in 13 countries.

AAA is an established leader in molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. AAA currently markets 9 radiopharmaceuticals (8 in Europe and 1 in the US) mainly used in clinical oncology, cardiology and neurology.

AAA is also developing a pipeline of theragnostic pairings for oncology indications. The company's theragnostic platform involves radiolabeling a targeting molecule with either Ga-68 for diagnostic use, or Lu-177 for therapy.

AAA's first theragnostic pairing addresses neuroendocrine tumors, an orphan indication. The diagnostic drug, marketed as NETSPOT® in the US or SomaKit TOC™ in Europe, is approved for use; while"



Institute of Isotopes Co. Ltd.

Booth No. 305

Konkoly-Thege M. u. 29-33.

1121 Budapest

Hungary

Phone: +36 1 392 2577

Fax: +36 1 395 9247

E-Mail: commerce@izotop.huWeb: <http://www.izotop.hu>

IZOTOP is the major Hungarian centre for the research, development and production of radioisotopes and other products for a broad range of application areas, especially healthcare, research and industry. Hundreds of products manufactured in our facilities and distributed worldwide.

Company operates in accordance with ISO 9001 and ISO 14001 QA system. We have GMP Certificate for pharmaceutical preparation and ISO 13485 standard for design, production and distribution of radioactive immunoassay kits.

Products / Services:

Radiopharmaceuticals /Thyrotop I-131 sodium iodide hard capsules, I-131 sodium iodide sterile solution, I-131 MIBG injection for therapy and for diagnostic use/Radiochemicals /I-125, I-131/Cold kits for 99mTc-labelling: DMSA, DTPA, PYRON, FYTON, MDP, TECHIDA, EC

Sm-153 -labelling MULTIBONE kit for pharmaceutical preparation

Ready to take part in R&D and manufacturing of active pharmaceutical ingredients, cold kits as well as investigational products for clinical trials.

Immunoassay kits for diagnostic (thyroid, tumour markers, protein hormones etc.) and research purposes (RIA/IRMA and ELISA)

Organic compounds labelled with C-14 or H-3 radioisotopes / Custom radiosynthesis / Service for GMP syntheses of C-14 labelled APIs or Drug Substances / Radiochemical repurification service

Ir-192 and Co-60 industrial sources / Laboratory and industrial gamma irradiators / Hot cells/ Containers for transportation of radioactive material

Inter Medical Medizintechnik GmbH

Booth No. 235

Daimlerstraße 34-36

32312 Luebbecke

Germany

Phone: +49 (0) 5741 2359 -0

Fax: +49 (0) 5741 2359-10

E-Mail: contact@IntMed.deWeb: <http://www.intmed.eu/>

The Inter Medical Medizintechnik GmbH Company is specialized in medicine software and hardware with the focal point in Nuclear Medicine technique.

Long time experience in product innovations, development and production of Nuclear systems make Inter Medical to a competent partner for all technical requirements in the Nuclear Medicine and other medical departments. Quality on each step of our business is our main goal, also expressed through the certifications for the European ISO standard given to Inter Medical.

Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head Gamma Cameras.



International Atomic Energy Agency (IAEA)

Booth No. 364

Wagramerstrasse, 5
Vienna International Center
A-1400 Vienna
Austria
Phone: +43 1 2600 00000
Web: <http://www-naweb.iaea.org/nahu/NM/about.html>

The IAEA is the world's center of cooperation in the nuclear field. It was set up as the world's „Atoms for Peace“ organization in 1957 within the United Nations family. The Agency works with its Member States and multiple partners worldwide to promote safe, secure and peaceful nuclear technologies. The IAEA Secretariat is headquartered at the Vienna International Centre in Vienna, Austria. The mission of the Section of Nuclear Medicine and Diagnostic Imaging (NMDI) of the Division of Human Health: “The Agency shall seek to accelerate and enlarge the contribution of atomic energy to peace, health and prosperity throughout the world”. It has the specific mission of fostering the application of nuclear medicine techniques as part of the clinical management of certain types of diseases. Different activities are run under this subprogram: Coordinated Research Projects (CRPs); Expert Meetings to advise the Agency on specific topics; Publications and Manuals, including educational material, and creation of educational website and databases. Also, the section manages projects related to quality improvement in the clinical practice of nuclear medicine.

INVIA Medical Imaging Solutions

Booth No. 227

3025 Boardwalk Street
Suite 200
48108 Ann Arbor, Michigan
United States
Phone: +1 734-205-1231
E-Mail: info@inviasolutions.com
Web: <http://www.inviasolutions.com>

With a foundation of clinically validated algorithms, 4DM provides advanced cardiovascular quantification and image displays in a single, configurable application which has been commercially available for more than 15 years. 4DM is integrated with all major scanner and PACS environments. 4DM is also available as stand-alone software that can be installed on Windows laptops and PCs.

Based in Ann Arbor, Michigan, INVIA is dedicated to advancing patient care by developing state-of-the-art, non-invasive cardiology imaging software solutions. Physicians use our software, 4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. 4DM originated at The University of Michigan, an institution devoted to excellence and leadership. Today, INVIA preserves close-ties to the University and remains dedicated to quality; committed to accuracy; and devoted to 4DM customers.

Visit us at booth #227 in Hall X2 to explore 4DM's latest features, including all-new reporting and enhancements for PET – the new Inflammatory protocol as well as enhanced CFR review for PET and SPECT.

For more information, visit www.inviasolutions.com

Invicro

Booth No. 207

27 Drydock Avenue

7th Floor West

2210 Boston

United States

Phone: +1 6179042100

E-Mail: info@invicro.com

Web: <http://www.invicro.com>

We are the quantitative imaging experts working across the entire drug development spectrum to better diagnose, characterize, treat and cure disease. Invicro is leading innovation to elucidate biological processes for our pharmaceutical and biotechnology partners around the world.

Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of quantitative imaging in translational drug discovery and development across all therapeutic areas. Our 300+ team provides a full range of imaging informatics, imaging engineering and imaging science services including contract imaging, research and clinical trial management services, custom data analysis, and biomarker development and utilization. Our integrated software offerings include VivoQuant™ and iPACS® for image data management, visualization and high-throughput processing for data management.

IQ Medical Services

Booth No. 229

4390 SW 73 Avenue

33155 Miami

United States

Phone: +1-305-290-4176

E-Mail: customerservice@iqmedicalsolutions.com

Web: <http://www.iqmedicalsolutions.com/>

iQ Medical Services was founded in 2007 as a consulting service provider and supply chain management company oriented to the Healthcare Industry.

iQ Medical Services is mainly focused and highly specialized in PET/SPECT Radiopharmacy Solutions, with orientation and expertise in the integration of products and services that would support customers on how to design, build, start-up, and operate a complete PET/SPECT facility. Our core expertise in this area include:

- PET/SPECT Product Expertise and Applications Consulting
- QA/RA/GMP Consulting
- Project Management
- Supply Chain and Order Management
- Equipment Procurement and Installation Services, Start-Up and Qualification with Integrated multivendor Warranty and Service Solution
- Customized Lab Equipment Configurations a for Tracer of Choice
- Facility Start-up and QMS Integration
- Site Management and Operation

iQ Medical Services is an ISO 9001 certified company that operates at a global level. Our Services have been executed in over 70 sites and more than 20 countries for the past 10 years.



IRE ELiT

Booth No. 318

Avenue de l'Espérance, 1
6220 FLEURUS
Belgium
Phone: +32 71 82 9493
E-Mail: radiopharmaceutical@ire-elit.eu
Web: <http://www.ire.eu>

We offer SIMPLE, INNOVATIVE and SUSTAINABLE solutions for development, production, end-use of RADIOPHARMACEUTICALS.

Our portfolio is supported by R&D team committed in research programs with several universities and academic centers across the world. This cooperation is a key factor to develop new radiopharmaceuticals like our new Ga-68 generator Galli Eo®.

Producing 25% of 99Mo world demand, we have industrial culture, knowhow and GMP certified facilities to produce and deliver high quality products. Our daily challenge: provide promising and easy to use radiopharmaceuticals for your preparations. YOUR SUCCESS IS OUR PASSION.

Let's start to talk on booth 318!

Isotope Technologies Dresden GmbH

Booth No. 239

Rosendorfer Ring 42
1328 Dresden
Germany
Phone: +49 351 266 34-0
Fax: +49 351 266 34-10
E-Mail: info@isotope-td.de
Web: <http://www.isotope-td.de>

Isotope Technologies Dresden (ITD) GmbH is a globally active company that manufactures turnkey solutions in the area of Nuclear Medicine (NUC), Radionuclide-Production (RN-P), Material Testing (MAT), Positron-Emission-Tomography (PET) and Ionisation-Detector-Recycling (ISD).

Services include

- Advisory and Project Management
- Development and Design
- Sourcing and Production
- Qualification and Validation
- Installation and After-Sales-Service

for producers, manufacturers and users of radioactive substances.

The high quality of the products is ensured by the collaboration of an experienced team that consists of designers, assembly technicians, radiochemists and project managers.

The product scope includes the following necessary systems and components, among others:

- Hot cells, mini cells, dispensing and distribution cells
- Laminar flow work benches for aseptic work
- Radionuclide fume hoods
- Shielding and specific radiation protection solutions for α -, β - and γ -radiation
- Laboratory equipment - containers, cabinets, tables, lead castles
- Manipulators
- Equipment for the production of radiochemicals and radiopharmaceuticals

Isotope Technologies Dresden GmbH was founded in 2008 in Dresden-Rosendorf and since 1 June 2017, ITD is part of the Eckert & Ziegler Strahlen- und Medizintechnik AG.



Isotope4life

Booth No. 403

Chateau de la Chantrerie

95 route de Gachet

44300 Nantes

France

Phone: +33 2 40251399

E-Mail: hallouin@atlanpole.fr

Web: <http://www.atlanpolebiotherapies.com>

The first consortium dedicated to Radioisotopes applications, aiming at mutualisation and coordination of skills and actors concerned by the use of radioisotopes for health in order to overcome hurdles to innovation in the radiopharmaceutical domain. The main goal of ISOTOP4LIFE is to facilitate the use of Radiopharmaceuticals for diagnostic and therapeutic applications.

ISOTOP4LIFE is a one-stop offer providing R&D, technology transfer and industrialization capacities, with academic, clinical, industrial partners as well as a high-energy, high-intensity cyclotron ARRONAX. It is also a commercial coordination offer with an identified gate for Pharmaceutical industry.

ISOTOP4LIFE is leading the project of "LA FABRIQUE", a building dedicated to GMP production in order to welcome companies and academics for radiopharmaceuticals production and distribution at a National and European level.

ITEL Telecomunicazioni Srl

Booth No. 256

Via Labriola 39

70037 Ruvo di Puglia

Italy

Phone: +39 0803611033

Fax: +39 0803611114

E-Mail: itel@itelte.it

Web: <http://www.itelte.it>

Established 30 years ago in the telecommunications sector, thanks to the expertise acquired in electromagnetic waves, fields and radiations, ITEL Telecomunicazioni® today works in the medical, pharmaceutical and electromagnetic compatibility fields, offering high-tech products and services that have in common the application of ionizing and non-ionizing radiations: electromagnetic and magnetic field shielding for diagnostic and intraoperative imaging and industrial environments, medical site auditing, integrated project planning and design of complex healthcare facilities, radiopharmaceuticals and services for nuclear medicine (division ITELPHARMA), research and development of medical mechatronics technologies, electromagnetic compatibility tests & measurements (division EMC TEST LAB).

As part of these activities, ITEL has developed a range of services for Radiopharmacies, both those already operational and those of new construction. From Sterility Tests, to Bioburden Analysis, to advice and training on GMP, ITEL is configured as a global partner for each Radiopharmacy and Nuclear Medicine Department.

Of course ITEL can be configured as a „full service provider“ able to follow the planned construction of a radiopharmacy from design, to commissioning, qualification and validation activities and preparation of the quality system, with full knowledge and competence in relation to GMP requirements.



ITM Isotopen Technologien München AG

Booth No. 231

Lichtenbergstrasse 1

85748 Garching

Germany

Phone: +49 89 329 8986 60

E-Mail: info@itm.ag

Web: <http://www.itm.ag>

ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, ITM and its subsidiaries have established the GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing a range of cancers such as neuroendocrine cancers or bone metastases. ITM's main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

For more information about ITM, please visit: www.itm.ag

Japanese Society of Nuclear Medicine

Booth No. 358

2-28-45 Hon-Komagome, Bunkyo-ku

113-0021 Tokyo

Japan

Phone: +81-3-3947-0976

Fax: +81-3-3947-2535

E-Mail: anm@xvg.biglobe.ne.jp

Web: <http://www.jsnm.org>

The JSNM was established in 1964 which currently has over 3,600 members. The JSNM has been working hard to promote the development of nuclear medicine through the collaboration with the SNMMI, EANM, AOFNMB (Asia and Oceania Federation of Nuclear Medicine and Biology), ARCCNM (Asian Regional Cooperative Council for Nuclear Medicine), World Federation of Nuclear Medicine and Biology (WFNMB) and individual societies of many countries.

The JSNM is proud to announce that the 2022 Congress of the WFNMB will be held in Kyoto, Japan. The JSNM's campaign for three years for this bid had been keenly supported by many countries and societies. The JSNM sincerely appreciate this.

The Annals of Nuclear Medicine (ANM) is the official journal indexed in the most of major sites such as Journal Citation Reports/Science Edition, PubMed/Medline. The ANM is now one of the most popular journal in the field. The Best papers are selected every year and the winners are awarded with grant. Please come to the web site at <http://www.springer.com/medicine/nuclear+medicine/journal/12149>.

We are waiting for you to treat you with a variety of Japanese traditions at our booth with the utmost hospitality, OMOTENASHI. Join us!



JSC Isotope / Rosatom Healthcare

Booth No. 415

Pogodinskaya str. 22
119435 Moscow
Russia
Phone: +7 4959819617
Fax: +7 4992452492
E-Mail: isotop@isotop.ru
Web: <http://www.isotop.ru/en/>

JSC Isotope is a subsidiary 100% owned by Rosatom State Atomic Energy Corporation, responsible for distribution and marketing of isotope products manufactured by Rosatom enterprises. On the strength of Rosatom unique production capacities, we guarantee reliable supplies of high quality isotope products to the international market.

JSC Isotope has a deep expertise in organizing prompt supplies of products and solutions for nuclear medicine, in particular: isotopes (especially Mo-99) and radiopharmaceuticals (Mo-99/Tc-99m, W-188/Re-188, I-131, Sm-153).

Among JSC „Isotope“ partners there are more than 100 foreign customers in over 30 countries and more than 600 organizations in Russia.

JSC Rosatom Healthcare is the integrator within Rosatom State Atomic Energy Corporation, established for purposes of development and production of equipment and radionuclide products for nuclear medicine and medical radiology, as well as industrial equipment based on radiation technologies.

The main mission of Rosatom Healthcare is the organization and integration of production facilities to create a full-fledged domestic market for modern high-tech equipment and innovative radionuclide products and radiopharmaceuticals for nuclear medicine and medical radiology, as well as modern industrial equipment based on radiation technologies, with subsequent promotion of competitive products abroad.

KEOSYS

Booth No. 403

13 impasse Serge Reggiani
BP 10222
44815 SAINT HERBLAIN CEDEX
France
Phone: +33 2 53 59 12 90
E-Mail: sales@keosys.com
Web: <http://www.keosys.com>

Founded in 2001, Keosys has established itself as a leading full-service Imaging CRO focused on bringing high quality images and services to its customers. With over 15 years' experience in medical imaging, Keosys helps pharmaceutical and biotechnology companies bring new drugs to market by leveraging imaging data in clinical trials. In addition to its leading proprietary cloud-based platform to centralize and analyze imaging data Keosys offers project management services and scientific expertise that allow sponsors to focus on their core business rather than operational bottlenecks and difficulties managing large complex data sets.

Keosys has worked on more than 90 clinical trials and has centralized over 68 million DICOM images for 35,000 patients over the past 10 years. Keosys has a long track record working on Phase II and III trials in the oncology, neurology, and cardiology space and has long history managing trials in the fields of Molecular Imaging and Nuclear Medicine.

The company is headquartered in France and has subsidiary in the United States (New York City) and Asia (Singapore).

Kliniken.de

Booth No. 371

Betenstr. 13-15
44137 Dortmund
Germany
Phone: +49 231 91448877
E-Mail: anzeigen@kliniken.de
Web: <http://www.kliniken.de>

Kliniken.de the recruiting specialist works exclusively for hospitals, clinics , private practices and retirement homes. We have in-depth knowledge concerning all the special aspects of staffing in medical professions. With over 17 years of experience our company supports our clients to succeed in a proven quality.

KSNM – The Korean Society of Nuclear Medicine

Booth No. 203

Gumho palace B/D #1705, 29th Jibong-ro, Jongno-Gu
3121 Seoul
Korea
Phone: +82-2-745-2040
Fax: +82-2-745-3833
E-Mail: ksnm@ksnm.or.kr
Web: <http://ksnm.or.kr/>

The Korean Society of Nuclear Medicine (KSNM) is a scientific and professional organization founded in 1961. The business of KSNM includes holding academic meetings, publication of journals and books, planning and research of promoting science and health, training and qualification of NM specialists. There are 360 NM specialists, 140 PET/CT and 290 SPECT cameras in Korea.

The aims of KSNM are the promotion of nuclear medicine and cooperation of each member from nuclear Medicine's various related scientific fields of radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. KSNM hosted Asia Oceania Congress of Nuclear Medicine and (1984, 2015) and World Congress of Nuclear Medicine and Biology (2006).

The official journal of KSNM is 'Nuclear Medicine and Molecular Imaging (NMMI)', published from 1967 and is being published six times a year by Springer.

For the future, the Korean Society of Nuclear Medicine provides effective training and cultivates future talent to prepare for upcoming changes in an ever-diversifying environment. Clinical practice and research applying molecular imaging and PET/CT and treatment procedures using radiopharmaceuticals will continue to flourish, and the KSNM will lead the advancement of the field of nuclear medicine in Korea.

LabLogic Systems Limited

Booth No. 406

Paradigm House
3 Melbourne Avenue
Broomhill
S10 2QJ Sheffield
United Kingdom
Phone: +44 114 266 7267
Fax: +44 114 266 3944
E-Mail: solutions@lablogic.com
Web: <http://www.lablogic.com>

LabLogic is a manufacturer of instruments and software to the Life Science, PET/Nuclear Medicine and Radiation Safety sectors. We have over 35 years' experience and expertise in providing solutions within highly regulated environments.

Within PET and Nuclear Medicine, LabLogic have a range of market leading products which can be found in some of the world's most prestigious laboratories. Our products include a range of QC equipment including innovative r-TLC, r-HPLC instruments and a single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic, just ask about the QC solution.

Furthermore Lablogic offer PETra, a purpose built PET LIMS system designed to improve efficiency and compliance. What's unique about PETra is that it directly captures data from all the equipment used. It acts as a central repository all information within PET production including batch record management, QMS, trending, inventory, instrument maintenance etc.

LabLogic will be showcasing its Tracer QC system at EANM'17. Utilising an instrument smaller than a desktop PC to perform the essential PET QC tests with just single touch operation, this system is already creating a great deal of interest across the nuclear medicine community. For further information please contact our office or visit booth #406 at the show to see it demonstrated.

Lemer Pax / Medisystem

Booth No. 403

72 rue de Lorraine 44240 LA CHAPELLE SUR ERDRE
Z.A. Erdre Active - Malabry
44240 LA CHAPELLE SUR ERDRE
France
Phone: +33 6 86 65 21 21
E-Mail: charlotte.bebin@lemerpax.com
Web: <http://www.lemerpax.com>

Live a unique Virtual Reality experience and discover a complete offer of effective radiation protection solutions from preparation to injection of any radioisotopes - come visit us on booth n° 403 / hall X4.

Indeed, the two French historic leaders in the radiation protection industry join forces to serve you better and to offer you a full array of innovative solutions, incorporating the most advanced technologies to protect yourself efficiently against ionizing radiations.

To discover the breadth of our product range, we invite you to dive in a virtual nuclear medicine department to manipulate virtually ergonomic hotcells, automatic injectors, or mobile shields for preparation, injection and storage of radiopharmaceuticals.

Among many innovative products, you will discover the latest version of Posijet®, an independent fractionation and injection unit for high energy radiopharmaceuticals which has been co-developed by the Lemer Pax design office in partnership with nuclear medicine operators and which offers a unique and very user-friendly interface. You will also discover the Medi 9000 Research 2R, a brand new research hotcell with 2 glove ports designed by Medisystem engineers to offer an ergonomic and compact solution for the Ga68 synthesis, fractionation and measurement as well as for the fractionation of fluorinated pharmaceuticals (Medi 9000 is compatible with all synthesis modules on the market).

Feel free to visit our experts on booth n° 403 / hall X4 to



Lightpoint Medical Ltd

Booth No. 228

Misbourne Works, Waterside
Bucks
HP5 1PE Chesham
United Kingdom
Phone: +44(0)1494917697
E-Mail: info@lightpointmedical.com
Web: <http://www.lightpointmedical.com>

Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's products address the pressing medical need for better tools to detect cancer during surgery in order to improve clinical outcomes and reduce healthcare costs.

The company has three products: The LightPath™ Imaging System (CE marked) for imaging surgical specimens, the EnLight™ laparoscopic probe for minimally-invasive prostate surgery (under development), and HARLI™ for open surgery and life sciences (2017 launch).

Lynax s.r.o.

Booth No. 202

MAP Medical Technologies Oy

Booth No. 254

Elementitie 24
41160 Tikkakoski
Finland
Phone: +358 14 3345 211
Fax: +358 14 3753 611
E-Mail: marketing@mapmedical.fi
Web: <http://www.mapmedical.fi>

MAP Medical Technologies Oy, founded in 1991, is an independent Finnish company. The mission of our company is to develop and manufacture radiopharmaceuticals to serve nuclear medicine professionals. Our highly devoted team and modern production facilities offer a unique setting for production of best quality pharmaceuticals.

We can provide to our customers and partners several products and services in the field of nuclear medicine.

- Our products: FDG, Fluorocholine, Sodium Fluoride, Fluorothymidine (FLT), Fluoroestradiol (FES), Ga-68 DOTA-NOC, Ga-68 PSMA, Lu-177-PSMA, P-32 solution for injection, I-123 CLINDE, I-123 beta-CIT, I-123 Epidepride and others.
- Investigational products: New diagnostic radiopharmaceuticals in close collaboration with our partners in prominent research institutions for such degenerative brain disorders like Parkinson's disease, Alzheimer's disease and others, which are related to activity and amount of neurotransmitters like dopamine, serotonin and others.
- Contract manufacturing of radiopharmaceuticals: We can offer our GMP facility and know how to other medical communities to test label and produce their own radiopharmaceutical compounds. We have possibility a small scale manufacturing set up for the customer needs. With this unique set up we can save both money and time of the customer for example in production for clinical trial batch.

We are committed for collaboration with nuclear medicine professionals.

MED Nuklear-Medizintechnik Dresden GmbH

Booth No. 238

Dornblüthstraße 14 A**1277 Dresden****Germany****Phone: +49 (0)351 433 00 50****Fax: +49 (0)351 433 00 518****E-Mail: export@nuklear-medizintechnik.de****Web: <http://www.nuklear-medizintechnik.de>**

MED Nuklear-Medizintechnik Dresden GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET-centres and therapy stations:

- dose calibrators
- uptake-counters, incorporation counters, well-counters, waste water counters
- patient dose monitoring systems
- contamination monitors (portable and hand-foot-clothing monitors)
- waste and release monitors

All laboratory counters and dose calibrators are PC-based.

The product line of MED Nuklear-Medizintechnik Dresden GmbH also contains instruments for dose and/or dose rate measurement and radiation protection accessories, e.g. syringe shieldings.

MED Nuklear-Medizintechnik Dresden GmbH is a company of NUVIA since 2014.

Medi-Radiopharma Ltd.

Booth No. 319

10-12, Szamos utca**2030 Érd****Hungary****Phone: +36 23521261****Fax: +36-23-521-260****E-Mail: order@mediradiopharma.hu****Web: <http://www.mediradiopharma.com>**

Our company is for research, development and manufacturing of generic in vivo kits for Tc-99m labelling as MIBI, HM-PAO (stabilized and non-stabilized), MAA, HSA nanocolloids, MDP, DMSA, Br-IDA, DTPA and PYP. Three Technetium-99m labelled kits (Senti-Scint, Nano-Scan and Nano-Albumon kit) are available with different particle sizes to support various sentinel studies. All products are registered in several countries all over the world and manufactured under cGMP conditions.

We offer CE-marked MediCheck Q.C. kit (and its refill-packs) for rapid quality control of registered and extemporaneously prepared radiopharmaceuticals. CE-marked Medi-Media Fill kits are for controlling aseptic manufacturing process, the environment and personnel. Next to these, sterile and sterile, evacuated vials of different sizes and types are available in our assortment.

Chemical precursors for radiopharmaceutical preparation are synthesized in our recently opened GMP API laboratory. Contractual research, quality control evaluations from radio HPLC, animal distribution, subvisible particles determination, etc., manufacturing of investigational medicinal products as well as development and manufacturing validated analytical methods are part of our cGMP licence. Sterile and vacuum vials, compilation of sterile centrifuge-tubes and solutions for preparation of radio-labelled blood-cells are also available.



Mediso

Booth No. 304

MiE medical imaging electronics GmbH

Booth No. 408

Hauptstrasse 112
23845 Seth
Germany
Phone: +49 4194 9977-0
Fax: +49 41494 9977-55
E-Mail: mie@miegermany.de
Web: <http://www.miegermany.de/>

MiE has produced nuclear medicine systems (SPECT & PET) and accessories for the complete customer needs since 1981. During this time MiE have gained extensive experience in user specific requirements and have adapted it to the market and specific user needs. All our products are CE certified and FDA cleared, thus new with full warranty and min. 10 years guaranteed spare part support.

Our workstation name SCINTRON is developed to close the gap between shortened development cycles and more durable mechanics and electronics. This computer is design to acquire data as well as process and view studies from our new or already installed Gamma Camera and PET systems.

The in-house research, development, electronic and mechanic department ensure that we provide always the latest technologies. This allows us to meet the specific needs of our customers.

The MiE company is certified in accordance with EN ISO 9001:2008, EN ISO 13485:2012 + AC: 2012 and all our systems are with Annex II of Directive 93/42/EWG approved. Also, we are registered at the FDA – our systems are 510(k) approved since 1995. This extensive certification is the basis for the manufacture and distribution of medical products on the world market.

MILabs

Booth No. 226

Heidelberglaan 100 STR 4.105
3584 Utrecht
Netherlands
Phone: +31 88 756 5343
Fax: +31 88 756 0094
E-Mail: info@milabs.com
Web: <https://www.milabs.com>

MILabs provides molecular imaging solutions for biomedical and pharmaceutical research. MILabs' imaging platforms let's you do more by imaging less.

These imaging systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac, neurodegenerative diseases and more.

U-SPECT is the fastest, most sensitive and highest resolution small-animal SPECT system currently available. MILabs fused state-of-the-art adaptive PET with its SPECT technology, by introducing the VECTorCT. This versatile nuclear imaging system is extremely user friendly, fully integrated and enables simultaneous ultra-high resolution PET/SPECT imaging in combination with a choice of in-line low-dose high-resolution CT systems. MILabs' concurrent PET/SPECT and Hybrid Optical Imaging (OI) system empowers you to study different physiological and molecular functions at the same time.

MIM Software Inc.

Booth No. 237

25800 Science Park Drive
Suite 180
44122 Cleveland, OH
United States
Phone: +1 216 455 0600
Fax: +1 216-455-0601
Web: <https://www.mimsoftware.com/>

MIM Software Inc. provides a single platform solution for all of your PET and Nuclear Medicine viewing and quantitation needs. MIM Encore, the backbone of MIM's solution, provides tools for customized workflow management, automated serial exam review, advanced PET/CT and SPECT/CT visualization, automatic PET tumor segmentation, and nuclear medicine processing. MIMneuro includes quantitative PET/SPECT analysis tools to aid in the detection of neurological disorders for the following tracers: FDG, Amyvid™, NeuraCeq™, Vizamyli™, HMPAO and DaTscan™. MIM provides an integrated cardiac PET and SPECT quantitative analysis solution, MIMcardiac, which offers advanced left-ventricle segmentation for calculating ejection fractions, polar plots, and difference imaging. MIM's SurePlan Liver Y90 package provides time saving tools for liver VOI definition, multi-modality fusion, and Y90 PET and SPECT dose calculation.* MIM Assistant, a data management and archiving solution, is easily integrated for fast data transfer and automated study routing, retrieval, and workflow processing. Professionals can collaborate securely and reliably by sharing images from anywhere with MIMcloud. All these solutions provide unmatched efficiency and save time while enhancing patient care.

* This functionality is pending 510(k) clearance, and is not yet commercially available in the United States or in some other countries. Please contact your MIM rep for details.

Mirada Medical Ltd

Booth No. 215

Oxford Centre for Innovation,
New Road
Oxford
OX1 1BY Oxford
United Kingdom
E-Mail: annamaria.albano@mirada-medical.com

Mirada develops software applications that provide simple and accessible solutions to complex image analysis problems in the diagnosis and treatment of cancer and other diseases. Through automation, our products improve consistency and productivity while enabling clinicians to deliver more personalized care. By combining deep learning technology with our thorough understanding of the challenges faced, Mirada is leading the development of next generation imaging software and decision support products. Our staff are passionate about using their expertise to help our customers provide better healthcare for more patients.

Mirada offers vendor-neutral applications for reading Nuclear Medicine, SPECT/CT, PET/CT, and PET/MR, with flexible display protocols and workflows. Deformable registration is performed for image comparison and quantitative response to therapy is assessed with comprehensive tools for PERCIST, WHO and RECIST analysis. Results are saved for editing and review, allowing convenient time-saving access.

Mirada's portfolio also includes knowledge sharing solutions providing referring physicians access to rich images and reports, plus software designed exclusively for efficient preparation and elegant presentation of images at tumor board. Mirada software is available in an array of deployments including stand-alone, thin client, floating license and PACS integrations.

Products: XD, XD Nuclear Medicine, Casemeeting, Caseaccess, RTx, Workflow Box, Simplicit90Y



MNT Kwint International BV**Booth No. 238**

Industrieweg 4a
4104 AR Culemborg
Netherlands
Phone: +31 (0)345535127
E-Mail: geert@mnt-int.com
Web: <http://www.mnt-int.com>

In general our company is specialized in the field of Health Physics, Radiochemistry, Nuclear Medicine, Radiotherapy and –diagnostics & Waste-management. For more than 30 years our program is based on:

- handling and storing radioactive pharmaceuticals; radioactive solid- & liquid waste
- furnishing radioactive laboratories, rooms for production radioactive chemicals/materials, clean rooms, treatment- and accelerator rooms, waste-rooms, etc.;
- Personal protection;
- Waste water vacuum plants for Iodine 131 treatments
- Shielded and unshielded hospital furniture

MOLECUBES NV**Booth No. 250**

Ottergemsesteenweg Zuid 808 BUS 325
9000 Ghent
Belgium
E-Mail: info@molecubes.com
Web: <http://www.molecubes.com/>

MOLECUBES stand for modular benchtop preclinical imaging. Three high-end imaging cubes allow you to combine SPECT (Gamma-Cube), PET (Beta-Cube) and CT (X-Cube) imaging in a time and space efficient way. The combination of patented pinhole design, additive manufacturing techniques and high-resolution detector technology ensures competitive performance for full body mice and rat imaging. Intuitive user-interfacing and fast post-processing also allow for high-throughput scanning.

MR Solutions Ltd

Booth No. 201

Ashbourne House
The Guildway, Old Portsmouth Road
GU3 1LR Guildford
United Kingdom
Phone: +44 (0) 1483 532146
Fax: +44 (0) 1483 594086
E-Mail: info@mrsolutions.com
Web: <http://www.mrsolutions.com>

MR SOLUTIONS is the worldwide leader in superconducting cryogen-free, preclinical MRI systems with multiple proven installations of its 7T, 4.7T, 3T and PET/MRI. Recently, MR SOLUTIONS has pushed its' technology even higher and introduced a new 9.4T cryogen-free MR imaging system. Two product lines are available: Powerscan and Flexiscan. Flexiscan requires no specialist knowledge and can be operated by running predefined settings. Powerscan is focused on high end MR applications and is available with adjustable magnetic field strengths ranging from 0.1T to 9.4T. The system allows physicists to alter the hardware, software and pulse sequences. For multi-modality imaging, MR SOLUTIONS has developed PET and SPECT modules that are very light, compact and detachable. This unique and innovative design allows the users to interchange these modules either on the MRI or on the CT for your research applications: PET/MR, PET/CT, SPECT/MR, SPECT/CT, or simply to operate them as a stand-alone device. MR Solutions holds the prestigious Queen's awards for enterprise, Innovation 2016 and is the winner in the global R&D 100 awards. MR SOLUTIONS has over 30 years of imaging technology development and manufactures all its product in house.

NICESOFT

Booth No. 238

79 avenue Denfert Rochereau
75014 Paris
France
Phone: +33 153 622 400
Fax: +33 153 620 010
E-Mail: sales@nicesoft.com
Web: <http://nicesoft.com>

Since 1998, NICESOFT seeks to exceed customer expectations by developing innovative Web solutions for Medical Imaging departments.

We combine zero-footprint Web technology with a high specialization in Nuclear Medicine & Radiology to design applications that can run on any device or platform (PC, Mac, tablets, smartphones) without any installation.

Our VENUS product line provides a complete range of solutions for Nuclear Medicine and Radiology departments, from online appointment booking to a full-Web Viewing & Processing Application Server that allows to access your images from anywhere.

We are the leading RIS provider for Nuclear Medicine departments in France and have also equipped sites across Europe (Germany, Belgium, Italy, Finland, Ireland, Luxembourg, etc), the US, China and the Middle East. Come and see why!



Norgine Limited

Booth No. 223

Norgine House, Widewater Place
Moorhall Road
Harefield
UB9 6NS Uxbridge
United Kingdom
Web: <http://www.norgine.com>

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine's total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

Nuclear Shields B.V.

Booth No. 424

Akkervoortweg 5
5827 AP Vortum-Mullem
Netherlands

Nuclear Shields has a Holland based production facility and has over 40 years of experience in producing lead products for nuclear medical purposes. Nuclear Shields is the go-to place for transparent, quick & reliable purchasing of high-quality radiation related products. Nuclear shields offers a wide range of products, including shielded hotlab cabinets, radiation monitoring products, personal radiation protection products, waste and storage solutions and custom made solutions. Next to this, Nuclear Shields also offers a wide range of collimators.

Visit booth #424 in exhibitor's hall X4, or visit our webshop at www.Nuclear-Shields.com

Nucleis

Booth No. 318

Allée du Six-Août, 8
4000 Liège
Belgium
E-Mail: info@nucleis.eu
Web: <http://www.nucleis.eu>

Nucleis is a pharmaceutical company developing, manufacturing and commercialising radiopharmaceuticals drugs dedicated to PET Imaging, for diagnostic and therapy monitoring.

We are focused on helping our customer to provide the best care thanks to the highest reliability, flexibility and also by offering an innovative portfolio of radiopharmaceuticals drugs.

Nucleis holds a FDG Marketing Authorisation (Glucotrace) in Belgium, The Netherlands, Germany, France and Luxembourg. Our company is a spin-out from the University of Liège, created in 2017, which can rely on a highly skilled team. This expertise is illustrated by more than 4000 manufactured batches and more than 150.000 distributed doses from the manufacturing site of Liège in Belgium.

Nucleis is also the partner of choice for Contract Manufacturing Officer activities and is an authorised manufacturer of GE Healthcare radiopharmaceuticals and of Blue Earth Diagnostics.

NUVIA

Booth No. 238

85 Avenue Archimède
13857 Aix-en-Provence
France
E-Mail: healthcare@nuviatech.com
Web: <http://www.nuvia-group.com>

Nuvia offers a unique array of technologies and services for application of ionizing radiation in a catalogue of highly reliable products which can be tailored on-request, such as dose calibrators, different types of counters, contamination monitors, and radiation protection equipment. Our components are manufactured in our workshops and are the result of our R&D processes. From modelling to implementation, we use exclusive know-how and state-of-the art technologies in its systems. Being a strong partner in system deliveries, Nuvia provides tailor-made solutions fitted to needs and requirements of the customer.

OGNMB - Austrian Society of Nuclear Medicine and Molecular Imaging

Booth No. 359

Schmalzhofgasse 26
1060 Vienna
Austria
E-Mail: office@ogn.at
Web: <http://www.ogn.at>

The Austrian Society of Nuclear Medicine and Molecular Imaging (OGNMB) represents the activities of the nuclear medical community in Austria to all official bodies (such as ministries, federal and regional medical societies or health authorities) and comprises all scientific fields closely related to NM and MI, e.g. medicinal radiochemistry, radiopharmacy, medical physics and radiation protection.

Founded in 1968 in Vienna, the OGNMB currently welcomes around 250 members in good standing (ca. 180 NM specialists and ca. 40 NM physicians in training). Bi-annually the OGNMB organizes the prestigious Austrian Winter Symposium „Radioactive Isotopes in Molecular Imaging“ (formerly also known as Bad Gastein meeting) – in upcoming January for its 33rd time! For more informations come to our booth and collect flyers for next year's meetings and further info-material.



Oncidium Foundation

Booth No. 347

Chemin de l'Infante, 84

1420 Braine-l'Alleud

Belgium

E-Mail: richard.zimmermann@oncidium-life.org

Web: <http://www.oncidium-life.org>

The Oncidium Foundation based in Belgium (creation 2011) aims at increasing awareness about radiotherapy in NM and promoting at a worldwide level the development of radiotherapeutics (RTs). Very recently Oncidium was confirmed for larger funding and is presently in a process to completely refurbish its website and reorganize itself. Oncidium will become a platform to create cohesion between RT stakeholders, building a community strong enough to lobby for RTs.

For the first time Oncidium will be present with a booth during a NM congress thanks to the EANM team. This will help to make the foundation more visible and better explain the different foundation's programs. In particular the foundation is looking for volunteers who can help to gather but also to spread information about marketed or under clinical development RTs, represent Oncidium locally, help to translate information in any language. In particular, on top of providing the latest data on progresses in RTs through weekly news, the web site aims at connecting directly patients with physicians and will display information about nearest treatment centers through interactive maps. This information must be as complete as possible and provided in the language of the patient.

Eventually, depending upon funding from new sponsors, Oncidium intends to support financially the clinical development of efficient RTs disregarded by industry and to support access to RTs for patients that cannot afford such therapies.

ONCOVISION

Booth No. 421

C/JERONIMO DE MONSORIU N° 92 BAJO IZDA

46022 VALENCIA

Spain

E-Mail: info@oncovision.com

Web: <http://www.oncovision.com>

Oncovision is a leading provider of innovative medical imaging devices for the diagnosis and treatment of cancer. Has grown into a dynamic brand in a technologically competitive, high-growth industry.

We boast a clinical product line that includes market-leading Sentinella, a unique intra-operative Gamma Camera and the revolutionary Mammi PET, a breast cancer diagnostic device capable of visualizing lesions of less than 1.6mm and quantifying tumor activity. Completes its portfolio with Wprobe, the gold standard in radio guided surgery.

Oncovision has distinguished itself through for developing and bring to the market innovative products to generate significant benefits on patients. Also, the company plans to bring forth technical and clinical solutions for an accurate diagnosis and treatment of cancer, providing the highest-quality, best-performing products.

You can also visit us on the web at www.oncovision.com

Optimized Radiochemical Applications (ORA-NEPTIS)

Booth No. 211

50B Rue de la Gendarmerie

5600 Philippeville

Belgium

Phone: +32 71 61 38 23

Fax: +32 71 61 40 53

E-Mail: info@oradiochem.eu

Web: <http://www.neptis-vs.com>

ORA, a certified ISO13485 medical devices manufacturer, is a leading supplier of innovative radiochemistry solutions for the radiopharmaceutical industry. ORA provides the NEPTIS® synthesizers, a range of open and flexible platforms. These platforms offer the most freedom and the best efficiency for the competitive deployment of new PET tracers and innovative radiopharmaceuticals to support the nuclear medicine community.

NEPTIS® platforms are combinations of multi-purpose synthesizers coupled with advanced software system meeting the latest GMP requirements. NEPTIS® platforms are offering the capability of creating an unlimited number of individualized radio-tracer synthesis applications. Therefore NEPTIS® concept contributes in restoring freedom for researchers with an open platform, in providing developers with a robust tool from clinical trials to commercial production, and in offering producers a guarantee for reliable and repetitive performance.

The proven expertise of ORA coupled with the NEPTIS® platform and its extensive regulatory documentation support, makes it possible to meet new challenges of maximizing current PET tracers production and speeding up the development of new drugs to market.

Osimis

Booth No. 318

rue des chasseurs ardennais 3

4031 Angleur

Belgium

Phone: +32 478132163

E-Mail: fl@osimis.io

Web: <http://www.osimis.io>

It is our mission to re-wire the medical imaging space through the use of open source, interoperable and standards compliant software.

Osimis offers products and solutions that enable simple and lightweight transmission, visualisation, collaboration and artificial intelligence for medical imaging.





PARS Isotope

Booth No. 418

88, East 23 St, Azadegan Blvd.
South Sheykh Bahaei St.
Tehran
Iran
Phone: +98 2188630303
Fax: +98 2188337024
E-Mail: info@parsisotope.com
Web: <http://www.parsisotope.com>

Pars Isotope is a leading producer and supplier of medical radioisotopes in the Middle East. With more than 50 products in the world of nuclear medicine, we are the one who can supply different radiopharmaceuticals used in treatment and diagnosis. Based on our deep-seated knowledge and experience in radiopharmaceuticals production.

To enhance the quality and quantity of medical products according to cGMP regulations Pars Isotope is involved in a project to implement new modern facilities for RRP, CKP and PET in Iran. Additionally, we are focused on the following activities according to our profession and capabilities:

- Production of 12 different types of Tc-99m cold kits like MIBI, EC, ECD, Sulfurcolloid, BrIDA, MDP, DTPA, DMSA, MAA, PYP, RBC, Antimony and ...
- Production of 5 different types of Tc-99m peptide kits like Trodat, Octreotide, UBI and ...
- Production of 5 types of radionuclide generators used in PET & SPECT like Ga-68 Generator, Re-188 Generator, Tc99m-Generator and ...
- Production of 22 various ready-to-use radiopharmaceuticals in diagnostics and therapeutics like I-131, Sm-153 EDTMP, I-131 MIBG, Lu-177 PSMA and ...
- Production of 7 different types of radiochemical used in production of radiopharmaceuticals like P-32, Y-90, Sm-153 and ...
- Development and optimization of advanced methodologies in production of radiopharmaceuticals.

PerkinElmer

Booth No. 269

68 Elm Street
MA 01748 Hopkinton
United States
Phone: 00508-435-9500
E-Mail: info@perkinelmer.com
Web: <http://www.perkinelmer.com/invivo>

PerkinElmer is uniquely positioned to bring instruments, reagents and services to enable comprehensive translational imaging & detection solutions for your research. Our offering includes multiple imaging modalities: PET, SPECT, Fluorescence, Cerenkov, Bioluminescence and x-ray imaging. Learn more about our PET/CT imaging system with a compact, easy-to-use footprint that fits on your bench-top. PerkinElmer's PET system and radionuclides such as 89Zr and 124I offers excellent sensitivity and quantification of lead compounds for applications such as oncology, cardiology, and PK/biodistribution studies.

Philips

Booth No. 402

Royal Philips

Amstelplein 2

1096 BC Amsterdam

Netherlands

Phone: +31 20 59 77777

Web: <http://www.philips.com>

Philips is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. This commitment to continuous health can be seen in Philips focus on precision medicine and portfolio of molecular imaging and nuclear medicine solutions, which combine people, processes and technology to enhance imaging and improve patient care. At EANM, Philips will showcase its suite of advanced molecular imaging solutions and applications, including Vereos Digital PET/CT and IntelliSpace Portal 9, for a comprehensive experience in transformative patient care. <https://www.usa.philips.com/healthcare/about/events-calendar/eam-2017>

PI Medical Diagnostic Equipment B.V.

Booth No. 238

Bliet 14

NL-4941 SG RAAMSDONKSVEER

Netherlands

Phone: +31 162 729102

E-Mail: info@pi-medical.nlWeb: <http://www.pi-medical.nl>

PI Medical Diagnostic Equipment B.V. works closely together with a group of well established international producers of high-quality equipment and represents these companies in the Netherlands.

PI Medical offers a wide range of instruments and accessories for the nuclear medicine market. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms and other QA devices, radiation shielding materials, laser systems for PET/CT, patient positioning devices, etc.

PI Medical is furthermore specialized in gamma probes and ICG probes for the sentinel node procedure, the company has been deeply involved in the development of these products.

Next to equipment PI Medical also supplies I-125 seeds for tumor localization and calibration sources for PET and SPECT applications in the Benelux countries.



PMB-ALCEN

Booth No. 409

Route des Michels CD56
 Chemin de la Corneirelle
 13790 PEYNIER
 France
 Phone: +33 442531313
 Fax: +33 42533083
 E-Mail: contact@pmb-alcen.com
 Web: <http://www.pmb-alcen.com/en>

PMB-ALCEN designs, manufactures and commercializes high-technology products used in the medical, nuclear power, research, defense & security and industry fields. Our expertise lies in the complex assembly of materials which are dissimilar, such as metals and ceramics, as well as in the development and manufacture of linear accelerators and cyclotrons.

We have been designing and developing a cutting-edge automated system for the production of radiotracers. These are essential in clinical medicine, especially in PET imaging. It combines a superconducting cyclotron with an innovative radiochemistry room, complete with an automated QC system. We are more than just another radiopharmaceutical dispenser. We have envisioned a unique system designed to improve and optimize patient care, while providing new grounds for further research in the nuclear medicine and medical imaging fields.

We offer an alternative to traditional radiotracer production centers, by providing an unprecedented proximity to both patients and imaging departments, allowing a same-day diagnosis with multiple radiotracers and decreasing the need in staff. iMiGINE is a game-changing solution that grants imaging centers access to a variety of radiopharmaceuticals, at a low cost.

PMOD Technologies LLC

Booth No. 232

Sumatrastrasse 25
 8006 Zurich
 Switzerland
 Phone: +41 44 350 46 00
 Fax: +41 44 350 46 01
 E-Mail: info@pmod.com
 Web: <http://www.pmod.com>

PMOD Technologies aims to equip researchers with best-in-class software tools for biomedical imaging in humans and animals. Founded in 2003 as a spin-off from the Zurich PET center, PMOD has a strong background in PET image quantification.

The PMOD suite of software tools is a comprehensive platform for quantitative biomedical imaging. It arguably represents the leading solution for PET kinetic modeling, and supports all required image pre-processing steps such as image matching, brain image normalization, and automated volume-of-interest definition. Furthermore, it encompasses solutions for the pattern analysis of brain images and for attractive 3D image visualization.

PMOD boasts an expanding customer base comprising more than 500 sites with over 1500 active users worldwide. As of 2016, the use of PMOD has been reported in more than 1300 publications. Vibrant collaborations with a number of flagship institutions ensure that the methodology and scope of the PMOD software remain leading-edge and come to the end user at unprecedented speed.

Brands: PBAS, PKIN, PXMOD, PCARD, PGEM, PFUS, P3D, PNEURO, PALZ, PSEG, PSAMPLE.



**POLATOM National Centre for Nuclear Research
Radioisotope Centre**

Booth No. 410

Andrzej Soltan str. 7
05-400 Otwock
Poland
Phone: +48 22 2731820
Fax: +48 22 7797381
E-Mail: export@polatom.pl
Web: <http://www.polatom.pl>

Radioisotope Centre POLATOM is manufacturer and distributor of the radioisotopic products applied in medicine, research and development, industry and environment protection.

In the nuclear medicine field, POLATOM offers the radiopharmaceuticals for diagnosis and therapy: 131I-Sodium iodide capsules, 131I-solution for injection, 131I-hippurate, 131I-MIBG,

123I-MIBG, 89Sr-Strontium chloride, 32P-Ortho-phosphate, kits for technetium labelling (Tektrotyd, PoltechMIBI, PoltechColloid, PoltechDMSA, PoltechDTPA, PoltechMBrIDA, PoltechMDP, PoltechRBC – Pyrophosphate), 99Mo / 99mTc– generators, ItraPol 90Y and LutaPol 177Lu for peptide labelling and accessories for nuclear medicine. The medical production is certified for compliance with cGMP. Quality Assurance System established at the Radioisotope Centre POLATOM in the area of manufacturing, sales, dispatching and transport of radioactive materials is certified according to PN-EN ISO 9001:2009.

POLATOM is a world famous supplier of high quality radiopharmaceuticals and diagnostic kits for nuclear medicine and important manufacturer of radiochemical products for customers all over the world.

Progenics Pharmaceuticals, Inc.

Booth No. 411

One World Trade Center
47th Floor, Suite J
10007 New York
United States
Phone: +1 6469752500
Web: <http://progenics.com>

Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and Pyl™), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for OIC, is partnered with Valeant Pharmaceuticals International, Inc.



rapp-iso GmbH

Booth No. 220

Mehlbydiek 50

24376 Kappeln

Germany

Phone: +49 (0) 46 42 / 96429-0

Fax: +49 (0) 46 42 / 96429-29

E-Mail: info@rapp-iso.de

Web: <http://www.rapp-iso.de>

Our customers protect, save and preserve life. We support them.

Since 1981, we have been advising and supporting companies, institutions and institutes in the fields of medicine and environmental protection in technology issues. We take responsibility in all phases of planning, purchasing, installation and maintenance of your technical equipment.

With our work we contribute to achieving the highest quality standards in the areas of medicine and environmental protection.

We rely on:

- continuous knowledge updating and training
- comprehensive industry monitoring and vendor independence
- individual advice and around-the-clock service

Our knowledge ensures your treatment success

Our customers never just buy products. They always acquire the long-term benefits that the products have for them.

For more than 30 years, our company tradition has been providing expert advice and reliable support to our customers.

Precise measuring instruments support the diagnosis and thus the healing. Our offer covers the entire product range of all manufacturers. In this way, we are always able to offer the latest technical innovations to your needs. Regular inspection of the instruments and calibration of the measuring instruments is a responsibility for us.

Short distances, direct communication and fast, efficient solutions are our basis.

Rotem GmbH

Booth No. 244

Rathenaustraße 4

4179 Leipzig

Germany

Phone: +49 341 2444925

Fax: +49 341 2444922

E-Mail: rotemur@hyox18.de

Web: <http://www.rotem-medical.com>

Rotem, a longtime world leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production. Our product line is centered on Oxygen-18 enriched water, plastic cassettes, precursors and full reagent kits for various synthesis modules. All products are produced in accordance with cGMP requirements according to the EU & PIC/S and are manufactured at our US FDA-inspected facility. Rotem's cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM. Production is supported by Rotem's in-house certified analytical lab with a wide array of equipment and QC method development capabilities. Users enjoy full technical and regulatory support from our highly qualified staff along with excellent customer service.

Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, the result of a longstanding and close cooperation with radiopharmacies worldwide.

Rotem GmbH in Leipzig serves customers in Europe, with local representatives in the U.K. and Ireland.

ROTOP Pharmaka GmbH

Booth No. 414

Bautzner Landstrasse 400
1328 Dresden
Germany
Phone: +49 351 26310100
Fax: +49 351 26310313
E-Mail: service@rotop-pharmaka.de
Web: <http://www.rotop-pharmaka.de>

ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.

Our portfolio includes:

- A comprehensive range of Tc-99m kits
- GMP-compliant production of agents for Tc-99m kits
- Quality control sets for Tc-99m radiopharmaceuticals
- Distribution of pharmaceuticals that are produced by subcontractors for ROTOP
- Pharmaceutical Development

We will be happy to welcome you at our booth #414.

RoweMed AG

Booth No. 214

Juri-Gagarin-Ring 4
19370 Parchim
Germany
Phone: +49 (0) 3871 - 451280
Fax: +49 (0) 3871 - 451282
E-Mail: info@rowemed.de
Web: <http://www.rowemed.de>

RoweMed AG is an innovative plastic-manufacturing MedTech company. Our focus is on complex customized systems, especially for the handling of sensitive pharmaceuticals.

We realize „turnkey“ projects for our customers, from the initial sketch to CAD design and rapid prototyping right through to an approved serial product. For our projects we offer the complete documentation.

In our certified clean rooms, we offer injection molding, assembly and packaging from a single source. This is how we realize high-efficiency individual processing, small series and automated large series.



Sanofi Genzyme

Booth No. 247

Gooimeer 10
1411 DD Naarden
Netherlands
Web: <http://www.sanofigenzyme.com/>

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.

Scintomics GmbH

Booth No. 230

Lindach 4
82256 Fürstfeldbruck
Germany
Phone: +49 8141 150550
Fax: +49 8141 1505515
E-Mail: info@scintomics.com
Web: <http://www.scintomics.com>

SCINTOMICS is a worldwide active private company, developing and providing synthesizers for GMP production of innovative and routine radiopharmaceuticals, quality control equipment and corresponding services.

AT THIS YEAR'S EANM MEETING, SCINTOMICS LAUNCHES >RADIOHYBRID TRACERS<, A GROUNDBREAKING NEW TRACER CONCEPT. FIRST POWERFUL EXAMPLES OF RADIOHYBRID TRACERS ARE [F-18]rhPSMA-7 AND [Ga-68]rhPSMA-7 WHICH OFFER HIGH AFFINITY AND EXCELLENT BIODISTRIBUTION IN MAN AND ARE PRODUCED IN LESS THAN 1000SECONDS WITH OUTSTANDING YIELDS.

The Radiohybrid Tracer platform is an extremely valuable and groundbreaking addition to SCINTOMICS tracer portfolio, comprising of the unique CXCR4 PET-ligand Ga-68-Pentixafor, the therapeutic CXCR4-ligand Pentixather, the newest generation of CXCR4 ligands with high affinity to murine CXCR4 and the high affinity $\alpha\beta 3$ -ligand Ga-68-Avebetrin.

SEDECAL MOLECULAR IMAGING

Booth No. 241

PELAYA 13, POL. IND. RIO DE JANEIRO
28110 MADRID
Spain
Phone: +34 916280544
E-Mail: info@sedecal.com
Web: <http://www.sedecal.com>

SEDECAL MOLECULAR IMAGING (SMI) with headquarters in Spain, is one of the oldest provider of Preclinical Molecular Imaging Devices with equipment all over the world in the most prestigious organizations. The company is part of SEDECAL GROUP, founded in 1994 with the investment in R&D as philosophy. The wide range of portfolio covers PET, CT, SPECT, PET/CT, SPECT/CT, PET/SPECT/CT and PET/MR systems. Our State of the art technology, PET in REAL TIME make us unique in the market. The PET in real Time will revolutionize the way of how the PET systems perform, being more accurate and faster.

We continue investing in I+D to design new systems introducing new technology and the way we are flexible to include changes into our systems depending of the client's need.

SEDECAL is at the cutting edge of Molecular Imaging systems development due to the R&D investment and the flexibility with their clients, creating specified equipment to satisfy the professional needs in any country. This season SEDECAL will launch a new edge of compact systems more suitable for Molecular Imaging professionals.

Seibersdorf Labor GmbH

Booth No. 262

Forschungszentrum

2444 Seibersdorf

Austria

Phone: +43 50 550 2500

Fax: +43 50 550 2502

E-Mail: office@seibersdorf-laboratories.atWeb: <http://www.seibersdorf-laboratories.at>

ALL-IN-ONE SERVICE FOR NUCLEAR MEDICINE

Our team offers a comprehensive service covering everything linked to work with radiation, from ionizing radiation to laser radiation. We focus specifically on the needs of our customers in the field of nuclear medicine.

EXPERT OPINIONS | PLANNING | ADMINISTRATIVE PROCEDURES

- Radiation protection expert opinions
- Safety and incident analyses, emergency planning, waste disposal concepts
- Expert opinions on laser and optical radiation safety
- Classification of measurement devices
- Consultation on approval procedures
- Documents and reports required for approval

DOSIMETERS

- Whole body dosimeters
- Ring and forehead dosimeters
- Area dosimeters
- Approved dosimetry service

TRAINING | EXERCISES

- Radiation protection officers in medicine
- Authorized doctors
- Advanced training courses

RADIOPHARMACEUTICALS

- Production and development of radiopharmaceuticals
- Production to order for in-house pharmacies, pharmacokinetics and microPET

CALIBRATION

- Therapy and radiation protection dosimeters
- Diagnostic dosimeters and dosimeters for constancy testing

OUR QUALITY STANDARDS

- Accredited testing center for ionizing radiation and radiation protection
- Accredited calibration laboratory for radiation protection
- Authorized verification body for r



Sichuan Tianle Photonics Co., Ltd.

Booth No. 213

#70 Li xing zhi jia, Keji Road
Economic Development Zone
Chongzhou
611230 Chengdu
China
Phone: +86 (0)28 8222 8986
Fax: +86 (0)28 8222 6797
E-Mail: info@sctlx.com
Web: <http://www.tianlephotonics.com>

Sichuan Tianle Photonics Co., Ltd. (hereinafter referred to as "Tianle Photonics" or "Company") was founded in March 2014, by a team from rare earth industry and artificially synthesized crystal/ceramic industry experts. Tianle Photonics dedicates its whole effort and intelligence to the producing and manufacturing of scintillation materials, laser materials and related appliances. The products of Tianle Photonics are mainly used in medical imaging systems such as PET/CT scan system, neutron sensor and oil detection equipment.

The industry of artificially synthesized crystal/ceramic materials have been developed for decades. Different methodologies have been implemented for different products. As for the scintillation crystals and ceramic materials, the variety of physical properties of materials have limited their applications in certain areas. The main products Tianle Photonics is producing are rare earth silicates such as Lutetium Silicate (Ce:LSO), Yttrium Lutetium Silicate (Ce:LYSO) and Yttrium Silicate (Ce:YSO) and rare earth aluminates such as rare earths doped Yttrium Orthoaluminate (Lu:YAP) and rare earths doped Yttrium Aluminum Garnet (Nd:YAG and Ce:YAG), with the major applications in the high energy physical, high energy detection facilities, and nuclear applications. We're a company that dedicate to scintillator crystal growth and crystal array assembly.

Siemens Healthcare GmbH

Booth No. 401

Henkestraße 127
91052 Erlangen
Germany
Web: <https://www.healthcare.siemens.com/molecular-imaging>

Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling you to improve patient outcomes while reducing costs. Siemens Healthineers is dedicated to helping our partners be successful – clinically, operationally and financially – from prevention through diagnosis and treatment.

In June 2017, Symbia Intevo Bold^{TM1} was introduced at SNMMI. This system combines proven SPECT technologies with the latest CT innovations to make high-performance CT even better. In addition to highlighting the advantages of Symbia Intevo Bold, xSPECT BoneTM and xSPECT Quant^{TM1} will be featured at EANM. These technologies provide an opportunity to expand into advanced nuclear medicine applications, such as orthopedics and therapy monitoring.

Visit the Siemens booth to also see the future of PET/CT imaging and to learn more about the value of FlowMotionTM continuous bed motion technology. For more information, please visit <https://www.healthcare.siemens.com/molecular-imaging>

1 Symbia Intevo Bold, xSPECT Quant for 123I, 111In and 177Lu are not yet commercially available in some countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Sirtex Medical Europe GmbH

Booth No. 405

Joseph Schumpeter Allee 33
53227 Bonn
Germany
Phone: +49 (0) 228 18407 30
Fax: +49 (0) 228 18407 35
E-Mail: info@sirtex-europe.com
Web: <http://www.sirtex.com>

Sirtex is a global life-sciences company and actively engaged in the field of liver-directed therapies for cancer patients. The current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads). To date, more than 73,000 doses have been supplied worldwide to treat patients with liver cancer at more than 1,000 medical centres in over 40 countries.

The innovative technology of Sirtex, SIR-Spheres® Y-90 resin microspheres are a medical device used in an interventional radiology procedure known as selective internal radiation therapy (SIRT), or radioembolisation, which targets high doses of short-range beta radiation directly to liver tumours.

SIR-Spheres® microspheres were approved in 2002 for use in the treatment of a variety of unresectable liver tumours as well as in hepatocellular carcinoma within the European Union under a CE Mark.

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Booth No. 356

1850 Samuel Morse Drive
20190 Reston
United States
Phone: +1-703-708-9000
Fax: +1-703-708-9020
E-Mail: nwenzel-lamb@snmmi.org
Web: <https://www.snmmi.org>

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, Va., is a nonprofit scientific and professional organization, founded in 1954, that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 17,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field.

In addition to publishing journals, newsletters and books, the Society also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine and molecular imaging practitioners and to promote new advances in the science of nuclear medicine, molecular imaging and therapy. The Society maintains an active advocacy program to promote and encourage research and the advancement of nuclear medicine science and produces a number of programs to help physicians and technologists remain current with the latest advances. The Society also sponsors education programs for consumers to help them understand nuclear medicine, molecular imaging and therapy and the constructive role it can play in both diagnostic and therapeutic therapies.

Southern Scientific Ltd.

Booth No. 402



Spectrum Dynamics Medical

Booth No. 404

Rue de Lausanne 31
1110 Morges
Switzerland
Phone: +41-21-544-4710
Fax: +41-21-544-4711
E-Mail: info@spectrum-dynamics.com
Web: <http://www.spectrum-dynamics.com>

Spectrum Dynamics Medical revolutionized the practice of nuclear cardiology with the 1st clinical & commercially available CZT imaging scanner.

The D-SPECT® and D-SPECT-L™ nuclear cardiology imaging systems dramatically enhances image quality, improves workflow, allows the ability to reduce radiation exposure by implementing unique low dose protocols and provides the platform for advanced imaging protocols, i.e. Dynamic SPECT and Simultaneous Multi Isotope.

For more information , visit www.spectrum-dynamics.com or call +1-941-256-3660 or +41-21-544-4710. Please visit us at Booth 404 in Hall X4

Springer Nature

Booth No. 360

Tiergartenstr. 17
69121 Heidelberg
Germany
Phone: +49 6221 487-0
Fax: +49 6221 487 8366
Web: <http://www.springernature.com>

Springer Nature is one of the world's leading global research, educational and professional publishers, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world's largest academic book publisher, publisher of the world's most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries and has a turnover of approximately EUR 1.5 billion. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. Find out more: www.springernature.com

SurgicEye GmbH

Booth No. 238

Friedenstr. 18A
81671 Munich
Germany
Phone: +49 89 54 99 89 001
E-Mail: info@surgiceye.com
Web: <http://www.surgiceye.com>

SurgicEye is a solution provider for mobile nuclear medicine imaging for image guided interventions. With declipseSPECT SurgicEye has products for 3D radio-guided surgery supporting the operations with images on the spot. Besides the declipseSPECT product line, SurgicEye provides OEM solution for image processing, image reconstruction, image fusion and software based dose planning and dosimetry solutions.

Synthra GmbH

Booth No. 263

Albert-Einstein-Ring 21**22761 Hamburg****Germany****Phone: +49 (0) 40 881674370****E-Mail: info@synthra.com****Web: <http://www.synthra.com>**

Expert in radio synthesizer for 11C, 18F, 13N, 68Ga and QC Synthra – Desire and Passion for Radio Synthesizer Synthra is a worldwide leading and specialized manufacturer of branded radio synthesizer and concentrates over 35 years of real experiences in the field of targetry radiopharmaceutical production, quality control and lab automation.

We undertake automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for PET and MI. Our portfolio comprises 11C, 18F, 13N and 68Ga. It includes targets, radio synthesizer (incl. customized modules), quality control equipment, spare parts and service. Our radio synthesizer combine high performance and efficiency with high flexibility that enable the production of research 11C-, 18F-, 13N- and 68Ga-radiotracers.

Besides the attractive design, our software and synthesizer are user-friendly. Most common our modules offer an easy possibility to create own sequences for the synthesis of new radiopharmaceuticals. It also offers an integrated self-cleaning system which is a far more ecofriendly and a time-efficient feature.

Product line and brands:

18F Fluorine synthesizer: RNplus, RNplus Research, Multitracer, FDGtwo, F-Dopa (electrophile), NaF

11C Carbon synthesizer: C-Choline, GPextent, Mel, Melplus (CO₂, CH₄ or Research)

Radiometal synthesizer: 68Ga Peptide

RadChrom+ Quality Control Equipment, Metabolite Analysis

TAIYO NIPPON SAN SO Corporation

Booth No. 255

1-3-26 Koyama**Shinagawa-ku****142-8558 Tokyo****Japan****Phone: +81 3 57888550****Fax: +81 3 57888710****E-Mail: Isotope.TNS@tn-sanso.co.jp****Web: <https://stableisotope.tn-sanso.co.jp/english/>**

TAIYO NIPPON SAN SO, established in 1910, is a leading global industrial gas manufacturer. We developed the most energy efficient Oxygen-18O separation process utilizing our cryogenic air separation and ultra-clean technology. Since 2004, we have been supplying Water-18O to the world PET market. To meet the growing demand we completed our three plants with capacity of 600kg/year in 2015 by using state of the art separation technology.

The largest capacity of 600kg/year with these three independent plants and GMP capability enable us to secure the stable supply of the highest and consistent quality of Water-18O, continuing to contribute to the advancement of the PET industry.



Tema Sinergie, S.p.A

Booth No. 303

Via Malpighi, 120

48018 Faenza RA

Italy

Phone: +39 0546 622 663

Fax: +39 0546 621 640

E-Mail: tema@temasinergie.comWeb: <http://www.temasinergie.com>

Tema Sinergie is a dynamic and innovative company that designs, produces and installs solutions and systems suitable for PET Cyclotron, Nuclear Medicine, Radiotherapy, Radiodiagnostics, Industrial and Metrology applications; and works with Hospitals, Research Laboratories & Institutes, Universities and Industrial Companies that work in fields requiring the control of ionizing radiation. For thirty years, Tema Sinergie has improved the design and production of complete systems for the handling of Radiopharmaceuticals, to meet the highest standards for GMP and radioprotection safety levels, while improving the work quality of all who are involved in Radiochemistry & Radiopharmaceuticals R & D and Nuclear Medicine.

Tema Sinergie will be showing several kinds of equipments among which you will find some of its flagship products such as Karl100, the smallest and safest dose administration system; AGLTS, the most advanced GMP compliant glove integrity testing system for isolators and RABs; and ENVIRO, a complete real time monitoring system for the detection and measurement of environmental radiation, air contamination, temperature, humidity and pressure. You will also be introduced to our brand new concept of Radioprotection, the groundbreaking NEXT combo of a non-shielded isolator and a shielded automatic dispenser.

TERUMO

Booth No. 224

7 rue Eugène et Armand Peugeot

92500 Rueil Malmaison

France

Web: <http://www.terumo-europe.com/en-emea>

Founded in Tokyo in 1921, Terumo is a multinational company with more than 90 years' experience in developing best in class medical devices. At Terumo Interventional Systems, we constantly work to refine and perfect our products so that interventionists and healthcare patients can do more to support their patients.

Terumo offers intervention in all dimensions: from access to closure with specialized resources dedicated to Interventional Oncology particularly focusing on Selective Internal Radiation Therapy (SIRT) and nuclear medicine support.

Within Interventional Oncology, Terumo is working in partnership with Interventional Radiologists and Nuclear Medics to ensure they have access to the high quality tools for their patients. This partnership is based on Terumo's comprehensive range of technology and services to support HealthCare Professionals with their patient needs. Terumo offers a large range of devices ranging from access devices Progreat® microcatheter, GT Wire® and Occlusafe® balloon occlusion catheter as well as embolics including Azur®, HydroPearl to a complete range of loco-regional therapies including LifePearl® drug-eluting microspheres and QuiremSpheres®.

QuiremSpheres® the next generation SIRT technology was launched at CIRSE 2017 with further updates planned for EANM 2017.



The Nuclear Health Accelerator

Booth No. 306

Westerduinweg 3
1755 LE PETTEN
Netherlands
Phone: +31 224 564 950
Fax: +31 224 568 912
E-Mail: info@nrg.eu
Web: <http://www.theNuclearHealthAccelerator.com>

The Nuclear Health Accelerator

NRG | PALLAS

For a Long Healthy Life

Our quest for saving lives began back in the 1960s with research & production of medical isotopes. On our site in Petten, north of Amsterdam, the right infrastructure and expertise came together to make this happen. Breakthroughs in scanning technology increasingly allowed for precise diagnosis of cancer and cardiovascular diseases. This led to phenomenal growth and worldwide acceptance of radiopharmaceuticals. Now, NRG has become a world leader in the production of key ingredients for these medicines.

We expect amazing, future breakthroughs in the treatment of life-threatening diseases by using personalized and targeted radiopharmaceuticals. To support this, the NRG site is being overhauled with a major investment program. Next to a new reactor (PALLAS) and processing plant, a state-of-art R&D environment and supporting facilities will be created to cater for the needs of all pioneers in this exciting field of medicine.

Pioneering Medical Solutions

The Nuclear Health Accelerator is set up by NRG | PALLAS to explore, innovate and create amazing new medical solutions together with our academic partners. We know that such advances can only be realised when curiosity, knowledge, funds and facilities marry. The setup of this gateway is such that expertise and academic know-how from all around the world and across all disciplines can start working together in proximity of and in safety to the source.

Theraclion

Booth No. 423

102 rue Etienne Dolet
92240 Malakoff
France
Phone: +33 155489070
Fax: +33 155489078
E-Mail: contact@theraclion.com
Web: <http://www.theraclion.com>

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules.

Trasis

Booth No. 419

Rue Gilles Magnée, 90
5530 Ans
Belgium
E-Mail: info@trasis.com
Web: <http://www.trasis.com>

At Trasis our primary focus is allowing the medical community to access new radiolabelled therapeutic and diagnostic substances easier and faster. To this end, we design, manufacture, sell and support high performance synthesizers, dose preparation equipment, their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.

Our proven radiopharmaceutical expertise, coupled with our high end instruments allows us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization. Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies.

Triskem International

Booth No. 403

3 rue des Champs Géons ZAC de l'Eperon 35170 BRUZ
ZAC de l'Eperon
35170 BRUZ
France
Phone: +33 2 99 05 42 14
E-Mail: mlanger@triskem.fr
Web: <http://www.triskem.com/>

TrisKem International is a leading provider of extraction chromatographic resins and solutions for the separation of radioactive elements.

TrisKems main product line consists of a wide selection of different extraction chromatographic resins which allow the separation of radionuclides from various samples and matrices (irradiated targets, environmental, medical and bioassay as well as waste and decommissioning samples). Our products are standard technology in radiochemistry and they are used by international accredited laboratories and monitoring agencies such as the IAEA, AREVA, IRSN, CEA, BfS...).

Our resins are increasingly finding application in the production and quality control of radionuclides (such as Cu-64/7, Sc-44/7, Zr-89, Ge-68, Ga-67, Ti-44, alpha emitters...) for medical use, and are employed by leading radionuclide manufacturers worldwide.

TrisKem International places a strong focus on the development of new resins and separation methods to meet your separation needs. If you'd like to receive more detailed information, or if you'd like to discuss a specific separation problem please contact us under: contact@triskem.fr.

Turkish Society of Nuclear Medicine (TSNM)

Booth No. 357

Cinnah Caddesi Pilot Sokak No:10/12
6650 Ankara
Turkey
Phone: +90 312441 00 45
Fax: +90 312 441 12 97
E-Mail: dernekmerkezi@tsnm.org
Web: <http://www.tsnm.org>

Turkish Society of Nuclear Medicine (TSNM) was founded in 1975 soon after the approval of Nuclear Medicine as an independent medical specialty by the Ministry of Health. TSNM aims to promote clinical practice, research and education in nuclear medicine for the benefit of public health. TSNM also holds a unique position to provide collaboration between national health authorities, departments of nuclear medicine in universities and training and research hospitals, industrial suppliers and other medical societies. The society organizes several scientific activities each year, national congresses in spring and a symposium dedicated on a different topic of interest in winter season and regular educational events called "School of Nuclear Medicine" designed for residents and young physicians by the experts of the scientific task groups involved within TSNM. Currently TSNM has 777 members including physicians, physicists, pharmacists and technologists. The official journal of TSNM is "Molecular Imaging and Radionuclide Therapy, MIRT" (<http://mirt.tsnmjournals.org>). MIRT is published in English and indexed in PubMed, PubMed Central, EBSCO and some other scientific indexes and provides open access to its content. The society also publishes an electronic journal, "Nuclear Medicine Seminars" which is in Turkish dedicated to educational articles on specific topics by the invited editors in each issue.

UEMS / EBNM - European Board of Nuclear Medicine

Booth No. 348

Schmalzhofgasse 26
1060 Vienna
Austria
Phone: +43 (0)1 890 44 27
Fax: +43 (0)1 890 44 27 9
E-Mail: office@uems.eanm.org
Web: <http://www.uems.eanm.org>

The European Union of Medical Specialists (UEMS) is the oldest medical organisation in Europe as it celebrated its 50th anniversary in 2008.

With a current membership from 37 countries, it is the representative organisation of the National Associations of Medical Specialists in the European Union and its associated countries.

Medical Specialities

The UEMS represents more than 50 medical disciplines through various bodies and structures. The most important ones are the 43 Specialist Sections, which represent independently recognised specialties. They have created a European Board as a subgroup, in conjunction with the relevant European Society, with a view to defining European standards of medical education and training. They also contribute to the work of Multidisciplinary Joint Committees (MJC) which address fields of a multidisciplinary nature.

Section and European Board of Nuclear Medicine

Nuclear Medicine has been an independent medical specialty since 1988. The Section of Nuclear Medicine was constituted in 1990 and the European Board of Nuclear Medicine (EBNM) was created in 1993 with the main objective to guarantee the highest standards in the field of nuclear medicine. In 2003, the UEMS Section and European Board of Nuclear Medicine (UEMS/EBNM) merged in order to unify and facilitate activities.



Uniteko Co., Ltd

Booth No. 212

77, Seondong-gil, Chowol-eup
12732 Gyeonggi-do
South Korea

Incorporated 2010, Uniteko Co., Ltd has accelerated its rate of growth as a leader of radiation measurement system developer. We have many customers including general hospitals, a variety of R&D institutes, nuclear power plants, military-related institutes, and fire-defense related institutes.

Our product areas include import and developing of radiation measurement equipments and systems and radiation shielding equipments.

In addition, we are a supplier of many types of isotopes for biological and chemical research purpose, a consultant for radiation safety and a service provider for radiation-related businesses.

We are growing with our reliable supplying and customer satisfactory service, and are trying to be a leading company with sustainable investment for new facility and system development.

US DOE ISOTOPE PROGRAM

Booth No. 240

1 Bethel Valley Road
37831-6158 Oak Ridge
United States

Phone: +1 865 574 6984

E-Mail: isotopes@ornl.gov

Web: <https://isotopes.gov/>

The United States Department of Energy Isotope Program is an Isotope subprogram that supports the production, and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the Nation and are essential for energy, medical and national security applications and for basic research; a goal of the program is to make critical isotopes more readily available to meet domestic U.S. needs.

VANDERWILT techniques bv

Booth No. 238

Parallelweg-zuid 33-02**5281 LB Boxtel****Netherlands****Phone: +31 0411 686019****E-Mail: G.vanderwilt@wxs.nl****Web: <http://www.FOR-MED.nl>**

VANDERWILT techniques is a design, engineering and manufacturing company for medical devices in nuclear medicine and custom made accessories:

- Custom-moulded polymer FOR-MED patient positioning supports
- Foot support for SPECT/CT
- Breast support prone position
 - Dedicated pinhole collimators
 - Tungsten syringe shields
 - Manual dispensing and dose calibrator unit PET
 - Lead and tungsten vial containers
 - High Resolution Micro phantoms for small animal systems
 - Thyroid phantom
- Dynamic Heart phantom (AGATE)
- SeHCAT panels, Place resolution phantoms and NEMA calibration panels
- Sharp Needle Waste containers
- Waste containers
- OP containers
- Shielded heating device

VANDERWILT techniques design and manufacture customized products for daily laboratory and clinical nuclear medicine practice as well as research purposes, using state-of-the-art and innovative production methods.

Typically, our customers are universities, hospitals and nuclear medicine departments, as well as radiopharmaceutical and imaging equipment companies.

Von Gahlen Nederland B.V.

Booth No. 315

Kelvinstraat 9**6902 PW Zevenaar****Netherlands****Phone: +31 (0)316 528 275****Fax: +31 (0)316 333 649****E-Mail: info@vongahlen.nl****Web: <http://www.vongahlen.com>**

Von Gahlen designs and manufactures lead shielding products for the radio pharmacy and nuclear medicine industry. Our products range from transportation solutions to complete manufacturing lines, including semi or fully automated dispensing systems. Since its founding over 4 decades ago, Von Gahlen has become a world leader and global player in these industries. With our strong customer focus, we have managed to provide high quality products that meet or exceed industry standards and safety requirements. Von Gahlen hot cell installations may be found all over the world, including many of the largest turnkey installations in the field.

Due to its extensive experience, Von Gahlen is involved from the earliest planning and design stages up to and including the completed installation and validation, working closely with the customer at all stages to ensure that every requirement is met and to produce the best equipment available for the application.

Our team of professionals includes highly qualified technical designers as well as experienced manufacturing and installation personnel. Our modern factory is equipped with the latest computerized equipment. Von Gahlen is an ISO 9001 Certified Company. Our quality assurance program has been audited and approved by numerous customers.

Von Gahlen is proud to be at the forefront of advancing technology.



Wallonia Export & Investment (AWEX)

Booth No. 318

Place Sainctelette no 2
1080 Brussels
Belgium
Phone: +32 2 421 87 09
Fax: +32 2 421 85 37
E-Mail: g.marien@awex.be
Web: <http://www.awex-export.be>

The Wallonia Export & Investment Agency (AWEX) is the Wallonia Region of Belgium's government agency in charge of foreign trade promotion and foreign investment attraction. The agency has a worldwide network of more than 100 Economic Commercial Advisors.

WARMTH - World Association of Radiopharmaceutical and Molecular Therapy

Booth No. 349

Nuclear Medicine Rajiv Gandhi Cancer Institute & Research Centre
Sector 5 Rohini
110085 Delhi
India
Phone: +1-650-219-1030
E-Mail: info@warmth.org
Web: <http://warmth.org>

The „World Association of Radiopharmaceutical and Molecular Therapy“ (WARMTH) extends its activities throughout the world. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy, and of the relatively novel paradigm of 'Theragnostics'.

WARMTH is a voluntary non-profit organization of individuals specifically associated for the purposes, and for using the means, to achieve the following research and educational objectives:

- Advance science and education of therapeutic nuclear medicine and radiopharmaceutical therapy including dosimetry, treatment evaluation, radiation physics, radiation biology and radiation protection for the benefit of public health and humanity.
- Work towards worldwide access to radionuclide therapy by harmonizing good practice.
- Educating nuclear medicine professionals in the use of radionuclide therapies and to facilitate research in this area. WARMTH's major initiatives for sharing and disseminating information are:
 1. annual International Conferences on Radionuclide Therapy (ICRT)
 2. Timely workshops and symposia on focused clinical areas
 3. Provide a suitable platform for the dissemination and discussion of the latest results in the field of Nuclear Medicine Therapy, and related subjects through the quarterly academic publication of World Journal of Nuclear Medicine, and
 4. Establishment of the World Theragnostics Academy, for training and promoting educational activities.

Wisepress Medical Bookshop

Booth No. 400

15 Lyon Road
Merton
SW19 2RL London
United Kingdom
Phone: +44 2087151812
E-Mail: marketing@wisepress.com
Web: <http://www.wisepress.com>

Wisepress.com, Europe's leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.

Wolfmet

Booth No. 238

M&I Materials Ltd
Hibernia Way
Trafford Park
M320ZD Manchester
United Kingdom
Phone: +44 1618645506
Fax: +44 1618645444
E-Mail: stevejeffery@mimaterials.com
Web: <http://www.wolfmet.com/>

NEW – Wolfmet 3D printed tungsten collimators

Wolfmet tungsten alloy has been the automatic choice for radiation shielding and collimators in nuclear medicine for many years.

Now Wolfmet is opening up a world of new possibilities with the introduction of Wolfmet 3D printed tungsten. This revolutionary new process makes complex high-precision tungsten collimators a reality.

The benefits of this new technology include:

- High density components which reduce septal penetration and therefore improve imaging
- Collimator compatibility with the new generation of SPECT/MRI scanners
- Reduced development costs – no tooling charges
- Rapid production of prototypes
- Easy modifications of designs
- Reduced time from development to actual production

Wolfmet is part of the Pavilion consortium. Come and visit us to learn more about this exciting new development.

In addition, we will have examples of our standard shields for nuclear medicine – FDG pots, vial shields and customised shields.



World Federation of Nuclear Medicine & Biology /
Australian and New Zealand Society of Nuclear Medicine Booth No. 361

ANZSNM: Postal Address PO Box 6178 Vermont South Victoria 3133 Australia
WFNMB: Congress venue: MCEC (Melbourne Convention and Exhibition Centre)
Victoria
3133 Melbourne
Australia
Phone: +61 1300 330 402
E-Mail: secretariat@anzsnm.org.au
Web: <http://www.wfnmb2018.com/>

About the WFNMB: One of our principal activities is to support education efforts for nuclear physicians, physicists, radiopharmacists, radiochemists, technologists and other nuclear medicine scientists, especially from the developing world. In achieving its programmatic goals, the WFNMB will work with its member societies, and with international health and scientific bodies like the International Atomic Energy Agency (IAEA) and the World Health Organisation (WHO). This will enable us to enhance nuclear medicine education and improve access to the highest quality nuclear medicine care.

YanTai DongCheng Pharmaceutical Group Co.,Ltd Booth No. 248



ESMIT


European School of Multimodality Imaging and Therapy

ESMIT eLearning

No Limits, Full Education

Level

1



87 Recorded CME Sessions

This section features selected CME and Plenary sessions recorded at EANM congresses since 2012 onwards.



Webinars on

Basic Nuclear Medicine,
Paediatric Nuclear Medicine,
PET and MoRe, PET/CT,
PET/CT for Technologists
Many more to come soon...

Corporate Members

EANM wishes to thank the following companies for their support as Corporate Members (alphabetical order):

Advanced Accelerator Applications



Biocompatibles UK Ltd



Bruker BioSpin Preclinical Imaging Division



Comecer



Curium



Eckert & Ziegler



Eli Lilly



GE Healthcare

GE Healthcare



Hermes



IBA



IBA Molecular



Isotope4life



JSC Isotope



Mediso Medical Imaging Systems



Monrol (Eczacıbaşı)



NRG



PARS Isotope



Philips



Siemens Healthineers



Spectrum Dynamics Medical



Tema Sinergie



The Pavilion



Imprint

Publisher

European Association of Nuclear Medicine
Schmalzhofgasse 26, 1060 Vienna, Austria
Phone: +43-(0)1-890 44 27
Fax: +43-(0)1-890 44 27-9
Email: office@eanm.org
URL: www.eanm.org

Editors

Francesco Giammarile, EANM Congress Chair 2017-2019
Andreas Felser, EANM Executive Director
Susanne Koebe, EANM Project Manager, Congress

Content

No responsibility is taken for the correctness of this information.
Information as per date of printing September 2017.


Layout & Design

Robert Punz, EANM Executive Office



EANM'18

WORLD LEADING MEETING



Annual Congress of the European Association of Nuclear Medicine

October 13 – 17, 2018
Düsseldorf, Germany

eanm18.eanm.org



Visit us on
[.com/officialEANM](https://www.facebook.com/officialEANM)